ribavirin profile

Rebetron: Rebetron is tradename [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	37542
CHEMBL ID	1643
CHEBI ID	63580
SCHEMBL ID	3727
MeSH ID	M0019062

Synonym
AB00430481-15
AB00430481-16
smr000058315
MLS000028486
KBIO1_000782
DIVK1C_000782
EU-0101063
ribavirin, antiviral
drg-0028
ribavirin capsules
varazid
ribamidil
1,2,4-triazole-3-carboxamide, 1-beta-d-ribofuranosyl-
1h-1,2,4-triazole-3-carboxamide, 1-beta-d-ribofuranosyl-
ribovirin
1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide
ribavirina [inn-spanish]
ribavirinum [inn-latin]
rebetron
ribavirine [inn-french]
SPECTRUM_001826
brn 0892462
ribamidyl
hsdb 6513
1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide
cas-36791-04-5
BSPBIO_003352
IDI1_000782
LOPAC0_001063
SMP1_000261
PRESTWICK3_000993
SPECTRUM5_002075
icn-1229
tribavirin
1h-1,2,4-triazole-3-carboxamide, 1-.beta.-d-ribofuranosyl-
1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,2,4-triazole-3-carboxamide
ribav
rbv ,
virazid
1-.beta.-d-ribofuranosyl-1,2,4-triazolo-3-carboxamide
rebretron
ribavirine
NCGC00090726-01
AB00430481
rtca
36791-04-5
nsc-163039
rebetol
ribasphere
nsc163039
copegus
virazole
RIBAVIRIN ,
viramid
vilona
DB00811
copegus (tn)
rebetol (tn)
virazole (tn)
ribavirin (jp17/usp/inn)
ribasphere (tn)
D00423
BPBIO1_001195
KBIOSS_002331
KBIO2_004896
KBIOGR_001804
KBIO2_002328
KBIO3_002854
KBIO2_007464
SPECTRUM3_001876
NINDS_000782
SPECTRUM4_001252
SPECTRUM1503938
SR-01000076112-3
BSPBIO_001085
NCGC00090726-06
NCGC00090726-04
NCGC00090726-03
NCGC00090726-05
virazide
HMS2090L15
R 9644 ,
HMS2094O09
R0077
1-(beta-d-ribofuranosyl)-1,2,4-triazole-3-carboxamide
NCGC00090726-07
ro-20-9963
ravanex
rg-964
c-virin
r-964
ribacine
cotronak
1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide
MLS002222317
HMS502H04
ribavirin mylan
ribavirin teva
ribavirin biopartners
chebi:63580 ,
sch 18908
sch-18908
CHEMBL1643
AKOS001715163
NCGC00090726-08
NCGC00090726-09
HMS2098G07
HMS3263E08
EN300-59237
tox21_200967
NCGC00258520-01
1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-1,2,4-triazole-3-carboxamide
A823370
1-[(2r,3s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,2,4-triazole-3-carboxamide
nsc-758650
pharmakon1600-01503938
nsc758650
dtxcid603557
dtxsid8023557 ,
tox21_110259
HMS2232P07
CCG-38985
ribavirin [usan:usp:inn:ban]
unii-49717awg6k
49717awg6k ,
ribavirina
ribavirinum
1-((2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1h-1,2,4-triazole-3-carboxamide
1-(beta-d-ribofuranosyl)-1h-1,2,4-triazole-3-carboxamide
ribavirine;
BCP0726000138
252269-50-4
LP01063
BRD-K60369935-001-02-7
S2504
ribofluranosyl carboxamide
gtpl6842
bdbm50154375
cid_37542
ribavirin [vandf]
ribavirin component of peginterferon
ribavirin [usp-rs]
ribavirin [orange book]
ribavirin [mart.]
ribavirin teva pharma b.v.
ribavirin [ema epar]
ribavirin [ep monograph]
ribavirin [usp monograph]
ribavirin [usan]
ribavirin [hsdb]
ribavirin [jan]
ribavirin [mi]
ribavirin [who-dd]
ribavirin [inn]
HY-B0434
1-beta-ribofuranosyl-1,2,4-triazole-3-carboamide
1-(beta -d-ribofuranosyl)-1,2,4-triazole-3-carboxamide
IWUCXVSUMQZMFG-AFCXAGJDSA-N
SCHEMBL3727
tox21_110259_1
NCGC00090726-12
NCGC00261748-01
tox21_501063
1-?-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide
ribavirin, british pharmacopoeia (bp) reference standard
AB00430481_17
AB00430481_18
mfcd00058564
4PB1
GS-3572
SR-01000721904-2
sr-01000721904
ribavirin, united states pharmacopeia (usp) reference standard
ribavirin, pharmaceutical secondary standard; certified reference material
ribavirin, european pharmacopoeia (ep) reference standard
SR-01000076112-2
sr-01000076112
SR-01000076112-4
SR-01000076112-11
SBI-0051033.P003
HMS3715G07
Q421862
Z594284196
ribavirin (copegus)
AS-34178
ribavirin,(s)
BRD-K60369935-001-18-3
SDCCGSBI-0051033.P004
NCGC00090726-25
1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide
NCGC00090726-30
ribavirin 100 microg/ml in acetonitrile:methanol
1-beta-d-ribofuranosyl-1h-1,2,4-triazole-3-carboxamide
HB4522
1-ss-d-ribofuranosyl-1,2,4-triazole-3-carboxamide
ribavirin (usp monograph)
ribavirinum (inn-latin)
riba
1-beta-d-ribofuranosyl-1h-1,2, 4-triazole-3-carboxamide
ribavirin (ep monograph)
virazolee
ribavirin (mart.)
ribavirin (usp-rs)
ribavirina (inn-spanish)
j05ap01
ribavirine (inn-french)
ribavirin (usan:usp:inn:ban)
1-beta-d-ribofuranosyl-1,2,4-triazolo-3-carboxamide

Excerpt	Reference	Relevance
" The selective index (ratio of the median toxic dose: median efficacious dose) of LY253963 in HEp2 tissue culture cells was greater than 100 against both RSV and PIV3."	( Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Ambrose, MW; Gilbert, BE; Meyer, HL; Wyde, PR, )	0.13
" 3N-3DU exhibited comparable toxicity to ribavirin in KB cells, was 4-fold less toxic in WISH cells and 4-fold more toxic in LLC-MK2 cells."	( Antiviral and cytotoxicity evaluation of 3-nitro-3-deazauridine. Allen, LB; Cook, PD; Holland, CS; Kehoe, MJ; McNamara, DJ; Teepe, AG, 1989)	0.28
" Their adverse effects mostly involve bone marrow depression (e."	( Adverse effects and drug interactions of clinical importance with antiviral drugs. Morris, DJ, 1994)	0.29
" The children tolerated the drug well, and treatment was not associated with any clinically significant adverse effects."	( Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Connor, E; Connor, J; Lane, J; Morrison, S; Oleske, J; Sonke, RL, 1993)	0.29
" The combination regimen was safe and well tolerated."	( A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Bassiakos, Y; Booth, D; Clax, PA; Connor, JD; Cooney, E; Crumpacker, CS; Erice, A; Griffith, BP; Holden-Wiltse, J; Hussey, S; Japour, AJ; Johanneson, N; Lertora, JJ; McLaren, C; Meehan, PM; Pollard, R; Timpone, J; Walesky, M; Wood, K, 1996)	0.29
" No serious adverse events were observed and less than 10% withdrew."	( Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. Alberti, A; Bellobuono, A; Brouwer, JT; Cavalletto, L; Chemello, L; Hansen, BE; Ideo, G; Schalm, SW; Schvarcz, R; Weiland, O, 1997)	0.3
"To determine adverse events of ribavirin in the treatment of chronic hepatitis C, 41 patients (18 with cirrhosis), treated with ribavirin at an initial dose of 600-1200mg day(-1), were analysed retrospectively (six patients were treated twice because adverse effects during the first treatment necessitated cessation of ribavirin)."	( Effects of cirrhosis, interferon and azathioprine on adverse events in patients with chronic hepatitis C treated with ribavirin. Blot, C; Mathurin, P; Moussalli, J; Opolon, P; Perrin, M; Plassart, F; Poynard, T; Thevenot, T, 1997)	0.3
" The potential for ribavirin to likewise exacerbate the adverse events associated with the alpha interferons is reviewed."	( Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Maddrey, WC, 1999)	0.3
" This observational study arguably provides the most complete information available on ribavirin-associated adverse effects."	( Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Ribavirin Study Group. Baum, KF; Behrman, RE; Bell, LJ; Chapman, LE; Christenson, JC; Holman, RC; Jolson, HM; Khan, AS; Koster, FT; Ksiazek, TG; Mertz, GJ; Pavia, AT; Peters, CJ; Rollin, PE; Rubin, PJ; Sadek, RF; Simpson, GL, 1999)	0.3
" The adverse effects of IFN are well established and familiar to hepatologists all over the world."	( Adverse effects and other safety aspects of the hepatitis C antivirals. Chutaputti, A, 2000)	0.31
" Clinical and biological adverse effects were recorded."	( Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Benhamou, Y; Bochet, M; Bréchot, C; Chaix, ML; Fontaine, H; Katlama, C; Lagneaux, JL; Landau, A; Pialoux, G; Pol, S; Poynard, T; Zylberberg, H, 2000)	0.31
"3% of treated subjects (who were previous non-responders to interferon therapy), respectively; (3) anaemia is a frequent adverse event."	( Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Benhamou, Y; Bochet, M; Bréchot, C; Chaix, ML; Fontaine, H; Katlama, C; Lagneaux, JL; Landau, A; Pialoux, G; Pol, S; Poynard, T; Zylberberg, H, 2000)	0.31
" During the treatment the patient developed a typical flue-like syndrome, dry cough with exertional dyspnea that was initially interpreted as a typical side effect of interferon-alpha treatment."	( [Pulmonal sarcoidosis: A rare side effect of interferon-alpha treatment for chronic hepatitis C infection]. Kallinowski, B; Pohl, J; Stremmel, W, 2000)	0.31
"The purpose of this descriptive study is to review the adverse effects of combination therapy, interferon alfa-2b and ribavirin, in a sample of patients with chronic hepatitis C who were part of a larger multi-center trial (Bonkovsky, 1999)."	( Assessment of side effects in patients with chronic hepatitis C receiving combination therapy. Miller, BW; Zucker, DM, )	0.13
" Since BR does exhibit myelosuppression, the most common chemotherapy-related side effect in humans, careful judgment is warranted should BR be included in multidrug regimens, although BR's potent cytotoxicity to tumor cells in preclinical models still makes it a promising drug."	( Toxicity and efficacy of benzamide riboside in cancer chemotherapy models. Arguello, F; Greene, JF; Jayaram, HN; Yalowitz, JA, 2002)	0.31
" The temporal relation between the administration of the drug and the detection of toxic affects (nephrotic syndrome) and subsequent improvement upon withdrawal also supports a causative role for interferon-ribavirin."	( Nephrotoxicity of interferon alfa-ribavirin therapy for chronic hepatitis C. Willson, RA, 2002)	0.31
"Interferon-alpha plus ribavirin therapy for chronic hepatitis C is associated with adverse effects that lead to therapy discontinuation in up to 27% of patients in randomized controlled trials."	( Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Ascione, T; Bruno, R; Campanone, A; De Sena, R; Felaco, FM; Filice, G; Gaeta, GB; Piccinino, F; Precone, DF; Spadaro, A; Stanzione, M; Stornaiuolo, G, 2002)	0.31
"8%] patients failed to finish combination therapy because of adverse events."	( Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C. Ascione, T; Bruno, R; Campanone, A; De Sena, R; Felaco, FM; Filice, G; Gaeta, GB; Piccinino, F; Precone, DF; Spadaro, A; Stanzione, M; Stornaiuolo, G, 2002)	0.31
" Management of these adverse effects has a great impact on the compliance of affected patients during the course of their treatment."	( The role of nursing in managing treatment-associated adverse effects in patients with hepatitis C. Leone, NE, )	0.13
" Combination therapy with pegylated interferons (peginterferon alfa-2a and alfa-2b) yields an adverse event profile similar to standard interferon, although the frequency of certain adverse events may vary by preparation."	( Side effects of therapy of hepatitis C and their management. Fried, MW, 2002)	0.31
"The treatment of chronic hepatitis C patients was enhanced when the combination of interferon alfa-2b and ribavirin was shown to be safe and more effective than interferon monotherapy."	( The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients. Boyd, DG; McHutchinson, J; Pockros, PJ; Reddy, R; Reindollar, R; Wilkes, LB; Wright, T, 2003)	0.32
" The adverse effects are dose dependent and often reversible."	( Chronic hepatitis C treatment. Side effects and their management. Al-Kayyal, BM; Shobokshi, OA; Tantawe, AO, 2003)	0.32
"Although information on efficacy and adverse drug reactions is lacking, ribavirin has been used empirically for the treatment of severe acute respiratory syndrome (SARS)."	( Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Dresser, L; Knowles, SR; Matukas, L; Phillips, EJ, 2003)	0.32
" Approximately 8% of patients receiving recombinant IFNalpha-2b plus ribavirin discontinue treatment because of adverse events."	( Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study. Annese, M; Babudieri, S; Bacca, D; Barbarini, G; Barbaro, G; Belloni, G; Francavilla, R; Fruttaldo, L; Grisorio, B; Hazra, C; Lucchini, A; Matarazzo, F; Rizzo, G; Torre, D, 2003)	0.32
" There were no serious adverse events, and most adverse events were mild."	( Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. Lin, CC; Philips, L; Xu, C; Yeh, LT, 2004)	0.32
"Among 35 patients who received concomitant didanosine (400 mg/day in 86%) and ribavirin (> or = 10 mg/kg/day in 91%), 20 (57%) developed one or more adverse events after a mean of 87 days."	( High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antela, A; Bárcena, R; Casado, JL; Dronda, F; Moreno, A; Moreno, L; Moreno, S; Muriel, A; Navas, E; Perez-Elías, MJ; Quereda, C, 2004)	0.32
"An evaluation of the US Food and Drug Administration's Adverse Event Reporting System identified that patients coinfected with human immunodeficiency virus and chronic hepatitis C virus who were treated with a regimen of ribavirin and didanosine, with or without stavudine, were at increased risk for events associated with mitochondrial toxicity, including fatal hepatic failure, peripheral neuropathy, pancreatitis, and symptomatic hyperlactatemia/lactic acidosis."	( Nucleoside analogues and mitochondrial toxicity. Boxwell, D; Fleischer, R; Sherman, KE, 2004)	0.32
" Ribavirin is directly toxic to red blood cells and is associated with hemolysis, which is usually dose-related but self-limited."	( Hematologic side effects of interferon and ribavirin therapy. Kowdley, KV, 2005)	0.33
" Unfortunately though, lighter patients may also suffer, as fixed dosing can provide these patients with an excessive amount of drug, increasing their risk for adverse events."	( Weight-based dosing: which impact on efficacy and safety of therapy? Almasio, PL, 2004)	0.32
" Therapy was discontinued by 4, 6 and 2 patients because of adverse events in the above three groups."	( Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients. Angarano, G; Cibelli, DC; Fazio, V; Palumbo, E; Saracino, A; Scotto, G, 2005)	0.33
" Adverse events leading to reduction of dose of drugs occurred in 40% and adverse events leading to discontinuation treatment occurred in 12%."	( [Efficacy and safety of pegylated-interferon plus ribavirin in HIV-infected patients co-infected with hepatitis C virus in clinical practice: a 32 cases observational follow-up]. Bernard, N; Beylot, J; Bonarek, M; Bonnet, F; Dramé, M; Lacoste, D; Lafon, ME; Morlat, P; Ramanampamonjy, R; Rambeloarisoa, J; Seydi, M; Trimoulet, P, 2005)	0.33
" Tolerance and safety were evaluated by the rate of treatment's discontinuation for any reason, and occurrence of serious clinical adverse events, respectively."	( Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. Boyer, N; Cazals-Hatem, D; Consigny, Y; Degott, C; Marcellin, P; Marrache, F; Martinot, M; Ripault, MP; Valla, D, 2005)	0.33
" The adverse events were the typical of those reported in the treatment with interferon and ribavirin."	( [An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C]. Chen, DW; Dong, Y; Jia, WZ; Mao, YL; Tang, HM; Xu, ZQ; Yang, XJ; Zhang, HF; Zhu, SS, 2005)	0.33
" No severe adverse events occurred and most of the patients well tolerated the treatment."	( [An open-label pilot study evaluating the efficacy and safety of peginterferon alfa-2a combined with ribavirin in children with chronic hepatitis C]. Chen, DW; Dong, Y; Jia, WZ; Mao, YL; Tang, HM; Xu, ZQ; Yang, XJ; Zhang, HF; Zhu, SS, 2005)	0.33
" All subjects in Group 1 completed treatment, while two subjects in Group 2 stopped therapy due to treatment-related adverse events."	( Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. Alberti, A; Almasio, PL; Berrutti, M; Boccato, S; Cattaneo, C; Craxi, A; Demelia, L; Ideo, G; Pellicano, R; Picciotto, A; Rizzetto, M; Sorbello, O; Torre, F; Valenza, M; Venezia, G, 2005)	0.33
" There were no serious adverse events and it was not necessary to reduce dosages or even cease therapy prematurely."	( Efficacy and safety of chronic hepatitis C treatment in hemophilic patients. Dite, P; Husa, P; Husova, L; Penka, M; Roznovsky, L; Smejkal, P, )	0.13
"PSE allowed the safe use of peg-IFN plus ribavirin in HCV cirrhotic patients with severe cytopenias who otherwise would never have been treated."	( Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Bárcena, R; Blázquez, J; Foruny, JR; Gil-Grande, L; Moreno, A; Moreno, J; Moreno, S; Muriel, A; Pérez-Elías, MJ; Quereda, C; Rodriguez-Sagrado, MA; Sánchez, J, 2005)	0.33
" Adverse events led to dose modification in 37 (31%) and discontinuation in 8 (7%)."	( Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Baczkowski, A; Geffner, M; González-Peralta, RP; Gupta, S; Haber, B; Jonas, MM; Kelly, DA; Lang, T; Laughlin, M; Lurie, Y; Martin, S; Mieli-Vergani, G; Molleston, J; Murray, KF; Shelton, M, 2005)	0.33
"The adverse effects of antiviral drugs are dose dependent and often reversible."	( [Treatment of the side effects of antiviral therapy]. Vcev, A, 2005)	0.33
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."	( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004)	0.32
" As the use of aerosolized ribavirin to treat respiratory syncytial virus infections continues, it is imperative that careful attention be paid to possible adverse effects of therapy in the high-risk population of immunosuppressed patients."	( Aerosolized ribavirin-induced reversible hepatotoxicity in a hematopoietic stem cell transplant recipient with Hodgkin lymphoma. Bueso-Ramos, C; Chaves, J; Huen, A; Safdar, A; Vadhan-Raj, S, 2006)	0.33
"6%) was discontinuation due to adverse events."	( Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. Altés, J; Baguena, F; Casanova, A; de Castro, ER; Delejido, A; Garcia, MJ; Rota, R; Sala, M; Santin, M; Shaw, E; Valero, S, 2006)	0.33
"7%) patients stopped IFN therapy due to the adverse events after initiation of IFN alone therapy."	( [Side effects of interferon therapy for chronic hepatitis C]. Arase, Y, 2006)	0.33
" Limited efficacy in patients with hepatitis C virus (HCV) genotype 1 and the side effect profile will necessitate the development of new therapeutic approaches."	( Treating viral hepatitis C: efficacy, side effects, and complications. Cornberg, M; Manns, MP; Wedemeyer, H, 2006)	0.33
"peg-IFNalpha-2a plus RBV is effective and safe to achieve SVR in HCV/HIV coinfected patients non-responsive to prior IFN treatment."	( Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy. Fernández-Carbia, A; González-Lassalle, E; Marxuach-Cuétara, AM; Ríos-Bedoya, CF; Rodríguez-Orengo, JF; Rodríguez-Torres, M; Salgado-Mercado, R, 2007)	0.34
" The introduction of combined therapy with pegylated interferons and ribavirin has increased the sustained virologic response (SVR) in the much higher percentage than with previous treatment options, while the level of adverse effects has not changed significantely."	( [Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection]. Delić, D, )	0.13
" Physicians were instructed to adjust the dose of both drugs if adverse events occurred."	( [Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection]. Delić, D, )	0.13
" The safety record was good, the most common adverse effects including cytopenia, rash and local reactions at the site of administration."	( [Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection]. Delić, D, )	0.13
"Combination therapy with peginterferon alfa-2a and ribavirin is safe and well tolerated, with SVR achieved in 86."	( [Efficacy and safety of peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C virus infection]. Delić, D, )	0.13
"To distinguish adverse events related to ribavirin therapy from those attributable to severe acute respiratory syndrome (SARS), and to determine the rate of potential ribavirin-related adverse events."	( Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Dresser, L; Loeb, M; Louie, M; Mazzulli, T; McGeer, A; Muller, MP; Raboud, J; Rea, E; Richardson, SE, 2007)	0.34
" Logistic regression was used to evaluate the association between ribavirin use and each adverse event (progressive anemia, hypomagnesemia, hypocalcemia, bradycardia, transaminitis, and hyperamylasemia) after adjusting for SARS-related prognostic factors and corticosteroid use."	( Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Dresser, L; Loeb, M; Louie, M; Mazzulli, T; McGeer, A; Muller, MP; Raboud, J; Rea, E; Richardson, SE, 2007)	0.34
"High-dose ribavirin is associated with a high rate of adverse events."	( Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Dresser, L; Loeb, M; Louie, M; Mazzulli, T; McGeer, A; Muller, MP; Raboud, J; Rea, E; Richardson, SE, 2007)	0.34
"This study investigates whether dose modifications for adverse hematologic effects or the use of hematopoietic growth factors influenced the outcome of therapy for hepatitis C virus (HCV) infection in patients who were coinfected with HCV and human immunodeficiency virus (HIV) and who were participants in a randomized, controlled trial."	( Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Behler, CM; Chung, RT; Lin, F; Peters, MG; Robbins, GK; Vittinghoff, E; Volberding, PA, 2007)	0.34
" Doses were modified for a number of adverse effects (including hematologic toxicity), and hematopoietic growth factors were administered at the discretion of the physician."	( Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Behler, CM; Chung, RT; Lin, F; Peters, MG; Robbins, GK; Vittinghoff, E; Volberding, PA, 2007)	0.34
" Agranulocytosis was detected which was accounted as a side effect of pegylated interferon treatment."	( [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis]. Farkas, A; Halász, T; Horváth, G; Tolvaj, G, 2006)	0.33
"Therapies including nucleoside analogs are associated with severe toxic side effects and acquirement of drug resistance."	( Formulations of biodegradable Nanogel carriers with 5'-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity. Han, HY; Kohli, E; Vinogradov, SV; Zeman, AD, 2007)	0.34
"Commonly reported adverse effects were noted in 90% of patients, most occurring during the first three months, with a stable prevalence thereafter and resolution after treatment end."	( Safety and efficacy of combination therapy with peginterferon alfa-2a (40kD) and ribavirin in the outpatient setting: prospective analysis of 197 patients with chronic hepatitis C viral infection. Beorchia, S; Chandelier, C; Combis, JM; Delassalle, P; Desmorat, H; Douvin, C; Filoche, B; Fontanges, T; Hanslik, B; Jacques, JP; Ouzan, D, )	0.13
" The aim of this study was to analyze adverse effects during the treatment with pegylated IFN-alpha and ribavirin in children with CHC."	( Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W, 2007)	0.34
" After 12-16 weeks of the therapy somatic adverse effects decreased significantly."	( Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W, 2007)	0.34
"Administration of pegylated IFN-alpha and ribavirin in children with CHC is related to characteristic adverse effects."	( Adverse effects during the treatment with pegylated interferon and ribavirin in children with chronic hepatitis C. Figlerowicz, M; Kowala-Piaskowska, A; Mozer-Lisewska, I; Słuzewski, W, 2007)	0.34
" Despite the lack of benefit with this regimen, induction therapy with this schedule was safe and well tolerated in co-infected patients."	( Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study. Berenguer, J; Clotet, B; Montes-Ramírez, M; Planas, R; Quereda, C; Rubio, R; Santín, M; Solà, R; Tural, C, 2007)	0.34
"7% of the patients experienced at least one adverse event."	( Safety, tolerability and efficacy of peginterferon alpha-2a and ribavirin in chronic hepatitis C in clinical practice: The German Open Safety Trial. Alshuth, U; Gelbmann, CM; Hüppe, D; Lafrenz, M; Link, R; Lohmeyer, J; Mauss, S; Möller, B; Niederau, C; Wiedmann, KH; Witthöft, T, 2007)	0.34
"The adverse reactions (ADR) derived from the treatment of hepatitis C with peginterferon alpha and ribavirin causes dose reductions and discontinuations of the treatment that compromise its efectiveness."	( [Toxicity of the treatment of chronic hepatitis C with peginterferon alpha (2a or 2b) plus ribavirin in patients not previously treated]. Llopis González, A; Márquez Peiró, JF; Morales Suárez-Varela, M; Pérez Peiró, C; Valero Alcocer, VE, 2007)	0.34
" Frequencies of adverse events (AEs) and serious AEs were similar among treatment arms and CD4 strata."	( Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection. Clotet, B; Clumeck, N; Cooper, DA; Depamphilis, J; Dieterich, DT; Montaner, J; Opravil, M; Rockstroh, JK; Sasadeusz, J; Torriani, FJ, 2008)	0.35
" Therapy was discontinued in 3 patients as a result of adverse events."	( Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Camarena, C; de Guevara, CL; de la Vega, A; Díaz, C; Díez-Dorado, R; Frauca, E; Hierro, L; Jara, P; Larrauri, J; Miños-Bartolo, G; Rueda, M, 2008)	0.35
" PEG-IFN-alpha2b and ribavirin were reasonably well tolerated, with no unexpected or permanent adverse effects."	( Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection. Camarena, C; de Guevara, CL; de la Vega, A; Díaz, C; Díez-Dorado, R; Frauca, E; Hierro, L; Jara, P; Larrauri, J; Miños-Bartolo, G; Rueda, M, 2008)	0.35
"Haematological adverse events related to pegylated interferon (PEG-IFN) and ribavirin (RBV) therapy could affect the patients' quality of life; however, the risk factors for severe haematological toxicity associated with this therapy in patients coinfected with hepatitis C virus (HCV) and HIV are unclear."	( Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Arizcorreta-Yarza, A; Collado, A; Fernández-Fuertes, E; Girón-González, JA; González-Serrano, M; López-Cortés, LF; Lozano, F; Macías, J; Merino, D; Mira, JA; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortoso, M; Valera-Bestard, B, 2007)	0.34
"The safety of albinterferon alfa-2b was acceptable, with a similar adverse event profile in both treatment arms."	( Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Bailey, RJ; Bain, VG; Cronin, PW; Kaita, KD; Marotta, P; McHutchison, JG; Patel, K; Pulkstenis, E; Subramanian, GM; Swain, MG; Yoshida, EM, 2008)	0.35
"Albinterferon alfa-2b administered at 4-week intervals was safe and well-tolerated and demonstrated significant antiviral activity in patients with genotype 2/3, chronic hepatitis C virus."	( Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Bailey, RJ; Bain, VG; Cronin, PW; Kaita, KD; Marotta, P; McHutchison, JG; Patel, K; Pulkstenis, E; Subramanian, GM; Swain, MG; Yoshida, EM, 2008)	0.35
"The combination of telaprevir, peginterferon alfa-2a, and ribavirin was well tolerated, with no serious adverse events or treatment discontinuations."	( Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. Khunvichai, A; Kieffer, TL; Lawitz, E; McHutchison, JG; McNair, L; Muir, AJ; Rodriguez-Torres, M, 2008)	0.35
"The aim of the study was an assessment of the incidence and types of neuropsychiatric serious adverse events (NSAE) in patients with compensated chronic hepatitis C (CHC) treated with recombinant or pegylated interferon-alpha (IFN-alpha) plus ribavirin (RBV)."	( [Neuropsychiatric adverse events in patients with chronic hepatitis C treated with pegylated or recombinant interferon-alpha]. Borkowska, A; Drózdz, W; Dybowska, D; Halota, W; Kozielewicz, D; Ziółkowska-Kochan, M, 2008)	0.35
" In conclusion, antiviral treatment is safe if transfusion requirement, iron toxicities and neutropenia are monitored."	( Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Fischer, R; Giardina, PJ; Harmatz, P; Jonas, MM; Kwiatkowski, JL; Neufeld, EJ; Olivieri, N; Porter, J; Vichinsky, E; Wright, EC, 2008)	0.35
" Approximately 90% of patients suffer from at least one adverse effect; 15% will therefore have reduced drug dose and 5% will discontinue treatment."	( [Side effects during interferon-alpha therapy of hepatitis C with special consideration of thyroid dysfunction]. Obołończyk, L; Siekierska-Hellmann, M; Sworczak, K, 2007)	0.34
" Improved treatment regimens, including the standard of care pegylated interferon alfa and ribavirin, have increased sustained virologic response rates; however, treatment has a long duration and is often associated with adverse events that may affect adherence."	( Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Smith, JP, 2008)	0.35
"To determine the incidence and severity of adverse effects of treatment in patients with chronic hepatitis B and C (CHB and CHC)."	( [Haematologic adverse effects of treatment of chronic viral hepatitis B and C]. Kristian, P; Pellová, A; Porubcin, S; Schréter, I, 2008)	0.35
" In two cases, the treatment was discontinued due to its adverse effects."	( [Haematologic adverse effects of treatment of chronic viral hepatitis B and C]. Kristian, P; Pellová, A; Porubcin, S; Schréter, I, 2008)	0.35
"The data confirm a high incidence of haematologic adverse effects, mostly mild."	( [Haematologic adverse effects of treatment of chronic viral hepatitis B and C]. Kristian, P; Pellová, A; Porubcin, S; Schréter, I, 2008)	0.35
"To illustrate the side effect profile of pegIFN-alpha in the treatment of CHC."	( Safety of peginterferon in the treatment of chronic hepatitis C. Hashemi, N; Herrine, SK; Navarro, VJ; Rossi, S, 2008)	0.35
"Most adverse events occurring with combination therapy can be anticipated and managed appropriately; therefore, premature discontinuation of therapy owing to side effects is not required in most patients."	( Safety of peginterferon in the treatment of chronic hepatitis C. Hashemi, N; Herrine, SK; Navarro, VJ; Rossi, S, 2008)	0.35
" We also show that T-705 is as effective as, and less toxic than, ribavirin, as infected T-705-treated hamsters on average maintain their weight better and recover more rapidly than animals treated with ribavirin."	( Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. Bailey, KW; Furuta, Y; Gowen, BB; Hall, JO; Jung, KH; Morrey, JD; Smee, DF; Stevens, JR; Wong, MH, 2008)	0.35
" Fifteen patients (22%) did not complete the study, in 5 (8%) cases because of severe adverse events."	( Swiss multicenter study evaluating the efficacy, feasibility and safety of peginterferon-alfa-2a and ribavirin in patients with chronic hepatitis C in official opiate substitution programs. Broers, B; Frei, M; Fried, R; Herold, M; Huber, M; Isler, M; Kölliker, C; Monnat, M; Oppliger, R; Schmid, P; Schönbucher, P; Seidenberg, A, 2008)	0.35
" Unfortunately, both peg-IFN alpha and RBV are responsible for a wide range of adverse events and potentially severe toxicities, particularly hematological alterations."	( Bone marrow toxicity in HCV genotype 5a-infected patient after peg-IFN alpha-2a and ribavirin therapy. Boumis, E; Capone, A; Drapeau, CM; Noto, P; Petrosillo, N; Remotti, D, 2008)	0.35
"7%) due to adverse effects."	( Efficacy and safety of peginterferon alpha-2a/ribavirin in treatment-naive Cameroonian patients with chronic hepatitis C. Nerrienet, E; Njouom, R; Pasquier, C; Rousset, D; Sartre, MT; Tchendjou, P; Timba, I, 2008)	0.35
" This case report illustrates vestibulocochlear and autonomic nervous system adverse effects of pegylated interferon-alpha-2b/ribavirin, emphasizing the importance of early recognition and cessation of therapy to prevent permanent neurootologic injury."	( Interferon-alpha-2b/ribavirin-induced vestibulocochlear toxicity with dysautonomia in a chronic hepatitis C patient. Galizio, C; Johnson, K; Sargent, LA; Ubogu, EE, 2008)	0.35
" A multi-centre, randomized, controlled, prospective study assessed sustained virological response (SVR), adverse events such as depressive episodes and retention rate of HCV treatment in opioid-dependent patients."	( Retention rate and side effects in a prospective trial on hepatitis C treatment with pegylated interferon alpha-2a and ribavirin in opioid-dependent patients. Ebner, N; Fischer, G; Jachmann, CA; Matzenauer, C; Thau, K; Wanner, C; Winklbaur, B, 2009)	0.35
" Antiviral treatment with pegylated interferon-alfa (IFN-alpha) plus ribavirin is often complicated by psychiatric adverse events, significantly affecting patients adherence."	( Hepatitis C treatment in patients with drug addiction: clinical management of interferon-alpha-associated psychiatric side effects. Mauss, S; Schaefer, M, 2008)	0.35
" HCV therapy is generally safe in the population of coinfected patients with advanced immunosuppression."	( Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Arponen, S; Collado, A; Delgado, M; Gil, Ide L; González-Serrano, M; Gutiérrez-Valencia, A; López-Ruz, MA; Macías, J; Merino, D; Mira, JA; Omar, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortosa, M, 2009)	0.35
" Adverse event rates were similar between groups except for diarrhea (viramidine 29."	( Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. Chun, E; Gish, RG; Gitlin, N; Halliman, DG; Heise, J; Marcellin, P; Rodriguez-Torres, M, 2010)	0.36
"This study aimed to assess the relationship between interferon (IFN)-related adverse effects and Hepatitis C virus (HCV) virologic response in HIV/HCV-coinfected individuals treated with pegylated interferon and ribavirin."	( HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. Bishop, R; Cortez, KJ; Kottilil, S; Masur, H; McLaughlin, M; Murphy, A; Osinusi, A; Polis, MA; Proschan, M; Rasimas, JJ; Rosenstein, D, 2010)	0.36
" Other adverse effects, such as anemia and ophthalmologic toxicities, were also more frequent in responders compared with nonresponders."	( HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. Bishop, R; Cortez, KJ; Kottilil, S; Masur, H; McLaughlin, M; Murphy, A; Osinusi, A; Polis, MA; Proschan, M; Rasimas, JJ; Rosenstein, D, 2010)	0.36
"Our study demonstrates coupling of antiviral effect and occurrence of adverse events in HIV/HCV-coinfected patients."	( HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. Bishop, R; Cortez, KJ; Kottilil, S; Masur, H; McLaughlin, M; Murphy, A; Osinusi, A; Polis, MA; Proschan, M; Rasimas, JJ; Rosenstein, D, 2010)	0.36
"001) and grade 3 or 4 adverse events (34."	( Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML, 2010)	0.36
"Older patients with HCV infection, especially those in the subgroup infected with HCV-1, had a greater frequency of adverse events and poorer adherence to the standard-of-care regimen, which may be the major reason for treatment inferiority."	( Efficacy and safety of pegylated interferon combined with ribavirin for the treatment of older patients with chronic hepatitis C. Chang, WY; Chen, SC; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yu, ML, 2010)	0.36
"The adverse effects of antiviral drugs are dose dependent and often reversible."	( [Management of side effects during antiviral therapy]. Vcev, A, 2009)	0.35
" I will review the most common adverse events reported during the therapy of chronic hepatitis B and C, with some recommendations for proper management."	( Adverse effects of drugs in the treatment of viral hepatitis. Negro, F, 2010)	0.36
" Ten patients developed cirrhotic complications during the treatment, and 11 stopped treatment due to treatment-related adverse events."	( [Clinical efficacy and safety of the combination therapy of peginterferon alpha and ribavirin in cirrhotic patients with HCV infection]. Cheong, HR; Cho, M; Heo, J; Kang, DH; Kim, DU; Kim, GH; Song, GA; Woo, HY; Yoon, KT, 2010)	0.36
"Of the 24 study patients, no patient stopped the treatment due to treatment-related adverse events."	( Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients with genotype 2 and high virus load. Akuta, N; Arase, Y; Hirakawa, M; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Matsumoto, N; Saito, S; Sezaki, H; Suzuki, F; Suzuki, Y; Yatsuji, H, 2010)	0.36
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."	( Developing structure-activity relationships for the prediction of hepatotoxicity. Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010)	0.36
" The standard of care (SOC) of pegylated IFN and ribavirin combination therapy has limited efficacy with ~50% sustained viral response, and is associated with a considerable adverse event profile in many patients."	( Safety of small molecules in combination with interferon-based therapy for hepatitis C virus. Rustgi, VK, 2010)	0.36
"Patient sub-classes with poor prognosis with SOC are identified, as are their associated adverse event profiles."	( Safety of small molecules in combination with interferon-based therapy for hepatitis C virus. Rustgi, VK, 2010)	0.36
"In HIV/ hepatitis C virus (HCV) coinfection, adverse events (AEs) during HCV therapy account for 12%-39% of treatment discontinuations."	( Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. Andersen, J; Bhattacharya, D; Carrat, F; Chung, RT; Currier, JS; Peters, MG; Torriani, F; Umbleja, T, 2010)	0.36
" Interferons may induce adverse events that usually, but not always, reverse within a few days after the end of therapy."	( A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. Abate, G; Bertino, G; Boemi, P; Calvagno, GS; Di Pino, A; Giancarlo, C; Ignaccolo, L; Judica, A; Maiorca, D; Mastrosimone, G; Mauceri, B; Misseri, M; Neri, S; Palermo, F; Petralia, A; Rizzotto, A; Vadalà, G, 2010)	0.36
"Treatment of patients with chronic hepatitis C with alpha-interferon and ribavirin usually produces adverse events within the first 3 months."	( An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C. Cottone, M; D'Amico, G; Fasola, S; Giannuoli, G; Graviano, D; Madonia, S; Malizia, G; Patti, S; Tinè, F, 2010)	0.36
" The baseline viral load had no impact on SVR in the present series nor were any serious adverse events reported."	( Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. El-Ghannam, M; El-Ray, A; Mounir, B; Taha, AA, 2010)	0.36
"The novel pegylated interferon alpha-2a assessed in the present study was effective for the treatment of patients with genotype 4 CHC, and was safe and well tolerated."	( Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C. El-Ghannam, M; El-Ray, A; Mounir, B; Taha, AA, 2010)	0.36
" The incidence of severe adverse events did not differ between the two groups."	( The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial. Chen, SC; Chiu, CF; Chuang, WL; Dai, CY; Hou, NJ; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Lin, ZY; Wang, LY; Yang, JF; Yeh, ML; Yu, ML, 2011)	0.37
" No serious adverse event was observed."	( Safety and efficacy of peginterferon alpha plus ribavirin in patients with chronic hepatitis C and coexisting heart disease. De Vincentiis, L; Durante-Mangoni, E; Iossa, D; Pinto, D; Ragone, E; Utili, R, 2011)	0.37
" The use of these drugs has been correlated with a range of adverse effects, including influenza-like symptoms, hematological changes and neuropsychiatric disturbances."	( Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects. Almasio, PL; Calvaruso, V; Mazza, M, 2011)	0.37
"The research literature was reviewed with the aim of answering the question 'is irritability an underappreciated side effect of interferon and ribavirin treatment for hepatitis C'."	( Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C? Blacklaws, H; Gardner, A; Usher, K, 2011)	0.37
" Good research is the foundation for evidence-based practice; therefore, the possibility exists that, based on current research evidence, patients may not be receiving a standard care that adequately addresses the entirety of the side effect spectrum."	( Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C? Blacklaws, H; Gardner, A; Usher, K, 2011)	0.37
"Irritability is an underappreciated psychological side effect of interferon therapy."	( Irritability: an underappreciated side effect of interferon treatment for chronic hepatitis C? Blacklaws, H; Gardner, A; Usher, K, 2011)	0.37
" Treatment of HCV infection with Peg-IFN in combination with ribavirin can eradicate HCV infection in 40-90% of patients; however, a major barrier to treatment uptake and delivery is the association of this therapy with frequent and, at times, serious adverse effects."	( Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C. Cooper, C; Dalgard, O; Hunyady, B; Jia, J; Ogurtsov, P; Peck-Radosavljevic, M; Shiffman, ML; Sulkowski, MS; Yurdaydin, C, 2011)	0.37
" Thirty patients were enrolled to receive pegIFN once a week with ribavirin twice daily for 12 weeks; viral load and experienced adverse effects were then assessed."	( Efficacy and safety of pegylated interferon in children and adolescents infected with chronic hepatitis C: a preliminary study. Abdel-Aziz, DH; El-Gazayerly, ON; El-Sayed, MH; Sabry, NA, 2011)	0.37
" After the intervention, the increase in both hemoglobin and absolute neutrophil counts did not differ between the 2 side effect management strategies."	( Randomized trial comparing dose reduction and growth factor supplementation for management of hematological side effects in HIV/hepatitis C virus patients receiving pegylated-interferon and ribavirin. Aberg, JA; Aboulafia, D; Bonilla, H; Dimova, R; Doonquah, L; Dove, L; Galpin, J; Glesby, MJ; Hassanein, T; Jacobson, IM; Johnston, B; Liu, RC; Pearce, D; Rodriguez, J; Talal, AH; Zeremski, M, 2011)	0.37
"Dermatological adverse events (AEs) are an existing concern during hepatitis C virus (HCV) infection and peginterferon/ribavirin treatment."	( Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. Bourlière, M; Buggisch, P; Cacoub, P; Dupin, N; Dusheiko, G; Hézode, C; Lübbe, J; Picard, O; Pujol, R; Roujeau, JC; Segaert, S; Thio, B, 2012)	0.38
" All of the patients continued the combination therapy owing to disappearance of severely adverse events contained the exacerbation of depression."	( Efficacy and safety of combination therapy of natural human interferon beta and ribavirin in chronic hepatitis C patients. Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Imai, N; Kawamura, Y; Kobayashi, M; Kumada, H; Matsumoto, N; Saito, S; Seko, Y; Sezaki, H; Suzuki, F; Suzuki, Y, 2011)	0.37
"Single oral doses of ribavirin 400 mg were safe and well tolerated in this population."	( Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. Glue, P; Gupta, SK; Kantesaria, B, 2012)	0.38
" The aim of this study is to evaluate the reason for premature discontinuation during PEG-IFN α-2b and RBV treatment due to adverse effects in patients with chronic HCV infection."	( Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kotoh, K; Maruyama, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y, 2012)	0.38
"7%) discontinued treatment because of adverse effects."	( Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kotoh, K; Maruyama, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y, 2012)	0.38
"Premature discontinuation due to the adverse effects of PEG-IFN α-2b and RBV treatment by patients with chronic HCV infection is mainly due to neuropsychiatric symptoms and is more common for older than for younger patients."	( Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kotoh, K; Maruyama, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y, 2012)	0.38
"Effective management of adverse events (AEs) is important to prevent treatment discontinuation and optimize hepatitis C virus infection eradication rates."	( Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management in clinical practice. Hézode, C, 2012)	0.38
" The ratios of discontinuation of telaprevir only or of all the study drugs because of adverse events were 21."	( Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C. Chayama, K; Hayashi, N; Kumada, H; Okanoue, T; Toyota, J; Tsubouchi, H, 2012)	0.38
" This large multinational open-label study aimed to better define the incidence of serious adverse events (SAEs) and non-serious adverse events of special interest in patients receiving peginterferon alfa-2a/ribavirin."	( Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients. Berak, H; Dusheiko, GM; Ferenci, P; Gane, EJ; Hadziyannis, SJ; Han, KH; Harley, HA; Horsmans, YJ; Husa, P; Jenny Heathcote, E; Lee, SS; Messinger, D; Roberts, SK; Tatsch, F, 2012)	0.38
"Pegylated-interferon (peg-IFN) and ribavirin combination therapy for the treatment of hepatitis C virus (HCV) infection is well known to be associated with significant adverse effects."	( Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C. Casale, M; Faiella, F; Galati, G; Mazzarelli, C; Pappacena, M; Picardi, A; Potena, M; Salvinelli, F; Vespasiani Gentilucci, U, )	0.13
"The efficacy of pegylated interferon-α and ribavirin (pegIFN/RBV) in the treatment of Hepatitis C infection is limited by psychiatric adverse effects (IFN-PE)."	( Gene expression profiles predict emergence of psychiatric adverse events in HIV/HCV-coinfected patients on interferon-based HCV therapy. Katsounas, A; Kottilil, S; Lempicki, RA; Masur, H; Murphy, AA; Osinusi, A; Polis, M; Rasimas, J; Raza, H; Rosenstein, D; Yang, J, 2012)	0.38
" Determining precisely the risk of serious adverse events (SAEs) and mortality from a single study is rather difficult because of the infrequency of such events."	( Meta-analysis: mortality and serious adverse events of peginterferon plus ribavirin therapy for chronic hepatitis C. Kishikawa, T; Koike, K; Minami, T; Sato, M; Tateishi, R; Yoshida, H, 2013)	0.39
" The adverse event (AE) impact of PI-PR remains under-reported."	( Impact of adverse events on costs and quality of life in protease inhibitor-based combination therapy for hepatitis C. Carter, JA; Gao, X; Haider, S; Rustgi, VK; Stephens, JM, 2012)	0.38
" The primary endpoints were composed of the rates of SVR, the rates of relapse, the rates of anemia, and the rates of discontinuation due to severe adverse events, respectively."	( [Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis]. Li, MY; Yuan, XL; Zhang, DZ, 2012)	0.38
"01 and higher discontinuation rate owing to severe adverse events, 12."	( [Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis]. Li, MY; Yuan, XL; Zhang, DZ, 2012)	0.38
" Both the incidence of adverse events and the frequency of discontinuation owing to severe adverse events were higher in patients receiving the triple therapy than those receiving the standard double therapy."	( [Efficacy and safety of a protease inhibitor with pegylated interferon and ribavirin in patients with untreated chronic hepatitis C: a meta analysis]. Li, MY; Yuan, XL; Zhang, DZ, 2012)	0.38
" In the prospect of the imminent introduction of new direct acting antiviral agents, with demonstrated higher rates of adverse effects, our study aimed to assess the severity and incidence of several types of adverse effects in a cohort of genotype 1 infected Romanian patients."	( Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort. Irimia, E; Mogoantă, L; Predescu, O; Streba, L; Streba, LA, 2012)	0.38
" We recorded their viral loads, hemoglobin values and thrombocyte counts, as well as any dermatological, psychiatric or constitutional adverse effect after twelve doses, eight and twelve months of treatment, with two follow-up examinations at three and six months after treatment completion."	( Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort. Irimia, E; Mogoantă, L; Predescu, O; Streba, L; Streba, LA, 2012)	0.38
" We only encountered grade 1 and 2 dermatological adverse effects."	( Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort. Irimia, E; Mogoantă, L; Predescu, O; Streba, L; Streba, LA, 2012)	0.38
"We did not encounter severe hematological adverse effects that would require Ribavirin dosage adjustments."	( Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort. Irimia, E; Mogoantă, L; Predescu, O; Streba, L; Streba, LA, 2012)	0.38
"This article focuses on the adverse effects of hepatitis C therapy, which includes pegylated interferon alfa-2a or -2b with ribavirin."	( Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV. Afridi, MS; Slim, J, 2012)	0.38
"9% had adverse affects (G1/4 50."	( [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia]. Bojović, K; Božić, M; Fabri, M; Milošević, I; Nožić, D; Trkulja, B, )	0.13
" Longer therapy increases the possibility of the development of adverse affects."	( [Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia]. Bojović, K; Božić, M; Fabri, M; Milošević, I; Nožić, D; Trkulja, B, )	0.13
" Data were abstracted for complete early virologic response (EVR), sustained virologic response (SVR), relapse, treatment discontinuations, hematologic and dermatologic adverse events, and growth inhibition."	( Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Cooper, CL; Druyts, E; Kanters, S; Mills, EJ; Thorlund, K; Wu, P; Yaya, S, 2013)	0.39
" Discontinuation due to adverse events and discontinuation due to viral breakthrough were each 4%, discontinuation due to a lack of response was 15%, and relapse was 7%."	( Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Cooper, CL; Druyts, E; Kanters, S; Mills, EJ; Thorlund, K; Wu, P; Yaya, S, 2013)	0.39
"The results of this meta-analysis indicate that peg-IFN/RBV combination treatment is effective and safe in treating children and adolescents with HCV."	( Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Cooper, CL; Druyts, E; Kanters, S; Mills, EJ; Thorlund, K; Wu, P; Yaya, S, 2013)	0.39
" Baseline and demographic characteristics, response to treatment at weeks 12, 48 and 72, and the nature and frequency of adverse effects were analyzed."	( Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Antón, MD; Arocena, C; Barrera, JM; Boadas, J; Crespo, J; Dalmau, B; Del Olmo, JA; Diago, M; Erdozaín, JC; Giné, J; Gracia-Samaniego, J; Montoro, M; Perez, R; Planas, R; Solá, R; Suarez, D; Urquijo, JJ, )	0.13
"Chemi-enzymatic synthesis of ribavirin acrylate and subsequent RAFT co-polymerization with acrylic acid afforded a formulation of a broad spectrum antiviral drug which avoids accumulation in erythrocytes, the origin of the main side effect of ribavirin."	( Macromolecular prodrugs of ribavirin combat side effects and toxicity with no loss of activity of the drug. Kryger, MB; Smith, AA; Wohl, BM; Zelikin, AN, 2013)	0.39
" However, there was an increased risk of serious adverse events in the TPR group (RR=1."	( The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials. Jia, Z; Li, D; Liang, HJ; Ma, L; Wei, X; Yang, D, 2013)	0.39
" Adverse effects resulted in treatment discontinuation by 12."	( Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y, 2013)	0.39
"To report the rates of grade IV adverse events and hepatitis C virus (HCV) treatment discontinuation associated with the use of telaprevir, pegylated interferon, and ribavirin."	( High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. Ballard, C; Cachay, ER; Colwell, B; Hill, L; Lin, JC; Mathews, WC; Torriani, FJ; Wyles, DL, 2013)	0.39
" The United States of America National Institutes of Health Division of AIDS grading system was used to rate severity of adverse events."	( High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. Ballard, C; Cachay, ER; Colwell, B; Hill, L; Lin, JC; Mathews, WC; Torriani, FJ; Wyles, DL, 2013)	0.39
"Of the 24 consecutive patients treated for HCV using telaprevir/pegylated interferon/ribavirin, 50% (12/24) developed serious adverse events and 29% (7/24) discontinued HCV treatment due to adverse events, despite an intensive multidisciplinary monitoring approach."	( High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. Ballard, C; Cachay, ER; Colwell, B; Hill, L; Lin, JC; Mathews, WC; Torriani, FJ; Wyles, DL, 2013)	0.39
"In this HIV clinic-based experience, a high rate of grade IV adverse events and treatment discontinuations were observed associated with HCV telaprevir-based treatment."	( High incidence of serious adverse events in HIV-infected patients treated with a telaprevir-based hepatitis C virus treatment regimen. Ballard, C; Cachay, ER; Colwell, B; Hill, L; Lin, JC; Mathews, WC; Torriani, FJ; Wyles, DL, 2013)	0.39
" IBD can become exacerbated during treatment with interferon (IFN), and serious adverse events, such as pancytopenia or hepatotoxicity, can be compounded by drug interactions."	( Efficacy and safety of treatment of hepatitis C in patients with inflammatory bowel disease. Allen, AM; Kim, WR; Larson, J; Loftus, EV, 2013)	0.39
" There was one serious adverse event, which was not considered to be treatment related."	( Safety and efficacy of faldaprevir with pegylated interferon alfa-2a and ribavirin in Japanese patients with chronic genotype-1 hepatitis C infection. Kuboki, M; Nishiguchi, S; Omata, M; Sakai, Y; Sakamoto, W; Steinmann, G; Tsuda, Y; Tsunematsu, S; Urano, Y, 2014)	0.4
" The main adverse effects of telaprevir therapy are anemia and skin rash."	( [Clinical use of telaprevir: stopping rules, predicting response, treatment length, and management of adverse effects]. Planas, R; Tural, C, 2013)	0.39
" Similarly, the adverse effects in this trial did not differ from those found in patients with genotype 1 HCV monoinfection."	( [Safety and efficacy of telaprevir in patients with HIV and hepatitis C virus coinfection]. Macías, J; Rivero, A, 2013)	0.39
" Single-dose ribavirin was safe and well tolerated in all subjects."	( Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Glue, P; Gupta, SK; Kantesaria, B, 2013)	0.39
" The RBV dose was reduced because of adverse events (AEs) in 71% and 53% of severe and moderate renal impairment groups, respectively."	( Safety, tolerability, and pharmacokinetics of ribavirin in hepatitis C virus-infected patients with various degrees of renal impairment. Blotner, S; Brennan, BJ; Grippo, JF; Magnusson, MO; Martin, P; Nieforth, K; Solsky, J; Wang, K; Wat, C; Wilkins, JJ, 2013)	0.39
" Such lesions may develop as adverse effects by telaprevir, since the lesions disappeared following discontinuation of telaprevir in a 65-year-old man, in whom both pegylated-interferon (Peg-IFN) and ribavirin were continued, and reappeared when he took telaprevir again by his decision."	( Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C. Inao, M; Mochida, S; Nakayama, N; Sugawara, K, 2014)	0.4
"Ophthalmologic examinations should be done carefully during triple therapy, since the incidence was higher than that in previous Peg-IFN therapy, and lesions may develop as adverse effects by telaprevir, but not by Peg-IFN, especially in those showing preferable IL28B SNPs allele and/or anemia during the therapy."	( Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C. Inao, M; Mochida, S; Nakayama, N; Sugawara, K, 2014)	0.4
" Adverse events were consistent with those reported in clinical trials of peginterferon and ribavirin, and no unique adverse events appeared to be associated with GSK2336805."	( A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected Adkison, K; Cutrell, A; Elko-Simms, C; Gardner, S; Hamatake, R; Hong, Z; Rodriguez-Torres, M; Walker, J, 2014)	0.4
"Only two adverse events, anaemia and dysgeusia, occurred 20% more often with the BOC-containing regimens compared with PR."	( Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials. Albrecht, JK; Bacon, B; Balart, L; Bourliere, M; Brass, CA; Bronowicki, JP; Bruno, S; Burroughs, M; Davis, MN; Felizarta, F; Helmond, FA; Kwo, P; Manns, MP; McCone, J; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Schiff, E; Shiffman, ML; Sings, HL; Sulkowski, MS; Vierling, JM, 2014)	0.4
"Severe adverse events (AEs) compromise the outcome of direct antiviral agent-based treatment in patients with advanced liver fibrosis due to HCV infection."	( Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C. Abdurakhmanov, D; Colombo, M; DeMasi, R; Fernández, I; Ferreira, PA; Hill, A; Iraqi, W; Läuffer, JM; Lonjon-Domanec, I; Moreno, C; Strasser, SI; Streinu-Cercel, A; Urbanek, P; Verheyen, A; Wedemeyer, H, 2014)	0.4
"Data about adverse events are needed to optimise telaprevir-based therapy in a broad spectrum of patients."	( Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Bansal, M; Bichoupan, K; Branch, AD; Dieterich, DT; Gaglio, PJ; Giannattasio, ER; Kalia, H; Liu, LU; Marfo, K; Martel-Laferriere, V; Odin, JA; Perumalswami, P; Reinus, JF; Schiano, TD; Schwartz, JM, 2014)	0.4
"To investigate adverse events of telaprevir-based therapy in patients with and without advanced fibrosis or cirrhosis in a real-world setting."	( Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Bansal, M; Bichoupan, K; Branch, AD; Dieterich, DT; Gaglio, PJ; Giannattasio, ER; Kalia, H; Liu, LU; Marfo, K; Martel-Laferriere, V; Odin, JA; Perumalswami, P; Reinus, JF; Schiano, TD; Schwartz, JM, 2014)	0.4
" Multivariable fully adjusted models were built to assess the effect of advanced fibrosis on specific adverse events and discontinuation of treatment due to an adverse event."	( Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Bansal, M; Bichoupan, K; Branch, AD; Dieterich, DT; Gaglio, PJ; Giannattasio, ER; Kalia, H; Liu, LU; Marfo, K; Martel-Laferriere, V; Odin, JA; Perumalswami, P; Reinus, JF; Schiano, TD; Schwartz, JM, 2014)	0.4
" More critical monitoring in older and female patients with low platelets throughout treatment may reduce adverse event-related discontinuations."	( Effect of fibrosis on adverse events in patients with hepatitis C treated with telaprevir. Bansal, M; Bichoupan, K; Branch, AD; Dieterich, DT; Gaglio, PJ; Giannattasio, ER; Kalia, H; Liu, LU; Marfo, K; Martel-Laferriere, V; Odin, JA; Perumalswami, P; Reinus, JF; Schiano, TD; Schwartz, JM, 2014)	0.4
" Two patients withdrew prematurely from study medications due to adverse events."	( Efficacy and safety of danoprevir-ritonavir plus peginterferon alfa-2a-ribavirin in hepatitis C virus genotype 1 prior null responders. Brennan, BJ; Gane, EJ; Kulkarni, R; Larrey, DG; Le Pogam, S; Morcos, PN; Nájera, I; Petric, R; Rouzier, R; Shulman, NS; Smith, P; Tran, JQ; Wiercinska-Drapalo, A; Yetzer, ES; Zhang, Y, 2014)	0.4
" These results suggested that the side-effect profiles differed among the various IFNs."	( [Comparative study of the time period between the initiation of various interferon therapies and the onset of suicide- or diabetes-related side effect]. Kobayashi, T, 2013)	0.39
"In a dose of 400 mg once daily, the drug has been safe and generally well tolerated with most adverse reactions attributable to the concurrent use of ribavirin or peginterferon plus ribavirin."	( Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Koff, RS, 2014)	0.4
" These combinations significantly increase sustained virological response (SVR) rates, but they also increase the rates of adverse events (AEs)."	( Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Ridruejo, E, 2014)	0.4
"Every patient will experience adverse effects to differing degrees; a systematic approach to their management can be very helpful."	( Safety of direct-acting antivirals in the treatment of chronic hepatitis C. Ridruejo, E, 2014)	0.4
" During treatment, there were no adverse reactions such as dizziness, vomiting, and notable decreases in hemoglobin, white blood cells, and platelets in the two groups."	( [Efficacy and safety of ribavirin aerosol in children with hand-foot-mouth disease]. Cai, K; Chen, YH; Qian, JH; Wang, L; Yu, HJ; Zhang, HP; Zhang, QL, 2014)	0.4
" With low dosage and few adverse reactions, it holds promise for clinical application."	( [Efficacy and safety of ribavirin aerosol in children with hand-foot-mouth disease]. Cai, K; Chen, YH; Qian, JH; Wang, L; Yu, HJ; Zhang, HP; Zhang, QL, 2014)	0.4
" As transplant community identified HCV viral clearance as a critical matter, efficacious and safe anti-HCV therapies are awaited."	( Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial. Brambilla, N; Bringiotti, RS; Castellaneta, A; Castellaneta, NM; D'Amato, M; Di Leo, A; Giacovelli, G; Rendina, M; Rizzi, SF; Rovati, L; Zappimbulso, M, 2014)	0.4
" Treatment discontinuation due to adverse effects and the development of bacterial infection did not differ between the Spx and non-Spx/TCP groups."	( Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis. Akahoshi, T; Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Maehara, Y; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y, 2014)	0.4
" The occurrence of adverse effects was assessed during treatment and follow up."	( Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. Abdel-Aty, EF; Abdel-Ghaffar, AY; Abdel-Ghaffar, TY; Allam, AA; Behairy, BE; Ehsan, NA; El Naghi, S; El-Araby, HA; El-Guindi, MA; El-Hennawy, AM; El-Karaksy, H; El-Raziky, MS; El-Sebaie, H; Helmy, H; Sira, MM, 2014)	0.4
" Only mild reversible adverse effects were observed and children tolerated the treatment well."	( Safety and efficacy of Hansenula-derived PEGylated-interferon alpha-2a and ribavirin combination in chronic hepatitis C Egyptian children. Abdel-Aty, EF; Abdel-Ghaffar, AY; Abdel-Ghaffar, TY; Allam, AA; Behairy, BE; Ehsan, NA; El Naghi, S; El-Araby, HA; El-Guindi, MA; El-Hennawy, AM; El-Karaksy, H; El-Raziky, MS; El-Sebaie, H; Helmy, H; Sira, MM, 2014)	0.4
"Interferon-beta plus ribavirin therapy was safe in elderly patients, with lower proportions of patients with a dose reduction of interferon-beta or ribavirin and treatment discontinuation."	( Interferon-beta plus ribavirin therapy can be safely and effectively administered to elderly patients with chronic hepatitis C. Miyagi, Y; Nomura, H; Tanimoto, H; Yamashita, N, 2014)	0.4
" A high rate of serious adverse events (N = 30) was observed in 22 patients including 2 fatalities in cirrhotic diabetes patients."	( Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection. Degen, O; Eißing, F; Hennigs, A; Hertling, S; Hüfner, A; Jordan, S; Lohse, AW; Lüth, S; Röder, C; Schmiedel, S; Schulze zur Wiesch, J; Sterneck, M; van Lunzen, J; Wehmeyer, MH, 2014)	0.4
"The results of this meta-analysis suggest that Peg-IFN plus RBV is effective and safe for HCV-6 patients."	( Efficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis. Hu, H; Liu, F; Ren, H; Wang, X; Wei, F, 2014)	0.4
" Anticipating the adverse events of PIs, informing patients about their risk and manage them appropriately and efficiently is important for safe and successful treatment outcome."	( [Management of side effects induced by antiviral therapy for chronic hepatitis infection]. Smolić, M; Smolić, R; Vcev, A, 2013)	0.39
" A high rate of serious adverse events (28%) was documented during treatment."	( Limited effectiveness and safety profile of protease inhibitor-based triple therapy against chronic hepatitis C in a real-world cohort with a high proportion of advanced liver disease. Cornberg, M; Deterding, K; Höner Zu Siederdissen, C; Maasoumy, B; Manns, MP; Markova, AA; Port, K; Rogalska-Taranta, M; Wedemeyer, H, 2014)	0.4
" Adverse effects such as tuberculosis, anemia, and cardiac failure resulting in discontinuation of therapy were seen in three."	( Efficacy and safety of hepatitis C antiviral therapy in moderate and severe chronic kidney disease. Abraham, P; Alagammai, PL; Basu, G; Goel, A; Mahajan, R; Ramachandran, J; Sivakumar, J; Tamilarasi, V, 2014)	0.4
"5% of patients (n = 62) reported at least one serious adverse events (SAEs) (total SAEs = 103)."	( Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. Arenas, JI; Bárcena, R; Buti, M; Calleja, JL; Crespo, J; de la Revilla, J; Delgado, M; Fernández-Rodríguez, CM; Forns, X; Gea, F; Larrubia, JR; Navarro, JM; Pascasio, JM; Pérez-Álvarez, R; Planas, R; Romero-Gómez, M; Ruiz-Antorán, B; Solá, R; Sousa, JM, 2015)	0.42
"The aim of the study was to analyze the incidence, management and cost associated to hematological and dermatological adverse effects (AE) in chronic hepatitis C patients on triple therapy (TT) with telaprevir (TVR) or boceprevir (BOC)."	( [Incidence, management and costs of adverse effects in chronic hepatitis C patients on triple therapy with telaprevir or boceprevir: first 12 weeks of treatment]. Climente-Martí, M; Gómez-Álvarez, S; Guglieri-López, B; Ventura-Cerdá, JM, 2015)	0.42
"In conclusion, substantial dose reduction and daily administration of low doses of TAC compose a safe and efficient immunosuppressive regimen during TVR-based triple therapy."	( Daily low-dose tacrolimus is a safe and effective immunosuppressive regimen during telaprevir-based triple therapy for hepatitis C virus recurrence after liver transplant. Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J, 2015)	0.42
" Adjusting the TVR starting dose may reduce these adverse effects."	( Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate. Anan, A; Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kitamura, Y; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takata, K; Takeyama, Y; Tanaka, T; Tsuchiya, N; Watanabe, H; Yokoyama, K; Yoshikane, M; Yotsumoto, K, 2015)	0.42
"Adjusting the TVR starting dose according to the TVR/unadjusted eGFR ratio decreased adverse effects and affected the SVR rate."	( Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate. Anan, A; Fukunaga, A; Hirano, G; Irie, M; Iwashita, H; Iwata, K; Kitamura, Y; Kunimoto, H; Kuno, S; Morihara, D; Nishizawa, S; Sakisaka, S; Sakurai, K; Shakado, S; Sohda, T; Takata, K; Takeyama, Y; Tanaka, T; Tsuchiya, N; Watanabe, H; Yokoyama, K; Yoshikane, M; Yotsumoto, K, 2015)	0.42
" They were divided into group A (age: <65 years; n = 21) and group B (age: ≥65 years; n = 14) in order to compare the treatment completion rate, sustained virological response at week 24 (SVR24), and adverse events between the groups."	( Efficacy and safety of telaprevir-based antiviral treatment for elderly patients with hepatitis C virus. Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kouno, M; Kudo, M; Minami, Y; Takita, M; Ueshima, K; Yada, N, 2014)	0.4
" Sofosbuvir-based combinations are safe and well tolerated without side effects directly related to the drug."	( Overall efficacy and safety results of sofosbuvir-based therapies in phase II and III studies. Mangia, A; Piazzolla, V, 2014)	0.4
" No patient discontinued due to an adverse event or laboratory abnormality."	( Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E, 2015)	0.42
" Adverse events reported in more than 10% of patients were fatigue (66 patients, 26% [95% CI 21-32]), headache (58 patients, 23% [95% CI 18-29]), and asthenia (35 patients, 14% [95% CI 10-19])."	( Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous Alric, L; Balart, L; Barr, E; Bronowicki, JP; Dutko, F; Gane, E; Ghalib, R; Ghesquiere, W; Guyader, D; Haber, B; Howe, AY; Hwang, P; Lagging, M; Lawitz, E; Lester, L; Pearlman, B; Robertson, M; Shaughnessy, M; Sievert, W; Sund, F; Tam, E; Wahl, J, 2015)	0.42
" The most frequent adverse events in patients with/without cirrhosis were gastrointestinal and skin events, which were mostly mild or moderate in intensity."	( Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. Angus, P; Asselah, T; Böcher, W; Bourlière, M; Bronowicki, JP; Buti, M; Gallivan, JP; Gane, EJ; Lohse, AW; Manns, M; Mensa, FJ; Müllhaupt, B; Roberts, S; Sabo, JP; Schuchmann, M; Soriano, V; Stern, JO; Stickel, F; Voss, F; Zeuzem, S, 2015)	0.42
" Adverse events (AEs) were mainly grade 1/2; serious AEs were infrequent (4."	( Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. Beumont, M; Bourgeois, S; Fevery, B; Francque, S; Grange, JD; Hezode, C; Jessner, W; Lenz, O; Marcellin, P; Moreno, C; Ouwerkerk-Mahadevan, S; Peeters, M; Samuel, D; Shukla, U; Zoulim, F, 2015)	0.42
" Comparison of ivermectin and ribavirin showed that ivermectin was safe at 50μg/ml and lower concentrations."	( Evaluation of cytotoxicity and antiviral activity of ivermectin against Newcastle disease virus. Anjum, AA; Ashraf, M; Azeem, S; Hameed, R; Rasheed, MA, 2015)	0.42
" No adverse effect due to PSE pretreatment was found in any patients."	( Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C. Abe, H; Aizawa, Y; Atsukawa, M; Fukuda, T; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Matsushita, Y; Nakagawa, A; Nakatsuka, K; Sakamoto, C; Shimada, N; Tsubota, A, 2015)	0.42
"PSE, in conjunction with triple combination therapy, is a useful and safe method to treat genotype 1b chronic hepatitis C patients with hypersplenism-induced thrombocytopenia."	( Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C. Abe, H; Aizawa, Y; Atsukawa, M; Fukuda, T; Itokawa, N; Iwakiri, K; Kawamoto, C; Kondo, C; Matsushita, Y; Nakagawa, A; Nakatsuka, K; Sakamoto, C; Shimada, N; Tsubota, A, 2015)	0.42
" Unfortunately, anemia remains a common adverse effect."	( Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K, 2015)	0.42
" Moreover, ITPA genotype and age may be useful for individualizing treatment to reduce the risk of anemia-related adverse effects."	( Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K, 2015)	0.42
"There is little information regarding the incidence of bacterial infections as an adverse effect of telaprevir (TVR)-based triple therapy."	( Bacterial infection as an adverse effect of telaprevir-based triple therapy for chronic hepatitis C infection. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y, 2015)	0.42
" Commonly observed adverse drug reactions included fever, hair fall, fatigue, anemia, and diarrhea."	( Safety and efficacy of Qurse-e-istisqua in chronic hepatitis C infection: an exploratory study. Aslam, M; Chopra, D; Manak, S; Rehan, HS; Siddiqui, KM; Wardhan, N; Yadav, M, )	0.13
" One patient discontinued LDV-SOF because of an adverse event (AE)."	( Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S, 2015)	0.42
"This analysis suggests that 12 weeks of LDV-SOF is safe and effective for treatment-naïve patients with HCV genotype 1 and compensated cirrhosis."	( Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Afdhal, N; Bourlière, M; Ding, X; Dvory-Sobol, H; Feld, JJ; Gane, E; Hyland, R; Knox, S; Lawitz, E; Mangia, A; Marcellin, P; McHutchison, JG; Mizokami, M; Omata, M; Pang, P; Pol, S; Reddy, KR; Subramanian, GM; Sulkowski, M; Symonds, W; Welzel, TM; Yang, J; Zeuzem, S, 2015)	0.42
" The occurrence of anemia and hyperamylasemia was associated with SFTS patients receiving ribavirin therapy, which might be adverse event of this drug administration."	( Common adverse events associated with ribavirin therapy for Severe Fever with Thrombocytopenia Syndrome. Cao, WC; Cui, N; Fan, YD; Guo, CT; Hu, JG; Liu, W; Lu, QB; Qin, SL; Wang, HY; Wang, LY; Yang, ZD; Zhang, SY; Zhang, XA, 2015)	0.42
" Sustained virologic response 12 weeks after the scheduled end of therapy date (SVR12) and the rate of discontinuations due to adverse events (AE) were evaluated."	( Boceprevir or Telaprevir Based Triple Therapy against Chronic Hepatitis C in HIV Coinfection: Real-Life Safety and Efficacy. Bhagani, S; Collado, A; de Los Santos-Gil, I; Delgado, M; Fehr, J; Haberl, A; López-Cortés, LF; Lutz, T; Mandorfer, M; Márquez, M; Mauss, S; Munteanu, DI; Neukam, K; Pineda, JA; Rivero, A; Rivero-Juárez, A; Rockstroh, JK; Scholten, S; Stoeckle, M, 2015)	0.42
" We analyzed treatment-emergent adverse events (AEs) and laboratory abnormalities in patients who were randomized to 8, 12, and 24 weeks of LDV/SOF with or without RBV."	( Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Afdhal, N; Alqahtani, SA; Ding, X; Fried, M; Gordon, SC; Kowdley, KV; Kwo, P; Mangia, A; Marcellin, P; McHutchison, JG; Pang, PS; Pound, D; Reddy, KR; Sulkowski, M; Yang, JC; Zeuzem, S, 2015)	0.42
"8%) discontinued treatment due to adverse events."	( Efficacy and safety of low accelerating dose regimen of interferon/ribavirin antiviral therapy in patients with hepatitis C virus recurrence after liver transplantation. Gao, Y; Li, H; Liu, Z; Su, H; Sun, Y; Tang, R; Zhang, D; Zhang, M; Zhou, S; Zhou, X, 2015)	0.42
" 1%), adverse events (AEs) requiring hospitalization (22% vs."	( Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Dasgupta, A; Nyberg, A; Nyberg, L; Pauly, M; Piasecki, B; Ready, J; Redd, J; Saxena, V; Terrault, NA; Winston, B, 2015)	0.42
" Frequency of adverse safety outcomes were similar to matched untreated controls, suggesting that safety events reflect the natural history of cirrhosis and are not related to treatment."	( Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Dasgupta, A; Nyberg, A; Nyberg, L; Pauly, M; Piasecki, B; Ready, J; Redd, J; Saxena, V; Terrault, NA; Winston, B, 2015)	0.42
" Adverse events included eye stye, insomnia, and pain from an infiltrated intravenous line."	( Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ, 2015)	0.42
" The incidence of adverse effects, such as anemia, severe rash, and the elevation of serum creatinine, was markedly higher in the telaprevir group."	( Comparative effectiveness and safety study of triple therapy with simeprevir or telaprevir for non-cirrhotic patients with chronic hepatitis C virus genotype 1b infection. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K, 2015)	0.42
" DCV + ASV had lower adverse events rates than comparators."	( Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection. Behl, AS; Betts, KA; Kalsekar, A; Li, J; Signorovitch, JE; Song, Y; Sorg, RA, 2015)	0.42
" Interferon-based treatments are associated with a high incidence of adverse effects."	( Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment. Faus, MJ; Gallego, A; Guardiola, JM; Mangues, MA; Masip, M; Pagès, N; Torras, X; Tuneu, L, 2015)	0.42
"The aim of the study was to evaluate neuropsychiatric adverse effects of interferon-based treatment for chronic hepatitis C in standard multidisciplinary clinical practice."	( Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment. Faus, MJ; Gallego, A; Guardiola, JM; Mangues, MA; Masip, M; Pagès, N; Torras, X; Tuneu, L, 2015)	0.42
"Neuropsychiatric adverse effects were evaluated in relation to severity, management and outcome."	( Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment. Faus, MJ; Gallego, A; Guardiola, JM; Mangues, MA; Masip, M; Pagès, N; Torras, X; Tuneu, L, 2015)	0.42
" During treatment, we detected 1679 neuropsychiatric adverse effects in 618 patients (86."	( Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment. Faus, MJ; Gallego, A; Guardiola, JM; Mangues, MA; Masip, M; Pagès, N; Torras, X; Tuneu, L, 2015)	0.42
"Neuropsychiatric adverse effects during interferon-based treatments in patients with chronic hepatitis C were common but mostly mild or moderate."	( Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment. Faus, MJ; Gallego, A; Guardiola, JM; Mangues, MA; Masip, M; Pagès, N; Torras, X; Tuneu, L, 2015)	0.42
" However, the treatment may be associated with important adverse effects and a high economic impact."	( [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice]. Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M, 2015)	0.42
" We evaluated sustained virological response, the cost per patient achieving sustained virological response, and the cost of the supportive treatment for adverse events associated with triple therapy."	( [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice]. Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M, 2015)	0.42
" Due to adverse events, 8 (13."	( [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice]. Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M, 2015)	0.42
" Due to adverse events, a high number of patients required supportive care, whose costs should be added to those of triple therapy."	( [Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice]. Clemente-Ricote, G; García-González, X; Giménez-Manzorro, Á; Ochoa-Palominos, A; Rodríguez-González, CG; Sanjurjo-Sáez, M, 2015)	0.42
" Treatment was well tolerated overall with more than one-half (57%) reporting no adverse events."	( Safety and efficacy of simeprevir plus sofosbuvir with or without ribavirin in patients with decompensated genotype 1 hepatitis C cirrhosis. Barnes, M; Gautam, M; Gonzalez, S; Habib, A; Mantry, P; McAfee, J; Modi, AA; Nazario, H; Teachenor, O; Trotter, JF; Tujague, L; Weinstein, J, 2016)	0.43
" Fever was the most frequently reported side effect occurring in 98."	( Safety and Efficacy of Combined Treatment with Pegylated Interferon Alpha-2b and Ribavirin for HCV Genotype 4 in Children. Besheer, M; El-Karaksy, HM; El-Raziky, MS; Mogahed, EA; Mubarak, S; Saleh, D, 2016)	0.43
" Correction of adverse events was held lower dosages of interferon and/or ribavirin."	( [Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C]. Gusev, DA; Kozlov, KV; Shakhmanov, DM; Shishkin, MK; Sukachev, VS; Zhabrov, SS; Zhdanov, KV, 2015)	0.42
" Sustained virological response at 12 weeks, treatment-emergent adverse events (AEs), and graded laboratory abnormalities were analyzed according to age group."	( Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Afdhal, NH; Eggleton, E; Knox, SJ; Kowdley, K; Mangia, A; Mizokami, M; Omata, M; Pang, P; Park, SH; Saab, S; Subramanian, M; Zhu, Y, 2016)	0.43
" This study aimed to compare severe adverse events (SAEs) amongst therapeutic combinations for HCV in a community clinic setting."	( Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ, 2016)	0.43
" Adverse events were recorded from baseline to 12 or 24 weeks of treatment."	( Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ, 2016)	0.43
" Conversely, sofosbuvir plus simeprevir reached similar SVR rates at week 12 post-treatment compared to all ribavirin-containing regimens, but with significantly fewer adverse events (P = 0."	( Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience. Chang, PW; Huynh, TT; Rosinski, AA; Tong, LT; Tong, MJ, 2016)	0.43
"The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions."	( Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ, 2015)	0.42
" Only five patients (20%) experienced minor adverse events, including grade 1 fatigue and headache."	( Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ, 2015)	0.42
"In a real clinical practice, sofosbuvir-based therapy for CHC patients in Korea achieved optimal antiviral efficacy with insignificant adverse events."	( Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea. Cho, EJ; Cho, Y; Kim, YJ; Lee, JH; Yoon, JH; Yu, SJ, 2015)	0.42
" In this pharmacokinetic study, sofosbuvir full dose (400mg once daily) administered every day with another direct antiviral agent did not accumulate in hemodialysis patients and was safe and effective."	( Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D, 2016)	0.43
" Cases were patients who experienced hepatic decompensation and/or serious adverse events (SAE) during or within one month of completing treatment."	( Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus. Agarwal, R; Ahmad, J; Bach, N; Bansal, M; Bichoupan, K; Branch, A; Chang, C; Dieterich, D; Friedman, S; Gardenier, D; Grewal, P; Harty, A; Im, G; Khaitova, V; Kim-Schluger, L; Ku, L; Leong, J; Liu, L; Motamed, D; Ng, M; Odin, J; Patel, N; Perumalswami, P; Schiano, T; Yalamanchili, R, 2016)	0.43
" In orthotopic liver transplantation (OLT) recipients, the interferon-free treatment of HCV re-infection with novel direct-acting antivirals has been demonstrated to be safe and effective in clinical trials, but real-world data are missing."	( Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Ciesek, S; Costa, R; Klempnauer, J; Lohse, AW; Lüthgehetmann, M; Manns, MP; Mix, H; Nashan, B; Otto, B; Pischke, S; Polywka, S; Proske, V; Sterneck, M; von Hahn, T; Wedemeyer, H, 2016)	0.43
" Regarding safety, adverse events and serious adverse events were more frequently reported in patients taking concomitant ARAs, though baseline population differences may have played a role."	( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML, 2016)	0.43
" HCV treatment was discontinued for adverse events in 17% of patients."	( Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. Alric, L; Bellissant, E; Bourlière, M; Carrieri, P; Colson, P; Garraffo, R; Ghosn, J; Halfon, P; Molina, JM; Naqvi, A; Piroth, L; Poizot-Martin, I; Renault, A; Solas, C, 2016)	0.43
" Skin eruptions and isolated cases of severe cutaneous adverse reactions (SCAR) have been reported."	( [Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study]. Botta, D; Gaudy-Marqueste, C; Grob, JJ; Lorcy, S; Mancini, J; Oulies, V; Portal, I; Quiles, N; Richard, MA, 2016)	0.43
"Our aim was to assess the incidence of skin eruption and the clinical characteristics of mucocutaneous adverse events (AE), and to identify potential risk factors for telaprevir-associated skin eruption."	( [Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study]. Botta, D; Gaudy-Marqueste, C; Grob, JJ; Lorcy, S; Mancini, J; Oulies, V; Portal, I; Quiles, N; Richard, MA, 2016)	0.43
" There were no serious adverse events (AEs), discontinuations due to AEs or grade 3/4 elevations in total and/or direct bilirubin."	( Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1 infection. Baruch, Y; Ben Ari, Z; Bhanja, S; Bruck, R; Gane, E; Howe, AY; Hwang, P; Mollison, L; Robertson, MN; Wahl, J; Zhao, Y; Zuckerman, E, 2016)	0.43
" Patients with GT3 HCV were analyzed to assess predictors of treatment response and adverse events using descriptive statistics and multivariable logistic regression."	( Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study. Akushevich, L; Di Bisceglie, AM; Feld, JJ; Frazier, LM; Fried, MW; Kuo, A; Maan, R; Mailliard, M; Manns, MP; Nelson, DR; Schmidt, M; Sherman, K; Sterling, R; Vainorius, M; Zeuzem, S, 2016)	0.43
" Therefore, rOC43-ns2DelRluc represents a promising safe and sensitive platform for high-throughput antiviral screening and quantitative analysis of viral replication."	( Safe and Sensitive Antiviral Screening Platform Based on Recombinant Human Coronavirus OC43 Expressing the Luciferase Reporter Gene. Desforges, M; Liu, G; Shen, L; Talbot, PJ; Tan, W; Yang, Y; Ye, F, 2016)	0.43
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."	( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships. Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016)	0.43
" Adverse events were reported in 11 patients (46%) and were managed clinically without discontinuation of therapy."	( Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection. Amundsen, BM; Chandraker, A; Chung, RT; Chute, D; Curry, MP; Elias, N; Gabardi, S; Hanifi, JM; Heher, EC; Lin, MV; Pavlakis, M; Riella, LV; Rutherford, AE; Sise, ME, 2016)	0.43
" Common adverse events (AEs) included fatigue, anaemia, nausea, headache, insomnia, rash and flu-like symptoms."	( Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Akushevich, L; Alqahtani, S; Darling, J; Di Bisceglie, A; Frazier, LM; Fried, MW; Galati, JS; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Pockros, P; Reddy, RK; Sulkowski, MS; Vainorius, M; Welzel, TM; Zeuzem, S, 2017)	0.46
"In this clinical practice setting, SOF and RBV was safe and effective for treatment of patients with HCV GT2 infection."	( Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study. Akushevich, L; Alqahtani, S; Darling, J; Di Bisceglie, A; Frazier, LM; Fried, MW; Galati, JS; Kuo, A; Lim, JK; Morelli, G; Nelson, DR; Pockros, P; Reddy, RK; Sulkowski, MS; Vainorius, M; Welzel, TM; Zeuzem, S, 2017)	0.46
" Safety outcomes were presented by the incidence of adverse events."	( Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice. Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C, 2016)	0.43
" Adverse events occurred in 91."	( Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice. Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C, 2016)	0.43
" Combination of peginterferon/ribavirin with first generation direct acting antivirals is less effective and associated with serious adverse events."	( von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. Etschmaier, A; Ferenci, P; Ferlitsch, A; Ferlitsch, M; Hametner, S; Hofer, H; Horvatits, T; Maieron, A; Paternostro, R; Peck-Radosavljevic, M; Quehenberger, P; Reiberger, T; Rutter, K; Salzl, P; Trauner, M, 2016)	0.43
" The combination of elbasvir/grazoprevir also demonstrated a superior safety and tolerability profile based on fewer serious adverse events, no serious drug-related adverse events, and no treatment discontinuations."	( Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial. Asante-Appiah, E; Barr, E; Flisiak, R; Gerstoft, J; Halota, W; Horvath, G; Jancoriene, L; Kazenaite, E; Kileng, H; Koklu, S; Leiva, R; Nguyen, BY; Patel, S; Platt, HL; Prinzing, R; Qiu, J; Ruiz-Tapiador, JA; Sperl, J; Streinu-Cercel, A; Urbanek, P; Wahl, J; Werling, K, 2016)	0.43
" Interferon-based hepatitis C virus (HCV) therapy is safe and effective among people receiving opioid substitution therapy (OST), but treatment uptake remains low."	( Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y, 2016)	0.43
"28), and serious adverse events (4% vs 3%; P = ."	( Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials. Brainard, DM; Bronowicki, JP; Brown, A; Carr, V; Dore, GJ; Grebely, J; Kreter, B; Mauss, S; Natha, M; Puoti, M; Wyles, D; Yang, J; Yun, C; Zhu, Y, 2016)	0.43
" Therapy was discontinued because of severe adverse events (SAEs) in 39% of cases and virological inefficacy in 24%."	( Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT). Alric, L; Anty, R; Beaulieux, F; Botta-Fridlund, D; Bouix, C; Canva, V; Carrieri, MP; Conti, F; D'Alteroche, L; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fontaine, H; Lebray, P; Leroy, V; Maynard, M; Métivier, S; Pageaux, GP; Paul, C; Petrov-Sanchez, V; Pradat, P; Roche, B; Roque-Afonso, AM; Samuel, D; Vilotitch, A; Wellems, C, 2017)	0.46
" Adverse events occurred in 151 (72."	( Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study. Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D, 2016)	0.43
" The primary outcome measures were the sustained virological response weeks 12 (SVR12) post-treatment and adverse events (AEs)."	( Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis. He, QF; Zhang, DZ; Zhang, QF, 2016)	0.43
"This study compares the safety profiles of pegylated interferon (PEG-IFN) α-2a and α-2b administered in combination with ribavirin, based on the variable of time to withdrawal from treatment due to adverse events."	( Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study. Hawke, P; Ide, K; Imai, T; Kawasaki, Y; Masaki, N; Sato, I; Yamada, H, 2016)	0.43
"Excellent SVR12 rates and the favorable side-effect profile of DAA-combination therapy can be well translated into "real-world"."	( Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12. Beck, R; Berg, CP; Egetemeyr, DP; Lauer, UM; Malek, NP; Schwarz, JM; Werner, CR, 2016)	0.43
" Among the side effects of this therapy, alopecia universalis is a rarely reported side effect which causes significant cosmetic concern to the patient."	( Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report. Amrani, A; Dayal, S; Jain, VK; Verma, P, 2017)	0.46
" The most common adverse event (AE) in elderly patients was a grade 2 anaemia (35."	( Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P, 2017)	0.46
"Sofosbuvir/simeprevir plus a daily flat dose of RBV 800 mg for 12 weeks was highly effective and safe in genotype 1 elderly patients with compensated cirrhosis."	( Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Ascione, A; Barbarini, G; Ceccherini-Silberstein, F; D'Ambrosio, C; Ettorre, GM; Fondacaro, L; Giannelli, V; Ialongo, P; Izzi, A; Marignani, M; Messina, V; Moretti, A; Pace Palitti, V; Pellicelli, AM; Perno, CF; Sacco, R; Scifo, G; Siciliano, M; Tarquini, P; Vignally, P, 2017)	0.46
" The most common adverse effect was anemia (hemoglobin <10 g/dL), especially for patients aged ≥ 65 with the inosine triphosphate pyrophosphatase CC genotype at rs1127354 (26."	( Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Higashi, N; Kajiwara, E; Kato, M; Kawano, A; Koyanagi, T; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K, 2016)	0.43
" Secondary end-points of the study include SVR 4, virological relapse and appearance of adverse events."	( Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort. Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R, 2016)	0.43
"9 %) patients reported adverse events during the course of sofosbuvir-based treatment."	( Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort. Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R, 2016)	0.43
"Sofosbuvir-based treatment is safe and efficacious in clinical practice in Indian patients with HCV genotype-1 and genotype-3 infection."	( Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort. Bhayani, V; Kabrawala, M; Mehta, R; Nandaniya, P; Nandwani, S; Shah, M; Tekriwal, R, 2016)	0.43
" Nine patients (15%) had ≥ 1 drug-related serious adverse event and 7 (11%) discontinued all study drugs due to an adverse event."	( Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Brown, KA; Brown, RS; Fontana, RJ; Levitsky, J; Rubin, RA; Russo, MW; Vargas, H; Yoshida, EM, 2018)	0.48
" Adverse events were similar to, but exceeded, those in immunocompetent patients."	( Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Brown, KA; Brown, RS; Fontana, RJ; Levitsky, J; Rubin, RA; Russo, MW; Vargas, H; Yoshida, EM, 2018)	0.48
"Paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin is effective and safe in patients with genotype 1 HCV infection in real-life clinical setting in Hong Kong."	( Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong. But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF, 2017)	0.46
" We included in the analysis demographic, clinical, and virologic data and details of serious adverse events (SAEs), including mortality rate 6 months after treatment."	( Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Castells, L; Fernandez Vazquez, I; Herrero, JI; Londoño, M; Narvaez Rodriguez, I; Otero, A; Pascasio, JM; Prieto, M; Sanchez Antolin, G; Testillano, M, 2016)	0.43
"3%) had serious adverse events, including three deaths (1."	( Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. Alonso, S; Ampuero, J; Badia, E; Baliellas, C; Buti, M; Carrión, JA; Castro, Á; Devesa, MJ; Esteban, R; Fernandez, I; Fernandez-Carrillo, C; Fernández-Rodríguez, CM; Gea, F; Gómez, A; Granados, R; Lens, S; Llerena, S; Montero, JL; Olveira, A; Pascasio, JM; Planas, JM; Polo, B; Real, Y; Rincón, D; Riveiro-Barciela, M; Rubín, A; Salmeron, J; Turnes, J, 2017)	0.46
" LDV- SOF plus RBV therapy had significantly higher rate of the overall adverse events (RR=0."	( Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Chen, Y; Jiang, X; Song, Y; Tao, T, 2017)	0.46
"This meta-analysis suggests that LDV-SOF based therapy is a safe and effective treatment for patients with GT 1 HCV."	( Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis. Chen, Y; Jiang, X; Song, Y; Tao, T, 2017)	0.46
" The safety data available for LDV/SOF±RBV and OBV/PTV/r±DSV±RBV show that discontinuation due to adverse events was necessary in no more than 3% of patients and the frequency of serious adverse events was between 0 and 11%, in particular in real-world studies."	( Hepatitis C: efficacy and safety in real life. Flisiak, R; Flisiak-Jackiewicz, M; Pogorzelska, J, 2017)	0.46
" The safety analysis showed more adverse events and a stronger decline of haemoglobin for RBV containing regimens."	( Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Berg, T; Böker, KH; Cornberg, M; Günther, R; Hüppe, D; Link, R; Manns, MP; Mauss, S; Niederau, C; Petersen, J; Pfeiffer-Vornkahl, H; Sarrazin, C; Schober, A; Serfert, Y, 2017)	0.46
" The most common adverse events (AEs) were rash and/or pruritus (23."	( Safety and effectiveness of a 12-week course of sofosbuvir and simeprevir ± ribavirin in HCV-infected patients with or without HIV infection: a multicentre observational study. Angarano, G; Bruno, G; Buccoliero, G; Dell'Acqua, R; Fabrizio, C; Fasano, M; Giammario, A; Ladisa, N; Milano, E; Milella, M; Minniti, S; Saracino, A; Scudeller, L; Tartaglia, A, 2017)	0.46
" The primary endpoint was dropout from treatment due to adverse events during the relevant standard treatment duration based on guidelines from the Japan Society of Hepatology."	( The Safety Profile of Telaprevir-Based Triple Therapy in Clinical Practice: A Retrospective Cohort Study. Ide, K; Iketani, R; Kawasaki, Y; Masaki, N; Yamada, H, 2017)	0.46
" No deaths, serious adverse events (AEs), Grade 4 AEs or AEs leading to treatment discontinuation occurred."	( Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection. Arastéh, K; Bourgeois, S; Buggisch, P; Francque, S; Hoeben, E; Horsmans, Y; Jacquemyn, B; Kakuda, TN; Luo, D; Moreno, C; Nevens, F; Orlent, H; Schattenberg, JM; Van Remoortere, P; Van Vlierberghe, H; Vandebosch, A; Verloes, R; Vijgen, L, 2017)	0.46
" Details of serious adverse events (SAEs) were recorded."	( Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort. Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J, 2017)	0.46
" Serious adverse events were reported in 3% (8 of 264) patients and no patient had a decompensation-related event."	( Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis. Barr, E; Haber, BA; Hézode, C; Howe, AYM; Hwang, P; Jacobson, IM; Kwo, PY; Lawitz, E; Peng, CY; Robertson, M; Wahl, J, 2017)	0.46
" Most common adverse events (AEs) were fatigue, neutropenia, anemia, asthenia and headache."	( Efficacy and safety of daclatasvir plus pegylated-interferon alfa 2a and ribavirin in previously untreated HCV subjects coinfected with HIV and HCV genotype-1: a Phase III, open-label study. Ackerman, P; Berenguer, J; Cheinquer, H; Côté, P; Dieterich, D; Eley, T; Fessel, WJ; Gadano, A; Hernandez, D; Hughes, E; Lazzarin, A; Liu, Z; Matthews, G; McPhee, F; Mendez, P; Molina, JM; Moreno, C; Noviello, S; Pineda, JA; Pulido, F; Rivero, A; Rockstroh, J; Sulkowski, MS; Zakharova, N, 2017)	0.46
"In this study, a nationwide database was used to identify the risk factors for treatment discontinuation due to adverse events during telaprevir, peginterferon, and ribavirin (T/PR) treatment, and estimate the increase in the occurrence of adverse events when patients have multiple risk factors at the same time."	( Risk Factors for Treatment Discontinuation Caused by Adverse Events When Using Telaprevir, Peginterferon, and Ribavirin to Treat Chronic Hepatitis C: A Real-World Retrospective Cohort Study. Ide, K; Iketani, R; Kawasaki, Y; Masaki, N, 2017)	0.46
" Rates of discontinuation due to adverse events (AEs) (3."	( Safety and Efficacy of Pegylated Interferon Lambda, Ribavirin, and Daclatasvir in HCV and HIV-Coinfected Patients. Conway, B; Lazzarin, A; Luetkemeyer, A; Molina, JM; Nelson, M; Portsmouth, S; Romanova, S; Rubio, R; Srinivasan, S; Xu, D, 2017)	0.46
"8%) reporting adverse events."	( Efficacy and Safety of Direct Acting Antivirals for the Treatment of Mixed Cryoglobulinemia. Almarzooqi, S; Emery, JS; Feld, JJ; Janssen, HLA; Kowgier, M; Kuczynski, M; La, D; Shah, H; Wong, D, 2017)	0.46
" The combination was generally well tolerated, with an adverse event profile consistent with that observed in previous clinical trials of SMV or DCV separately."	( Efficacy, safety, and pharmacokinetics of simeprevir, daclatasvir, and ribavirin in patients with recurrent hepatitis C virus genotype 1b infection after orthotopic liver transplantation: The Phase II SATURN study. Andreone, P; Berenguer, M; Calleja, JL; Cieciura, T; Donato, MF; Durlik, M; Fagiuoli, S; Forns, X; Herzer, K; Janssen, K; Jessner, W; Kalmeijer, R; Lenz, O; Mariño, Z; Ouwerkerk-Mahadevan, S; Peeters, M; Shukla, U; Sterneck, M; Verbinnen, T, 2017)	0.46
" The therapy was found to be reasonably safe with no major adverse effects noted with the use of sofosbuvir, ledipasvir or daclatasvir."	( Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study. Akhil, MS; Arumugam, K; Ganesh Prasad, NK; Kirushnan, B; Martin, M; Ravichandran, R, 2018)	0.48
" Other correlates with adverse events of clinical importance included concomitant ribavirin treatment, sex, race, and presence of cirrhosis, consistent with previous observations."	( Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies. Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N, 2017)	0.46
" Clinical and laboratory adverse events (AEs) were recorded from baseline to FU12."	( Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study. Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M, 2017)	0.46
" The aim of this study was to compare the efficacy and safety of PrOD-based therapy in hepatitis C genotype 1 patients with and without cirrhosis, and to explore pre-treatment factors predictive of sustained viral response (SVR) and serious adverse events (SAEs) on treatment."	( Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017)	0.46
" Baseline demographic, clinical and laboratory information, on-treatment biochemical, virological and haematological indices and details on serious adverse events were collected locally."	( Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study. Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A, 2017)	0.46
" Although the most frequent adverse event was anemia, no patients discontinued the use of either ribavirin or sofosbuvir."	( Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Abe, H; Arai, T; Atsukawa, M; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kondo, C; Okubo, T; Shimada, N; Tanaka, Y; Tsubota, A, 2017)	0.46
"Treatment with sofosbuvir/ribavirin for genotype 2-infected CHC was effective and safe even for elderly patients, although the incidence of adverse events including ribavirin-related anemia was relatively high."	( Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Abe, H; Arai, T; Atsukawa, M; Iio, E; Itokawa, N; Iwakiri, K; Kato, K; Kondo, C; Okubo, T; Shimada, N; Tanaka, Y; Tsubota, A, 2017)	0.46
" Adverse events were generally mild and transient."	( Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M, 2017)	0.46
"Treatment with LDV/SOF±RBV is an effective and safe option for patients with HCV, including those with advanced liver disease or a history of non-response to PEG-IFN-based therapy."	( Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study. Augustyniak, K; Badurek, A; Baka-Ćwierz, B; Berak, H; Białkowska, J; Flisiak, R; Garlicki, A; Gietka, A; Janczewska, E; Kozielewicz, D; Mazur, W; Mozer-Lisewska, I; Musialik, J; Nowak, K; Olszok, I; Piekarska, A; Pleśniak, R; Sikorska, K; Simon, K; Stolarz, W; Tomasiewicz, K; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D; Łucejko, M, 2017)	0.46
" Combination of Interferon and Ribavirin is the current anti-HCV therapy in practice and is associated with certain hematologic adverse effects."	( Hematologic adverse effects and efficacy monitoring in chronic Hepatitis C patients treated with interferon and ribavirin combination therapy. Ashraf, M; Bukhsh, A; Gul, A; Khiljee, S; Omer, MO; Rafique, G, 2017)	0.46
"To compare the rate of treatment discontinuation due to adverse events for telaprevir-based triple (T/PR) and pegylated interferon-alfa-2b and ribavirin (PR) therapy for the treatment of hepatitis C virus (HCV) infection in patients over the age of 65 years, in Japan."	( Safety Profile of Telaprevir-Based Triple Therapy in Elderly Patients: A Real-World Retrospective Cohort Study. Akutagawa, M; Ide, K; Iketani, R; Kawasaki, Y; Masaki, N; Yamada, H; Yamanaka, M, 2017)	0.46
" The number and percentage of patients with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs consistent with hepatic decompensation were reported."	( Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis. Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H, 2017)	0.46
" Data were analyzed to assess the on-treatment and off-therapy HCV viral load and on-treatment adverse events."	( Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan. Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC, 2018)	0.48
" The primary efficacy endpoint was sustained virologic response 12, whereas the primary safety endpoint was drug discontinuation or occurrence of grade 3/4 adverse events."	( Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection. Alaseeri, A; Albenmousa, A; Albiladi, H; Alghamdi, AS; Aljarodi, M; Almugharbal, M; Alothmani, HS; Alsahafi, A; Babatin, MA; Bzeizi, KI; Sanai, FM, )	0.13
" Adverse events occurred in 32% of patients (grade 1 and 2), but none discontinued treatment."	( Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection. Alaseeri, A; Albenmousa, A; Albiladi, H; Alghamdi, AS; Aljarodi, M; Almugharbal, M; Alothmani, HS; Alsahafi, A; Babatin, MA; Bzeizi, KI; Sanai, FM, )	0.13
"SMV/SOF or DCV/SOF combinations are safe and highly effective in HCV-GT4 treatment."	( Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection. Alaseeri, A; Albenmousa, A; Albiladi, H; Alghamdi, AS; Aljarodi, M; Almugharbal, M; Alothmani, HS; Alsahafi, A; Babatin, MA; Bzeizi, KI; Sanai, FM, )	0.13
" In our study, we will report the real-life experience of serious adverse events (SAEs) that were reported by the National Committee for Control of Viral Hepatitis (NCCVH, Cairo, Egypt) program while treating chronic HCV using the triple therapy, sofosbuvir combined with pegylated interferon and ribavirin (PEG/RIBA/SOF), which led to premature discontinuation of treatment."	( Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. Abdo, M; Abouelkhair, M; Doss, W; Elakel, W; Elbaz, T; Elgarem, N; Elsayed, MH; Elserafy, M; Elshazly, Y; Esmat, G; Gaballa, A; Hassany, M; Mahran, Z; Mehrez, M; Mohey, MA; Omar, A; Waked, I; Yosry, A, 2017)	0.46
" The most common adverse events were headache (143 [22%] of 664), fatigue (129 [19%] of 664), and nausea (83 [13%] of 664)."	( Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, Almasio, PL; Barr, E; Bruno, S; Buti, M; Butterton, JR; Dutko, FJ; Fernsler, D; Gao, W; Grandhi, A; Hassanein, TI; Huang, HC; Jancoriene, L; Lawitz, E; Li, JJ; Liu, H; Muellhaupt, B; Nguyen, BT; Pearlman, B; Plank, RM; Robertson, MN; Ruane, PJ; Shepherd, A; Su, FH; Tannenbaum, B; Vierling, JM; Wahl, J; Wan, S; Yeh, WW; Yoshida, EM, 2017)	0.46
"02), while it increased the risk of serious adverse events (p = 0."	( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis. Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Loutfy, SA; Menshawy, A; Mohamed, A; Negida, A, 2017)	0.46
" No serious adverse events (AEs) were observed."	( Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection. Li, T; Liu, F; Qu, YD; Wang, L; Xue, Y; Zhang, LX, 2017)	0.46
"In our cohort of cirrhotic HCV/HIV-coinfected patients, DAAs were highly safe and efficacious."	( Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. Cairó, M; Carrion, JA; Cifuentes, C; Crespo, M; Cucurull, J; Erice, E; Force, L; Guardiola, JM; Laguno, M; Marco, A; Navarro, J; Roget, M; Vilaró, J; Vilchez, HH, 2017)	0.46
" The safety profile was similar across treatment arms, with adverse events tending to occur more frequently among participants receiving RBV."	( Efficacy and safety of 12 weeks of elbasvir ± grazoprevir ± ribavirin in participants with hepatitis C virus genotype 2, 4, 5 or 6 infection: The C-SCAPE study. Badshah, C; Barr, E; Brown, A; Durkan, C; Foster, GR; Haber, B; Hézode, C; Lahser, F; Roberts, SK; Robertson, M; Wahl, J; Zekry, A; Zhang, B; Zuckerman, E, 2018)	0.48
" All patients reported at least one (serious) adverse event, of which 28% of patients developed anaemia."	( Peg-interferon and ribavirin treatment in HIV/HCV co-infected patients in Thailand: efficacy, safety and pharmacokinetics. Apornpong, T; Avihingsanon, A; Burger, DM; Chaiyahong, P; Chittmittraprap, S; Colbers, A; Cuprasitrut, T; de Kanter, CTMM; Khemnark, S; Smolders, EJ; Tangkijvanich, P; Thammajaruk, N, 2018)	0.48
" Demographic, clinical, adverse event, and virologic data were collected every 12 weeks during treatment and during the follow-up period."	( Safety and Effectiveness of Ledipasvir and Sofosbuvir, With or Without Ribavirin, in Treatment-Experienced Patients With Genotype 1 Hepatitis C Virus Infection and Cirrhosis. Akushevich, L; Ben-Ari, Z; Fried, MW; Gallant, J; Hassan, M; Kuo, A; Landis, CS; Liapakis, AM; Lim, JK; Lok, AS; Michael, L; Nelson, DR; Park, JS; Pockros, PJ; Shiffman, ML; Terrault, NA; Vainorius, M; Zeuzem, S, 2018)	0.48
" The main endpoints were assessment of sustained virological response and serious adverse events rates."	( Effectiveness and safety of original and generic sofosbuvir for the treatment of chronic hepatitis C: A real world study. Bessone, F; Borzi, SM; Cartier, M; D'Amico, C; Descalzi, VI; Fainboim, HA; Figueroa Escuti, S; Frías, S; Gadano, AC; Gaite, LA; Galdame, OA; Haddad, L; Longo, C; Marciano, S; Marino, M; Peralta, M; Perez Ravier, R; Reggiardo, MV; Vistarini, C, 2018)	0.48
" Direct-acting antiviral (DAA) drug regimens are safe and highly effective, allowing administration of treatment also in elderly."	( Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older. Bataga, S; Brisc, C; Caruntu, FA; Chiriac, S; Cijevschi Prelipcean, C; Curescu, M; Gheorghe, L; Girleanu, I; Goldis, A; Iacob, S; Miftode, E; Mihai, C; Preda, C; Rogoveanu, I; Singeap, AM; Sporea, I; Stanciu, C; Stefanescu, G; Trifan, A, 2017)	0.46
"To determine frequency and pattern of adverse events reporting in a subset of Pakistani population being treated for chronic hepatitis C with sofosbuvir combination therapy."	( Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population. Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH, 2018)	0.48
" Patients were screened for subjective as well as objective evidence of adverse events at regular intervals."	( Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population. Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH, 2018)	0.48
"Sofosbuvir showed less severe adverse effects in terms of symptomatology and less frequent neutropenia and thrombocytopenia as compared to previous regimens."	( Sofosbuvir Adverse Events Profile in a Subset of Pakistani Population. Iqbal, S; Raza, A; Yousaf, MI; Yousuf, MH, 2018)	0.48
" Patients were closely monitored for treatment-related adverse effects and the potential need for adjustment in their immunosuppression."	( The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P, 2018)	0.48
"The combination of LED/SOF with RBV for 12 weeks or LED/SOF for 24 weeks is very effective and safe in treating OLT recipients with RHC."	( The safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in the treatment of orthotopic liver transplant recipients with recurrent hepatitis C: real-world data. Fung, P; Lingiah, VA; Punnoose, M; Pyrsopoulos, N; Trilianos, P, 2018)	0.48
" Our aim was to analyze the characteristics associated with the presence of adverse events in patients receiving this antiviral regimen, with ribavirin in cirrhotic patients."	( Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin. Calina, OC; Hristea, A; Jipa, RE; Manea, ED; Olariu, C; Stefan, I, )	0.13
" We recorded 201 adverse events in 98 (71."	( Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin. Calina, OC; Hristea, A; Jipa, RE; Manea, ED; Olariu, C; Stefan, I, )	0.13
"We found a high number of adverse events, but most of them were mild or moderate and only one quarter of them required medical intervention."	( Safety assessment in Child A cirrhotic patients treated with Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin. Calina, OC; Hristea, A; Jipa, RE; Manea, ED; Olariu, C; Stefan, I, )	0.13
" Treatment was well tolerated with 37% reporting no adverse events."	( Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvir. Gonzales, GR; Gonzalez, SA; Modi, AA; Nazario, HE, 2018)	0.48
" The most common adverse events recorded were fatigue, headache, nausea, asthenia, and gastrointestinal troubles."	( Efficacy and safety of sofosbuvir plus daclatasvir with or without ribavirin: large real-life results of patients with chronic hepatitis C genotype 4. Abdel-Gabaar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, MI, 2018)	0.48
"Patients who suffered any adverse event (AE) were 74/240 (30."	( Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL, 2018)	0.48
"Our findings suggest that OBV/PTV/r + DSV + RBV is safe and effective in real-life use in patients with compensated cirrhosis, HCV-GT1 infection, and age over 65."	( Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL, 2018)	0.48
" Other adverse events, including dizziness, indigestion, and headache, were found in 26 (16."	( Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study. Chae, HB; Jang, JW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Kim, YM; Ko, SY; Lee, BS; Lee, JD; Lee, SH; Lee, TH; Song, IH; Song, MJ, 2018)	0.48
" Adverse events leading to treatment discontinuations were not observed."	( Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study. Aghemo, A; Brancaccio, G; D'Offizi, G; Gaeta, GB; Giorgini, A; Hasson, H; Menzaghi, B; Palma, M; Termini, R, 2018)	0.48
" However, information about the rate of adverse events (AEs) across different DAA regimens is limited."	( Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study. Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N, 2018)	0.48
" One patient had three serious adverse events, which were considered to be not related to study treatment: tooth abscess, abdominal pain, and gastroenteritis."	( Safety and Efficacy of Ledipasvir-Sofosbuvir With or Without Ribavirin for Chronic Hepatitis C in Children Ages 6-11. Arnon, R; Balistreri, WF; Bansal, S; Brainard, DM; Evans, HM; Garrison, KL; Gillis, LA; Gonzalez-Peralta, RP; Jonas, MM; Kersey, K; Lin, CH; Massetto, B; Murray, KF; Narkewicz, MR; Parhy, B; Rosenthal, P; Schwarz, K; Shao, J; Wen, J; Whitworth, S, 2018)	0.48
" As advanced age is associated with increasing risk of development of cirrhosis and hepatocellular carcinoma, elderly patients are in special need of safe and effective antiviral therapies."	( Efficacy and safety of sofosbuvir and daclatasvir with or without ribavirin in elderly patients with chronic hepatitis C virus infection. Abdel-Samiee, M; Abdo, M; Elbaz, T; Esmat, G; Gamil, M; Hassan, EA; Moustafa, A; Omar, H; Qawzae, A; Zaghloul, AM, 2019)	0.51
" Most adverse events (AEs) were consistent with clinical sequelae of advanced liver disease or known toxicities of ribavirin."	( Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial. Brainard, DM; Chayama, K; De-Oertel, S; Dvory-Sobol, H; Ikeda, F; Kanda, T; Kurosaki, M; Matsuda, T; Mita, E; Nishiguchi, S; Sakamoto, M; Sakamoto, N; Stamm, LM; Takehara, T; Takikawa, Y; Tamori, A; Tanaka, Y; Tatsumi, T; Ueno, Y; Yatsuhashi, H; Zhang, G, 2019)	0.51
" No serious adverse effects like anemia and decompensation were reported."	( Direct-acting antiviral Therapy Is Safe and Effective in Pediatric Chronic Hepatitis C: The Public Health Perspective. Dhiman, RK; Duseja, A; Grover, GS; Premkumar, M; Rathi, S; Satsangi, S; Taneja, S, 2019)	0.51
" Demographic, clinical and virologic data were analysed, and adverse events (AEs) recorded."	( Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort. Anton, MD; Badia, E; Bonacci, M; Calleja, JL; Carmona, I; Carrión, JA; Castellote, J; Castro Urda, JL; de la Vega, J; Diago, M; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; Gallego, A; García Buey, L; García, ND; García-Samaniego, J; Gea, F; Hernández-Conde, M; Llerena, S; Menéndez, F; Molina, E; Montoliu, S; Moreno-Palomares, JJ; Moreno-Planas, JM; Morillas, RM; Pascasio, JM; Perelló, C; Piqueras Alcol, B; Romero-Gómez, M; Rosales-Zabal, JM; Salmeron, FJ; Sánchez Ruano, JJ; Souto-Rodríguez, R, 2019)	0.51
" Adverse events were recorded for safety analysis."	( Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC, 2019)	0.51
" SOF/DCV/ribavirin regimen resulted in more adverse events, significantly higher bilirubin levels, and decline of hemoglobin during treatment than SOF/DCV regimen."	( Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC, 2019)	0.51
"SOF/DCV with or without ribavirin is highly effective and safe for patients with genotype 2 HCV infection in real-world experience in Taiwan."	( Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan. Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC, 2019)	0.51
" SOF-based therapy was well-tolerated, and no serious adverse events were reported."	( Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study. Chen, B; Chen, EQ; Jiang, W; Tang, H; Tao, YC; Wang, ML; Wang, YH; Wu, DB, 2019)	0.51
" Adverse events were monitored during the treatment period."	( The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. Choe, WH; Kim, AR; Kim, JH; Kwon, SY; Park, SJ; Yoo, BC, 2018)	0.48
" The most common adverse events were anemia, dyspepsia, and insomnia."	( The Efficacy and Safety of Direct-acting Antiviral Treatment for Chronic Hepatitis C Patients: A Single Center Study. Choe, WH; Kim, AR; Kim, JH; Kwon, SY; Park, SJ; Yoo, BC, 2018)	0.48
" A total of 4 serious adverse events were reported and considered treatment-unrelated."	( Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. Chen, DS; Chen, PJ; Cheng, PN; Chien, RN; Chuang, WL; Hsu, SJ; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Lin, CY; Liu, CH; Liu, CJ; Peng, CY; Su, CW; Yu, ML, 2019)	0.51
"Truncated regimen of DCV + ASV plus ribavirin for 12 weeks was highly effective and safe in HCV-1b patients without NS5A L31/Y93 RAS."	( Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. Chen, DS; Chen, PJ; Cheng, PN; Chien, RN; Chuang, WL; Hsu, SJ; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Lin, CY; Liu, CH; Liu, CJ; Peng, CY; Su, CW; Yu, ML, 2019)	0.51
" The treatment discontinuation rate due to adverse events (AEs) and serious AE rate were assessed for safety."	( Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan. Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC, 2018)	0.48
"Interferon-alpha (IFN-α)-based therapy is associated with several hematological adverse events in hepatitis C virus (HCV)-infected patients with advanced fibrosis."	( Fib-4 Predicts Early Hematological Adverse Events Induced by Interferon-Based Triple Therapy in Chronic Hepatitis C Virus Patients. Abushouk, AI; Al-Husseini, M; El-Raey, F; Johar, D; Mohammed, EG; Montasser, MF; Salaheldin, M; Zaky, S, 2019)	0.51
" Sustained virologic response at post-treatment Week 12 (SVR12), adverse events (AEs) and comedication management were assessed for patients initiating treatment before 1 June 2017."	( Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studi Back, D; Bondin, M; Bourgeois, S; Buggisch, P; Charafeddine, M; Crown, E; Curescu, M; Dorr, P; Ferenci, P; Flisiak, R; Kleine, H; Larrey, D; Marra, F; Norris, S, 2019)	0.51
" The primary safety endpoint was treatment withdrawal rates secondary to severe adverse events."	( Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019)	0.51
" No patient treatment withdrawal secondary to severe adverse events was observed."	( Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019)	0.51
" The regimen was safe and well tolerated."	( Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019)	0.51
" Sustained virological response (SVR12/24) rate and serious adverse event (SAE) rate with 95% confidence intervals were aggregated."	( Sofosbuvir-based regimen is safe and effective for hepatitis C infected patients with stage 4-5 chronic kidney disease: a systematic review and meta-analysis. Chen, J; Fang, Z; Li, M; Li, Y; Lin, Q, 2019)	0.51
" Data on treatment outcomes and adverse events (AE) were analysed in patients with available sustained virologic response 12 weeks after cessation of treatment (SVR12) information overall and by subgroups."	( Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany. Atanasov, PK; Buggisch, P; Lee, J; Petersen, J; Stoehr, A; Supiot, R; Ting, J; Wursthorn, K, 2019)	0.51
" However, ribavirin is associated with adverse events that can limit its use."	( Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis. Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K, 2019)	0.51
"Our results show that DAAs are highly effective and safe in elderly patients."	( Efficacy and safety of direct-acting antivirals for hepatitis C in the elderly: A systematic review and meta-analysis. Graf, C; Herrmann, E; Mücke, MM; Mücke, VT; Vermehren, J; Zeuzem, S, 2019)	0.51
" The patients were evaluated in respect of demographic, clinical and virological data, sustained virologic response (SVR) and adverse events."	( [EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN PATIENTS WITH HCV 1B GENOTYPE INFECTION: REAL WORLD DATA]. Skorokhodova, N; Tsarova, O; Zhyvytsia, D, 2019)	0.51
" Adverse events (AEs) were reported by 61."	( Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6. Barr, E; Burnevich, E; Buti, M; Feld, JJ; Foster, GR; Gane, E; Hanna, GJ; Jackson, B; Katchman, H; Klopfer, S; Lahser, F; Lawitz, E; Platt, HL; Rabinovitz, M; Robertson, MN; Shaughnessy, M; Tomasiewicz, K; Yeh, WW, 2019)	0.51
"7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision."	( Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study. Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ, 2019)	0.51
" Direct-acting antiviral therapy is efficacious and safe even in patients with advanced liver disease and/ or previous virological failure; Model-for-End-Liver-Disease <10 and alanine aminotransferase reduction during therapy were found to be reliable predicting markers of sustained-virological-response."	( Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases. Cescon, M; De Pace, V; Galli, S; Maggi, F; Morelli, MC; Pistello, M; Ravaioli, M; Re, MC; Vero, V, 2019)	0.51
"Sofosbuvir-based regimens are effective and safe for treating patients with chronic HCV and moderate to severe CKD, and in those with associated hepatic decompensation."	( Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. Abdel Haleem, H; Abdel-Razek, W; Anees, M; El-Sayed, MH; El-Serafy, M; El-Shazly, Y; Eletreby, R; Elkhouly, R; Elshenawy, M; Esmat, G; Hamdy, M; Hassany, M; Kamal, E; Kasem, G; Salama, M; Salama, R; Shafeek, A, 2020)	0.56
" Incidence rates of liver adverse events (LAE) were calculated; Poisson regression model was used to identify factors associated with LAE."	( Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C, 2020)	0.56
" Adverse events were observed in 191 patients (41."	( Real-Life Effectiveness and Safety of Sofosbuvir-Based Therapy in Genotype 2 Chronic Hepatitis C Patients in South Korea, with Emphasis on the Ribavirin Dose. Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ, 2020)	0.56
"This work aims to evaluate the therapeutic survey of adverse events during antiviral treatment of hepatitis in the three major University Hospitals in Abidjan."	( Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals . Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG, 2020)	0.56
"A retrospective cross-sectional descriptive study of 203 patients from August 1, 2015, to July 31, 2018, enumerated adverse events during antiviral treatments, drugs used for their management, and their clinical or biological impact."	( Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals . Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG, 2020)	0.56
"Correction of the adverse events was made either using causal treatment or using symptomatic drugs."	( Pharmacological management of adverse events during treatment of chronic viral hepatitis in three Ivorian university hospitals . Allah-Kouadio, E; Allouka, KCE; Gnépéhi, OB; Kohi, DS; N'guessan-Irié, AG; Siransy-Kouakou, NG, 2020)	0.56
" Only four patients discontinued treatment before week 4 due to non-hepatic adverse events."	( Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study. Bunchorntavakul, C; Charatcharoenwitthaya, P; Chonprasertsuk, S; Komolmit, P; Piratvisuth, T; Sanpajit, T; Sethasine, S; Siripipattanamongkol, C; Sobhonslidsuk, A; Sukeepaisarnjaroen, W; Sutthivana, C; Tangkijvanich, P; Tanwandee, T; Wongpaitoon, V, 2020)	0.56
" All the studies that reported the sustained virologic response (SVR) and adverse events of DAAs in HIV/HCV co-infected patients were included."	( Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis. Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX, 2020)	0.56
"6%) were the most effective combinations for HIV/HCV co-infected patients, with SVR rates of approximately 94% and above while severe adverse events were rare."	( Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis. Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX, 2020)	0.56
" GZR/EBR ± RBV was the optimal combination recommended for HIV/HCV co-infected patients based on the excellent treatment effects and insignificant adverse events."	( Efficacy and safety of direct acting antiviral regimens for hepatitis C virus and human immunodeficiency virus co-infection: systematic review and network meta-analysis. Fan, XG; Ma, SJ; Xiong, YH; Zheng, YX, 2020)	0.56
" Safety was determined by adverse events and ribavirin, when combined, was administered in escalating doses to all patients with GFR <60 mL/min."	( HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Amaral, ACC; Carvalho-Filho, RJ; Ferraz, MLG; Michels, FBL; Souza, ALDS; Vieira, GA, )	0.13
" The treatment was well tolerated and there were no major clinically relevant adverse events, with the most prevalent being asthenia (57."	( HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Amaral, ACC; Carvalho-Filho, RJ; Ferraz, MLG; Michels, FBL; Souza, ALDS; Vieira, GA, )	0.13
"The direct-acting antivirals were safe and efficacious in CKD patients treated with SOF-containing regimens, with the observation of high SVR rates, good tolerability and few severe adverse events."	( HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. Amaral, ACC; Carvalho-Filho, RJ; Ferraz, MLG; Michels, FBL; Souza, ALDS; Vieira, GA, )	0.13
" The safety variable was withdrawal secondary to severe adverse events (SAEs)."	( Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P, 2020)	0.56
"SOF/VEL±RBV or GLE/PIB are safe and effective for treating G3-HCV-infections, with a lower effectiveness in patients with advanced fibrosis F3-4."	( Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients. Castro-Iglesias, Á; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, Á; Rotea-Salvo, S; Sanclaudio-Luhia, AI; Suárez-López, F; Vázquez-Rodríguez, P, 2020)	0.56
" Rates of adverse events (AEs) in the patients was 59."	( Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Asan, A; Aygen, B; Barut, Ş; Batırel, A; Bilgin, H; Çelen, MK; Çelik, İ; Demirtürk, N; Ersöz, G; Karakeçili, F; Kınıklı, S; Mıstık, R; Şimşek, F; Türker, N; Turkish Society Of Clinical Microbiology And Infectious Diseases, TSGFVHOT; Ural, O; Yıldız, O; Zararsız, G, 2020)	0.56
" Demographic data, adverse events, renal function and metabolic profiles were recorded."	( Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH, 2021)	0.62
" Neither drug-related severe adverse events nor discontinuation due to drug-related adverse event were reported."	( Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH, 2021)	0.62
"Twelve weeks of LDV/SOF treatment provided an excellent and safe regimen for GT2 CHC infection, particularly in non-cirrhotic patients."	( Effectiveness and safety of ledipasvir/sofosbuvir for genotype 2 chronic hepatitis C infection: Real-world experience from Taiwan. Chang, TT; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Wu, CH; Wu, IC; Yang, EH, 2021)	0.62
" Serious adverse events were reported in 16/349 (4."	( Efficacy and Safety of Ledispavir/Sofosbuvir with or without Ribavirin in patients with Decompensated Liver Cirrhosis and Hepatitis C Infection: a Cohort Study. Baicus, C; Chifulescu, AE; Diculescu, M; Gheorghe, LS; Iacob, S; Iliescu, L; Istratescu, D; Manuc, M; Meianu, C; Pop, CS; Preda, C; Stanciu, C; Tieranu, C; Trifan, A; Tugui, L; Voiosu, T, 2020)	0.56
" The secondary outcome includes the hospital length of stay, ventilator-free days in 28 days, median time from start of study treatment to negative nasopharyngeal swab, and adverse events."	( Assessment of the efficacy and safety of Ribavirin in treatment of coronavirus-related pneumonia (SARS, MERS and COVID-19): A protocol for systematic review and meta-analysis. Jiang, Z; Li, W; Wang, Y; Xi, X; Zhu, Y, 2020)	0.56
"We aimed to analyze and evaluate the safety signals of ribavirin-interferon combination through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS), so as to provide reference for the rationale use of these agents in the management of relevant toxicities emerging in patients with novel coronavirus pneumonia (COVID-19)."	( Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy. Hong, D; Shan, W; Zhao, Q; Zhu, J, 2020)	0.56
"A total of 55 safety signals were detected from the top 250 adverse event reactions in 2200 reports, but 19 signals were not included in the drug labels."	( Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy. Hong, D; Shan, W; Zhao, Q; Zhu, J, 2020)	0.56
"The ADE (adverse drug event) signal detection based on FAERS is helpful to clarify the potential adverse events related to ribavirin-interferon combination for novel coronavirus therapy; clinicians should pay attention to the adverse reactions of gastrointestinal and blood systems, closely monitor the fluctuations of the platelet count, and carry out necessary mental health interventions to avoid serious adverse events."	( Assessment of the Potential Adverse Events Related to Ribavirin-Interferon Combination for Novel Coronavirus Therapy. Hong, D; Shan, W; Zhao, Q; Zhu, J, 2020)	0.56
" Increased bilirubin was the most common grade 3 or 4 laboratory adverse event (n = 15."	( Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study. Aho, I; Amele, S; Bhagani, S; Chkhartisvili, N; Clarke, A; Domingo, P; Falconer, K; Fonquernie, L; Jabłonowska, E; Leen, C; Lundgren, J; Maltez, F; Matulionyte, R; Mocroft, A; Peters, L; Rockstroh, J; Rodger, A; Sarcletti, M; Stephan, C; Szlavik, J; Wandeler, G; Zaccarelli, M; Østergaard, L, 2021)	0.62
" It was associated with high risk IFN-related adverse reactions due to reduced renal clearance of IFN."	( Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience. Abd-Elsalam, S; Abo-Amer, YE; Ahmed, R; Badawi, R; El-Abgeegy, M; Elguindy, AMA; Elkadeem, M; Elsergany, HF; Elshweikh, SA; Hawash, N; Mansour, L; Mohmed, AA; Soliman, MY; Soliman, S, 2020)	0.56
" Secondary Endpoints: All causes mortality, Frequency of respiratory progression (defined as SPO2≤ 94% on room air or PaO2/FiO2 <300mmHg and requirement for supplemental oxygen or more advanced ventilator support), time to defervescence (in those with fever at enrolment), frequency of requirement for supplemental oxygen or non-invasive ventilation, frequency of requirement for mechanical ventilation, frequency of serious adverse events as per DAIDS table grade of severity."	( Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial. Bahurupi, YA; Bandyopadhyay, A; Chikara, G; Moirangthem, B; Panda, PK; Saha, S; Singh, BC, 2020)	0.56
" The secondary outcome measures were SVR12 stratified by the presence of decompensated cirrhosis, prior treatment, HCC, and HIV/hepatitis C virus coinfection and the occurrence rate of serious adverse events requiring treatment cessation or hospitalization."	( Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ, 2021)	0.62
" Apart from one patient who developed myositis, no other serious adverse events were observed."	( Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ, 2021)	0.62
"The SOF/VEL ± RBV is a safe and efficacious treatment option for GT3 HCV patients in a real-world setting."	( Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. Ang, TL; Fock, KM; Koh, J; Kumar, LS; Kumar, R; Kwek, A; Law, NM; Lee, ZC; Li, W; Tan, J; Tan, YB; Teo, EK; Thurairajah, PH; Wong, YJ, 2021)	0.62
" Adverse effects were not observed."	( Sofosbuvir-based Treatment for HCV: A Safe Option in Patients Undergoing Hemodialysis. Farooq, MO; Malik, K; Mengal, FUA; Salim, A, 2020)	0.56
" In conclusion Pegylated interferon based therapy showed better clinical response with less adverse events as compared to conventional interferon based therapy."	( Comparative safety and efficacy of conventional interferon versus pegylated-interferon based therapy for HCV: A retrospective cohort study from Gujranwala, Pakistan. Ahmed, M; Bashir, A; Farooq, MS; Iftikhar, U; Kamran, SH; Saeed, H; Saleem, N; Saleem, Z, 2020)	0.56
" Body temperature returning to normal within 72 h and remaining so for 24 h was the primary outcome; release of oral herpes and adverse events were the secondary outcomes."	( Efficacy and safety of interferon α-2b spray for herpangina in children: A randomized, controlled trial. Chen, BQ; Chen, Y; Deng, JK; Dou, YL; Gan, L; Hao, JH; Lei, M; Liao, YN; Lin, AW; Long, YY; Luo, RP; Nong, GM; Wang, SN; Yan, WL; Yang, Z; Ye, YZ; Yu, H; Zhou, L, 2021)	0.62
" No adverse reaction occurred."	( Efficacy and safety of interferon α-2b spray for herpangina in children: A randomized, controlled trial. Chen, BQ; Chen, Y; Deng, JK; Dou, YL; Gan, L; Hao, JH; Lei, M; Liao, YN; Lin, AW; Long, YY; Luo, RP; Nong, GM; Wang, SN; Yan, WL; Yang, Z; Ye, YZ; Yu, H; Zhou, L, 2021)	0.62
" It was safe for use."	( Efficacy and safety of interferon α-2b spray for herpangina in children: A randomized, controlled trial. Chen, BQ; Chen, Y; Deng, JK; Dou, YL; Gan, L; Hao, JH; Lei, M; Liao, YN; Lin, AW; Long, YY; Luo, RP; Nong, GM; Wang, SN; Yan, WL; Yang, Z; Ye, YZ; Yu, H; Zhou, L, 2021)	0.62
" Virological response (VR) was measured, as well as the biochemical parameters related to treatment efficacy and adverse events at baseline and after treatment, at 4 (VR4) and 12 (VR12) weeks post-treatment."	( Efficacy and Safety of Ombitasvir plus Paritaprevir, Ritonavir and Ribavirin in Non-cirrhotic Treatment-naïve and Treatment-experienced Egyptians with Chronic HCV Genotype-4 Infection. Ahmed, M; Gomaa, AA; Mansey, AE; Rabea, HM; Wahsh, EA, 2021)	0.62
" Adverse events (A/Es) were reported in 59."	( Real-world Effectiveness and Safety of Direct-acting Antiviral Agents in Patients with Chronic Hepatitis C Genotype 2 Infection: Korean Multicenter Study. Baek, YH; Cho, HC; Heo, NY; Hong, Y; Kang, YW; Lee, SS; Lee, SW; Park, SJ; Seo, KI; Shin, JW; Yoon, JS; Yoon, KT, 2021)	0.62
" The secondary endpoint was virologic response rate at end-of-treatment and adverse event outcome."	( Efficacy and safety of danoprevir plus sofosbuvir in GT 1, 2, 3, or 6 chronic hepatitis C patients with or without cirrhosis in China. Feng, K; Huang, P; Ke, L; Lin, C; Liu, J; Pan, S; Yang, X; Zeng, Y, 2021)	0.62
" The most common adverse events were hepatic steatosis, upper respiratory tract infection, hypercholesterolaemia, hypertriglyceridaemia, blood bilirubin increased, and total bile acids increased."	( Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open-label, phase 2 study. Chen, J; Gao, H; Guan, Y; Hua, R; Huang, Y; Jiang, Y; Kong, F; Li, C; Li, G; Ma, H; Mao, X; Meng, C; Niu, J; Tan, Y; Wang, J; Wang, Z; Wen, X; Wu, Q; Xin, Y; Xiong, Q; Xu, B; Zhang, X; Zhang, Y; Zhao, L, 2022)	0.72
" It has been found that this combination may change the severity of XYP-associated adverse events (AEs)."	( Clinical features of adverse events associated with Xiyanping-Ribavirin combination: A systematic review. Chen, S; Chen, Z; Liang, A; Qiu, R; Shang, H; Sun, Y; Wang, P; Zhang, X; Zhao, C; Zheng, R, 2022)	0.72
"To provide a comprehensive review about the clinal features of AEs of XYP-RB combination from randomized controlled trials, cohort studies, case-control studies, case reports, case series, and data from the National Adverse Drug Reaction Monitoring Information System (NADRMIS)."	( Clinical features of adverse events associated with Xiyanping-Ribavirin combination: A systematic review. Chen, S; Chen, Z; Liang, A; Qiu, R; Shang, H; Sun, Y; Wang, P; Zhang, X; Zhao, C; Zheng, R, 2022)	0.72
" The sustained virologic response (SVR) and adverse event (AE) rates were calculated with a random-effects model."	( Efficacy and safety of direct-acting antiviral therapy for hepatitis C virus in elderly patients (≥65 years old): A systematic review and meta-analysis. Ahn, SB; An, J; Jun, DW; Ko, MJ; Lee, J; Park, DA; Yim, SY; Yoo, JJ, 2022)	0.72
" Studies suggest ribavirin aerosol could be a safe and efficacious treatment option in the fight against coronaviruses."	( A randomized, placebo-controlled study to evaluate safety and pharmacokinetics of inhaled ribavirin. Barakat, M; Brkovic, A; Couroux, P; Israel, RJ; Pamidi, C; Patel, J; Vittitow, JL, 2022)	0.72
"Included studies were randomized trials comparing the same SOF-based medication regimens with and without RBV in HCV patients and measuring serious adverse events (SAEs) and/or sustained virologic response at 12 weeks post-treatment (SVR-12)."	( Safety and efficacy of sofosbuvir-based medication regimens with and without ribavirin in hepatitis C patients: A systematic review and meta-analysis. Ebell, M; Elshafie, S; Trivedi-Kapoor, R, 2022)	0.72
" In terms of safety, we monitored the development of adverse reactions, liver cytolysis, cholestasis, and hematologic disorders."	( A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania. Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A, 2022)	0.72
" Methods Adults receiving 24-week SOF+RBV treatment for HCV GT3-6 infection were prospectively enrolled and observed through 24 weeks post-treatment for treatment-emergent adverse events (AEs) considered related to SOF and/or RBV by treating physicians and for a sustained virologic response at 12 and 24 weeks post-treatment (SVR12, SVR24)."	( Real-world Safety and Effectiveness of 24-week Sofosbuvir and Ribavirin Treatment in Patients Infected with Rare Chronic Hepatitis C Virus Genotypes 3, 4, 5, or 6 in Japan. Aoki, K; Force, L; Ishizaki, A; Konishi, H; Liu, LJ; Mita, E; Mizutani, H; Nakamoto, D; Ng, LJ; Shing, D, 2023)	0.91
" This study aims to measure the urinary concentration of RBV and its main metabolites in order to evaluate the drug metabolism ability of HCV patients and to evaluate the adverse effects, such as anemia, with respect to RBV metabolite levels."	( Precision Medicine: Determination of Ribavirin Urinary Metabolites in Relation to Drug Adverse Effects in HCV Patients. Biliotti, E; Calvani, R; Capuani, G; Giampaoli, O; Miccheli, A; Sciubba, F; Spagnoli, M; Taliani, G; Tomassini, A, 2022)	0.72
" Safety was determined by adverse effects reported in records and efficacy was documented by clearance of HCV-RNA to see ETR and SVR."	( Effectiveness And Safety Of Direct Acting Antiviral Agents In Thalassaemic Patients With Chronic Hepatitis C. Ahmed, SH; Hayat, M; Hussain, W; Memon, NA; Merchant, AA; Parkash, A, )	0.13
"Combined Sofosbuvir and Daclatasvir were found to be effective and safe for treating HCV in Thalassaemia Major Children."	( Effectiveness And Safety Of Direct Acting Antiviral Agents In Thalassaemic Patients With Chronic Hepatitis C. Ahmed, SH; Hayat, M; Hussain, W; Memon, NA; Merchant, AA; Parkash, A, )	0.13
" However, a comprehensive review of the adverse event (AE) profile of the DAAs is lacking."	( Evaluation of the Safety Profile of Direct-Acting Antivirals on Patients with Hepatitis C Virus: A Pharmacovigilance Study. El-Marakby, MG; Sabri, NA; Solayman, MH, 2023)	0.91

Excerpt	Reference	Relevance
" We present pharmacokinetic parameters of our clinical study and examine some of the reasons for the lower toxicity found in our trials."	( Clinical pharmacokinetic study of tiazofurin administered as a 1-hour infusion. Engeler, GP; Hoffman, R; Jayaram, HN; Kneebone, P; Lapis, E; Paulik, E; Tricot, G; Weber, G; Zhen, W, 1992)	0.28
" After a single 400 mg intravenous infusion, mean terminal plasma half-life (t1/2) was 27."	( Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Agrawal, KC; Ferencz, N; George, WJ; Hyslop, NE; Lacour, JT; Lertora, JJ; Rege, AB; VanDyke, RB, 1991)	0.28
" To determine if this beneficial effect was due to increased delivery of drug, the pharmacokinetic properties of ribavirin and RTA when administered as an aerosol or by intraperitoneal injection were examined."	( Aerosol and intraperitoneal administration of ribavirin and ribavirin triacetate: pharmacokinetics and protection of mice against intracerebral infection with influenza A/WSN virus. Gilbert, BE; Robins, RK; Wilson, SZ; Wyde, PR, 1991)	0.28
"A phase I and pharmacokinetic study of tiazofurin (NSC 286193), a C-nucleoside that inhibits IMP dehydrogenase, has been completed."	( Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. Bishop, J; Coates, A; Fox, R; Grygiel, J; Raghavan, D; Sampson, D; Woods, R, 1986)	0.27
"The pharmacokinetic disposition of tiazofurin in plasma and cerebrospinal fluid was examined in rhesus monkeys."	( Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. Balis, FM; Collins, JM; Grygiel, JJ; Lester, CM; Poplack, DG, 1985)	0.27
" Tiazofurin levels were measured using a high-pressure liquid chromatography assay, and pharmacokinetic studies were performed in patients treated at each dose level."	( Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193). Boldt, DH; Clark, GM; Hersh, MR; Kuhn, JG; Melink, TJ; Patton, TF; Siegler, R; Sternson, LA; Von Hoff, DD, 1985)	0.27
" Safety and pharmacokinetic parameters were monitored; five children had comprehensive pharmacokinetic evaluations."	( Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Connor, E; Connor, J; Lane, J; Morrison, S; Oleske, J; Sonke, RL, 1993)	0.29
" The pharmacokinetic studies performed at weeks 4, 6, and 12 on specimens collected from the 15 individuals who completed 12 weeks of therapy revealed no pharmacokinetic interaction between ddI and ribavirin."	( A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team. Bassiakos, Y; Booth, D; Clax, PA; Connor, JD; Cooney, E; Crumpacker, CS; Erice, A; Griffith, BP; Holden-Wiltse, J; Hussey, S; Japour, AJ; Johanneson, N; Lertora, JJ; McLaren, C; Meehan, PM; Pollard, R; Timpone, J; Walesky, M; Wood, K, 1996)	0.29
"The primary objective of this study was to determine whether pharmacokinetic interactions occurred between interferon alpha-2b (IFN) and ribavirin in patients with chronic hepatitis C infections."	( Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Bell, A; Dash, C; Dusheiko, GM; Flannery, B; Glue, P; Grellier, L; Khakoo, S; Lypnyj, D; Murray-Lyon, I; Walters, K; Wells, B, 1998)	0.3
" Ribavirin and IFN pharmacokinetic parameters for combined ribavirin and IFN were similar to those during monotherapy with either compound, although the power of this study to detect differences was low."	( Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Bell, A; Dash, C; Dusheiko, GM; Flannery, B; Glue, P; Grellier, L; Khakoo, S; Lypnyj, D; Murray-Lyon, I; Walters, K; Wells, B, 1998)	0.3
"There was no evidence of pharmacokinetic interactions between IFN and ribavirin in this study."	( Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Bell, A; Dash, C; Dusheiko, GM; Flannery, B; Glue, P; Grellier, L; Khakoo, S; Lypnyj, D; Murray-Lyon, I; Walters, K; Wells, B, 1998)	0.3
" A three-compartment model was chosen for the pharmacokinetic analysis with the Akaike Information Criterion."	( Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Drusano, GL; Glue, P; Gupta, SK; McNamara, P; Nash, J; Preston, SL, 1999)	0.3
" Pharmacokinetic sampling and tolerability assessments were performed up to 168 h post dose."	( The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Clement, RP; Glue, P; Gupta, S; Salfi, M; Schenker, S; Zambas, D, 2000)	0.31
" Although mean Cmax increased with the severity of hepatic dysfunction, there was no change in extent of absorption or renal clearance of ribavirin."	( The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Clement, RP; Glue, P; Gupta, S; Salfi, M; Schenker, S; Zambas, D, 2000)	0.31
"There are no pharmacokinetic reasons for initial dose adjustment of ribavirin in patients with hepatic dysfunction."	( The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. Clement, RP; Glue, P; Gupta, S; Salfi, M; Schenker, S; Zambas, D, 2000)	0.31
" Loss of HCV-RNA at 24 weeks after completion of treatment was considered a response to interferon and ribavirin treatment in a logistic regression analysis of clinical and pharmacokinetic variables and treatment response in the interferon-naive patients."	( Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Glue, P; Gupta, S; Hajian, G; Jen, JF; Zambas, D, 2000)	0.31
" Single- and multiple-dose pharmacokinetic studies and viral dynamics were assessed by serial measurements of serum concentrations of both compounds and HCV RNA, respectively, at weeks 1 and 24."	( Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2002)	0.31
" Pharmacokinetic analysis of ribavirin provides information on its mechanism of action and for developing more rational treatment for IFN-resistant HCV."	( Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2002)	0.31
" A population pharmacokinetic model was used to describe the ribavirin dose-concentration relationship and the influence of covariates."	( Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Affrime, MB; Chung, C; Glue, P; Gupta, SK; Hajian, G; Heft, S; Jen, J; Laughlin, M, 2002)	0.31
" The aim of this study was to critically evaluate current dosage recommendations on the basis of a population pharmacokinetic analysis."	( Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Bruchfeld, A; Lindahl, K; Schvarcz, R; Ståhle, L, 2002)	0.31
" Single- and multiple-dose pharmacokinetic studies were assessed by serial measurements of serum concentrations of both compounds at weeks 1 and 24."	( Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Hirose, Y; Izumi, N; Kumada, H; Tsubota, A, 2003)	0.32
"To compare the two-stage method, a widely used analytical method in pharmacokinetic studies, with nonparametric population modeling by using the same data set for determining the oral bioavailability of ribavirin."	( Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Drusano, GL; Preston, SL; Tam, VH, 2003)	0.32
" Having accurate and precise estimation of population pharmacokinetic parameters and their true variances is crucial, as, at any dose, there'will be a lower probability of encountering a concentration-driven toxicity because of fewer outliers as the variance associated with the parameters decreases."	( Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Drusano, GL; Preston, SL; Tam, VH, 2003)	0.32
"The authors performed a pharmacokinetic study in 21 HCV-positive renal or liver transplant patients."	( Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Chatelut, E; Izopet, J; Kamar, N; Lafont, T; Manolis, E; Rostaing, L, 2004)	0.32
"A total of 428 plasma concentrations were analyzed by a population pharmacokinetic method using the NONlinear Mixed Effect Model program."	( Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Chatelut, E; Izopet, J; Kamar, N; Lafont, T; Manolis, E; Rostaing, L, 2004)	0.32
" We aimed to adjust the individual dose and frequency of intraventricular administration based on the peak level and half-life of ribavirin in the CSF in order to maintain the CSF ribavirin concentration at the target level."	( Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Hosoya, M; Kimura, H; Mori, K; Mori, S; Sawaishi, Y; Shigeta, S; Suzuki, H; Tomoda, A, 2004)	0.32
" The pharmacokinetic profiles of ribavirin were assessed by the measurement of plasma concentrations."	( Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Fujiyama, S; Hamada, A; Saito, H; Sasaki, Y; Uchida, M; Yamasaki, M, 2004)	0.32
"The current study was carried out to evaluate pharmacokinetic profiles of viramidine and ribavirin in patients (n = 8 per dose group) with compensated hepatitis C infection following oral dosing of viramidine (400, 600, or 800 mg bid for 4 weeks)."	( Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. Aora, S; Gish, R; Lau, D; Lin, CC; Peterson, J; Rossi, S; Teng, A; Xu, C; Yeh, LT, 2005)	0.33
"The intracellular triphosphorylation and plasma pharmacokinetics of lamivudine (3TC), stavudine (d4T), and zidovudine (ZDV) were assessed in a pharmacokinetic substudy, in 56 human immunodeficiency virus-hepatitis C virus (HIV-HCV) coinfected patients receiving peginterferon alfa-2a (40KD) 180 microg/week plus either placebo or ribavirin (RBV) 800 mg/day in the AIDS PEGASYS Ribavirin International Coinfection Trial."	( Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Back, D; Borucki, MJ; Dieterich, D; Gries, JM; Hoggard, PG; Lissen, E; Rodriguez-Torres, M; Soriano, V; Sulkowski, M; Torriani, FJ; Wang, K, 2005)	0.33
" Pharmacokinetic sampling was performed on days 1 through 4 and 22 through 25."	( Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects. Cheng, A; Ebrahimi, R; Kearney, BP; Mittan, A; Ramanathan, S, 2006)	0.33
" We modeled HCV kinetics incorporating pharmacokinetic and pharmacodynamic parameters."	( Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Cullen, C; Grace, M; Hussain, M; Markatou, M; Perelson, AS; Powers, KA; Ribeiro, RM; Talal, AH, 2006)	0.33
" The pharmacokinetic profile of both peginterferons, mRNA expression of a selected group of interferon-induced gene transcripts, and serum HCV-RNA levels were assessed."	( A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE). Bordens, R; Cullen, C; Cutler, D; Grace, M; Harvey, J; Jackson, M; Laughlin, M; Poo, J; Silva, M; Wagner, F, 2006)	0.33
"A population pharmacokinetic analysis was performed using plasma concentration data (n = 7025) from 380 patients to examine the relationship between ribavirin dose and its pharmacokinetics."	( Pharmacokinetics of ribavirin in patients with hepatitis C virus. Duff, F; Jorga, K; Lamb, M; Snoeck, E; Wade, JR, 2006)	0.33
"This study investigated the molecular and pharmacokinetic mechanisms of the enhanced antiviral efficacy associated with pegylated interferon (PEG-IFN) alpha-2b and ribavirin."	( Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. Asahina, Y; Doi, F; Higaki, M; Hosokawa, T; Izumi, N; Kitamura, T; Kurosaki, M; Matsunaga, K; Miyake, S; Nakanishi, H; Tsuchiya, K; Uchihara, M; Ueda, K; Umeda, N, 2007)	0.34
"Peginterferon alpha-2a pharmacokinetic and pharmacodynamic variability is associated with EVR in both AA and CA with HCV infection, but do not explain the racial disparity in combination treatment efficacy."	( Peginterferon pharmacokinetics in African American and Caucasian American patients with hepatitis C virus genotype 1 infection. Dowling, TC; Hoofnagle, JH; Howell, CD; Jeffers, L; Paul, M; Taylor, M; Terrault, NA; Wahed, AS, 2008)	0.35
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"A rapid and sensitive quantitative assay method was developed for determining ribavirin pharmacokinetic in human plasma."	( Rapid and sensitive HPLC-MS/MS method for pharmacokinetic assessment of ribavirin in healthy Chinese. Chen, TF; Deng, CY; Huang, XZ; Lin, QX; Lin, SG; Liu, XY; Peng, HY; Shan, ZX; Yang, M; Yu, XY; Zhou, ZL; Zhu, P, 2008)	0.35
"Bioequivalence of the new Russian oral ribavirin-containing agents was estimated by the pharmacokinetic and bioavailability parameters vs."	( [Comparative estimation of pharmacokinetics of generic ribavirin-containing drugs]. Nisrin, A; Pisarev, VV; Savchenko, AIu; Smirnova, LB, 2008)	0.35
" Blood samples were collected predose and up to 168 h after the first dose and at week 12 for pharmacokinetic analysis."	( Pharmacokinetics and response of obese patients with chronic hepatitis C treated with different doses of PEG-IFN alpha-2a (40KD) (PEGASYS). Bressler, B; Grippo, JF; Heathcote, EJ; Wang, K, 2009)	0.35
"In this study we sought to characterize the relationship between several pharmacokinetic and pharmacodynamic parameters and virologic responses among HIV/hepatitis C virus genotype-1 co-infected patients receiving pegylated interferon-alpha-2b (peg-IFN2b) and ribavirin."	( Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. Chen, G; Dewar, RL; Ferenci, P; Haagmans, BL; Kottilil, S; Levy-Drummer, RS; Masur, H; McLaughlin, M; Neumann, AU; Polis, MA; Rozenberg, L; Silva, M; Viola, MS, 2009)	0.35
" However, peg-IFN2b concentrations and pharmacokinetic parameters, peg-IFN2b(max) and peg-IFN2b half-life, were similar in both groups and did not predict sustained virologic responders."	( Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. Chen, G; Dewar, RL; Ferenci, P; Haagmans, BL; Kottilil, S; Levy-Drummer, RS; Masur, H; McLaughlin, M; Neumann, AU; Polis, MA; Rozenberg, L; Silva, M; Viola, MS, 2009)	0.35
"Further studies are needed to evaluate whether these pharmacodynamic predictions are a result of differential host response to peg-IFN2b or other viral factors conferring relative resistance to peg-IFN2b."	( Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics. Chen, G; Dewar, RL; Ferenci, P; Haagmans, BL; Kottilil, S; Levy-Drummer, RS; Masur, H; McLaughlin, M; Neumann, AU; Polis, MA; Rozenberg, L; Silva, M; Viola, MS, 2009)	0.35
" A modeling framework that includes pharmacokinetic and pharmacodynamic parameters was developed."	( Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. Affonso de Araujo, ES; Barone, AA; Cotler, SJ; Dahari, H; Haagmans, BL; Layden, TJ; Neumann, AU, 2010)	0.36
"15) and overall pharmacokinetic parameters were similar in SVRs and non-SVRs."	( Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes. Affonso de Araujo, ES; Barone, AA; Cotler, SJ; Dahari, H; Haagmans, BL; Layden, TJ; Neumann, AU, 2010)	0.36
" We retrospectively assessed the pharmacodynamic effects of pegylated interferon (PEG-IFN) alfa-2a and ribavirin by evaluating the relationship between changes in hematologic parameters, body weight, and virologic response."	( Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C. Chung, RT; Di Bisceglie, AM; Hassanein, T; Lentz, E; Poordad, FF; Prabhakar, A; Zhou, X, 2010)	0.36
"We examined the association between IL28B single-nucleotide polymorphism rs12979860, hepatitis C virus (HCV) kinetic, and pegylated interferon alpha-2a pharmacodynamic parameters in HIV/HCV-coinfected patients from South America."	( Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients. Barone, AA; Cotler, SJ; Dahari, H; de Araujo, ES; Layden, TJ; Melo, CE; Neumann, AU, 2011)	0.37
" The aim of this study was to assess the safety and pharmacokinetic (PK) profile of raltegravir and ribavirin when dosed separately and together."	( Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. Ashby, J; Back, D; D'Avolio, A; Dickinson, L; Erlwein, OW; Garvey, L; Lamba, H; Latch, N; Legg, K; McClure, MO; Weston, R; Winston, A, 2011)	0.37
" Nevertheless, valuable pharmacokinetic (PK) and safety data were obtained at moderate dose, with potential treatment implications for other indications."	( Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis. Caceres, M; Carr, R; Chebib, MG; De Los Reyes, EC; Hunt, WG; Khan, RR; McJunkin, JE; Minnich, LL; Nahata, MC; Taravath, S; Welch, CA; Whitley, RJ, 2011)	0.37
"Although the results do not support the use of RBV for LACVE, this nevertheless is the largest study of antiviral treatment for LACVE to date and the largest pharmacokinetic analysis of IV RBV in children for any indication."	( Safety and pharmacokinetics of ribavirin for the treatment of la crosse encephalitis. Caceres, M; Carr, R; Chebib, MG; De Los Reyes, EC; Hunt, WG; Khan, RR; McJunkin, JE; Minnich, LL; Nahata, MC; Taravath, S; Welch, CA; Whitley, RJ, 2011)	0.37
" The difference in pegylation between the two peginterferons has a significant impact on their pharmacokinetic properties."	( Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. Bruno, R; Cima, S; Fagiuoli, S; Filice, G; Maiocchi, L; Novati, S; Sacchi, P, 2012)	0.38
" Pharmacokinetic parameters (C(max), T(max), AUC, CL/F) were estimated using noncompartmental methods."	( The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Blotner, SD; Brennan, BJ; Grippo, JF; Hagedorn, CH; Marbury, TC; Morcos, PN; Morrison, R; Sulkowski, M; Wang, K, 2012)	0.38
"There was no difference in the pharmacokinetic parameters for PEG-IFN alfa-2a following single-dose or steady-state administration between African American or Hispanic patients compared with Caucasian patients."	( The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Blotner, SD; Brennan, BJ; Grippo, JF; Hagedorn, CH; Marbury, TC; Morcos, PN; Morrison, R; Sulkowski, M; Wang, K, 2012)	0.38
"No differences were observed in PEG-IFN alfa-2a pharmacokinetic parameters between African American or Hispanic patients compared with Caucasian patients."	( The pharmacokinetics of peginterferon alfa-2a and ribavirin in African American, Hispanic and Caucasian patients with chronic hepatitis C. Blotner, SD; Brennan, BJ; Grippo, JF; Hagedorn, CH; Marbury, TC; Morcos, PN; Morrison, R; Sulkowski, M; Wang, K, 2012)	0.38
"We report a population pharmacokinetic (PK) and pharmacodynamic (PD) model of orally administered ribavirin in patients with chronic hepatitis C virus (HCV) infection enrolled in a multicenter clinical trial, including the estimation of covariate effects on ribavirin PK parameters and sustained viral response (SVR)."	( Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. Dowling, TC; Fossler, MJ; Howell, CD; Jin, R; McHutchison, JG, 2012)	0.38
" This article reviews the pharmacokinetic and drug interaction profile of telaprevir."	( Telaprevir: pharmacokinetics and drug interactions. Beaumont, M; Garg, V; Kauffman, RS; van Heeswijk, RP, 2012)	0.38
" Week one PEGIFN serum concentrations in 42 HCV genotype 1-infected patients treated with conventional PEGIFN/RBV were analyzed using multicompartmental pharmacokinetic models."	( Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Alder, L; Gumbo, T; Jain, MK; Lee, WM; Pasipanodya, JG, 2013)	0.39
" The elimination half-life of both plasma and erythrocyte RBV did not differ between the 2 phases."	( Effects of dipyridamole coadministration on the pharmacokinetics of ribavirin in healthy volunteers. Abei, M; Homma, M; Hyodo, I; Kohda, Y; Suzuki, Y, 2013)	0.39
" Blood and urine samples were collected pre-dose and up to 168 hours post-dose for pharmacokinetic analyses."	( Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment. Glue, P; Gupta, SK; Kantesaria, B, 2013)	0.39
"In this article, the authors summarize boceprevir's pharmacokinetic and pharmacodynamic properties."	( The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus. Bichoupan, K; Dieterich, DT; Shankar, H, 2013)	0.39
" In a prior Phase I study, GSK2336805 was well tolerated and had an antiviral and pharmacokinetic profile suitable for once-daily administration."	( A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected Adkison, K; Cutrell, A; Elko-Simms, C; Gardner, S; Hamatake, R; Hong, Z; Rodriguez-Torres, M; Walker, J, 2014)	0.4
" In this review we provide an overview of the clinical pharmacokinetic characteristics of these agents by describing their absorption, distribution, metabolism and excretion."	( Viral hepatitis C therapy: pharmacokinetic and pharmacodynamic considerations. Arends, JE; Burger, DM; de Kanter, CT; de Knegt, RJ; Drenth, JP; Reesink, HW; van der Valk, M, 2014)	0.4
" Blood and urine samples were collected pre-dose and up to 168 h post-dose for pharmacokinetic analyses."	( Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. Glue, P; K Gupta, S; Kantesaria, B, 2014)	0.4
"Blood samples for pharmacokinetic and VK analyses were collected from 51 patients enrolled in the PROGRESS study."	( Induction dosing of peginterferon alfa-2a (40 KD) and/or high-dose ribavirin in genotype 1 CHC patients with difficult-to-treat characteristics: pharmacokinetic and viral kinetic (PK/VK) assessment from PROGRESS. Brennan, BJ; DePamphilis, J; Grippo, JF; Leong, R; Morcos, PN; Thommes, JA, )	0.13
" Plasma samples were collected through 144 hours after administration for pharmacokinetic assessments."	( Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment. Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ, 2015)	0.42
" Raltegravir pharmacokinetic parameters remained unchanged whether administered on or off anti-HCV therapy."	( Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir. Barrail-Tran, A; Cheret, A; Furlan, V; Molina, JM; Piroth, L; Rosa, I; Rosenthal, E; Taburet, AM; Vincent, C, 2015)	0.42
" Pharmacokinetic parameters were determined in rats following oral (p."	( Effects of Silymarin, Glycyrrhizin, and Oxymatrine on the Pharmacokinetics of Ribavirin and Its Major Metabolite in Rats. Fan, S; Jin, X; Li, J; Liao, S; Shi, W; Wang, J; Wang, X; Zhang, T; Zhang, W; Zhang, Z; Zhong, B, 2016)	0.43
" In one patient receiving the once daily regimen, sofosbuvir-007 half-life was slightly higher (38h) than for patients with normal renal function receiving a full dose."	( Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D, 2016)	0.43
" In this pharmacokinetic study, sofosbuvir full dose (400mg once daily) administered every day with another direct antiviral agent did not accumulate in hemodialysis patients and was safe and effective."	( Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D, 2016)	0.43
" In this study, we present a pharmacokinetic profile of ribavirin in Atlantic salmon (Salmo salar), efficacy prediction indexes, and the measure of its withdrawal time."	( Pharmacokinetics, efficacy prediction indexes, and residue depletion of ribavirin in Atlantic salmon's (Salmo salar) muscle after oral administration in feed. Anadón, A; Araya-Jordán, C; Cornejo, J; Maddaleno, A; Martínez, MA; Muñoz, R; San Martín, B, 2016)	0.43
" A population pharmacokinetic model for paritaprevir was developed using data from formulation, bioavailability, and drug-drug interaction studies that evaluated the pharmacokinetics of paritaprevir (coadministered with ritonavir to enhance exposure) with or without ombitasvir and/or dasabuvir at different paritaprevir dose levels."	( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016)	0.43
" Coadministration of dasabuvir increased paritaprevir bioavailability by 59 %; however, ombitasvir coadministration did not affect the pharmacokinetic profile of paritaprevir."	( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016)	0.43
"To evaluate the efficacy and safety of this drug regimen and the impact of the addition of boceprevir(BOC) on atazanavir (ATV) or raltegravir (RAL) pharmacokinetic parameters in a subgroup of patients."	( Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study. Alric, L; Bellissant, E; Bourlière, M; Carrieri, P; Colson, P; Garraffo, R; Ghosn, J; Halfon, P; Molina, JM; Naqvi, A; Piroth, L; Poizot-Martin, I; Renault, A; Solas, C, 2016)	0.43
"Total exposure, measured by area under the plasma concentration-time curve (AUC), was generated for the DAAs, ritonavir, and ribavirin using population pharmacokinetic modeling of data (N = 2093 patients) from 6 Phase 3 studies and 1 Phase 2 study."	( Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection. Badri, PS; Eckert, D; Menon, RM; Mensing, S; Polepally, AR, 2017)	0.46
"The population pharmacokinetic models for each component of the 3D ± ribavirin regimen (DAAs and ritonavir, n = 2348) and ribavirin (n = 1841) adequately described their respective plasma concentration-time data."	( Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S, 2017)	0.46
" Serial pharmacokinetic sampling was performed for calcineurin inhibitors, telaprevir, and ribavirin."	( Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Brown, KA; Brown, RS; Fontana, RJ; Levitsky, J; Rubin, RA; Russo, MW; Vargas, H; Yoshida, EM, 2018)	0.48
" Pharmacokinetics and safety assessments were performed, and pharmacokinetic parameters were calculated using non-compartmental methods and summarized using descriptive statistics and compared statistically by geometric least-squares mean ratios and 90% confidence intervals."	( Pharmacokinetics and Safety of Velpatasvir and Sofosbuvir/Velpatasvir in Subjects with Hepatic Impairment. Brainard, DM; Curtis, C; Lasseter, K; Lawitz, E; Ling, KHJ; Marbury, T; Mathias, A; Mogalian, E; Moorehead, L; Murray, B; Osinusi, A; Perry, R, 2018)	0.48
" A population pharmacodynamic model will be developed."	( A population pharmacodynamic model characterizing neutropenia associated with pegylated interferon alpha 2-a therapy in patients with chronic hepatitis C viral infection. Hindi, NN; Saleh, MI, 2018)	0.48
" Expert opinion: This combination, taken orally with or without food, has an excellent pharmacokinetic and pharmacodynamic profile."	( Pharmacodynamic and pharmacokinetic evaluation of the combination of daclatasvir/sofosbuvir/ribavirin in the treatment of chronic hepatitis C. Brieva, T; Frias, M; Rivero, A; Rivero-Juarez, A, 2018)	0.48
"Ribavirin is used in the treatment of respiratory paramyxovirus infection in lung transplant recipients; however, its pharmacokinetic profile in the transplant population is unknown despite the potential for alterations due to underlying pathology."	( Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. Alffenaar, JC; de Zwart, AES; Evans, AM; Glanville, AR; Marriott, DJE; Milliken, E; Reuter, SE; Riezebos-Brilman, A; Schteinman, A; Verschuuren, EAM, 2019)	0.51
"Population pharmacokinetic modelling was conducted in NONMEM using concentration-time data from 24 lung transplant recipients and 6 healthy volunteers."	( Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. Alffenaar, JC; de Zwart, AES; Evans, AM; Glanville, AR; Marriott, DJE; Milliken, E; Reuter, SE; Riezebos-Brilman, A; Schteinman, A; Verschuuren, EAM, 2019)	0.51
" Pharmacokinetic data on both calcineurin inhibitors and direct-acting antiviral exposure in liver transplant recipients remain sparse."	( Comparison of the effect of direct-acting antiviral with and without ribavirin on cyclosporine and tacrolimus clearance values: results from the ANRS CO23 CUPILT cohort. Barrail-Tran, A; Botta-Fridlund, D; Cagnot, C; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; De Ledinghen, V; Duclos-Vallée, JC; Durand, F; Duvoux, C; Fougerou-Leurent, C; Gelé, T; Goldwirt, L; Houssel-Debry, P; Kamar, N; Laforest, C; Lavenu, A; Leroy, V; Moreno, C; Pageaux, GP; Radenne, S; Samuel, D; Taburet, AM, 2019)	0.51
" However, evidence for ribavirin efficacy in patients with LF is poor and pharmacokinetic (PK) data are not available."	( Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria. Akhideno, P; Duraffour, S; Edeawe, O; Eifediyi, G; Erameh, C; Groger, M; Günther, S; Koch, T; Kurth, F; Oestereich, L; Ogbaini-Emovon, E; Okogbenin, S; Omansen, TF; Pahlmann, M; Ramharter, M; Sarpong, F; Wagner, C; Wicha, S, 2020)	0.56
" The primary objective is to describe classical PK parameters for ribavirin (maximum plasma drug concentration, time to maximum plasma drug concentration, area under the plasma drug concentration vs time curve, half-life time T1/2, volume of distribution)."	( Prospective observational study on the pharmacokinetic properties of the Irrua ribavirin regimen used in routine clinical practice in patients with Lassa fever in Nigeria. Akhideno, P; Duraffour, S; Edeawe, O; Eifediyi, G; Erameh, C; Groger, M; Günther, S; Koch, T; Kurth, F; Oestereich, L; Ogbaini-Emovon, E; Okogbenin, S; Omansen, TF; Pahlmann, M; Ramharter, M; Sarpong, F; Wagner, C; Wicha, S, 2020)	0.56
" In this two-part study, we assessed the pharmacodynamic effects and therapeutic potential of ribavirin in human papillomavirus (HPV)-related malignancies."	( Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies. Burman, B; Drutman, SB; Fury, MG; Ho, AL; Katabi, N; Pfister, DG; Wong, RJ, 2022)	0.72
"In the pharmacodynamic study, ribavirin (400 mg BID for 14 days) was evaluated in 8 patients with HPV-positive localized oropharyngeal carcinoma with phosphorylated-eIF4E (p-eIF4E) ≥ 30%."	( Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies. Burman, B; Drutman, SB; Fury, MG; Ho, AL; Katabi, N; Pfister, DG; Wong, RJ, 2022)	0.72
"Six patients were evaluable in the pharmacodynamic study: 4 had decreased p-eIF4E after 14 days of ribavirin."	( Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies. Burman, B; Drutman, SB; Fury, MG; Ho, AL; Katabi, N; Pfister, DG; Wong, RJ, 2022)	0.72
" Evidence for the safety and efficacy of ribavirin in Lassa fever patients is poor and pharmacokinetic data for both regimens are lacking."	( Pharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria. Aihonwalan, L; Akhideno, P; Akhigbe, T; Babatunde, FO; Duraffour, S; Edeawe, O; Eifediyi, G; Erameh, C; Groger, M; Günther, S; Hinrichs, M; Hinzmann, J; Kleist, CJ; Koch, T; Müller, J; Nwatuzor, J; Oestereich, L; Ogbaini-Emovon, E; Okogbenin, S; Pahlmann, M; Ramharter, M; Riedner, M; Sarpong, FN; Thielebein, A; Wagner, C; Wicha, SG, 2023)	0.91
"Polymerase chain reaction-confirmed Lassa fever patients with mild to moderate disease severity were invited to participate in this prospective, observational pharmacokinetic study."	( Pharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria. Aihonwalan, L; Akhideno, P; Akhigbe, T; Babatunde, FO; Duraffour, S; Edeawe, O; Eifediyi, G; Erameh, C; Groger, M; Günther, S; Hinrichs, M; Hinzmann, J; Kleist, CJ; Koch, T; Müller, J; Nwatuzor, J; Oestereich, L; Ogbaini-Emovon, E; Okogbenin, S; Pahlmann, M; Ramharter, M; Riedner, M; Sarpong, FN; Thielebein, A; Wagner, C; Wicha, SG, 2023)	0.91
"Using a population pharmacokinetic approach, plasma concentrations of ribavirin were best described by a 3-compartment model."	( Pharmacokinetics of Ribavirin in the Treatment of Lassa Fever: An Observational Clinical Study at the Irrua Specialist Teaching Hospital, Edo State, Nigeria. Aihonwalan, L; Akhideno, P; Akhigbe, T; Babatunde, FO; Duraffour, S; Edeawe, O; Eifediyi, G; Erameh, C; Groger, M; Günther, S; Hinrichs, M; Hinzmann, J; Kleist, CJ; Koch, T; Müller, J; Nwatuzor, J; Oestereich, L; Ogbaini-Emovon, E; Okogbenin, S; Pahlmann, M; Ramharter, M; Riedner, M; Sarpong, FN; Thielebein, A; Wagner, C; Wicha, SG, 2023)	0.91

Excerpt	Reference	Relevance
"The antiviral activities of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide; virazole), either alone or in combination with recombinant human leukocyte (alpha) interferon (rHuIFN-alpha), were evaluated against feline infectious peritonitis virus (FIPV) in feline kidney-cell cultures."	( Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Oostrom-Ram, T; Weiss, RC, 1989)	0.28
" Inoculation of remantadine in combination with nontoxic concentrations of sodium selenite was found to be a promising combination for inhibition of experimental influenza infection."	( [Antiviral action of sodium selenite and its combination with remantadine]. Abdullaev, FI; Abdullaev, II; Lazymova, ZA; Sycheva, IV; Veselovskaia, TV, )	0.13
" Treatment with ribavirin combined with immune serum was more successful; all infected monkeys given combination treatment survived, including six treated initially on day 10."	( Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. Jahrling, PB; Peters, CJ; Stephen, EL, 1984)	0.27
" They must be administered with caution during pregnancy, because some are known teratogens (e."	( Adverse effects and drug interactions of clinical importance with antiviral drugs. Morris, DJ, 1994)	0.29
" MDL 74,428 does not also affect the inhibitory effect of ddI combined with ribavirin on the transformation in vitro of C3H/3T3 cells by Moloney murine sarcoma virus (MSV)."	( Potentiating effect of (2-[2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methyl]-phenyl]ethenyl) -phosphonic acid (MDL 74,428), a potent inhibitor of purine nucleoside phosphorylase, on the antiretroviral activities of 2',3'-dideoxyinosine combined with rib Balzarini, J; Bernhardt, A; Mamont, P; Weibel, M, 1994)	0.29
"The effect of interferon in combination with ribavirin on the plus and minus strands of hepatitis C virus (HCV) RNA in patients with chronic hepatitis C (CHC) was studied by means of nested RT-PCR."	( [The effect of interferon in combination with ribavirin on the plus and minus strands of hepatitis C virus RNA in patients with hepatitis]. He, Y; Liu, W; Zeng, L, 1996)	0.29
"It was shown advisable to use ribavirin (a weak inhibitor of Sindbis virus reproduction) in combination with ACAA."	( [Effect of the amide of 1-adamantanecarboxylic acid (AACA) and its combination with ribavirin on the course of experimental infection, caused by the sindbis virus in tissue culture and in mouse brain. Possible isolation of the virus mutant resistant to ri Andronova, VL, 1997)	0.3
"In mice administered with the same dose of free or conjugated [3H]ribavirin we determined the levels of radioactivity in liver and erythrocytes and measured the hepatic concentrations of ribavirin triphosphate."	( Enhanced accumulation of ribavirin and its metabolites in liver versus erythrocytes in mice administered with the liver targeted drug. Bignamini, A; Busi, C; Colonna, FP; Di Stefano, G; Fiume, L, 1997)	0.3
"7-fold higher than in animals administered with the free drug given intramuscularly or orally, respectively."	( Enhanced accumulation of ribavirin and its metabolites in liver versus erythrocytes in mice administered with the liver targeted drug. Bignamini, A; Busi, C; Colonna, FP; Di Stefano, G; Fiume, L, 1997)	0.3
"We randomly assigned 912 patients with chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin (1000 or 1200 mg orally per day, depending on body weight) for 24 or 48 weeks."	( Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. Albrecht, JK; Cort, S; Goodman, ZD; Gordon, SC; Lee, WM; Ling, MH; McHutchison, JG; Rustgi, VK; Schiff, ER; Shiffman, ML, 1998)	0.3
" However, the impact of the drug combination upon lymphocyte activity is unknown."	( Alpha interferon combined with ribavirin potentiates proliferative suppression but not cytokine production in mitogenically stimulated human lymphocytes. Kimball, PM; Shiffman, ML; Verbeke, SB, 2000)	0.31
"Interferon combined with ribavirin has efficacy in the treatment of patients with chronic hepatitis C virus (HCV) infection."	( Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. Bodenheimer, HC; Bodian, C; Esposito, S; Geders, JM; Goldman, IS; Jacobson, IM; Jones, JL; Klion, FM; Lebovics, E; Min, AD; Tobias, H, 2001)	0.31
"In this study, 5 MU of IFN combined with a standard dose of ribavirin has yielded the highest rate of sustained response reported to date."	( Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial. Andriulli, A; Attino, V; Bacca, D; Carretta, V; Cela, M; Giangaspero, A; Leandro, G; Mangi, A; Minerva, N; Ventrella, F; Villani, MR, 2001)	0.31
"To find the criteria for optimisation of the interferon dose, to be used in combination with ribavirin in patients with hepatitis C non responders to interferon alpha monotherapy."	( Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. Barni, MC; Cadeo, GP; Carosi, G; Cristini, G; Forleo, MA; Gargiulo, F; Paraninfo, G; Puoti, M; Putzolu, V; Quiros-Roldan, E; Rossi, S; Spinetti, A; Zaltron, S; Zanini, B, 2001)	0.31
"These results suggest that higher interferon doses administered daily in combination with ribavirin could be more effective in those patients with hepatitis C who had not responded to interferon alone."	( Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. Barni, MC; Cadeo, GP; Carosi, G; Cristini, G; Forleo, MA; Gargiulo, F; Paraninfo, G; Puoti, M; Putzolu, V; Quiros-Roldan, E; Rossi, S; Spinetti, A; Zaltron, S; Zanini, B, 2001)	0.31
" As treatment strategies to fight cHC have been essentially ameliorated within the recent two years in using pegylated interferon-alfa2b (Peg-IFN-alfa2b) combined with ribavirin, t here is hope that the successful therapeutic outcomes in HCV-mono-infected individuals may be partly translated into benefits for the difficult-to-treat patients with HCV-HIV co-infection."	( Interferon-alpha in treatment of chronic hepatitis C in co-infected HIV-patients in combination with ribavirin and as a pre-load therapy in treatment-naive HIV-positive patients. 8th European Conference on Clinical Aspects and Treatment of HIV Infection ( Tossing, G, 2002)	0.31
" We compared the efficacy and safety of daily interferon alfa-2b in combination with ribavirin with those of interferon alfa-2b three times a week alone or in combination with ribavirin."	( Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. Bernard, PH; Bourlière, M; Canva, V; Capron, D; Chêne, G; Couzigou, P; de Lédinghen, V; Desmorat, H; Fleury, H; Foucher, J; Lévy, S; Mannant, PR; Mion, F; Trimoulet, P; Winnock, M, 2002)	0.31
"We randomly assigned 321 patients with chronic hepatitis C to receive standard-dose interferon alfa-2b alone or in combination with ribavirin for 48 weeks or daily interferon alfa-2b (3 million units per day for 12 weeks then 3 million units three times per week for 24 weeks) and ribavirin (36 week treatment)."	( Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. Bernard, PH; Bourlière, M; Canva, V; Capron, D; Chêne, G; Couzigou, P; de Lédinghen, V; Desmorat, H; Fleury, H; Foucher, J; Lévy, S; Mannant, PR; Mion, F; Trimoulet, P; Winnock, M, 2002)	0.31
"5 million units of interferon-alpha(2a) thrice weekly in combination with ribavirin 1,000 or 1,200 mg daily."	( Interferon-alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients with persistently normal aminotransferase levels. Al-Khalid, J; Al-Mekhaizeem, K; Al-Nakib, B; Al-Shamali, M; Asker, H; Hasan, F; Siddique, I, 2002)	0.31
"We compared the efficacy and safety of the combined therapy of daily interferon alpha-2b and ribavirin with those of interferon alpha-2b three times per week alone or in combination with ribavirin in non-responder patients with hepatitis C virus (HCV) infection."	( Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. Abergel, A; Bernard, PH; Bourlière, M; Chêne, G; Couzigou, P; de Lédinghen, V; Fleury, H; Lévy, S; Portal, I; Rémy, AJ; Szostak, N; Tran, A; Trimoulet, P; Winnock, M, 2002)	0.31
"A total of 376 patients were randomly assigned to receive interferon alpha-2b (6 MU three times per week for 24 weeks followed by 3 MU three times per week for 24 weeks) alone (group A) or in combination with ribavirin for 48 weeks (group B), or daily interferon alpha-2b (3 MU per day for 24 weeks followed by 3 MU three times per week for 24 weeks) and ribavirin (group C)."	( Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. Abergel, A; Bernard, PH; Bourlière, M; Chêne, G; Couzigou, P; de Lédinghen, V; Fleury, H; Lévy, S; Portal, I; Rémy, AJ; Szostak, N; Tran, A; Trimoulet, P; Winnock, M, 2002)	0.31
"The aim of the present, open-labelled, controlled study was to determine whether 5 MU of interferon (IFN) alpha 2b combined with a standard dose of ribavirin might increase the rate of viral clearance in all patients with chronic HCV hepatitis or at least in those with an unfavourable genotype."	( High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. Andriulli, A; Annese, M; Bacca, D; Carretta, V; Cela, M; Leandro, G; Mangia, A; Minerva, N; Piattelli, M; Santoro, R; Spirito, F; Ventrella, F, 2002)	0.31
"1%) the standard 3 MU dose of IFN in combination with ribavirin (P=0."	( High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. Andriulli, A; Annese, M; Bacca, D; Carretta, V; Cela, M; Leandro, G; Mangia, A; Minerva, N; Piattelli, M; Santoro, R; Spirito, F; Ventrella, F, 2002)	0.31
"Our study suggests that when treating naive patients with genotype 1, there is a significant increase in the rate of sustained virologic clearance by increasing the dose of IFN given in combination with ribavirin."	( High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype 1 chronic hepatitis. Andriulli, A; Annese, M; Bacca, D; Carretta, V; Cela, M; Leandro, G; Mangia, A; Minerva, N; Piattelli, M; Santoro, R; Spirito, F; Ventrella, F, 2002)	0.31
" Higher rates of sustained response (33%) without increase of side effects have been observed in preliminary experiences with the new long-acting pegylated interferons in combination with ribavirin."	( Clinical experiences with interferon as monotherapy or in combination with ribavirin in patients co-infected with HIV and HCV. Airoldi, M; Bruno, R; Carosi, G; Castelli, F; El Hamad, I; Filice, G; Moretti, F; Puoti, M; Quiros Roldan, E; Rossi, S; Sacchi, P; Zanini, B, )	0.13
"Patients received IFN 3 MU daily for 14 days followed by 3 MU three times a week (induction group; n = 10), or IFN 3 MU three times a week from start (standard group; n = 21), in combination with ribavirin 1000-1200 mg/day."	( Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirin. Carlsson, T; Reichard, O; Weiland, O, 2002)	0.31
" Patients were randomized for either IFN/Riba and amantadine (Ama) including a 2-week initial high IFN induction course (18 MU IFN daily) (group A) or the same 2-week IFN induction course combined with Riba/Ama, followed by Riba/Ama without IFN (group B)."	( Chronic hepatitis C patients with a post-treatment virological relapse re-treated with an induction dose of 18 MU interferon-alpha in combination with ribavirin and amantadine: a two-arm randomized pilot study. Beld, MG; Dijkgraaf, MG; Reesink, HW; Sentjens, RE; Weegink, CJ, 2003)	0.32
"A randomized trial was conducted to assess the efficacy of daily (QD) or thrice weekly (TIW) administration of interferon-alpha (IFN) in high doses in combination with ribavirin (1."	( A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha nonresponders with chronic hepatitis C: superior efficacy of high daily dosage of interferon alpha in genotype 1. Aggelis, P; Akriviadis, E; Avgerinos, A; Giannoulis, G; Goritsas, K; Hatzakis, A; Hatzis G, G; Kanatakis, S; Ketikoglou, I; Manolakopoulos, S; Paraskevas, E; Raptopoulou, M; Sypsa, V; Tassopoulos, NC; Thomopoulos, K; Tsantoulas, D; Tzathas, C; Vafiadis, I; Vassiliadis, T, 2003)	0.32
"A randomized trial was conducted to assess the efficacy of interferon-alpha (IFN) daily in combination with ribavirin in 301 naïve patients with chronic hepatitis C (CHC)."	( A randomized trial to assess the efficacy of interferon-alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C. Anagnostopoulos, G; Hatzakis, A; Hatzis, G; Kanatakis, S; Ketikoglou, I; Raptopoulou, M; Sidiropoulos, L; Sypsa, V; Tassopoulos, NC; Tsantoulas, D; Vafiadis, I, 2003)	0.32
"Two hundred twenty five consecutive non-responders to previous antiviral treatment(s) with IFN-alpha alone or in combination with ribavirin or amantadine were treated with IFN-alpha 2b 5 MU daily for 4 weeks, 5 MU tiw for 20 weeks, followed by 3 MU tiw for additional 24 weeks combined with ribavirin 1000-1200 mg/d."	( Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. Arnold, R; Berg, T; Herrmann, E; Junge, U; Kullmann, F; Lafrenz, M; Musch, E; Pascu, M; Pausch, J; Ramadori, G; Teuber, G; Weidenbach, H; Wiedmann, KH; Zankel, M; Zeuzem, S, 2003)	0.32
"The differential tolerability profile of various interferon (IFN)-alpha preparations used in combination with ribavirin for the treatment of chronic hepatitis C needs to be elucidated."	( Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study. Annese, M; Babudieri, S; Bacca, D; Barbarini, G; Barbaro, G; Belloni, G; Francavilla, R; Fruttaldo, L; Grisorio, B; Hazra, C; Lucchini, A; Matarazzo, F; Rizzo, G; Torre, D, 2003)	0.32
" Recently, we undertook an in vitro drug-drug combination analysis using surrogate model systems of HCV replication and found a reproducible synergy of antiviral effects between the two drugs at physiologically relevant drug concentrations."	( Implications of finding synergic in vitro drug-drug interactions between interferon-alpha and ribavirin for the treatment of hepatitis C virus. Buckwold, VE, 2004)	0.32
"6%) to interferon alpha-2b in combination with ribavirin therapy."	( Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response. Gudinaviciene, I; Jonaitis, L; Kupcinskas, L; Petrenkiene, V, 2004)	0.32
"0 x 10(5) copies/mL) when given with interferon (IFN)."	( Effects of ribavirin combined with interferon-alpha 2b on viral kinetics during first 12 weeks of treatment in patients with hepatitis C virus genotype 1 and high baseline viral loads. Enomoto, M; Habu, D; Kohmoto, M; Nishiguchi, S; Seki, S; Shiomi, S; Takeda, T; Tamori, A, 2004)	0.32
" These results indicate that mizoribine in combination with IFN-alpha may have potential for the treatment of HCV infection."	( Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-alpha. Baba, C; Baba, M; Yanagida, K, 2004)	0.32
" The aim of this study was to investigate the safety and tolerance to treatment with a high and individualized dose of ribavirin in combination with peginterferon."	( High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Bruchfeld, A; Lindahl, K; Schvarcz, R; Stahle, L, 2005)	0.33
"Ribavirin has recently been demonstrated to be efficacious in combination with interferon (IFN) alpha-2b for the treatment of relapsed hepatitis C infections."	( Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Fujiyama, S; Hamada, A; Saito, H; Sasaki, Y; Uchida, M; Yamasaki, M, 2004)	0.32
" Since mizoribine is currently used in several clinical applications and has not been associated with severe side effects, mizoribine is considered to be of potential use as a new anti-HCV reagent in combination with IFN-alpha."	( Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. Abe, K; Dansako, H; Ikeda, M; Kato, N; Naka, K, 2005)	0.33
"Open, randomized trial was performed in 6 Italian tertiary centers: 102 of the 108 patients screened were randomized to receive 6 MIU of recombinant human IFN beta-1a subcutaneously daily for 24 wk, alone (Group 1, n = 51) or in combination with ribavirin 1,000 to 1,200 mg/d (Group 2, n = 51)."	( Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. Alberti, A; Almasio, PL; Berrutti, M; Boccato, S; Cattaneo, C; Craxi, A; Demelia, L; Ideo, G; Pellicano, R; Picciotto, A; Rizzetto, M; Sorbello, O; Torre, F; Valenza, M; Venezia, G, 2005)	0.33
"Recombinant human IFN beta-1a, alone or in combination with ribavirin, has an excellent safety profile and, may represent an alternative for chronic hepatitis C patients who are unable to tolerate pegylated alpha-interferon."	( Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. Alberti, A; Almasio, PL; Berrutti, M; Boccato, S; Cattaneo, C; Craxi, A; Demelia, L; Ideo, G; Pellicano, R; Picciotto, A; Rizzetto, M; Sorbello, O; Torre, F; Valenza, M; Venezia, G, 2005)	0.33
"To evaluate the daily high-dose induction therapy with interferon-alpha2b (IFN-alpha2b) in combination with ribavirin for the treatment of patients who failed with interferon monotherapy and had a relapse, based on the assumption that the viral burden would decline faster, thus increasing the likelihood of higher response rates in this difficult-to-treat patient group."	( High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy. Fischinger, J; Hass, HG; Kaiser, S; Kreysel, C; Menzel, J, 2005)	0.33
" Treatment was started with 10 MU IFN-alpha2b daily for 3 wk, followed by IFN-alpha2b 5 MU/TIW in combination with ribavirin (1 000-1 200 mg/d) for 21 wk."	( High-dose interferon-alpha2b induction therapy in combination with ribavirin for treatment of chronic hepatitis C in patients with non-response or relapse after interferon-alpha monotherapy. Fischinger, J; Hass, HG; Kaiser, S; Kreysel, C; Menzel, J, 2005)	0.33
"To study antiviral activity of arbidol in relation to various antigenic subtypes of influenza virus isolated from humans; efficacy of arbidol action in combination with adamantanic antiviral drugs, ribavirin and ribamidil on reproduction of influenza virus A (IVA) in cell culture."	( [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]. Fediakina, IT; Glushkov, RG; Gus'kova, TA; Leneva, IA, 2005)	0.33
" The inhibiting activity of arbidolin on cell culture viral reproduction enhanced if arbidol was used in combination with amantadine, remantadin, ribavirin and ribamidil."	( [Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A]. Fediakina, IT; Glushkov, RG; Gus'kova, TA; Leneva, IA, 2005)	0.33
" We determined the optimal ribavirin dose in an initial cohort of a phase 1 study and then subsequently used it, in combination with interferon alfa-2b, in a second cohort of this study and a phase 3 trial."	( Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Baczkowski, A; Geffner, M; González-Peralta, RP; Gupta, S; Haber, B; Jonas, MM; Kelly, DA; Lang, T; Laughlin, M; Lurie, Y; Martin, S; Mieli-Vergani, G; Molleston, J; Murray, KF; Shelton, M, 2005)	0.33
" We describe a case of a HCV genotype 1b patient who had failed previous combination therapies of interferon plus ribavirin and pegylated interferon plus ribavirin and was subsequently successfully treated with a novel triple drug combination consisting of interferon-gamma plus interferon alfacon plus ribavirin with the outcome of a sustained virologic response."	( Successful treatment with novel triple drug combination consisting of interferon-gamma, interferon alfacon-1, and ribavirin in a nonresponder HCV patient to pegylated interferon therapy. Anderson, MH; Balan, V; Rakela, J; Rosati, MJ, 2006)	0.33
" To clarify the usefulness of combination therapy with IFN and ribavirin in Japanese hepatitis C patients, we treated patients with a relatively high dose of IFN in combination with ribavirin for 24 weeks and examined the effects in relation to the viral parameters."	( Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1. Arakawa, Y; Fujiwara, K; Imazeki, F; Kato, N; Komine, F; Moriyama, M; Omata, M; Shiratori, Y; Tanaka, N; Yokosuka, O; Yoshida, H, 2006)	0.33
"The aim of the study was to assess the cost-effectiveness of peginterferon alfa-2b (pegIFN) compared to interferon alfa-2b (IFN), both in combination with ribavirin, as initial therapy for chronic hepatitis C in Sweden."	( Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Bernfort, L; Reichard, O; Sennfält, K, 2006)	0.33
"5 microg/kg) alone as monotherapy (n=16) or in combination with ribavirin (n=22), for 48 weeks."	( Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Andriulli, A; Brancaccio, G; Ciancio, A; David, E; Fontana, R; Gaeta, GB; Marrone, A; Niro, GA; Olivero, A; Perri, F; Rizzetto, M; Smedile, A; Stanzione, M, 2006)	0.33
" We evaluated the safety, efficacy and tolerability of standard interferon-alpha in an accelerating dose regimen in combination with ribavirin in patients with HCV-induced liver cirrhosis and thrombocytopenia."	( Standard interferon-alpha in combination with ribavirin for hepatitis C patients with advanced liver disease and thrombocytopenia. Bergholz, U; Ferenci, P; Gurguta, C; Hofer, H; Steindl-Munda, P, 2006)	0.33
" We evaluated the efficacy and safety of Viusid in combination with interferon alpha-2b (IFN alpha-2b) and ribavirin in patients with CHC."	( Viusid, a nutritional supplement, in combination with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Gra Oramas, B; Llanio Navarro, R; Ruenes Domech, C; Soler, E; Vilar Gomez, E, 2007)	0.34
"Interferon (IFN) has been well documented to cause thyroid dysfunction, especially in high risk patients and when combined with ribavirin (RBV)."	( Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. Attia, JR; Batey, RG; Jones, TL; Tran, HA, 2007)	0.34
"The pegylation of IFN, in combination with RBV, did not aggravate thyroid diseases in the hepatitis C population."	( Pegylated interferon-alpha2beta in combination with ribavirin does not aggravate thyroid dysfunction in comparison to regular interferon-alpha2beta in a hepatitis C population: meta-analysis. Attia, JR; Batey, RG; Jones, TL; Tran, HA, 2007)	0.34
"To evaluate the safety and efficacy of interferon alpha daily induction regimen in combination with ribavirin."	( Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study. Braga, EL; Kalabrik, L; Lyra, AC; Lyra, LG; Nascimento, L; Netto, E, )	0.13
" ribavirin combined with pegylated interferon in patients with chronic hepatitis C (CHC)."	( Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study. Arora, S; Gish, RG; Murphy, B; Nelson, DR; O'Brien, C; Rajender Reddy, K; Xu, Y, 2007)	0.34
"Efficacy and safety of interferon induction therapy alone or in combination with ribavirin or ribavirin plus amantadine were evaluated in chronic hepatitis C patients who were nonresponders to primary antiviral treatment."	( A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C. Andreone, P; Attard, L; Bernardi, M; Biselli, M; Boccia, S; Bonvicini, F; Cursaro, C; Furlini, G; Galli, S; Giacomoni, PL; Gramenzi, A; Lorenzini, S; Verucchi, G, 2007)	0.34
" This study aimed to assess the safety and efficacy of two different regimens of peg-IFN alfa-2b, in combination with ribavirin, in genotype 3 patients."	( Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience. Bansal, M; Hissar, S; Kumar, M; Midha, V; Sakhuja, P; Sarin, SK; Sood, A; Sood, N; Suneetha, PV, 2008)	0.35
" We chose a low initial RBV dose, later increased due to tolerance to a mean dose of 600 mg daily (range 200-1000 mg daily) in combination with a peg-IFN alpha-2a 180 mcg weekly in an effort to improve tolerance and minimize withdrawals."	( High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation. Gjertsen, H; Hörnfeldt, E; Weiland, O, 2008)	0.35
"The clinical laboratory investigations of patients with chronic viral hepatitises combined with chronic opisthorchosis are presented."	( Clinical-epidemiological features, diagnostics, treatment of chronic viral hepatitises, combined with opisthorchosis in inhabitants of Siberia and the Northern regions of Russia. Paltsev, AI, 2007)	0.34
"To report the results of a pilot study using rituximab combined with Peg-interferon (IFN) alpha2b-ribavirin in severe refractory hepatitis C virus (HCV) related mixed cryoglobulinaemia (MC) vasculitis."	( Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Cacoub, P; Karras, A; Perard, L; Resche-Rigon, M; Saadoun, D; Sene, D, 2008)	0.35
" They were treated with rituximab (375 mg/m2 intravenously weekly for 4 weeks) combined with Peg-IFNalpha2b (1."	( Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Cacoub, P; Karras, A; Perard, L; Resche-Rigon, M; Saadoun, D; Sene, D, 2008)	0.35
"Rituximab combined with Peg-IFNalpha2b-ribavirin represents a safe and effective treatment option in severe refractory HCV-MC vasculitis."	( Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Cacoub, P; Karras, A; Perard, L; Resche-Rigon, M; Saadoun, D; Sene, D, 2008)	0.35
" In contrast, we demonstrate that a triple drug combination of IFN, RBV, and an iminosugar eradicated the BVDV infection in a time- and a dose-dependent manner, leading to sustained viral clearance."	( Iminosugars in combination with interferon and ribavirin permanently eradicate noncytopathic bovine viral diarrhea virus from persistently infected cells. Branza-Nichita, N; Dwek, RA; Hussey, M; Michelet, M; Smith, C; Woodhouse, SD; Zitzmann, N, 2008)	0.35
" The present study evaluated the efficacy and safety of R1626 administered for 4 weeks in combination with peginterferon alfa-2a +/- ribavirin in HCV genotype 1-infected treatment-naive patients."	( R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Najera, I; Nelson, D; Nyberg, L; Pockros, PJ; Rodriguez-Torres, M; Shiffman, ML, 2008)	0.35
"The aim of our study was to conduct a systematic review of studies evaluating antiviral therapy with pegylated interferon (PEG-IFN) alfa in combination with ribavirin for the management of recurrent hepatitis C after liver transplantation."	( Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. Berenguer, M, 2008)	0.35
" Hence, combinations of nucleoside analogues beta-D-2'-C-methylcytidine (2'-C-MeC; NM-107) or beta-D-2'-deoxy-2'-fluoro-2'-C-methyleytidine (2'-F-C-MeC; PSI-6130) with interferon-alpha2b (IFN-alpha2b) or triple combination with ribavirin (RBV) were evaluated."	( Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Bassit, L; Bennett, M; Grier, J; Schinazi, RF, 2008)	0.35
"Huh-7 cells containing the self-replicating subgenomic HCV replicon (Clone B) were used for drug combination studies."	( Combinations of 2'-C-methylcytidine analogues with interferon-alpha2b and triple combination with ribavirin in the hepatitis C virus replicon system. Bassit, L; Bennett, M; Grier, J; Schinazi, RF, 2008)	0.35
" The aim of this study was to compare virological response rates in patients with chronic hepatitis C virus (HCV)-1 infection treated with 400 mg amantadine or placebo in combination with peginterferon alfa-2a (40 kD) and ribavirin for 48 weeks."	( Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Berg, T; Buggisch, P; Gerken, G; Goeser, T; Herrmann, E; Hinrichsen, H; Hofmann, WP; Manns, M; Spengler, U; Teuber, G; von Wagner, M; Weidenbach, H; Zeuzem, S, 2008)	0.35
"6 log(10) units was obtained in phase II studies when Debio 025 was combined with interferon (R."	( Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors. Coelmont, L; Dumont, JM; Kaptein, S; Neyts, J; Paeshuyse, J; Vliegen, I; Vuagniaux, G, 2009)	0.35
" These mt-QSARs offer also a good opportunity to construct drug-drug Complex Networks (CNs) that can be used to explore large and complex drug-viral species databases."	( Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks. Chou, KC; González-Díaz, H; Martinez de la Vega, O; Prado-Prado, FJ; Ubeira, FM; Uriarte, E, 2009)	0.35
" For inclusion, patients should have been treated with interferon alone or combined with ribavirin, with no virological response (non responders and relapsers) and had a liver biopsy before and after treatment."	( Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin. Bergamaschi, D; Focaccia, R; Patzina, R; Prado, K, 2008)	0.35
"The aim of this study was to compare the efficacy of high-dose interferon (IFN)-alpha-2b with standard dose of IFN-alpha-2b in combination with ribavirin (RBV) for patients with chronic hepatitis C virus (HCV) infection, and to investigate the predictive factors associated with virological response."	( Randomized trial of high-dose interferon-alpha-2b combined with ribavirin in patients with chronic hepatitis C: Correlation between amino acid substitutions in the core/NS5A region and virological response to interferon therapy. Aikata, H; Chayama, K; Imamura, M; Kawakami, Y; Kawaoka, T; Mori, N; Saneto, H; Takahashi, S; Takaki, S, 2009)	0.35
" The effect of Virazole in combination with Stimforte in reducing the replication of infectious HCV and the accumulation of antigens in HCV-infected mice was additive or synergic, suggesting that it is expedient to use them concurrently."	( [Effect of Stimforte in combination with Virazole on infection induced by hepatitis C virus in mice]. Bel'kov, AP; Deriabin, PG; Il'ichev, AV; Isaeva, EI; Mal'dov, DG, )	0.13
"A large multicenter trial to compare the efficacy of peginterferon alfa-2a with interferon alfa-2a, in combination with ribavirin, in chronic hepatitis C patients."	( A randomized, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients. Adler, M; Bastens, B; Brenard, R; D'Heygere, E; Delwaide, J; Hendlisz, A; Henrion, J; Laureys, A; Lenaerts, A; Michielsen, P; Nevens, F; Van Vlierberghe, H, )	0.13
"7 and 5 log(10) IU/mL, respectively, associated with 1500-mg doses twice daily after monotherapy for 2 weeks and with 1000-mg and 1500-mg doses twice daily after treatment in combination with the standard of care (SOC) for 4 weeks."	( RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. Berrey, M; Cammack, N; De La Rosa, A; Ewing, A; Kang, H; Kosaka, A; Le Pogam, S; Nájera, I; Seshaadri, A; Symonds, B; Yan, JM, 2010)	0.36
" From 85 patients receiving RG7128 in combination with SOC, 1 HCV genotype 1-infected patient experienced a viral rebound, and 2 genotype 3-infected patients experienced a transient rebound."	( RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients. Berrey, M; Cammack, N; De La Rosa, A; Ewing, A; Kang, H; Kosaka, A; Le Pogam, S; Nájera, I; Seshaadri, A; Symonds, B; Yan, JM, 2010)	0.36
" Twelve weeks thereafter, he received IFN-α 3 MU daily for 2 weeks and then 3 times a week for 14 weeks combined with oral ribavirin 600 mg daily during 16 weeks."	( Interferon alone or combined with ribavirin for acute prolonged infection with hepatitis C virus in chimpanzees. Katayama, K; Miyakawa, Y; Mizui, M; Tanaka, J; Tomoguri, T; Yoshizawa, H; Yugi, H, 2011)	0.37
"To study the clinical efficacy of PEG-Interferon alpha-2a combined with ribavirin in eldly chronic hepatitis."	( [Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C]. Jia, CH; Lan, L; Liu, BW; Yu, J; Yuan, Y; Zhang, H, 2010)	0.36
" The twenty eldly patients of treatment group receive peg-interferon alpha-2a 135-180 microg subcutaneous injection every week combined with ribavirin 600-1000 mg/d for 48 weeks, and twenty adult patients of control group receive peg-interferon 135-180 microg subcutaneous injection every week combined with ribavirin 800-1200 mg/d for 48 weeks."	( [Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C]. Jia, CH; Lan, L; Liu, BW; Yu, J; Yuan, Y; Zhang, H, 2010)	0.36
"The eldly patients with Chronic Hepatitis C using general dose peg-IFNalpha-2a combined with lower dose ribavirin can still obtain the similar efficiency and excellent tolerance when the basic diseases such as hypertension, diabetes and side effects were treated successfully."	( [Efficacy of peginterferon alpha-2a in combination with ribavirin in treatment of eldly patients with chronic hepatitis C]. Jia, CH; Lan, L; Liu, BW; Yu, J; Yuan, Y; Zhang, H, 2010)	0.36
" Finally, we demonstrated the additive or synergistic antiviral effect of siRNAs used in combination with ribavirin."	( Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin. Bouloy, M; Crance, JM; Flusin, O; Iseni, F; Peyrefitte, CN; Vigne, S, 2011)	0.37
"Our study highlights the interest of using RNAi (alone or in combination with ribavirin) to treat nairovirus infection."	( Inhibition of Hazara nairovirus replication by small interfering RNAs and their combination with ribavirin. Bouloy, M; Crance, JM; Flusin, O; Iseni, F; Peyrefitte, CN; Vigne, S, 2011)	0.37
"The safety and antiviral efficacy of danoprevir was examined over 14 days in combination with pegylated interferon α-2a (180 μg once weekly) and ribavirin (1000-1200 mg/day) in a double-blind, placebo-controlled, phase 1b, multiple ascending dose study consisting of 6 dose cohorts (400 mg, 600 mg, and 900 mg twice daily and 100 mg, 200 mg, and 300 mg 3 times daily)."	( Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. Bradford, W; Forestier, N; Guyader, D; Larrey, D; Lim, S; Marcellin, P; Patat, A; Porter, S; Qin, X; Rouzier, R; Seiwert, SD; Smith, PF; Zeuzem, S, 2011)	0.37
"Danoprevir in combination with pegylated interferon α-2a and ribavirin was safe and generally well tolerated."	( Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. Bradford, W; Forestier, N; Guyader, D; Larrey, D; Lim, S; Marcellin, P; Patat, A; Porter, S; Qin, X; Rouzier, R; Seiwert, SD; Smith, PF; Zeuzem, S, 2011)	0.37
"Our study showed substantial antiviral efficacy of danoprevir in combination with pegylated interferon α-2a and ribavirin."	( Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis C. Bradford, W; Forestier, N; Guyader, D; Larrey, D; Lim, S; Marcellin, P; Patat, A; Porter, S; Qin, X; Rouzier, R; Seiwert, SD; Smith, PF; Zeuzem, S, 2011)	0.37
" Our aims were to prospectively assess the antiviral efficacy and safety of this drug combination in chronic hepatitis C (CHC) patients."	( Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. Altmeyer, R; Cheng, CW; Chopra, N; Lawitz, E; Lim, SG; McHutchison, JG; Patel, K; Randle, JC; Tillmann, HL, 2011)	0.37
" Although data sets were not complete, patients with IL28B CT and TT genotype appear to significantly improve when these agents are combined with PEG-INF and RBV."	( Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Kwo, PY, 2012)	0.38
" The adverse events related to ribavirin and drug-drug interactions during therapy for hepatitis C are discussed."	( Severe anaemia related to oseltamivir during treatment of chronic hepatitis C: a new drug interaction? Buti, M; Esteban, R; Simón-Talero, M, 2012)	0.38
" We evaluated ITX 5061 in combination with interferon-α, ribavirin, and HCV protease and polymerase inhibitors in a genotype 2a infectious virus system."	( Evaluation of ITX 5061, a scavenger receptor B1 antagonist: resistance selection and activity in combination with other hepatitis C virus antivirals. Lee, H; McKelvy, J; Schooley, RT; Syder, A; Wong-Staal, F; Wyles, DL; Zhu, H, 2012)	0.38
", Minneapolis, MN, USA) in combination with ribavirin (1,000-1,600 mg) for 48 weeks."	( Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients. Bergmann, JF; Boonstra, A; de Knegt, RJ; Haagmans, BL; Hansen, BE; Janssen, HL; Kwadijk-de Gijsel, S; Roomer, R; van Vuuren, AJ, 2012)	0.38
"In this double-blind, placebo-controlled study, 57 HCV genotype (GT)-1 patients (n=27 treatment-naïve [TN]; n=30 treatment-experienced [TE]) with compensated liver disease were randomised for 28-day treatment with 400, 600, or 800 mg BI 207127 three times daily (TID) or placebo (only TN) in combination with peginterferon alfa 2a and ribavirin (PegIFN/RBV)."	( Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. Abdallah, N; Arastéh, K; Berger, F; Böcher, W; Cerny, A; de Ledinghen, V; Dikopoulos, N; Gerken, G; Gerlach, T; Girlich, B; Heim, MH; Kukolj, G; Larrey, D; Lohse, AW; Marquis, M; Mathurin, P; Scherer, J; Schuchmann, M; Steffgen, J; Stern, JO; Thimme, R; Tran, A; Trautwein, C; Trepo, C; Wu, K; Zarski, JP, 2012)	0.38
"BI 207127 in combination with PegIFN/RBV demonstrated strong antiviral activity with a favourable safety and tolerability profile."	( Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin. Abdallah, N; Arastéh, K; Berger, F; Böcher, W; Cerny, A; de Ledinghen, V; Dikopoulos, N; Gerken, G; Gerlach, T; Girlich, B; Heim, MH; Kukolj, G; Larrey, D; Lohse, AW; Marquis, M; Mathurin, P; Scherer, J; Schuchmann, M; Steffgen, J; Stern, JO; Thimme, R; Tran, A; Trautwein, C; Trepo, C; Wu, K; Zarski, JP, 2012)	0.38
"To study the clinical efficacy of PEG Interferon alpha-2a combined with ribavirin in treatment of with hepatitis C cirrhosis patients."	( [Efficacy of peg interferon alpha-2a in combination with ribavirin in treatment of with hepatitis C cirrhosis patients]. Liu, GW; Ma, SP; Wang, CF; Zhao, WX, 2011)	0.37
" Its combination with pegylated interferon and ribavirin needs further evaluation."	( Randomized controlled trial of interferon gamma versus amantadine in combination with interferon alpha and ribavirin for hepatitis C genotype 3 non-responders and relapsers. Abbas, Z; Hamid, S; Jafri, W; Raza, S, 2012)	0.38
" 23 patients received pegylated interferon in monotherapy or in combination with ribavirin."	( The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Cacopardo, B; Fatuzzo, F; Montineri, A; Nunnari, G; Portelli, V; Savalli, F, 2012)	0.38
" The combination with ribavirin did not appear to impact our sustained response rate, although ribavirin appeared to induce a faster normalization of ALT levels."	( The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Cacopardo, B; Fatuzzo, F; Montineri, A; Nunnari, G; Portelli, V; Savalli, F, 2012)	0.38
" When used in combination with pegylated interferon and ribavirin, telaprevir has demonstrated a substantial increase in sustained virological response compared with pegylated interferon and ribavirin used alone."	( Telaprevir: pharmacokinetics and drug interactions. Beaumont, M; Garg, V; Kauffman, RS; van Heeswijk, RP, 2012)	0.38
" Four hundred and twenty-nine HCV genotype (GT)-1 treatment-naïve patients without cirrhosis were randomized 1:1:2:2 to receive 24 weeks of pegylated interferon alfa-2a and ribavirin (PegIFN/RBV) in combination with placebo, faldaprevir 120 mg QD with 3 days of PegIFN/RBV lead-in (LI), 240 mg QD with LI, or 240 mg QD without LI, followed by an additional 24 weeks of PegIFN/RBV."	( Faldaprevir combined with pegylated interferon alfa-2a and ribavirin in treatment-naïve patients with chronic genotype 1 HCV: SILEN-C1 trial. Asselah, T; Bessone, F; Böcher, WO; Datsenko, Y; Fainboim, H; Ferenci, P; Heo, J; Kukolj, G; Lalezari, J; Leggett, B; Mauss, S; Nehmiz, G; Scherer, J; Steinmann, GG; Stern, JO; Sulkowski, MS, 2013)	0.39
" Sequential cohorts of 20 patients, randomized 16:4 (active:placebo), received IDX184 for 14 days at rising daily doses of 50, 100, 150 or 200 mg in combination with P/R for 14 days."	( IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C. Box, T; Chen, J; Dejesus, E; Dubuc-Patrick, G; Godofsky, E; Kwo, P; Lalezari, J; Lawrence, S; Mayers, D; McCarville, J; Mehra, P; Nguyen, T; O'Riordan, W; Pietropaolo, K; Poordad, F; Sullivan-Bólyai, J; Zhou, XJ, 2013)	0.39
"IDX184 in combination with P/R for 14 days was well tolerated and demonstrated greater antiviral activity with more patients achieving undetectable viral load than P/R."	( IDX184 in combination with pegylated interferon-α2a and ribavirin for 2 weeks in treatment-naive patients with chronic hepatitis C. Box, T; Chen, J; Dejesus, E; Dubuc-Patrick, G; Godofsky, E; Kwo, P; Lalezari, J; Lawrence, S; Mayers, D; McCarville, J; Mehra, P; Nguyen, T; O'Riordan, W; Pietropaolo, K; Poordad, F; Sullivan-Bólyai, J; Zhou, XJ, 2013)	0.39
" We randomly allocated all eligible patients with HCV genotype 1 (cohort A) to receive sofosbuvir 200 mg, sofosbuvir 400 mg, or placebo (2:2:1) for 12 weeks in combination with peginterferon (180 μg per week) and ribavirin (1000-1200 mg daily), after which they continued peginterferon and ribavirin for an additional 12 weeks or 36 weeks (depending on viral response)."	( Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Abrams, GA; Afdhal, NH; Albanis, E; Bernstein, DE; Berrey, MM; Bzowej, NH; Darling, JM; Dejesus, E; Dieterich, DT; Freilich, B; Hassanein, T; Hindes, R; Hyland, RH; Jacobson, IM; Jensen, D; Kowdley, KV; Lalezari, JP; Lawitz, E; Lin, M; Mader, M; Mo, H; Muir, A; Nelson, DR; Poordad, FF; Reddy, KR; Rodriguez-Torres, M; Sheikh, AM; Sulkowski, MS; Symonds, WT, 2013)	0.39
" In all, 290 noncirrhotic HCV genotype (GT)-1 patients with prior null (<1 log10 viral load [VL] drop at any time on treatment) or partial response (≥1 log10 VL drop but never undetectable on treatment) were randomized 2:1:1 to receive 48 weeks of peginterferon alfa-2a and ribavirin (PegIFN/RBV) in combination with faldaprevir 240 mg once daily (QD) with 3 days PegIFN/RBV lead-in (LI), 240 mg QD without LI, or 240 mg twice daily (BID) with LI."	( Faldaprevir combined with peginterferon alfa-2a and ribavirin in chronic hepatitis C virus genotype-1 patients with prior nonresponse: SILEN-C2 trial. Asselah, T; Böcher, WO; Bourlière, M; Bronowicki, JP; Datsenko, Y; Kukolj, G; Larrey, D; Mauss, S; Nehmiz, G; Pawlotsky, JM; Pol, S; Scherer, J; Shafran, SD; Steinmann, GG; Stern, JO; Sulkowski, MS, 2013)	0.39
"Patients who participated in randomised, controlled trials or an extended access programme of treatment with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral (telaprevir, danoprevir, faldaprevir, simeprevir, mericitabine, balapiravir) were followed after achieving SVR."	( Durability of SVR in chronic hepatitis C patients treated with peginterferon-α2a/ribavirin in combination with a direct-acting anti-viral. Beinhardt, S; Dulic, M; Ferenci, P; Gschwantler, M; Hofer, H; Holzmann, H; Laferl, H; Maieron, A; Rutter, K; Scherzer, TM; Stättermayer, AF; Steindl-Munda, P; Strassl, R, 2013)	0.39
" This analysis evaluated the cost-effectiveness of TVR combined with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin (RBV) compared with Peg-IFN alfa-2a and RBV (PR) alone or BOC plus Peg-IFN alfa-2b and RBV in treatment-experienced patients."	( Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients. Bianic, F; Cure, S; Curtis, S; Dusheiko, G; Gavart, S; Lee, S, 2014)	0.4
"To evaluate the efficacy and safety of telaprevir combined with peginterferon alfa (Peg-IFNa) plus ribavirin (RBV) (collectively, TPR therapy) in patients with chronic hepatitis C (CHC) using a meta-analysis approach."	( [Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C]. Wang, P; Wang, X; Xu, DH; Yan, SS; Yin, J; Zhang, PJ, 2013)	0.39
"The therapeutic effect of research group is better than that of control group, suggesting that ornithine aspartate combined with naloxone treatment in hepatic encephalopathy is worthy of promoting."	( [Meta-analysis of the efficacy and safety of telaprevir combined with peginterferon alfa plus ribavirin in patients with chronic hepatitis C]. Wang, P; Wang, X; Xu, DH; Yan, SS; Yin, J; Zhang, PJ, 2013)	0.39
" This 28-day, double-blind, randomized, placebo-controlled study evaluated once daily GSK2336805 60 mg alone or in combination with peginterferon alfa-2a (180 μg per week) and ribavirin (1000-1200 mg daily) (PEG/RIBA) in treatment-naive genotype 1 CHC subjects."	( A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected Adkison, K; Cutrell, A; Elko-Simms, C; Gardner, S; Hamatake, R; Hong, Z; Rodriguez-Torres, M; Walker, J, 2014)	0.4
"GSK2336805 is a potent NS5A inhibitor that showed a substantial antiviral effect as a monotherapy and in combination with peginterferon and ribavirin."	( A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected Adkison, K; Cutrell, A; Elko-Simms, C; Gardner, S; Hamatake, R; Hong, Z; Rodriguez-Torres, M; Walker, J, 2014)	0.4
" This analysis evaluated the cost-effectiveness of TVR combined with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin (RBV), with Peg-IFN and RBV (PR) alone or with boceprevir (B, BOC) plus Peg-IFN alfa-2b and RBV, in naïve patients."	( Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. Bianic, F; Cure, S; Curtis, S; Dusheiko, G; Gavart, S; Lee, S, 2014)	0.4
"CIGB-230, combined with IFN-α-based therapy, modifies the immune response in chronic patients."	( HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin. Aguilar-Noriega, D; Alvarez-Lajonchere, L; Amador-Cañizares, Y; Armas, A; Castellanos, M; Cinza-Estévez, Z; Dausá, M; Dubuisson, J; Dueñas-Carrera, S; González, Y; Guerra, I; Martínez-Donato, G; Núñez, M; Pérez Aguiar, A; Raíces, I; Revé, I; Valenzuela, C; Vasallo, C; Wychowski, C, 2014)	0.4
" The efficacy and safety of daclatasvir combined with peginterferon alfa-2a (alfa-2a) and ribavirin were assessed in a randomized, double-blind Phase IIa study of Japanese patients with chronic HCV genotype-1 infection."	( Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Hu, W; Hughes, EA; Ishikawa, H; Izumi, N; Kawada, N; Kumada, H; McPhee, F; Osaki, Y; Sata, M; Ueki, T; Yamamoto, K; Yokosuka, O, 2014)	0.4
"Japanese patients who were treatment-naive (n=25) or prior null (n=12) or partial (n=5) responders received once-daily daclatasvir 10 mg or 60 mg or placebo in combination with alfa-2a and ribavirin."	( Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Hu, W; Hughes, EA; Ishikawa, H; Izumi, N; Kawada, N; Kumada, H; McPhee, F; Osaki, Y; Sata, M; Ueki, T; Yamamoto, K; Yokosuka, O, 2014)	0.4
"Daclatasvir combined with alfa-2a/ribavirin in treatment-naive patients showed greater efficacy than alfa-2a/ribavirin alone and was generally well tolerated."	( Daclatasvir combined with peginterferon alfa-2a and ribavirin in Japanese patients infected with hepatitis C genotype 1. Hu, W; Hughes, EA; Ishikawa, H; Izumi, N; Kawada, N; Kumada, H; McPhee, F; Osaki, Y; Sata, M; Ueki, T; Yamamoto, K; Yokosuka, O, 2014)	0.4
" Further evaluation of filibuvir in combination with other direct-acting antiviral agents may be considered."	( A phase 2 study of filibuvir in combination with pegylated IFN alfa and ribavirin for chronic HCV. Hammond, JL; Marcellin, P; Purohit, VS; Rodriguez-Torres, M; Srinivasan, S; Wang, C; Yoshida, EM, )	0.13
"To conduct a network meta-analysis (NMA) to determine the comparative efficacy, as measured by sustained virological response (SVR), between boceprevir (BOC), telaprevir (TEL), faldaprevir (FAL), simeprevir (SIM) and sofosbuvir (SOF) in combination with peginterferon-ribavirin (PR) against a control of PR."	( Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. Druyts, E; Lorenzi, M; Mills, EJ; Thorlund, K; Toor, K, 2015)	0.42
" RCTs assessing standard duration therapy (SDT) or response-guided therapy (RGT) BOC, TEL, FAL, SIM or SOF in combination with PR against a control of PR were eligible for inclusion."	( Network meta-analysis of direct-acting antivirals in combination with peginterferon-ribavirin for previously untreated patients with hepatitis C genotype 1 infection. Druyts, E; Lorenzi, M; Mills, EJ; Thorlund, K; Toor, K, 2015)	0.42
"The first generation protease inhibitors, boceprevir (BOC) and telaprevir (TVR), are both CYP3A4 inhibitors, which predispose drug-drug interactions (DDIs)."	( Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence. Bory, F; Broquetas, T; Cabrero, B; Cañete, N; Carrión, JA; Coll, S; García-Retortillo, M; Giménez, MD; González-Colominas, E; Knobel, H; Pellicer, R; Retamero, A; Salas, E; Solà, R, 2015)	0.42
" The introduction of triple therapy using SMV in combination with peginterferon and ribavirin (PR) significantly improves the cure rate."	( Cost-effectiveness analysis of simeprevir in combination with peginterferon and ribavirin for treatment-naïve chronic hepatitis C genotype 1 patients in Japan. Cerri, K; Kuwabara, H; Mahlich, J; Treur, M; Westerhout, K; Yatsuhashi, H, 2015)	0.42
"5 μg/day) for 4 weeks, and then they were given pegylated interferon (Peg-IFN)-α2a plus ribavirin therapy in combination with either vitamin D3 for 48 or 72 weeks according to the response-guided manner."	( Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C. Asabe, S; Funyu, J; Hashimoto, Y; Hosoda, Y; Inao, M; Koshima, Y; Mochida, S; Nakayama, N; Nishikawa, K; Omori-Mizuno, Y; Tanaka, M; Tomita, K; Yakabi, K, 2015)	0.42
" Because boceprevir is metabolized by metabolic routes common to many other drugs, and is an inhibitor of cytochrome P450 (CYP) 3A4/5, there is a high potential for drug-drug interactions when boceprevir is administered with other therapies, particularly when treating patients with chronic HCV infection who are often receiving other medications concomitantly."	( Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions. Butterton, JR; Feng, HP; Hulskotte, EG; Khalilieh, S; Wenning, LA, 2015)	0.42
" The efficacy, tolerability, and absence of drug-drug interactions of ledipasvir-sofosbuvir suggest that it could be an important option for treatment of genotype 1 hepatitis C virus in Japanese patients."	( Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Betular, J; Enomoto, H; Gao, B; Garrison, K; Genda, T; Ide, T; Ikeda, F; Ishizaki, A; Izumi, N; Knox, SJ; Korenaga, M; McHutchison, JG; Mizokami, M; Mo, H; Mochizuki, H; Nakane, K; Nirei, K; Nishigaki, Y; Omata, M; Omote, M; Pang, PS; Sakamoto, N; Symonds, WT; Takehara, T; Toda, N; Toyoda, H; Ueno, Y; Umemura, T; Yanase, M; Yatsuhashi, H; Yokosuka, O, 2015)	0.42
" We examined the utility of plasma MERS-CoV PCR as a prognostic indicator and compared the efficacies of IFN-α2a and IFN-β1a when combined with ribavirin in reducing MERS-CoV-related mortality rates."	( IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study. Al-Jiffri, A; Farahat, F; Mushtaq, A; Shalhoub, S; Shamma, O; Siddiqi, N; Simhairi, R, 2015)	0.42
"Although several vitamin D-related gene polymorphisms were reported to affect the outcome of pegylated interferon/ribavirin (PR) therapy in chronic hepatitis C patients, there are no reports on the impact of the vitamin D-related gene polymorphisms in PR therapy combined with protease inhibitor (PI)."	( Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C. Abe, H; Aizawa, Y; Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Shimada, N; Tsubota, A, 2015)	0.42
" Here, we investigated the antiviral efficacy of the peptidomimetic furin inhibitor MI-701 in combination with oseltamivir carboxylate and ribavirin against the infection of highly pathogenic avian influenza viruses (HPAIV) that are activated by the host protease furin."	( Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells. Böttcher-Friebertshäuser, E; Dahms, SO; Garten, W; Hardes, K; Klenk, HD; Lu, Y; Steinmetzer, T; Than, ME, 2015)	0.42
"The percent of serum NS5A-Y93H strains relative to the total strains was quantified using cycling-probe real-time PCR combined with direct sequencing in 444 patients with genotype 1b HCV, and the factors associated with mutation were analyzed."	( Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. Ando, S; Imai, Y; Inao, M; Kouyama, J; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Uchida, Y, 2016)	0.43
"We studied the therapeutic potential of favipiravir (T-705) for Lassa fever, both alone and in combination with ribavirin."	( Efficacy of Favipiravir Alone and in Combination With Ribavirin in a Lethal, Immunocompetent Mouse Model of Lassa Fever. Bockholt, S; Günther, S; Krasemann, S; Lüdtke, A; Muñoz-Fontela, C; Oestereich, L; Pallasch, E; Rieger, T; Ruibal, P; Wurr, S, 2016)	0.43
"Most patients with chronic hepatitis C virus (HCV) genotype 1 infection who have had a previous null response (<2-log10 reduction in HCV RNA by treatment week 12) to peginterferon/ribavirin (PegIFN/RBV) do not achieve a sustained virological response (SVR) when re-treated with a first-generation HCV protease inhibitor (PI) administered in combination with PegIFN/RBV."	( Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies. Forns, X; Hézode, C; Le Pogam, S; Lee, SS; Nájera, I; Scalori, A; Thommes, JA; Voulgari, A; Wedemeyer, H, 2016)	0.43
" Amongst the various NSAID compounds, Mefenamic acid (MEFE) and Meclofenamic acid (MECLO) showed considerable antiviral activity against viral replication individually or in combination with the common antiviral drug, Ribavirin (RIBA)."	( Mefenamic acid in combination with ribavirin shows significant effects in reducing chikungunya virus infection in vitro and in vivo. Abdulrahman, AY; Bahrani, H; Mohamed, Z; Othman, S; Rahman, NA; Rashid, NN; Rothan, HA; Teoh, TC; Yusof, R, 2016)	0.43
"Daclatasvir (DCV) is a potent, pangenotypic nonstructural protein 5A inhibitor with demonstrated antiviral efficacy when combined with sofosbuvir (SOF) or simeprevir (SMV) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection."	( Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. Bahirwani, R; Berg, C; Brown, RS; Castells, L; Chacko, KR; Durand, CM; ElSharkawy, AM; Emond, B; Ferenci, P; Fontana, RJ; Herzer, K; Ionescu-Ittu, R; Jafri, SM; Joshi, S; Knop, V; Lionetti, R; Loiacono, L; Londoño, MC; Montalbano, M; Moreno-Zamora, A; Mubarak, A; Pellicelli, AM; Prieto, M; Reddy, KR; Stadler, B; Stauber, RE; Stenmark, S; Torti, C; Vekeman, F; Weiland, O, 2016)	0.43
"To evaluate the possible hepatoprotective effects of Jerusalem artichoke tubers (JAT) in combination with interferon and ribavirin."	( Synergistic Effects of Jerusalem Artichoke in Combination with Pegylated Interferon Alfa-2a and Ribavirin Against Hepatic Fibrosis in Rats. Abdel-Hamid, NM; Eisa, MA; Nazmy, MH; Wahid, A, 2016)	0.43
"This study compares the safety profiles of pegylated interferon (PEG-IFN) α-2a and α-2b administered in combination with ribavirin, based on the variable of time to withdrawal from treatment due to adverse events."	( Comparison of the Safety Profiles of Pegylated Interferon α-2a and α-2b Administered in Combination with Ribavirin for Chronic Hepatitis C Infection: A Real-World Retrospective Cohort Study. Hawke, P; Ide, K; Imai, T; Kawasaki, Y; Masaki, N; Sato, I; Yamada, H, 2016)	0.43
"Sofosbuvir in combination with simeprevir +/- ribavirin in GT 4 HCV patients with advanced fibrosis achieved high SVR12 rates and was well tolerated."	( Sofosbuvir in Combination with Simeprevir +/- Ribavirin in Genotype 4 Hepatitis C Patients with Advanced Fibrosis or Cirrhosis: A Real-World Experience from Belgium. Bourgeois, S; de Galocsy, C; Degré, D; Delwaide, J; Geerts, A; Gustot, T; Laleman, W; Langlet, P; Lasser, L; Lepida, A; Moreno, C; Negrin Dastis, S; Orlent, H; Reynaert, H; Sersté, T; Starkel, P; Van Steenkiste, C; Vanwolleghem, T, 2017)	0.46
" We aimed to determine the efficacy and safety of SOF in combination with either SMV or DCV in GT4-infected patients."	( Efficacy and Safety of Simeprevir or Daclatasvir in Combination With Sofosbuvir for the Treatment of Hepatitis C Genotype 4 Infection. Alaseeri, A; Albenmousa, A; Albiladi, H; Alghamdi, AS; Aljarodi, M; Almugharbal, M; Alothmani, HS; Alsahafi, A; Babatin, MA; Bzeizi, KI; Sanai, FM, )	0.13
" In our study, we will report the real-life experience of serious adverse events (SAEs) that were reported by the National Committee for Control of Viral Hepatitis (NCCVH, Cairo, Egypt) program while treating chronic HCV using the triple therapy, sofosbuvir combined with pegylated interferon and ribavirin (PEG/RIBA/SOF), which led to premature discontinuation of treatment."	( Serious Adverse Events with Sofosbuvir Combined with Interferon and Ribavirin: Real-Life Egyptian Experience. Abdo, M; Abouelkhair, M; Doss, W; Elakel, W; Elbaz, T; Elgarem, N; Elsayed, MH; Elserafy, M; Elshazly, Y; Esmat, G; Gaballa, A; Hassany, M; Mahran, Z; Mehrez, M; Mohey, MA; Omar, A; Waked, I; Yosry, A, 2017)	0.46
"Although a contributory role of vitamin D levels for the development of chronic hepatitis C has been suggested, the efficacy of vitamin D supplementation in combination with conventional antiviral therapy consisting of pegylated interferon-α (Peg-IFN-α) injection and oral ribavirin (RBV) remains unclear."	( Efficacy of vitamin D supplementation in combination with conventional antiviral therapy in patients with chronic hepatitis C infection: a meta-analysis of randomised controlled trials. Kim, HB; Lee, YJ; Myung, SK; Park, BJ, 2018)	0.48
" When a combination therapy with interferon-free, direct-acting antivirals is used in patients post-transplantation, consideration of drug-drug interactions with and monitoring CyA are of vital importance."	( Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels. Hashimoto, S; Hayashi, K; Nakagawa, Y; Saito, K; Takahashi, K; Takamura, M; Takeuchi, S; Tanabe, Y; Tasaki, M; Terai, S; Tomita, Y; Yamagiwa, S; Yoshida, T, 2018)	0.48
"This study aimed to compare the efficacy and safety of ulinastatin combined with creatine phosphate sodium and ribavirin combined with creatine phosphate sodium in the treatment of pediatric viral myocarditis."	( The efficacy observation of ulinastatin combined with creatine phosphate sodium in pediatric viral myocarditis. An, XJ; Gao, J; Jia, LB; Li, CL; Wang, ZZ, 2019)	0.51
" 80 of them received ulinastatin combined with creatine phosphate sodium, and were regarded as observation group; other 75 patients received ribavirin combined with creatine phosphate sodium and were regarded as the control group."	( The efficacy observation of ulinastatin combined with creatine phosphate sodium in pediatric viral myocarditis. An, XJ; Gao, J; Jia, LB; Li, CL; Wang, ZZ, 2019)	0.51
"The results indicated that, compared with ribavirin combined with creatine phosphate sodium, ulinastatin combined with creatine phosphate sodium had better clinical efficacy in the treatment of pediatric viral myocarditis."	( The efficacy observation of ulinastatin combined with creatine phosphate sodium in pediatric viral myocarditis. An, XJ; Gao, J; Jia, LB; Li, CL; Wang, ZZ, 2019)	0.51
" Lastly, we investigated the use of baloxavir acid in combination with ribavirin in vitro by implementing the Zero Interaction Potency response surface model."	( Enhanced efficacy of endonuclease inhibitor baloxavir acid against orthobunyaviruses when used in combination with ribavirin. Bassetto, M; Brancale, A; Fernandez-Garcia, Y; Günther, S; Neyts, J; Rocha-Pereira, J; Ter Horst, S, 2020)	0.56
"Although the combination with PrOD significantly affects the pharmacokinetics of CsA, it is effective and safe with regular monitoring of the CsA blood concentrations and appropriate CsA dose adjustment."	( Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022)	0.72
" KM mice were randomly divided into 8 groups namely control group, PCV2 infected, Matrine combined with Osthole high dose treatment (40 mg/kg + 12 mg/kg), medium dose treatment (20 mg/kg + 6 mg/kg), low dose treatment (10 mg/kg + 3 mg/kg), Matrine treatment (40 mg/kg), Osthole treatment (12 mg/kg) and Ribavirin positive control (40 mg/kg) groups."	( Matrine combined with Osthole inhibited the PERK apoptosis of splenic lymphocytes in PCV2-infected mice model. Fan, K; Guo, J; Khan, A; Li, H; Sun, N; Sun, P; Sun, Y; Wan, S; Xu, Y; Yin, W; Zheng, X, 2023)	0.91
" The expression of GRP78, p-PERK, p-eIF2α, ATF4, CHOP, cleaved caspase-3 and Bax proteins were significantly reduced, while that of Bcl-2 was significantly increased in Matrine combined with Osthole groups, which alleviated the pathological changes caused by PCV2, such as interstitial pneumonia, loss of spleen lymphocytes, infiltration of macrophages and eosinophils."	( Matrine combined with Osthole inhibited the PERK apoptosis of splenic lymphocytes in PCV2-infected mice model. Fan, K; Guo, J; Khan, A; Li, H; Sun, N; Sun, P; Sun, Y; Wan, S; Xu, Y; Yin, W; Zheng, X, 2023)	0.91

Excerpt	Reference	Relevance
" Oral bioavailability was 44."	( Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Agrawal, KC; Ferencz, N; George, WJ; Hyslop, NE; Lacour, JT; Lertora, JJ; Rege, AB; VanDyke, RB, 1991)	0.28
" While readily bioavailable by systemic routes, it was poorly bioavailable by the oral route."	( Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Dempsey, MH; Penn, CR; Ryan, DM; Ticehurst, J, 1994)	0.29
" Ribavirin is well absorbed orally and is typically given in doses of 1,000 to 1,200 mg/d."	( Therapy of hepatitis C: alpha interferon and ribavirin. Reichard, O; Schvarcz, R; Weiland, O, 1997)	0.3
" IFN demonstrated an increase in bioavailability (approximately 2-fold) upon multiple dose administration."	( Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Bell, A; Dash, C; Dusheiko, GM; Flannery, B; Glue, P; Grellier, L; Khakoo, S; Lypnyj, D; Murray-Lyon, I; Walters, K; Wells, B, 1998)	0.3
" Ribavirin appears to be extensively absorbed; however, absolute bioavailability is approximately 50%, probably due to first-pass metabolism."	( The clinical pharmacology of ribavirin. Glue, P, 1999)	0.3
" The marked improvement in the response rate after treatment with the combination regimen (10-fold higher versus that from monotherapy with alpha interferon) highlights the importance of determining the absolute bioavailability of ribavirin as a first step in beginning to investigate the pharmacodynamics of the combination."	( Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Drusano, GL; Glue, P; Gupta, SK; McNamara, P; Nash, J; Preston, SL, 1999)	0.3
"5% in monkeys, and the bioavailability was 29."	( Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. Lau, JY; Lin, CC; Lourenco, D; Luu, T; Yeh, LT, 2003)	0.32
" However, recent preliminary pharmacological studies have suggested that the bioavailability of ribavirin displays great interindividual variability."	( Ribavirin quantification in combination treatment of chronic hepatitis C. Bessard, G; Larrat, S; Plages, A; Souvignet, C; Stanke-Labesque, F; Zarski, JP, 2003)	0.32
" The oral absorption and bioavailability were 83 and 59%, respectively, in rats and 87 and 55%, respectively, in monkeys."	( Pharmacokinetics and metabolism of [(14)C]ribavirin in rats and cynomolgus monkeys. Lau, JY; Lin, CC; Lourenco, D; Luu, T; Yeh, LT, 2003)	0.32
"To compare the two-stage method, a widely used analytical method in pharmacokinetic studies, with nonparametric population modeling by using the same data set for determining the oral bioavailability of ribavirin."	( Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Drusano, GL; Preston, SL; Tam, VH, 2003)	0.32
"Oral bioavailability data of ribavirin determined previously in six healthy adults."	( Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Drusano, GL; Preston, SL; Tam, VH, 2003)	0.32
" Both methods were similar in determining the mean +/- SD bioavailability (51."	( Comparative pharmacokinetic analysis by standard two-stage method versus nonparametric population modeling. Drusano, GL; Preston, SL; Tam, VH, 2003)	0.32
" Cyclodextrins (CDs) can form complexes with numerous molecules, improving their bioavailability and their biological properties."	( Improved antiviral activity in vitro of ribavirin against measles virus after complexation with cyclodextrins. Ammerlaan, W; Finance, C; Grancher, N; Kedzierewicz, F; Le Faou, A; Muller, CP; Venard, V, 2004)	0.32
"A functional food with a high content of natural antioxidants and with high carotenoid bioavailability was developed."	( Tomato-based functional food as interferon adjuvant in HCV eradication therapy. Ascione, A; Caporaso, N; Carbone, A; Fogliano, V; Marmo, R; Morisco, F; Scarpati, S; Stingo, S; Vitaglione, P, 2004)	0.32
" Human oral bioavailability is an important pharmacokinetic property, which is directly related to the amount of drug available in the systemic circulation to exert pharmacological and therapeutic effects."	( Hologram QSAR model for the prediction of human oral bioavailability. Andricopulo, AD; Moda, TL; Montanari, CA, 2007)	0.34
" Furthermore, interindividual RBV bioavailability shows high variation, and dose-limiting haemolytic anaemia is a common adverse event."	( Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Crespo, M; Curran, A; Esteban, JI; Falcó, V; Feijoo, M; Lopez, R; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Sauleda, S; Villar del Saz, S, 2007)	0.34
" When mizoribine was administered orally in conscious rats, the bioavailability of mizoribine estimated by urinary excretion percentage of unchanged mizoribine was a dose dependent: 53."	( Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats. Kamio, Y; Mori, N; Murakami, T; Yokooji, T, 2008)	0.35
"Bioequivalence of the new Russian oral ribavirin-containing agents was estimated by the pharmacokinetic and bioavailability parameters vs."	( [Comparative estimation of pharmacokinetics of generic ribavirin-containing drugs]. Nisrin, A; Pisarev, VV; Savchenko, AIu; Smirnova, LB, 2008)	0.35
" Celgosivir is well absorbed in vitro and in vivo, and is rapidly converted to castanospermine."	( Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Durantel, D, 2009)	0.35
" Pharmacokinetic studies reveal that both compounds are well tolerated at doses up to 100mg/kg in rats and have favorable pharmacokinetic properties and bioavailability in mice."	( Combination of α-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo. Alonzi, D; Block, TM; Borune, N; Butters, TD; Chang, J; Goh, A; Guo, JT; Kinch, MA; Lakshminarayana, SB; Liu, B; Moriarty, R; Pan, X; Qu, X; Rayahin, JE; Reinkensmeier, G; Schul, W; Shi, PY; Wang, L; Weidner, JM; Xu, X; Yip, A; Yu, W, 2011)	0.37
" First-order absorption rate constant (0."	( Population pharmacokinetics and exposure-response of albinterferon alfa-2b. Bergsma, TT; Chen, C; Corey, AE; Devalaraja, M; Gastonguay, MR; Riggs, MM; Rogers, JA; Stein, DS; Subramanian, GM; Sun, H; Yu, J, 2012)	0.38
"5-fold higher than that in control rats, whereas the bioavailability of cephalexin remained unchanged."	( Modulation in concentrative nucleoside transporters-mediated intestinal absorption of mizoribine, an immunosuppressive agent, in lipopolysaccharide-treated rats. Ishiguro, M; Kamio, Y; Mori, N; Murakami, T; Shimomukai, Y; Yokooji, T, 2011)	0.37
" In vivo, prodrug 2 is orally bioavailable and well-tolerated in rats in which it is processed to ribavirin and accumulates in the liver."	( Synthesis and evaluation of a new phosphorylated ribavirin prodrug. Dong, SD; Lin, CC; Schroeder, M, 2013)	0.39
" GS-9451 showed good oral bioavailability in all three species tested."	( Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Cheng, G; Corsa, AC; Delaney, WE; Kim, CU; Krawczyk, S; Mo, H; Pakdaman, R; Peng, B; Qi, X; Robinson, M; Shen, M; Sheng, XC; Tay, C; Tian, Y; Wang, Y; Yang, C; Yang, H, 2014)	0.4
"These results suggest that lower early bioavailability of RBV could be one of the reasons for lower SVR in HIV-HCV coinfected patients treated with pegylated interferon/RBV combination therapy."	( Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients. Bailly, F; Chiarello, P; Gagnieu, MC; Hatu, G; Livrozet, JM; Maynard, M; Miailhes, P; Parant, F; Pourcelot, E; Pradat, P; Zoulim, F, 2014)	0.4
" Mean oral bioavailability of ribavirin was 35%, 60%, 57%, and 71% in control subjects and patients with mild, moderate, and severe renal dysfunction, respectively."	( Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing. Glue, P; K Gupta, S; Kantesaria, B, 2014)	0.4
" ombitasvir and dasabuvir) on paritaprevir bioavailability were included in the model."	( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016)	0.43
" Paritaprevir bioavailability was formulation- and dose-dependent, and increased supraproportionally."	( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016)	0.43
"Acid-reducing agents (ARAs) and proton-pump inhibitors (PPIs) that increase gastric pH can alter the bioavailability of antiviral drugs, particularly relevant in patients with advanced liver disease caused by chronic hepatitis C virus (HCV) infection seeking therapy."	( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML, 2016)	0.43
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" The mortality rate from viral infection was significantly reduced (greater than or equal to 30%) by the following treatment regimens: cytosine arabinoside, adenine arabinoside, iododeoxyuridine, and ribavirin, administered daily for seven consecutive days starting immediately after inoculation of virus, at dosage levels of 4-20 mg/kg, 20-100mg/kg, 100mg/kg, and 20-100 mg/kg, respectively; and chlorite-oxidized oxyamylose, polyriboinosinic-polyribocytidylic acid, and mouse interferon, administered 24 hr before viral challenge, as single doses of 100-500 mg/kg, 20mg/kg, and 10(7)-10(8) international reference units/kg respectively."	( Intranasal challenge of mice with herpes simplex virus: an experimental model for evaluation of the efficacy of antiviral drugs. De Clercq, E; Luczak, M, 1976)	0.26
" Antiviral activity was manifested by partial to complete suppression of viral cytopathic effect and of viral replication, depending on concentration of ribavirin in the culture medium and dosage of viral inoculum."	( In vitro antiviral efficacy of ribavirin against feline calicivirus, feline viral rhinotracheitis virus, and canine parainfluenza virus. Povey, RC, 1978)	0.26
" Moderate rhinovirus activity was observed for several compounds at nontoxic dosage levels."	( Imidazo[1,2-a]-s-triazine nucleosides. Synthesis and antiviral activity of the N-bridgehead guanine, guanosine, and guanosine monophosphate analogues of imidazo[1,2-a]-s-triazine. Allen, LB; Bartholomew, DG; Kim, SH; Revankar, GR; Robins, RK, 1978)	0.26
"1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) at a dosage of 300 mg/day, or disguised placebo was administered to patients in a closed population during an epidemic outbreak of influenza in Mexico City."	( Clinical evaluation of 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin) in a double-blind study during an outbreak of influenza. Briseno-Garcia, B; Nasser-Quinones, H; Salido-Rengell, F, 1977)	0.26
" Dosage and course of treatment of this drug are discussed."	( Interruption study of viremia of patients with hemorrhagic fever with renal syndrome in the febrile phase. Cosgriff, TM; Hu, ZJ; Huggins, JW; Qu, CF; Smith, JI; Xiang, JM; Yang, ZQ; Zhang, MV; Zhang, TM; Zheng, ZM, 1991)	0.28
" With long-term dosing (400 mg orally twice a day) ribavirin accumulated, reaching steady state in 2 to 4 weeks in plasma and red blood cells."	( Pharmacokinetics and long-term tolerance to ribavirin in asymptomatic patients infected with human immunodeficiency virus. Agrawal, KC; Ferencz, N; George, WJ; Hyslop, NE; Lacour, JT; Lertora, JJ; Rege, AB; VanDyke, RB, 1991)	0.28
" Five men in each ribavirin dosage group completed at least 2 months of treatment."	( Clinical, virologic, and immunologic effects of combination therapy with ribavirin and isoprinosine in HIV-infected homosexual men. Courtless, J; LeLacheur, S; Meyer, WA; Parenti, DM; Paxton, H; Schlesselman, SB; Schulof, RS; Simon, GL; Sztein, MB, 1990)	0.28
" Long treatment schedules and potential for environmental contamination have stimulated the search for alternative dosing schedules."	( Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats. Ambrose, MW; Gilbert, BE; Knight, V; Wilson, SZ; Wyde, PR, 1992)	0.28
"A high-dose, short-duration treatment with ribavirin aerosol consisting of a three-fold increase in concentration of drug (60 mg versus 20 mg of ribavirin per mL in the liquid reservoir of the generator administered for about one-third the time of the standard treatment) was as effective as the standard dosage in the treatment of experimental influenza A and B infections in mice and in the treatment of experimental respiratory syncytial virus infection in cotton rats."	( High dose-short duration ribavirin aerosol treatment--a review. Englund, JA; Gilbert, BE; Knight, V; Wyde, PR, )	0.13
"We have described a reasonably accurate method of predicting ribavirin small-particle aerosol dosage administered by nasal inhalation or endotracheal tube adjusted for age, sex, weight, and fever."	( Aerosol treatment of respiratory viral disease. Gilbert, BE; Knight, V, 1990)	0.28
" This allowed a total dosage not much less than might have been given by other routes, but with the advantage that it was evenly deposited over the surface of the infected respiratory tract beginning within seconds of the start of treatment and reached higher concentration in nasal secretions than in serum."	( Chemotherapy of respiratory viruses. Gilbert, BE; Knight, V, 1986)	0.27
" Dosage of the drug and the course of treatment are discussed."	( [Interruption of early viremia in patients with epidemic hemorrhagic fever]. Yang, ZQ, 1989)	0.28
" The imidates 4 and 6 differed greatly in solubility and dosing requirements."	( Synthesis and antitumor activity of ribavirin imidates. A new facile synthesis of ribavirin amidine (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride). Avery, TL; Kini, GD; Robins, RK, 1989)	0.28
" The optimal dosage varied according to the treatment route and dosage schedule."	( Inhibition of murine hepatitis virus infections by the immunomodulator 2,3,5,6,7,8-hexahydro-2-phenyl-8,8-dimethoxy-imidazo[1,2a]pyridine (PR-879-317A). Call, EW; Huffman, JH; Murray, RJ; Radov, LA; Sidwell, RW; Warren, RP, 1987)	0.27
" No objective remission was observed at the dosage of 800 mg/m2 for 5 consecutive days."	( Phase II study of tiazofurin (NSC 286193) in the treatment of advanced small cell bronchogenic carcinoma. Carr, DT; Dhingra, HM; Glisson, BS; Holoye, PY; Jeffries, D; Lee, JS; Murphy, WK; Umsawasdi, T, 1988)	0.27
" These questions concern appropriate routes of administration for antiviral compounds, optimal dosage regimens, risks of long-term prophylaxis, and the emergence of resistant organisms."	( Antiviral chemotherapy and chemoprophylaxis. Dolin, R, 1985)	0.27
"We describe a method for estimating the dosage of aerosolized ribavirin according to age."	( Estimating the dosage of ribavirin aerosol according to age and other variables. Divine, GW; Gilbert, BE; Knight, V; Yu, CP, 1988)	0.27
" Although currently available drugs have improved our ability to manage a variety of viral illnesses, much needs to be learned about specific dosage guidelines based on the studies of pharmacokinetics, pharmacodynamics, potential adverse effects and viral resistance, and the role of combination therapy to optimize therapy."	( Clinical use of antiviral drugs. Nahata, MC, 1987)	0.27
" In conclusion, ribavirin is incompletely absorbed from the gastrointestinal tract, its renal excretion accounts for approximately one third of the drug's elimination, and drug accumulation (greater than threefold) will result with repetitive dosing at the 6- to 8-hour dosing interval currently used."	( Ribavirin disposition in high-risk patients for acquired immunodeficiency syndrome. Connor, JD; Hart, CC; Kalman, CM; Laskin, OL; Longstreth, JA; Roberts, RB; Scavuzzo, D, 1987)	0.27
" We test new structures in 20 well-selected human tumor xenografts and in the P388 mouse leukemia in dose-response relationships."	( Colony assay with human tumor xenografts, murine tumors and human bone marrow. Potential for anticancer drug development. Bieser, W; Fiebig, HH; Henss, H; Lohr, GW; Schmid, JR, 1987)	0.27
" A definite relationship exists between dosage and steady-state levels."	( Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. Bishop, J; Coates, A; Fox, R; Grygiel, J; Raghavan, D; Sampson, D; Woods, R, 1986)	0.27
" Dose-response experiments indicated that the GTP pool was significantly reduced (65% of control) at 25 microM ribavirin, and increasing concentrations of the drug caused only a small further reduction in the GTP pool (5-10% at 100 microM)."	( Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis. Gilbert, BE; Knight, V; Noall, MW; Wray, SK, 1985)	0.27
" Although the lowest effective in vitro dose of ribavirin is 30-50 mcg/ml, the in vivo dosage requirement may be different."	( Ribavirin suppresses replication of lymphadenopathy-associated virus in cultures of human adult T lymphocytes. Getchell, JP; Hicks, DR; McCormick, JB; Mitchell, SW, 1984)	0.27
" In a dose-response study, injection of varying amounts of the drug decreased NAD pools in the hepatoma in a dose-dependent fashion."	( Tiazofurin-induced selective depression of NAD content in hepatoma 3924A. Faderan, MA; Liepnieks, JJ; Lui, MS; Weber, G, 1984)	0.27
" With this dosage regimen, there were no side effects or changes in laboratory values that could be associated with drug-related toxicity."	( Evaluation of ribavirin in the treatment of acute hepatitis. Gupta, P; Patki, SA, 1982)	0.26
" At the high dosage level, maximum ribavirin serum levels of 24 microgram/ml were observed 2 h postribavirin administration."	( Development of antiviral levels of ribavirin in serum and urine of orally treated rats. Barnett, BB; Sharma, RP; Sidwell, RW; Smee, DF; Spendlove, RS, 1981)	0.26
" 9-beta-D-Ribofuranosylpurine-6-carboxamide (6a), the corresponding 6-thiocarboxamide (7b), and 4-amino-8-(beta-D-ribofuranosylamino)pyrimido[5,4-d]pyrimidine (8) showed significant in vitro antiviral activity at nontoxic dosage levels."	( Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides. Madsen, RD; Mancuso, RW; North, JA; Ogden, JR; Revankar, GR; Robins, RK; Rousseau, RJ; Stephen, EL; Westover, JD, 1981)	0.26
"01), and a negative correlation between NK activities and RTC dosage was obtained."	( [Effect of ribavirin on NK activities of murine spleen cells in vitro]. Chen, QY; Mi, CM; Yang, JQ, 1995)	0.29
" Six patients who continued to have elevated serum ALT and positive HCV RNA after the initial 4 weeks treatment received oral ribavirin at the same dosage for an additional 24 weeks."	( Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin. Co, RL; Conrad, A; Hwang, SJ; Lee, SD; Lefkowitz, M; Lo, KJ; Schmid, P; Tong, MJ, )	0.13
" This emphasizes the need for well-designed research to develop optimal dosage regimens in paediatric patients with bronchiolitis."	( Pattern of drug usage in bronchiolitis. Nahata, MC; Schad, PA, 1994)	0.29
"To assess whether therapy with Ribavirin may affect the course of chronic delta hepatitis, nine Italian patients with this disease received the drug orally at a dosage of 15 mg/kg daily for 16 weeks."	( Ribavirin treatment for chronic hepatitis D: a pilot study. Bonino, F; Costa, C; Cozzolongo, R; Craxi, A; Di Marco, V; Fabiano, A; Garripoli, A; Rizzetto, M; Smedile, A; Verme, G, 1994)	0.29
" The most profound and consistent haematologic change, particularly among the moderate and high dosage groups regardless of route of administration, was a significant and severe thrombocytopenia (range, 33-78% reduction in mean platelet counts vs."	( Toxicologic effects of ribavirin in cats. Boudreaux, MK; Cox, NR; Weiss, RC, 1993)	0.29
" The clinical efficacy of free ribavirin given intravenously at a reduced dosage (5."	( Evaluation of free or liposome-encapsulated ribavirin for antiviral therapy of experimentally induced feline infectious peritonitis. Cox, NR; Martinez, ML; Weiss, RC, 1993)	0.29
" Ribavirin was well tolerated, but we transiently reduced the dosage in two cases because of mild hemolytic anemia, although all patients completed the treatment schedule."	( Pilot study of ribavirin and interferon-beta for chronic hepatitis B. Higashi, Y; Ishikawa, T; Kakumu, S; Takayanagi, M; Wakita, T; Yoshioka, K, 1993)	0.29
" Further studies are needed to determine the optimal dosage and duration of therapy."	( A pilot study of ribavirin therapy for recurrent hepatitis C virus infection after liver transplantation. Cameron, R; Cattral, MS; Chung, SW; Greig, PD; Krajden, M; Levy, GA; Rezig, M; Wanless, IR, 1996)	0.29
" When ribavirin was administered intracranially at a dosage of 10 mg/kg of body weight per day for 10 days, a dosage which results in 100% survival of hamsters infected with subacute sclerosing panencephalitis (SSPE) virus and which inhibits the replication of SSPE virus in hamster brains, the ribavirin concentration in the brains estimated by HPLC and bioassay was kept higher than 50 micrograms/g for 10 days."	( Effective ribavirin concentration in hamster brains for antiviral chemotherapy for subacute sclerosing panencephalitis. Hosoya, M; Ishii, T; Mori, S; Shigeta, S; Suzuki, H, 1996)	0.29
"5%) were withdrawn prematurely from combination therapy because of side-effects; ribavirin therapy was ceased or dosage reduced in six other patients (25%), again because of side-effects."	( Ribavirin and interferon-alpha combination therapy vs interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. Bellobuono, A; Idéo, G; Mondazzi, L; Silini, E; Tempini, S; Vicari, F, 1997)	0.3
"Ribavirin (RIBV) is a useful drug in the treatment of chronic type C hepatitis but displays a toxicity for red blood cells (RBC), which limits its dosage and necessitates withdrawal in some patients."	( Ribavirin conjugated with lactosaminated poly-L-lysine: selective delivery to the liver and increased antiviral activity in mice with viral hepatitis. Bongini, A; Busi, C; Colonna, FP; Di Stefano, G; Fiume, L; Mattioli, A, 1997)	0.3
" Drug doses of 125 and 250 mg/kg on a day-1, -3 and -5 dosing schedule increased the life span (ILS) relative to untreated control mice of 36."	( In vitro and in vivo antiproliferative activity of IPCAR, a new pyrazole nucleoside analog. La Colla, P; Manfredini, S; Marongiu, ME; Montis, AD; Pani, A; Perra, G; Pinna, E; Scintu, F, )	0.13
" Upon multiple dosing there is extensive accumulation in plasma, and steady state is achieved by approximately 4 weeks."	( The clinical pharmacology of ribavirin. Glue, P, 1999)	0.3
" Such treatment could be achieved with either a fixed dose of interferon administered daily (QD) or TIW, an induction regimen in which doses greater than 3 MU QD are administered for several weeks to months followed by a reduction in the dose or dosing frequency, or by escalation in the interferon dose."	( Use of high-dose interferon in the treatment of chronic hepatitis C. Shiffman, ML, 1999)	0.3
" Using the hypothesis to fit the changes in serum HCV RNA measured in a set of patients, it was found that 5 mIU daily dosing on average blocks 81% of HCV production/release, whereas 10 or 15 mIU blocks about 95% of HCV production/release."	( Enhancing the response to interferon-alpha. Begemann, F; Jablonowski, H, 1999)	0.3
" Two placebo-controlled randomised studies including 150 patients have shown that ribavirin as single therapy at standard dosage (15 mg/kg bodyweight in two divided doses daily) only reduces ALT levels transiently during therapy, whereas HCV RNA levels are not substantially reduced."	( Treatment of naive patients with chronic hepatitis C. Weiland, O, 1999)	0.3
" In 4 (17%) patients who suffered nausea and diarrhea the ribavirin dosage was reduced by 50% after 1 month of therapy and finally discontinued in all of them."	( Pilot study of combination therapy with ribavirin and interferon alfa for the retreatment of chronic hepatitis B e antibody-positive patients. Carreño, V; Clouet, R; Cotonat, T; López-Alcorocho, JM; Manzarbeitia, F; Pardo, M; Quiroga, JA, 2000)	0.31
" For the future better optimised treatment schedules and dosing regimens for IFN in combination with ribavirin need to be worked out and individualised according to genotype to further improve treatment results."	( Interferon and ribavirin combination therapy: indications and schedules. Weiland, O, )	0.13
" The therapeutic response rate can be enhanced by combining interferon-alpha with ribavirin as well as by increasing interferon dosage or prolonging treatment."	( [New therapeutic possibilities in chronic hepatitis C]. Criblez, DH, 2000)	0.31
" The aim of the study was to determine the effect of a higher and daily dosage of IFN-alpha2b plus ribavirin on the viral load and on the response rate in patients infected by genotype 1 and previous nonresponders to interferon."	( Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C. Buti, M; Esteban, R; Guardi, J; Olive, G; Stalgis, C, 2000)	0.31
" <100 copies/mL) at the end of treatment (week 24) and after 24 weeks of follow-up (week 48) showed dose-response trends for PEG-Intron."	( A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Clement, RP; Glue, P; Gupta, SK; Jacobs, S; Raffanel, C; Rouzier-Panis, R; Sabo, R; Salfi, M, 2000)	0.31
" Therefore, we compared the efficacy of ribavirin addition to alpha-interferon with a doubling of the dosage of alpha-interferon in case of lack of early virological response to alpha-interferon therapy."	( Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy. Bellobuono, A; Chiodo, F; Furione, L; Idéo, G; Magliano, E; Mondazzi, L; Tempini, S, 2000)	0.31
"Sixty patients were administered interferon alpha2b at the dosage of 3 million units 3 times a week."	( Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy. Bellobuono, A; Chiodo, F; Furione, L; Idéo, G; Magliano, E; Mondazzi, L; Tempini, S, 2000)	0.31
" Sustained response was observed in 5/12 (42%) patients with early virological response, in 10/24 (42%) patients without early virological response who were administered ribavirin and alpha-interferon, and in only 1/24 (4%) patients who were administered the double dosage of alpha-interferon (p=0."	( Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy. Bellobuono, A; Chiodo, F; Furione, L; Idéo, G; Magliano, E; Mondazzi, L; Tempini, S, 2000)	0.31
"This study shows the efficacy of the addition of ribavirin to alpha-interferon and the lack of efficacy of doubling the dosage of alpha-interferon in patients without clearance of hepatitis C virus early on in treatment."	( Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy. Bellobuono, A; Chiodo, F; Furione, L; Idéo, G; Magliano, E; Mondazzi, L; Tempini, S, 2000)	0.31
" The assistance of nurses in patient education, in side effect management, in hematologic parameter monitoring, and in medication dosing and administration is crucial to maximizing patient compliance and therapy outcome."	( Combination Interferon alfa-2b/ribavirin therapy for the treatment of hepatitis C: nursing implications. Benson, L; Birkel, A; Caldwell, L; Casarico, B; Stafford-Fox, V, )	0.13
"A series of 100 patients with chronic hepatitis C not responding to recombinant alpha-interferon 3 MU tiw, were randomly assigned to two groups of 50 patients each: Group A, treated with recombinant alpha-interferon therapy for an additional six months but at a double dosage (6 MU tiw) in association with ribavirin."	( High-dose interferon plus ribavirin in chronic hepatitis C not responding to recombinant alpha-interferon. Bertoni, M; Bresci, G; Capria, A; Parisi, G, 2000)	0.31
" When interferon alfa-n/n3 and a lower dosage of ribavirin (600-800 mg/d) were used, the risk difference was 0% (95% CI, -7% to 7%)."	( Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. Aoki, Y; Cid-Ruzafa, J; Cummings, KJ; Fein, SG; Goodman, SN; Lee, SM; Sulkowski, MS; West, ES, 2001)	0.31
" Strategies to further improve response rates include modification of the interferon dosing schedule with induction dosing and daily interferon, new interferons such as consensus interferon, or interferon with longer half-life and more favorable pharmacokinetics such as pegylated interferons."	( Current and future treatment of hepatitis C. Cornberg, M; Manns, MP; Wedemeyer, H, 2001)	0.31
" Multivariate analysis showed that infection by hepatitis C virus genotypes 2 or 3 and interferon alpha dosage of 5 million units daily were independent predictors of sustained response."	( Pilot dose-finding trial on interferon alpha in combination with ribavirin for the treatment of chronic hepatitis C in patients not responding to interferon alone. Barni, MC; Cadeo, GP; Carosi, G; Cristini, G; Forleo, MA; Gargiulo, F; Paraninfo, G; Puoti, M; Putzolu, V; Quiros-Roldan, E; Rossi, S; Spinetti, A; Zaltron, S; Zanini, B, 2001)	0.31
" Oral dosing of interferon is in clinical trials for hepatitis B, and the results may be applicable to HCV."	( Can science meet the challenges of the HCV pandemic: new treatment options for chronic hepatitis C. Roehr, B, 1998)	0.3
" He believes the Food and Drug Administration's (FDA) approved interferon dosing regimen is not appropriate."	( Treating hepatitis C: a clinician's perspective. Interview by Bob Roehr. Powell, J, 1998)	0.3
" Results of clinical trials are summarized, and dosing options and side effects are detailed."	( Product information. Bartlett, JG, 1999)	0.3
"To determine whether a higher dosage of interferon (IFN) associated with ribavirin and/or prolonged time of administration may improve therapeutic efficacy, we conducted a 4-arm randomized trial on patients with chronic hepatitis C not responding to one or more previous treatment courses with IFN monotherapy."	( A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C not responding to interferon alone. Andreoni, M; Biglino, A; Calleri, G; Cariti, G; Ciancio, A; Ciccone, G; Colletta, C; Croce, G; Di Napoli, A; Macor, A; Maggi, G; Olivero, A; Orsi, PG; Rinaldi, E; Rizzetto, M; Roffi, L; Saracco, G; Smedile, A; Tappero, GF; Terreni, N, 2001)	0.31
" In dialysis patients only interferon therapy is currently used due to the lack of knowledge concerning ribavirin dosage and side-effects."	( Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection--a pilot study. Andersson, J; Bruchfeld, A; Schvarcz, R; Ståhle, L, 2001)	0.31
" The exponential decay slopes of the second phase were significantly higher in the combination or twice-daily dosing regimen groups compared with groups 2 or 4 (0."	( A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Asahina, Y; Hamano, K; Itakura, J; Izumi, N; Kanazawa, N; Miyake, S; Noguchi, O; Sakai, T; Tsuchiya, K; Uchihara, M, 2001)	0.31
" Interstitial pneumonitis is a rare but known complication of IFN-alpha when given at a high dosage of 6 to 10 million units per day."	( Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Ahmed, S; Karim, A; Khan, A; Mattana, J; Steinberg, H, 2001)	0.31
" Dosage reduction was required in 10 patients (26%) because of ribavirin-related anemia or IFN-related side effects."	( Sustained suppression of hepatitis C virus by interferon and ribavirin in hemophilic patients not responding to interferon monotherapy. Colombo, M; Mannucci, PM; Rivi, M; Rumi, MG; Santagostino, E, 2002)	0.31
" Interferon therapy at a dosage of 3 MU and subcutaneous injection 3 times per week for 6 months normalized serum transaminase in 50% of patients with chronic hepatitis C at the end of treatment."	( Hepatitis C virus infection: an overview. Hwang, SJ, 2001)	0.31
" Twenty-six percent of patients required dosage modifications of one or both drugs during combination therapy."	( Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Perry, CM; Scott, LJ, 2002)	0.31
" Serum ribavirin concentrations in steady state, and maximum concentration and accumulation rate of ribavirin after multiple dosing were significantly higher in the presence of sustained virologic response."	( Viral dynamics and pharmacokinetics in combined interferon alfa-2b and ribavirin therapy for patients infected with hepatitis C virus of genotype 1b and high pretreatment viral load. Akuta, N; Arase, Y; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2002)	0.31
" Options to further enhance response rates include modification of the IFN-dosing schedule with daily dosing of IFN, new IFN such as consensus interferon or modified IFN with longer half-life and more favourable pharmacokinetics such as pegylated IFN (PEG-IFN)."	( Hepatitis C: therapeutic perspectives. Cornberg, M; Manns, MP; Wedemeyer, H, )	0.13
" In a randomized open study, 61 patients with haemophilia or von Willebrand disease received treatment with a combination of interferon alpha-2b and ribavirin at standard dosage for 6 or 12 months."	( A randomized study of alpha-interferon plus ribavirin for 6 months or 12 months for the treatment of chronic hepatitis C in patients with bleeding disorders. Kinnman, N; Lindmarker, P; Schulman, S; von Sydow, M, 2002)	0.31
" The dose of 800 mg/day may be the most appropriate lower dose for those patients who require dosage modification for anemia or other side-effects."	( Hepatitis C advances in antiviral therapy: what is accepted treatment now? McHutchison, JG, 2002)	0.31
"Patients living in Kuwait were assigned to take either interferon alone at a dosage of 5 million units thrice weekly (26 patients) or interferon 5 million units thrice weekly combined with ribavirin 1,000 mg/d (21 patients) for 24 weeks."	( Treatment of hepatitis C virus genotype 4-related cirrhosis: ribavirin and interferon combination compared with interferon alone. Koshy, A; Madda, JP; Marcellin, P; Martinot, M, 2002)	0.31
" To reduce the likelihood of viral replication, mutation and subsequent development of resistance, daily dosing with IFN may be appropriate."	( High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy. Abbas, Z; Hamid, S; Tabassum, S, 2002)	0.31
" Dosage modifications were according to a standard protocol incorporating laboratory values and clinical side effects."	( Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Burgart, LJ; Charlton, M; El-Amin, OM; Kremers, WK; Narayanan Menon, KV; Poterucha, JJ; Rosen, CB; Wiesner, RH, 2002)	0.31
"Fifty eligible MM patients with active HCV and concomitant liver fibrosis were treated with interferon/ribavirin combination therapy using standard dosing regimens."	( Treating hepatitis C in methadone maintenance patients: an interim analysis. Sylvestre, DL, 2002)	0.31
" The outcomes evaluated were withdrawal from the study due to anaemia, ribavirin dosage reduction due to a decrease in haemoglobin and haemoglobin levels below 10 g/dL."	( Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Chan, KA; Chang, CH; Chen, KY; Lai, MY, 2002)	0.31
" Reported risks were higher among Asian studies, which may be due to differences in study entrance criteria, dosage titration strategy or ethnic vulnerability."	( Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Chan, KA; Chang, CH; Chen, KY; Lai, MY, 2002)	0.31
"To determine whether a higher dosage of interferon (IFN) and/or a prolonged time of administration may improve the efficacy of combination therapy, we conducted a 4-arm randomized trial on patients with chronic hepatitis C relapsing after 1 or more previous treatment courses with IFN monotherapy."	( A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy. Andreoni, M; Biglino, A; Carenzi, S; Cariti, G; Ciancio, A; Ciccone, G; Croce, G; Manca, A; Olivero, A; Orsi, PG; Rizzetto, M; Roffi, L; Saracco, G; Smedile, A; Tabone, M; Tappero, G, 2002)	0.31
" An open label prospective trial of 5 MU of interferon daily plus ribavirin dosed according to weight was performed utilizing 40 patients, who were identified as being IFN nonresponders to 1 year or more of continuous IFN administered at a dose of 5 MU/day."	( Retreatment of high-dose interferon (5 MU daily) nonresponders with high-dose IFN + ribavirin. Friedlander, L; Kondaveeti, K; Van Thiel, DH, 2002)	0.31
"HCV-1-infected patients who can be maintained on >80% of their interferon or peginterferon alpha-2b and ribavirin dosage for the duration of treatment in the setting of a clinical trial exhibit enhanced sustained response rates."	( Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Albrecht, JK; Dienstag, J; Garaud, JJ; Lee, WM; Lindsay, KL; Mak, C; Manns, M; McHutchison, JG; Patel, K; Poynard, T; Trepo, C, 2002)	0.31
" Approved ribavirin dosages vary from a fixed dosage of 800 mg/d to as much as 1200 mg/d on the basis of body weight."	( Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Affrime, MB; Chung, C; Glue, P; Gupta, SK; Hajian, G; Heft, S; Jen, J; Laughlin, M, 2002)	0.31
"Our objective was to evaluate ribavirin dosing strategies by comparison of their relative efficacy and toxicity profiles."	( Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Affrime, MB; Chung, C; Glue, P; Gupta, SK; Hajian, G; Heft, S; Jen, J; Laughlin, M, 2002)	0.31
" Simulations of these models were developed for different ribavirin doses to obtain efficacy and toxicity profiles across the various dosing strategies."	( Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Affrime, MB; Chung, C; Glue, P; Gupta, SK; Hajian, G; Heft, S; Jen, J; Laughlin, M, 2002)	0.31
"This simulation suggests that ribavirin dosage (in combination with pegylated interferon alfa-2b) for patients with chronic hepatitis C should be based on body weight."	( Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Affrime, MB; Chung, C; Glue, P; Gupta, SK; Hajian, G; Heft, S; Jen, J; Laughlin, M, 2002)	0.31
" In using peginterferon in combination therapy, the benefits of once weekly dosing need to be weighed against the higher risks of cytopenias and greater costs with the pegylated formulations."	( Treatment of patients with hepatitis C and cirrhosis. Wright, TL, 2002)	0.31
" Ongoing research on the use of pegylated IFN, weight-adjusted dosing of ribavirin, and the treatment of relapsers and nonresponders will provide valuable data that could be incorporated into future CEAs."	( Motion - the available treatments for hepatitis C are cost effective: arguments for the motion. Terrault, N, 2002)	0.31
" Ribavirin dosage is currently based on body weight."	( Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis. Bruchfeld, A; Lindahl, K; Schvarcz, R; Ståhle, L, 2002)	0.31
" It allows once-weekly dosing and increases sustained response rates without changing the safety profile."	( Polyethylene glycol-interferon: current status in hepatitis C virus therapy. Cornberg, M; Manns, MP; Wedemeyer, H; Wiegand, J, 2002)	0.31
"Patients received IFNalpha for a mean +/- SD of 20 +/- 14 months and ribavirin (at a mean +/- SD dosage of 895 +/- 250 mg/day) for 14 +/- 12 months."	( Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Cacoub, P; Duhaut, P; Ghillani, P; Leger, JM; Lidove, O; Maisonobe, T; Myers, RP; Piette, JC; Servan, J; Thibault, V, 2002)	0.31
" Excretion of total radioactivity in urine after oral dosing accounted for 15."	( Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. Lau, JY; Lin, CC; Lourenco, D; Luu, T; Yeh, LT, 2003)	0.32
" It is concluded that the safety and tolerability profiles of the two treatments were similar suggesting that daily dosing of CIFN may be difficult to tolerate resulting in discontinuation of therapy in a significant proportion of patients."	( The safety and tolerability of daily infergen plus ribavirin in the treatment of naíïve chronic hepatitis C patients. Boyd, DG; McHutchinson, J; Pockros, PJ; Reddy, R; Reindollar, R; Wilkes, LB; Wright, T, 2003)	0.32
" Stepwise multiple logistic regression analysis of the factors (age, gender, viral load, cirrhosis rate, IFN dosage and amino acid substitutions) revealed that the mutation in NS5A-ISDR (>/= 4 vs < 4) was the only independent variable of treatment outcome."	( Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin. Changchien, CS; Chen, TM; Chen, WJ; Hu, TH; Hung, CH; Lee, CM; Lee, JF; Lu, SN; Tung, HD; Wang, JH, 2003)	0.32
" Subcutaneous peginterferon-alpha-2a (40kD) was administered at a dosage of 180 micro g once weekly and oral ribavirin was usually administered at a dosage of 1000 or 1200 mg/day."	( Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. Curran, MP; Keating, GM, 2003)	0.32
" at a daily dosage of 30 mg/kg in two treatment protocols: from the start of immunization (preventive treatment) or from the onset of the first EAE signs after the induction (therapeutic treatment)."	( Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. Medic-Mijacevic, L; Milicevic, I; Mostarica-Stojkovic, M; Pejanovic, V; Pekovic, S; Rakic, L; Stojiljkovic, M; Stosic-Grujicic, S; Subasic, S, 2003)	0.32
" The steady-state concentration correlated significantly with serum ribavirin clearance after multiple dosing (r = -0."	( Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Hirose, Y; Izumi, N; Kumada, H; Tsubota, A, 2003)	0.32
" While the rationale for erythropoietin treatment of ribavirin-induced anaemia is not straightforward, the currently recommended dosing regimen should be reassessed."	( Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia. Del Vecchio, C; Durante Mangoni, E; Marrone, A; Ruggiero, G; Saviano, D; Utili, R, 2003)	0.32
" IFN-alpha dose-response studies on viral kinetics suggest that inadequate dosing might be a key factor but drug levels have hardly been tested, which is in part due to difficulties in measuring this cytokine in patient samples."	( A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. Bartenschlager, R; Haagmans, BL; Hansen, BE; Kaul, A; Lohmann, V; Schalm, SW; Vrolijk, JM, 2003)	0.32
" Sixty-eight patients were randomized to receive IFN-alpha-2a at a dosage of either (1) 6 MU given 3 times per week for 24 weeks, followed by 3 MU 3 times per week for an additional 24 weeks (group A; 31 patients); or (2) 9 MU per day for 2 weeks, followed by 3 MU per day for 22 weeks, followed by 3 MU 3 times per week for 24 weeks (group B; 37 patients)."	( Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Bioulac-Sage, P; Chêne, G; Dupon, M; Lacoste, D; Lafon, ME; Le Bail, B; Neau, D; Ragnaud, JM; Rullier, A; Trimoulet, P; Winnock, M, 2003)	0.32
" Sustained response with induction dosing was 57%."	( Chronic hepatitis C--treatment results in northern India. Awasthi, G; Midha, V; Sood, A; Sood, N, )	0.13
" Induction dosing improves the sustained virological response further."	( Chronic hepatitis C--treatment results in northern India. Awasthi, G; Midha, V; Sood, A; Sood, N, )	0.13
"2 g/day) (group A=127 patients) or IFN alpha-2b (group B=60 patients) of same dosage and duration for 1 year."	( High rate of long-term virological response after a 1-year course of interferon +/- ribavirin in chronic hepatitis C relapsers. Results of a 191 patients randomized trial. Boucher, EJ; Brissot, P; Canva, V; Colimon, R; Deugnier, Y; Guyader, D; Jacquelinet, C; Jacquelinet, S; Turlin, B, 2003)	0.32
" Initial use of pulse methylprednisolone therapy appears to be a more efficacious and an equally safe steroid regimen when compared with regimens with lower dosage and should be considered as the preferred steroid regimen in the treatment of SARS, pending data from future randomized controlled trials."	( High-dose pulse versus nonpulse corticosteroid regimens in severe acute respiratory syndrome. Chan, JW; Chan-Yeung, M; Ho, JC; Ho, PL; Hung, I; Ip, MS; Lai, KN; Lam, B; Lam, WK; Li, PC; Mok, TY; Ng, CK; Ooi, GC; Tsang, KW; Wong, PC, 2003)	0.32
" In a whole body autoradiography study in rats following oral dosing (30 mg/kg) of [14C]ribavirin or [14C]viramidine to monkeys, viramidine produced 32% higher radioactivity in the liver than ribavirin, indicating a better liver-targeting properties."	( Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Hong, Z; Lin, CC; Vitarella, D; Yeh, LT, 2003)	0.32
"In treating SARS, ICWM was superior to the treatment with western medicine alone in aspects of improving clinical symptom, promoting recovery of immune function and absorption of lung inflammation, decreasing the dosage of hormone used and shortening the therapeutic course."	( [Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine]. Jiao, Q; Wang, BG; Zhang, RL, 2003)	0.32
" Other ongoing studies using alternative antibody preparations and more intensive dosing schedules are underway."	( Prophylactic and preemptive therapies for hepatitis C virus-infected patients undergoing liver transplantation. Terrault, NA, 2003)	0.32
" In fact, daily dosing is still proposed for non-pegylated interferon."	( First-line therapy with daily versus thrice-weekly interferon alfa-2b plus ribavirin for chronic hepatitis C. Buggisch, P; Grossmann, J; Koop, K; Reiser, M; Schmiegel, W; Wursthorn, K, 2003)	0.32
" Rats were dosed orally with 120 mg kg(-1) day(-1) of ribavirin and viramidine and 2000 mg kg(-1) day(-1) of levovirin for 8 days."	( Effect of ribavirin, levovirin and viramidine on liver toxicological gene expression in rats. Fang, C; Lin, CC; Srivastava, P, )	0.13
"We applied viral response and drug dosage from an international randomized clinical trial of ribavirin plus peginterferon alfa-2b or ribavirin plus interferon alfa-2b to a previously published computer cohort simulation to project lifelong clinical and economic outcomes."	( Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Albrecht, JK; Davis, GL; Manns, MP; McHutchison, JG; Wong, JB, 2003)	0.32
"0001), and the mean changes in RBV dosage were -34 mg/day for epoetin alfa versus -146 mg/day (p=0."	( Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Bini, EJ; Bowers, PJ; Bräu, N; Dieterich, DT; Hassanein, TI; Sulkowski, MS; Wasserman, R, 2003)	0.32
"5 microg/kg) and pegylated IFN alpha-2a (40 kDa) (fixed dosage of 180 microg)."	( Combined antiviral options for the treatment of chronic hepatitis C. García-Buey, L; Medina, J; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugán, M, 2003)	0.32
" However, no recommendation exists for dosing patients with impaired renal function."	( Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. Chatelut, E; Izopet, J; Kamar, N; Lafont, T; Manolis, E; Rostaing, L, 2004)	0.32
" The current dosage recommendations for ribavirin are based on body weight (bw)."	( Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. Bruchfeld, A; Lindahl, K; Schvarcz, R; Ståhle, L, 2004)	0.32
" In the present study, the authors examined factors influencing total plasma clearance (CL(total)) and the toxic level on red blood cells of ribavirin in such body weight-based dosage adjustment in Japanese chronic hepatitis C patients (13 male and 6 female)."	( Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Funakoshi, S; Kiribayashi, Y; Maeda, Y; Maruhashi, A; Moriya, T; Murakami, T; Omoda, K; Takano, M, 2004)	0.32
" Early reduction of viral load by daily dosage of IFN could enhance viral clearance."	( A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C. Goyal, A; Guptan, RC; Hashmi, AZ; Kumar, S; Malhotra, V; Sakhuja, P; Sarin, SK, 2004)	0.32
"Daily IFN dosage with ribavirin is safe and can achieve response in up to 65% patients."	( A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C. Goyal, A; Guptan, RC; Hashmi, AZ; Kumar, S; Malhotra, V; Sakhuja, P; Sarin, SK, 2004)	0.32
" Viramidine dosing yielded 50% higher ribavirin levels in the monkey liver but only half in plasma and red blood cells compared to ribavirin dosing."	( Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers. Lin, CC; Philips, L; Xu, C; Yeh, LT, 2004)	0.32
" In conclusion, genotype 1b naive end-therapy responders to usual combined therapy, after a period of daily consolidation therapy with a low dosage of IFN without ribavirin, achieved a better rate of sustained response than the control group."	( Low daily dosage of interferon for 1 year after HCV-related end-therapy response. A randomized-controlled study. Conca, P; Perrella, A; Perrella, O; Ragucci, P; Sorrentino, P; Tarantino, G, 2003)	0.32
" A retrospective study carried out of 72 probable SARS patients has shown that cases who received pulse methylprendisolone did not differ in cumulative steroid dosage or adverse reactions, although the former patients had less oxygen requirement, better radiographic outcome, and less likelihood of requiring rescue pulse steroid therapy than their counterparts."	( SARS: pharmacotherapy. Tsang, K; Zhong, NS, 2003)	0.32
" However, recent studies suggest that epoetin alfa can increase hemoglobin levels and facilitate maintenance of RBV dosage in patients with chronic hepatitis C who became anemic during standard combination therapy."	( Role of epoetin alfa in maintaining ribavirin dose. Afdhal, NH, 2004)	0.32
" Treatment dosage had to be reduced in 20 patients (59%)."	( Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients. Colombo, M; De Filippi, F; Mannucci, PM; Rivi, M; Rumi, MG; Santagostino, E, 2004)	0.32
" Anaemia in patients treated with interferon plus RBV combination therapy can be managed effectively and safely with once weekly epoetin alfa without sacrificing optimal dosing of RBV."	( Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. Bräu, N, 2004)	0.32
" Study 2 included 485 interferon alpha-experienced patients randomized to receive RBV 1000-1200 mg daily plus interferon alpha-2b 3 million IU daily or three times weekly for 4 weeks, followed by three times weekly dosing for 44 weeks."	( Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. Ball, L; Brooks, L; Gish, R; Sulkowski, MS; Wasserman, R, 2004)	0.32
"Early applying of CH-HZ treatment showed good effects in improving CK, LDH, oxygenation index and absolute value of neutrophils, and could reduce the daily maximal dosage of glucocorticoid needed for SARS patients."	( [Clinical observation on treatment of SARS with combination of chaihu droplet pill and huoxiang zhengqi droplet pill]. Li, H; Lu, CZ; Tang, KC, 2004)	0.32
"Early application of CH-HZ treatment in treating SARS could alleviate the injury in lung of SARS patients and the neutrophil dependent inflammatory reaction, and reduce the dosage of glucocorticoid used."	( [Clinical observation on treatment of SARS with combination of chaihu droplet pill and huoxiang zhengqi droplet pill]. Li, H; Lu, CZ; Tang, KC, 2004)	0.32
" All patients were treated with IFNAlpha2b daily for 2 weeks, followed by three times weekly dosing for 22 weeks, with oral ribavirin twice daily, at a total daily dose of 600 or 800 mg."	( Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Someya, T; Suzuki, F; Suzuki, Y; Takaki, S; Tsubota, A, 2004)	0.32
" Although side effects continue to be a hindrance to the success of therapy, agents such as growth factors and antidepressants may help patients to maintain medication dosing and complete treatment."	( Hepatitis C treatment update. Pearlman, BL, 2004)	0.32
" We investigated triple combination treatment with induction dosing of interferon-alpha plus ribavirin plus amantadine in these difficult-to-treat patients."	( Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Datz, C; Hackl, F; Hegenbarth, K; Hofer, H; Jessner, W; Peter, F; Schütze, K; Stauber, RE; Steindl-Munda, P, 2004)	0.32
" In the 1-month study in rats, viramidine or ribavirin dosing at 120 mg/kg/day reduced Hgb concentrations (12-16% and 13-20% compared to controls, respectively) and caused slight erythroid hyperplasia in the bone marrow."	( Viramidine demonstrates better safety than ribavirin in monkeys but not rats. Dadgostari, S; Lin, CC; Vitarella, D; Xu, C; Yeh, LT, 2004)	0.32
" Dosage reductions of ribavirin and/or peginterferon alfa-2b were required in 10 patients (20%) and seemed less frequent than that needed in clinical trials."	( Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Bagheri, H; Barange, K; Fouladi, A; Lapeyre-Mestre, M; Montastruc, JL; Payen, JL; Vinel, JP, 2004)	0.32
" In particular, results of APRICOT - the largest study conducted to date with a pegylated interferon plus ribavirin in patients with HIV-HCV co-infection - indicate that a substantial proportion of patients will achieve sustained virological response (SVR) at week 72 when these drugs are administered for 48 weeks in an appropriate dosage regimen."	( Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in hepatitis C Virus And HIV co-infection. Keating, GM; Plosker, GL, 2004)	0.32
" The treatment schedule was based on subcutaneous administration of recombinant IFNalpha-2b (Intron A) at a dosage of 3 million IU every day, or IL-2 (aldesleukin) at a dose of 1 million IU every day, with oral ribavirin administered 400 mg twice daily (morning and night) [for patients weighing <75 kg] or 500 mg twice daily (for those weighing > or = 75 kg)."	( Interleukin-2 plus ribavirin versus interferon-alpha-2b plus ribavirin in patients with chronic hepatitis C who did not respond to previous interferon-alpha-2b treatment. Brogna, A; Malaguarnera, M; Musumeci, S; Neri, S; Pistone, G; Romano, M, 2004)	0.32
" Baseline cytopenias, in particular, may limit dosing of interferon and/or ribavirin or preclude therapy entirely when standard guidelines are followed."	( Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation. Fredrick, RT; Hassanein, TI, 2005)	0.33
" Dose adjustments effectively treat these hematologic side effects, but the resulting suboptimal dosing and potential impact on virologic response are major concerns."	( The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. Collantes, RS; Younossi, ZM, 2005)	0.33
" Future studies should focus on alternative dosing schedules with more aggressive use of adjuvant therapies, including GFs."	( Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Ascher, NA; Bollinger, K; Khalili, M; Roberts, JP; Shergill, AK; Straley, S; Terrault, NA, 2005)	0.33
" Therefore, under this dosing scheme, heavier patients do not have an equal chance at achieving SVR as do lighter patients."	( Weight-based dosing: which impact on efficacy and safety of therapy? Almasio, PL, 2004)	0.32
" In this study, we evaluated the effect of drug dosage reduction or the duration of the expected therapy in patients treated with interferon (IFN)-alpha2b plus ribavirin."	( The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naive and nonresponder chronic hepatitis C patients. Akriviadis, E; Hatzis, G; Kanatakis, S; Ketikoglou, I; Paraskevas, E; Raptopoulou, M; Sidiropoulos, L; Tsantoulas, D; Vafiadi, I; Vassiliadis, T, 2005)	0.33
" These results suggest that the monitoring of plasma ribavirin concentrations may be valid for predicting the early phase of adverse drug reactions, thereby providing useful information for the adjustment of the ribavirin dosing for each patient."	( Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Fujiyama, S; Hamada, A; Saito, H; Sasaki, Y; Uchida, M; Yamasaki, M, 2004)	0.32
"The current study was carried out to evaluate pharmacokinetic profiles of viramidine and ribavirin in patients (n = 8 per dose group) with compensated hepatitis C infection following oral dosing of viramidine (400, 600, or 800 mg bid for 4 weeks)."	( Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection. Aora, S; Gish, R; Lau, D; Lin, CC; Peterson, J; Rossi, S; Teng, A; Xu, C; Yeh, LT, 2005)	0.33
" Overall, a sustained virological response occurred in over 50% of patients who received combination therapy for 48 weeks, albeit with a low daily dosage of ribavirin."	( Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels. Keating, GM; Plosker, GL, 2005)	0.33
" Weekly dosing of peginterferon alfa-2b is a considerable advance for this age group."	( Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Ballauff, A; Gerner, P; Jenke, A; Kullmer, U; Lang, T; Pieper-Boustani, H; Wintermeyer, P; Wirth, S, 2005)	0.33
"Entry criteria were serum HCV-RNA level >/=100 KIU/ml, HCV-genotype 1b, chronic hepatitis, and initial combination treatment of IFN-alpha-2b (6 million units daily for 2 weeks and then 3 times weekly for 6 weeks) and ribavirin (600-800 mg/day) for 8 weeks without stopping or decreasing the dosage of IFN and/or ribavirin."	( Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Someya, T; Suzuki, F; Suzuki, Y; Tsubota, A, 2005)	0.33
" In addition, we also intended to establish a simple rule defining the need for dosage adjustment, using data obtained during the first month of treatment."	( Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Bouton, V; Boyer, N; Farcy-Afif, M; Marcellin, P; Sinègre, M; Stocco, J; Tod, M, 2005)	0.33
"A retrospective analysis of 99 patients treated with IFNalpha plus ribavirin, with known dosage administration history, liver biopsy, demographic data, red blood cell counts, haemoglobin level (1037 measurements, median 10 per patient, range 2-31) and serum creatinine during the entire treatment period (178 days, range 53-382 days) was conducted."	( Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Bouton, V; Boyer, N; Farcy-Afif, M; Marcellin, P; Sinègre, M; Stocco, J; Tod, M, 2005)	0.33
" The proposed rule for the need of dosage adjustment was able to predict the actual evolution of the dosage regimen in 76% of non-adapted patients and 69% of adapted patients."	( Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Bouton, V; Boyer, N; Farcy-Afif, M; Marcellin, P; Sinègre, M; Stocco, J; Tod, M, 2005)	0.33
"The current guidelines for ribavirin dosage administration, based on bodyweight, are adequate, at least in the 45-105 kg range."	( Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Bouton, V; Boyer, N; Farcy-Afif, M; Marcellin, P; Sinègre, M; Stocco, J; Tod, M, 2005)	0.33
"Only 12/24 patients (50%) completed a full year of therapy; 17 (71%) experienced side-effects requiring a 50% dosage reduction or discontinuation of the IFN, PEG-IFN and/or ribavirin."	( Pegylated versus standard interferon-alpha in antiviral regimens for post-transplant recurrent hepatitis C: Comparison of tolerability and efficacy. Apollonio, L; Avellini, C; Caldato, M; Fabris, C; Fumo, E; Minisini, R; Pirisi, M; Toniutto, P, 2005)	0.33
" Ribavirin could cause dose-dependent reversible haemolytic anaemia, which can be managed with dose reductions or with administration of epoetin alpha at 40,000 IU once weekly without sacrificing the optimal dosing of ribavarin."	( Ribavirin in the treatment of hepatitis C. Abonyi, ME; Lakatos, PL, )	0.13
"One reason for dosing a drug by body weight is to reduce interpatient variability in clinical response."	( Area-under-the-curve for peginterferon alpha-2a and peginterferon alpha-2b is not related to body weight in treatment-naive patients with chronic hepatitis C. Bruno, R; Ciappina, V; Filice, G; Maiocchi, L; Patruno, S; Sacchi, P; Zocchetti, C, 2005)	0.33
" Extractability of total ribavirin from liver has been confirmed with liver obtained from monkey dosed with [14C]ribavirin."	( A sensitive and specific method for the determination of total ribavirin in monkey liver by high-performance liquid chromatography with tandem mass spectrometry. Lin, CC; Lourenco, D; Nguyen, M; Yeh, LT, 2005)	0.33
" No interference could be observed from the excipients commonly present in dosage forms."	( Simple fluorimetric method for determination of certain antiviral drugs via their oxidation with cerium (IV). Askal, HF; Darwish, IA; Khedr, AS; Mahmoud, RM, )	0.13
" Frequent monitoring of patients and, often, adjustments in the dosage of one or both components of the therapy are necessary during the treatment course."	( Patient education and treatment strategies implemented at a pharmacist-managed hepatitis C virus clinic. Kolor, B, 2005)	0.33
"4% less (37,638 US dollars) for Peg-2b plus flat dosing of RBV as compared with Peg-2a plus RBV (46,717 US dollars)."	( Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C. Malone, DC; Poordad, FF; Tran, TT, 2005)	0.33
" Eleven patients required erythropoietin; their mean ribavirin dosage was higher but mean ribavirin concentration was lower compared to the 11 patients who did not require erythropoietin factor."	( Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection. Fung, J; Jain, A; Kashyap, R; Marcos, A; Vekatramanan, R; Yelochan, B, 2005)	0.33
" However, there is no consensus on the best dosage or duration of IFN therapy."	( Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Akarca, US; Batur, Y; Ersoz, G; Gunsar, F; Ilter, T; Karasu, Z; Kobak, AC; Yuce, G, 2005)	0.33
"Patients (n = 31) with CDH were randomized with a 1:2 ratio as 10 patients (3 females/7 males, age 39 +/- 9) receiving IFN monotherapy (9 MU IFN-alpha2a three times weekly) and 21 patients (8 females/13 males, age 38 +/- 11) receiving IFN plus RBV for 2 years (IFN at the same dosage and RBV at 1000-1200 mg/day)."	( Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Akarca, US; Batur, Y; Ersoz, G; Gunsar, F; Ilter, T; Karasu, Z; Kobak, AC; Yuce, G, 2005)	0.33
" There was no significant effect of dosing regimen."	( A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. Ahmed, F; Aytaman, A; Berman, DH; Bini, EJ; Bodenheimer, HC; Bräu, N; Brodsky, N; Brown, RS; Cerulli, MA; Chait, M; Edlin, BR; Ehrlich, J; Esposito, SP; Gardner, PW; Geders, JM; Gonzalez, SA; Jacobson, IM; Klion, FM; Lebovics, E; Min, AD; Rahmin, MG; Rovner, D; Russo, MW; Spivack, JE; Tobias, H, 2005)	0.33
" Comparative trials have been initiated that will provide insight into relative importance of pharmacokinetics, bioactivity and dosing regimen."	( Pegylated IFNs for chronic hepatitis C: an update. Bordens, RW; Cutler, DL; Grace, MJ, 2005)	0.33
"To assess the baseline factors associated with haematological toxicity that lead to ribavirin or pegylated interferon (peginterferon) dosage reductions in hepatitis C and human immunodeficiency virus (HCV/HIV)-coinfected patients."	( Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy. Clotet, B; Force, L; Fuster, D; Gómez, G; González García, J; Huertas, JA; Pedrol, E; Planas, R; Sirera, G; Solà, R; Tor, J; Tural, C; Videla, S; Vilaró, J, 2005)	0.33
"Daily dosing of CIFN plus ribavirin may be a promising concept for selected non-responder patients before considering therapies which are anti-viral but not curative."	( Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. Cornberg, M; Hadem, J; Herrmann, E; Manns, MP; Marschal, O; Reiser, M; Schmidt, HH; Schuppert, F; Steffen, M; Wedemeyer, H, 2006)	0.33
"028), treatment dosage and duration (P=0."	( Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Gui Qiang, W; Jian Wu, Y; Shu Chen, L, 2006)	0.33
" The BMI, WHR, the levels of plasma insulin, genotype, presence of fatty liver, treatment dosage and duration and HOMA-IR were associated with the sustained virologic response."	( Effects of fatty liver and related factors on the efficacy of combination antiviral therapy in patients with chronic hepatitis C. Gui Qiang, W; Jian Wu, Y; Shu Chen, L, 2006)	0.33
" We investigated the efficacy and safety of a 24-wk course of thalidomide at a dosage of 200 mg/day in eight patients with HCV chronic hepatitis nonresponders to interferon alpha plus ribavirin."	( Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and ribavirin. Biasin, M; Clerici, M; Galli, M; Gatti, N; Milazzo, L; Moroni, M; Niero, F; Piacentini, L; Riva, A; Zanone Poma, B, 2006)	0.33
" The proportion of patients who discontinued the treatment or reduced drug dosage because of adverse events was significantly higher in group B than in group A (27."	( Effect of combination therapy with ribavirin and high-dose interferon-alpha2b for 24 weeks in chronic hepatitis C. Abe, S; Narita, R; Oto, T; Otsuki, M; Tabaru, A, 2006)	0.33
" Two pegylated interferons are commercially available, both of which have distinct pharmacokinetic properties that necessitate different dosing strategies."	( Pegylated interferon plus ribavirin for chronic hepatitis C: the role of combination therapy today, tomorrow and in the future. Ferenci, P, 2006)	0.33
" Sixty patients received the same dosage of IFN plus placebo."	( Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study. Chao, YC; Chen, CL; Chen, DS; Chen, PJ; Hsiao, TJ; Hsieh, TY; Hu, JT; Kao, JH; Lai, MY; Liao, LY; Lin, CL; Liu, CJ; Yang, SS, 2006)	0.33
" Other IMP dehydrogenase inhibitors administered near maximum tolerated doses using the same dosing regimen as for ribavirin were found to slightly enhance virus replication in the lungs."	( Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Bailey, K; Barnard, DL; Carson, DA; Cottam, HB; Day, CW; Heiner, M; Hoopes, J; Lauridsen, L; Lee, J; Li, JK; Montgomery, R; Sidwell, RW; Winslow, S, 2006)	0.33
"The aim of this study was to assess the efficacy, safety and tolerability of pegylated interferon and ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients, prescribed for the same duration and at the same dosage as that used in HCV monoinfection studies."	( Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals. Bergin, C; Clarke, S; Farrell, G; Hennessy, M; Hopkins, S; Lambourne, J; McCullagh, L; Mulcahy, F, 2006)	0.33
" However the pharmacokinetics and tolerability of both peg-alfa-2a and 2b need to be studied more closely in prospective studies before definite dosing recommendations can be made."	( Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. Bruchfeld, A; Carlsson, T; Lindahl, K; Reichard, O; Schvarcz, R, 2006)	0.33
" With a presumptive diagnosis of PCT a cutaneous/skin biopsy was performed as well as a porphyrin dosage with urine porphyirins of 4185 microg/24 hs (nv<250)."	( [Development of porphyria cutanea tarda in a chronic hepatitis C patient with indetectable viremia under treatment with peg-interferon plus ribavirin]. Alessio, A; Buonsante, ME; Frider, B; Pellerano, G; Tiscornia, J, 2006)	0.33
"7%) needed a dosage reduction."	( Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. Boninsegna, S; Brolese, A; Burra, P; Canova, D; D'Aloiso, C; Fagiuoli, S; Germani, G; Guido, M; Masier, A; Pevere, S; Targhetta, S; Tomat, S, 2006)	0.33
"The combination of alpha-IFN plus ribavirin induced a sustained virologic response in 20% of liver transplant recipients with recurrent HCV, but intolerance of the therapy prompted its discontinuation or a dosage reduction in a large proportion of patients."	( Antiviral therapy for hepatitis C virus recurrence following liver transplantation: long-term results from a single center experience. Boninsegna, S; Brolese, A; Burra, P; Canova, D; D'Aloiso, C; Fagiuoli, S; Germani, G; Guido, M; Masier, A; Pevere, S; Targhetta, S; Tomat, S, 2006)	0.33
"The results of this study underscore the importance of adequate dosing of ribavirin as well as pegylated interferons in achieving an SVR when treating genotype 1 chronic hepatitis C patients with combination therapy."	( A study of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C. Ashikaga, T; Gordon, SR; Grace, ND; Krawitt, EL; Moskowitz, S; Palmer, M; Ray, MA; Yarze, JC, 2006)	0.33
" Although the recommended dosage was the same as that used at the end of the initial trial, adjustments were permitted."	( Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin. Berg, C; Bernstein, DE; Cooksley, G; Diago, M; Goncales, FL; Graham, P; Jensen, DM; Rasenack, J; Sette, H, 2006)	0.33
"5 microg/kg body weight (BW), in spite of the previously shown flat dose-response curve at doses of > or =1."	( Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis. Arn, M; Borovicka, J; Criblez, D; Egger, H; Gonvers, JJ; Helbling, B; Meyenberger, C; Meyer-Wyss, B; Müllhaupt, B; Oneta, C; Rammert, C; Renner, EL; Rich, P; Rossi, L, 2006)	0.33
"The purpose of the present paper was to investigate the factors possibly involved in the failure of pegylated interferon (Peg IFN) plus ribavirin treatment at standard dosage in hepatitis C virus (HCV) 1b patients, with chronic hepatitis."	( Metabolic factors involved in the therapeutic response of patients with hepatitis C virus-related chronic hepatitis. Ariello, M; Conca, P; Sorrentino, P; Tarantino, G, 2006)	0.33
" Once-weekly dosing with peg-INF-alpha2a, which has a longer half-life than other forms of INF, plus daily dosing with ribavirin, has been shown to be effective in reducing viral load."	( Viral kinetics in the treatment of chronic hepatitis C. Cotler, SJ; Layden, TJ; Layden-Almer, JE, 2006)	0.33
" We present herein the results of plasma measurement of ribavirin levels in transplanted patients when using increasing dosage of ribavirin, in comparison with a control cohort of nontransplanted patients."	( Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. Boillot, O; Chevallier, P; Ducos, E; Dumortier, J; Gagnieu, MC; Scoazec, JY, 2006)	0.33
" Treatment was discontinued in 25% of the patients, and dosing was modified in 58%."	( Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Andriulli, A; Brancaccio, G; Ciancio, A; David, E; Fontana, R; Gaeta, GB; Marrone, A; Niro, GA; Olivero, A; Perri, F; Rizzetto, M; Smedile, A; Stanzione, M, 2006)	0.33
" The use of ZDV but not weight-based RBV dosing was associated with an increased risk of anaemia, RBV dose reduction or EPO use in coinfected patients treated with PEG-IFN/RBV."	( Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. Alvarez, D; Ball, L; Brau, N; Dieterich, DT; Moorehead, L; Sulkowski, MS, 2006)	0.33
" This randomized trial showed that the saturation of ribavirin uptake after taking ribavirin capsules does not occur within a dose range of 600 to 800 mg/day, which is a standard dosage used clinically in Japan."	( Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. Ebinuma, H; Hibi, T; Ishii, H; Kashiwazaki, K; Nishida, J; Saito, H; Shiozaki, H; Tada, S; Takahashi, M; Tanaka, S; Tsukada, N, 2006)	0.33
" The method has been used to simultaneously determine the total concentrations of ribavirin and viramidine in monkey RBC following 5, 15, and 36 weeks dosing of viramidine or ribavirin (60 mg/kg)."	( LC-MS/MS method for simultaneous determination of viramidine and ribavirin levels in monkey red blood cells. Bu, W; Dadgostari, S; Lin, CC; Nguyen, M; Yeh, LT, 2007)	0.34
" Further, combination therapy reduces the effective dosage of ribavirin, which would serve to limit its toxicity."	( Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Bailey, KW; Blatt, LM; Gowen, BB; Jung, KH; Pace, AM; Sidwell, RW; Smee, DF; Wong, MH, 2006)	0.33
"5 and 5 mg/kg/day; ribavirin at 5, 10 and 20 mg/kg/day) certain dosage combinations were superior to either compound used alone as assessed by decreased mortality, lung virus titre, lung score and lung weight parameters."	( Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Bailey, KW; Sidwell, RW; Smee, DF; Wong, MH, 2006)	0.33
"Compared with different combination therapy strategies, peg-interferon alpha-2b plus weight-based dosing of ribavirin in all patients for 24 weeks is the most cost-effective treatment strategy."	( Cost-utility analysis of different peg-interferon alpha-2b plus ribavirin treatment strategies as initial therapy for naïve Chinese patients with chronic hepatitis C. Lin, WA; Tang, SL; Tarn, YH, 2006)	0.33
"CIFN in combination with ribavirin when given to HCV genotype 1 relapsers after rIFN monotherapy obtains an unsatisfactory rate of sustained viral clearance independently of dosage of the drug."	( Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial. Alaimo, G; Almasio, PL; Calvaruso, V; Craxì, A; D'Angelo, F; Di Marco, V; Di Stefano, R; Ferraro, D; Porrovecchio, S, 2006)	0.33
" Weight-based dosing of ribavirin has emerged as another important consideration."	( Customizing treatment to patient populations. Brown, RS, 2007)	0.34
" Reducing the dose of ribavirin from full dose (> or =98%) to < or =60% did not affect either W20 VR or SVR as long as ribavirin dosing was not interrupted for more than 7 consecutive days."	( Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Bonkovsky, HL; Di Bisceglie, AM; Dienstag, JL; Everson, GT; Ghany, MG; Gretch, DR; Lee, WM; Lindsay, KL; Lok, AS; Morgan, TR; Shiffman, ML; Wright, EC, 2007)	0.34
" Depression occurs in approximately one-third of patients during antiviral therapy and can lead to reduction in treatment dosage or discontinuation of treatment, thus reducing the likelihood of clearing HCV infection."	( A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. Hauser, P; Indest, DW; Loftis, JM; Moles, JK; Morasco, BJ; Rifai, MA, 2007)	0.34
"Ready dosage form (eye drops) prepared on the basis of recombinant alpha2-IFN exhibits high activity towards herpes simplex type 1 virus in vitro."	( Combined antiherpetic effect of complex preparation "Viferon-eye drops" and modified nucleosides. Andronova, VL; Galegov, GA; Malinovskaya, VV; Vyzhlova, EN, 2006)	0.33
" The aims of this study were to assess the rate of early (EVR) and sustained virological response (SVR), tolerability and baseline predictive factors associated with EVR and SVR in patients with chronic hepatitis C treated with individualized weight-based dosing regimen for both PegIFN alpha-2b and ribavirin."	( Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Sirli, R; Sporea, I, 2007)	0.34
"PegIFN alpha-2b and ribavirin can be safe and successful when using a weight-based dosing regimen, leading to high response rates even in overweight patients."	( Efficacy, tolerability and predictive factors for early and sustained virologic response in patients treated with weight-based dosing regimen of PegIFN alpha-2b ribavirin in real-life healthcare setting. Damian, D; Gheorghe, C; Gheorghe, L; Grigorescu, M; Iacob, R; Iacob, S; Sirli, R; Sporea, I, 2007)	0.34
" To manage the growing populations of hard-to-treat patients with chronic viral hepatitis, there is a need for more effective treatment modalities, including optimized, individualized dosing and novel antivirals."	( [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)]. Pár, A; Szalay, F; Tornai, I, 2007)	0.34
" To improve the efficacy of retreatment, either interferon and/or ribavirin dosage have been increased, either other antiviral drugs have been added to combination therapy."	( [Retreatment of chronic hepatitis C patients non responder to a previous antiviral treatment]. Biliotti, E; Taliani, G, 2007)	0.34
" It has demonstrated strong antiviral activity in patients chronically infected with genotype 1 HCV when dosed alone or in combination with peginterferon alfa-2a."	( Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha. Bartels, DJ; Brennan, DL; Hanzelka, BL; Kwong, AD; Lin, C; Müh, U; Rao, BG; Swenson, L; Tigges, AM; Wei, Y; Zhou, Y, 2007)	0.34
" The third step consisted in the use of pegylated interferon in order to adapt its pharmacokinetics and to allow a better efficacy with a more tolerable dosing schedule: once weekly subcutaneous injection instead of thrice weekly."	( Interferon-based treatment of chronic hepatitis C. Lejeune, O; Souvignet, C; Trepo, C, )	0.13
" Thus, this method provides a simple, sensitive, precise and reproducible assay for dosing ribavirin that can be readily adaptable to routine use by clinical laboratories with standard equipment."	( Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection. Loregian, A; Pagni, S; Palù, G; Parisi, SG; Scarpa, MC, 2007)	0.34
" The timing and dosage regimens of steroid in the treatment of SARS are controversial."	( Pharmacologic treatment of SARS: current knowledge and recommendations. Tai, DY, 2007)	0.34
" The optimal dosing regimen for ZnAL42 was achieved at 17."	( Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice. Bailey, K; Barnard, DL; Day, CW; Hall, TJ; Hickok, SS; Sidwell, RW; Wong, MH, 2007)	0.34
"The response to pegylated interferon (pegIFN) plus ribavirin (RBV) as treatment of chronic hepatitis C virus (HCV) infection is lower in HIV-coinfected than in HCV-monoinfected patients and could be due to suboptimal RBV dosing and/or insufficient duration of therapy in prior trials."	( Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. Aguirrebengoa, K; Arazo, P; Asensi, V; Barreiro, P; Berdún, MA; Cervantes, M; de Los Santos, I; Echeverría, S; Galindo, MJ; García-Samaniego, J; Guardiola, JM; Hernandez-Burruezo, JJ; Losada, E; Miralles, C; Núñez, M; Ocampo, A; Romero, M; San Joaquín, I; Sola, J; Soriano, V, 2007)	0.34
" No significant differences were observed in the dosage of medicines or other clinical data during the treatment."	( Zinc supplementation prevents the increase of transaminase in chronic hepatitis C patients during combination therapy with pegylated interferon alpha-2b and ribavirin. Kakibuchi, N; Kawakami, T; Kawashima, A; Kita, K; Koyabu, T; Murakami, Y; Okita, M; Takaguchi, K, 2007)	0.34
" Good virological outcomes can be achieved in HIV co-infected haemophiliacs particularly when growth factors are used to facilitate full dosing of peg-IFN and RBV."	( Haematological support during peg-interferon therapy for HCV-infected haemophiliacs improves virological outcomes. Bergin, C; Farrell, G; Hopkins, S; Kevans, D; Mahmud, N; Norris, S; White, B, 2007)	0.34
" Moreover, best treatment duration and dosage of recurrent HCV infection with pegylated interferon in combination with ribavirin remains to be defined."	( Prophylaxis and treatment of recurrent viral hepatitis after liver transplantation. Berberat, PO; Encke, J; Gotthardt, D; Mehrabi, A; Merle, U; Riediger, C; Sauer, P; Stremmel, W; Weiss, KH, 2007)	0.34
" Besides greater hemoglobin reductions with weight-based RBV, safety profiles were similar across RBV dosing groups, including the 1400-mg/day group."	( Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Afdhal, N; Becker, S; Bernstein, D; Brass, CA; Brown, RS; Flamm, S; Freilich, B; Godofsky, E; Griffel, LH; Jacobson, IM; Kwo, PY; Mukhopadhyay, P; Pauly, MP; Pound, D; Santoro, J; Strauss, R; Wakil, AE, 2007)	0.34
"WIN-R (Weight-based dosing of pegINterferon alfa-2b and Ribavirin) was a multicenter, randomized, open-label, investigator-initiated trial involving 236 community and academic sites in the United States, comparing response to pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in treatment-naive patients with chronic hepatitis C and compensated liver disease."	( Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. Albert, C; Araya, V; Black, M; Brass, CA; Brown, RS; Dragutsky, MS; Freilich, B; Galler, GW; Griffel, LH; Hargrave, T; Harvey, J; Jacobson, IM; Kwo, PY; Lambiase, L; McCone, J; Siddiqui, FA, 2007)	0.34
" Further trials and clinical studies are necessary for the optimal treatment of patients with recurrent hepatitis C, and to determine the dosage of pegylated interferon and ribavirin, to decrease the duration of therapy and the side effects, finally to achieve a healing phase of higher degree."	( [Treatment of recurrent hepatitis C virus infection after liver transplantation]. Lengyel, G; Tulassay, Z, 2007)	0.34
"High-dose peginterferon-alpha (PegIFN-alpha) induction and prolongation of therapy may be an option to improve sustained virological response (SVR) rates among hepatitis C virus (HCV) non-responders, although a higher and a longer dosing of PegIFN-alpha may intensify side effects."	( Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders. Bergmann, JF; Brouwer, JT; de Knegt, RJ; de Vries, RA; Hansen, BE; Janssen, HL; Schalm, SW; van der Schaar, P; van der Sluys Veer, A; van Hoek, B; Verhey, E; Vrolijk, JM; Vroom, B, 2007)	0.34
" Therapy if given with weight-based dosing may be shortened from 24 to 12, 14 or 16 weeks (genotypes 2 and 3), and from 48 to 24 weeks (genotype 1) in case of hepatitis C virus (HCV) clearance at week 4, without reducing sustained virologic response (SVR)."	( Antiviral therapy: chronic hepatitis C. Heathcote, EJ, 2007)	0.34
"Currently, the approved dosage of ribavirin has not been studied in patients with 'normal' alanine aminotransferase (ALT) levels."	( Predicting efficacy and safety outcomes in patients with hepatitis C virus genotype 1 and persistently 'normal' alanine aminotransferase levels treated with peginterferon alpha-2a (40KD) plus ribavirin. Berg, T; Hadziyannis, SJ; Jorga, K; Marcellin, P; Puoti, C; Snoeck, E; Swain, MG; Zarski, JP; Zeuzem, S, 2008)	0.35
" Ribavirin was given daily at a dosage of 30 mg/kg and tiazofurin was given at a dosage of 10 mg/kg every other day for 15 days."	( Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: clinical and histopathological evaluation. Bjelobaba, I; Dacic, S; Jovanovic, S; Lavrnja, I; Mostarica-Stojkovic, M; Nedeljkovic, N; Pekovic, S; Rakic, L; Stojiljkovic, M; Stojkov, D; Stosic-Grujicic, S, 2008)	0.35
" In the combination therapy group, patients maintaining a full dosage schedule of PEG IFN-alpha-2a and ribavirin and those requiring dose reductions of either study drug had similar SVR rates (64."	( Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Hayashi, N; Iino, S; Kiyosawa, K; Kumada, H; Okuno, T; Omata, M; Sakai, T; Yamada, G, 2008)	0.35
"In peg-IFN alpha-2b plus RBV treatment for chronic hepatitis C, it is important to complete the target length of treatment and to continue the target dosage to achieve SVR, especially for genotype 1 patients."	( Association between the treatment length and cumulative dose of pegylated interferon alpha-2b plus ribavirin and their effectiveness as a combination treatment for Japanese chronic hepatitis C patients: project of the Kyushu University Liver Disease Study Azuma, K; Enjoji, M; Furusyo, N; Hayashi, J; Kajiwara, E; Maruyama, T; Masumoto, A; Nakamuta, M; Nomura, H; Sakai, H; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y, 2008)	0.35
" Dosage and duration depend on some factors as weight, genotype, viral load and a rapid virological response presented by the patient."	( Treatment regimens for patients with chronic hepatitis C. Borque, MJ; Chaparro-Sánchez, M; González-Moreno, L; Moreno-Monteagudo, JA; Moreno-Otero, R; Trapero-Marugan, M, 2008)	0.35
" Drug dosage was modified or temporarily discontinued if anaemia or bone marrow suppression developed."	( Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India. Dey, S; Nayyar, I; Pal, S; Ray, G, )	0.13
" Through a better understanding of treatment response and viral kinetics, clinicians are employing altered dosing schedules to minimize the burden of viral illness."	( Hepatitis C: current options for nonresponders to peginterferon and ribavirin. Fried, MW; Thomas, E, 2008)	0.35
"A prospective non-randomized, open-label comparison was made of naive HCV-infected patients undergoing standard 24- or 48-week treatment with two PEG-IFN combined with weight-based dosing regimen of ribavirin (PEG-IFN-alpha2a/ribavirin, n = 91; PEG-IFN-alpha2b/ribavirin, n = 92)."	( Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. Del Olmo, JA; Escudero, A; Montes, F; Rodrigo, JM; Rodríguez, F; Serra, MA, 2008)	0.35
" Furthermore, intensified ribavirin dosing might also improve SVR rates in 'difficult-to-cure' patients."	( Ribavirin considerations in treatment optimization. Dusheiko, G; Nelson, D; Reddy, KR, 2008)	0.35
"4% cirrhotics) who had been treated with weight-adjusted dosing (1."	( Patient's age modifies the impact of the proposed predictors of sustained virological response in chronic hepatitis C patients treated with PEG-interferon plus ribavirin. Elefsiniotis, IS; Ketikoglou, I; Koutsounas, S; Moulakakis, A; Pantazis, KD; Pavlidis, C; Scarmeas, N; Tsianos, EV, 2008)	0.35
" Serum HCV-RNA levels before initial dosing (baseline level) and at 24 h, week 1, week 4, week 12, week 24, week 48 and week 72 were assessed in 84 HCV genotype-4 patients treated weekly by PEG-IFN alpha 2a and daily ribavirin."	( Viral kinetic of HCV genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. Al Kaabi, SR; Al Khinji, MA; Al Mohanadi, M; Al-Marri, AD; Amer, AM; Bener, AB; Butt, MT; Derbala, MF; El Dweik, NZ; John, A; Pasic, F; Shebl, FM; Yakoob, R, 2008)	0.35
" We found that 135 microg peg-IFN alfa-2a weekly was sufficient for treatment of genotype 2 and 3 chronic hepatitis C when combined with RBV dosed daily according to body weight."	( Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. Enquist, R; Glaumann, H; Hollander, A; Lindahl, K; Lindh, G; Mattsson, L; Quist, A; Schvarcz, R; Weiland, O, 2008)	0.35
" Dosing of R1626 was limited by neutropenia; a study of different dosages of R1626 in combination with peginterferon alfa-2a and ribavirin is underway."	( R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Chan, A; Everson, GT; Fried, MW; Ghalib, R; Godofsky, E; Harrison, S; Hill, G; Najera, I; Nelson, D; Nyberg, L; Pockros, PJ; Rodriguez-Torres, M; Shiffman, ML, 2008)	0.35
" This review discusses strategies to optimize peginterferon and ribavirin dosing and the impact that growth factors may have on the ability to achieve a sustained virologic response."	( Optimizing the current therapy for chronic hepatitis C virus: peginterferon and ribavirin dosing and the utility of growth factors. Shiffman, ML, 2008)	0.35
" Results of several recent trials evaluating optimal dosing of RBV and higher than standard dosing of PEG-IFN in treatment-naïve genotype 1 patients, as well as data from retreatment trials with "induction" doses of PEG-IFN or high-dose RBV in prior non-responders to IFN-based therapy will be reviewed here."	( Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C. Gambarin-Gelwan, M; Jacobson, IM, 2008)	0.35
"Alb-IFN administered q2wk or q4wk may offer comparable efficacy, with an improved dosing schedule, compared with PEG-IFNalpha-2a."	( Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Bain, VG; Benhamou, Y; Cronin, PW; Flisiak, R; Grigorescu, M; Kaita, K; McHutchison, JG; Pianko, S; Pulkstenis, E; Rehak, V; Shouval, D; Subramanian, GM; Yoshida, EM; Zeuzem, S, 2008)	0.35
" Interferon-induced adverse events include flu-like symptoms, bone marrow suppression, and emotional or cognitive effects, whereas hemolytic anemia accounts for most ribavirin dosage reductions."	( Treatment options for patients with hepatitis C: role of pharmacists in optimizing treatment response and managing adverse events. Smith, JP, 2008)	0.35
"5 g/dL by week 2 was an excellent early predictor for subsequent considerable hemoglobin decreases and might be used to identify candidates for early intervention against anemia in order to help maintain ribavirin dosing and avoid suboptimal exposure."	( Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Fried, MW; Hadziyannis, SJ; Jensen, DM; Messinger, D; Reau, N, 2008)	0.35
" The hits were evaluated for their antiviral activity, cell toxicity, and selectivity in dose-response experiments."	( High-throughput screening of a 100,000-compound library for inhibitors of influenza A virus (H3N2). Ananthan, S; Chung, DH; Jonsson, CB; McDowell, M; Noah, J; Rasmussen, L; Severson, WE; Sosa, MI; White, EL, 2008)	0.35
" Our data suggest that more than once a week dosing might be desirable early during treatment to maintain high levels of response as measured by gene expression."	( Cyclic changes in gene expression induced by Peg-interferon alfa-2b plus ribavirin in peripheral blood monocytes (PBMC) of hepatitis C patients during the first 10 weeks of treatment. Edenberg, HJ; Kwo, P; McClintick, JN; Taylor, MW; Tsukahara, T, 2008)	0.35
" Several strategies have been evaluated in order to optimize outcome of current peginterferon-based therapy, including higher dosing of peginterferon and/or ribavirin, and adjusting therapy duration."	( What is on the horizon for treatment of chronic hepatitis C? Bergmann, JF; De Knegt, RJ; Janssen, HL, 2008)	0.35
" A recent Phase II trial investigating early and sustained virological response showed no statistically significant differences between ribavirin 1000/1200 mg and taribavirin at 800-, 1200-, or 1600-mg dosing, while illustrating a lesser degree of anemia in 800- and 1200-mg dosing of taribavirin."	( Taribavirin for the treatment of chronic hepatitis C. Kearney, KR; Navarro, VJ; Thornton, JJ, 2008)	0.35
" However, for treatment with pegylated (PEG)-IFN-alpha2b dosed weekly, drug levels fall substantially and viral load rebounds have been observed toward the end of the weekly dosing interval, implying non-constant drug efficacy."	( A hepatitis C viral kinetic model that allows for time-varying drug effectiveness. Perelson, AS; Ribeiro, RM; Shudo, E; Talal, AH, 2008)	0.35
" RBV dosing was 213."	( Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Bonet, L; Cifuentes, C; Gatell, JM; Laguno, M; Laufer, N; Mallolas, J; Murillas, J; Perez, I; Veloso, S; Vidal, F, 2008)	0.35
"Suboptimal drug exposure attributable to physician-directed dosage reductions of pegylated interferon and/or ribavirin are associated with decreased sustained virologic response rates."	( Adherence to hepatitis C virus therapy and early virologic outcomes. Amorosa, VK; Dorey-Stein, Z; Gross, R; Kostman, JR; Lo Re, V; Localio, AR; O'Flynn, R; Teal, V, 2009)	0.35
" Ribavirin dosage varies by bodyweight for genotype 1 disease (1000mg/day in patients 75kg), whereas 800mg/day is sufficient to ensure optimal response in all genotype 2/3 patients."	( Ribavirin: current role in the optimal clinical management of chronic hepatitis C. Nelson, DR; Reddy, KR; Zeuzem, S, 2009)	0.35
" We conducted a pilot study with a sequential regimen using a reduced dosage of peginterferon-alfa 2b in patients with chronic hepatitis C and normal transaminases."	( Ribavirin priming in patients with chronic hepatitis C and normal ALT: a pilot study. Drebber, U; Goeser, T; Heindl, B; Schulte, S; Steffen, HM; Stelzer, A; Töx, U, )	0.13
"The cumulative dosage of ribavirin per kilogram of body-weight prevents relapse and thus is a significant predictor of sustained virological response (SVR)."	( Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation. Ganslmayer, M; Hahn, EG; Herold, C; Zopf, S, 2009)	0.35
"2 mg/kg ribavirin dosed group (59."	( Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation. Ganslmayer, M; Hahn, EG; Herold, C; Zopf, S, 2009)	0.35
"Weight-adapted ribavirin dosing in combination with peg-IFN alfa-2a to avoid giving low doses of ribavirin should be evaluated."	( Peginterferon alfa-2a relapse rates depend on weight-based ribavirin dosage in HCV-infected patients with genotype 1: results of a retrospective evaluation. Ganslmayer, M; Hahn, EG; Herold, C; Zopf, S, 2009)	0.35
" The multivariate logistic regression analysis revealed that retreatment, centre with more patients treated, patient age (<55 years), male, genotype 2 and dosage of IFN per weight (<0."	( Factors associated with adherence to combination therapy of interferon and ribavirin for patients with chronic hepatitis C: importance of patient's motivation and physician's treatment experience. Ando, M; Araki, Y; Ikeda, H; Iwasaki, Y; Kobashi, H; Osawa, T; Sakaguchi, K; Shiratori, Y; Tanioka, D; Yamamoto, K, 2009)	0.35
"For the dosage schedule used in our study, oral ribavirin has no effect in reducing early mortality associated with Japanese encephalitis."	( Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Banerjee, G; Baranwal, M; Kumar, R; Singh, S; Tripathi, P; Tripathi, S, 2009)	0.35
" A small-molecule thrombopoietin mimetic, eltrombo-pag, has demonstrated a dose-response associated increase in platelet count in a phase 2 study, allowing initiation and completion of a 12-week course of peginterferon plus ribavirin in 36%, 53%, and 65% of patients receiving 30 mg, 50 mg, or 75 mg of eltrombopag daily, respectively, compared with 6% in the placebo arm."	( Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. McHutchison, JG; Patel, K; Tillmann, HL, 2009)	0.35
"Daily weight based interferon alpha-2b dosing and PEG interferon alpha-2b weighed based dosing once weekly both in combination with Ribavirin offer the same efficacy and safety rates."	( Weekly pegylated interferon alpha-2b vs daily interferon a-2b versus standard regimen of interferon a-2b in the treatment of patients with chronic hepatitis C virus infection. Adler, M; Bourgeois, N; Brenard, R; Bruckers, L; Colle, I; Goossens, A; Horsmans, Y; Langlet, P; Michielsen, P; Van Vlierberghe, H, )	0.13
" Treatment followed standard guidelines with weight-based dosing of pegylated interferon-alpha2b and ribavirin."	( Treatment outcomes with pegylated interferon and ribavirin for male prisoners with chronic hepatitis C. Allen, SA; Chew, KW; Feller, E; Rich, JD; Taylor, LE, 2009)	0.35
" Also, the median darbepoetin-alfa-weighted dose in group no rHuEPO increased while it remained stable in group rHuEPO, as did the median daily dosage of ribavirin; however, these differences were not statistically significant."	( A monocentric observational study of darbepoetin alfa in anemic hepatitis-C-virus transplant patients treated with ribavirin. Esposito, L; Guitard, J; Kamar, N; Ribes, D; Rostaing, L, 2008)	0.35
" Patients with absolute neutrophil counts less than 900 cells/mmc and early viral response received lenograstim at the dosage of 263 mcg 24 hours prior to administration of Peg-IFN alpha 2b."	( Lenograstim in the treatment of severe neutropenia in patients treated with Peg-IFN and ribavirin: the experience of a single hepatology unit. Celiento, M; De Rosa, A; Ripa, C; Schiano, A; Tambaro, O; Tarantino, L, 2009)	0.35
" Dosage regimens of ribavirin might need to be adjusted according to the purine content of the meal."	( Effect of dietary purines on the pharmacokinetics of orally administered ribavirin. Han, L; Hashim, KB; Koo, SH; Lee, EJ; Li, L; Limenta, LM; Quek, HH, 2009)	0.35
" At the multivariate analysis, only EVR, genotypes 2 and 3, and adherence to full course and dosage of therapy retained their independent predictive power, with corresponding ORs of 25."	( Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Niro, GA; Siciliano, M; Valvano, MR, 2009)	0.35
" Treatment ought to be pursued among patients who attain an EVR, and maintain a full course and dosage of therapy."	( Sustained virological responses following standard anti-viral therapy in decompensated HCV-infected cirrhotic patients. Accadia, L; Andriulli, A; Annicchiarico, BE; Bombardieri, G; Caruso, N; Iacobellis, A; Niro, GA; Siciliano, M; Valvano, MR, 2009)	0.35
"As HCV treatment becomes more complex with new classes of agents, adherence will be increasingly important to treatment success as resistance mutations may develop with suboptimal dosing of HCV enzyme inhibitors."	( Review article: adherence to medication for chronic hepatitis C - building on the model of human immunodeficiency virus antiretroviral adherence research. Bräu, N; Fishbein, D; Stivala, A; Swan, T; Weiss, JJ, 2009)	0.35
" The United States-based WIN-R trial confirmed the value of combining weight-based ribavirin dosing with weight-based PEG-IFN alfa-2b dosing across a spectrum of patient body weights."	( Efficacy of chronic hepatitis C therapy in community-based trials. Hueppe, D; Jacobson, I; Kwo, P; Marotta, P; Zehnter, E, 2009)	0.35
"A validated lifetime Markov model was used to project life expectancy, QALYs and lifetime costs for the following strategies: (i) no antiviral therapy (NoAVT); (ii) interferon-alpha-2b plus ribavirin for 48 weeks (IFN + R); (iii) peginterferon-alpha-2b plus weight-based ribavirin for 48 weeks (PEG + R); (iv) peginterferon-alpha-2b plus ribavirin according to German guidelines with genotype-dependent treatment duration, dosage and 12-week viral response evaluation (GUIDE)."	( Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines. Aidelsburger, P; Manns, MP; McHutchison, JG; Rossol, S; Siebert, U; Sroczynski, G; Wasem, J; Wong, JB, 2009)	0.35
"Patients treated with PEG-IFN and ribavirin had plasmatic ribavirin dosage at weeks 4 and 12."	( Impact of ribavirin plasma level on sustained virological response in patients treated with pegylated interferon and ribavirin for chronic hepatitis C. Breilh, D; Castéra, L; Couzigou, P; de Lédinghen, V; Djabarouti, S; Foucher, J; Merrouche, W; Saux, MC; Trimoulet, P, 2009)	0.35
" Because of the high frequency of hemotoxicity and renal insufficiency, ribavirin should be dosed according to renal function."	( A practical guide to the management of HCV infection following liver transplantation. Charlton, M; Veldt, B; Watt, K, 2009)	0.35
" By means of observing the cytopathic effects (CPE), measuring the absorbance [D(lambda)] and counting the PFU, according to Reed-Muench assay, the TCM-ES's effective dosage of 50 percentage (EC50) and treatment index (TI) to FM1 were calculated."	( [Antiviral effects of an effective section of a prescription of traditional Chinese medicine on influenza virus A in vitro]. Feng, XL; Huang, SH; Wei, W; Wu, CY; Xu, SP; Zhang, LL, 2009)	0.35
" The questionnaire contained items about facility, duration and dosing of treatment, and side effect management using clinical vignettes followed by short questions."	( Current clinical care compared with new Dutch guidelines for hepatitis C treatment. de Knegt, RJ; Drenth, JP; Lamers, MH; Roomer, R; Slavenburg, S; van Oijen, MG, 2009)	0.35
" The majority of physicians follow the stipulated dosage regimens of pegylated interferon (88%) and ribavirin (83%)."	( Current clinical care compared with new Dutch guidelines for hepatitis C treatment. de Knegt, RJ; Drenth, JP; Lamers, MH; Roomer, R; Slavenburg, S; van Oijen, MG, 2009)	0.35
" These results suggest fixed-dose VRD given 600 mg BID is insufficient to treat patients with chronic hepatitis C; a weight-based dosing trial of viramidine is currently under way."	( A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results. Afdhal, NH; Benhamou, Y; Chun, E; Halliman, DG; Heise, J; Nelson, DR; Pockros, PJ; Shiffman, ML, 2009)	0.35
" Dose-response curves were generated for all drug combinations, and the degree of drug interaction was quantified using a model that calculates the synergy (or antagonism) between the drugs in double and triple combinations."	( Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Driebe, EM; Engelthaler, DM; Hoopes, JD; Keim, PS; Le, MH; Nguyen, JT; Prichard, MN; Smee, DF; Spence, RP; Went, GT, 2009)	0.35
" Pharmacokinetic data demonstrated high exposure and good oral bioavailability, supporting once-daily dosing of TMC-435 in humans."	( TMC-435, an NS3/4A protease inhibitor for the treatment of HCV infection. Tsantrizos, YS, 2009)	0.35
"Induction dosing with 360 microg/week PEG-IFNalpha-2a for 12 weeks was well tolerated and enhanced early virological response but not SVR rates."	( Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Cheng, WS; Crawford, DH; Depamphilis, JK; Desmond, PV; Dore, GJ; Marks, PS; McCaughan, GW; Rawlinson, W; Rizkalla, B; Roberts, SK; Sievert, W; Weltman, MD; Yoshihara, M, 2009)	0.35
" In the CD4 cell count 250 cells/mm(3) group, severe hematological toxicity and pegylated IFN or RBV dosage reductions occurred in 16 (41%) and 12 (31%) patients, respectively."	( Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Arponen, S; Collado, A; Delgado, M; Gil, Ide L; González-Serrano, M; Gutiérrez-Valencia, A; López-Ruz, MA; Macías, J; Merino, D; Mira, JA; Omar, M; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Torres-Tortosa, M, 2009)	0.35
" New formulations of intravenous iron (iron carboxymaltose) and the new generation of erythropoietic agents (darbepoetin and continuous erythropoietin receptor activator) will allow better dosing with the same efficacy and safety."	( Use of agents stimulating erythropoiesis in digestive diseases. Gomollón García, F; Moreno López, R; Sicilia Aladrén, B, 2009)	0.35
"The antiviral efficacy, as well as the adverse effects, of PEG-IFN alfa-2a and PEG-IFN alfa-2b are similar in US patients with HCV genotype 1 when used in a standard dosing regimen in combination with ribavirin."	( Pharmacotherapy of chronic hepatitis C virus infection - the IDEAL trial: '2b or not 2b (= 2a), that is the question'. Kumada, T; Toyoda, H, 2009)	0.35
" To date, there is no general consensus on modality, timing and dosing of antiviral treatment of HCV in patients with advanced liver disease and after liver transplantation."	( Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Hofmann, WP; Peveling-Oberhag, J; Zeuzem, S, 2010)	0.36
" Determination of a viramidine dosage that would yield superior efficacy over ribavirin is needed."	( Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients. Chun, E; Gish, RG; Gitlin, N; Halliman, DG; Heise, J; Marcellin, P; Rodriguez-Torres, M, 2010)	0.36
" Monitoring of RBV C(trough) may permit early adjustment of RBV dosage to avoid HCV relapse."	( Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Barreiro, P; González-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Madejón, A; Medrano, J; Morello, J; Rodríguez-Novoa, S; Soriano, V, 2010)	0.36
" Two pegylated interferon (peginterferon)-alpha molecules are commercially available for the treatment of chronic hepatitis C, and these differ in the size and nature of the covalently attached polyethylene glycol (PEG) moiety, with resulting differences in pharmacokinetics and in dosing regimens."	( Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b. Foster, GR, 2010)	0.36
" BIT225 has successfully completed a phase Ia dose escalating, single dose safety trial in healthy volunteers and a phase Ib/IIa trial to evaluate the safety and pharmacokinetics of repeated dosing for selected doses of BIT225 in HCV-infected persons."	( A novel Hepatitis C virus p7 ion channel inhibitor, BIT225, inhibits bovine viral diarrhea virus in vitro and shows synergism with recombinant interferon-alpha-2b and nucleoside analogues. Ewart, GD; Huang, Z; Luscombe, CA; Miller, M; Murray, MG; Wilkinson, J, 2010)	0.36
" The latter include a reduction in the dosage of IFN or RBV and discontinuation of the treatment."	( [Adverse reactions of different treatments in chronic hepatitis C]. Dorobăţ, C; Grigore, L; Luca, C; Vâţă, A, )	0.13
" The main reasons for relapse include treatment initiation with insufficient ribavirin dosage or failure to continue treatment long enough, especially in patients with a slow virologic response."	( [Retreatment options for patients with chronic hepatitis C]. Hrstić, I; Ostojić, R; Vucelić, B, 2009)	0.35
" The presence of this side effect leads to a trade-off between continuing the treatment and exacerbating the side effects versus decreasing dosage to relieve severe side effects while allowing the disease to progress."	( Evaluating treatment of hepatitis C for hemolytic anemia management. Cardona-Meléndez, GM; DebRoy, S; Diaz, E; Kang, M; Kribs-Zaleta, C; Medina-Rios, L; Mubayi, A, 2010)	0.36
" The dosage of tacrolimus was decreased gradually to minimize immunocompromise."	( Flexible and individualized treatment to achieve sustained viral response for recurrent hepatitis C in liver transplant recipients. Chan, KM; Cheng, SS; Chou, HS; Lee, CF; Lee, WC; Wu, TJ, 2010)	0.36
" Such an association has not been demonstrated for HCV genotype 2/3 infection, where a fixed 800 mg daily dosing of ribavirin is generally recommended."	( Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. Alsiö, Å; Buhl, MR; Christensen, PB; Färkkilä, M; Lagging, M; Langeland, N; Mørch, K; Norkrans, G; Pedersen, C; Sangfelt, P; Westin, J, 2011)	0.37
"We retrospectively analyzed a total of 80 HCV genotype 1 patients (39 SVR and 41 non-SVR patients), who received an enough dosage and a complete 48-week treatment of PEG-IFN alpha-2b plus RBV."	( Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. Furusyo, N; Hayashi, J; Kainuma, M; Murata, M; Ogawa, E; Otaguro, S; Sawayama, Y; Taniai, H; Toyoda, K, 2010)	0.36
"5 microg/kg PegIFN-alpha2b once weekly plus ribavirin at a dosage of 1000 mg/d for those under 75 kg or 1200 mg/d for those over 75 kg."	( Alkaline phosphatase predicts relapse in chronic hepatitis C patients with end-of-treatment response. Berg, J; Biesenbach, G; Bodlaj, G; Hubmann, R; Saleh, K; Stojakovic, T, 2010)	0.36
" Patients treated with peginterferon alfa-2a and ribavirin in standard dosing were included: 49 with genotype 1 treated for 48weeks and 139 with genotype 2 or 3 treated for 24weeks."	( Hepatitis C treatment response kinetics and impact of baseline predictors. Arnholm, B; Buhl, MR; Eilard, A; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Mørch, K; Nilsson, S; Norkrans, G; Pedersen, C; Wahlberg, T; Wejstål, R; Westin, J, 2011)	0.37
" RibaPak (RBP), available as 400 mg and 600 mg ribavirin tablets, offers simplified dosing at two pills daily."	( Enhanced adherence to HCV therapy with higher dose ribavirin formulation: final analyses from the ADHERE registry. Alam, I; Cecil, B; Kistler, KD; Stainbrook, T, 2010)	0.36
" Studies are focusing on daily or high-dose induction therapy with interferon, the titration of interferon dosing to initial viral load, higher doses of interferon throughout treatment, and adjustment of interferon dosing to the viral responses."	( Interferon-ribavirin treatment in chronic hepatitis C--the less talked about aspects. Ahmed, I; Alam, A; Alvi, A; Butt, AK; Khalid, SR; Khan, AA; Lak, NH; Niazi, A; Sarwar, S; Shafqat, F, )	0.13
" Strategies including induction dosing with interferon and ribavirin, use of combination high-potency STAT-C molecules and an intensive emphasis on adherence to HCV antiviral therapy will be critical to the success of this promising advance in HCV therapy."	( Viral response to specifically targeted antiviral therapy for hepatitis C and the implications for treatment success. Cooper, C, 2010)	0.36
" Ribavirin dosage was reduced in 12 patients, and peginterferon dosage was reduced in 2 patients."	( Aggressive use of ribavirin and prolonged course of peginterferon to improve the rate of viral response in liver transplant patients with recurrent hepatitis C viral infection. Black, M; Burke, M; Jain, AB; Singhal, A, 2010)	0.36
" The study aimed to determine if weight-based dosing of taribavirin (TBV), an oral prodrug of ribavirin (RBV), demonstrated efficacy comparable to RBV while maintaining its previously demonstrated anemia advantage with fixed dose administration."	( Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Bacon, BR; Chun, E; Halliman, D; Hammond, J; Hassanein, T; Heise, J; Lawitz, E; Muir, AJ; Poordad, F; Shiffman, ML, 2010)	0.36
" When patients received a dosage at least 80% or more of the target dosage of PEG-IFN α-2b and 60% or more of the target dosage of RBV, the SVR rate significantly increased to 66."	( Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. Azuma, K; Furusyo, N; Hayashi, J; Kainuma, M; Kajiwara, E; Kotoh, K; Maruyama, T; Nakamuta, M; Nomura, H; Satoh, T; Shimoda, S; Shimono, J; Takahashi, K; Tanabe, Y, 2010)	0.36
"Patients were identified using data from the WIN-R trial database, a US multicenter study comparing fixed (800 mg) versus weight-based (800 to 1400 mg) daily dosing of ribavirin in combination with PEG-IFNα-2b (1."	( Seizures during pegylated interferon and ribavirin therapy for chronic Hepatitis C: observations from the WIN-R trial. Ahmed, F; Albert, C; Brand, M; Brass, C; Brown, R; Fixelle, AM; Herrera, JL; Jacobson, IM; Rustgi, VK; Wasserman, RB, 2011)	0.37
"A high proportion (>80%) of patients achieved an SVR regardless of the telaprevir dosing frequency (q8 h or q12 h) or type of peginterferon alfa used (alfa-2a or alfa-2b)."	( Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Beumont, M; Carosi, G; De Backer, K; Drenth, JP; Ferenci, P; Forns, X; Goeser, T; Luo, D; Marcellin, P; Nevens, F; Picchio, G; Serfaty, L; Van Heeswijk, R, 2011)	0.37
" We will also focus on how drug dosing may have influenced the outcome of treatment."	( Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. Mangia, A, 2011)	0.37
" The individualized dosing efficacy vs flat dosing to assess optimaL pegylated interferon therapy (IDEAL) trial enrolled 3070 patients from 118 United States centres to compare treatment with peginterferon (PEG-IFN) alfa-2a and ribavirin (RBV) and two doses of PEG-IFN alfa-2b and RBV."	( Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. Albrecht, JK; Boparai, N; Gordon, SC; Hu, KQ; Koury, K; McCone, J; Muir, AJ; Noviello, S; Sulkowski, MS, 2011)	0.37
" Therefore monitoring plasma concentration of ribavirin is a useful tool for individualizing ribavirin dosing regimens."	( Influence of pre-analytical conditions on plasma ribavirin concentrations. Alric, L; Barange, K; Gandia, P; Houin, G; Izopet, J; Lavit, M; Nicot, F; Séraissol, P; Trancart, S, 2010)	0.36
"To investigate the association between early plasma ribavirin concentrations and ribavirin dosing with steady-state (Css) concentration and the between- and within-patient variability in plasma ribavirin concentration in clinical practice."	( Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations. Burger, DM; Dofferhoff, TS; Drenth, JP; Huntjens-Fleuren, HW; Koopmans, PP; Richter, C; Slavenburg, S; Verwey-Van Wissen, CP, 2011)	0.37
" It is important to complete the target length of treatment and to continue the target dosage to achieve SVR."	( [Association between the influential factors and the effectiveness of pegylated interferon alpha-2a plus ribavirin as a combination treatment for chronic hepatitis C patients]. Chen, Y; Chen, Z; He, LL; Lei, BJ; Lei, XZ; Tang, H; Xu, H, 2011)	0.37
" A key limitation, however, is the toxic side-effect of ribavirin, hemolytic anemia, which often necessitates a reduction of ribavirin dosage and compromises treatment response."	( Ribavirin-induced anemia in hepatitis C virus patients undergoing combination therapy. Dixit, NM; Krishnan, SM, 2011)	0.37
" IFN therapy requires dosage reduction and close monitoring in patients with a GFR <50 ml/min/1."	( Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects? Bob, F; Bozdog, G; Cioca, D; Curescu, M; Gadalean, F; Gluhovschi, C; Gluhovschi, G; Kaycsa, A; Petrica, L; Sporea, I; Velciov, S; Vernic, C, 2011)	0.37
" The aim of this study was to assess the safety and pharmacokinetic (PK) profile of raltegravir and ribavirin when dosed separately and together."	( Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers. Ashby, J; Back, D; D'Avolio, A; Dickinson, L; Erlwein, OW; Garvey, L; Lamba, H; Latch, N; Legg, K; McClure, MO; Weston, R; Winston, A, 2011)	0.37
" Encouraging data from small trials have shown a significant increase in SVR rates with the use of different dosing regimens of ribavirin in addition to interferon-based therapy and aggressive erythroid-stimulating agent support in dialysis patients."	( Should ribavirin be used to treat hepatitis C in dialysis patients? Carrion, AF; Fabrizi, F; Martin, P, )	0.13
"5) months and was treated by CsA and prednisone dosage adjustments."	( Successful treatment of fibrosing cholestatic hepatitis after liver transplantation. Arvelakis, A; Assis, D; Caldwell, C; Cimsit, B; Emre, S; Kulkarni, S; Schilsky, M; Taddei, T, 2011)	0.37
" The filibuvir doses evaluated ranged from 200-1400 mg daily, and the duration of dosing ranged from 3-10 days."	( Antiviral activity of the hepatitis C virus polymerase inhibitor filibuvir in genotype 1-infected patients. Hammond, JL; Jagannatha, S; Kantaridis, C; Neelakantan, S; Purohit, VS; Simpson, P; Thompson, R; Troke, PJ; Wagner, F, 2011)	0.37
"Anemia was manageable by carefully adjusting the ribavirin dosage in the standard therapy that followed telaprevir monotherapy."	( Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients. Akaike, J; Arakawa, T; Chayama, K; Kamiya, N; Karino, Y; Kumada, H; Kuwata, Y; Ohmura, T; Ozeki, I; Sato, T; Toyota, J; Yamada, I, 2011)	0.37
"Patients receiving the investigational dosing had lower levels of HCV RNA at all time points after initiation of therapy."	( Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy. Chung, TL; Haagmans, BL; Herrmann, E; Kottilil, S; Lempicki, RA; Murphy, AA; Osinusi, AO; Polis, MA; Sachau, W; Wood, BJ; Wu, L; Yang, J, 2011)	0.37
" Group 1 comprised patients who received ≥80% of the recommended dosage of both peginterferon and ribavirin."	( [Importance of medication adherence to peginterferon-ribavirin combination therapy in patients with chronic hepatitis C]. Eun, HS; Goh, PG; Kim, ES; Kim, HJ; Kim, MJ; Kim, SH; Kim, YJ; Lee, BS; Lee, ES; Lee, HY; Lee, SY; Moon, HS, 2011)	0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."	( FDA-approved drug labeling for the study of drug-induced liver injury. Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011)	0.37
" CIFN was primarily dosed as 15 mcg subcutaneously daily combined with standard doses of RBV."	( Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study. Chapman, S; Cozen, M; Cunningham, F; Currie, SL; Monto, A; Shen, H; Tortorice, K; Yee, HS, 2011)	0.37
" Our present results may provide a valuable pharmacogenetic diagnostic tool for tailoring PEG-IFN/RBV dosing to minimize drug-induced adverse events."	( Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Enomoto, N; Hiasa, Y; Hige, S; Hino, K; Honda, M; Itoh, Y; Izumi, N; Kaneko, S; Koike, A; Kurosaki, M; Matsuura, K; Mizokami, M; Mochida, S; Nishida, N; Nishiguchi, S; Sakamoto, N; Sugauchi, F; Sugiyama, M; Tanaka, E; Tanaka, Y; Tokunaga, K; Yatsuhashi, H, 2011)	0.37
" The optimal dosage of ribavirin remains unresolved, in light of frequent side effects."	( Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Canva, V; Castel, H; Colin, M; Deltenre, P; Dharancy, S; Glowacki, F; Hazzan, M; Henrion, J; Lazrek, M; Louvet, A; Mathurin, P; Moreno, C; Noel, C; Ollivier, I; Provôt, F; Stanke, F; Tran, A, 2011)	0.37
" The aim of this subanalysis of the Weight-based Dosing of PegINterferon α-2b and Ribavirin (WIN-R) study was to assess the impact of Asian (n=118), Hispanic (n=289), and white (n=3919) ethnicity on CHC treatment outcomes."	( Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. Brass, C; Brown, RS; Freilich, B; Hu, KQ; Jacobson, IM, 2011)	0.37
" The literature suggests that weight-based dosing of taribavirin at 25 mg/kg demonstrates lower rates of hemolytic anemia with comparable rates of sustained virologic response (SVR) and is the optimum dose for further studies comparing the efficacy of taribavirin with weight-based dosing of ribavirin."	( Taribavirin in the treatment of hepatitis C. Arora, S; Deming, P, 2011)	0.37
" The dosing strategy of taribavirin favors concentration within the liver to reduce treatment-limiting rates of anemia but may be insufficient to prevent virologic relapse."	( Taribavirin in the treatment of hepatitis C. Arora, S; Deming, P, 2011)	0.37
"HIV and HCV genotype 1- and 4-coinfected subjects were randomized to receive pegylated interferon-α2a 270 μg/week plus ribavirin 1,600 mg daily and epoetin-β for 4 weeks, followed by pegylated interferon-α2a at standard dosages plus weight-based ribavirin (WBR) dosage for 8 weeks (induction arm [IA]), or pegylated interferon-α2a plus WBR for 12 weeks (standard therapy arm [SA])."	( Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study. Alvarez, NP; Clotet, B; González, J; Laguno, M; Moltó, J; Ornelas, A; Paredes, R; Sánchez, M; Solà, R; Téllez, MJ; Tural, C; von Wichmann, MÁ; Zamora, AM, 2011)	0.37
"01]), although rates of dosage reduction and treatment discontinuation were similar across settings."	( Outcomes of chronic hepatitis C therapy in patients treated in community versus academic centres in Canada: final results of APPROACH (a prospective study of peginterferon alfa-2a and ribavirin at academic and community centres in Canada). Balshaw, R; Cooper, C; Elkashab, M; Harris, P; Lalonde, R; Marrotta, PJ; Myers, RP; Sherman, M; Usaty, C; Witt-Sullivan, H, 2011)	0.37
" Therefore, the ribavirin dosing regimen might need to be reassessed."	( Ribavirin dose and treatment outcome of Korean patients with genotype 1 chronic hepatitis C. Choi, MS; Gwak, GY; Kim, J; Koh, KC; Lee, JH; Paik, SW; Shin, SR; Sinn, DH; Yoo, BC, )	0.13
" Based on clinical, histological, immunological parameters, and cumulative dosage of PEG-IFNα2b and ribavirin, multivariate analyses revealed that higher platelet counts and higher regulatory T cell frequency at week 12 are indicative of SVR."	( Dynamics of regulatory T cells and plasmacytoid dendritic cells as immune markers for virological response in pegylated interferon-α and ribavirin therapy for chronic hepatitis C patients. Hagiwara, H; Hayashi, N; Higashitani, K; Hiramatsu, N; Iio, S; Inoue, M; Kakita, N; Kanto, T; Kasahara, A; Katayama, K; Matsubara, T; Mita, E; Miyazaki, M; Oze, T; Sakakibara, M; Takehara, T, 2012)	0.38
" Induction dosing strategies have not yielded positive results, though twice weekly peg-IFN-alpha-2a induction therapy merits further investigation."	( Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin. Bhagani, S, 2011)	0.37
" Their main advantages consist in maintenance of viral suppression across a longer dosing interval, avoidance of interdose trough and reduced dosing frequencies (twice or even once per month compared to once per week for the actual PEG-IFNs)."	( New interferons in the treatment of chronic hepatitis C. Cernescu, C; Ruţă, S, )	0.13
" Furthermore, 100 patients were extracted from each Peg-IFN dosage category to adjust for characteristic factors, using the propensity score method."	( Reducing Peg-IFN doses causes later virologic response or no response in HCV genotype 1 patients treated with Peg-IFN alfa-2b plus ribavirin. Doi, Y; Hagiwara, H; Hayashi, E; Hayashi, N; Hijioka, T; Hiramatsu, N; Hosui, A; Iio, S; Imai, Y; Inoue, A; Inui, Y; Ito, T; Kanto, T; Kasahara, A; Kato, M; Kiso, S; Mita, E; Miyagi, T; Miyazaki, M; Oshita, M; Oze, T; Song, C; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yoshida, Y; Yoshihara, H, 2012)	0.38
" No subject discontinued dosing due to adverse events."	( Open-label phase 1b pilot study to assess the antiviral efficacy of simvastatin combined with sertraline in chronic hepatitis C patients. Altmeyer, R; Cheng, CW; Chopra, N; Lawitz, E; Lim, SG; McHutchison, JG; Patel, K; Randle, JC; Tillmann, HL, 2011)	0.37
"The pharmacokinetics and in dosing regimens of the currently available pegylated interferon (peginterferon) alfa molecules differ greatly, depending on the size and nature of their polyethylene glycol (PEG) moiety."	( Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. Bruno, R; Cima, S; Fagiuoli, S; Filice, G; Maiocchi, L; Novati, S; Sacchi, P, 2012)	0.38
" Clinical studies have demonstrated the importance of adherence to therapy, that is, the ability of patients to tolerate and sustain a fully dosed therapy regimen."	( Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C. De Gottardi, A; Geier, A; Gerlach, T; Heim, M; Helbling, B; Hirschi, C; Negro, F; Stickel, F; Terziroli, B; Wehr, K, 2012)	0.38
" Their dosage and the duration of therapy are tailored to the HCV genotype and the time to viral response."	( [Chronic hepatitis C virus infection: clinical picture and treatment possibilities]. Annicchiarico, BE; Gasbarrini, A; Siciliano, M, )	0.13
" However, the side effect profile remains challenging and the dosing schedule complicated."	( Hepatitis C treatment highlights from the 2011 American Association for the Study of Liver Disease meeting. Cooper, C, 2012)	0.38
"The safety and efficacy of weight-based ribavirin (RBV) dosing regimens in patients with HIV-HCV coinfection has not been demonstrated in randomized clinical trials."	( Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. Bertasso, A; Bhatti, L; Hassanein, T; Passe And, S; Rodriguez-Torres, M; Serrão, R; Slim, J; Sola, R; Stancic, S; Sterling, R; Sulkowski, M, )	0.13
"Compared with the standard RBV dose (800 mg/day), weight-based RBV dosing (1000/1200 mg/day) did not significantly increase SVR rates, but did increase the incidence of anemia in HIV-HCV (genotype 1) coinfected patients."	( Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. Bertasso, A; Bhatti, L; Hassanein, T; Passe And, S; Rodriguez-Torres, M; Serrão, R; Slim, J; Sola, R; Stancic, S; Sterling, R; Sulkowski, M, )	0.13
" These findings suggest that optimization of ribavirin plasma concentrations during the first week of ribavirin dosing is most critical in AA patients in order to increase the rate of SVR, especially those with the IL-28B TT genotype."	( Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. Dowling, TC; Fossler, MJ; Howell, CD; Jin, R; McHutchison, JG, 2012)	0.38
"This study evaluated impact of obesity on outcome as well as interferon and ribavirin concentrations following standard-of-care fixed dosing with peginterferon-α2a 180 µg once weekly and ribavirin 800 mg daily among 303 HCV genotype 2/3-infected patients enrolled in the per-protocol analysis of a recently completed phase III trial (NORDynamIC)."	( Impact of obesity on the bioavailability of peginterferon-α2a and ribavirin and treatment outcome for chronic hepatitis C genotype 2 or 3. Alsiö, Å; Askarieh, G; Buhl, MR; Christensen, PB; Färkkilä, M; Haagmans, BL; Hellstrand, K; Lagging, M; Langeland, N; Mørch, K; Nasic, S; Norkrans, G; Pedersen, C; Rembeck, K; Westin, J, 2012)	0.38
" The initial phase of combination pegylated interferon, ribavirin and a protease inhibitor will be associated with increased toxicity and complexity of therapeutic management but, over the course of the decade, strategies including interferon-free combination direct-acting antiviral regimens with enhanced tolerability and simplified dosing schedules and monitoring protocols will emerge."	( The changing therapeutic landscape for hepatitis C. Dore, GJ, 2012)	0.38
"Therapy-naïve patients with chronic hepatitis C virus (HCV) genotype 1 (G1) were randomised to receive (i) TBV 600 mg BID monotherapy for 4 weeks followed by combination therapy with PIFN [pre-dosing arm (n = 23)] or (ii) TBV administered concurrently with PIFN [standard dosing arm (n = 19)]."	( Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Palmer, M; Rubin, R; Rustgi, V, 2012)	0.38
" the standard dosing arm [33% vs."	( Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1. Palmer, M; Rubin, R; Rustgi, V, 2012)	0.38
"Several direct-acting antivirals for chronic hepatitis C virus (HCV) infection are available, but they are limited by tolerability and dosing schedules."	( Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial. Abrams, GA; Bräu, N; Bronowicki, JP; Diva, U; Everson, GT; Ghalib, RH; Hernandez, D; Hézode, C; Hindes, R; Hughes, EA; Lim, JK; Martorell, C; McPhee, F; Morris, DW; Pol, S; Reindollar, RW; Rustgi, VK; Schnittman, S; Tatum, HA; Thuluvath, PJ; Wind-Rotolo, M; Yin, PD, 2012)	0.38
"HIV/HCV-coinfected individuals naive to interferon were prospectively randomized to receive peginterferon-α-2a (180 μg/d) plus either RBV standard dosing (1000 or 1200 mg/d if <75 or ≥ 75 kg, respectively) or RBV induction (2000 mg/d) along with subcutaneous erythropoietin β (450 IU/kg/wk), both during the first 4 weeks, followed by standard RBV dosing until completion of therapy."	( Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. Aguirrebengoa, K; Asensi, V; Barreiro, P; Castro, A; da Silva, A; Echeverría, S; Guardiola, JM; Hernández-Quero, J; Labarga, P; Mariño, A; Miralles, P; Morano, L; Pineda, JA; Portu, J; Ríos, MJ; Rubio, R; Soriano, V; Téllez, MJ; Terrón, A; Vispo, E, 2012)	0.38
"14 μg/mL) were comparable in both arms, whereas mean hemoglobin decay was less pronounced in the RBV induction plus erythropoietin arm than in the RBV standard dosing arm (-1."	( Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. Aguirrebengoa, K; Asensi, V; Barreiro, P; Castro, A; da Silva, A; Echeverría, S; Guardiola, JM; Hernández-Quero, J; Labarga, P; Mariño, A; Miralles, P; Morano, L; Pineda, JA; Portu, J; Ríos, MJ; Rubio, R; Soriano, V; Téllez, MJ; Terrón, A; Vispo, E, 2012)	0.38
"A 4-week course of induction therapy with high RBV dosing along with erythropoietin does not improve SVR rates in HIV/HCV-coinfected patients."	( Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial. Aguirrebengoa, K; Asensi, V; Barreiro, P; Castro, A; da Silva, A; Echeverría, S; Guardiola, JM; Hernández-Quero, J; Labarga, P; Mariño, A; Miralles, P; Morano, L; Pineda, JA; Portu, J; Ríos, MJ; Rubio, R; Soriano, V; Téllez, MJ; Terrón, A; Vispo, E, 2012)	0.38
" The maximum dosage of ribavirin that can be tolerated by patients with different ITPA polymorphisms remains unknown."	( A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms. Dixit, NM; Krishnan, SM, 2012)	0.38
" Patients with moderate ITPA deficiency are predicted to tolerate twice the ribavirin dosage as patients with wild-type ITPA."	( A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms. Dixit, NM; Krishnan, SM, 2012)	0.38
" By keeping anaemia tolerable, the predicted optimal dosage may improve adherence, reduce the need for drug monitoring, and increase response rates."	( A formula to estimate the optimal dosage of ribavirin for the treatment of chronic hepatitis C: influence of ITPA polymorphisms. Dixit, NM; Krishnan, SM, 2012)	0.38
" To improve tolerance for SOC, and ribavirin (RBV) in particular, concentration-guided RBV dosing calculated by a formula taking renal function and weight into consideration was utilized."	( Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantation. Ackefors, M; Gjertsen, H; Weiland, O; Wernerson, A, 2012)	0.38
" Estimated oral clearances of IT decreased on average by 50%, requiring reduced dosing regimens."	( Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antonini, TM; Barau, C; Bonhomme-Faivre, L; Coilly, A; Duclos-Vallée, JC; Furlan, V; Noël, C; Roche, B; Roque-Afonso, AM; Samuel, D; Taburet, AM, 2012)	0.38
"A continuous dosing schedule of aerosolized ribavirin has been used for respiratory syncytial virus (RSV) upper respiratory tract infection and lower respiratory tract infection (LRTI) but is associated with high cost and inconvenient administration."	( An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection. Bodey, GP; Champlin, RE; Chemaly, RF; Hosing, C; Munsell, MF; Raad, II; Rathod, DB; Saifan, C; Shah, DP; Torres, HA, 2012)	0.38
" In conclusion, this pilot study provides evidence showing that TVR-based triple therapy is effective within the first 4 to 12 weeks in LT patients suffering from HCV genotype 1 recurrence, and it also provides evidence showing that drug-drug interactions between TVR and immunosuppressants can be handled appropriately through the close monitoring of trough levels and adequate dosage adjustments."	( Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Berg, CP; Egetemeyr, DP; Königsrainer, A; Lauer, UM; Malek, NP; Nadalin, S; Werner, CR, 2012)	0.38
"Intensified dosing of PegIFN α-2a increases SVR rates in patients with elevated LDL even with the difficult-to-cure characteristics of genotype 1, high baseline viral load, and high body weight."	( Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein. Abdurakhmanov, D; Bakulin, I; Cheinquer, H; Connell, EV; Harrison, SA; Mazur, W; McKenna, M; Messinger, D; Reddy, KR; Rodriguez-Torres, M; Shiffman, ML; Silva, GF; Tatsch, F, 2013)	0.39
"We did not encounter severe hematological adverse effects that would require Ribavirin dosage adjustments."	( Adverse effects of peg-Interferon and Ribavirin combined antiviral treatment in a Romanian hepatitis C virus infected cohort. Irimia, E; Mogoantă, L; Predescu, O; Streba, L; Streba, LA, 2012)	0.38
" All eligible patients were provided peg-interferon at the dosage of 180 μg weekly with ribavirin thrice a day for 6 months."	( Efficacy of PEG-interferon based treatment in patients with hepatitis C refractory to previous conventional interferon-based treatment. Devrajani, BR; Kalhoro, M; Shaikh, S, 2012)	0.38
" Optimization and individualization of PEGIFN dosing could improve outcomes."	( Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection. Alder, L; Gumbo, T; Jain, MK; Lee, WM; Pasipanodya, JG, 2013)	0.39
" In a phase three III clinical trial, 2250 mg of telaprevir, which is the same dosage used in clinical trials in Western countries, was given to Japanese patients."	( Treatment of chronic hepatitis C virus infection in Japan: update on therapy and guidelines. Chayama, K; Hayes, CN; Kawakami, Y; Ohishi, W, 2013)	0.39
"Among the strictly selected nonresponders, IFN-γ-1b (at a dosage of 100 μg thrice a week) in combination with PEG-IFN-α-2a and ribavirin failed to show virological efficacy."	( Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI). Bourlière, M; Bronowicki, JP; Chêne, G; Couzigou, P; Foucher, J; Leroy, V; Marcellin, P; Pérusat, S; Poynard, T; Trimoulet, P, 2013)	0.39
" According to HCV RNA levels at weeks 4 and 12, patients were reallocated to receive different interferon dosage forms or different courses of treatment."	( A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms. Hou, W; Lu, W; Ma, P; Song, SD; Wang, L; Yang, JM, 2013)	0.39
" These may lead to dosage reduction and sometimes discontinuation of therapy."	( How to optimize HCV therapy in genotype 1 patients: management of side-effects. Chopra, A; Drinnan, T; Klein, PL; Lee, SS, 2013)	0.39
" Unfortunately, any attempt to modify the duration or dosing of the SOC according to baseline factors has been disappointing and should not be continued at present."	( How to optimize HCV therapy in genotype 2 patients. Aghemo, A; Grassi, E, 2013)	0.39
" A second wave of protease inhibitors are in phase II and III trials and promise to provide a drug regimen with a better dosing schedule and improved tolerance."	( New therapeutic strategies in HCV: second-generation protease inhibitors. Clark, VC; Nelson, DR; Peter, JA, 2013)	0.39
" Timely adjustment to dosage and time periods was made according to the virological response to treatment, and the predictive value of rapid virological response (RVR) and complete early virological response (cEVR) for sustained virological response (SVR) were analyzed."	( [The effects of individualized therapeutic programs on chronic hepatitis C and the influential factors of virological response]. Cheng, ML; Liu, XF; Wang, J; Zeng, AP, 2012)	0.38
" Treatment-naïve HCV genotype 1 or 4 patients were randomized to double-blind treatment with oral mericitabine at a dosage of 500 mg twice-daily (BID) for 12 weeks (A), 1,000 mg BID for 8 (B) or 12 weeks (C and D), or placebo BID for 12 weeks (E)."	( PROPEL: a randomized trial of mericitabine plus peginterferon alpha-2a/ribavirin therapy in treatment-naïve HCV genotype 1/4 patients. Bzowej, N; Chen, YC; Ferenci, P; Herring, R; Ipe, D; Jensen, D; Ma, MM; Munson, ML; Najera, I; Pockros, P; Rodriguez-Torres, M; Thommes, J; Vierling, J; Wedemeyer, H; Zeuzem, S, 2013)	0.39
" Patients received ABT-450/r 150/100 mg once daily and ABT-072 400 mg once daily with weight-based ribavirin 1000-1200 mg/day dosed twice daily for 12 weeks."	( A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1. Bernstein, B; Cohen, DE; Koev, G; Kowdley, KV; Larsen, L; Lawitz, E; Menon, R; Pilot-Matias, T; Podsadecki, T; Poordad, F; Siggelkow, S; Tripathi, R, 2013)	0.39
" They were treated with pegylated interferon (PEG-IFN) alpha 2a and ribavirin, with the standard dosing schedule."	( Replication of hepatitis C virus in peripheral blood mononuclear cells in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Inglot, M; Malyszczak, K; Pawlowski, T; Radkowski, M; Szymczak, A; Zalewska, M, 2013)	0.39
" However, its utilization can be limited by its potential to cause hemolytic anemia as well as its variability in dosing levels and efficacy outcomes."	( Synthesis and evaluation of a new phosphorylated ribavirin prodrug. Dong, SD; Lin, CC; Schroeder, M, 2013)	0.39
" Among the STAT6 SNPs examined, the dosage effect of the A allele and allele frequency in rs1059513 were inversely correlated with SVR in patients infected with HCV-1 (P = 0."	( The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese. Hsu, YA; Hung, DZ; Liao, WL; Lim, YP; Lin, CY; Peng, CY; Tien, N; Tsai, FJ; Tsai, KH; Wan, L, 2013)	0.39
" Adherence to the assigned duration of the dosing regimen and adherence to the three times a day (t."	( Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Albrecht, JK; Bacon, BR; Brass, CA; Bronowicki, JP; Burroughs, MH; Davis, M; Deng, W; Dutko, FJ; Esteban, R; Gordon, SC; Lawitz, EJ; Poordad, F; Rajender Reddy, K; Sniukiene, V; Sulkowski, MS; Yoshida, EM, 2013)	0.39
" dosing interval with boceprevir."	( Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Albrecht, JK; Bacon, BR; Brass, CA; Bronowicki, JP; Burroughs, MH; Davis, M; Deng, W; Dutko, FJ; Esteban, R; Gordon, SC; Lawitz, EJ; Poordad, F; Rajender Reddy, K; Sniukiene, V; Sulkowski, MS; Yoshida, EM, 2013)	0.39
"In the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study, the participation of 76 academic-based and 42 community-based US centers provided an opportunity to evaluate various metrics of quality and site performance."	( Analysis of site performance in academic-based and community-based centers in the IDEAL Study. Jou, JH; Long, J; McHutchison, JG; Muir, AJ; Noviello, S; Pedicone, LD; Sulkowski, MS, )	0.13
"A secondary data analysis of the Individualized Dosing Efficacy Versus Flat Dosing to Assess Optimal Pegylated Interferon Therapy study was performed."	( Analysis of site performance in academic-based and community-based centers in the IDEAL Study. Jou, JH; Long, J; McHutchison, JG; Muir, AJ; Noviello, S; Pedicone, LD; Sulkowski, MS, )	0.13
" Adherence to ≥80% of peginterferon-α and ribavirin dosing for ≥80% assigned duration was also similar (46% in academic and 47% in community centers)."	( Analysis of site performance in academic-based and community-based centers in the IDEAL Study. Jou, JH; Long, J; McHutchison, JG; Muir, AJ; Noviello, S; Pedicone, LD; Sulkowski, MS, )	0.13
" The factors determining the complexity of treatment were the number of medications, dosing schedules, administration methods, special instructions, and required preparations associated with antiviral regimens."	( Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C. Almeida, CV; Cidoncha, EC; Galán, RJ; Martin, MF; Rodriguez, CC; Verdugo, RM, )	0.13
" These processes will be important to investigate as the dosing schedules of antiviral regimens become increasingly complex."	( Adherence to PEG/ribavirin treatment for chronic hepatitis C: prevalence, patterns, and predictors of missed doses and nonpersistence. Bonner, JE; Esserman, DA; Evon, DM; Fried, MW; Golin, CE; Rao, T, 2013)	0.39
" Eligible patients were assigned to receive thrice weekly subcutaneous injection of 3MIU standard interferon > or = -2b and weight-base dosage of ribavirin."	( Validity of aspartate aminotransferase to platelet ratio index as predictor of early viral response in patients with hepatitis C treated by interferon-based therapy. Bikharam, D; Musarat, K; Samiullah, S, 2012)	0.38
" Patients who became anemic (levels of hemoglobin approximately ≤10 g/dL) during the study treatment period (n = 500) were assigned to groups that were managed by ribavirin dosage reduction (n = 249) or erythropoietin therapy (n = 251)."	( Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Afdhal, NH; Albrecht, JK; Alves, K; Bacon, BR; Balart, L; Brass, CA; Brown, RS; Burroughs, MH; Calleja, JL; Craxi, A; Deng, W; Dutko, FJ; Flamm, SL; Hézode, C; Koury, KJ; Kowdley, KV; Lawitz, E; Lee, SS; Morgan, TR; Nelson, DR; Nyberg, L; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Sulkowski, MS; Wahl, J; Wedemeyer, H; Zeuzem, S, 2013)	0.39
"Rates of SVR were comparable between patients whose anemia was managed by ribavirin dosage reduction (71."	( Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Afdhal, NH; Albrecht, JK; Alves, K; Bacon, BR; Balart, L; Brass, CA; Brown, RS; Burroughs, MH; Calleja, JL; Craxi, A; Deng, W; Dutko, FJ; Flamm, SL; Hézode, C; Koury, KJ; Kowdley, KV; Lawitz, E; Lee, SS; Morgan, TR; Nelson, DR; Nyberg, L; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Sulkowski, MS; Wahl, J; Wedemeyer, H; Zeuzem, S, 2013)	0.39
"Reduction of ribavirin dosage can be the primary approach for management of anemia in patients receiving peginterferon, ribavirin, and boceprevir for HCV infection."	( Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. Afdhal, NH; Albrecht, JK; Alves, K; Bacon, BR; Balart, L; Brass, CA; Brown, RS; Burroughs, MH; Calleja, JL; Craxi, A; Deng, W; Dutko, FJ; Flamm, SL; Hézode, C; Koury, KJ; Kowdley, KV; Lawitz, E; Lee, SS; Morgan, TR; Nelson, DR; Nyberg, L; Pedicone, LD; Poordad, F; Reddy, KR; Rossaro, L; Sulkowski, MS; Wahl, J; Wedemeyer, H; Zeuzem, S, 2013)	0.39
"The dosage of immunosuppressants had to be reduced significantly (TAC: 30-fold; CSA 3,5-fold)."	( [HCV reinfection after liver transplantation - management and first experiences with telaprevir-based triple therapy]. Gerken, G; Herzer, K; Jochum, C; Papadopoulos-Köhn, A; Paul, A; Timm, J, 2013)	0.39
" In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing."	( Predictors of consent to pharmacogenomics testing in the IDEAL study. Albrecht, JK; Brass, CA; Clark, PJ; Gordon, SC; Jazwinski, AB; Lawitz, EJ; Muir, AJ; Noviello, S; Pedicone, LD; Sulkowski, MS; Thompson, AJ, 2013)	0.39
" Because of its pharmacokinetics, telaprevir has been designed for administration every 8 hours but efficacy is maintained in a twice-daily dosing regimen."	( [Biochemical and pharmacological features of telaprevir]. Andrade, RJ; García-Samaniego, J, 2013)	0.39
" In addition, they review Phase II and III trials of boceprevir as well as its clinical efficacy, dosing and safety."	( The pharmacokinetic evaluation of boceprevir for treatment of hepatitis C virus. Bichoupan, K; Dieterich, DT; Shankar, H, 2013)	0.39
" These may lead to dosage reduction and early discontinuation of therapy."	( Management of anaemia and other treatment complications. Hézode, C, 2013)	0.39
" To achieve SVR, an adequate dosage of PEG-IFNα2b (≥1."	( Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Azuma, K; Dohmen, K; Furusyo, N; Hayashi, J; Kajiwara, E; Kawano, A; Kotoh, K; Nakamuta, M; Nomura, H; Ogawa, E; Satoh, T; Shimoda, S; Takahashi, K; Tanabe, Y, 2013)	0.39
"1 years after narlaprevir dosing in two patients in 5% and 45% of the viral population."	( Evolutionary dynamics of hepatitis C virus NS3 protease domain during and following treatment with narlaprevir, a potent NS3 protease inhibitor. Bergmann, JF; de Bruijne, J; de Knegt, RJ; Hughes, E; Janssen, HL; Molenkamp, R; Rebers, SP; Reesink, HW; Schinkel, J; Thomas, XV; Treitel, MA; Weegink, CJ, 2013)	0.39
" Patients receiving combination therapy required a higher dosage (mean, 13 946 IU per week [SD, 6449] vs."	( Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial. Chen, DS; Chen, PJ; Chen, SI; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Hung, PH; Kao, JH; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tsai, HB; Tsai, MK; Yang, HC; Yang, SS; Yu, ML, 2013)	0.39
" Thus, shortening treatment together with a weight-based RBV dosing approach has been considered satisfactory in patients with positive predictors of response."	( How to optimize current treatment of genotype 2 hepatitis C virus infection. Gadano, AC; Marciano, S, 2014)	0.4
" The ultimate goal of therapy in chronic HCV infection should include an easily dosed all-oral regimen that is highly effective, inexpensive, pan-genotypic, safe and tolerable, with minimal to no resistance."	( What is the future of ribavirin therapy for hepatitis C? Koh, C; Liang, TJ, 2014)	0.4
" Previous studies using higher, weight-based ribavirin dosing report that patients carrying polymorphisms encoding reduced predicted ITPase activity show decreased risk of ribavirin-induced anemia but increased risk of thrombocytopenia, with no impact on elimination of virus."	( Variants of the inosine triphosphate pyrophosphatase gene are associated with reduced relapse risk following treatment for HCV genotype 2/3. Buhl, MR; Christensen, PB; Färkkilä, M; Hellstrand, K; Lagging, M; Langeland, N; Lindh, M; Martner, A; Mørch, K; Nilsson, S; Norkrans, G; Nyström, K; Pedersen, C; Rembeck, K; Waldenström, J; Westin, J, 2014)	0.4
" Therefore it permitted the start of anti-HCV therapy despite severe thrombocytopenia and also avoided any peg-interferon dosage modification or discontinuation."	( Romiplostim for severe thrombocytopenia in the treatment of chronic hepatitis C virus infection: a new option for clinicians? Buccoliero, G; Massa, P; Pisconti, S; Resta, F; Urbano, T, 2014)	0.4
" With low dosage and few adverse reactions, it holds promise for clinical application."	( [Efficacy and safety of ribavirin aerosol in children with hand-foot-mouth disease]. Cai, K; Chen, YH; Qian, JH; Wang, L; Yu, HJ; Zhang, HP; Zhang, QL, 2014)	0.4
" Neither changes in immunosuppressant through levels nor dosage adjustments were necessary."	( Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: a randomized clinical trial. Brambilla, N; Bringiotti, RS; Castellaneta, A; Castellaneta, NM; D'Amato, M; Di Leo, A; Giacovelli, G; Rendina, M; Rizzi, SF; Rovati, L; Zappimbulso, M, 2014)	0.4
" Anemia and ribavirin dosage reduction were common."	( Telaprevir in treatment of recurrent hepatitis C infection in liver transplant recipients. Nair, S; Waters, B, 2014)	0.4
" Patients in the control group (n = 66) received a combination of boceprevir and PR, dosed in accordance with boceprevir's US product circular."	( The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis. Bacon, BR; Baruch, Y; Bruno, S; Caro, L; Cooreman, MP; Dutko, FJ; Fandozzi, C; Gilbert, CL; Gress, J; Howe, AY; Hwang, P; Manns, MP; Marcellin, P; Mobashery, N; Robertson, MN; Shaw, PM; Shibolet, O; Vierling, JM; Wahl, J, 2014)	0.4
"001) and required a higher dosage [mean: 13,417 vs."	( Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial. Chen, DS; Chen, PJ; Chen, SI; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Hung, PH; Kao, JH; Lee, CY; Liang, CC; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Tsai, HB; Tsai, MK; Yang, HC; Yang, SS; Yu, ML, 2015)	0.42
" Moreover, the impact of ribavirin dosage on the response to treatment was studied."	( Characteristics, treatment, and virologic responses of chronic hepatitis C patients treated with peginterferon alfa-2a and ribavirin in belgium: a sub-analysis of the PROPHESYS study. Bourgeois, S; De Galocsy, C; Horsmans, Y; Lasser, L; Mulkay, JP; Tomasovic, S; Van Vlierberghe, H, 2014)	0.4
" Barriers to adherence involved changes in daily routine, being preoccupied with family or work responsibilities, and sleeping through dosing times."	( Adherence during antiviral treatment regimens for chronic hepatitis C: a qualitative study of patient-reported facilitators and barriers. Bonner, JE; Evon, DM; Golin, CE; Grodensky, C; Velloza, J, )	0.13
" Fixed dosage of Peg-IFN-α2a (135 μg/week) plus RBV (10 mg/kg per day) were given for 4 weeks to treatment group who passed the 4-week waiting time according to clinical safety assessment."	( Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients. Chen, CL; Chiu, KW; Hu, TH; Kabiling, C; Lin, CC; Lin, YH; Liu, YW; Wang, CC, 2014)	0.4
" Five asunaprevir-treated patients had grade 4 alanine aminotransferase elevations that resolved following discontinuation (n=4) or with continued dosing (n=1)."	( Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. Bessone, F; Bronowicki, JP; Cohen, D; Eley, T; Gadano, A; He, B; Hernandez, D; Hughes, E; Martorell, CT; McPhee, F; Mendez, P; Pol, S; Ratziu, V; Terg, R; Thuluvath, PJ; Younes, Z; Yu, F, 2014)	0.4
"This is the second of two manuscripts detailing the pharmacodynamic derivation of peginterferon lambda-1a (Lambda) dosing and treatment durations for Phase 3 studies in hepatitis C virus (HCV) infection, based on Phase 2 data."	( Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 2: Exposure-response analyses for efficacy and safety variables. Ahmad, A; Chan, P; Freeman, J; Hillson, J; Horga, MA; Hruska, M; Kansra, V; Lopez-Talavera, JC; Wang, X, 2015)	0.42
" This is the first of two manuscripts detailing the pharmacodynamic derivation of Lambda dosing and treatment durations for Phase 3 studies in HCV, based on Phase 2 data."	( Derivation of Phase 3 dosing for peginterferon lambda-1a in chronic hepatitis C, Part 1: Modeling optimal treatment duration and sustained virologic response rates. Ahmad, A; Chan, P; Freeman, J; Hillson, J; Horga, MA; Hruska, M; Kansra, V; Lopez-Talavera, JC; Wang, X, 2015)	0.42
" However, impact of dosage changes on antiviral and adverse effects remains unclear."	( The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1. Harada, N; Hayashi, N; Hiramatsu, N; Imai, Y; Inada, M; Inui, Y; Ito, T; Kasahara, A; Kato, M; Mita, E; Miyagi, T; Morishita, N; Oshita, M; Oze, T; Takehara, T; Tamura, S; Tatsumi, T; Yakushijin, T; Yamada, R; Yoshida, Y; Yoshihara, H, 2015)	0.42
" Daclatasvir 60 mg once daily and asunaprevir 600 mg twice daily were dosed for 7 days alone followed by combination dosing for 14 days at 30 mg once daily and 200 mg twice daily, respectively."	( The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus. Bertz, R; Bifano, M; Eley, T; Gardiner, D; Grasela, DM; He, B; Huang, SP; Kandoussi, H; Sevinsky, H; Zhu, K, 2014)	0.4
"Treatment with GS-9669, a novel nonnucleoside inhibitor (site II) of hepatitis C virus (HCV) nonstructural 5B (NS5B) polymerase, resulted in significant antiviral activity in HCV genotype (GT) 1 patients dosed at 50 and 500 mg once daily (QD) and at 50, 100, and 500 mg twice daily (BID) for 3 days."	( Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase. Delaney, W; Dvory-Sobol, H; Lawitz, EJ; Mabery, E; McHutchison, J; Miller, MD; Mo, H; Skurnac, T; Svarovskaia, ES; Voitenleitner, C, 2014)	0.4
"83×10(-4)), a dosage effect of the T allele was observed, with the dominance term not significant for this SNP."	( Homozygosity for HLA group 2 alleles predicts treatment failure with interferon-α and ribavirin in chronic hepatitis C virus genotype 1 infection. Abu Shanab, A; Carr, MJ; Chin, JL; Collison, M; Connell, J; Coughlan, S; Hall, WW; Mac Nicholas, R; McCormick, PA; Merriman, RB; Segurado, R, 2015)	0.42
"Population and selective clonal sequencing were performed at baseline and at virologic failure in the 4 MK-5172 dosing arms."	( Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Barnard, RJ; Black, S; Caro, L; Curry, S; DiNubile, MJ; Gilbert, C; Howe, AY; Hwang, PM; Liu, R; Ludmerer, SW; Mobashery, N; Newhard, W; Nickle, D, 2014)	0.4
" Although more effective than the earlier standard of care, these regimens have complex dosing schedules, prolonged duration, and deleterious side effects."	( Impact of specialty pharmacy on telaprevir-containing 3-drug hepatitis C regimen persistence. Bridges, GG; Dorholt, M; Frazee, SG; Henderson, RR; Levin, RJ; Visaria, J, 2014)	0.4
" Randomisation was by presence or absence of ribavirin, 8 or 12 weeks of treatment, and dosage of elbasvir."	( Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a rando Barr, E; Bourliere, M; DeJesus, E; Dutko, F; Gerstoft, J; Haber, B; Hezode, C; Howe, AY; Hwang, P; Kugelmas, M; Mallolas, J; Murillo, A; Nahass, R; Pol, S; Robertson, M; Serfaty, L; Shaughnessy, M; Shibolet, O; Sulkowski, M; Vierling, JM; Wahl, J; Weis, N; Zuckerman, E, 2015)	0.42
"A total of 69 patients with chronic hepatitis C whose hemogloblin (HGB) level had decreased to 100 g/L were divided into two groups for receiving a reduced dosage of ribavirin when their HGB level fell to less than or equal to 100 g/L or for withdrawal of the ribavirin treatment when their HGB level fell to less than or equal to 80 g/L (restricted group), or for receiving a reduced dosage when the HGB level fell to less than or equal to 80 g/L or for withdrawal of the ribavirin treatment when the HGB level fell below less than or equal to 60 g/L (adjusted group)."	( [Research of relationship between antiviral efficacy on chronic hepatitis C and the application time and dose of ribavirin]. Guo, L; Han, Y; Zhu, J, 2014)	0.4
"When patients with chronic hepatitis C develop anemia during the course of anti-HCV ribavirin therapy with Peg-IFNat2a, adjustment of the ribavirin treatment duration and dosage can increase the likelihood of achieving and sustaining SVR and decrease the rate of relapse; these treatment adjustments are not associated with changes in severe adverse effects."	( [Research of relationship between antiviral efficacy on chronic hepatitis C and the application time and dose of ribavirin]. Guo, L; Han, Y; Zhu, J, 2014)	0.4
" Sixty-two patients were randomized into combination therapy with standard ribavirin dosing (group 1) or low and escalating ribavirin dosing (group 2)."	( Randomized trial of peginterferon alpha-2b plus low and escalating dose of ribavirin in patients with chronic hepatitis C with high viral load genotype 1. Araki, Y; Ikeda, F; Iwasaki, Y; Kobashi, H; Miyake, Y; Okamoto, R; Takaki, A; Taniguchi, H; Yamamoto, K, 2015)	0.42
" This phase 2, randomized, open-label study evaluated an IFN- and RBV-free regimen of once-daily ombitasvir (ABT-267), an NS5A inhibitor, plus paritaprevir (ABT-450), an NS3/4A protease inhibitor dosed with ritonavir (paritaprevir/ritonavir), in pegylated IFN/RBV treatment-experienced Japanese patients with hepatitis C virus subtype 1b or genotype 2 infection."	( Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients. Badri, P; Chayama, K; Kumada, H; Kurosaki, M; Notsumata, K; Pilot-Matias, T; Rodrigues, L; Sato, K; Setze, C; Vilchez, RA, 2015)	0.42
"We used concentration-guided RBV dosing to achieve an intended 10 μmol/L concentration with darbepoetin support in combination with peg-IFN alfa-2a, 180 μg for genotype 1 and 135 μg for genotype 2/3 to improve tolerance."	( Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation. Ackefors, M; Castedal, M; Dahlgard, O; Gjertsen, H; Verbaan, H; Weiland, O; Wernerson, A, 2015)	0.42
"Concentration-guided RBV dosing with darbepoetin support substantially improves tolerance and offers high adherence to a full peg-IFN and RBV treatment course in patients with post-transplant HCV relapse."	( Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation. Ackefors, M; Castedal, M; Dahlgard, O; Gjertsen, H; Verbaan, H; Weiland, O; Wernerson, A, 2015)	0.42
" Allelic discrimination was performed by real-time PCR; plasma concentrations were determined at the end of dosing interval (Ctrough) using an HPLC-UV method."	( Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Gatto, A, 2015)	0.42
" The results show that increasing antiviral drug (ribavirin) intake was observed by SWCNTs carrier and therapeutic dosage to kill grass carp reovirus is significantly reduced."	( Carbon nanotube-based nanocarrier loaded with ribavirin against grass carp reovirus. Ling, F; Liu, GL; Wang, GX; Zhu, B, 2015)	0.42
" Her ribavirin dosage was adjusted based on her changing renal function."	( Severe Interferon/Ribavirin-Induced Hyperuricemia and Urate Nephropathy Requiring Rasburicase and Hemodialysis in a Liver Transplant Recipient. Chewaproug, D; Knorr, JP; Neeli, S; Torres, E; Zaki, R, 2015)	0.42
"The aim of the study was to investigate whether patients with a previous nonresponse to standard of care treatment with ribavirin dosed according to body weight would respond to a high individualized dose of concentration-monitored ribavirin."	( High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients. Carlsson, T; Hörnfeld, E; Lindahl, K; Parke, Å; Schvarcz, R; Ståhle, L; Weiland, O, 2015)	0.42
" Ribavirin was dosed aiming at a plasma concentration of >15 μmol/L."	( High-Dose Ribavirin Enhances Early Virological Response in Hepatitis C Genotype 1-Infected Patients. Carlsson, T; Hörnfeld, E; Lindahl, K; Parke, Å; Schvarcz, R; Ståhle, L; Weiland, O, 2015)	0.42
" We examined the efficacy and safety of an all-oral interferon-free regimen of ombitasvir, an NS5A inhibitor, and paritaprevir (ABT-450), an NS3/4A protease inhibitor dosed with ritonavir (ombitasvir plus paritaprevir plus ritonavir), given with or without ribavirin."	( Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Asselah, T; Berenguer, M; Fleischer-Stepniewska, K; Hall, C; Hassanein, T; Hézode, C; Marcellin, P; Mobashery, N; Pilot-Matias, T; Pol, S; Reddy, KR; Redman, R; Schnell, G; Vilchez, RA, 2015)	0.42
" After the lead-in pe- riod boceprevir was added in the dosage of 800 mg three times a day orally."	( Boceprevir in genotype 1 chronic hepatitis C: first experiences in Serbia. Babić, JS; Bojović, K; Fabri, M; Janković, G; Jovanović, M; Kostić, V; Mijailović, Z; Svorcan, P, )	0.13
" Dosage regimens were based on the EMA approved label for each treatment."	( A cost utility analysis of simeprevir used with peginterferon + ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service. Belsey, J; Ladha, I; Mehnert, A; Pascoe, K; Treur, M; Westerhout, K, 2015)	0.42
" A therapeutic range was identified for RBV-MP in persons with HCV GT1 disease receiving 24 weeks of sofosbuvir plus ribavirin, suggesting a potential pharmacological basis for individualized ribavirin dosing in IFN-free regimens."	( Serum and cellular ribavirin pharmacokinetic and concentration-effect analysis in HCV patients receiving sofosbuvir plus ribavirin. Bushman, LR; Jimmerson, LC; Kiser, JJ; Kottilil, S; McHutchison, JG; Meissner, EG; Osinusi, A; Petersen, T; Rower, JE; Sims, Z; Wolfe, P, 2015)	0.42
" Importantly, adjustments to the immunosuppressant dosage were not required."	( Daclatasvir, Simeprevir and Ribavirin as a Promising Interferon-Free Triple Regimen for HCV Recurrence after Liver Transplant. Achterfeld, A; Canbay, A; Gerken, G; Herzer, K; Papadopoulos-Köhn, A; Paul, A; Timm, J; Walker, A, 2015)	0.42
" Moreover, the utility of prodrug 8t was demonstrated through similar exposure of the parent compound when the prodrugs were dosed in vivo."	( Design and synthesis of imidazole N-H substituted amide prodrugs as inhibitors of hepatitis C virus replication. Cai, J; Chen, B; Chen, J; Ji, M; Li, W; Wang, P; Zhou, G; Zong, X, 2015)	0.42
" Patients were carefully followed-up for anemia development which was classified as mild, moderate or severe in relation to levels of haemoglobin decreasing; ribavirin dosage reduction and/or epoietin administration were carried out, where needed."	( Role of ITPA and IL28B variants in the management of chronic hepatitis C treatment. Adinolfi, LE; Alessio, L; Boemio, A; Coppola, N; Grandone, A; Marrone, A; Minichini, C; Pisaturo, M; Sagnelli, E; Stanzione, M; Starace, M; Zampino, R, 2015)	0.42
" According to percentage of expected dose, our patients were divided into two groups: the first group included 7 patients that performed an overall dosage of PEG-IFNα2b ≥ 75% of the scheduled full dose; the second group included 9 patients that performedm PEG-IFNα2b dose < 75% of scheduled full dose."	( Treatment of chronic hepatitis C in children with pegylated interferon and ribavirin: the impact of dose. Immacolata Spagnuolo, M; Iorio, R; Pia Cicalese, M; Terlizzi, V; Tufano, M, )	0.13
"Plasma and intracellular telaprevir concentrations were determined at the end of dosing interval (Ctrough) using ULPC-MS/MS validated methods; allelic discrimination was performed through real-time PCR."	( Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. Allegra, S; Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Fatiguso, G; Mohamed Abdi, A, 2015)	0.42
" Variation in treatment duration and dosing of ribavirin were analyzed as indicators for individualization."	( Benefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort Study. Alshuth, U; Baumgarten, A; Böker, K; Hofmann, WP; Hüppe, D; Lutz, T; Manns, MP; Mauss, S; Moog, G; Pfeiffer-Vornkahl, H; Schober, A; Schott, E; Wedemeyer, H, 2015)	0.42
" The identification of ITPA protective and SLC29A1 risk genotypes still appears to be a current methodology in RBV dosing during hepatitis C virus therapy with DAAs."	( ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors. Cheli, S; Clementi, E; Falvella, FS; Landonio, S; Lombardi, A; Magni, C; Mazzali, C; Mondelli, MU; Rizzardini, G, 2015)	0.42
" The following data in the treatment-naïve population were reserved to verify the model: (1) a T/PR regimen where T was dosed every 8 h for 8 weeks (T8(q8h)/PR) and (2) a T/PR regimen where T was dosed twice daily for 12 weeks (T12(b."	( Modeling population heterogeneity in viral dynamics for chronic hepatitis C infection: Insights from Phase 3 telaprevir clinical studies. Bartels, DJ; Garg, V; Haseltine, EL; Kieffer, TL; Kimko, H; Luo, H; Tolsma, J, 2015)	0.42
" Our findings suggest that in interferon-free ribavirin-containing regimens, concerns over ribavirin dosing to achieve previously determined target plasma concentrations are unnecessary."	( The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin. Alavi, M; Day, R; Dore, GJ; Martinello, M; Matthews, GV; Schteinman, A; Williams, K, 2016)	0.43
" Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase."	( Replication-Competent Influenza Virus and Respiratory Syncytial Virus Luciferase Reporter Strains Engineered for Co-Infections Identify Antiviral Compounds in Combination Screens. Chung, HK; Lamb, K; Lin, MZ; Plemper, RK; Weisshaar, M; Yan, D, 2015)	0.42
" Previously, we have shown that ribavirin when applied in clinically relevant dosage (10 μM) modulates activated microglia in complex fashion inducing both anti- and proinflammatory effects, simultaneously causing cytotoxicity."	( Low-dose ribavirin treatments attenuate neuroinflammatory activation of BV-2 Cells by interfering with inducible nitric oxide synthase. Bjelobaba, I; Bozic, I; Jovanovic, M; Laketa, D; Lavrnja, I; Nedeljkovic, N; Pekovic, S; Savic, D; Stojiljkovic, M, 2015)	0.42
"The impact of ribavirin (RBV) dosage on sustained virologic response (SVR) rates remains elusive in hepatitis C virus genotype 2 (HCV-2) rapid responders receiving 16 weeks of peginterferon (Peg-IFN) plus RBV."	( Peginterferon alfa-2a plus Weight-Based or Flat-Dose Ribavirin for Treatment-Naïve Hepatitis C Virus Genotype 2 Rapid Responders: A Randomized Trial. Chen, DS; Chen, PJ; Chuang, WL; Dai, CY; Huang, CF; Huang, JF; Kao, JH; Liang, CC; Lin, CL; Lin, JW; Liu, CH; Liu, CJ; Su, TH; Yang, HC; Yang, SS; Yu, ML, 2015)	0.42
"Antiviral treatment for patients with HCV infection and decompensated cirrhosis using interferon in a low accelerating dosage regimen in combination with ribavirin is feasible."	( [Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection]. Cai, Z; Dang, S; Deng, H; Guo, Y; Huang, N; Ji, F; Jia, X; Li, Z; Liu, L; Wang, Y; Xue, H; Zhang, S, 2015)	0.42
" The open-label ALLY-1 study assessed the safety and efficacy of a 60-mg once-daily dosage of daclatasvir (pan-genotypic NS5A inhibitor) in combination with sofosbuvir at 400 mg once daily (NS5B inhibitor) and ribavirin at 600 mg/day for 12 weeks with a 24-week follow-up in two cohorts of patients with chronic HCV infection of any genotype and either compensated/decompensated cirrhosis or posttransplantation recurrence."	( Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Fontana, RJ; Hughes, EA; Landis, C; McPhee, F; Noviello, S; Poordad, F; Schiff, ER; Swenson, ES; Vierling, JM; Yang, R, 2016)	0.43
" Orally administered SA-2 effectively protected mice infected with lethal doses of H1N1 or oseltamivir-resistant strain H1N1-H275Y, conferring 70% or 50% survival at a dosage of 100 mg/kg/d, reducing body weight loss, alleviating the influenza-induced acute lung injury, and reducing lung virus titer."	( Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase. Dou, J; Jin, J; Li, M; Wang, D; Wang, H; Xu, J; Yu, J; Zhou, C, 2016)	0.43
" The resulting model framework will aid the development of dosing strategies that minimize the incidence of anemia in treatment regimens that include ribavirin."	( Modeling Ribavirin-Induced Anemia in Patients with Chronic Hepatitis C Virus. D'Argenio, DZ; Jimmerson, LC; Kiser, JJ; MacBrayne, CE; Wu, LS, 2016)	0.43
" We aimed to describe the pharmacokinetics, safety and efficacy of sofosbuvir in 2 dosing regimens and associated antiviral agents in HCV-infected patients requiring hemodialysis."	( Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. Bernard Chabert, B; Descamps, D; Desnoyer, A; Fontaine, H; Gervais, A; Harent, S; Heurgué-Berlot, A; Hillaire, S; Laradi, A; Larrouy, L; Lê, MP; Muret, P; Peytavin, G; Pinto, A; Pospai, D; Salmon, D; Simonpoli, AM; Yazdanpanah, Y; Zucman, D, 2016)	0.43
"Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing for the approval of immediate release solid oral dosage forms containing ribavirin are reviewed."	( Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Ribavirin. Abrahamsson, B; Barazesh Morgani, A; Cristofoletti, R; Dressman, JB; Goodarzi, N; Groot, DW; Langguth, P; Mehta, MU; Polli, JE; Shah, VP, 2016)	0.43
" RBV dosage affected SVR dose-dependently in patients with the IL28B non-TT genotype treated with SMV triple therapy."	( Impact of ribavirin dosage in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin combination therapy. Hagiwara, H; Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Imai, Y; Inada, M; Ito, T; Kaneko, A; Katayama, K; Mita, E; Morishita, N; Oshita, M; Oze, T; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Urabe, A; Yakushijin, T; Yamada, R; Yamada, Y; Yoshida, Y, 2016)	0.43
"57-fold on repeated dosing compared with the first dose."	( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016)	0.43
"The complex pharmacokinetics of paritaprevir were well described by the model, which can be used as a basis for clinical trial dosing and further evaluations in patients with HCV."	( Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies. Awni, WM; Beck, D; Dutta, S; Khatri, A; Liu, W; Menon, RM; Mensing, S; Polepally, AR, 2016)	0.43
"Among 2,053 patients enrolled and dosed with study drug, 410 (20%) were receiving concomitant ARAs; of these, 308 (15%) were taking concomitant PPIs."	( Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents. Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML, 2016)	0.43
"In this pilot study (RibaC), 58 hepatitis C virus (HCV) genotype 1 infected treatment-naïve patients were randomized to (i) 2 weeks ribavirin double dosing concomitant with pegylated interferon-α (pegIFN-α), (ii) 4 weeks ribavirin mono-therapy prior to adding pegIFN-α, or (iii) standard-of-care (SOC) ribavirin dosing concurrent with pegIFN-α."	( Randomized Trial Evaluating the Impact of Ribavirin Mono-Therapy and Double Dosing on Viral Kinetics, Ribavirin Pharmacokinetics and Anemia in Hepatitis C Virus Genotype 1 Infection. Christensen, P; Dalgard, O; Färkkilä, M; Krarup, H; Lagging, M; Lindahl, K; Nilsson, S; Norkrans, G; Norrgren, H; Nyström, K; Rauning Buhl, M; Stenmark, S; Waldenström, J; Westin, J, 2016)	0.43
" Anticipated increases in plasma concentrations of tacrolimus and cyclosporin A occurred during telaprevir treatment and were successfully managed through immunosuppressant dose reduction and, for tacrolimus, reduced dosing frequency."	( Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C. Agarwal, K; Berenguer, M; Colombo, M; Daems, B; Didier, S; Fagiuoli, S; Forns, X; Herzer, K; Janssen, K; Kimko, H; Lathouwers, E; Mutimer, D; Navasa, M; Nevens, F; Ouwerkerk-Mahadevan, S; Van Solingen-Ristea, R; Witek, J, )	0.13
" No clinically relevant drug-drug interactions were noted, but 52% of patients required a change to the dosage of immunosuppressive drugs."	( Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study. Abergel, A; Anty, R; Besch, C; Botta-Fridlund, D; Canva, V; Coilly, A; Conti, F; D'Alteroche, L; Danjou, H; de Ledinghen, V; Debette-Gratien, M; Di Martino, V; Duclos-Vallée, JC; Dumortier, J; Duvoux, C; Fougerou-Leurent, C; Francoz, C; Habersetzer, F; Houssel-Debry, P; Kamar, N; Lebray, P; Leroy, V; Moreno, C; Pageaux, GP; Perre, P; Radenne, S; Rohel, A; Roque-Afonso, AM; Rossignol, E; Samuel, D; Silvain, C, 2016)	0.43
"67) and ribavirin dosage (OR=0."	( Predictors of early treatment discontinuation and severe anemia in a Brazilian cohort of hepatitis C patients treated with first-generation protease inhibitors. Goncales, ES; Goncales, FL; Lazarini, MS; Mendes, LC; Miotto, N; Pedro, MN; Stucchi, RS; Vigani, AG; Zanaga, LP, 2016)	0.43
"While data are scarce to draw conclusions applicable for modern DAA therapies, these results support ribavirin treatment based on serum levels instead of purely weight-based dosing in combination with pegylated interferon."	( Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. Geier, A; Kuhn, S; Kuntzen, D; Kuntzen, T; Müllhaupt, B; Seifert, B, 2016)	0.43
" The patients (N=32) received 180 mcg pegylated interferon alfa-2a once a week plus oral ribavirin in dosage of 800 mg or 1000/1200 mg/day for 24 or 48-week treatment."	( ANTIVIRAL TREATMENT OF HEPATITIS C IN SERBIAN PRISON SETTING: MEDICAL TREATMENT OUTCOMES AND PATIENTS' ADHERENCE. Bojović, K; Delić, D; Katanić, N; Malinić, J; Mitrović, N; Simonović Babić, J, )	0.13
"To describe international normalized ratio (INR) trends and warfarin dosage adjustments required for four veterans who were receiving warfarin therapy and started treatment for hepatitis C virus (HCV) with ledipasvir/sofosbuvir with or without ribavirin."	( Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans. Britnell, SR; Britt, RB; Vanderman, AJ; Willets, AE; Woodard, CL, 2016)	0.43
"5 mg/kg per week of Peg-IFN plus RBV and placebo, while Group B received the same dosage of Peg-IFN plus RBV plus association of Silybin 94 mg + vitamin E 30 mg + phospholipids 194 mg in pills for 12 months."	( Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability. Bertino, G; Caraci, F; Chisari, G; Drago, F; Greco, C; Malaguarnera, G; Malaguarnera, M; Motta, M; Nunnari, G; Vacante, M; Vecchio, M, 2016)	0.43
" Target exposures were achieved for telaprevir with twice daily dosing and for ribavirin with reduced initial dosing."	( Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Brown, KA; Brown, RS; Fontana, RJ; Levitsky, J; Rubin, RA; Russo, MW; Vargas, H; Yoshida, EM, 2018)	0.48
" Calcineurin inhibitor dosing levels were substantially reduced with telaprevir."	( Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Brown, KA; Brown, RS; Fontana, RJ; Levitsky, J; Rubin, RA; Russo, MW; Vargas, H; Yoshida, EM, 2018)	0.48
" SOF 400 mg/day and R (median dosage 800 mg/day) were given for a median of 35 days before LT."	( Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. Berardi, S; Bhoori, S; Caraceni, P; Donato, MF; Iemmolo, RM; Invernizzi, F; Lenci, I; Martini, S; Mazzarelli, C; Montalbano, M; Morelli, C; Pieri, G; Romagnoli, R, 2017)	0.46
" In the phase II/III clinical studies, ALT and bilirubin increases were reversible with continued dosing or after treatment cessation."	( Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies. Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N, 2017)	0.46
" Patients were randomly assigned (1:1) to receive 25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir once daily, with weight-based ribavirin dosed twice daily for either 12 weeks or 16 weeks."	( Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Asselah, T; ElKhashab, M; Feld, JJ; Ferenci, P; Hassanein, T; Hézode, C; Mobashery, N; Moreno, C; Papatheodoridis, G; Pilot-Matias, T; Qaqish, RB; Redman, R; Yu, Y; Zeuzem, S, 2016)	0.43
" We assessed the efficacy and safety of the two direct-acting antiviral drugs ombitasvir, an NS5A inhibitor, and paritaprevir, an NS3/4A protease inhibitor dosed with ritonavir, plus ribavirin in treatment of chronic HCV infection in Egypt."	( Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Allam, N; Asselah, T; Doss, W; Esmat, G; Hall, C; Hassany, M; Mobashery, N; Mohey, MA; Qaqish, RB; Redman, R; Shiha, G; Soliman, R; Waked, I; Yosry, A; Zayed, N, 2016)	0.43
" The patient continued with this warfarin dosage until 18 weeks after completion of his HCV regimen."	( Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin. Peterson, D; Van Ermen, A, 2017)	0.46
"Our data shows that successful treatment of CHC patients with and without prior RG-101 dosing results in reduction of broad immune activation, and normalisation of miR-122 levels (EudraCT: 2014-002808-25)."	( Immune responses in DAA treated chronic hepatitis C patients with and without prior RG-101 dosing. Barnes, E; Brown, A; de Vree, JML; Klenerman, P; Kootstra, NA; Reesink, HW; Sinnige, MJ; Stelma, F; Swadling, L; van der Ree, MH; van der Valk, M; van Nuenen, AC; Willemse, SB, 2017)	0.46
" Ribavirin dosing was weight based."	( Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. Dunn, LA; Fury, MG; Haque, SS; Ho, AA; Katabi, N; Pfister, DG; Sherman, EJ, 2018)	0.48
" RBV was dosed by physician discretion between 200 mg weekly and 200 mg daily."	( High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease. Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM, 2018)	0.48
" We describe the clinical management of ribavirin dosing in hepatitis C virus-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin."	( Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Bernstein, DE; Feld, JJ; Ferenci, P; Larsen, L; Tatsch, F; Vlierberghe, HV; Younes, Z, 2018)	0.48
" These include the optimal dosing and duration of treatment, and the potential beneficial effects of therapeutic drug monitoring on the virological response and the incidence of side effects."	( Dosing ribavirin in hepatitis E-infected solid organ transplant recipients. De Winter, BCM; Hesselink, DA; Kamar, N, 2018)	0.48
" On 23 August, Tac level was found undetectable; hence, dosage was increased."	( Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis. Cheung, CYS; Cooper, SE; Liu, HY, 2018)	0.48
" The hemopoietic toxicity, sometimes forced patients to reduce the dosage or to discontinue treatment in rare occasions."	( Effect of black seed oil supplementation on selected immunological, hematological and Iron status parameters in ribavirin treated female albino rats. Abd-Elmonem, HA, 2018)	0.48
" With the development of moderate "early" (less than 12 weeks of antiviral therapy) and for the prevention of "late" (more than 12 weeks of treatment) neutropenia, appointment of immune medicine likopid (glucosaminylmuramyldipeptide) at a dosage of 1 mg, 2 times a day for 20 days, in patients with chronic hepatitis C (genotype 1b ) with	( [Cytopenias and their correction during antiviral therapy of chronic hepatitis C in patients with genotype 1]. Fazylov, VC; Guryanova, SV; Manapova, ER, 2017)	0.46
" RBV was dosed by physician discretion between 600-1200 mg daily."	( Real life efficacy of ledipasvir/sofosbuvir in hepatitis C genotype 4-infected patients with advanced liver fibrosis and decompensated cirrhosis. Abdo, AA; Al-Hamoudi, WK; Alalwan, AM; Albenmousa, A; Albiladi, H; Alghamdi, AS; AlGhamdi, H; Aljawad, MS; Aljumah, AA; AlMousa, A; Almutairi, NH; Alothmani, HS; Alsahafi, A; AlSaleemi, MS; Alswat, K; Altraif, IH; AlZanbagi, A; Assiri, AM; Awny, A; Babatin, MA; Dahlan, Y; Mousa, WA; Sanai, FM, 2018)	0.48
" The standardization of dosage method is necessary to carry out treatment with RBV more safely and effectively."	( Maintaining Concentration of Ribavirin in Cerebrospinal Fluid by a New Dosage Method; 3 Cases of Subacute Sclerosing Panencephalitis Treated Using a Subcutaneous Continuous Infusion Pump. Abe, Y; Hashimoto, K; Hosoya, M; Kanno, S; Kawasaki, Y; Maeda, H; Miyazaki, K; Sato, M; Suyama, K; Watanabe, M, 2019)	0.51
"This study examined the pharmacokinetics of ribavirin in a lung transplant population for which current and alternative dosing regimens were assessed."	( Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. Alffenaar, JC; de Zwart, AES; Evans, AM; Glanville, AR; Marriott, DJE; Milliken, E; Reuter, SE; Riezebos-Brilman, A; Schteinman, A; Verschuuren, EAM, 2019)	0.51
" Monte Carlo simulation was used to assess the ability of dosing regimens to achieve pre-specified target concentrations."	( Population pharmacokinetics of ribavirin in lung transplant recipients and examination of current and alternative dosing regimens. Alffenaar, JC; de Zwart, AES; Evans, AM; Glanville, AR; Marriott, DJE; Milliken, E; Reuter, SE; Riezebos-Brilman, A; Schteinman, A; Verschuuren, EAM, 2019)	0.51
"5%, both at 12 and 24 weeks) whose average ribavirin dosage was 937."	( Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting? Cho, HA; Cho, JY; Cho, SB; Choi, SK; Jun, CH; Kim, MW; Lim, SW; Seo, JH; Yoon, JH, 2019)	0.51
" Age ≥70 years, with liver cirrhosis, and female gender were associated with ribavirin dosage reduction."	( Sofosbuvir plus ribavirin for the treatment of hepatitis C virus genotype 2 in Korea: What's the optimal dosage of ribavirin in real-world setting? Cho, HA; Cho, JY; Cho, SB; Choi, SK; Jun, CH; Kim, MW; Lim, SW; Seo, JH; Yoon, JH, 2019)	0.51
" Treatment was a combination of sofosbuvir 400 mg/day + daclatasvir 60 mg/day, with or without a weight-adjusted dosing of ribavirin for 12 or 24 weeks."	( Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients. Results in real clinical practice. Castro-Iglesias, A; Cid-Silva, P; Delgado-Blanco, M; Margusino-Framiñán, L; Martín-Herranz, I; Mena-de-Cea, A; Pernas-Souto, B; Pertega-Díaz, S; Rodríguez-Osorio, I, 2019)	0.51
" For all patients, ribavirin dosing was determined by baseline weight (up to 1,400 mg/day, two divided doses)."	( Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection. Balistreri, WF; Bansal, S; Brainard, DM; Davison, S; Feiterna-Sperling, C; Gillis, LA; Gonzalez-Peralta, RP; Hsueh, CH; Indolfi, G; Jonas, MM; Kelly, DA; Lin, CH; Massetto, B; Murray, KF; Nightingale, S; Parhy, B; Rosenthal, P; Schwarz, KB; Shao, J; Sokal, EM; Wirth, S, 2020)	0.56
" Patients from 46 centers were dosed for 12 or 24 weeks with or without ribavirin, in line with existing guidelines."	( SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial. Merat, S, 2020)	0.56
" We evaluated overall adherence (proportion of prescribed doses taken) and nonadherence (<90% adherent) between dosing patterns."	( Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Amin, J; Bruggmann, P; Bruneau, J; Conway, B; Cooper, C; Cunningham, EB; Dalgard, O; Dillon, JF; Dore, GJ; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Lacombe, K; Litwin, AH; Marks, P; Matthews, GV; Powis, J; Read, P; Shaw, D, 2020)	0.56
" Median effective dose was interpolated from the triplicated experiments and the dose-response curves were generated for each drug-virus combination."	( A preclinical assessment to repurpose drugs to target type 1 diabetes-associated type B coxsackieviruses. Honkimaa, A; Hyöty, H; Sioofy-Khojine, AB, 2020)	0.56
" Data were analyzed with respect to age, gender, ethnicity, previous ADRs, family history of ADRs, dosage specification, medication frequency specification, body weight, route of administration, herb-drug interactions (ribavirin, cefatriaxone, penicillin sodium, ambroxol hydrochloride, clindamycin, cefoxitin sodium, azithromycin, ceftazidime, amoxicillin sodium and clavulanate potassium, levofloxacin, cefazolin sodium pentahydrate, acyclovir) by univariate analysis and multivariate analysis."	( Risk factors associated with the severity of adverse drug reactions by Xiyanping injection: A propensity score-matched analysis. Chen, S; Kwong, JSW; Li, C; Shang, H; Sun, Y; Tao, L; Zhang, X; Zheng, R; Zhong, C, 2020)	0.56
"4%) received DCV at a dosage of 60 mg, 52 (16."	( Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C, 2020)	0.56
"DCV use resulted in high SVR rate regardless of dosage and correctness of prescription."	( Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepaICONA foundation cohorts. Bonora, S; Cingolani, A; d'Arminio Monforte, A; Lo Caputo, S; Marinaro, L; Mussini, C; Puoti, M; Rossotti, R; Saracino, A; Soria, A; Tavelli, A; Uberti-Foppa, C, 2020)	0.56
" Ribavirin-PRINT-CFI was well tolerated in healthy participants after single dosing and ribavirin-PRINT-IP was well tolerated in healthy and COPD participants after single and repeat dosing."	( A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study. Baker, SJ; Billiard, J; Chandrasekaran, V; Dennison, J; Dumont, EF; Georgiou, A; Gillies, A; Harrell, AW; Hopchet, N; Ioannou, C; Lahiry, A; Oliver, AJ; Starbuck, DC; van den Berg, F; Yang, S; Young, GC, 2020)	0.56
" The apparent COVID-19 pandemic provides an opportunity to follow dosage guidelines for treatment with ribavirin, test new therapeutic concepts, and conduct controlled testing to apply the scientific rigor required to address the controversy around this mainstay of antiviral therapy."	( Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID-19. Khalili, JS; Mak, NSA; Yan, Y; Zhu, H; Zhu, Y, 2020)	0.56
" We developed a long-acting DAA system (LA-DAAS) capable of prolonged dosing and explored its cost-effectiveness."	( Development of a long-acting direct-acting antiviral system for hepatitis C virus treatment in swine. Chu, JN; Collins, J; Eweje, F; Faiz, MT; Gwynne, D; Hayward, A; Hess, K; Hua, T; Ishida, K; Katz, S; Koeppen, R; Langer, R; Lopes, A; McManus, R; Miller, JB; Salama, JAF; Slocum, AH; Soares, V; Steiger, C; Sulkowski, MS; Tamang, SM; Thomas, DL; Traverso, G; Verma, M, 2020)	0.56
" However, practical approaches to the use of this antiviral treatment in a post-transplant patient, including drug interactions, dosing adjustments, and monitoring parameters, are lacking."	( Practical considerations when treating chronic hepatitis E in solid organ transplant recipients. Chacra, W; Chan, C; Choi, DK; Koppe, S; Landers, L; Martin, MT; Mikolajczyk, AE; Naveed, A, 2021)	0.62
" This review summarizes the current data for the most commonly used drugs for coronavirus disease 2019 and will cover the unique factors that may affect the dosing of these medications in patients with CKD."	( Treatment Options for Coronavirus Disease 2019 in Patients With Reduced or Absent Kidney Function. Govil, A; Luckett, K; Miller-Handley, H, 2020)	0.56
" This retrospective study compared two dosage forms of interferon; conventional interferon (IR) and Pegylated interferon (PIR) in 370 Hepatitis C patients selected through non probability convenient sampling technique."	( Comparative safety and efficacy of conventional interferon versus pegylated-interferon based therapy for HCV: A retrospective cohort study from Gujranwala, Pakistan. Ahmed, M; Bashir, A; Farooq, MS; Iftikhar, U; Kamran, SH; Saeed, H; Saleem, N; Saleem, Z, 2020)	0.56
" In the 194 subjects treated with sofosbuvir/ribavirin, median initial ribavirin dosage was 13."	( Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose. Bellan, M; Crobu, MG; D'Avolio, A; Gualerzi, A; Pirisi, M; Smirne, C, 2021)	0.62
"The current use of ribavirin in difficult-to-cure chronic hepatitis C patients (HCV) and patients with severe respiratory infections is constrained by the issue of ribavirin-induced hemolytic anemia that affects 30% of treated patients, requiring dosage modification or discontinuation."	( Novel variant in glycophorin c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. Al-Judaibi, B; Carleton, BC; Drögemöller, BI; Ford, JA; Kim, RB; Lee, SS; Lin, JJ; Loucks, CM; Ramji, A; Ross, CJ; Schwarz, UI; Tam, E; Trueman, JN; Wright, GEB; Yoshida, EM, 2021)	0.62
"The clinical guidelines suggest that the dosing of cyclosporine (CsA), during combination therapy with paritaprevir/ritonavir-ombitasvir and dasabuvir (PrOD), would be only one-fifth of the pre-PrOD total daily dose to be administered once daily."	( Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022)	0.72
" The authors proposed reducing the CsA dosage during PrOD treatment to one-seventh of that of the pre-PrOD treatment of the total daily dose to maintain target CsA levels."	( Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis. Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH, 2022)	0.72
" Recent studies showed sofosbuvir (SOF) can inhibit HEV replication in vitro and has add-on effect when combined with RBV, but the clinical effect of SOF against HEV infection remains controversial and the dosage of SOF warrants further exploration."	( High dose sofosbuvir and sofosbuvir-plus-ribavirin therapy inhibit Hepatitis E Virus (HEV) replication in a rabbit model for acute HEV infection. Dai, L; He, Q; Liang, Z; Lu, F; Shu, J; Wang, L; Zhang, F, 2022)	0.72
" We report a case of a 48-year-old female patient diagnosed with CVID enteropathy possibly related to norovirus infection who failed a ribavirin-based therapy despite dosage optimization through drug plasma level monitoring."	( Ribavirin-resistant chronic norovirus infection-associated enteropathy in common variable immunodeficiency. Case report and review of the literature. Calderón-Hernanz, B; de Hita-Santabaya, AI; González-Morcillo, G; Riera-Oliver, J; Serrano-López de Las Hazas, J, 2022)	0.72
" Methods: In this randomized, open label, controlled pilot trial, we evaluated RBV (n=4) dosed for the initial 24 weeks of treatment versus no RBV (n=4) in tenofovir recipients dosed over 48 weeks."	( Ribavirin Does Not Enhance Hepatitis B Virus Nucleotide Antiviral Activity: A Pilot Study. Coffin, C; Cooper, C; Crawley, A; Fung, S; Keeshan, A; Ma, M; Mortimer, L; Osiowy, C; Patel, N; Vachon, A, 2022)	0.72

Role	Description
antimetabolite	A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
antiviral agent	A substance that destroys or inhibits replication of viruses.
antiinfective agent	A substance used in the prophylaxis or therapy of infectious diseases.
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor	A DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce.
anticoronaviral agent	Any antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
1-ribosyltriazole	A 1-glycosyltriazole in which the glycosyl residue is specified as ribosyl.
aromatic amide	An amide in which the amide linkage is bonded directly to an aromatic system.
monocarboxylic acid amide	A carboxamide derived from a monocarboxylic acid.
primary carboxamide	A carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
The impact of Nsp14 on metabolism (COVID-19 Disease Map)	0	84
Nsp9 interactions (COVID-19 Disease Map)	83	30

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
interleukin 8	Homo sapiens (human)	Potency	66.8242	0.0473	49.4806	74.9780	AID651758
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	4.8831	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
TDP1 protein	Homo sapiens (human)	Potency	1.2017	0.0008	11.3822	44.6684	AID686978; AID686979
Thrombopoietin	Homo sapiens (human)	Potency	12.5893	0.0251	7.3048	31.6228	AID917; AID918
AR protein	Homo sapiens (human)	Potency	10.0847	0.0002	21.2231	8,912.5098	AID1259243; AID1259381
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	25.1189	0.0112	12.4002	100.0000	AID1030
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	15.8489	0.0013	18.0743	39.8107	AID926; AID938
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	7.5846	0.0010	22.6508	76.6163	AID1224838; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	7.7619	0.0123	7.9835	43.2770	AID1645841
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	51.1478	0.0030	41.6115	22,387.1992	AID1159552; AID1159555
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	1.9740	0.0015	30.6073	15,848.9004	AID1224819; AID1224820; AID1224821; AID1224823; AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	28.7486	0.3758	27.4851	61.6524	AID588526; AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	9.1024	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	24.0701	0.0002	29.3054	16,493.5996	AID1259244; AID743069; AID743075; AID743078
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	50.1187	0.0010	19.4141	70.9645	AID588537
arylsulfatase A	Homo sapiens (human)	Potency	16.9441	1.0691	13.9551	37.9330	AID720538
alpha-galactosidase	Homo sapiens (human)	Potency	50.1187	4.4668	18.3916	35.4813	AID2107
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a	Homo sapiens (human)	Potency	3.8874	0.0017	23.8393	78.1014	AID743083
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	34.1606	0.0391	47.5451	146.8240	AID1224845; AID1224896
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	23.9341	23.9341	23.9341	23.9341	AID1967
chromobox protein homolog 1	Homo sapiens (human)	Potency	89.1251	0.0060	26.1688	89.1251	AID540317
nuclear factor erythroid 2-related factor 2 isoform 2	Homo sapiens (human)	Potency	10.3225	0.0041	9.9848	25.9290	AID504444
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	20.2735	0.0003	23.4451	159.6830	AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	30.4899	0.0006	27.2152	1,122.0200	AID743219
urokinase-type plasminogen activator precursor	Mus musculus (house mouse)	Potency	7.0795	0.1585	5.2879	12.5893	AID540303
plasminogen precursor	Mus musculus (house mouse)	Potency	7.0795	0.1585	5.2879	12.5893	AID540303
urokinase plasminogen activator surface receptor precursor	Mus musculus (house mouse)	Potency	7.0795	0.1585	5.2879	12.5893	AID540303
geminin	Homo sapiens (human)	Potency	0.1836	0.0046	11.3741	33.4983	AID624297
survival motor neuron protein isoform d	Homo sapiens (human)	Potency	21.1699	0.1259	12.2344	35.4813	AID1458
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	0.7943	0.0316	10.2792	39.8107	AID884; AID885
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	0.0501	0.0010	6.0009	35.4813	AID943
lamin isoform A-delta10	Homo sapiens (human)	Potency	0.0040	0.8913	12.0676	28.1838	AID1487
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	26.6032	0.0015	57.7890	15,848.9004	AID1259244
Rap guanine nucleotide exchange factor 3	Homo sapiens (human)	Potency	89.1251	6.3096	60.2008	112.2020	AID720707
Cellular tumor antigen p53	Homo sapiens (human)	Potency	37.4338	0.0023	19.5956	74.0614	AID651631; AID651743; AID720552
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	26.6032	0.0015	51.7393	15,848.9004	AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Nuclear receptor ROR-gamma	Homo sapiens (human)	Potency	18.8336	0.0266	22.4482	66.8242	AID651802
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
Ataxin-2	Homo sapiens (human)	Potency	31.6228	0.0119	12.2221	68.7989	AID588378
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	0.7943	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)	IC50 (µMol)	622.5000	0.0003	2.6311	9.0000	AID1207766
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
Adenosine receptor A3	Homo sapiens (human)	Ki	7.4100	0.0000	0.9306	10.0000	AID1802102
Adenosine receptor A2a	Homo sapiens (human)	Ki	7.4100	0.0000	1.0609	9.7920	AID1802102
Adenosine receptor A1	Homo sapiens (human)	Ki	7.4100	0.0002	0.9316	10.0000	AID1571891; AID1802102
Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)	IC50 (µMol)	622.5000	0.0003	2.5955	9.0000	AID1207766
Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)	IC50 (µMol)	622.5000	0.0003	2.6311	9.0000	AID1207766
Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)	IC50 (µMol)	622.5000	0.0003	2.2545	9.6000	AID1207766
Adenosine receptor A1	Mus musculus (house mouse)	Ki	4.4300	0.0001	0.4242	4.4300	AID1571893
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	133.0000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
NS5	Zika virus	EC50 (µMol)	20.8000	0.0087	0.5475	1.3000	AID1558305
Spike glycoprotein	Betacoronavirus England 1	EC50 (µMol)	109.5000	0.0030	4.5755	9.8200	AID1804127
Replicase polyprotein 1ab	Betacoronavirus England 1	EC50 (µMol)	109.5000	0.0030	4.5755	9.8200	AID1804127
glycogen synthase kinase-3 beta isoform 1	Homo sapiens (human)	EC50 (µMol)	300.0000	0.2125	22.1562	83.9400	AID434954
Transmembrane protease serine 2	Homo sapiens (human)	EC50 (µMol)	109.5000	0.0030	4.5168	9.8200	AID1804127
Polymerase basic protein 2	Influenza A virus (A/Puerto Rico/8/1934(H1N1))	EC50 (µMol)	20.0000	0.0006	0.0006	0.0006	AID1729931; AID1778629
Polymerase acidic protein	Influenza A virus (A/Puerto Rico/8/1934(H1N1))	EC50 (µMol)	21.2667	3.2200	3.2200	3.2200	AID1408128; AID1729931; AID1778629
Procathepsin L	Homo sapiens (human)	EC50 (µMol)	109.5000	0.0030	4.4874	9.8200	AID1804127
Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus	EC50 (µMol)	109.5000	0.0030	4.6136	9.8200	AID1804127
Replicase polyprotein 1ab	Human coronavirus 229E	EC50 (µMol)	109.5000	0.0030	4.6136	9.8200	AID1804127
Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus	EC50 (µMol)	109.5000	0.0030	4.4554	9.8200	AID1804127
Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2	EC50 (µMol)	109.5000	0.0030	4.1105	9.8200	AID1804127
Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus	EC50 (µMol)	109.5000	0.0030	4.5755	9.8200	AID1804127
Angiotensin-converting enzyme 2	Homo sapiens (human)	EC50 (µMol)	109.5000	0.0030	4.5755	9.8200	AID1804127
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
viral translation	Transmembrane protease serine 2	Homo sapiens (human)
proteolysis	Transmembrane protease serine 2	Homo sapiens (human)
protein autoprocessing	Transmembrane protease serine 2	Homo sapiens (human)
positive regulation of viral entry into host cell	Transmembrane protease serine 2	Homo sapiens (human)
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
detection of light stimulus involved in visual perception	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adaptive immune response	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
associative learning	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Rap protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
intracellular signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of GTPase activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of angiogenesis	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of protein export from nucleus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of stress fiber assembly	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
establishment of endothelial barrier	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cellular response to cAMP	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
Ras protein signal transduction	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
regulation of insulin secretion	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
adaptive immune response	Procathepsin L	Homo sapiens (human)
proteolysis	Procathepsin L	Homo sapiens (human)
protein autoprocessing	Procathepsin L	Homo sapiens (human)
fusion of virus membrane with host plasma membrane	Procathepsin L	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Procathepsin L	Homo sapiens (human)
antigen processing and presentation	Procathepsin L	Homo sapiens (human)
antigen processing and presentation of exogenous peptide antigen via MHC class II	Procathepsin L	Homo sapiens (human)
collagen catabolic process	Procathepsin L	Homo sapiens (human)
zymogen activation	Procathepsin L	Homo sapiens (human)
enkephalin processing	Procathepsin L	Homo sapiens (human)
fusion of virus membrane with host endosome membrane	Procathepsin L	Homo sapiens (human)
CD4-positive, alpha-beta T cell lineage commitment	Procathepsin L	Homo sapiens (human)
symbiont entry into host cell	Procathepsin L	Homo sapiens (human)
antigen processing and presentation of peptide antigen	Procathepsin L	Homo sapiens (human)
proteolysis involved in protein catabolic process	Procathepsin L	Homo sapiens (human)
elastin catabolic process	Procathepsin L	Homo sapiens (human)
macrophage apoptotic process	Procathepsin L	Homo sapiens (human)
cellular response to thyroid hormone stimulus	Procathepsin L	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Procathepsin L	Homo sapiens (human)
positive regulation of peptidase activity	Procathepsin L	Homo sapiens (human)
immune response	Procathepsin L	Homo sapiens (human)
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
symbiont-mediated perturbation of host ubiquitin-like protein modification	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
inflammatory response	Adenosine receptor A3	Homo sapiens (human)
signal transduction	Adenosine receptor A3	Homo sapiens (human)
activation of adenylate cyclase activity	Adenosine receptor A3	Homo sapiens (human)
regulation of heart contraction	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A3	Homo sapiens (human)
response to wounding	Adenosine receptor A3	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A3	Homo sapiens (human)
negative regulation of cell migration	Adenosine receptor A3	Homo sapiens (human)
negative regulation of NF-kappaB transcription factor activity	Adenosine receptor A3	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A3	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A3	Homo sapiens (human)
one-carbon metabolic process	Adenosylhomocysteinase	Homo sapiens (human)
S-adenosylmethionine cycle	Adenosylhomocysteinase	Homo sapiens (human)
synaptic transmission, dopaminergic	Adenosine receptor A2a	Homo sapiens (human)
response to amphetamine	Adenosine receptor A2a	Homo sapiens (human)
regulation of DNA-templated transcription	Adenosine receptor A2a	Homo sapiens (human)
phagocytosis	Adenosine receptor A2a	Homo sapiens (human)
apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
cellular defense response	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
cell-cell signaling	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, cholinergic	Adenosine receptor A2a	Homo sapiens (human)
central nervous system development	Adenosine receptor A2a	Homo sapiens (human)
blood coagulation	Adenosine receptor A2a	Homo sapiens (human)
sensory perception	Adenosine receptor A2a	Homo sapiens (human)
locomotory behavior	Adenosine receptor A2a	Homo sapiens (human)
blood circulation	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A2a	Homo sapiens (human)
response to xenobiotic stimulus	Adenosine receptor A2a	Homo sapiens (human)
response to inorganic substance	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of glutamate secretion	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmission	Adenosine receptor A2a	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A2a	Homo sapiens (human)
response to purine-containing compound	Adenosine receptor A2a	Homo sapiens (human)
response to caffeine	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of urine volume	Adenosine receptor A2a	Homo sapiens (human)
vasodilation	Adenosine receptor A2a	Homo sapiens (human)
eating behavior	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of vascular permeability	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of neuron apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleep	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of alpha-beta T cell activation	Adenosine receptor A2a	Homo sapiens (human)
astrocyte activation	Adenosine receptor A2a	Homo sapiens (human)
neuron projection morphogenesis	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of protein secretion	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
regulation of mitochondrial membrane potential	Adenosine receptor A2a	Homo sapiens (human)
membrane depolarization	Adenosine receptor A2a	Homo sapiens (human)
regulation of calcium ion transport	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
excitatory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
inhibitory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
prepulse inhibition	Adenosine receptor A2a	Homo sapiens (human)
apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
temperature homeostasis	Adenosine receptor A1	Homo sapiens (human)
response to hypoxia	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A1	Homo sapiens (human)
regulation of respiratory gaseous exchange by nervous system process	Adenosine receptor A1	Homo sapiens (human)
negative regulation of acute inflammatory response	Adenosine receptor A1	Homo sapiens (human)
negative regulation of leukocyte migration	Adenosine receptor A1	Homo sapiens (human)
positive regulation of peptide secretion	Adenosine receptor A1	Homo sapiens (human)
positive regulation of systemic arterial blood pressure	Adenosine receptor A1	Homo sapiens (human)
negative regulation of systemic arterial blood pressure	Adenosine receptor A1	Homo sapiens (human)
regulation of glomerular filtration	Adenosine receptor A1	Homo sapiens (human)
protein targeting to membrane	Adenosine receptor A1	Homo sapiens (human)
phagocytosis	Adenosine receptor A1	Homo sapiens (human)
inflammatory response	Adenosine receptor A1	Homo sapiens (human)
signal transduction	Adenosine receptor A1	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Adenosine receptor A1	Homo sapiens (human)
cell-cell signaling	Adenosine receptor A1	Homo sapiens (human)
nervous system development	Adenosine receptor A1	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A1	Homo sapiens (human)
response to inorganic substance	Adenosine receptor A1	Homo sapiens (human)
negative regulation of glutamate secretion	Adenosine receptor A1	Homo sapiens (human)
response to purine-containing compound	Adenosine receptor A1	Homo sapiens (human)
lipid catabolic process	Adenosine receptor A1	Homo sapiens (human)
negative regulation of synaptic transmission, GABAergic	Adenosine receptor A1	Homo sapiens (human)
positive regulation of nucleoside transport	Adenosine receptor A1	Homo sapiens (human)
negative regulation of neurotrophin production	Adenosine receptor A1	Homo sapiens (human)
positive regulation of protein dephosphorylation	Adenosine receptor A1	Homo sapiens (human)
vasodilation	Adenosine receptor A1	Homo sapiens (human)
negative regulation of circadian sleep/wake cycle, non-REM sleep	Adenosine receptor A1	Homo sapiens (human)
negative regulation of apoptotic process	Adenosine receptor A1	Homo sapiens (human)
positive regulation of potassium ion transport	Adenosine receptor A1	Homo sapiens (human)
positive regulation of MAPK cascade	Adenosine receptor A1	Homo sapiens (human)
negative regulation of hormone secretion	Adenosine receptor A1	Homo sapiens (human)
cognition	Adenosine receptor A1	Homo sapiens (human)
leukocyte migration	Adenosine receptor A1	Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain	Adenosine receptor A1	Homo sapiens (human)
negative regulation of lipid catabolic process	Adenosine receptor A1	Homo sapiens (human)
positive regulation of lipid catabolic process	Adenosine receptor A1	Homo sapiens (human)
regulation of sensory perception of pain	Adenosine receptor A1	Homo sapiens (human)
negative regulation of synaptic transmission, glutamatergic	Adenosine receptor A1	Homo sapiens (human)
fatty acid homeostasis	Adenosine receptor A1	Homo sapiens (human)
excitatory postsynaptic potential	Adenosine receptor A1	Homo sapiens (human)
long-term synaptic depression	Adenosine receptor A1	Homo sapiens (human)
mucus secretion	Adenosine receptor A1	Homo sapiens (human)
negative regulation of mucus secretion	Adenosine receptor A1	Homo sapiens (human)
triglyceride homeostasis	Adenosine receptor A1	Homo sapiens (human)
regulation of cardiac muscle cell contraction	Adenosine receptor A1	Homo sapiens (human)
apoptotic signaling pathway	Adenosine receptor A1	Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentration	Adenosine receptor A1	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Adenosine receptor A1	Homo sapiens (human)
negative regulation of long-term synaptic depression	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Adenosine receptor A1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
xenobiotic metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of glucose metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of steroid metabolic process	Nuclear receptor ROR-gamma	Homo sapiens (human)
intracellular receptor signaling pathway	Nuclear receptor ROR-gamma	Homo sapiens (human)
circadian regulation of gene expression	Nuclear receptor ROR-gamma	Homo sapiens (human)
cellular response to sterol	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of circadian rhythm	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of fat cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
positive regulation of DNA-templated transcription	Nuclear receptor ROR-gamma	Homo sapiens (human)
adipose tissue development	Nuclear receptor ROR-gamma	Homo sapiens (human)
T-helper 17 cell differentiation	Nuclear receptor ROR-gamma	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Nuclear receptor ROR-gamma	Homo sapiens (human)
calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
sensory perception of sound	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
positive regulation of adenylate cyclase activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
positive regulation of calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarization	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion import	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
membrane depolarization during SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of potassium ion transmembrane transporter activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
regulation of potassium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
skeletal system development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
extraocular skeletal muscle development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calcium ion transport	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
striated muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
endoplasmic reticulum organization	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
myoblast fusion	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
neuromuscular junction development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
skeletal muscle adaptation	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
positive regulation of muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
skeletal muscle fiber development	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
release of sequestered calcium ion into cytosol	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
cellular response to caffeine	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
immune system development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
heart development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
embryonic forelimb morphogenesis	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
camera-type eye development	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of adenylate cyclase activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
positive regulation of muscle contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transport into cytosol	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channel	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion transmembrane transport	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cardiac muscle cell action potential involved in contraction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of heart rate by cardiac conduction	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
regulation of ventricular cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calcium ion import across plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
negative regulation of signaling receptor activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
symbiont entry into host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cytokine production	Angiotensin-converting enzyme 2	Homo sapiens (human)
angiotensin maturation	Angiotensin-converting enzyme 2	Homo sapiens (human)
angiotensin-mediated drinking behavior	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of systemic arterial blood pressure by renin-angiotensin	Angiotensin-converting enzyme 2	Homo sapiens (human)
tryptophan transport	Angiotensin-converting enzyme 2	Homo sapiens (human)
viral life cycle	Angiotensin-converting enzyme 2	Homo sapiens (human)
receptor-mediated endocytosis of virus by host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of vasoconstriction	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of transmembrane transporter activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cell population proliferation	Angiotensin-converting enzyme 2	Homo sapiens (human)
symbiont entry into host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
receptor-mediated virion attachment to host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
negative regulation of smooth muscle cell proliferation	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of inflammatory response	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of amino acid transport	Angiotensin-converting enzyme 2	Homo sapiens (human)
maternal process involved in female pregnancy	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of cardiac muscle contraction	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane fusion	Angiotensin-converting enzyme 2	Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascade	Angiotensin-converting enzyme 2	Homo sapiens (human)
blood vessel diameter maintenance	Angiotensin-converting enzyme 2	Homo sapiens (human)
entry receptor-mediated virion attachment to host cell	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of gap junction assembly	Angiotensin-converting enzyme 2	Homo sapiens (human)
regulation of cardiac conduction	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of L-proline import across plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
serine-type endopeptidase activity	Transmembrane protease serine 2	Homo sapiens (human)
protein binding	Transmembrane protease serine 2	Homo sapiens (human)
serine-type peptidase activity	Transmembrane protease serine 2	Homo sapiens (human)
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
guanyl-nucleotide exchange factor activity	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
protein domain specific binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cAMP binding	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
fibronectin binding	Procathepsin L	Homo sapiens (human)
cysteine-type endopeptidase activity	Procathepsin L	Homo sapiens (human)
protein binding	Procathepsin L	Homo sapiens (human)
collagen binding	Procathepsin L	Homo sapiens (human)
cysteine-type peptidase activity	Procathepsin L	Homo sapiens (human)
histone binding	Procathepsin L	Homo sapiens (human)
proteoglycan binding	Procathepsin L	Homo sapiens (human)
serpin family protein binding	Procathepsin L	Homo sapiens (human)
cysteine-type endopeptidase activator activity involved in apoptotic process	Procathepsin L	Homo sapiens (human)
RNA-dependent RNA polymerase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
G protein-coupled adenosine receptor activity	Adenosine receptor A3	Homo sapiens (human)
3'-5'-RNA exonuclease activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoesters	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
protein guanylyltransferase activity	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
adenosylhomocysteinase activity	Adenosylhomocysteinase	Homo sapiens (human)
protein binding	Adenosylhomocysteinase	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Homo sapiens (human)
protein binding	Adenosine receptor A2a	Homo sapiens (human)
calmodulin binding	Adenosine receptor A2a	Homo sapiens (human)
lipid binding	Adenosine receptor A2a	Homo sapiens (human)
enzyme binding	Adenosine receptor A2a	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Adenosine receptor A2a	Homo sapiens (human)
identical protein binding	Adenosine receptor A2a	Homo sapiens (human)
protein-containing complex binding	Adenosine receptor A2a	Homo sapiens (human)
alpha-actinin binding	Adenosine receptor A2a	Homo sapiens (human)
G protein-coupled receptor binding	Adenosine receptor A1	Homo sapiens (human)
purine nucleoside binding	Adenosine receptor A1	Homo sapiens (human)
protein binding	Adenosine receptor A1	Homo sapiens (human)
heat shock protein binding	Adenosine receptor A1	Homo sapiens (human)
G-protein beta/gamma-subunit complex binding	Adenosine receptor A1	Homo sapiens (human)
heterotrimeric G-protein binding	Adenosine receptor A1	Homo sapiens (human)
protein heterodimerization activity	Adenosine receptor A1	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A1	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Nuclear receptor ROR-gamma	Homo sapiens (human)
DNA-binding transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
protein binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
oxysterol binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
zinc ion binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
ligand-activated transcription factor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
sequence-specific double-stranded DNA binding	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear receptor activity	Nuclear receptor ROR-gamma	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
ankyrin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
small molecule binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
molecular function activator activity	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
calmodulin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
high voltage-gated calcium channel activity	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
metal ion binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
alpha-actinin binding	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potential	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
virus receptor activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
endopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
carboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallocarboxypeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
metallopeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
peptidyl-dipeptidase activity	Angiotensin-converting enzyme 2	Homo sapiens (human)
zinc ion binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
identical protein binding	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
extracellular region	Transmembrane protease serine 2	Homo sapiens (human)
nucleoplasm	Transmembrane protease serine 2	Homo sapiens (human)
plasma membrane	Transmembrane protease serine 2	Homo sapiens (human)
extracellular exosome	Transmembrane protease serine 2	Homo sapiens (human)
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
photoreceptor outer segment	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1F	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
cortical actin cytoskeleton	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
plasma membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
microvillus	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
endomembrane system	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
membrane	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
lamellipodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
filopodium	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
extracellular exosome	Rap guanine nucleotide exchange factor 3	Homo sapiens (human)
extracellular region	Polymerase basic protein 2	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
extracellular region	RNA-directed RNA polymerase catalytic subunit	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
extracellular region	Polymerase acidic protein	Influenza A virus (A/Puerto Rico/8/1934(H1N1))
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
extracellular region	Procathepsin L	Homo sapiens (human)
extracellular space	Procathepsin L	Homo sapiens (human)
nucleus	Procathepsin L	Homo sapiens (human)
lysosome	Procathepsin L	Homo sapiens (human)
multivesicular body	Procathepsin L	Homo sapiens (human)
Golgi apparatus	Procathepsin L	Homo sapiens (human)
plasma membrane	Procathepsin L	Homo sapiens (human)
apical plasma membrane	Procathepsin L	Homo sapiens (human)
endolysosome lumen	Procathepsin L	Homo sapiens (human)
chromaffin granule	Procathepsin L	Homo sapiens (human)
lysosomal lumen	Procathepsin L	Homo sapiens (human)
intracellular membrane-bounded organelle	Procathepsin L	Homo sapiens (human)
collagen-containing extracellular matrix	Procathepsin L	Homo sapiens (human)
extracellular exosome	Procathepsin L	Homo sapiens (human)
endocytic vesicle lumen	Procathepsin L	Homo sapiens (human)
extracellular space	Procathepsin L	Homo sapiens (human)
lysosome	Procathepsin L	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1a	Severe acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A3	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Adenosine receptor A3	Homo sapiens (human)
dendrite	Adenosine receptor A3	Homo sapiens (human)
plasma membrane	Adenosine receptor A3	Homo sapiens (human)
synapse	Adenosine receptor A3	Homo sapiens (human)
double membrane vesicle viral factory outer membrane	Replicase polyprotein 1ab	Severe acute respiratory syndrome coronavirus 2
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
nucleus	Adenosylhomocysteinase	Homo sapiens (human)
endoplasmic reticulum	Adenosylhomocysteinase	Homo sapiens (human)
cytosol	Adenosylhomocysteinase	Homo sapiens (human)
melanosome	Adenosylhomocysteinase	Homo sapiens (human)
extracellular exosome	Adenosylhomocysteinase	Homo sapiens (human)
cytosol	Adenosylhomocysteinase	Homo sapiens (human)
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
intermediate filament	Adenosine receptor A2a	Homo sapiens (human)
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
membrane	Adenosine receptor A2a	Homo sapiens (human)
dendrite	Adenosine receptor A2a	Homo sapiens (human)
axolemma	Adenosine receptor A2a	Homo sapiens (human)
asymmetric synapse	Adenosine receptor A2a	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
neuronal cell body	Adenosine receptor A2a	Homo sapiens (human)
postsynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
presynaptic active zone	Adenosine receptor A2a	Homo sapiens (human)
glutamatergic synapse	Adenosine receptor A2a	Homo sapiens (human)
plasma membrane	Adenosine receptor A1	Homo sapiens (human)
plasma membrane	Adenosine receptor A1	Homo sapiens (human)
basolateral plasma membrane	Adenosine receptor A1	Homo sapiens (human)
axolemma	Adenosine receptor A1	Homo sapiens (human)
asymmetric synapse	Adenosine receptor A1	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A1	Homo sapiens (human)
neuronal cell body	Adenosine receptor A1	Homo sapiens (human)
terminal bouton	Adenosine receptor A1	Homo sapiens (human)
dendritic spine	Adenosine receptor A1	Homo sapiens (human)
calyx of Held	Adenosine receptor A1	Homo sapiens (human)
postsynaptic membrane	Adenosine receptor A1	Homo sapiens (human)
presynaptic active zone	Adenosine receptor A1	Homo sapiens (human)
synapse	Adenosine receptor A1	Homo sapiens (human)
dendrite	Adenosine receptor A1	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleoplasm	Nuclear receptor ROR-gamma	Homo sapiens (human)
nuclear body	Nuclear receptor ROR-gamma	Homo sapiens (human)
chromatin	Nuclear receptor ROR-gamma	Homo sapiens (human)
nucleus	Nuclear receptor ROR-gamma	Homo sapiens (human)
virion membrane	Spike glycoprotein	Severe acute respiratory syndrome-related coronavirus
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1D	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
sarcoplasmic reticulum	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
T-tubule	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
I band	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1S	Homo sapiens (human)
cytoplasm	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
Z disc	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
dendrite	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
perikaryon	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
postsynaptic density membrane	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
L-type voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
voltage-gated calcium channel complex	Voltage-dependent L-type calcium channel subunit alpha-1C	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular region	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
endoplasmic reticulum lumen	Angiotensin-converting enzyme 2	Homo sapiens (human)
plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
cilium	Angiotensin-converting enzyme 2	Homo sapiens (human)
cell surface	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
apical plasma membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
endocytic vesicle membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
brush border membrane	Angiotensin-converting enzyme 2	Homo sapiens (human)
membrane raft	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular exosome	Angiotensin-converting enzyme 2	Homo sapiens (human)
extracellular space	Angiotensin-converting enzyme 2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2691)

Assay ID	Title	Year	Journal	Article
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Current protocols in cytometry, Oct, Volume: Chapter 13	Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2006	Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5	Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501	High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set	2010	Assay and drug development technologies, Feb, Volume: 8, Issue:1	High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1186339	Antiviral activity against Vaccinia Virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID539956	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1082875	In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana. tabacum L. leaves assessed as curative effect at 500 ug/mL measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23	Design, synthesis, antiviral activity, and SARs of 14-aminophenanthroindolizidines.
AID87161	Minimum inhibitory concentration required to reduce Coxsackie virus B4 induced cytopathogenicity by 50% in HeLa cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID376983	Cytotoxicity against african green monkey Vero cells after 3 days by MTT reduction assay	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID395951	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1638589	Antiviral activity against West Nile virus infected in human A549 cells incubated for 4 days by crystal violet staining based plaque reduction assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.
AID665835	In vivo antiviral activity against TMV assessed as curative effect at 500 ug/mL	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and antiviral activity of novel quinazolinones.
AID1265176	Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of E2 protein expression at 5 uM measured at 24 hrs postinfection by Western blot method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID712811	Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID548441	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1687966	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID673221	Antiviral activity at Hepatitis C virus genotype 1b infected in human HuH7 cells assessed as inhibition of viral replication at 10 uM after 3 days by renilla luciferase reporter gene assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	C-6 aryl substituted 4-quinolone-3-carboxylic acids as inhibitors of hepatitis C virus.
AID1408333	Cytotoxicity against MDCK cells assessed as alteration in cell morphology after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1443675	Cytotoxicity against human 293T cells expressing Gluc assessed as inhibition of cell proliferation after 24 hrs by CCK8 assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Anti-influenza triterpenoid saponins (saikosaponins) from the roots of Bupleurum marginatum var. stenophyllum.
AID1252407	Antiviral activity against Punta Toro virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of L-ascorbic or imino-L-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations.
AID1349207	Cytotoxicity against human Ava5 cells assessed as cell viability at 200 uM after 72 hrs by XTT assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression.
AID419594	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID535531	Transport through ENT1 in rat hepatocytes by oil filtration assay in presence 100 nM of transporter inhibitor NBMRP	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID768188	Antiviral activity against influenza A virus H3N3 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID105960	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in madin-Darby canine kidney cells (MDCK)	2001	Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16	Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups.
AID1186330	Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID94737	Evaluated for cell growth inhibition and induction of cellular differentiation of Murine leukemia cell line (L-1210)	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Growth inhibition and induction of cellular differentiation of human myeloid leukemia cells in culture by carbamoyl congeners of ribavirin.
AID1113455	Cytotoxicity against MDCK cells assessed as change in cellular morphology	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID658750	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1611060	Selectivity index, ratio of CTD50 for dog MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34 (H1N1)) pdm09 infected in MDCK cells	2019	Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23	Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
AID442290	Antiviral activity HCV in replicon cells assessed as inhibition of NS3-4A protease activity by RT-PCR	2010	European journal of medicinal chemistry, Feb, Volume: 45, Issue:2	Synthesis, anti-HCV, antioxidant, and peroxynitrite inhibitory activity of fused benzosuberone derivatives.
AID1717749	Cytotoxicity against African green monkey Vero E6 cells by the CCK8 assay	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1631433	Antiviral activity against Dengue virus 2 16681 infected in human HuH7 cells after 72 hrs by indirect immunofluorescent flow cytometry	2016	Journal of medicinal chemistry, 06-23, Volume: 59, Issue:12	The Medicinal Chemistry of Dengue Virus.
AID1783353	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1853005	Cytotoxicity against human HCT-116 cells assessed as reduction on cell viability at 100 uM incubated for 48 hrs by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID395691	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1205007	Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B5 infected in african green monkey Vero cells	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID453100	Antiviral activity against HCV by cell based replicon assay	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID1873828	Selectivity index, ratio of CC50 for cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability to IC50 for antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in African green monkey Vero cells assessed	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID216364	Effects on cell morphology of Vero cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1498138	Cytotoxicity against human HeLa cells assessed as alteration of cell morphology by microscopic analysis	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1783359	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based direct yield reduction a	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1113465	Cytotoxicity against Homo sapiens (human) HeLa cells assessed as change in cellular morphology	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1450217	Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID1594022	Antiviral activity against Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as reduction in viral replication preincubated for 1 hr followed by compound washout and measured after 48 hrs	2019	Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13	Discovery of 5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrazin-2(1H)-one derivatives as new potent PB2 inhibitors.
AID474327	Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 3 days by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID87139	Concentration required for microscopically detectable alteration of the normal cell morphology in HeLa cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID1503324	Cytotoxicity against African green monkey Vero 76 cells assessed as decrease in cell viability after 48 to 96 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation.
AID1688552	Antiviral activity against recombinant HCV genotype 2a JFH-1 infected in human Huh7.5 cells after 3 days by renilla luciferase reporter gene assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment.
AID392726	Antiviral activity against VSV assessed as inhibition of virus-induced cytopathicity	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	Synthesis of 5-isoxazol-5-yl-2'-deoxyuridines exhibiting antiviral activity against HSV and several RNA viruses.
AID474337	Cytotoxicity against MDCK cells after 3 days by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1571901	Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5-N-methyluronamide from mouse A3A adenosine receptor expressed in CHO cell membranes at 10 uM after 60 mins by scintillation proximity assay relative to adenosine 5-N-ethyluronamide	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design and in Vivo Characterization of A
AID376980	Cytotoxicity against human Hep2 cells after 3 days by MTT reduction assay	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID1783386	Cytotoxicity against human Huh-7 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID105801	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on MDCK cell line infected with influenza B virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID528352	Antiviral activity against Poliovirus infected in human HeLaS3 cells assessed as frequency of viral mutagenesis plaque at 300 uM by guanidine resistance assay	2010	Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22	Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses.
AID1075688	Cytotoxicity against human HuH7 cells after 2 days by XTT assay	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	4'-Substituted pyrimidine nucleosides lacking 5'-hydroxyl function as potential anti-HCV agents.
AID383515	Antiviral activity against HSV2 G in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID68121	Concentration required to reduce HSV-1(KOS) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID1207766	Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits	2013	Scientific reports, , Volume: 3	MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID216972	Minimum inhibitory conc. for 50% inhibition of Sindbis virus induced cytopathicity in Vero cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID300584	Antiviral activity against influenza A/Jingfang/Fm1 (H1N1) infected in mouse assessed as mean survival time of mouse at 100 mg/kg, ip bid after 2 hrs of viral infection for 5 days	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID535511	Transport through CNT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID766686	Antiviral activity against Influenza A virus H3N3 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1372326	Antiviral activity against Influenza A virus H5N1 (A/duck/Novosibirsk/56/2005) infected in pig SPEV cells assessed as protection against virus-induced cytopathic effect	2018	Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1	Isosteric ribavirin analogues: Synthesis and antiviral activities.
AID533315	Antiviral activity against HCV genotype 1b in TIZ-9 replicon cell after 4 days by blot hybridization analysis	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID303229	Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID198433	Therapeutic index against Rift valley fever virus.	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of 5-thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides.
AID419600	Antiviral activity against RSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID1433140	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID34143	Antiviral activity at 100 uM determined in a culture of Adenovirus type 2; IA = inactive	1989	Journal of medicinal chemistry, Jun, Volume: 32, Issue:6	Synthesis and biological properties of purine and pyrimidine 5'-deoxy-5'-(dihydroxyphosphinyl)-beta-D-ribofuranosyl analogues of AMP, GMP, IMP, and CMP.
AID1274006	Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 72 hrs by crystal violet staining technique	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID611764	Antiviral activity against Punta Toro virus infected in Vero cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID474354	Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID221964	Compounds was tested for the effect of L-nucleosides of ribavirin on SEB (staphylococcal enterotoxin B)-stimulated T-cell expression of the type 1 cytokine IL-2.	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Monocyclic L-nucleosides with type 1 cytokine-inducing activity.
AID535508	Transport through CNT3 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1485251	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID87166	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Polio virus-1 in HeLa cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID278362	RBV metabolism in Vero E6 cells assessed as RBV-MP concentration at 40 ug/ml after 24 h	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID291034	Antiviral activity against reovirus1 virus in Vero cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID611762	Antiviral activity against Mammalian orthoreovirus 1 infected in Vero cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID634750	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1113453	Antiviral activity against Influenza A virus H3N2 infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1767880	Antiviral activity against Oseltamivir resistant Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1) infected in dog MDCK cells assessed as inhibition of surface glycoprotein hemagglutinin	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1.
AID216507	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with semliki forest virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID217588	In vitro antiviral activity against measles virus in Vero cells	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and biological activity of certain nucleoside and nucleotide derivatives of pyrazofurin.
AID1778628	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors.
AID393165	Selectivity index, ratio of MCC for MDCK cells to EC50 for influenza A virus H3N2	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID311524	Oral bioavailability in human	2007	Bioorganic & medicinal chemistry, Dec-15, Volume: 15, Issue:24	Hologram QSAR model for the prediction of human oral bioavailability.
AID105777	Tested for inhibitory effect on RNA virus cell morphology in MDCK cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID71777	Concentration that reduces Friend murine leukemia virus titer by 50%	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID1277820	Antiviral activity against Dengue virus 2 infected in human HepG2 cells assessed as NS1 level at < maximum non-toxic concentration after 72 hrs by sandwich ELISA (Rvb = 44.5 +/- 3.2 PbU)	2016	European journal of medicinal chemistry, Mar-03, Volume: 110	Discovery of antiviral molecules for dengue: In silico search and biological evaluation.
AID1118650	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1873816	Antiviral activity against Huh 7.5 cell culture derived HCV genotype 2a (JFH-AM71) infected in human Huh7-J20 cells assessed as inhibition of viral replication treated for 72 hrs by SEAP reporter gene assay	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID217586	In vitro antiviral activity against herpes simplex virus type 2 (HSV-2) in Vero cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and biological activity of certain nucleoside and nucleotide derivatives of pyrazofurin.
AID634754	Antiviral activity against thymidine kinase-deficient Varicella Zoster virus 07/1 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID548428	Antiviral activity against thymidine kinase deficient acyclovir-resistant Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID395695	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID88196	Cytotoxicity against HeLa cells	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	Synthesis and biological evaluation of thymine nucleosides fused with 3',4'-tetrahydrofuran ring.
AID1436795	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 48 hrs	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID1753361	Antiviral activity against Hantaan 76-118 pseudovirus infected in MDCK cells assessed as reduction in virus replication incubated for 48 hrs by luminescence assay	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
AID369861	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 75 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1773053	Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of IL-8 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID383531	Antiviral activity against Reo virus 1 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1415635	Cytotoxicity against MDCK cells after 48 hrs by MTT assay	2017	MedChemComm, May-01, Volume: 8, Issue:5	Synthesis and
AID86687	Minimum inhibitory concentration required to elicit microscopically visible cell morphology in HeLa cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID1691957	Antiviral activity against human Norovirus	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Anti-norovirus activity of C7-modified 4-amino-pyrrolo[2,1-f][1,2,4]triazine C-nucleosides.
AID357949	Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect	2001	Journal of natural products, Oct, Volume: 64, Issue:10	New antiviral cassane furanoditerpenes from Caesalpinia minax.
AID69823	Tested for the antimicrobial activity minimum inhibitory concentration) against Escherichia coli	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID1274007	Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 8 days by crystal violet staining technique	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID218448	Percent purine accumulated in human B lymphoblast WI-L2 cells cultured medium was determined	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	Synthesis and evaluation of 5-amino-1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine and certain related nucleosides as inhibitors of purine nucleoside phosphorylase.
AID634834	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID218029	Antiviral activity was measured against Coxsackie virus B4 in african green monkey kidney (Vero B) cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID659146	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID1360699	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 3 to 6 days by MTS assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID283990	Antiviral activity against vesicular stomatitis virus by CPE assay	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Design, synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives.
AID474326	Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID593221	Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
AID217890	Evaluated for minimum inhibitory concentration against Vero cells (African green monkey) infected with PV-3, RV-1, SV, Coxs B4, SFV virus	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID278037	Antiviral activity against RSV A2 in MA104 cells by CPE assay	2007	Journal of natural products, Feb, Volume: 70, Issue:2	Dysoxylins A-D, tetranortriterpenoids with potent anti-RSV activity from Dysoxylum gaudichaudianum.
AID216372	Antiviral activity against Semliki forest virus infected Vero cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID232803	Toxic level was evaluated; None	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Synthesis and antiviral/antitumor activities of certain 3-deazaguanine nucleosides and nucleotides.
AID489677	Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Benzylidene/2-chlorobenzylidene hydrazides: synthesis, antimicrobial activity, QSAR studies and antiviral evaluation.
AID617985	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as compound concentration required for inhibiting influenza virus yield at 48 h post-infection by crystal violet staining based CPE inhibition assay	2011	Journal of natural products, Sep-23, Volume: 74, Issue:9	Anti-influenza virus polyketides from the acid-tolerant fungus Penicillium purpurogenum JS03-21.
AID1436799	Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID1146288	Antiviral activity against Rhinovirus 2 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control	1978	Journal of medicinal chemistry, Sep, Volume: 21, Issue:9	Imidazo[1,2-a]-s-triazine nucleosides. Synthesis and antiviral activity of the N-bridgehead guanine, guanosine, and guanosine monophosphate analogues of imidazo[1,2-a]-s-triazine.
AID567526	Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Junin virus IV4454 infected in african green monkey Vero cells	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Imidazo[2,1-b]thiazole carbohydrate derivatives: Synthesis and antiviral activity against Junin virus, agent of Argentine hemorrhagic fever.
AID1873820	Antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in human Huh7.5 cells assessed as inhibition of viral replication by measuring ZIKV E glycoprotein level at 100 uM incubated for 3 days by ELISA analysis relative to control	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID223404	Antiviral activity against the influenza Ao/PR/8/34 virus strain	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and antiviral evaluation of carbocyclic analogues of 2-amino-6-substituted-purine 3'-deoxyribofuranosides.
AID712814	Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID383507	Antiviral activity against vesicular stomatitis virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1536099	Antiviral activity against Junin virus IV4454 infected in African green monkey Vero cells assessed as reduction in vrius yield after 48 hrs by plaque assay	2019	Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4	Modified ribavirin analogues as antiviral agents against Junín virus.
AID1066681	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay	2014	Journal of natural products, Feb-28, Volume: 77, Issue:2	Cladosins A-E, hybrid polyketides from a deep-sea-derived fungus, Cladosporium sphaerospermum.
AID1443676	Selectivity index, ratio of CC50 for human 293T cells expressing Gluc to EC50 for Influenza A virus WSN/33(H1N1)	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Anti-influenza triterpenoid saponins (saikosaponins) from the roots of Bupleurum marginatum var. stenophyllum.
AID1773424	Antiviral activity against Human herpesvirus-1 MacIntyre infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 4	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study.
AID1696832	Selectivity index, ratio of CC50 for cytotoxicity against human A549 cells to IC50 for antiviral activity against for influenza A virus (A/Duck/Guangdong/212/2004(H5N1)) infected in A549 cells	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Structure-aided optimization of 3-O-β-chacotriosyl epiursolic acid derivatives as novel H5N1 virus entry inhibitors.
AID1773012	Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as reduction in PARP cleavage measured after 48 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID548435	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID290453	Selectivity index, ratio of CC50 for Vero E6 cells to IC50 for SARS-CoV Frankfurt1	2007	Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9	Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.
AID301694	Inactivation of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 assessed as increase in fluorescence at 200 uM	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID1485231	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID257890	Antiviral activity against Herpes simplex virus 2 G strain in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID535521	Transport through CNT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and thymidine	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID217587	In vitro antiviral activity against herpes simplex virus type 2 virus was evaluated.	1985	Journal of medicinal chemistry, Aug, Volume: 28, Issue:8	Synthesis and biological activity of 6-azacadeguomycin and certain 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides.
AID84217	Inhibitory activity against HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID1336611	Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones.
AID280200	Antiviral activity against punta toro virus in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID1081159	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 100 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID575251	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza B virus B/Memphis/20/1996 harboring neuraminidase R152K mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic ana	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1408327	Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1687965	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID1610162	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 3 days by coulter counter method	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID751301	Antiviral activity against Influenza A virus A/Hong Kong/8/68(H3N2) infected in dog MDCK cells after 3 days by CPE assay	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Asperterrestide A, a cytotoxic cyclic tetrapeptide from the marine-derived fungus Aspergillus terreus SCSGAF0162.
AID63918	Effective concentration required to inhibit vesicular stomatitis virus(VSV) -induced cytopathicity by 50% in E6SM cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID463990	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID634837	Antiviral activity against Human immunodeficiency virus 2 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID535538	Transport through CNT2 in mouse hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID463994	Antiviral activity against PIV 3 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1724448	Selectivity index, ratio of CC50 for human Huh7.5 cells to EC50 for genotype 2a HCV JFH-1 infected in human Huh7.5 cells	2020	Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19	SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
AID1773427	Antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as reduction in virus titer treated 1 hr post viral infection followed by replacement with fresh medium with compounds and measured after 72 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study.
AID376982	Selectivity index, CC50 for human Hep2 cells to IC50 for RSV Long	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID751085	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Sesquiterpenes and alkaloids from the roots of Alangium chinense.
AID1753726	Antiviral activity against CHIKV infected in African green monkey Vero cells assessed as inhibition of viral replication at 20 uM measured after 4 days relative to control	2021	Journal of natural products, 04-23, Volume: 84, Issue:4	Semisynthesis of Dolabellane Diterpenes: Oxygenated Analogues with Increased Activity against Zika and Chikungunya Viruses.
AID216346	Tested for antiviral activity against Punta toro virus in African green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID369466	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Punta Toro virus Adames	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID64118	Tested for minimum inhibitory concentration against HSV-1 (KOS strain) in E6SM cells	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID1436796	Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID474353	Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID474350	Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID253419	Ratio of cytotoxicity to anti BVDV activity of the compound	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Synthesis of benzodithiol-2-yl-substituted nucleoside derivatives as lead compounds having anti-bovine viral diarrhea virus activity.
AID419603	Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID224344	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against G strain of Herpes simplex virus-2 in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID383523	Antiviral activity against Coxsackie virus B4 in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID257892	Antiviral activity against Vesicular stomatitis virus in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID301326	Cytotoxicity against Huh7 cells by XTT assay	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	5'-O-masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents.
AID1241029	Cytotoxicity against African green monkey Vero 76 cells relative to control	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	2- and 3-Fluoro-3-deazaneplanocins, 2-fluoro-3-deazaaristeromycins, and 3-methyl-3-deazaneplanocin: Synthesis and antiviral properties.
AID766694	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1204075	Antiviral activity against RSV infected in African green monkey Vero 76 cells after 5 days by plaque reduction assay	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.
AID54477	Selectivity index as the ratio of CC50/EC50 against Coxsackie B virus type-3	2002	Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10	Heterocyclic nucleoside analogues: design and synthesis of antiviral, modified nucleosides containing isoxazole heterocycles.
AID369463	Antiviral activity against Rift Valley fever virus MP-12 assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1186434	Inhibition of HCV RNA replication in human Li23 cells (ORL8 system) in presence of 1 IU/mL IFN-alpha by renilla luciferase reporter gene based replication assay	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Synthesis and inhibitory activity on hepatitis C virus RNA replication of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analogs.
AID395966	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1075690	Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level at 81.9 uM after 8 to 10 days by quantitative PCR analysis	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	4'-Substituted pyrimidine nucleosides lacking 5'-hydroxyl function as potential anti-HCV agents.
AID1092193	In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana tabacum L. leaves assessed as protection effect at 100 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Oct-17, Volume: 60, Issue:41	Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of phenanthroindolizidines and their analogues.
AID1783389	Cytotoxicity against African green monkey Vero E6 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID99700	In vitro antiviral activity against Para 3 virus in human laryngeal epithelioma cell line	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID725579	Antiviral activity against Lassa virus infected in guinea pig strain 13 assessed as host survival rate at 80 mg/kg/day, ip administered at 1 hr prior to infection for 14 days relative to control	2013	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 23, Issue:3	Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole.
AID478322	Antiviral activity against Influenza A virus H3N2 assessed as inhibition of viral induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID463982	Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1186327	Cytotoxicity against mock-infected human MT4 cells after 96 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1783348	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction ass	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1772991	Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells incubated for 60 hrs by MTT assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID763858	Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza B virus (B/Florida/4/2006)	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.
AID370223	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID392504	Antiviral activity against Cowpox virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1660631	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.
AID1524780	Antiviral activity against influenza A virus A/Vietnam/1203/2004 x A/PR/8/34 (H5N1) harboring recombinant NS1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured on day 5 by Celltiter-Glo luminescence assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.
AID83889	Concentration required to reduce HSV-1 (KOS) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID217102	Percentage plaque reduction was determined against rift valley fever(RVF) virus in african green monkey kidney (vero,V) at a conc of 100-250 ug/mL. Toxic level(>1000 ug/mL); 31-60	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID1081158	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 500 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID224918	Concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity by 50% in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID229234	Antiviral activity against vesicular stomatitis virus (VSV) in HeLa cell culture lines,	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID489679	Cytotoxicity against human HeLa cells after 3 days by MTS assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Benzylidene/2-chlorobenzylidene hydrazides: synthesis, antimicrobial activity, QSAR studies and antiviral evaluation.
AID87156	Minimum inhibitory concentration against polio virus 1 in HeLa cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID1246932	Cytotoxicity against MDCK cells assessed as cell viability by neutral red assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Synthesis and antiviral activity of some new bis-1,3-thiazole derivatives.
AID476929	Human intestinal absorption in po dosed human	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID427554	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1432502	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 40 hrs	2017	Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6	Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses.
AID228410	Concentration required to reduce reovirus type 1 induced cytopathogenicity by 50% in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID324822	Antiviral activity against YFV Jimenez infected in Syrian golden hamster liver treated 4 hrs before viral challenge assessed as mean day to death at 50 mg/kg/day, ip bid for 8 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of T-1106 in a hamster model of yellow Fever virus infection.
AID535509	Transport through ENT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID216181	Tested for inhibitory effect on RNA virus SFV in Vero cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID87131	Antiviral activity was measured against Coxsackie virus B4 in HeLa cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID1767877	Antiviral activity against Influenza A virus (H1N1) infected in dog MDCK cells assessed as inhibition of surface glycoprotein hemagglutinin	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1.
AID217902	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against parainfluenza 3 virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID85570	Minimum inhibitory concentration required to reduce Herpes simplex virus type 1 (HSV-1, strain KOS) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID1542953	Antiviral activity against Zika virus MR766 infected in African green monkey Vero E6 cells assessed as reduction in virus yield	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication.
AID217270	Minimum inhibitory concentration required to elicit microscopically visible cell morphology in Vero cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID1498119	Antiviral activity against Parainfluenza virus 3 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID593224	Cytotoxicity against african green monkey Vero cells	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
AID535528	Transport through CNT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID478323	Antiviral activity against Influenza A virus H3N2 assessed as cell viability by cell based MTS assay	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID768193	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID63768	The minimum inhibitory concentration was measured on E6SM cells for morphological alteration	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID370208	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID575244	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Washington/01/2007(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analy	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1171741	Cytotoxicity against human Hep2 cells after 48 hrs	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Anti-respiratory syncytial virus prenylated dihydroquinolone derivatives from the gorgonian-derived fungus Aspergillus sp. XS-20090B15.
AID1687962	Antiproliferative activity against rat C6 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID634835	Antiviral activity against Felid herpesvirus 1 infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1485255	Cytotoxicity against African green monkey Vero cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID434308	Antiviral activity against Herpes simplex virus 2 infected in HEL cells assessed as protection against in virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID87502	Evaluation for antiviral activity against herpes simplex virus type 1 (strain KOS) in primary rabbit kidney cell culture	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Structure-activity relationship of novel oligopeptide antiviral and antitumor agents related to netropsin and distamycin.
AID1140807	Antiviral activity against BVDV AV-69 infected in MDBK cells assessed as cytopathic effect after 3 to 4 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Synthesis and anti-BVDV activity of novel δ-sultones in vitro: implications for HCV therapies.
AID674872	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1))	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors.
AID1261316	Antiviral activity against human RSV infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by plaque reduction assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID66001	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (196) strain of HSV-2 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID1261310	Cytotoxicity against BHK cells assessed as cell viability after 48 to 96 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID535505	Transport through ENT2 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID551034	Antiviral activity against Tobacco mosaic virus after 72 hrs by half-leaf juice rubbing method	2011	Bioorganic & medicinal chemistry letters, Jan-01, Volume: 21, Issue:1	Bitriazolyl acyclonucleosides synthesized via Huisgen reaction using internal alkynes show antiviral activity against tobacco mosaic virus.
AID1113456	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1377335	Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells measured after 48 hrs post infection by plaque reduction assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity.
AID569237	Antiviral activity against HCMV Davis infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID300564	Antiviral activity against influenza B/Sichuan/83/2000 virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID1408326	Antiviral activity against Influenza A virus A/HK/7/87(H3N2) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1498121	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID768195	Cytotoxicity against human HeLa cells	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID301701	Inhibition of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form expressed in Escherichia coli JM109	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID383517	Antiviral activity against Vaccinia virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1082879	Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 500 ug/mL at 25 degC after 72 hr by half-leaf method	2012	Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23	Design, synthesis, antiviral activity, and SARs of 14-aminophenanthroindolizidines.
AID1229768	Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells incubated for 48 hrs assessed as inhibition of virus-induced cytopathic effect by crystal violet staining assay	2015	Journal of natural products, Jun-26, Volume: 78, Issue:6	Chrodrimanins I and J from the Antarctic Moss-Derived Fungus Penicillium funiculosum GWT2-24.
AID1638588	Antiviral activity against West Nile virus infected in African green monkey Vero cells incubated for 4 days by crystal violet staining based plaque reduction assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.
AID284539	Antiviral activity against Punta Toro virus-induced cytopathogenicity in Vero cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID1055980	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 2 log10 reduction of virus yield after 24 hrs by RT-PCR analysis	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1398130	Antiviral activity against Influenza A virus (A/Aichi/2/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 48 hrs by crystal violet staining based method	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Generation of methylated violapyrones with improved anti-influenza A virus activity by heterologous expression of a type III PKS gene in a marine Streptomyces strain.
AID1450225	Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID392527	Antiviral activity against influenza H1N1 virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID658615	Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID301692	Inactivation of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 at 100 uM	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID1408332	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID345881	Antiviral activity against HCV in human HuH5.2 cells assessed as inhibition of replicon replication	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity.
AID1716975	Antiviral activity against GFP-fused wild-type RSV subgroup A Long infected in human HEp-2 cells measured 24 to 72 hrs post infection by fluorescence assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID1710776	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID567525	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Imidazo[2,1-b]thiazole carbohydrate derivatives: Synthesis and antiviral activity against Junin virus, agent of Argentine hemorrhagic fever.
AID320046	Antiviral activity against influenza B virus expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Three-component, one-pot synthesis of novel 2,4-substituted 5-azolylthiopyrimidine library for screening against anti-influenza virus A.
AID416782	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID482705	Antiviral activity against VSV infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID1082992	Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus infection curative effect at 500 ug/mL measured 3 to 4 days post inoculation	2012	Journal of agricultural and food chemistry, Sep-05, Volume: 60, Issue:35	Design, synthesis, and antiviral activity evaluation of phenanthrene-based antofine derivatives.
AID280192	Antiviral activity against VSV in E6SM cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID1436806	Antiviral activity against Coxsackievirus A16 shzh05-1 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID216381	In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and Vesicular stomatitis virus control cells	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Synthesis and antiviral/antitumor activities of certain 3-deazaguanine nucleosides and nucleotides.
AID1360701	Cytotoxicity against human HeLa cells assessed as alterations in normal cell morphology measured after 3 to 6 days by microscopic analysis	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID1594642	Selectivity index, ratio of CC50 for cytotoxicity in BHK cells to IC50 for antiviral activity against Dengue virus 1 DGL2 replicon infected in BHK cells	2019	Bioorganic & medicinal chemistry, 06-01, Volume: 27, Issue:11	Synthesis and biological evaluation of novel imidazole nucleosides as potential anti-dengue virus agents.
AID357950	Cytotoxicity against human Hep2 cells	2001	Journal of natural products, Oct, Volume: 64, Issue:10	New antiviral cassane furanoditerpenes from Caesalpinia minax.
AID369862	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as protection against viral infection at 75 mg/kg, po twice daily for 5 to 7 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370219	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID634755	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID66006	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Mc Intyre) strain of HSV-1 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID216366	Antiviral activity against parainfluenza 3 virus infected Vero cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID68124	Concentration required to reduce vesicular stomatitis virus(VSV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID474551	Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza B virus Malaysia/2506/2004 by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID361408	Antiviral activity against Encephalomyocarditis virus EMC infected in human HeLa assessed as inhibition of virus-induced cytopathic effect after 2 days by MTT assay	2002	Journal of natural products, Nov, Volume: 65, Issue:11	New saponins from the starfish Certonardoa semiregularis.
AID634761	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID221963	Compounds was tested for the effect of L-nucleosides of ribavirin on SEB (staphylococcal enterotoxin B)-stimulated T-cell expression of the type 1 cytokine IFN-gamma	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Monocyclic L-nucleosides with type 1 cytokine-inducing activity.
AID776643	Cytotoxicity against mouse X5563 cells assessed as growth inhibition	2013	European journal of medicinal chemistry, Nov, Volume: 69	Pyrazole containing natural products: synthetic preview and biological significance.
AID1450218	Antiviral activity against HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID199168	Minimum inhibitory concentration required to reduce reo virus type 1 induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID419593	Antiviral activity against HSV2 G infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID472794	Antiviral activity against RSV A2 infected in african green monkey Vero cells after 5 days by plaque reduction assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID1505492	Cytotoxicity against MDCK cells assessed as change in cell morphology after 3 days by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID475851	Cytotoxicity against human HEL cells	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID86513	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HeLa cell line infected with polio 1 virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID1660634	Selectivity index, ratio of CC50 for cytotoxicity in dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by crystal violet staining based assay to IC50 for cytotoxicity in dog MDCK cells assessed as reduction in cell viability incu	2020	Journal of medicinal chemistry, 07-09, Volume: 63, Issue:13	Chemoreactive-Inspired Discovery of Influenza A Virus Dual Inhibitor to Block Hemagglutinin-Mediated Adsorption and Membrane Fusion.
AID257894	Antiviral activity against Parainfluenza-3 virus in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID87339	Compound was tested for antiviral activity in HeLa Cell cultures, against herpes simplex virus type 1 (HSV-1), cytopathic effect induced by the virus (CPE)	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Synthesis and antiviral evaluation of nucleosides of 5-methylimidazole-4-carboxamide.
AID659154	Antiviral activity against Human immunodeficiency virus 1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID434310	Antiviral activity against sVesicular stomatitis virus infected in HEL cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID1336609	Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones.
AID86834	concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID68119	Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(B2006) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID588218	FDA HLAED, lactate dehydrogenase (LDH) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1205001	Antiviral activity against Coxsackievirus B1 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID1724447	Cytotoxicity against human Huh7.5 cells assessed as decrease in cell viability after 3 days by MTT assay	2020	Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19	SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
AID1852999	Cytotoxicity against paclitaxel-resistant human HCT116tax cells incubated for 48 hrs by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID370204	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID436478	Antiviral activity against Bovine viral diarrhea virus infected in MDBK cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID472785	Cytotoxicity against BHK cells after 48 to 96 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID1716977	Safety index, ratio of CC50 for human HEp-2 cells to EC50 for GFP-fused wild-type RSV subgroup A long infected in human HEp-2 cells	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID569239	Cytotoxicity against HEL cells after 3 days by coulter counter analysis	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID1436805	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B6 (strain Schmitt) infected in African green monkey Vero cells	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID611772	Cytotoxicity against human CEM cells assessed as growth inhibition after 3 days by coulter counting analysis	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID588209	Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset	2010	Chemical research in toxicology, Jul-19, Volume: 23, Issue:7	Developing structure-activity relationships for the prediction of hepatotoxicity.
AID1729931	Inhibition of RdRP activity in Influenza A virus A/PR/8/34 (H1N1) infected in HEK293T cells co-transfected with NP/PA/PB1/PB2/pPolI-Flu-ffLuc/pRL-SV40 incubated for 24 hrs by minireplicon based dual luciferase assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase.
AID257471	Antiviral activity against influenza A H3N2 virus in MDCK cells	2005	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23	Synthesis and biological evaluation of novel bisheterocycle-containing compounds as potential anti-influenza virus agents.
AID1081200	Antiviral activity against Tobacco mosaic virus (TMV) infected leaves assessed as viral inhibition at 100 ug/mL at 25 degC for 72 hr	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis, crystal structure, and biological activity of 4-methyl-1,2,3-thiadiazole-containing 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID443827	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID474340	Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Duck/MN/1525/81/H5N1 by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1501508	Antiviral activity against EV71 Xiangyang-Hubei-09 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect at 16 ug/ml treated 1 hr post viral infection measured after 48 hrs by MTT dye based assay relative to control
AID1081545	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 100 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID105792	Antiviral activity against influenza B virus infected MDCK cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1650128	Antiviral activity against Influenza A virus H3N2 A/HK/7/87 infected in MDCK cells assessed as reduction in virus induced cytopathic effect after 4 days by microscopy based method	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID383532	Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID218401	Minimum inhibitory concentration required to reduce Coxsackie virus B4 induced cytopathogenicity by 50% in african green monkey (VeroB) cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID1699937	Selectivity index, ratio of CC50 for dog MDCK cells to IC50 for Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	New type of anti-influenza agents based on benzo[d][1,3]dithiol core.
AID297316	Antiviral activity against Vaccinia virus in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID464002	Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID370206	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1610160	Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1181494	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID224347	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vesicular stomatitis virus in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID82043	Antiviral activity against vesicular stomatitis virus infected HEF cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID216410	Evaluated for minimum inhibitory concentration against Vesicular stomatitis virus (VSV) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID216407	Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells vesicular stomatitis virus (VSV)	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID463993	Antiviral activity against acyclovir-sensitive Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID217870	Therapeutic index against Venezuelan equine encephalomyelitis virus.	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of 5-thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides.
AID1716986	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in MDCK cells measured after 24 hrs by Gaussia luciferase reporter gene method	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID1687964	Antiproliferative activity against human SK-OV-3 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID345882	Cytotoxicity against human HuH5.2 cells	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity.
AID774117	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect after 48 hrs by Reed-Muench analysis	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Diterpenoids and sesquiterpenoids from the roots of Illicium majus.
AID1578002	Cytotoxicity against MDCK cells assessed as reduction in cell viability incubated for 48 hrs	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents.
AID535524	Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and thymidine	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID442291	Antiviral activity against HCV infected in hamster brain assessed as subacute sclerosing panencephalitis	2010	European journal of medicinal chemistry, Feb, Volume: 45, Issue:2	Synthesis, anti-HCV, antioxidant, and peroxynitrite inhibitory activity of fused benzosuberone derivatives.
AID105978	In vitro antiviral activity against influenza virus (type A0/PR/8/34) in Madin-Darby canine kidney (MDCK) host cell cultures (MTC/ID50)	1990	Journal of medicinal chemistry, Apr, Volume: 33, Issue:4	Synthesis and biological evaluation of carbocyclic analogues of lyxofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines.
AID1135743	Antiviral activity against Adenovirus type 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Synthesis and antiviral acticity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin).
AID1409406	Antiviral activity against Influenza A virus A/duck/Guangdong/674/2014(H5N6) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID369867	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 75 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID533321	Selectivity Index, ratio of CC50 for TIZ-9 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in TIZ-9 replicon cell	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID634756	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1873813	Cytotoxicity against human Huh7-J20 cells assessed as reduction in cell viability by MTS assay	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID611770	Cytotoxicity against dog MDCK cells assessed as alteration of cell morphology after 3 days by microscopy	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID588219	FDA HLAED, gamma-glutamyl transferase (GGT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1853006	Cytotoxicity against human wild type HCT-116 cells assessed as reduction on cell viability at 100 to 200 uM incubated for 48 hrs in presence of paclitaxel by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID575250	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza B virus B/Memphis/20/1996 infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID419599	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID436477	Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID392536	Antiviral activity against Vaccinia virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID432184	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID673223	Cytotoxicity against human HuH7 cells assessed as cell viability at 10 uM after 3 days by CellTiter Glo assay	2012	Bioorganic & medicinal chemistry, Aug-01, Volume: 20, Issue:15	C-6 aryl substituted 4-quinolone-3-carboxylic acids as inhibitors of hepatitis C virus.
AID1873818	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTS assay	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID395680	Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Junin virus Candid-1	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1485247	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID86484	Minimum inhibitory conc. for 50% inhibition of vesicular stomatitis virus induced cytopathicity in HeLa cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID1408322	Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID427555	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID278038	Antiviral activity against RSV A2 in MA104 cells by plaque reduction assay	2007	Journal of natural products, Feb, Volume: 70, Issue:2	Dysoxylins A-D, tetranortriterpenoids with potent anti-RSV activity from Dysoxylum gaudichaudianum.
AID555930	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 2 passages at 30 ug/ml by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID1716984	Safety index, ratio of CC50 for HEK293T cells to EC50 for antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human HEK293T cells	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID1853001	Cytotoxicity against human HCT-116 cells overexpressing human BCRP incubated for 48 hrs by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1853003	Cytotoxicity against human HCT-116 cells assessed as reduction on cell viability at 100 uM incubated for 48 hrs in presence of paclitaxel by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID370218	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1253097	Selectivity index, ratio of CC50 for human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene incubated for 1 hr to EC50 for HCV JFH1 infected in human HuH7-J20 cells preincubated with cells for 1 hr followed by viral inoculation for 3	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents.
AID217479	Minimum inhibitory concentration required to reduce vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID1687958	Antiproliferative activity against human CaCo-2 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID369462	Antiviral activity against Punta Toro virus Adames assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID216538	The minimum inhibitory concentration required to reduce VSV induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID370199	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID257898	Antiviral activity against Punta Toro virus in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1647357	Antiviral activity against Chikungunya virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors.
AID218128	Minimum inhibitory concentration against Vaccinia virus	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID249265	Minimum inhibitory concentration against vesicular stomatitis virus was determined	2005	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6	QSAR for anti-RNA-virus activity, synthesis, and assay of anti-RSV carbonucleosides given a unified representation of spectral moments, quadratic, and topologic indices.
AID611627	Antiviral activity against HIV 1 3B infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1542955	Selectivity index, ratio of CC50 for African green monkey Vero B cells to EC50 for Dengue virus type 2 NGC infected in African green monkey Vero B cells	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication.
AID717173	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1472402	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) clone 1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity measured after 3 passages with 12.5 to 50 uM 2-Isopropyl-N-[2-(piperidin-1-yl)ethyl]aniline hydroc	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID539958	Antiviral activity against influenza B virus infected in MDCK cells assessed as cell viability after 2 days by MTS assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID106224	Tested for inhibitory effect on RNA virus HIV-2 in MT-4 cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID434315	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID1131474	Antiviral activity against Vesicular stomatitis virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Synthesis and determination of antiviral activity of the 2'(3')-O-methyl derivatives of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide).
AID1688554	Selectivity index, ratio of CC50 for human Huh7.5 cells to EC50 for HCV genotype 2a JFH-1 infected in human Huh7.5 cells	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment.
AID1133181	Antiviral activity against Parainfluenza virus 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.
AID464179	Cytotoxicity against Herpes simplex virus 2 G infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1433143	Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID539921	Antiviral activity against Para influenza-3 virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID396874	Antiviral activity against Venezuelan equine encephalomyelitis virus infected in african green monkey Vero cells assessed as plaque reduction at 250 ug/mL
AID223406	Antiviral activity is expressed as virus rating (VR) against the influenza Ao/PR/8/34 virus strain	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and antiviral evaluation of carbocyclic analogues of 2-amino-6-substituted-purine 3'-deoxyribofuranosides.
AID395945	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID611763	Antiviral activity against Sindbis virus infected in Vero cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1503655	Cytotoxicity against human HuH7 cells assessed as growth inhibition after 3 days by XTT method	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents.
AID235606	Ratio of minimum drug concentration to ID50 of the compound (Najayama strain)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.
AID54500	The minimum inhibitory concentration required to reduce Coxsackie virus type B4 induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID288916	Antiviral activity against HSV1 KOS in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID1076998	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus jifang/13/97	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID396876	Antiviral activity against Sandfly fever virus assessed as plaque reduction at 250 ug/mL
AID535518	Transport through CNT3 in rat hepatocytes by oil filtration assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID246174	Anti BVDV activity in MDBK (Madin-darby bovine kidney) cells	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Synthesis of benzodithiol-2-yl-substituted nucleoside derivatives as lead compounds having anti-bovine viral diarrhea virus activity.
AID395699	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID436486	Antiviral activity against Human poliovirus 1 strain Sabin after 2 days by plaque reduction assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID278352	Decrease in GTP level in Vero E6 cells at 10 ug/ml	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID1081547	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 100 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID217990	Minimum cytotoxic concentration against vaccinia virus in HeLa cell cultures	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1436797	Antiviral activity against Coxsackievirus B2 (strain Ohio-1) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID546576	Inhibition of recombinant GSK3-beta at 10 uM by Z'-LYTE kinase assay kit method	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
AID301697	Binding to human recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID1131477	Antiviral activity against Poliovirus type 1 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Synthesis and determination of antiviral activity of the 2'(3')-O-methyl derivatives of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide).
AID1436807	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus A16 shzh05-1 infected in African green monkey Vero cells	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID88685	Tested for inhibitory effect on RNA virus Polio-1 in HeLa cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1773047	Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of IRF3 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 4 days post infection by RT-PCR analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID235603	Ratio of minimum drug concentration to ID50 of the compound(Adems strain)	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.
AID1204074	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by MTT method	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.
AID395713	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID751302	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in dog MDCK cells after 3 days by CPE assay	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Asperterrestide A, a cytotoxic cyclic tetrapeptide from the marine-derived fungus Aspergillus terreus SCSGAF0162.
AID216180	Tested for inhibitory effect on RNA virus Reo-1 in Vero cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1168656	Antiviral activity against Dengue virus	2014	European journal of medicinal chemistry, Nov-24, Volume: 87	A perspective on targeting non-structural proteins to combat neglected tropical diseases: Dengue, West Nile and Chikungunya viruses.
AID1696830	Antiviral activity against Influenza A virus (A/Duck/Guangdong/212/2004(H5N1)) infected in A549 cells assessed as reduction in virus-induced cytopathic effect by CPE reduction assay	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Structure-aided optimization of 3-O-β-chacotriosyl epiursolic acid derivatives as novel H5N1 virus entry inhibitors.
AID217967	In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and Vaccinia virus control cells	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Synthesis and antiviral/antitumor activities of certain 3-deazaguanine nucleosides and nucleotides.
AID283441	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1415634	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in viral titer preincubated with cells for 1 hr followed by viral inoculation and measured after 48 hrs by hemagglutination test	2017	MedChemComm, May-01, Volume: 8, Issue:5	Synthesis and
AID543663	Selectivity index, ratio of CC50 for African green monkey vero cells to EC90 for Yellow fever virus 17D	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1710802	Cytotoxicity against human MT4 cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID543676	Toxicity in syrian golden hamster infected with 10'2 CCID50 Yellow fever virus Jimenez assessed as weight change at 10 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID66939	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-1 virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID1135867	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in MDCK cells at 1 mg/ml by agar diffusion method	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID1436804	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B5 Faulkner infected in African green monkey Vero cells	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID65711	Antiviral activity against herpes simplex virus-2 G (HSV-2) in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID87144	Tested for cytotoxic activity in human epithelial cell line (HeLa)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID1736919	Antiviral activity against Influenza A virus (A/Duck/Guangdong/674/2014 (H5N6)) group-2 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hem	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID288933	Antiviral activity against Punta Toro virus in vero cells	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID370222	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID665016	Inhibition of IMPDH in mouse L1210 cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations.
AID94049	Tested for the antimicrobial activity minimum inhibitory concentration) against Klebsiella pneumoniae	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID432180	Antiviral activity against Parainfluenza virus type 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID1503656	Selectivity index, ratio of CC50 for human HuH7 cells to IC50 for Fluc-tagged DENV2 strain 16681 infected in human HuH7 cells	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents.
AID1498123	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID345883	Antiviral activity against HCV in human Huh9.13 cells assessed as inhibition of replicon replication	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity.
AID474355	Antiviral activity against Influenza A virus Solomon Islands/03/2006/H1N1 infected MDCK cells after 3 days by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID1234159	Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect incubated for 48 hrs by crystal violet staining based assay	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Antiviral Limonoids Including Khayanolides from the Trang Mangrove Plant Xylocarpus moluccensis.
AID436482	Antiviral activity against Coxsackie virus type B2 virus infected in african green monkey Vero-76 cells after 3 days by plaque reduction assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID548447	Antiviral activity against Reovirus 1 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1066045	Antiviral activity against influenza A virus A/Padova/72/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID1150892	Antiviral activity against Parainfluenza virus type 3 infected in human KB cells	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Synthesis of 1-(4-thio-beta-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide.
AID659147	Antiviral activity against thymidine kinase-deficient Herpes simplex virus 1 infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID434319	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID156707	Evaluation for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID68256	Minimum inhibitory concentration required for antiviral activity to reduce Vesicular stomatitis virus (VSV) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID464184	Cytotoxicity against Reovirus 1 infected african green monkey Vero cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID156702	Evaluation for antiviral activity against herpes simplex virus-1(F) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID87672	In vitro antiviral activity was tested against herpes simplex type 2 (HSV-2)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of 5-thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides.
AID395953	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID218131	The minimum inhibitory concentration required to reduce vaccinia virus induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID1890795	Cytotoxicity against human HEK293T cells assessed as cell viability after 48 hrs by CCK-8 assay	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and anti-influenza A virus activity evaluation of novel indole containing derivatives of triazole.
AID588210	Human drug-induced liver injury (DILI) modelling dataset from Ekins et al	2010	Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12	A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID659290	Cytotoxicity against african green monkey Vero cells assessed as morphological changes by microscopic analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID1433144	Antiviral activity against Reovirus-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID1498124	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1731879	Selectivity index, ratio of CC50 for cytotoxicity against human HEK-293T cells to IC50 for antiviral activity against Influenza A virus A/WSN/33(H1N1) expressing mGFP infected in HEp-2 cells	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Synthesis and antiviral activity of a series of novel quinoline derivatives as anti-RSV or anti-IAV agents.
AID395958	Toxicity in Pichinde virus An 4763 infected po dosed Syrian golden hamster administered twice daily 72 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1081156	Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 100 ug/ml	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID659148	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID1542952	Cytotoxicity in African green monkey Vero B cells assessed as reduction in cell viability by MTS assay	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication.
AID1186333	Antiviral activity against Reovirus type-1 infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID395949	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID217563	concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID155590	Inhibitory dose against Parainfluenza type 3 viral strain Huebner C243 in H.Ep-2 cell line	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities.
AID539918	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID395968	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1092198	In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana tabacum L. leaves assessed as inactivation effect at 500 ug/mL co-incubated with virus measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Oct-17, Volume: 60, Issue:41	Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of phenanthroindolizidines and their analogues.
AID474344	Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Hong Kong/213/2003/H5N1	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID108459	In vitro antiviral activity was tested against, measles virus	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID1886802	Cytotoxicity against golden hamster BHK-21 cells measured after 6 days by MTT assay	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID345885	Antiviral activity against HCV in human HuH6 cells assessed as inhibition of replicon replication	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity.
AID283440	Inhibition of influenza A virus (A/duck/Minnesota/1525/1981 (H5N1)) replication in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1179390	Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity	2014	Bioorganic & medicinal chemistry, Jul-15, Volume: 22, Issue:14	Design, synthesis, antiviral and cytostatic activity of ω-(1H-1,2,3-triazol-1-yl)(polyhydroxy)alkylphosphonates as acyclic nucleotide analogues.
AID82041	Antiviral activity against vaccinia virus infected HEF cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1773015	Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as reduction in cleaved caspase-3 expression measured after 60 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID474547	Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Wisconsin/67/2005/H3N2 by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID658746	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID402750	Antiviral activity against respiratory syncytial virus A2 in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect	1998	Journal of natural products, Oct, Volume: 61, Issue:10	New iridoids from the medicinal plant Barleria prionitis with potent activity against respiratory syncytial virus.
AID395942	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection measured on day 7 of vi	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1495715	Selectivity index, ratio of CC50 for MDCK cells to IC50 for amantadine/rimantadine-resistant Influenza A virus (A/Puerto Rico/8/34(H1N1))	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Highly potent activity of isopulegol-derived substituted octahydro-2H-chromen-4-ols against influenza A and B viruses.
AID611761	Antiviral activity against Parainfluenza virus 3 infected in Vero cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID659152	Antiviral activity against Coxsackie virus B4 infected in HeLa cells	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID767052	Antiviral activity against Adenovirus type 7 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID474544	Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Solomon Islands/03/2006/H1N1 by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1127184	Cytotoxicity against human HuH7 cells assessed as cell viability after 3 days by XTT assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives.
AID99706	In vitro antiviral activity against V V virus in human laryngeal epithelioma cell line	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID1379365	Toxicity in ICR mouse infected with EV71 695F assessed as death at 50 mg/kg, ip qd administered for 7 days measured on day 6	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD.
AID1113458	Antiviral activity against Sendai virus infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1379348	Inhibition of Enterovirus 71 Shenzhen/120F1/09 capsid infected in human RD cells assessed as reduction in virus-induced cell death after 72 hrs by CCK-8 assay	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD.
AID1126468	Antiviral activity against Enterovirus 71 BrCr infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 4 days by MTT assay	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Prenylated benzoylphloroglucinols and xanthones from the leaves of Garcinia oblongifolia with antienteroviral activity.
AID717169	Cytotoxicity against dog MDCK cells assessed as cell viability by MTS assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID718741	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID283988	Antiviral activity against encephalomyocarditis virus by CPE assay	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Design, synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives.
AID427558	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID659150	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID297315	Antiviral activity against HSV2 G in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID105806	Minimum toxic concentration required to cause a microscopically detectable alteration of normal MDCK cell morphology	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID407615	Cytotoxicity against human Huh-5-2 cells	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication.
AID1118651	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID105976	In vitro minimum drug concentration that inhibited the influenza virus-induced cytopathogenic effects by 50% in Madin-Darby canine kidney (MDCK) host cell cultures	1990	Journal of medicinal chemistry, Apr, Volume: 33, Issue:4	Synthesis and biological evaluation of carbocyclic analogues of lyxofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines.
AID84599	In vitro antiviral activity was tested against, herpes simplex type 2 virus (HSV-2)	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID1501505	Selectivity index, ratio of CC50 for human RD cells to EC50 for EV71 Xiangyang-Hubei-09 infected in human RD cells
AID1503651	Antiviral activity against Fluc-tagged DENV2 strain 16681 infected in human HuH7 cells assessed as inhibition of viral replication at 10 uM after 3 days by luciferase reporter gene assay relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents.
AID588216	FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID648649	Selectivity index, ratio of TC50 for MDCK cells to IC50 for influenza A virus H3N2	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Synthesis and anti-influenza activity of aminoalkyl rupestonates.
AID1081162	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 500 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID1873814	Antiviral activity against Huh 7.5 cell culture derived HCV genotype 2a (JFH-AM71) infected in human Huh7-J20 cells assessed as inhibition of viral replication at 100 uM treated for 72 hrs by SEAP reporter gene assay relative to control	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID401227	Antiviral activity against PIV3 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2004	Journal of natural products, Apr, Volume: 67, Issue:4	Antiviral flavonoids from the seeds of Aesculus chinensis.
AID1571470	Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	Synthesis of d-(+)-camphor-based
AID216392	Minimum inhibitory concentration against Vesicular stomatitis virus	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID634833	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID284533	Antiviral activity against HSV1 TK- KOS ACV-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID86500	The compound was tested for antiviral activity against VSV-virus in human epithelial cells	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID1252404	Antiviral activity against Reovirus 1 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of L-ascorbic or imino-L-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations.
AID280199	Antiviral activity against sindbis virus in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID569233	Antiviral activity against HSV2 G infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID1736917	Antiviral activity against Influenza A virus (A/goose/Guangdong/SH7/2013(H5N1)) group-1 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hem	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID249870	Anti-bovine viral diarrhoea virus activity relative to ribavirin	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Synthesis of benzodithiol-2-yl-substituted nucleoside derivatives as lead compounds having anti-bovine viral diarrhea virus activity.
AID1377336	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	2017	European journal of medicinal chemistry, Sep-29, Volume: 138	Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity.
AID634749	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID288918	Antiviral activity against Vaccinia virus in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID396941	Antiviral activity against VSV assessed as reduction in plaque formation at 100 ug
AID105769	Inhibitory concentration against influenza virus A in MDCK cells	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID257895	Antiviral activity against Reovirus 1 in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID718740	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID634090	Antiviral activity against HCV genotype 1b infected in human HuH7 cells after 3 days by renilla luciferase reporter assay	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID474341	Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Gull/PA/4175/83/H5N1	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID283445	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1778629	Inhibition of RdRP activity in Influenza A virus A/PR/8/34(H1N1) infected in HEK293T cells incubated for 24 hrs by minireplicon based dual luciferase assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors.
AID1082872	In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana. tabacum L. leaves assessed as protection effect at 100 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23	Design, synthesis, antiviral activity, and SARs of 14-aminophenanthroindolizidines.
AID464175	Cytotoxicity against VSV infected human HeLa cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1132045	Antibacterial activity against Staphylococcus aureus Oxford	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID432171	Antiviral activity against Vaccinia virus infected in in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID1651273	Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as reduction in viral induced cytopathic effect	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Design, synthesis, and evaluation of novel 4-amino-2-(4-benzylpiperazin-1-yl)methylbenzonitrile compounds as Zika inhibitors.
AID1092195	In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana tabacum L. leaves assessed as curative effect at 100 ug/mL measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Oct-17, Volume: 60, Issue:41	Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of phenanthroindolizidines and their analogues.
AID300569	Survival of mouse at 100 mg/kg, ip bid after 5 days	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID376986	Cytotoxicity against MDCK cells after 3 days by MTT reduction assay	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID1261341	Antiviral activity against VSV	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID436484	Antiviral activity against HSV1 infected in Vero-76 cells after 3 days by plaque reduction assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID88351	Compound was evaluated for its inhibitory effect on the replication of vesicular stomatitis virus (VSV) in HeLa cells	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	Synthesis and biological evaluation of thymine nucleosides fused with 3',4'-tetrahydrofuran ring.
AID105776	Tested for inhibitory effect on RNA virus Influenza B in MDCK cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID229059	Concentration required to cause a microscopically detectable alteration in cell morphology in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID533314	Antiviral activity against HCV genotype 1b in NTZ-11 replicon cell after 4 days by blot hybridization analysis	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID87351	Compound was tested for antiviral activity in HeLa Cell cultures, against herpes simplex virus type 1 (HSV-1)	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Synthesis and antiviral evaluation of nucleosides of 5-methylimidazole-4-carboxamide.
AID475855	Antiviral activity against Vaccinia virus lederle infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID275068	Antiviral activity against HSV2 in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID1077004	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/FM/1/1947(H1N1))	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID199875	Virus rating against rhinovirus type 1A	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Analysis of the in vitro antiviral activity of certain ribonucleosides against parainfluenza virus using a novel computer aided receptor modeling procedure.
AID156709	Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID432176	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID1118656	Cytotoxicity against MDCK cells assessed as concentration required to cause microscopically visible alternation of cell morphology	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID611757	Antiviral activity against VSV infected in HeLa cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID32219	Minimum inhibitory concentration of the compound, achieving a complete protection of ATH8 cells against the cytopathic effect of HTLV-III / LAV reverse transcriptase	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID1265173	Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of nsP1 protein expression at 5 uM measured at 24 hrs postinfection by Western blot method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID766695	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1873817	Selectivity index, ratio of CC50 for cytotoxicity against human Huh-7 J20 cells assessed as reduction in cell viability to IC50 for antiviral activity against Huh 7.5 cell culture derived HCV genotype 2a (JFH-AM71) infected in human Huh7-J20 cells assesse	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID402534	Cytotoxicity against MDCK cells by neutral red assay	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus.
AID275067	Antiviral activity against HSV1 KOS in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID658607	Cytotoxicity against MDCK cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID217561	concentration required to inhibit Punta Toro virus-induced cytopathicity by 50% in Vero cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID1498134	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1427857	Antiviral activity against Influenza A virus A/95-359 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect
AID1081202	Antiviral activity against Tobacco mosaic virus (TMV) infected leaves assessed as viral inhibition at 500 ug/mL at 25 degC for 72 hr	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis, crystal structure, and biological activity of 4-methyl-1,2,3-thiadiazole-containing 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID383516	Antiviral activity against Vaccinia virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID432183	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID419591	Cytotoxicity against human HEL cells assessed as alteration in cell morphology	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID634831	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID21263	Permeability coefficient reported (Expressed as Permeability coefficient x 10 e 4 cm/s)	1996	Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24	Computation of brain-blood partitioning of organic solutes via free energy calculations.
AID472783	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID611769	Cytotoxicity against african green monkey Vero cells assessed as alteration of cell morphology after 3 days by microscopy	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID421728	Antiviral activity against Parainfluenza virus type 3 infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Antiviral constituents against respiratory viruses from Mikania micrantha.
AID539916	Antiviral activity against Herpes simplex virus-2 G infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1538477	Antiviral activity against Coxsackievirus A16 TA271 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect preincubated with viral suspension for 2 hrs followed by cell addition and measured after 24 hrs by CCK-8 assay	2019	Journal of natural products, 05-24, Volume: 82, Issue:5	Effects of Acetylshikonin on the Infection and Replication of Coxsackievirus A16 in Vitro and in Vivo.
AID548423	Cytotoxicity against human HEL cells assessed as altered cell morphology	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID539949	Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID718739	Toxicity in MDCK cells assessed as induction of cell morphology changes	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID468093	Antiviral activity against SFV infected in BHK cells after 14 hrs by luciferase reporter gene assay	2009	Journal of natural products, Nov, Volume: 72, Issue:11	Betulin-derived compounds as inhibitors of alphavirus replication.
AID535523	Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM inosine	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1186430	Inhibition of HCV RNA replication in human Li23 cells (ORL8 system) by renilla luciferase reporter gene based replication assay	2014	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17	Synthesis and inhibitory activity on hepatitis C virus RNA replication of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-2-propyl)aniline analogs.
AID1503319	Cytotoxicity against bovine MDBK cells assessed as decrease in cell viability after 72 hrs by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation.
AID275089	Cytotoxicity against Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID217564	concentration required to inhibit reovirus-1-induced cytopathicity by 50% in Vero cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID691394	Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells after 2 days by q-PCR analysis	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
AID416784	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID588217	FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1773423	Antiviral activity against Vesicular stomatitis virus Indiana infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured af	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study.
AID275073	Antiviral activity against para influenza 3 virus in Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID1135881	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to da	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID216347	Tested for antiviral activity against Reo-1 virus in African green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID1230107	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID593227	Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus A16	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
AID514140	Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication.
AID1753727	Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as inhibition of viral replication at 20 uM measured after 4 days relative to control	2021	Journal of natural products, 04-23, Volume: 84, Issue:4	Semisynthesis of Dolabellane Diterpenes: Oxygenated Analogues with Increased Activity against Zika and Chikungunya Viruses.
AID395932	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1773049	Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of TLR3 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID395972	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID105967	Minimum inhibitory concentration required to reduce influenza A H2N2 virus induced cytopathogenicity by 50% in madin-Darby canine kidney cells (MDCK)	2001	Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16	Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID324792	Antiviral activity against YFV Jimenez infected in Syrian golden hamster assessed as mean day to death after 21 days post-infection at 50 mg/kg, ip bid for 7 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of T-1106 in a hamster model of yellow Fever virus infection.
AID1261342	Antiviral activity against Vaccinia virus	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1398129	Antiviral activity against Influenza A virus (A/Virginia/ATCC1/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 48 hrs by crystal violet staining based method	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Generation of methylated violapyrones with improved anti-influenza A virus activity by heterologous expression of a type III PKS gene in a marine Streptomyces strain.
AID387602	Cytotoxicity against human HeLa cells assessed as alteration in cell morphology by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID659285	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID1433156	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID217268	Effective concentration required to inhibit reovirus-induced cytopathicity by 50% in Vero cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID527723	Cytotoxicity against human HuH7 cells after 2 days by XTT assay	2010	Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21	Synthesis and in vitro antiviral activities of 3'-fluoro (or chloro) and 2',3'-difluoro 2',3'-dideoxynucleoside analogs against hepatitis B and C viruses.
AID324823	Antiviral activity against YFV Jimenez infected in Syrian golden hamster liver treated 4 hrs before viral challenge assessed as alanine aminotransferase at 50 mg/kg/day, ip bid for 8 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of T-1106 in a hamster model of yellow Fever virus infection.
AID1205006	Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B2 infected in african green monkey Vero cells	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID376984	Antiviral activity against HSV1 15577 in african green monkey Vero cells assessed as reduction of virus induced cytopathic effect	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID216177	Tested for inhibitory effect on RNA virus Coxsackie B4 in Vero cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID257341	Selectivity index (toxicity/antiviral activity)	2005	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24	Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.
AID162252	Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells polio virus type 1	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID1773430	Selectivity index, ratio of CC50 for cytotoxicity against human A549 cells to EC50 for antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as reduction in virus titer treated 1 hr post viral infection followed by replacement wit	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study.
AID569236	Antiviral activity against HCMV AD169 infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID370200	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1154645	Cytotoxicity against mock-infected human Hep2 cells by XTT assay	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Antiviral C-25 epimers of 26-acetoxy steroids from the South China Sea gorgonian Echinogorgia rebekka.
AID1886810	Antiviral activity against DENV2 infected in hamster BHK-21 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well incubated for 6 days by crystal violet staining based assay	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID368962	Antiviral activity against RSV B infected human Hep2 cells after 5 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID535513	Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID369461	Antiviral activity against La Crosse virus assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID434318	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID71890	Tested for inhibitory effect on RNA virus cell growth in FM3A cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1435481	Antiviral activity against Coxsackievirus B3 Nancy infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Synthesis and evaluation of halogenated 12N-sulfonyl matrinic butanes as potential anti-coxsackievirus agents.
AID419596	Antiviral activity against thymidine kinase-deficient acyclovir-resistant HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID482710	Cytotoxicity against human HeLa cells by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID1505498	Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as change in cell morphology after 3 days by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID86684	Effective concentration required to inhibit vesicular stomatitis virus (VSV)-induced cytopathicity by 50% in HeLa cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID1782693	Cytotoxicity in human Hep2 cells assessed as reduction in cell viability measured after 3 days by beckman coulter counting method	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.
AID593225	Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B3	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
AID763861	Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/California/07/2009(H1N1))	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.
AID370212	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 10 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID294253	Antiviral activity against HCV in Huh7 ET cells assessed as HCV RNA derived luciferase activity at 10 uM by replicon assay relative to control	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Structure-activity relationship studies on anti-HCV activity of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.
AID312072	Ratio of kcat/Km of Poliovirus RNA dependent RNA polymerase incorporation into sym/sub-C primer relative to control	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity.
AID66941	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against TK- HSV-1 virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID1485238	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1118652	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID368957	Antiviral activity against RSV RSS infected human Hep2 cells assessed as inhibition of virus-induced cell death after 6 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID1783341	Cytotoxicity against human A549 cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID674873	Antiviral activity against Influenza B virus (strain B/Jifang/13/97) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors.
AID82052	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with vesicular stomatitis virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID87137	Evaluation in HeLa cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID87154	Minimum inhibitory concentration against Coxsackie virus B4 in HeLa cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID1135894	Cytotoxicity against MDCK cells infected with Influenza A virus Port Chalmers/1/73 (H3N2) after 3 days by carbol fuchsin staining-based assay	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID427551	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease T54A double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID96660	Dose required to inhibit proliferation of L-1210 Cells by 50%	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID94995	Evaluated for cell growth inhibition and induction of cellular differentiation of human myeloid leukemia cell line (K562)	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Growth inhibition and induction of cellular differentiation of human myeloid leukemia cells in culture by carbamoyl congeners of ribavirin.
AID1783340	Antiviral activity against Influenza A Puerto Rico/8/34/H1N1 infected in human A549 cells assessed as inhibition of viral replication after 24 hrs by hemagglutination assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID247999	Antiviral activity against Coxsackie virus B3 growth by 50% in Vero cells	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Synthesis and antiviral activity against Coxsackie virus B3 of some novel benzimidazole derivatives.
AID765052	Cytotoxicity against african green monkey OR6 cells after 72 hrs by WST1 assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
AID86682	Effective concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in HeLa cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID1204069	Antiviral activity against BVDV infected in bovine MDBK cells assessed as protection against viral-induced cytopathogenecity after 3 to 4 days by MTT method	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.
AID87158	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against polio 1 virus in HeLa cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID1391708	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells cocultured with human 293T-Gluc cells at 20 uM preincubated with compound for 2 hrs followed by virus infection measured after 24 hrs by luciferase reporter gene assay	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Secoiridoid analogues from the fruits of Ligustrum lucidum and their inhibitory activities against influenza A virus.
AID1503654	Antiviral activity against Fluc-tagged DENV2 strain 16681 infected in human HuH7 cells after 3 days by luciferase reporter gene assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents.
AID1767881	Selectivity index, ratio of CC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Oseltamivir resistant Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in dog MDCK cells	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1.
AID1127185	Selectivity index, ratio of CC50 for human HuH7 cells to IC50 for DENV2 16681	2014	European journal of medicinal chemistry, May-22, Volume: 79	Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives.
AID395931	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID416767	Antiviral activity against Coxsackievirus B4 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID273213	Antiviral activity against coxsackievirus B3 in HeLa S3 cells assessed as reduction in viral titer	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases.
AID105973	Concentration required to reduce the viability of MDCK cells	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID87165	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Coxsackie virus B4 in HeLa cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID693526	Antiviral activity against Influenza B/HK/5/72 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID1655773	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor.
AID548438	Cytotoxicity against MDCK cells assessed as altered cell morphology	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID291037	Antiviral activity against coxsackie B4 virus in HeLa cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID1432501	Cytotoxicity against MDCK cells after 48 hrs by by Reed and Muench analysis	2017	Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6	Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses.
AID84218	Inhibitory activity against TK-deficient HSV-1 (KOS) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID464186	Cytotoxicity against Human coxsackievirus B4 infected african green monkey Vero cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1081549	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 100 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID294255	Selectivity index, ratio of toxicity against Huh7 ET cells to viral activity against HCV	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Structure-activity relationship studies on anti-HCV activity of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.
AID198431	In vitro antiviral activity was tested against rift valley fever virus(RVF)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of 5-thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides.
AID1427860	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect
AID622533	Selectivity index, ratio of TC50 for african green monkey vero cells to IC50 for Enterovirus 71	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis, structure-activity relationship and in vitro biological evaluation of N-arylethyl isoquinoline derivatives as Coxsackievirus B3 inhibitors.
AID588215	FDA HLAED, alkaline phosphatase increase	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1873829	Selectivity index, ratio of CC50 for cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability to IC50 for antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in human Huh7.5 cells assessed as reduction in viral tite	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID1783395	Cytotoxicity against human Calu-3 cells infected with SARS-COV-2 by celltiter-glo luminescent cell viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID588214	FDA HLAED, liver enzyme composite activity	2004	Current drug discovery technologies, Dec, Volume: 1, Issue:4	Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1443672	Antiviral activity against Influenza virus A/WSN/33(H1N1) infected in human 293T cells assessed as inhibition of viral replication at 20 uM preincubated for 2 hrs followed by viral infection measured after 24 hrs by luciferase reporter gene assay relative	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Anti-influenza triterpenoid saponins (saikosaponins) from the roots of Bupleurum marginatum var. stenophyllum.
AID712807	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1135880	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID283442	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID308657	Antiviral activity against influenza A/Hong Kong/7/87 (H3N2) in MDCK cells assessed as inhibition of virus-induced cytopathic effect by MTS assay	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Design and synthesis of bioactive adamantane spiro heterocycles.
AID657387	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 48 hrs	2012	Bioorganic & medicinal chemistry letters, May-01, Volume: 22, Issue:9	Pyronepolyene C-glucosides with NF-κB inhibitory and anti-influenza A viral (H1N1) activities from the sponge-associated fungus Epicoccum sp. JJY40.
AID1505490	Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID1659828	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human 293T cells pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene assay	2020	Bioorganic & medicinal chemistry letters, 06-01, Volume: 30, Issue:11	Design, synthesis and anti-influenza A virus activity of novel 2,4-disubstituted quinazoline derivatives.
AID1235016	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition by CPE assay	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum.
AID383511	Cytotoxicity against human HEL cells assessed as alteration of cell morphology	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1505496	Antiviral activity against Influenza virus B/Ned/537/05 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID1783354	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1498139	Cytotoxicity against MDCK cells assessed as alteration of cell morphology by microscopic analysis	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID622444	Cytotoxicity against african green monkey Vero cells infected with Coxsackievirus B3 assessed as growth inhibition after 48 hrs by Reed-Muench analysis	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis, structure-activity relationship and in vitro biological evaluation of N-arylethyl isoquinoline derivatives as Coxsackievirus B3 inhibitors.
AID68122	Concentration required to reduce HSV-2(G) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID395967	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1578006	Selectivity index, ratio of TC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza A virus H3N2 infected in dog MDCK cells	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents.
AID1055007	Cytotoxicity against human BE(2)-C cells assessed as cell viability at 25 uM after 24 hrs by MTT assay relative to control	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication.
AID324804	Antiviral activity against YFV Jimenez infected in Syrian golden hamster assessed as weight change at 50 mg/kg, po bid for 7 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of T-1106 in a hamster model of yellow Fever virus infection.
AID87155	Minimum inhibitory concentration against Vesicular stomatitis virus in HeLa cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID105799	Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on MDCK cell line	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID156706	Evaluation for antiviral activity against herpes simplex virus-2(196) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID548433	Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID634746	Antiviral activity against Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1234202	Cytotoxic activity against African green monkey Vero cells assessed as cytopathogenic effect incubated for 48 hrs	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis.
AID1071699	Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza A virus H5N1	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID288917	Antiviral activity against HSV2 G in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID161449	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in primary rabbit kidney (PRK) cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID514138	Antiviral activity against HCV Con 1 by subgenomic replicon assay	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication.
AID105959	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of MDCK, Madin-Darby canine kidney cell morphology.	2003	Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10	Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
AID1610153	Cytotoxicity against human HELF cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1274010	Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 8 days by crystal violet staining technique	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID1501503	Cytotoxicity against human Hep2 cells assessed as reduction in cell viability after 3 days by MTT assay
AID658751	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID229230	Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID1432504	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 40 hrs	2017	Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6	Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses.
AID63915	Effective concentration required to inhibit Herpes simplex virus-1(HSV-1) / thymine kinase deficient (TK-)B2006 / VMW1837 induced cytopathicity by 50% in E6SM cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID1571468	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by MTT assay	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	Synthesis of d-(+)-camphor-based
AID1261315	Antiviral activity against human CVB5 infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity after 3 days by plaque reduction assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID436485	Cytotoxicity against hamster BHK21 cells assessed as reduction in cell viability after 48 to 96 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID1077006	Cytotoxicity against MDCK cells after 48 hrs	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID395948	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1450213	Antiviral activity against HSV1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID464190	Cytotoxicity against Influenza A virus subtype H1N1 infected MDCK cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID474338	Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Duck/MN/1525/81/H5N1	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID763860	Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/duck/Minnesota/1525/1981(H5N1))	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.
AID1201120	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	2015	European journal of medicinal chemistry, Apr-13, Volume: 94	A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1433155	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID1280361	Antiviral activity against oseltamivir-resistant influenza A virus LN/1109 (H1N1) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID217562	concentration required to inhibit Sindbis virus -induced cytopathicity by 50% in Vero cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID226343	Concentration required to reduce sindbis virus induced cytopathogenicity by 50% in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID68129	Tested for inhibitory effect on DNA virus VV in ESM cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID436483	Antiviral activity against Respiratory syncytial virus A2 infected in Vero-76 cells after 5 days by plaque reduction assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID659284	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID370215	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID283446	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1687963	Antiproliferative activity against human A-431 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID94763	Tested for inhibition of virus-induced cytopathogenic effect and cytotoxicity of compound against Japanese encephalitis virus with najayama strain in vero cell	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.
AID1696839	Antiviral activity against Influenza A virus (A/Duck/Guangdong/212/2004(H5N1)) infected in Balb/c mouse assessed as increase in animal survival rate at 80 mg/kg administered intranasally once daily for 5 days starting from 1 day prior to infection and mon	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Structure-aided optimization of 3-O-β-chacotriosyl epiursolic acid derivatives as novel H5N1 virus entry inhibitors.
AID1542954	Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability by MTS assay	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication.
AID432181	Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1783345	Antiviral activity against Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID370221	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID264705	Antiviral activity against TMV	2006	Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10	Discovery of bitriazolyl compounds as novel antiviral candidates for combating the tobacco mosaic virus.
AID392525	Antiviral activity against influenza B virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1886805	Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well at 12.4 to 100 ug/ml incubated for 72 hrs by crystal violet staining based assay relative to c	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID225769	Concentration required to reduce polio virus type 1 induced cytopathogenicity by 50% in HeLa cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID1229725	Selectivity index, ratio of CC50 for African green monkey Vero B cells to EC50 for DENV serotype 2 strain New Guinea V	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases.
AID1873819	Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability by MTS assay	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID1886801	Cytotoxicity against African green monkey Vero E6 cells measured after 72 hrs by MTT assay	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID301698	Binding to Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID1167618	Antiviral activity against Hepatitis C virus infected in African green monkey OR6 cells after 72 hrs by luciferase reporter gene assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID1433133	Cytotoxicity against african green monkey Vero cells assessed as alteration of normal cell morphology by microscopic analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID393164	Cytotoxicity against MDCK cells assessed as changes in cell morphology after 72 hrs by MTS assay	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID217836	Minimum inhibitory concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID674871	Antiviral activity against Influenza A virus (A/Guangdong-Luohu/219/2006(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors.
AID1071701	Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza A virus H3N2	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID1783356	Antiviral activity against West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based secondary yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID376981	Antiviral activity against RSV Long in human Hep2 cells assessed as reduction of virus induced cytopathic effect	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID1133178	Antiviral activity against HSV1 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.
AID278358	RBV metabolism in Vero E6 cells assessed as RBV-MP concentration at 10 ug/ml after 24 h	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID1773043	Antiviral activity against RSV infected in BALB/c mouse assessed as inhibition of viral replication by measuring RSV-M gene expression in lung after 2 to 6 days post infection by RT-PCR analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID478321	Antiviral activity against influenza A virus H1N1 assessed as cell viability by cell based MTS assay	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID539929	Cytotoxicity against human HeLa cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID634751	Antiviral activity against Human cytomegalovirus AD169 infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1501507	Selectivity index, ratio of CC50 for human HEP2 cells to EC50 for Coxsackievirus B3 (strain Nancy) infected in human HEP cells
AID416774	Antiviral activity against HSV2 G in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1869549	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability
AID368959	Antiviral activity against RSV RSS infected human Hep2 cells after 5 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID1150891	Antiviral activity against Rhinovirus type 13 infected in human KB cells	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Synthesis of 1-(4-thio-beta-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide.
AID92456	Inhibitory dose of compound required to inhibit cytopathogenic effects of influenza virus with A2/Aichi/2/68 strain in MDCK cells	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.
AID218063	Maximum tolerated concentration (MTC) was evaluated in vero cells.	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of 5-thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides.
AID768187	Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID1081164	In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 500 ug/ml	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID297320	Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID1716990	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in HEK293T cells assessed as relative fluorescence intensity at 20 uM pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene metho	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID1773032	Antiviral activity against RSV infected in human HEp-2 cells assessed as downregulation of RIG-1 expression at 25 uM treated 48 hpi and measured after 48 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID1372324	Cytotoxicity against pig SPEV cells by microscopic analysis	2018	Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1	Isosteric ribavirin analogues: Synthesis and antiviral activities.
AID1118648	Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1066046	Antiviral activity against influenza A virus A/Padova/30/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID1610161	Cytotoxicity against dog MDCK cells assessed as minimum cytotoxic concentration by observing alteration in cell morphology incubated for 3 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID763863	Antiviral activity against Influenza B virus (B/Florida/4/2006) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.
AID216386	Compound was tested for antiviral activity in HeLa Cell cultures, against vesicular stomatitis virus (VSV), cytopathic effect induced by the virus (CPE)	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Synthesis and antiviral evaluation of nucleosides of 5-methylimidazole-4-carboxamide.
AID701513	Cytotoxicity against uninfected human Hep2 cells assessed as cell viability at 25 uM measured after 144 hrs by Cell Titer-Glo assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.
AID280196	Antiviral activity against RSV Long in HeLa cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID216362	Antiviral activity against Coxsackie B4 virus infected vero cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID217824	In vitro antiviral activity was tested against, vaccinia virus (VV)	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID1271121	Antiviral activity against recombinant HCV genotype 2a JFH1 infected in human Huh7 cells incubated for 5 hrs measured on day 3 post infection by luciferase reporter gene assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID1082874	In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana. tabacum L. leaves assessed as curative effect at 100 ug/mL measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23	Design, synthesis, antiviral activity, and SARs of 14-aminophenanthroindolizidines.
AID464191	Cytotoxicity against Influenza A virus subtype H3N2 infected MDCK cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID217867	In vitro antiviral activity was tested against venezuelan equine encephalomyelitis (VEE)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of 5-thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides.
AID395973	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1226135	Cytotoxicity against human HEK293T cells assessed as decrease in cell viability by MTT assay	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits.
AID280195	Antiviral activity against coxsackie B4 virus in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID535504	Transport through ENT1 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID216229	Tested for its anti-polio activity against Vesicular stomatitis virus	2002	Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10	Heterocyclic nucleoside analogues: design and synthesis of antiviral, modified nucleosides containing isoxazole heterocycles.
AID1699936	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	New type of anti-influenza agents based on benzo[d][1,3]dithiol core.
AID1081553	In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 500 ug/ml	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID668362	In vitro antiviral activity against TMV at 500 ug/ml	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis and antiviral activity of novel pyridazines.
AID1234206	Antiviral activity against influenza A virus (A/Hanfang/359/95(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis.
AID1135412	Antiviral activity against type 1 parainfluenza virus infected in mouse assessed as mouse mean death day at 99 mg/kg, po thrice a day for 8 days after 1 hr viral infection (Rvb = 8.9 days)	1977	Journal of medicinal chemistry, Feb, Volume: 20, Issue:2	Synthesis and antiviral activity of certain thiazole C-nucleosides.
AID1200496	Antiviral activity against amantadine and ribavirin-resistant influenza A virus A/HuNan-huHui/1222/2010 (H3N2) strain	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1731877	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human HEK-293T cells assessed as inhibition of viral replication after 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Synthesis and antiviral activity of a series of novel quinoline derivatives as anti-RSV or anti-IAV agents.
AID539924	Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1433146	Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID392503	Antiviral activity against Camelpox virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1498133	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID393166	Antiviral activity against influenza B virus	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID216100	Evaluated for cell growth inhibition and induction of cellular differentiation of human B-lymphoblast cell line (WI-L2)	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Growth inhibition and induction of cellular differentiation of human myeloid leukemia cells in culture by carbamoyl congeners of ribavirin.
AID464176	Cytotoxicity against Human coxsackievirus B4 infected human HeLa cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID229232	Concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID217896	Minimum inhibitory concentration against reovirus in Vero cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID1135885	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to da	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID421725	Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Antiviral constituents against respiratory viruses from Mikania micrantha.
AID400425	Selectivity index, ratio of EC50 for RSV A-2 by plaque neutralization over IC50 for human Hep2 cells	1998	Journal of natural products, May, Volume: 61, Issue:5	Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea.
AID569231	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID105800	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on MDCK cell line infected with influenza A virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID535527	Transport through CNT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID387582	Cytotoxicity against african green monkey Vero cells assessed as alteration in cell morphology by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID288929	Antiviral activity against VSV in HeLa cells	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID436480	Antiviral activity against Reovirus-1 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID763923	Cytotoxicity against MDCK cells	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.
AID395976	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID217894	Minimum inhibitory concentration against Sindbis virus in Vero cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID1253098	Selectivity index, ratio of CC50 for human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene preincubated for 1 hr followed by fresh drug administration every 24 hrs for 48 hrs to EC50 for HCV JFH1 infected in human HuH7-J20 cells prei	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents.
AID539915	Antiviral activity against Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID156689	Antiviral activity was measured against Vaccinia virus in rabbit kidney cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID548448	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID216522	Minimum toxic concentration required to cause a microscopically detectable alteration of normal vero cell morphology	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID1303368	Selectivity index, ratio of CC50 for MDBK cells to EC50 for mock-infected BVDV NADL infected in MDBK cells	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1524777	Antiviral activity against Influenza A virus (A/California/7/2009(H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured on day 5 by Celltiter-Glo luminescence assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.
AID539948	Cytotoxicity against MDCK cells by MTS assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID765049	Antagonist activity at human PPARalpha assessed as effect on TIPP-703-induced activity at 10 uM	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
AID717281	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1113460	Antiviral activity against Human parainfluenza virus 3 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID395946	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID472784	Cytotoxicity against MDBK cells after 48 to 96 hrs by MTT assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID1194165	Antiviral activity against DENV serotype 2 strain New Guinea C infected in african green monkey Vero cells assessed as reduction in production and release of infectious progeny virions after 2 hrs by virus yield-reduction assay	2015	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8	Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors.
AID659287	Antiviral activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID68128	Tested for inhibitory effect on DNA virus TK-HSV-1(VMW 1837) in ESM cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1152080	Cytotoxicity against human HEK293T cells after 24 hrs by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.
AID395679	Cytotoxicity against african green monkey Vero cells after 7 to 8 days by neutral-red dye uptake assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID472795	Antiviral activity against Vaccinia virus Elstree-Lister infected in african green monkey Vero cells after 3 days by plaque reduction assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID434314	Antiviral activity against RSV infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID1443884	Antiviral activity against full length gluc-tagged Chikungunya virus IMT infected in human BJ cells assessed as reduction in virus infection after 24 hrs by gaussia luciferase reporter gene assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus.
AID668363	In vivo antiviral activity against TMV assessed as inactivation effect at 500 ug/ml	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis and antiviral activity of novel pyridazines.
AID1171740	Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by XTT assay	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Anti-respiratory syncytial virus prenylated dihydroquinolone derivatives from the gorgonian-derived fungus Aspergillus sp. XS-20090B15.
AID162251	Minimum inhibitory concentration required to reduce Polio virus type 1 induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID474542	Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus California/07/2009 /H1N1 by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID65707	Antiviral activity against Vaccinia virus in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID218033	Antiviral activity was measured against Sindbis virus in african green monkey kidney (Vero B) cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID300558	Antiviral activity against influenza A/Yuefang/243/72 (H3N2) virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID383512	Antiviral activity against HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1135879	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID1736920	Antiviral activity against Influenza A virus (A/goose/Jiangsu/1306/2014 (H5N8)) group-1 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hem	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID419592	Antiviral activity against HSV1 KOS infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID369465	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for La Crosse virus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID261589	Inhibition of West Nile virus VLP replicon in BHK21 cell line	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Identification of compounds with anti-West Nile Virus activity.
AID1571893	Displacement of [3H]N6-R-phenylisopropyladenosine from mouse A1A adenosine receptor expressed in CHO cell membranes after 60 mins by scintillation proximity assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design and in Vivo Characterization of A
AID659283	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID288930	Antiviral activity against Coxsackie virus B4 in HeLa cells	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID463981	Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID290451	Antiviral activity against SARS-CoV Frankfurt1 in Vero E6 cells by plaque reduction assay	2007	Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9	Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.
AID105793	Antiviral activity of compound was tested against morphology virus infec+ted MDCK cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID88349	Compound was evaluated for its inhibitory effect on the replication of Coxsackie virus B3 (Cox. B3) in HeLa cells	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	Synthesis and biological evaluation of thymine nucleosides fused with 3',4'-tetrahydrofuran ring.
AID1503653	Cytotoxicity against human HuH7 cells assessed as cell viability at 200 uM after 3 days by XTT method relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents.
AID1409614	Overall antiviral activity against SARS-CoV-2 (isolate France/IDF0372/2020) in the Vero E6 cell line at 48 h based on three assays 1) detection of viral RNA by qRT-PCR (targeting the N-gene), 2) plaque assay using lysate 3 days after addition of compound	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID261590	Inhibition of West Nile viral Rluc-Neo-Rep in Vero cells	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Identification of compounds with anti-West Nile Virus activity.
AID464181	Cytotoxicity against VSV infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID257897	Antiviral activity against Coxsackie virus B4 in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID369871	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 30 mg/kg, po twice daily for 5 days 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID427553	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID86801	Antiviral activity against polio 1 virus infected HeLa cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID762954	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) PR/8 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 48 hrs by crystal-violet staining-based assay	2013	Journal of natural products, Jul-26, Volume: 76, Issue:7	Indole-diterpenoids with anti-H1N1 activity from the aciduric fungus Penicillium camemberti OUCMDZ-1492.
AID535516	Transport through CNT1 in rat hepatocytes by oil filtration assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID370213	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1558283	Cytotoxicity against African green monkey Vero cells	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Drugs for the Treatment of Zika Virus Infection.
AID1246933	Selectivity index, ratio of CC50 for MDCK cells by visual method to EC50 for Influenza A virus (A/California/07/2009(H1N1) virus by visual method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Synthesis and antiviral activity of some new bis-1,3-thiazole derivatives.
AID463996	Antiviral activity against Human coxsackievirus B4 infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1069923	Selectivity index, ratio of beta-actin level in human HuH7 cells to viral RNA level in HCV infected in human Huh7 cells	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	Dual inhibition of HCV and HIV by ring-expanded nucleosides containing the 5:7-fused imidazo[4,5-e][1,3]diazepine ring system. In vitro results and implications.
AID611759	Antiviral activity against Coxsackievirus B4 infected in HeLa cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1450221	Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 F+ infected in African green monkey Vero E6 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID257886	Antiviral activity against HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID634757	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID88686	Tested for inhibitory effect on RNA virus RSV in HeLa cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1505494	Antiviral activity against Influenza virus A/X-31 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID1450224	Antiviral activity against acyclovir and cidofovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID548440	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID216502	Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on vero cell line	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID288919	Antiviral activity against thymidine kinase-deficient HSV1 B2006 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID535526	Transport through ENT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID63609	Tested for antiviral activity against vaccinia virus in human embryonic skin muscle fibroblast	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID1691562	Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) clone 2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by MTS assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.
AID63760	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (McIntyre strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID432169	Cytotoxicity against HEL cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID65844	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of E6SM cells	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID1571469	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction in virus titer pretreated with cells for 1 hr followed by viral infection for 1 hr and subsequent unbound virion washout measured after 24	2018	MedChemComm, Dec-01, Volume: 9, Issue:12	Synthesis of d-(+)-camphor-based
AID1486232	Selectivity index, ratio of CC50 for bovine MDBK cells to EC50 for Bovine viral diarrhea virus 1-NADL
AID1132058	Antiviral activity against Coxsackievirus B1 infected in human HeLa cells by agar diffusion assay	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID218405	Minimum inhibitory concentration required to reduce reovirus-1 induced cytopathogenicity by 50% in african green monkey (VeroB)cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID257891	Antiviral activity against Vaccinia virus in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID401230	Selectivity index, ratio of CC50 for MDCK cells to IC50 for influenza virus type A H1N1	2004	Journal of natural products, Apr, Volume: 67, Issue:4	Antiviral flavonoids from the seeds of Aesculus chinensis.
AID283447	Inhibition of viral replication of influenza A virus (A/Vietnam/1203/2004 (H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID474358	Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 3 days by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID395947	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID766691	Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID218007	Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 2	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID81761	In vitro antiviral activity against parainfluenza type 3 (para 3) type 1 (HSV-1) virus was determined in human laryngeal epithelioma (HEp-2,H)expressed as virus rating. Toxic level(>1000 ug/mL)	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID1205005	Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B1 infected in african green monkey Vero cells	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID395703	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1687968	Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 4 days by trypan blue exclusion assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID218005	Minimum inhibitory concentration against vaccinia virus in Vero cell cultures of experiment 2	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID453101	Antiviral activity against Measles virus infected in intracranially dosed hamster assessed as inhibition of subacute sclerosing panencephalitis	2009	Bioorganic & medicinal chemistry, Dec-01, Volume: 17, Issue:23	Synthesis, tautomerism, and antimicrobial, anti-HCV, anti-SSPE, antioxidant, and antitumor activities of arylazobenzosuberones.
AID105979	In vitro antiviral activity against influenza virus (type A0/PR/8/34) in Madin-Darby canine kidney (MDCK) host cell cultures	1990	Journal of medicinal chemistry, Apr, Volume: 33, Issue:4	Synthesis and biological evaluation of carbocyclic analogues of lyxofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines.
AID228985	Antiviral activity against semliki forest virus (SFV) in Vero cell culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID217903	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against reo type 1 virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID539931	Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1472390	Cytotoxicity against MDCK cells assessed as effect on cell morphology after 72 hrs by microscopic method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID1204999	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID249261	Minimum inhibitory concentration against coxsackie virus B4 was determined	2005	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6	QSAR for anti-RNA-virus activity, synthesis, and assay of anti-RSV carbonucleosides given a unified representation of spectral moments, quadratic, and topologic indices.
AID87147	Evaluation for antiviral activity against polio virus-1 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID360159	Antiviral activity against HCV 1b with NS3-4A R155T mutation in human Huh7 cells after 48 hrs by replicon cell assay	2007	The Journal of biological chemistry, Aug-03, Volume: 282, Issue:31	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
AID1638585	Cytotoxicity against African green monkey Vero cells after 3 days by MTT assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.
AID216979	Percentage plaque reduction was determined against Sandfly fever (SF) virus in african green monkey kidney (vero,V) at a conc of 25-100 ug/mL. Toxic level(>1000 ug/mL); 61-90	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID370217	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1495714	Antiviral activity against amantadine/rimantadine-resistant Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutination test	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Highly potent activity of isopulegol-derived substituted octahydro-2H-chromen-4-ols against influenza A and B viruses.
AID1682704	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34 (H1N1) infected in MDCK cells assessed as decrease in viral titer preincubated for 1 hr followed by viral infection and cultivated for 48 hrs followed by supernatant transferred to chicken e
AID1181484	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID434312	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID588220	Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset	2008	Toxicology mechanisms and methods, , Volume: 18, Issue:2-3	Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID278348	Inhibition of viral RNA levels in HTNV 76-118-infected Vero E6 cells at 2 ug/ml after 3 days	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1092194	In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana tabacum L. leaves assessed as protection effect at 500 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Oct-17, Volume: 60, Issue:41	Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of phenanthroindolizidines and their analogues.
AID1610157	Antiviral activity against Influenza B virus (B/Ned/537/05) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID693527	Cytotoxicity against MDCK cells assessed as minimum concentration required to cause microscopically detectable alteration measured on day 3 post infection by MTS assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID63759	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 1 (F strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID261586	Inhibition of Rluc-FL-WNV replicon in Vero cells	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Identification of compounds with anti-West Nile Virus activity.
AID1610155	Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1246930	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by neutral red assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Synthesis and antiviral activity of some new bis-1,3-thiazole derivatives.
AID1831637	Antiviral activity against Zika virus infected in human Huh-7 cells assessed as inhibition of viral replication at 12.5 uM measured after 48 hrs by Renilla reporter based luciferase assay relative to control	2021	ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12	Nanoparticular Inhibitors of Flavivirus Proteases from Zika, West Nile and Dengue Virus Are Cell-Permeable Antivirals.
AID220035	Concentration required to reduce coxsackie virus 4 induced cytopathogenicity by 50% in HeLa cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID1336613	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones.
AID283444	Inhibition of viral replication of influenza A virus (A/Hong Kong/213/03(H5N1)) and influenza A virus (A/Ann Arbor/6/60(H2N2)) hybrid virus in MDCK cells by neutral red uptake assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID536243	Selectivity index, ratio of MCC for MDCK cells to EC50 for Influenza A virus (A/Hong Kong/7/1987(H3N2))	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID1783350	Antiviral activity against Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1408325	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID217269	Effective concentration required to inhibit respiratory synaptial (RSV) virus-induced cytopathicity by 50% in Vero cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID63758	The minimum inhibitory concentration was measured against Herpes simplex virus type 1 (KOS strain) on E6SM cells	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID400417	Antiviral activity against RSV long infected in human Hep2 cells assessed as virus-induced cytopathic effect after 3 days	1998	Journal of natural products, May, Volume: 61, Issue:5	Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea.
AID370211	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1524779	Antiviral activity against Influenza A virus (A/Brisbane/10/2007(H3N2)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured on day 5 by Celltiter-Glo luminescence assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.
AID421730	Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Parainfluenza virus type 3 infected in human Hep2 cells	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Antiviral constituents against respiratory viruses from Mikania micrantha.
AID548430	Cytotoxicity against human HeLa cells assessed as altered cell morphology	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID226098	Minimum inhibitory concentration against Herpes simplex virus 1(KOS) in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID611766	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1691561	Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) clone 2 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by microscopic analysis	2020	European journal of medicinal chemistry, May-15, Volume: 194	N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.
AID229024	Inhibitory activity against vaccinia virus (VV) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID1055015	Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as inhibition of viral RNA replication after 18 to 20 hrs by luciferase reporter gene assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication.
AID1273992	Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction of viral titer at maximal non-toxic concentration after 72 hrs by crystal violet staining assay relative to control	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID434311	Antiviral activity against acyclovir-resistant thymidine kinase-deficient HSV1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID1578003	Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells assessed as inhibition in virus-induced cytopathic effect incubated for 40 hrs	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents.
AID1710782	Antiviral activity against Mammalian orthoreovirus 1 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID1655774	Selectivity index, ratio of CC50 for human HuH7 cells assessed as reduction in cell viability by measuring ATP level measured after 72 hrs by CellTiter-Glo luminescent assay to EC50 for Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human H	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor.
AID66942	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vaccinia virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID291036	Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID68257	Minimum inhibitory concentration to reduce cytopathicity by 50% in morphology of human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID395938	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1226134	Antiviral activity against Influenza A virus (A/PR/8/34) (H1N1) infected in MDCK cells assessed as reduction in plaque formation after 48 hrs by plaque reduction assay	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits.
AID86688	Antiviral activity against Coxsackie B4 virus infected HeLa cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID82045	Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on HEF cell line	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID428948	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1472389	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID424779	Therapeutic index, CC50 for human HeLa cells to IC50 for Coxsackie virus B3 Nacy	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Anti-coxsackie virus B3 norsesquiterpenoids from the roots of Phyllanthus emblica.
AID548431	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID766689	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1773013	Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as reduction in cleaved caspase-7 expression measured after 48 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID472786	Cytotoxicity against african green monkey Vero cells	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID361406	Cytotoxicity against human HeLa cells after 2 days by MTT assay	2002	Journal of natural products, Nov, Volume: 65, Issue:11	New saponins from the starfish Certonardoa semiregularis.
AID217118	Percentage plaque reduction was determined against yellow fever(YF) virus in african green monkey kidney (vero,V).Toxic level(>1000 ug/mL); 61-90	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID474335	Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1409404	Antiviral activity against Influenza A virus A/goose/Guangdong/SH7/2013(H5N1) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID297318	Antiviral activity against Reovirus 1 in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID371503	Selectivity index, ratio of CC50 for MDBK cells to EC50 for bovine viral diarrhoea virus type-1 NADL	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	New 1-indanone thiosemicarbazone derivatives active against BVDV.
AID167327	Concentration required to cause a microscopically detectable alteration in cell morphology in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID1485237	Antiviral activity against Coxsackie B4 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID70209	Antiviral activity against influenza B (Hong kong/5/72) in human epithelial cells	2003	Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10	Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
AID701507	Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as reduction in virus-induced cytopathogenicity by Cell Titer-Glo assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.
AID1578005	Antiviral activity against Influenza A virus H3N2 infected in dog MDCK cells assessed as inhibition in virus-induced cytopathic effect incubated for 40 hrs	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents.
AID395674	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as inhibition of liver damage at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID475235	Therapeutic index, ratio of CC50 for human HuH7 cells to EC50 for HCV 1b	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication.
AID82034	Antiviral activity against HSV-1 virus infected HEF cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID658612	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1783363	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 24 hrs by MTT assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID536241	Cytotoxicity against MDCK cells by MTS assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID474349	Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Vietnam/1203/ 2004H/H5N1 by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1610156	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID421731	Cytotoxicity against MDCK cells	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Antiviral constituents against respiratory viruses from Mikania micrantha.
AID1738756	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 48 hrs by microscopic analysis	2020	European journal of medicinal chemistry, Aug-01, Volume: 199	Discovery of dihydropyrrolidones as novel inhibitors against influenza A virus.
AID1717750	Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for 2019-nCoV Beta CoV/Wuhan/WIV04/2019 infected in African green monkey Vero E6 cells	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID199174	The minimum inhibitory concentration required to reduce reovirus type I induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID291033	Antiviral activity against parainfluenza 3 virus in Vero cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID464000	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID88296	The minimum inhibitory concentration required to reduce HSV-2 (G) induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID416773	Antiviral activity against HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID54506	Minimum inhibitory concentration required to reduce Coxsackie virus type B-4-induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID569238	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID156690	Antiviral activity was measured against Vesicular stomatitis virus in rabbit kidney cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID1058584	Antiviral activity against Influenza A/PR8/H1N1 virus infected in MDCK cells assessed as inhibition of virus yield after 24 hrs	2013	Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24	Tyrosinase and Layer-by-Layer supported tyrosinases in the synthesis of lipophilic catechols with antiinfluenza activity.
AID1274003	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 72 hrs	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID1716982	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in human HEK293T cells measured after 24 hrs by Gaussia luciferase reporter gene method	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID392533	Antiviral activity against Monkeypox virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID65705	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID63943	concentration required to inhibit vaccinia virus-induced cytopathicity by 50% in E6SM cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID257901	Antiviral activity against Vesicular stomatitis virus in HeLa cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID369467	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Rift Valley fever virus MP-12	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID383508	Antiviral activity against Coxsackie virus B4 in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1503320	Antiviral activity against Bovine viral diarrhea virus NADL ATCC VR 534 infected in bovine MDBK cells assessed as protection against virus-induced cytopathic effect after 3 to 4 days by MTT assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation.
AID1409407	Antiviral activity against Influenza A virus A/goose/Jiangsu/1306/2014(H5N8) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID86511	Tested for minimum inhibitory concentration required to cause a microscopically detectable alteration of normal cell morphology by 50% on HeLa cell line	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID767059	Cytotoxicity against human rhabdomyosarcoma cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID1186340	Antiviral activity against HSV1 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID224346	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vaccinia virus in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID1610159	Antiviral activity against Influenza A virus (A/HK/7/87(H3N2)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID1501504	Antiviral activity against EV71 Xiangyang-Hubei-09 infected in human RD cells assessed as inhibition of virus-induced cytopathic effect by MTT dye based assay
AID68120	Concentration required to reduce HSV-1 thymidine kinase deficient (TK-)(VMW 1837) induced cytopathogenicity in by 50% ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID216436	Concentration required for microscopically detectable alteration of the normal cell morphology in Wi-38 cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID324824	Antiviral activity against YFV Jimenez infected in Syrian golden hamster liver treated 4 hrs before viral challenge assessed as weight change at 50 mg/kg/day, ip bid for 8 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of T-1106 in a hamster model of yellow Fever virus infection.
AID535530	Transport through ENT1 in mouse hepatocytes by oil filtration assay in presence 100 nM of transporter inhibitor NBMRP	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID85120	Inhibitory activity against HSV-2 (G) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID1647358	Selectivity index, ratio of CC50 for African monkey Vero cells to EC50 for Chikungunya virus infected in African green monkey Vero cells	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors.
AID1152077	Inhibition of Influenza A virus GST-tagged PB1 (1 to 25) expressed in Escherichia coli binding to Influenza A virus 6His-tagged PA (239 to 716) expressed in Escherichia coli BL21(DE3) by ELISA	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.
AID427564	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID46601	Tested for inhibitory effect on RNA virus cell growth in CEM cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID774865	Selectivity index, ratio of CC50 for human Huh7.5 cells to IC50 for HCV expressing pFL-J6/JFH/JC1	2013	European journal of medicinal chemistry, Nov, Volume: 69	Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.
AID1261328	Antiviral activity against WNV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID257899	Antiviral activity against Respiratory syncytial virus in HeLa cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID275069	Antiviral activity against vaccinia virus in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID156688	Antiviral activity was measured against Herpes simplex virus (HSV-2 G) in rabbit kidney cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID1485243	Antiviral activity against para influenza 3 virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID427559	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1273993	Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as maximal non toxic concentration causing reduction of viral titer after 72 hrs by crystal violet staining assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID1501506	Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in human HEP2 cells assessed as inhibition of virus-induced cytopathic effect by MTT dye based assay
AID1408128	Inhibition of Influenza A virus A/PR/8/34 (H1N1) PA-PB1 interaction expressed in HEK293T cells assessed as decrease in RNA polymerase activity incubated for 24 hrs by minireplicon based luciferase reporter gene assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction.
AID1261309	Cytotoxicity against MDBK cells assessed as cell viability after 48 to 96 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID301700	Ratio of kinact for human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form to KI for human recombinant S-adenosyl-L-homocysteine hydrolase NAD+	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID416748	Antiviral activity against RSV Long in human HeLa cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID105964	Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza A H3N2 (X31)	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1647354	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors.
AID489680	Antiviral activity against VSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Benzylidene/2-chlorobenzylidene hydrazides: synthesis, antimicrobial activity, QSAR studies and antiviral evaluation.
AID1204998	Cytotoxicity against african green monkey Vero cells assessed as inhibition of cell growth after 24 hrs by CPE assay	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID1742427	Selectivity index, ratio of CC50 for human HEK293T cells to IC50 for Influenza A virus A/WSN/33(H1N1) infected in HEK293T-Gluc cells	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design, synthesis and in vitro anti-influenza A virus evaluation of novel quinazoline derivatives containing S-acetamide and NH-acetamide moieties at C-4.
AID303221	Cytotoxicity against HEL cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID99707	In vitro antiviral activity against VSV virus in human laryngeal epithelioma cell line	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID92451	Virus rating is measurement of degree of inhibition of virus-induced cytopathogenic effects and the degree of cytotoxicity produced by the test compound for influenza type A2	1987	Journal of medicinal chemistry, May, Volume: 30, Issue:5	Synthesis and biological activity of unsaturated carboacyclic purine nucleoside analogues.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1306320	Antiviral activity against Hepatitis C virus infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	An alternative route to the arylvinyltriazole nucleosides.
AID539917	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID156703	Evaluated for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID277835	Antiviral activity against CV B4	2007	Journal of natural products, Feb, Volume: 70, Issue:2	Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa.
AID717172	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID307142	Specific activity of human adenosine kinase	2007	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 17, Issue:11	Structural effects on the phosphorylation of 3-substituted 1-beta-D-ribofuranosyl-1,2,4-triazoles by human adenosine kinase.
AID218004	Minimum inhibitory concentration against vaccinia virus in Vero cell cultures of experiment 1	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID1450222	Antiviral activity against acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID1181480	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1501502	Cytotoxicity against human RD cells assessed as reduction in cell viability after 3 days by MTT assay
AID533319	Selectivity Index, ratio of CC50 for RP7 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in RP7 replicon cell	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID1408329	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1133182	Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.
AID1538478	Selectivity index, ratio of CC50 for cytotoxicity against human RD cells to EC50 for antiviral activity against Coxsackievirus A16 TA271 infected in human RD cells	2019	Journal of natural products, 05-24, Volume: 82, Issue:5	Effects of Acetylshikonin on the Infection and Replication of Coxsackievirus A16 in Vitro and in Vivo.
AID776646	Cytotoxicity against rat Walker 256 cells assessed as growth inhibition	2013	European journal of medicinal chemistry, Nov, Volume: 69	Pyrazole containing natural products: synthetic preview and biological significance.
AID472790	Antiviral activity against Yellow fever virus 17D infected in BHK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID1710789	Selectivity index, ratio of MCC for African green monkey Vero cells to EC50 for Punta Toro virus infected in African green monkey Vero cells	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID475856	Antiviral activity against HCV infected in human HuH5.2 cells carrying subgenomic HCV replicon assessed as inhibition of replicon replication by luciferase reporter gene assay	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID1436801	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B1 Conn-5 infected in African green monkey Vero cells	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID395954	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID478320	Antiviral activity against influenza A virus H1N1 assessed as inhibition of viral induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID155592	In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and Parainfluenza type 3 virus control cells.	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Synthesis and antiviral/antitumor activities of certain 3-deazaguanine nucleosides and nucleotides.
AID593220	Antiviral activity against Coxsackievirus B3 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
AID674874	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus (strain B/Jifang/13/97)	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors.
AID216942	In vitro antiviral activity against Para 3 virus in (vero) V cells of african green monkey kidney	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID1783355	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID712815	Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1092200	Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 500 ug/mL at 25 degC after 72 hr by half-leaf method	2012	Journal of agricultural and food chemistry, Oct-17, Volume: 60, Issue:41	Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of phenanthroindolizidines and their analogues.
AID1505488	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by microscopic analysis	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID593226	Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B6	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
AID87304	Concentration required to cause a microscopically detectable alteration in cell morphology in HeLa cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID1132057	Cytotoxicity against BHK cells	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1409405	Antiviral activity against Influenza A virus A/Chicken/Hebei/LZF/2014(H5N2) infected in chicken embryo fibroblasts assessed as reduction in cytopathic effect after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID395665	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID221965	Compounds was tested for the effect of L-nucleosides of ribavirin on SEB (staphylococcal enterotoxin B)-stimulated T-cell expression of the type 1 cytokine TNF-alpha	2000	Journal of medicinal chemistry, Mar-09, Volume: 43, Issue:5	Monocyclic L-nucleosides with type 1 cytokine-inducing activity.
AID539932	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID464185	Cytotoxicity against Sindbis virus infected african green monkey Vero cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1234205	Cytotoxic activity against MDCK cells assessed as cytopathogenic effect incubated for 48 hrs	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis.
AID482708	Antiviral activity against RSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID416781	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID204956	Minimum inhibitory concentration required to reduce sindbis virus induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID1118642	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID712810	Antiviral activity against amantadine-sensitive Influenza A virus (A/Ned/378/05 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1890794	Antiviral activity against Influenza A virus A/WSN/33 (H1N1) infected in HEK293T cells by Gaussia luciferase reporter assay	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and anti-influenza A virus activity evaluation of novel indole containing derivatives of triazole.
AID1205002	Antiviral activity against Coxsackievirus B2 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID535534	Transport through ENT2 in mouse hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1252406	Antiviral activity against Coxsackievirus B4 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of L-ascorbic or imino-L-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations.
AID105965	Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza B (Hong Kong/5/72)	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID1274008	Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID278378	Decrease in GTP level in Vero E6 cells at 40 ug/ml after 4 h	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID63604	Tested for antiviral activity against VSV-virus in human embryonic skin muscle fibroblasts	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID1600737	Antiviral activity against Tacaribe virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	l-like 3-deazaneplanocin analogues: Synthesis and antiviral properties.
AID253329	Cytotoxicity in MDBK (Madin-darby bovine kidney) cells	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Synthesis of benzodithiol-2-yl-substituted nucleoside derivatives as lead compounds having anti-bovine viral diarrhea virus activity.
AID1194166	Cytotoxicity against DENV serotype 2 strain New Guinea C infected african green monkey Vero B cells by virus yield-reduction assay	2015	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8	Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors.
AID217478	Minimum inhibitory concentration required to reduce Vesicular stomatitis virus (VSV) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID1186331	Cytotoxicity against mock-infected BHK21 cells after 48 to 96 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID521220	Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay	2007	Nature chemical biology, May, Volume: 3, Issue:5	Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1538476	Cytotoxicity against human RD cells assessed as reduction in cell viability after 12 hrs by CCK8 assay	2019	Journal of natural products, 05-24, Volume: 82, Issue:5	Effects of Acetylshikonin on the Infection and Replication of Coxsackievirus A16 in Vitro and in Vivo.
AID1873825	Antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in African green monkey Vero cells assessed as reduction in viral titer incubated for 3 days by plaque assay	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID85112	Inhibitory activity against HSV-2 (196) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID1731876	Selectivity index, ratio of CC50 for cytotoxicity against human HEp-2 cells to IC50 for antiviral activity against RSV Long expressing mGFP infected in HEp-2 cells	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Synthesis and antiviral activity of a series of novel quinoline derivatives as anti-RSV or anti-IAV agents.
AID474339	Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Duck/MN/1525/81/H5N1 by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1075687	Selectivity index, ratio of CC50 for human HuH7 cells to EC50 for HCV subtype 1a	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	4'-Substituted pyrimidine nucleosides lacking 5'-hydroxyl function as potential anti-HCV agents.
AID539919	Antiviral activity against acyclovir-resistant TK deficient Herpes simplex virus-1 KOS infected in human HEL cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID88275	The minimum inhibitory concentration required to reduce HSV-1(KOS) induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID1118645	Antiviral activity against Parainfluenza virus 3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID280194	Antiviral activity against coxsackie B4 virus in HeLa cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID395711	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1886808	Antiviral activity against DENV2 infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect measured after 72 hrs by crystal violet staining based inverted microscopic analysis	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID1409608	AUC (viral infection %) for SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID436481	Cytotoxicity against african green monkey Vero 76 cells by crystal violet staining	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID1265166	Antiviral activity against Chikungunya virus infected in HEK293T cells assessed as reduction of infectivity measured at 24 hrs postinfection by gaussia luciferase reporter gene assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID156845	Minimum inhibitory concentration required to reduce herpes simplex virus-2 (G)induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK)	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID257339	Antiviral activity against HCV in Huh7 ETcell line at 10 uM assessed by measuring HCV-RNA-derived LUC activity relative to control	2005	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24	Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.
AID1154646	Therapeutic ratio of TC50 for mock-infected human Hep2 cells to IC50 for Respiratory syncytial virus infected in human Hep2 cells	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Antiviral C-25 epimers of 26-acetoxy steroids from the South China Sea gorgonian Echinogorgia rebekka.
AID1853002	Cytotoxicity against human HEK293 cells incubated for 48 hrs by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID275087	Cytotoxicity against HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID717280	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1113464	Antiviral activity against Human coxsackievirus B4 infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID284531	Antiviral activity against in Vesicular stomatitis virus-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID434306	Cytotoxicity against human HeLa cells assessed as change in cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID543692	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum survival of animal at 50 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID611760	Antiviral activity against Coxsackievirus B4 infected in Vero cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID156079	Inhibitory activity against purine nucleoside phosphorylase (PNPase); E means not determined	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	Synthesis and evaluation of 5-amino-1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine and certain related nucleosides as inhibitors of purine nucleoside phosphorylase.
AID730331	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathic effect after 48 hrs by crystal violet staining method	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Aspulvinones from a mangrove rhizosphere soil-derived fungus Aspergillus terreus Gwq-48 with anti-influenza A viral (H1N1) activity.
AID1205000	Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B3 infected in african green monkey Vero cells	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID1853000	Cytotoxicity against human HCT-116 cells overexpressing human MDR1 incubated for 48 hrs by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID66004	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (KOS) strain of HSV-1 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID658614	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID718710	Antiviral activity against Influenza virus A/California/07/09 (H1N1) pdm09 infected in MDCK cells after 48 hrs followed by incubated in chicken erythrocytes for 1 hr by hemagglutinination based end-point dilution method	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009.
AID1371009	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 48 hrs by crystal-violet staining-based assay	2017	Journal of natural products, 04-28, Volume: 80, Issue:4	Chrodrimanins K-N and Related Meroterpenoids from the Fungus Penicillium sp. SCS-KFD09 Isolated from a Marine Worm, Sipunculus nudus.
AID1092196	In vivo antiviral activity against Tobacco mosaic virus (TMV) pre-inoculated Nicotiana tabacum L. leaves assessed as curative effect at 500 ug/mL measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Oct-17, Volume: 60, Issue:41	Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of phenanthroindolizidines and their analogues.
AID1427858	Cytotoxicity against MDCK cells assessed as growth inhibition after 48 hrs
AID1081160	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 500 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID421729	Antiviral activity against Influenza A virus infected in MDCK cells assessed as inhibition of virus-induced cytopathogenic effect by plaque reduction assay	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Antiviral constituents against respiratory viruses from Mikania micrantha.
AID82051	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with vaccinia virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID1450220	Antiviral activity against foscarnet-resistant HSV-1 F+ infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID1082877	In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana. tabacum L. leaves assessed as inactivation effect at 500 ug/mL co-incubated with virus measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23	Design, synthesis, antiviral activity, and SARs of 14-aminophenanthroindolizidines.
AID567524	Antiviral activity against Junin virus IV4454 infected in african green monkey Vero cells assessed as reduction in virus yield after 48 hrs by plaque assay	2011	European journal of medicinal chemistry, Jan, Volume: 46, Issue:1	Imidazo[2,1-b]thiazole carbohydrate derivatives: Synthesis and antiviral activity against Junin virus, agent of Argentine hemorrhagic fever.
AID1201116	Cytotoxicity against MDCK cells after 72 hrs by MTS assay	2015	European journal of medicinal chemistry, Apr-13, Volume: 94	A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID400704	Cytotoxicity against RSV A-2 infected human Hep2 cells after 3 days	1998	Journal of natural products, May, Volume: 61, Issue:5	Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea.
AID1146287	Antiviral activity against Rhinovirus 1A infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control	1978	Journal of medicinal chemistry, Sep, Volume: 21, Issue:9	Imidazo[1,2-a]-s-triazine nucleosides. Synthesis and antiviral activity of the N-bridgehead guanine, guanosine, and guanosine monophosphate analogues of imidazo[1,2-a]-s-triazine.
AID1274005	Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction in plaque formation administered simultaneously with virus for 1 hr measured after 72 hrs by crystal violet staining technique	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID658747	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1181481	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009 infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID275070	Antiviral activity against vesicular somatitis virus in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID774863	Cytotoxicity against human Huh7.5 cells after 96 hrs by MTT assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.
AID474330	Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 3 days by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1273990	Antiviral activity against HHV1 CDC Atlanta infected in African green monkey Vero cells assessed as reduction of viral titer at maximal non-toxic concentration after 48 hrs by crystal violet staining assay relative to control	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID474357	Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID387854	Cytotoxicity against HEL cells assessed as alteration in cell morphology by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID257472	Cytotoxicity in MDCK cells infected with influenza A H3N2 virus	2005	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 15, Issue:23	Synthesis and biological evaluation of novel bisheterocycle-containing compounds as potential anti-influenza virus agents.
AID1710780	Selectivity index, ratio of MCC for human HeLa cells to EC50 for Respiratory syncytial virus infected in human HeLa cells	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID1853007	Cytotoxicity against paclitaxel-resistant human HCT116tax cells assessed as reduction on cell viability at 100 to 200 uM incubated for 48 hrs in presence of paclitaxel by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID474540	Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus California/07/2009 /H1N1	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1742425	Antiviral activity against Influenza A virus A/WSN/33(H1N1) infected in HEK293T-Gluc cells pretreated for 2 hrs followed by viral infection and measured after 24 hrs by Gaussia luciferase reporter gene assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design, synthesis and in vitro anti-influenza A virus evaluation of novel quinazoline derivatives containing S-acetamide and NH-acetamide moieties at C-4.
AID1234204	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for coxsackievirus B3 infected in African green monkey Vero cells	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis.
AID82315	Evaluated for cell growth inhibition and induction of cellular differentiation of human myeloid leukemia cell line (HL-60)	1990	Journal of medicinal chemistry, Jan, Volume: 33, Issue:1	Growth inhibition and induction of cellular differentiation of human myeloid leukemia cells in culture by carbamoyl congeners of ribavirin.
AID87132	Antiviral activity was measured against Polio virus-1 in HeLa cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID66007	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by TK-(B2006) strain of HSV-1 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID218252	Evaluation for antiviral activity against forest virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1201121	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	2015	European journal of medicinal chemistry, Apr-13, Volume: 94	A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1146290	Antiviral activity against Rhinovirus 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control	1978	Journal of medicinal chemistry, Sep, Volume: 21, Issue:9	Imidazo[1,2-a]-s-triazine nucleosides. Synthesis and antiviral activity of the N-bridgehead guanine, guanosine, and guanosine monophosphate analogues of imidazo[1,2-a]-s-triazine.
AID1687956	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID1505489	Antiviral activity against Influenza virus A/X-31 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID535514	Transport through ENT1 in rat hepatocytes by oil filtration assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1773017	Inhibition of RSV induced ROS production in human HEp-2 cells assessed as reduction in accumulation of ROS-positive cells at 25 uM measured after 36 hrs by DCHF-DA staining based flow cytometry analysis (Rvb = 82.2%)	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID463983	Antiviral activity against VSV infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1831638	Antiviral activity against West Nile virus infected in human Huh-7 cells assessed as inhibition of viral replication at 12.5 uM measured after 48 hrs by plaque assay relative to control	2021	ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12	Nanoparticular Inhibitors of Flavivirus Proteases from Zika, West Nile and Dengue Virus Are Cell-Permeable Antivirals.
AID1076999	Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID166671	Evaluation for antiviral activity in primary rabbit kidney cell culture	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Structure-activity relationship of novel oligopeptide antiviral and antitumor agents related to netropsin and distamycin.
AID1336612	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones.
AID1710778	Selectivity index, ratio of MCC for human HeLa cells to EC50 for Vesicular stomatitis virus infected in human HeLa cells	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID1692501	Cytotoxicity against African green monkey Vero E6 cells by CCK8 assay	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	COVID-19: Drug Targets and Potential Treatments.
AID383530	Antiviral activity against Parainfluenza 3 virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1201117	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	2015	European journal of medicinal chemistry, Apr-13, Volume: 94	A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID383522	Cytotoxicity against african green monkey Vero cells	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID464192	Cytotoxicity against Influenza B virus infected MDCK cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID369870	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID436479	Antiviral activity against Yellow fever virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathicity after 3 to 4 days by MTT assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID1443674	Antiviral activity against Influenza virus A/WSN/33(H1N1) infected in human 293T cells assessed as inhibition of viral replication preincubated for 2 hrs followed by viral infection measured after 24 hrs by luciferase reporter gene assay	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Anti-influenza triterpenoid saponins (saikosaponins) from the roots of Bupleurum marginatum var. stenophyllum.
AID424777	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Anti-coxsackie virus B3 norsesquiterpenoids from the roots of Phyllanthus emblica.
AID482715	Cytotoxicity against african green monkey Vero cells by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID432178	Antiviral activity against RSV infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID1783344	Antiviral activity against Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1594641	Cytotoxicity in BHK cells assessed as reduction in cell viability incubated for 72 hrs by cell count reagent SF based microplate spectrophotometry	2019	Bioorganic & medicinal chemistry, 06-01, Volume: 27, Issue:11	Synthesis and biological evaluation of novel imidazole nucleosides as potential anti-dengue virus agents.
AID419602	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID548450	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID658744	Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID105958	Compound was evaluated in MDCK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1169736	Selectivity index, ratio of CC50 against human HuH7 cells to EC50 against dengue virus 2	2014	Journal of natural products, Nov-26, Volume: 77, Issue:11	Limonoids from the seeds of Swietenia macrophylla with inhibitory activity against dengue virus 2.
AID218065	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Vero cells	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID464182	Cytotoxicity against acyclovir-sensitive Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID463997	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1150890	Antiviral activity against Herpes simplex virus type 1 infected in human KB cells	1976	Journal of medicinal chemistry, Jun, Volume: 19, Issue:6	Synthesis of 1-(4-thio-beta-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide.
AID283448	Cytotoxicity against MDCK cells	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID229026	Antiviral activity against vaccinia virus (VV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1536100	Selectivity index, ratio of CC50 for African green monkey Vero cells to EC50 for Junin virus IV4454 infected in African green monkey Vero cells	2019	Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4	Modified ribavirin analogues as antiviral agents against Junín virus.
AID1118654	Cytotoxicity against human HeLa cells assessed as concentration required to cause microscopically visible alternation of cell morphology	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID383510	Cytotoxicity against human E6SM cells	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1472385	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by microscopic method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID217589	In vitro antiviral activity against measles virus was evaluated.	1985	Journal of medicinal chemistry, Aug, Volume: 28, Issue:8	Synthesis and biological activity of 6-azacadeguomycin and certain 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides.
AID1783360	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID395956	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1450219	Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 L2/Rp-ACV/2 infected in African green monkey Vero E6 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID218430	Antiviral activity was measured against Rhino virus-1A in human diploid (WI-38) cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID464187	Cytotoxicity against Punta Toro virus infected african green monkey Vero cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID155596	Virus rating against parainfluenza virus type 3	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Analysis of the in vitro antiviral activity of certain ribonucleosides against parainfluenza virus using a novel computer aided receptor modeling procedure.
AID1364928	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 4 days by MTT assay	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	The medicinal chemistry of Chikungunya virus.
AID1391707	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells cocultured with human 293T-Gluc cells at 100 uM preincubated with compound for 2 hrs followed by virus infection measured after 24 hrs by luciferase reporter gene assay	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Secoiridoid analogues from the fruits of Ligustrum lucidum and their inhibitory activities against influenza A virus.
AID1376907	Antiviral activity against VSV-G pseudotyped Influenza A virus infected in human SupT1 cells after 48 hrs by firefly luciferase reporter gene assay	2017	Journal of natural products, 06-23, Volume: 80, Issue:6	Stachybotrysins A-G, Phenylspirodrimane Derivatives from the Fungus Stachybotrys chartarum.
AID1647366	Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as reduction in viral replication at 10 uM treated with compound at 6 hrs post infection by plaque formation assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors.
AID275071	Antiviral activity against Coxsackie B4 virus in HeLa cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID432172	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID659282	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID474356	Antiviral activity against Influenza A virus Wisconsin/67/2005/H3N2 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1181478	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID99572	In vitro antiviral activity against COXB1 virus in human laryngeal epithelioma cell line	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID395935	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1691559	Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) clone 1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by microscopic analysis	2020	European journal of medicinal chemistry, May-15, Volume: 194	N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.
AID527722	Antiviral activity against HCV 1a infected in human HuH7 cells assessed as reduction of viral RNA level at 20 ug/ml after 2 days by QRT-PCR analysis	2010	Bioorganic & medicinal chemistry, Nov-01, Volume: 18, Issue:21	Synthesis and in vitro antiviral activities of 3'-fluoro (or chloro) and 2',3'-difluoro 2',3'-dideoxynucleoside analogs against hepatitis B and C viruses.
AID1280363	Antiviral activity against amantadine-resistant influenza A virus HN/1222 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1241020	Antiviral activity against Tacaribe virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	2- and 3-Fluoro-3-deazaneplanocins, 2-fluoro-3-deazaaristeromycins, and 3-methyl-3-deazaneplanocin: Synthesis and antiviral properties.
AID232130	Ratio measured as the VR of C-3''-deoxyribofuranoside to the VR at a MIC of 54 ug/mL	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and antiviral evaluation of carbocyclic analogues of 2-amino-6-substituted-purine 3'-deoxyribofuranosides.
AID674870	Cytotoxicity against MDCK cells incubated for 48 hrs by CPE method	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors.
AID1081157	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 100 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID1132048	Antibacterial activity against Streptococcus faecalis I	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID548439	Antiviral activity against Influenza A H1N1 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1524783	Selectivity index, ratio of CC50 for cytotoxicity against MDCK cells to EC50 for influenza A virus A/Vietnam/1203/2004 x A/PR/8/34 (H5N1) harboring recombinant NS1 infected in MDCK cells	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.
AID395936	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID280204	Cytotoxicity against HeLa cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID54507	Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells coxsackie virus type B4	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID533320	Selectivity Index, ratio of CC50 for NTZ-11 cell harboring HCV genotype 1b to EC50 for HCV genotype 1b in NTZ-11 replicon cell	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID1433152	Cytotoxicity against MDCK cells assessed as alteration of normal cell morphology by microscopic analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID1783347	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based secondary yield reduction	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID674875	Antiviral activity against Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors.
AID622448	Antiviral activity against Enterovirus 71 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis, structure-activity relationship and in vitro biological evaluation of N-arylethyl isoquinoline derivatives as Coxsackievirus B3 inhibitors.
AID712816	Antiviral activity against amantadine-resistant Influenza A virus (A/PR/8/34 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID82037	Antiviral activity against TK-HSV-1 virus infected HEF cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1571891	Displacement of [3H]N6-R-phenylisopropyladenosine from human A1A adenosine receptor expressed in CHO cell membranes after 60 mins by scintillation proximity assay	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design and in Vivo Characterization of A
AID1783391	Antiviral activity against SARS-COV 2 infected in human Caco-2 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by immunodetection assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1201119	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 72 hrs by microscopic analysis	2015	European journal of medicinal chemistry, Apr-13, Volume: 94	A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID156699	Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with PRK cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID1886813	Antiviral activity against CHIKV infected in African green monkey Vero E6 cells assessed as reduction factor at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID428949	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M mutation in human HuH7 cells after 48 hrs by RNA replicon assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1717748	Antiviral activity against 2019-nCoV BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated with virus for 1 hr followed by cell infection and measured after 2 hrs by qRT-PCR method	2020	Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22	Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID87163	Minimum inhibitory concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in HeLa cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID659291	Cytotoxicity against MDCK cells assessed as morphological changes by microscopic analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID406925	Selectivity index, ratio of CC50 for Vero cells to EC50 for Measles virus Leningrad 16	2008	Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13	Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex.
AID1503313	Selectivity index, ratio of CC50 for bovine MDBK cells to EC50 for Bovine viral diarrhea virus NADL ATCC VR 534	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation.
AID419604	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID88688	Tested for inhibitory effect on RNA virus cell morphology in HeLa cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1647362	Antiviral activity against Chikungunya virus infected in African green monkey Vero cells assessed as reduction in viral replication at 10 uM treated with compound up to 12 hrs post infection by plaque formation assay	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors.
AID217906	Minimum inhibitory concentration (MIC) required to elicit a microscopically visible alteration of cell morphology in Vero cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID1372325	Antiviral activity against Hepatitis C virus infected in pig SPEV cells assessed as protection against virus-induced cytopathic effect	2018	Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1	Isosteric ribavirin analogues: Synthesis and antiviral activities.
AID701509	Selectivity index, ratio of CC50 for human Hep2 cells to EC50 for Respiratory syncytial virus Long infected in human Hep2 cells	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.
AID283989	Antiviral activity against coxsackie B virus type 3 by CPE assay	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Design, synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives.
AID86482	Minimum inhibitory conc. for 50% inhibition of coxsackie B4 virus induced cytopathicity in HeLa cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID68123	Concentration required to reduce vaccinia virus(VV) induced cytopathogenicity by 50% in ESM(embryonic skin muscle) cell cultures.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID204964	The minimum inhibitory concentration required to reduce Sindbis virus induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID218035	Concentration required for microscopically detectable alteration of the normal cell morphology in Vero B cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID611758	Antiviral activity against RSV infected in HeLa cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID376990	Selectivity index, CC50 for human Hep2 cells to IC50 for Cox B3 virus	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID474328	Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID474360	Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID575124	Antiviral activity against adamantane-, oseltamivir-, zanamivir-susceptible Influenza A virus (A/Georgia/17/2006(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis using crystal violet stain	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID475858	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID1505491	Antiviral activity against Influenza virus B/Ned/537/05 infected in MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID766688	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID63761	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (196 strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID668364	In vivo antiviral activity against TMV assessed as curative effect at 500 ug/ml	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis and antiviral activity of novel pyridazines.
AID548443	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity by visual scoring of CPE	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1135882	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to da	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID244630	Selectivity index (TC50/IC50) against Coxsackie virus B3 in Vero cells	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Synthesis and antiviral activity against Coxsackie virus B3 of some novel benzimidazole derivatives.
AID283987	Cytotoxicity against human HeLa cells	2007	Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1	Design, synthesis, and biological evaluation of novel iso-D-2',3'-dideoxy-3'-fluorothianucleoside derivatives.
AID1082878	Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 100 ug/mL at 25 degC after 72 hr by half-leaf method	2012	Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23	Design, synthesis, antiviral activity, and SARs of 14-aminophenanthroindolizidines.
AID354679	Antiviral activity against respiratory syncytial virus assessed as effect on virus-induced cytopathic effect	1996	Journal of natural products, Aug, Volume: 59, Issue:8	Two new naphthoquinones with antiviral activity from Rhinacanthus nasutus.
AID1082876	In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana. tabacum L. leaves assessed as inactivation effect at 100 ug/mL co-incubated with virus measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23	Design, synthesis, antiviral activity, and SARs of 14-aminophenanthroindolizidines.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1687952	Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID216406	Evaluation for antiviral activity against vesion stomatitis virus in primary rabbit kidney cell culture	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Structure-activity relationship of novel oligopeptide antiviral and antitumor agents related to netropsin and distamycin.
AID1543375	Antiviral activity against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect by microscopic analysis	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Antiviral activities of Janus-type nucleosides and their related oxime-intermediates.
AID768197	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID63919	Minimum inhibitory concentration required to elicit microscopically visible cell morphology in E6SM cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID1485236	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID66005	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (Lyons) strain of HSV-2 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID1186342	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Respiratory syncytial virus	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID226101	Minimum inhibitory concentration against Vesicular stomatitis virus in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID273212	Antiviral activity against poliovirus in HeLa S3 cells assessed as reduction in viral titer	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases.
AID68255	Minimum inhibitory concentration required for antiviral activity to reduce Vaccinia virus (VV) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID1692496	Antiviral activity against nCoV-2019 BetaCoV/Wuhan/WIV04/2019 infected in African green monkey VeroE6 cells assessed as reduction in viral yield preincubated for 1 hr followed by viral infection and further replacement of fresh medium containing compound	2020	Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21	COVID-19: Drug Targets and Potential Treatments.
AID1450214	Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for HSV-1 L2 infected in African green monkey Vero E6 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID533318	Cytotoxicity against human TIZ-9 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID1742426	Cytotoxicity against human HEK293T cells assessed as reduction in cell viability after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Nov-15, Volume: 206	Design, synthesis and in vitro anti-influenza A virus evaluation of novel quinazoline derivatives containing S-acetamide and NH-acetamide moieties at C-4.
AID384286	Binding affinity to Plasmodium falciparum spermidine synthase by saturation transfer difference-NMR experiment	2008	Journal of medicinal chemistry, May-08, Volume: 51, Issue:9	Identification of Plasmodium falciparum spermidine synthase active site binders through structure-based virtual screening.
AID611628	Antiviral activity against HIV 2 ROD infected in CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopy	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID217994	Evaluation for antiviral activity against vaccinia virus in primary rabbit kidney cell culture	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Structure-activity relationship of novel oligopeptide antiviral and antitumor agents related to netropsin and distamycin.
AID369468	Selectivity index, ratio of CC50 for african green monkey Vero 76 cells to EC50 for Sandfly fever Naples virus	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID774869	Antiviral activity against Coxsackie B6 virus Schmitt in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	2013	European journal of medicinal chemistry, Nov, Volume: 69	Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.
AID659156	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID218170	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Sindbis virus in African green monkey kidney (Vero B)cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID548437	Cytotoxicity against MDCK cells assessed as cell viability by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID216199	Tested for antiviral activity against parainfluenza virus in african green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID278372	RBV metabolism in Vero E6 cells assessed as RBV-TP concentration at 40 ug/ml after 24 h	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID474543	Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Solomon Islands/03/2006/H1N1	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID216969	Minimum inhibitory conc. for 50% inhibition of Parainfluenza-3 virus induced cytopathicity in Vero cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID539957	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as cell viability after 2 days by MTS assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID249868	Anti BVDV activity relative to ribavirin	2004	Journal of medicinal chemistry, Oct-07, Volume: 47, Issue:21	Synthesis of benzodithiol-2-yl-substituted nucleoside derivatives as lead compounds having anti-bovine viral diarrhea virus activity.
AID303235	Antiviral activity against Sindbis virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID1436792	Antiviral activity against Coxsackievirus B1 Conn-5 infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID535510	Transport through ENT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1169734	Antiviral activity against dengue virus 2 infected in human HuH7 cells after 72 hrs by Western blot and ECL detection based assay	2014	Journal of natural products, Nov-26, Volume: 77, Issue:11	Limonoids from the seeds of Swietenia macrophylla with inhibitory activity against dengue virus 2.
AID1432505	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus H3N2 infected in MDCK cells	2017	Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6	Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses.
AID535522	Transport through CNT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM inosine	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID539922	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1241024	Antiviral activity against Influenza B virus infected in MDCK cells after 3 days by neutral red dye-based plaque reduction assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	2- and 3-Fluoro-3-deazaneplanocins, 2-fluoro-3-deazaaristeromycins, and 3-methyl-3-deazaneplanocin: Synthesis and antiviral properties.
AID361409	Antiviral activity against Vesicular stomatitis Indiana virus infected in human HeLa assessed as inhibition of virus-induced cytopathic effect after 2 days by MTT assay	2002	Journal of natural products, Nov, Volume: 65, Issue:11	New saponins from the starfish Certonardoa semiregularis.
AID106225	Tested for inhibitory effect on RNA virus cell growth in MT-4 cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1081546	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as inactivation effect at 500 ug/ml co-treated with virus for 30 min before inoculation onto leaves measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID767057	Selectivity index, ratio of CC50 for human rhabdomyosarcoma cells to EC50 for Enterovirus 71 infected in human rhabdomyosarcoma cells	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID1773007	Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as late apoptotic cells at 25 uM measured after 60 hrs by Annexin V-FITC/PI staining based flow cytometry analysis (Rvb = 20.2%)	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID774118	Cytotoxicity against African green monkey Vero cells after 48 hrs by Reed-Muench analysis	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Diterpenoids and sesquiterpenoids from the roots of Illicium majus.
AID1265167	Cytotoxicity against HEK293T cells assessed as cell viability at antiviral EC50 after 24 hrs by cell titer-glo luminescent cell viability assay	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID482704	Antiviral activity against Vaccina virus infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID489678	Antiviral activity against Coxsackie virus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 days by MTS assay	2010	European journal of medicinal chemistry, Jul, Volume: 45, Issue:7	Benzylidene/2-chlorobenzylidene hydrazides: synthesis, antimicrobial activity, QSAR studies and antiviral evaluation.
AID1293608	Inhibition of Influenza A virus PR/8/34 6His-tagged PA (239 to 716 residues) interaction with GST-tagged PB1 (1 to 25 residues) expressed in Escherichia coli compound treated in PBS buffer measured after overnight incubation by ELISA	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.
AID284535	Cytotoxicity against E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID1152079	Inhibition of Influenza A virus A/PR/8/34 infected in MDCK cells after 48 hrs by plaque reduction assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.
AID1265162	Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID156696	Concentration required for microscopically detectable alteration of the normal cell morphology in PRK cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID539925	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID218254	Evaluation for antiviral activity against parainfluenza-3 virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1132044	Antibacterial activity against Bacillus subtilis	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID575247	Antiviral activity against adamantane-resistant zanamivir-,oseltamivir-susceptible Influenza A virus (A/Florida/01/2009(H3N2)) harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microscopic analysis	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID395963	Toxicity in BALB/c mouse	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID108463	Compound was tested for antiviral activity against measles virus in vero cells	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID275072	Antiviral activity against RSV in HeLa cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID416776	Antiviral activity against VSV in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID297312	Antiviral activity against VSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID392725	Antiviral activity against Coxsackievirus B3 assessed as inhibition of virus-induced cytopathicity	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	Synthesis of 5-isoxazol-5-yl-2'-deoxyuridines exhibiting antiviral activity against HSV and several RNA viruses.
AID1783357	Antiviral activity against West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID535529	Transport through CNT3 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1687950	Antiproliferative activity against human HuH-7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID395952	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean viral titer per 0.1 mL of serum at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID216349	Tested for antiviral activity against coxsackie B-4 virus in African green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID1132049	Antibacterial activity against Streptococcus pyogenes CN10	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID1265168	Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of infectivity at 5 uM measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID1485244	Cytotoxicity against dog MDCK cells assessed as alterations in normal cell morphology measured after 5 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1886819	Cytotoxicity against African green monkey Vero E6 cells infected with ZIKV COL345Si measured after 6 days by MTT assay	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID1055008	Antiviral activity against Western equine encephalomyelitis virus infected in human BE(2)-C cells assessed as reduction of viral titer at 25 uM after 24 hrs by plaque reduction assay (Rvb = 25.7 +/- 5.2 x 10'6 pfu/ml)	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication.
AID1485249	Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by formazan-based colorimetric assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1450216	Antiviral activity against acyclovir-resistant HSV-1 L2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID370227	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean day of death at 30 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID482707	Antiviral activity against VSV infected in human HeLa cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID216945	In vitro antiviral activity against V V virus in (vero) V cells of african green monkey kidney	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID218433	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Rhinovirus 9 in human diploid (WI-38)cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID400418	Antiviral activity against RSV A-2 infected in human Hep2 cells after 3 days by plaque neutralization assay	1998	Journal of natural products, May, Volume: 61, Issue:5	Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea.
AID1081543	Phytotoxicity against Nicotiana tabacum (tobacco) plant	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID105788	Antiviral activity against influenza A,H2N2 virus infected MDCK cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1724446	Antiviral activity against HCV genotype 2a JFH-1 infected in human Huh7.5 cells after 3 days by renilla luciferase reporter gene assay	2020	Bioorganic & medicinal chemistry, 10-01, Volume: 28, Issue:19	SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
AID416766	Antiviral activity against Coxsackievirus B4 in human HeLa cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID312074	Antiviral activity against poliovirus infected HeLa S3 cells assessed as plaque formation at 2 mM	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity.
AID368958	Antiviral activity against RSV RSS infected human Hep2 cells assessed as reduction of viral antigen synthesis after 3 days by ELISA	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID658748	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction visual scoring of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID416749	Antiviral activity against VSV in human HeLa cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1578004	Selectivity index, ratio of TC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents.
AID217264	Effective concentration required to inhibit PuntaToro virus-induced cytopathicity by 50% in Vero cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID217590	In vitro antiviral activity against parainfluenza type 3 virus in Vero cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and biological activity of certain nucleoside and nucleotide derivatives of pyrazofurin.
AID400430	Antiviral activity against RSV infected in human Hep2 cells assessed as virus-induced cytopathic effect administered 3 hrs postinfection	1998	Journal of natural products, May, Volume: 61, Issue:5	Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea.
AID1230119	Cytotoxicity against African green monkey Vero cells assessed as alternation of cell morphology by microscopic analysis	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID1066042	Antiviral activity against Influenza A virus (A/Wisconsin/67/2005(H3N2)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID659157	Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID1235017	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3-induced cytopathic effect in African green monkey Vero cells	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum.
AID1360697	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID1253095	Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs and fresh drug admini	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents.
AID63945	Inhibition of virus-induced cytopathicity in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID474348	Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Vietnam/1203/ 2004H/H5N1 by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1238137	Antiviral activity against HCV genotype 1 in patient assessed as virological response rate	2015	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 25, Issue:16	Design and synthesis of imidazole N-H substituted amide prodrugs as inhibitors of hepatitis C virus replication.
AID217989	Minimum cytotoxic concentration against vaccinia virus embryonic skin muscle cell cultures	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID1691542	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by MTS assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.
AID658606	Cytotoxicity against MDCK cells assessed as cell viability by colorimetric formazan-based MTS assay	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID535519	Transport through ENT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID634832	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1237440	Antiviral activity against SARS-CoV assessed as inhibition of viral replication	2015	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 25, Issue:15	Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity.
AID156710	Evaluation for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID199175	Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells reovirus type 1	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID1443885	Cytotoxicity against human BJ cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus.
AID396873	Antiviral activity against Rift Valley fever virus infected in african green monkey Vero cells assessed as plaque reduction at 250 ug/mL
AID548424	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID634088	Antiviral activity against HCV genotype 1b infected in human HuH7 cells assessed as reduction in luciferase activity at 10 uM after 3 days	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID774870	Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Coxsackie B3 virus Schmitt	2013	European journal of medicinal chemistry, Nov, Volume: 69	Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.
AID1498135	Cytotoxicity against African green monkey Vero cells assessed as alteration of cell morphology by microscopic analysis	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID392501	Antiviral activity against Human adenovirus 2	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID1181192	Antiviral activity against influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining assay	2014	Journal of natural products, Jul-25, Volume: 77, Issue:7	Eleganketal A, a highly oxygenated dibenzospiroketal from the marine-derived fungus Spicaria elegans KLA03.
AID218369	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of Vero cells	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID548445	Cytotoxicity against african green monkey Vero cells assessed as altered cell morphology	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID68118	Concentration required to cause a microscopically detectable alteration of normal ESM cell morphology.	1992	Journal of medicinal chemistry, Jun-12, Volume: 35, Issue:12	(+-)-carbocyclic 5'-nor-2'-deoxyguanosine and related purine derivatives: synthesis and antiviral properties.
AID395971	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID665017	Inhibition of IMPDH in human CEM cells assessed as formation of [2,8-3H]hypoxanthine from [2,8-3H]IMP after 20 to 60 mins	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations.
AID693525	Antiviral activity against Influenza A/HK/7/87 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID1205003	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID767056	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID1204068	Cytotoxicity against bovine MDBK cells assessed as cell viability after 72 hrs by MTT method	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.
AID539920	Cytotoxicity against african green monkey Vero cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1736921	Cytotoxicity against chicken embryo fibroblast assessed as reduction in cell viability after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID63939	concentration required to inhibit HSV-1(KOS)-induced cytopathicity by 50% in E6SM cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID87153	Evaluated for minimum inhibitory concentration against HeLa cells (human carcinoma) infected with VSV, Coxs, B4, polio-1 virus	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID218002	Minimum inhibitory concentration against vaccinia virus embryonic skin muscle cell cultures	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID774868	Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for Coxsackie B3 virus Nancy	2013	European journal of medicinal chemistry, Nov, Volume: 69	Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.
AID1135884	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to da	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID1773418	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study.
AID231386	Adenylate to guanylate ratio for the cell fraction was determined	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	Synthesis and evaluation of 5-amino-1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine and certain related nucleosides as inhibitors of purine nucleoside phosphorylase.
AID1436798	Antiviral activity against Coxsackievirus B4 J.V.B infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID1407825	Antiviral activity against Influenza virus H5N1	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
AID1654870	Antiviral activity against Zika virus infected in Vero E6 cells assessed as reduction in virus-induced cytopathic effect incubated for 96 hrs by CCK8 assay	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1443862	Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by CellTiter-Glo luminescent assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus.
AID611765	Antiviral activity against Feline coronavirus infected in CRFK cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1066050	Cytotoxicity against HEK293 cells assessed as cell viability after 24 hrs by MTT assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID1127182	Cytotoxicity against human HuH7 cells assessed as cell viability at 100 uM after 3 days by XTT assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives.
AID658742	Cytotoxicity against human HeLa cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1485242	Antiviral activity against vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1736918	Antiviral activity against Influenza A virus (A/chicken/Hebei/LZF/ 2014(H5N2)) group-2 infected in chicken embryo fibroblast assessed as reduction in viral infection preincubated for 1 hrs followed by fibroblast infection and measured after 72 hrs by hema	2020	European journal of medicinal chemistry, Apr-01, Volume: 191	Discovery of novel "Dual-site" binding oseltamivir derivatives as potent influenza virus neuraminidase inhibitors.
AID1546421	Cytotoxicity in African green monkey Vero cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1	Synthesis and anti-CVB3 activity of 4-amino acid derivative substituted pyrimidine nucleoside analogues.
AID1133177	Antiviral activity against Adenovirus type 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.
AID370207	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1873824	Antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in human Huh7.5 cells assessed as reduction in viral titer incubated for 3 days by plaque assay	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID665836	In vivo antiviral activity against TMV assessed as protection effect at 500 ug/mL	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and antiviral activity of novel quinazolinones.
AID1055979	Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 24 hrs by MTS assay	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID1127180	Antiviral activity against DENV2 16681 infected in human Huh-7 cells at 20 uM after 3 days by luciferase reporter gene assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives.
AID1293611	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.
AID1858559	Antiviral activity against SARS-CoV 2 nCoV-2019BetaCoV/Wuhan/WIV04/2019 infected in african green monkey Vero E6 cells measured after 48 hrs	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Primed for global coronavirus pandemic: Emerging research and clinical outcome.
AID648648	Cytotoxicity against MDCK cells	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Synthesis and anti-influenza activity of aminoalkyl rupestonates.
AID87164	Minimum inhibitory concentration (MIC) required to elicit a microscopically visible alteration of cell morphology in HeLa cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID1234207	Selectivity index, ratio of TC50 for African green monkey MDCK cells to IC50 for influenza A virus (A/Hanfang/359/95(H3N2))	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis.
AID1594023	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured after 72 hrs by alamar blue assay	2019	Bioorganic & medicinal chemistry letters, 07-01, Volume: 29, Issue:13	Discovery of 5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrazin-2(1H)-one derivatives as new potent PB2 inhibitors.
AID659149	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID280197	Antiviral activity against parainfluenza3 virus in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID216370	Antiviral activity against sindbis virus infected Vero cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1204070	Selectivity index, ratio of CC50 for bovine MDBK cells to EC50 for BVDV infected in bovine MDBK cells	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.
AID280203	Cytotoxicity against E6SM cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID1271122	Selectivity index, ratio of CC50 for mock-infected human Huh7.5 cells to EC50 for recombinant HCV genotype 2a JFH1	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID392528	Antiviral activity against influenza H2N2 virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID357951	Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Parainfluenza virus type 3	2001	Journal of natural products, Oct, Volume: 64, Issue:10	New antiviral cassane furanoditerpenes from Caesalpinia minax.
AID235487	Selectivity index is the ratio of IC50 to EC50 of F-MuLV.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID301702	Ratio of kinact for Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form to KI for Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NAD form	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID401228	Selectivity index, ratio of CC50 for MDCK cells to IC50 for PIV3	2004	Journal of natural products, Apr, Volume: 67, Issue:4	Antiviral flavonoids from the seeds of Aesculus chinensis.
AID224916	Antiviral activity against parainfluenza virus type 3 in Vero cell culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID475861	Cytotoxicity against human HuH5.2 cells	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID1511214	Antiviral activity against RABV infected in BSR cells preincubated for 4 hrs followed by viral infection and further incubated with compounds for 24 hrs by immunostaining-based assay	2019	ACS medicinal chemistry letters, Aug-08, Volume: 10, Issue:8	DABMA: A Derivative of ABMA with Improved Broad-Spectrum Inhibitory Activity of Toxins and Viruses.
AID1071706	Antiviral activity against Influenza A virus H5N1 by cytopathy assay	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID1636440	Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID218166	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Parainfluenza virus-3 in African green monkey kidney (Vero B)cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID1890796	Selectivity index, ratio of CC50 for human HEK293T cells to IC50 for antiviral activity against Influenza A virus A/WSN/33 (H1N1) infected in HEK293T cells	2022	Bioorganic & medicinal chemistry letters, 05-15, Volume: 64	Design, synthesis, and anti-influenza A virus activity evaluation of novel indole containing derivatives of triazole.
AID474359	Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID768191	Antiviral activity against Punts virus B4 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID291035	Antiviral activity against sindbis virus in Vero cells assessed as reduction of virus plaque formation after 7 days	2007	Journal of medicinal chemistry, Jun-28, Volume: 50, Issue:13	Novel C-6 fluorinated acyclic side chain pyrimidine derivatives: synthesis, (1)H and (13)C NMR conformational studies, and antiviral and cytostatic evaluations.
AID395957	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as inhibition of liver damage at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID370216	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID217998	Evaluated for minimum inhibitory concentration against Vaccinia virus (VV) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID463995	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID625277	FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of less concern for DILI	2011	Drug discovery today, Aug, Volume: 16, Issue:15-16	FDA-approved drug labeling for the study of drug-induced liver injury.
AID1546420	Antiviral activity against CVB3 infected in African green monkey Vero cells by MTT assay	2020	Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1	Synthesis and anti-CVB3 activity of 4-amino acid derivative substituted pyrimidine nucleoside analogues.
AID474331	Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID297313	Antiviral activity against Parainfluenza 3 virus in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID87143	Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with HeLa cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID249185	Cytotoxic concentration required to inhibit Vero cell growth by 50%	2005	Bioorganic & medicinal chemistry letters, Jan-17, Volume: 15, Issue:2	Synthesis and antiviral activity against Coxsackie virus B3 of some novel benzimidazole derivatives.
AID301696	Inactivation of Trypanosoma cruzi recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109 assessed by measuring fluorescence	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID217884	Minimum cytotoxic concentration in Vero cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID1132046	Antibacterial activity against Staphylococcus aureus Russel	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID1638600	Antiviral activity against West Nile virus	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.
AID1409609	Cytotoxicity of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID1650129	Antiviral activity against IInfluenza A virus H3N2 A/HK/7/87 infected in MDCK cells after 4 days by MTS assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID1131475	Antiviral activity against Herpes simplex virus 1 infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 3 days after virus infection	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Synthesis and determination of antiviral activity of the 2'(3')-O-methyl derivatives of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide).
AID301325	Inhibition of HCV replication in Huh7 cells after 48 hrs by luciferase assay	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	5'-O-masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents.
AID87142	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in HeLa cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID1710786	Cytotoxicity against African green monkey Vero cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopy	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID766685	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID443830	Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as cell viability by cell-based MTS assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1135739	Antiviral activity against Vaccinia virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Synthesis and antiviral acticity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin).
AID300560	Antiviral activity against influenza A/Jingfang/262/95(H1N1) virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID1436794	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3 (strain Nancy) infected in African green monkey Vero cells	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID416771	Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID634753	Antiviral activity against thymidine kinase-positive Varicella Zoster virus Oka infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1280345	Cytotoxicity against MDCK cells after 40 hrs by Celltiter-Glo assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID396875	Antiviral activity against Yellow fever virus infected in rhesus monkey MK2 cells assessed as plaque reduction at 250 ug/mL
AID218434	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Rhinovirus-1A in human diploid (WI-38)cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID1132047	Antibacterial activity against Staphylococcus aureus 1517	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID63765	The minimum inhibitory concentration was measured on E6SM cells against TK-Herpes simplex virus type 1 (B2006 strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID197658	Concentration that reduces Rauscher murine leukemia virus titer by 50%	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID1498132	Antiviral activity against Coxsackie virus B4 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID360162	Antiviral activity against HCV 1b with NS3-4A R155M mutation in human Huh7 cells after 48 hrs by replicon cell assay	2007	The Journal of biological chemistry, Aug-03, Volume: 282, Issue:31	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
AID611629	Antiviral activity against VSV infected in HEL cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID68254	Minimum inhibitory concentration required for antiviral activity to reduce TK-HSV-1 (B2006) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID1071707	Antiviral activity against Influenza A virus H1N1 by cytopathy assay	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID548446	Antiviral activity against parainfluenza-3 virus infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1315540	Antiviral activity against Bovine viral diarrhea virus 1 infected in MDBK cells	2016	European journal of medicinal chemistry, Sep-14, Volume: 120	The therapeutic voyage of pyrazole and its analogs: A review.
AID1869551	Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells assessed as inhibition of virus-induced cytopathic effect by CPE inhibition assay
AID88278	Evaluated for minimum inhibitory concentration against TK-B2006 strain of Herpes simplex virus (HSV-1) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID1118655	Cytotoxicity against African green monkey Vero cells assessed as concentration required to cause microscopically visible alternation of cell morphology	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1409607	IC50 for antiviral activity against SARS-CoV-2 in the Vero E6 cell line at 48 h by immunofluorescence-based assay (detecting the viral NP protein in the nucleus of the Vero E6 cells).	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID345884	Cytotoxicity against human Huh-9-13 cells	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity.
AID395975	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID68126	Tested for inhibitory effect on DNA virus HSV-2 (G) in ESM cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID105946	Antiviral activity against influenza A H2N2(A2 japan/305/57) in MDCK cells	2003	Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10	Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
AID300579	Antiviral activity against influenza A/Jingfang/Fm1 (H1N1) infected in mouse assessed as survival of mouse at 100 mg/kg, ip bid after 2 hrs of viral infection for 5 days	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1167619	Cytotoxicity against human ORL8 cells after 72 hrs by WST-1 assay	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID226341	Antiviral activity against sindbis virus in Vero cell culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID368960	Antiviral activity against RSV Long infected human Hep2 cells after 5 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID1201115	Cytotoxicity against MDCK cells after 72 hrs by microscopic analysis	2015	European journal of medicinal chemistry, Apr-13, Volume: 94	A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID84959	Concentration required to reduce HSV-2 (G) induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID1505493	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID218044	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Coxsackie virus B4 in African green monkey kidney (Vero B)cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID648646	Antiinfluenza activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Synthesis and anti-influenza activity of aminoalkyl rupestonates.
AID535506	Transport through CNT1 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1144797	Antiviral activity against Influenza A virus (A2/Asian/J305) infected in Swiss albino mouse assessed as increase in host survival at 20 mg/kg, ip administered 4 hrs before infection, 1 hr after infection followed by twice daily for next 6 days for total o	1976	Journal of medicinal chemistry, Feb, Volume: 19, Issue:2	Synthesis of tetrazole ribonucleosides and their evaluation as antiviral agents.
AID369464	Antiviral activity against Sandfly fever Naples virus assessed as inhibition of virus-induced visual cytopathic effect after 3 to 5 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID86523	Minimum toxic concentration required to cause a microscopically detectable alteration of normal HeLa cell morphology	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID1349210	Selectivity index, ratio of CC50 for human Ava5 cells to IC50 for HCV	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression.
AID763865	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.
AID593228	Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Human enterovirus 71	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
AID634836	Antiviral activity against Feline coronavirus infected in CrFK cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID216182	Tested for inhibitory effect on RNA virus SV in Vero cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID156693	Minimum cytotoxic concentration in primary rabbit kidney (PRK) cell cultures	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID1073349	Antiviral activity against Chikungunya virus	2014	Journal of medicinal chemistry, Feb-27, Volume: 57, Issue:4	Chikungunya virus: emerging targets and new opportunities for medicinal chemistry.
AID66002	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (F) strain of HSV-1 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID395939	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID87141	Minimum cytotoxic concentration in HeLa cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID1069924	Antiviral activity against HCV infected in human Huh7 cells assessed as reduction in RNA level by luciferase reporter gene assay relative to control	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	Dual inhibition of HCV and HIV by ring-expanded nucleosides containing the 5:7-fused imidazo[4,5-e][1,3]diazepine ring system. In vitro results and implications.
AID1501509	Antiviral activity against Coxsackievirus B3 (strain Nancy) infected in human HEP2 cells assessed as inhibition of virus-induced cytopathic effect at 16 ug/ml after 48 hrs by MTT dye based assay
AID1691539	Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by microscopic analysis	2020	European journal of medicinal chemistry, May-15, Volume: 194	N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.
AID464178	Cytotoxicity against Herpes simplex virus 1 KOS infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID548434	Antiviral activity against coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1077005	Antiviral activity against Influenza A virus (A/FM/1/1947(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID434309	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID297314	Antiviral activity against HSV1 KOS in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID611767	Antiviral activity against Influenza A H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1710779	Selectivity index, ratio of MCC for human HeLa cells to EC50 for Human coxsackievirus B4 infected in human HeLa cells	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID228856	In vitro antiviral activity was tested against vaccinia virus(VV)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of 5-thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides.
AID1066678	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs by crystal violet staining technique	2014	Journal of natural products, Feb-28, Volume: 77, Issue:2	Sorbicatechols A and B, antiviral sorbicillinoids from the marine-derived fungus Penicillium chrysogenum PJX-17.
AID766690	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID766692	Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID419606	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID1066048	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 12 hrs by toluidine blue staining assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID1427837	Cytotoxicity against virus infected HEL cells assessed as alteration in cell morphology by microscopic method
AID482714	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID288931	Antiviral activity against Respiratory syncytial virus in HeLa cells	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID376987	Antiviral activity against influenza A virus H1N1 A/NWS/33 in human MDCK cells assessed as reduction of virus induced cytopathic effect	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID401225	Cytotoxicity against MDCK cells	2004	Journal of natural products, Apr, Volume: 67, Issue:4	Antiviral flavonoids from the seeds of Aesculus chinensis.
AID575125	Antiviral activity against adamantane-, zanamivir-susceptible oseltamivir-resistant Influenza A virus (A/Georgia/20/2006(H1N1)) harboring neuraminidase H274Y mutant infected in MDCK cells assessed as inhibition of viral replication after 3 days by microsc	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID1699935	Antiviral activity against Influenza A virus (A/California/07/09(H1N1))pdm09 infected in MDCK cells assessed as reduction in viral replication preincubated with compound for 1 hr followed by viral infection and measured after viral cultivation for 48 hrs	2020	Bioorganic & medicinal chemistry letters, 12-15, Volume: 30, Issue:24	New type of anti-influenza agents based on benzo[d][1,3]dithiol core.
AID1242265	Antiviral activity against human enterovirus 71 infected in ICR mouse assessed as increase in survival rate at 50 mg/kg, ip qd for 8 days dosed 2 hrs post infection and measured at 14 days post infection	2015	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 25, Issue:17	Quinolizidine alkaloids reduced mortality in EV71-infected mice by compensating for the levels of T cells.
AID206521	Tested for the antimicrobial activity minimum inhibitory concentration) against Staphylococcus hominis	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID32220	Selectivity index expressed as ratio of compound concentration required to reduce the growth of normal uninfected ATH8 cells by 50% to the compound concentration (MIC)	1986	Journal of medicinal chemistry, Sep, Volume: 29, Issue:9	Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
AID475233	Antiviral activity against HCV 1b infected in human HuH7 cells assessed as inhibition of viral RNA replication after 4 days by replicon assay	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication.
AID218032	Antiviral activity was measured against forest virus in african green monkey kidney (Vero B) cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID1272969	Cytotoxicity against MDCK cells after 72 hrs by MTT assay	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	The semi-synthesis of novel andrographolide analogues and anti-influenza virus activity evaluation of their derivatives.
AID1077003	Antiviral activity against oseltamivir-resistant Influenza A virus (A/Tianjinjinnan/15/2009/H1N1) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID474546	Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Wisconsin/67/2005/H3N2	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1886816	Cytotoxicity against African green monkey Vero E6 cells infected with Zika 459148 measured after 72 hrs by MTT assay	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID1578008	Selectivity index, ratio of TC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza B virus infected in dog MDCK cells	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents.
AID1696831	Cytotoxicity against human A549 cells assessed as reduction in cell viability by MTT assay	2020	Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22	Structure-aided optimization of 3-O-β-chacotriosyl epiursolic acid derivatives as novel H5N1 virus entry inhibitors.
AID474329	Antiviral activity against Influenza A virus Gull/PA/4175/83/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1118644	Antiviral activity against HIV-2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1485239	Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID665833	In vitro antiviral activity against TMV assessed as inhibition rate at 500 ug/mL	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and antiviral activity of novel quinazolinones.
AID1687948	Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID1503331	Antiviral activity against Human respiratory syncytial virus A2 ATCC VR 1540 infected in African green monkey Vero 76 cells assessed as protection against virus-induced cytopathic effect after 5 days by crystal violet staining-based plaque reduction assay	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Inhibitors of Yellow Fever Virus replication based on 1,3,5-triphenyl-4,5-dihydropyrazole scaffold: Design, synthesis and antiviral evaluation.
AID308659	Selectivity index, ratio of EC50 for influenza A/Hong Kong/7/87 (H3N2) to MCC for MDCK cells	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Design and synthesis of bioactive adamantane spiro heterocycles.
AID257888	Antiviral activity against HeLa cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID360157	Antiviral activity against wild type HCV 1b Con1 in human Huh7 cells after 48 hrs by replicon cell assay	2007	The Journal of biological chemistry, Aug-03, Volume: 282, Issue:31	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID463989	Antiviral activity against Herpes simplex virus 1 KOS infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID155597	The minimum inhibitory concentration required to reduce parainfluenza virus type 3 induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID303234	Antiviral activity against Reovirus 1 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID717171	Antiviral activity against Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1298244	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus induced cytopathic effect measured by visual scoring of cytopathic effect	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID223415	Concentration required to reduce influenza virus A (ishikawa) induced cytopathogenicity by 50%	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1710777	Cytotoxicity against human HeLa cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID634760	Antiviral activity against Vesicular stomatitis virus infected in human Hela cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID105977	Minimum concentration (ug/mL) for in vitro antiviral activity against influenza virus (type A0/PR/8/34) in Madin-Darby canine kidney (MDCK) host cell cultures	1990	Journal of medicinal chemistry, Apr, Volume: 33, Issue:4	Synthesis and biological evaluation of carbocyclic analogues of lyxofuranosides of 2-amino-6-substituted-purines and 2-amino-6-substituted-8-azapurines.
AID162241	The minimum inhibitory concentration required to reduce polio virus type I induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID294254	Cytotoxicity against Huh7 ET cells assessed as beta actin level relative to control	2007	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 17, Issue:8	Structure-activity relationship studies on anti-HCV activity of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.
AID371497	Cytotoxicity against MDBK cells after 3 days by MTS/PMS assay	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	New 1-indanone thiosemicarbazone derivatives active against BVDV.
AID320045	Cytotoxicity against dog MDCK cells	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Three-component, one-pot synthesis of novel 2,4-substituted 5-azolylthiopyrimidine library for screening against anti-influenza virus A.
AID419597	Cytotoxicity against human HeLa cells assessed as alteration in cell morphology	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID533313	Antiviral activity against HCV genotype 1b in RP7 replicon cell after 4 days by blot hybridization analysis	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID400432	Selectivity index, ratio of EC50 for RSV administered 3 hrs postinfection over IC50 for human Hep2 cells administered 3 hrs after infection	1998	Journal of natural products, May, Volume: 61, Issue:5	Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea.
AID86512	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HeLa cell line infected with RSV virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID767050	Antiviral activity against influenza A virus H1N1 infected in dog MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID395671	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean serum ALT levels at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID218169	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against forest virus in African green monkey kidney (Vero B)cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID1472403	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) clone 2 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity measured after 3 passages with 12.5 to 50 uM 2-Isopropyl-N-[2-(piperidin-1-yl)ethyl]aniline hydroc	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID261583	Inhibition of West Nile viral Rluc-Neo-Rep in BHK21 cell line	2006	Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6	Identification of compounds with anti-West Nile Virus activity.
AID1485246	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1710800	Cytotoxicity against dog MDCK cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopy	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID475859	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID474346	Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Hong Kong/213/2003/H5N1 by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID311338	Antiviral activity against Tobacco mosaic virus U1 after 72 hrs by half leaf method	2007	Journal of natural products, Sep, Volume: 70, Issue:9	Benzylphenethylamine alkaloids from Hosta plantaginea with inhibitory activity against tobacco mosaic virus and acetylcholinesterase.
AID1753360	Cytotoxicity against MDCK cells by MTT assay	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
AID1691541	Cytotoxicity against MDCK cells assessed as change in cell morphology measured after 72 hrs by microscopic analysis	2020	European journal of medicinal chemistry, May-15, Volume: 194	N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.
AID218167	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Reo virus-1 in African green monkey kidney (Vero B)cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID539954	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1772992	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 60 hrs by MTT assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID1171742	Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Respiratory syncytial virus	2014	Journal of natural products, Dec-26, Volume: 77, Issue:12	Anti-respiratory syncytial virus prenylated dihydroquinolone derivatives from the gorgonian-derived fungus Aspergillus sp. XS-20090B15.
AID1123336	Activity at rat liver nucleoside kinase assessed as phosphorylation using [gamma-32P]-ATP after 10 to 20 mins	1979	Journal of medicinal chemistry, Jun, Volume: 22, Issue:6	Studies on the mechanism of antiviral action of 1-(beta-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide (ribavirin).
AID1710785	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID1066047	Inhibition of influenza A virus RNA-dependent RNA polymerase expressed in HEK293 cells after 24 hrs by dual luciferase reporter gene assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID218376	Evaluation for antiviral activity against reo virus-1 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID482702	Antiviral activity against HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID634752	Antiviral activity against Human cytomegalovirus Davis infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID533316	Cytotoxicity against human RP7 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID1716976	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID216714	Antiviral activity at 1-3 uM determined in a culture of Visna virus; IA = inactive	1989	Journal of medicinal chemistry, Jun, Volume: 32, Issue:6	Synthesis and biological properties of purine and pyrimidine 5'-deoxy-5'-(dihydroxyphosphinyl)-beta-D-ribofuranosyl analogues of AMP, GMP, IMP, and CMP.
AID288932	Antiviral activity against Reovirus1 in vero cells	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID763859	Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Perth/16/2009(H3N2))	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.
AID369869	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID718711	Cytotoxicity against MDCK cells after 48 hrs by MTT assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009.
AID1118646	Antiviral activity against Reovirus 1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1852995	Cytotoxicity against human HCT-116 cells overexpressing human MDR1 assessed as DNA damage by measuring fluorescence intensity at 100 uM incubated for 30 mins by Hoechst 33342 staining accumulation assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID280205	Cytotoxicity against Vero cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID155587	Antiviral activity at 10-30 uM determined in a culture of Parainfluenza virus type 3; IA = inactive	1989	Journal of medicinal chemistry, Jun, Volume: 32, Issue:6	Synthesis and biological properties of purine and pyrimidine 5'-deoxy-5'-(dihydroxyphosphinyl)-beta-D-ribofuranosyl analogues of AMP, GMP, IMP, and CMP.
AID434307	Antiviral activity against HSV1 KOS infected in HEL cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID1077002	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Tianjinjinnan/15/2009/H1N1)	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID278368	RBV metabolism in Vero E6 cells assessed as RBV-TP concentration at 10 ug/ml after 24 h	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID767058	Antiviral activity against Enterovirus 71 infected in human rhabdomyosarcoma cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID1274004	Cytotoxicity against African green monkey Vero cells assessed as inhibition of cell proliferation after 8 days	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID301327	Antiviral index, ratio of CC50 for Huh7 cells to EC50 for HCV replication	2007	Bioorganic & medicinal chemistry, Nov-15, Volume: 15, Issue:22	5'-O-masked 2'-deoxyadenosine analogues as lead compounds for hepatitis C virus (HCV) therapeutic agents.
AID63917	Effective concentration required to inhibit Vaccinia virus-induced cytopathicity by 50% in E6SM cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID768189	Antiviral activity against influenza A virus H1N1 subtype infected in dog MDCK cells assessed as reduction of virus-induced cytopathogenicity by MTS assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID1364929	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Chikungunya virus KC969207	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	The medicinal chemistry of Chikungunya virus.
AID400419	Cytotoxicity against RSV long infected human Hep2 cells after 3 days	1998	Journal of natural products, May, Volume: 61, Issue:5	Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea.
AID395707	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1710799	Cytotoxicity against human HEL cells assessed as changes in cell morphology incubated for 3 to 6 days by light microscopy	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID1186332	Antiviral activity against Yellow fever virus infected in BHK21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID767053	Cytotoxicity against human HeLa cells after 72 hrs by MTT assay	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID1773059	Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of TNF-alpha expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID68253	Minimum inhibitory concentration required for antiviral activity to reduce HSV-2 (G) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID87162	Minimum inhibitory concentration required to reduce polio virus -1 induced cytopathogenicity by 50% in HeLa cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID303230	Antiviral activity against Coxsackie virus B4 in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID1131478	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Synthesis and determination of antiviral activity of the 2'(3')-O-methyl derivatives of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide).
AID401229	Antiviral activity against influenza virus type A H1N1 in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2004	Journal of natural products, Apr, Volume: 67, Issue:4	Antiviral flavonoids from the seeds of Aesculus chinensis.
AID1505495	Antiviral activity against Influenza virus A/X-31 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID1133194	Inhibition of guanine nucleotide biosynthesis in human EAC assessed as [14C]hypoxanthine incorporation at 1 mM after 60 mins by TLC analysis	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.
AID416780	Antiviral activity against influenza H1N1 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by visual cytopathic effect scoring method	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID548436	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1498122	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID218532	Inhibitory concentration against parainfluenza-3 virus in vero cells	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID434320	Cytotoxicity against HEL cells assessed as change in cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID395944	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as survival at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID284537	Antiviral activity against Sindbis virus-induced cytopathogenicity in Vero cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID701510	Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as log reduction in virus titer at 25 uM by virus plaque reduction assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.
AID1181479	Antiviral activity against Influenza A virus (A/PR/8/34(H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID82047	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with HSV-1 virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID1265164	Antiviral activity against O'nyong-nyong virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID300559	Antiviral activity against influenza A/Jifang/15/90 (H3N2) virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID395677	Antiviral activity against Pichinde virus An 4763 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID658613	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID84957	Compound was tested for antiviral activity against herpes simplex virus-2(G) in primary rabbit kidney cells	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID474334	Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID548442	Antiviral activity against Influenza A H3N2 virus subtype infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID320044	Antiviral activity against influenza A virus H3N2 (A3 China/15/90) expressed in dog MDCK cells assessed as reduction of virus-induced cytopathic effect	2008	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 18, Issue:3	Three-component, one-pot synthesis of novel 2,4-substituted 5-azolylthiopyrimidine library for screening against anti-influenza virus A.
AID1505499	Cytotoxicity against HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in cell viability after 3 days by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID1611059	Cytotoxicity against dog MDCK cells assessed as cell death incubated for 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23	Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
AID1306319	Antiviral activity against Herpes simplex virus type 1 L2 infected in African green monkey Vero E6 cells assessed as reduction of virus-induced cytopathic effect	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	An alternative route to the arylvinyltriazole nucleosides.
AID1066043	Antiviral activity against oseltamivir-resistant Influenza A virus (A/Parma/24/2009(H1N1)) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID1118647	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1081155	Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 50 ug/ml	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID1536097	Selectivity index, ratio of CC50 for human A549 cells to EC50 for Junin virus IV4454 infected in human A549 cells	2019	Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4	Modified ribavirin analogues as antiviral agents against Junín virus.
AID1235015	Antiviral activity against Coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Bioactive Sesquiterpenes and Lignans from the Fruits of Xanthium sibiricum.
AID427565	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1135868	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in MDCK cells assessed as plaque reduction after 3 days by agar diffusion method	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID217254	In vitro antiviral activity against parainfluenza type 3(para 3) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(>1000 ug/mL)	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID474332	Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID658743	Antiviral activity against Vesicular stomatitis virus infected in HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID393162	Antiviral activity against influenza A virus H3N2 assessed as inhibition of virus-induced cytopathic effect after 72 hrs by MTS assay	2009	Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4	Design and synthesis of 1,2-annulated adamantane piperidines with anti-influenza virus activity.
AID768196	Antiviral activity against Parainfluenza-3 virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID246794	Effective concentrations at which 10-fold depression of HCV RNA was observed in AVA5 cells (Huh 7 cells with subgenomic HCV replicon BB7I	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	5'-Homoneplanocin A inhibits hepatitis B and hepatitis C.
AID275076	Antiviral activity against Punta Toro virus in Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID87146	Evaluation for antiviral activity against Coxsackie virus B4 in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1542956	Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for Zika virus MR766 infected in African green monkey Vero E6 cells	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication.
AID665008	Cytostatic activity against mouse L1210/0 after 48 hrs by cell counting	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations.
AID1118649	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1303366	Cytotoxicity against mock-infected MDBK cells assessed as reduction in cell viability after 72 hrs by MTT assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems.
AID1126470	Selectivity index, ratio of CC50 for African green monkey Vero cells to IC50 for Enterovirus 71 BrCr	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Prenylated benzoylphloroglucinols and xanthones from the leaves of Garcinia oblongifolia with antienteroviral activity.
AID1408324	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1pdm) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID366287	Cytotoxicity against MDCK cells by MTT assay	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID217114	Percentage plaque reduction was determined against venezuelan equine encephalitis (VEE) virus in african green monkey kidney (vero,V) at a conc of 250-500 ug/mL. Toxic level(>1000 ug/mL); 10-30	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID216200	Tested for cytotoxic activity in African green monkey kidney cells (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID1092199	Antiviral activity against Tobacco mosaic virus (TMV) inoculated in 5-6 growth stage leaf assessed as inhibition effect at 100 ug/mL at 25 degC after 72 hr by half-leaf method	2012	Journal of agricultural and food chemistry, Oct-17, Volume: 60, Issue:41	Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of phenanthroindolizidines and their analogues.
AID301691	Inactivation of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 at 100 uM	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID1253093	Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability incubated for 1 hr by WST-1 assay	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents.
AID539930	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID383524	Antiviral activity against Punta Toro virus in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID65708	Antiviral activity against herpes simplex virus-1 KOS (HSV-1) in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID474333	Antiviral activity against Influenza A virus Hong Kong/213/2003/H5N1 infected MDCK cells after 3 days by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID395668	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in serum at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID105963	Anti-influenza virus activity was evaluated in Madin-Darby canine kidney (MDCK) cells against influenza A H2N2 strain (A2 Japan/305/57)	1999	Bioorganic & medicinal chemistry letters, Dec-20, Volume: 9, Issue:24	Synthesis of 2-(2-adamantyl)piperidines and structure anti-influenza virus A activity relationship study using a combination of NMR spectroscopy and molecular modeling.
AID395955	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 20 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1071709	Antiviral activity against Influenza A virus H3N2 by cytopathy assay	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID416778	Cytotoxicity against MDCK cells assessed as drug level causing microscopically detectable alteration of normal cell morphology	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1543374	Cytotoxicity against African green monkey Vero cells infected with Herpes simplex virus 1 after 72 hrs by MTT assay	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Antiviral activities of Janus-type nucleosides and their related oxime-intermediates.
AID1135873	Toxicity in ferret infected with Influenza A virus Port Chalmers/1/73 (H3N2) assessed as change in body weight at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured after 7 days relative to untreated control	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID1169735	Cytotoxicity against human HuH7 cells after 72 hrs by MTS assay	2014	Journal of natural products, Nov-26, Volume: 77, Issue:11	Limonoids from the seeds of Swietenia macrophylla with inhibitory activity against dengue virus 2.
AID1716983	Cytotoxicity against HEK293T cells assessed as reduction in cell viability measured after 48 hrs by CCK8 assay	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID1773045	Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of RIG-1 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 days post infection by RT-PCR analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID1135871	Toxicity in ferret infected with Influenza A virus Port Chalmers/1/73 (H3N2) assessed as change in body weight at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured after 7 days relative to untreated control	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID1071708	Antiviral activity against Influenza B virus by cytopathy assay	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID216368	Antiviral activity against Reo 1 virus infected vero cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1152081	Cytotoxicity against MDCK cells after 48 hrs by MTT assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.
AID1782691	Antiviral activity against Respiratory syncytial virus assessed as reduction in virus-induced cytopathic effect by MTS assay	2021	European journal of medicinal chemistry, Aug-05, Volume: 220	Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.
AID88297	Evaluated for minimum inhibitory concentration against G,196, Lyons strains of Herpes simplex virus (HSV-2) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID395937	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in serum at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID528351	Antiviral activity against Poliovirus infected in human HeLaS3 cells assessed as frequency of viral mutagenesis plaque at 150 uM by guanidine resistance assay	2010	Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22	Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses.
AID701514	Antiviral activity against Respiratory syncytial virus Long infected in human Hep2 cells assessed as post infection time duration of protection against virus-induced cytopathogenicity by Cell Titer-Glo assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.
AID1127183	Antiviral activity against DENV2 16681 infected in human Huh-7 cells after 3 days by luciferase reporter gene assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives.
AID776645	Cytotoxicity against mouse mammary carcinoma 755 cells assessed as growth inhibition	2013	European journal of medicinal chemistry, Nov, Volume: 69	Pyrazole containing natural products: synthetic preview and biological significance.
AID407614	Antiviral activity against Hepatitis C virus infected human Huh-5-2 cells assessed as inhibition of luciferase activity after 4 days by RNA replicon assay	2008	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 18, Issue:11	Arylethynyltriazole acyclonucleosides inhibit hepatitis C virus replication.
AID1687947	Antiproliferative activity against human MDA-MB-435 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID1773426	Antiviral activity against Human adenovirus 5 Adenoid 75 infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 7	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study.
AID514139	Cytotoxicity against human HuH7 cells	2010	Bioorganic & medicinal chemistry, Jul-15, Volume: 18, Issue:14	Studies on the anti-hepatitis C virus activity of newly synthesized tropolone derivatives: identification of NS3 helicase inhibitors that specifically inhibit subgenomic HCV replication.
AID218030	Antiviral activity was measured against Parainfluenza virus-3 in african green monkey kidney (Vero B) cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID539923	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID308658	Cytotoxicity against MDCK cells assessed as changes in cell morphology	2007	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 17, Issue:15	Design and synthesis of bioactive adamantane spiro heterocycles.
AID634091	Cytotoxicity against human HuH7 cells infected with HCV1b after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID1688553	Cytotoxicity against human Huh7.5 cells assessed as reduction in cell viability after 3 days by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Molecular design, synthesis, and biological evaluation of bisamide derivatives as cyclophilin A inhibitors for HCV treatment.
AID370214	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID108456	Minimum inhibitory concentration required to reduce measles virus induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID216504	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with coxsackie B4 virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID228733	Minimum cytotoxic concentration which causes microscopically detectable alteration of normal cell morphology after 2 days of incubation.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID443831	Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as inhibition of virus-induced cytopathic effect by cell-based assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID216409	Compound was tested for antiviral activity against vesicular stomatitis virus in primary rabbit kidney cells	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID1118641	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1498125	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathicity by MTS assay	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID303233	Antiviral activity against Parainfluenza 3 in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID218402	Minimum inhibitory concentration required to reduce Sindbis virus induced cytopathogenicity by 50% in african green monkey (VeroB) cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID1710784	Antiviral activity against Human coxsackievirus B4 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID300562	Antiviral activity against influenza B/Jifang/13/97 virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID228408	Antiviral activity against reovirus type 1 in Vero cell culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID434317	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID1271120	Cytotoxicity against mock-infected human Huh7.5 cells assessed as reduction in cell viability incubated for 5 hrs by MTT assay	2015	Journal of medicinal chemistry, Dec-24, Volume: 58, Issue:24	Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
AID1687969	Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 7 days by trypan blue exclusion assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID1135877	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in rectal temperature at 7 to 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 relative to untreated control	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID229235	Inhibitory activity against vesicular stomatitis virus (VSV) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID1687953	Antiproliferative activity against rat C6 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID659153	Antiviral activity against Respiratory syncytial virus infected in HeLa cells	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID474343	Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Gull/PA/4175/83/H5N1 by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1886806	Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well incubated for 72 hrs by crystal violet staining based assay	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID1524782	Selectivity index, ratio of CC50 for cytotoxicity against MDCK cells to EC50 for Influenza A virus (A/Brisbane/10/2007(H3N2)) infected in MDCK cells	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.
AID1372321	Antiviral activity against Human herpesvirus 1 L2 infected in African green monkey Vero E6 cells assessed as protection against virus-induced cytopathic effect	2018	Bioorganic & medicinal chemistry letters, 01-01, Volume: 28, Issue:1	Isosteric ribavirin analogues: Synthesis and antiviral activities.
AID68252	Minimum inhibitory concentration required for antiviral activity to reduce HSV-1 (KOS) induced cytopathicity in human embryonic skin-muscle cells (ESM)	1994	Journal of medicinal chemistry, Apr-29, Volume: 37, Issue:9	Synthesis and antiviral activities of 8-alkynyl-, 8-alkenyl-, and 8-alkyl-2'-deoxyadenosine analogues.
AID297321	Antiviral activity against Punta Toro virus in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID1261313	Antiviral activity against YFV infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID86803	Antiviral activity against vesicular stomatitis virus infected HeLa cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID217895	Minimum inhibitory concentration against parainfluenza 3 virus in Vero cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID475852	Cytotoxicity against MDCK cells	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID1783396	Antiviral activity against SARS-COV 2 infected in human Calu-3 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID443829	Antiviral activity against Influenza A virus (A/Hong Kong/7/87(H3N2)) assessed as inhibition of virus-induced cytopathic effect by cell-based assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID395970	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1273991	Antiviral activity against HHV-1 CDC Atlanta infected in African green monkey Vero cells assessed as maximal non toxic concentration causing reduction of viral titer after 48 hrs by crystal violet staining assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID1113454	Antiviral activity against Unidentified Influenza A virus (H1N1) infected MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID395950	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 50 mg/kg, po twice daily for 7 days administered 72 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID63916	Effective concentration required to inhibit Herpes simplex virus-2 (HSV-2) induced cytopathicity by 50% in E6SM cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID474325	Antiviral activity against Influenza A virus Duck/MN/1525/81/H5N1 infected MDCK cells assessed as inhibition of virus-induced cytopathic effect after 3 days	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1126469	Cytotoxicity against African green monkey Vero cells after 4 days by MTT assay	2014	Journal of natural products, Apr-25, Volume: 77, Issue:4	Prenylated benzoylphloroglucinols and xanthones from the leaves of Garcinia oblongifolia with antienteroviral activity.
AID1204076	Selectivity index, ratio of CC50 for African green monkey Vero 76 cells to EC50 for RSV infected in African green monkey Vero 76 cells	2015	Bioorganic & medicinal chemistry letters, Jun-01, Volume: 25, Issue:11	N-((1,3-Diphenyl-1H-pyrazol-4-yl)methyl)anilines: A novel class of anti-RSV agents.
AID1360698	Cytotoxicity against MDCK cells assessed as alterations in normal cell morphology measured after 3 to 6 days by microscopic analysis	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID284529	Antiviral activity against Vaccinia virus-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID535536	Transport through CNT2 in mouse hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in presence of sodium ions in Kreb-henseleit buffer containing 100 nM NBMPR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID432175	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID257893	Antiviral activity against herpes simplex virus 1 TK- KOS ACVr strain in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID1498142	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID284527	Antiviral activity against HSV2 G-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID1146289	Antiviral activity against Rhinovirus 8 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control	1978	Journal of medicinal chemistry, Sep, Volume: 21, Issue:9	Imidazo[1,2-a]-s-triazine nucleosides. Synthesis and antiviral activity of the N-bridgehead guanine, guanosine, and guanosine monophosphate analogues of imidazo[1,2-a]-s-triazine.
AID383514	Antiviral activity against HSV2 G in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1710783	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID1186336	Antiviral activity against Poliovirus type 1 Sabin strain infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1435482	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3 Nancy infected in African green monkey Vero cells	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Synthesis and evaluation of halogenated 12N-sulfonyl matrinic butanes as potential anti-coxsackievirus agents.
AID432174	Cytotoxicity against human HeLa cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID1873821	Antiviral activity against Zika virus H/PAN/2016/BEI-259634 infected in African green monkey Vero cells assessed as inhibition of viral replication by measuring ZIKV E glycoprotein level at 100 uM incubated for 3 days by ELISA analysis relative to control	2022	Bioorganic & medicinal chemistry, 08-15, Volume: 68	Anti-HCV and Zika activities of ribavirin C-nucleosides analogues.
AID1498141	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1186334	Cytotoxicity against mock-infected african green monkey Vero 76 cells after 48 to 96 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1783365	Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A Puerto Rico/8/34/H1N1 infected in MDCK cells	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1230106	Antiviral activity against Coxsackievirus B4 infected in African green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Design, antiviral and cytostatic properties of isoxazolidine-containing amonafide analogues.
AID1498131	Antiviral activity against Sindbis Virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID659286	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID85127	Inhibitory activity against HSV-2 (Lyons) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID368961	Antiviral activity against RSV A2 infected human Hep2 cells after 5 days by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID370230	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID474361	Antiviral activity against Influenza B virus Malaysia/2506/2004 infected MDCK cells after 3 days by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1731875	Cytotoxicity against human HEp-2 cells assessed as reduction in cell viability after 48 hrs by MTS assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Synthesis and antiviral activity of a series of novel quinoline derivatives as anti-RSV or anti-IAV agents.
AID303237	Cytotoxicity against HeLa cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID1131479	Inhibition of DNA synthesis in primary rabbit kidney cells assessed as inhibition of [3H]thymidine incorporation into DNA	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Synthesis and determination of antiviral activity of the 2'(3')-O-methyl derivatives of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide).
AID216970	Minimum inhibitory conc. for 50% inhibition of Reo-1 virus induced cytopathicity in Vero cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID718709	Selectivity index, ratio of CTD50 for MDCK cells to ED50 for influenza virus A/California/07/09 (H1N1) pdm09	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Anti-viral activity of (-)- and (+)-usnic acids and their derivatives against influenza virus A(H1N1)2009.
AID1725102	Cytotoxicity against human HepG2 cells assessed as cell viability at 100 uM measured after 4 days by CellTiter-Glo luminescent cell viability assay relative to control	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery of Zika Virus NS2B/NS3 Inhibitors That Prevent Mice from Life-Threatening Infection and Brain Damage.
AID395714	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID383506	Cytotoxicity against human HeLa cells	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID303231	Antiviral activity against Coxsackie virus B4 in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID324798	Antiviral activity against YFV Jimenez infected in Syrian golden hamster assessed as serum alanine aminotransferase at 50 mg/kg, ip bid for 7 days	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Activity of T-1106 in a hamster model of yellow Fever virus infection.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1485241	Antiviral activity against coxsackie B4 virus infected in human HeLa cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID482709	Cytotoxicity against human E6SM cells by MTT assay	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID400431	Cytotoxicity against human Hep2 cells administered 3 hrs postinfection	1998	Journal of natural products, May, Volume: 61, Issue:5	Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea.
AID701508	Cytotoxicity against human Hep2 cells by Cell Titer-Glo assay	2012	Journal of medicinal chemistry, Oct-25, Volume: 55, Issue:20	(S)-N-(2,5-Dimethylphenyl)-1-(quinoline-8-ylsulfonyl)pyrrolidine-2-carboxamide as a small molecule inhibitor probe for the study of respiratory syncytial virus infection.
AID535507	Transport through CNT2 in mouse hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1246931	Cytotoxicity against MDCK cells assessed as cell viability by visual assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Synthesis and antiviral activity of some new bis-1,3-thiazole derivatives.
AID217250	In vitro antiviral activity against herpes simplex type 1 (HSV-1) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(>1000 ug/mL)	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID475234	Cytotoxicity against human HuH7 cells after3 days by MTT assay	2010	Journal of medicinal chemistry, Apr-22, Volume: 53, Issue:8	Synthesis of new acridone derivatives, inhibitors of NS3 helicase, which efficiently and specifically inhibit subgenomic HCV replication.
AID66940	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against HSV-2 virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID1241033	Cytotoxicity against MDCK cells relative to control	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	2- and 3-Fluoro-3-deazaneplanocins, 2-fluoro-3-deazaaristeromycins, and 3-methyl-3-deazaneplanocin: Synthesis and antiviral properties.
AID395682	Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Tacaribe virus TRVL11573	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1081544	Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 100 ug/ml	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID767051	Selectivity index, ratio of CC50 for human HeLa cells to EC50 for Adenovirus type 7 infected in human HeLa cells	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID478324	Antiviral activity against influenza B virus assessed as inhibition of viral induced cytopathic effect	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID85704	In vitro antiviral activity (virus ratings (VR)) determined by comparing CPE development in drug-treated cells (T) and HSV-1 virus control cells	1984	Journal of medicinal chemistry, Nov, Volume: 27, Issue:11	Synthesis and antiviral/antitumor activities of certain 3-deazaguanine nucleosides and nucleotides.
AID217560	concentration required to inhibit Coxsackie virus B4-induced cytopathicity by 50% in Vero cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID1075686	Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level at 41 uM after 8 to 10 days by quantitative PCR analysis	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	4'-Substituted pyrimidine nucleosides lacking 5'-hydroxyl function as potential anti-HCV agents.
AID87798	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in Hela cells	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID155582	In vitro antiviral activity was tested against parainfluenza type 3 (para3)	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of 5-thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides.
AID395969	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1710787	Selectivity index, ratio of MCC for African green monkey Vero cells to EC50 for Sindbis virus infected in African green monkey Vero cells	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID463988	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as protection from virus-induced cytopathogenicity after 4 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1687955	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID387576	Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID1542949	Antiviral activity against Dengue virus	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication.
AID712813	Antiviral activity against Influenza A virus (A/HK/7/87 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect by MTS assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID235813	Selectivity ratio of MCC50 to that of EC50 of influenza A H2N2(A2 japan/305/57)	2003	Bioorganic & medicinal chemistry letters, May-19, Volume: 13, Issue:10	Spiro[pyrrolidine-2,2'-adamantanes]: synthesis, anti-influenza virus activity and conformational properties.
AID1638586	Cytotoxicity against human A549 cells after 3 days by MTT assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.
AID575245	Antiviral activity against oseltamivir-susceptible zanamivir-, adamantane-resistant Influenza A virus (A/Texas/12/2007 (clone)(H3N2)) harboring neuraminidase E119I mutant and harboring M2 S31N mutant infected in MDCK cells assessed as inhibition of viral	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.
AID204960	Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells sindbis virus	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID1636357	Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1081542	Induction of systemic acquired resistance activity in TMV infected-Nicotiana tabacum (tobacco) leaves at 50 ug/ml	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID1687946	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID1234203	Antiviral activity against coxsackievirus B3 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathogenic effect dosed 1 hr after viral adsorption	2015	Journal of natural products, Jul-24, Volume: 78, Issue:7	Antiviral Matrine-Type Alkaloids from the Rhizomes of Sophora tonkinensis.
AID1852998	Cytotoxicity against human HCT-116 cells incubated for 48 hrs by MTT assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1261314	Antiviral activity against Reo-1 virus infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1536095	Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4	Modified ribavirin analogues as antiviral agents against Junín virus.
AID1886812	Antiviral activity against HHV-1 29R strain infected in African green monkey Vero E6 cells assessed as concentration required for higher viral reduction factor measured after 72 hrs by crystal violet staining based inverted microscopic analysis	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID1435486	Antiviral activity against Coxsackievirus B4 JVB infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Synthesis and evaluation of halogenated 12N-sulfonyl matrinic butanes as potential anti-coxsackievirus agents.
AID1055986	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) harboring wild type M2 channel infected in MDCK cells assessed as concentration required to 1 log10 reduction of virus yield after 24 hrs by RT-PCR analysis	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	3-Azatetracyclo[5.2.1.1(5,8).0(1,5)]undecane derivatives: from wild-type inhibitors of the M2 ion channel of influenza A virus to derivatives with potent activity against the V27A mutant.
AID217585	In vitro antiviral activity against Parainfluenza type 3 was evaluated.	1985	Journal of medicinal chemistry, Aug, Volume: 28, Issue:8	Synthesis and biological activity of 6-azacadeguomycin and certain 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides.
AID1485248	Antiviral activity against Influenza A virus A/Ned/378/05(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1592373	Antiviral activity against Tobacco mosaic virus inoculated in Nicotiana tabacum leaves assessed as passivation by measuring local lesion numbers at 100 mg/l pre-incubated with virus for 30 mins followed by inoculation and measured up to 4 days	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	Chemical synthesis, crystal structure, versatile evaluation of their biological activities and molecular simulations of novel pyrithiobac derivatives.
AID1716978	Antiviral activity against GFP-fused wild-type RSV subgroup A Long infected in human HEp-2 cells assessed as relative fluorescence intensity at 20 uM pretreated for 1 hr followed by viral infection measured 24 to 72 hrs post infection by fluorescence assa	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID84402	Antiviral activity against HSV-1(KOS) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1075689	Antiviral activity against HCV subtype 1a infected in Huh-7 cells assessed as reduction in viral RNA level after 8 to 10 days by quantitative PCR analysis	2014	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 24, Issue:5	4'-Substituted pyrimidine nucleosides lacking 5'-hydroxyl function as potential anti-HCV agents.
AID1485240	Cytotoxicity against human HeLa cells assessed as alterations in cell morphology measured after 5 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID474336	Antiviral activity against Influenza A virus Vietnam/1203/ 2004H/H5N1 infected MDCK cells after 3 days by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1773034	Toxicity in BALB/c mouse infected with RSV-Long assessed as body weight loss at 50 mg/kg/day administered via gastric gavage once daily for 6 days	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID114980	The maximum tolerated dose was evaluated in mice (mg/kg of body weight).	1985	Journal of medicinal chemistry, Sep, Volume: 28, Issue:9	Synthesis and biological activity of 5-thiobredinin and certain related 5-substituted imidazole-4-carboxamide ribonucleosides.
AID1503650	Antiviral activity against Fluc-tagged DENV2 strain 16681 infected in human HuH7 cells assessed as inhibition of viral replication at 1 uM after 3 days by luciferase reporter gene assay relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents.
AID648684	Antiviral activity against C4 type Human enterovirus 71 FY0805 infected in human RD cells assessed as inhibition of viral replication by plaque reduction assay	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Antiviral effect of geraniin on human enterovirus 71 in vitro and in vivo.
AID1246929	Antiviral activity against Influenza A virus (A/California/07/2009(H1N1) infected in MDCK cell line assessed as reduction of virus induced cytopathic effect by visual assay	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Synthesis and antiviral activity of some new bis-1,3-thiazole derivatives.
AID155586	Minimum inhibitory concentration required to reduce parainfluenza type 3 induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID427563	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1783343	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability by Celltiter-Glo luminescent cell viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1181483	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as reduction in host cell viability after 72 hrs by MTS assay	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1055006	Antiviral activity against Fort Morgan virus infected in human BE(2)-C cells assessed as reduction of viral titer at 25 uM after 24 hrs by plaque reduction assay (Rvb = 47.1 +/- 10.5 x 10'6 pfu/ml)	2013	Journal of medicinal chemistry, Nov-27, Volume: 56, Issue:22	Optimization of novel indole-2-carboxamide inhibitors of neurotropic alphavirus replication.
AID369127	Drug resistance, ratio of EC50 for plaque picked A-33903-resistant RSV RSS from passage 2 to EC50 for DMSO-passaged wild type RSV RSS	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID1249918	Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 1-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis	2015	ACS medicinal chemistry letters, Aug-13, Volume: 6, Issue:8	Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID156705	Evaluation for antiviral activity against herpes simplex virus-1(TK-) (B2006) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID366289	Selectivity index, ratio of CC50 to MDCK cells to IC50 to Influenza A Jinan/15/90 H3N2 virus	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID1682702	Selectivity index, ratio of CC50 for MDCK cells to IC50 for Influenza A virus (A/Puerto Rico/8/34 (H1N1)) infected in MDCK cells
AID1650130	Cytotoxicity against MDCK cells assessed as minimum cytotoxic concentration after 4 days by MTS assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID1610168	Antiviral activity against Human coronavirus 229E infected in human HELF cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by microscopic analysis	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID474342	Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Gull/PA/4175/83/H5N1 by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1391710	Cytotoxicity against MDCK cells assessed as reduction in cell viability by CCK8 assay	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Secoiridoid analogues from the fruits of Ligustrum lucidum and their inhibitory activities against influenza A virus.
AID1853008	Inhibition of recombinant human P-gp ATPase activity in presence of MgATP preincubated for 40 min measured after 20 min by Pgp-Glo assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID216179	Tested for inhibitory effect on RNA virus PV-3 in Vero cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID288915	Cytotoxicity against E6SM cells assessed as alteration in cell morphology	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID1783352	Antiviral activity against Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID475854	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID1710801	Cytotoxicity against cat CRFK cells assessed as reduction in cell viability incubated for 3 to 6 days by MTS assay	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID416772	Cytotoxicity against human HEL cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1253096	Cytotoxicity against human HuH7-J20 cells expressing secreted alkaline phosphatase reporter gene assessed as cell viability preincubated for 1 hr followed by fresh drug administration every 24 hrs at 1/10th of initial concentration for 48 hrs by WST-1 ass	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents.
AID482711	Antiviral activity against Parainfluenza virus 3 infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID54505	Compound was tested for antiviral activity (minimum inhibition concentration) in HeLa cells coxsackie virus type 4	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID1081199	Induction of systemic acquired resistance in Nicotiana tabacum (tobacco) mosaic virus infected Nicotiana tabacum (tobacco) plant at 100 ug/mL at 25 degC for 72 hr	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis, crystal structure, and biological activity of 4-methyl-1,2,3-thiadiazole-containing 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID88350	Compound was evaluated for its inhibitory effect on the replication of encephalomyocarditis virus (EMCV) in HeLa cells	2003	Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20	Synthesis and biological evaluation of thymine nucleosides fused with 3',4'-tetrahydrofuran ring.
AID1435485	Antiviral activity against Coxsackievirus B2 Ohio-1 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Synthesis and evaluation of halogenated 12N-sulfonyl matrinic butanes as potential anti-coxsackievirus agents.
AID1408125	Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells measured after 2 days by plaque reduction assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction.
AID217099	Percentage plaque reduction was determined against pichinde(PICH) virus in african green monkey kidney (vero,V). Toxic level(>1000 ug/mL); 61-90	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID87192	Minimum inhibitory concentration against Herpes simplex virus 1(KOS)	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID1092197	In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated left side of Nicotiana tabacum L. leaves assessed as inactivation effect at 100 ug/mL co-incubated with virus measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Oct-17, Volume: 60, Issue:41	Design, synthesis, and anti-tobacco mosaic virus (TMV) activity of phenanthroindolizidines and their analogues.
AID1226136	Cytotoxicity against MDCK cells assessed as decrease in cell viability by MTT assay	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits.
AID303236	Antiviral activity against Punta Toro virus in Vero cells reduction of virus-induced cytopathogenicity after 4 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID392529	Antiviral activity against influenza H3N2 virus	2009	Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2	Unified QSAR approach to antimicrobials. 4. Multi-target QSAR modeling and comparative multi-distance study of the giant components of antiviral drug-drug complex networks.
AID463992	Antiviral activity against VSV infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 1 to 2 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1113452	Antiviral activity against Influenza B virus infected in MDCK cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID1638584	Cytotoxicity against human HuH7 cells after 3 days by MTT assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.
AID290452	Cytotoxicity against Vero E6 cells	2007	Bioorganic & medicinal chemistry letters, May-01, Volume: 17, Issue:9	Synthesis and biological evaluation of nucleoside analogues having 6-chloropurine as anti-SARS-CoV agents.
AID1505497	Antiviral activity against Influenza virus B/Ned/537/05 infected in HGPRT deficient 6-thioguanine-resistant MDCK cells assessed as reduction in viral replication at 3 days post infection by formazan-based MTS assay	2018	Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14	Prodrugs of the Phosphoribosylated Forms of Hydroxypyrazinecarboxamide Pseudobase T-705 and Its De-Fluoro Analogue T-1105 as Potent Influenza Virus Inhibitors.
AID218249	Evaluation in Vero cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1261326	Antiviral activity against DENV-2 infected in BHK-21 cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID658616	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID29735	Toxic level was evaluated; None	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID63766	The minimum inhibitory concentration was measured on E6SM cells against Vaccinia virus	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID767055	Antiviral activity against Coxsackievirus B5 infected in human HepG2 cells assessed as inhibition of virus-induced cytopathogenicity after 48 hrs by crystal violet staining method	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID395940	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean serum ALT levels at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID726614	Antiviral activity against wild type Measles virus mWTFb infected in simian B95a cells assessed as virus-induced cytopathogenicity incubated for 30 mins prior to inoculation measured after 3 days by phase contrast microscopy	2013	Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3	Novel antiviral activity of l-dideoxy bicyclic nucleoside analogues versus vaccinia and measles viruses in vitro.
AID224345	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against KOS strain of Herpes simplex virus-1 in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID1293615	Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus PR/8/34 infected in MDCK cells	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.
AID303238	Cytotoxicity against Vero cells assessed as alteration in morphology after 3 days	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID712809	Antiviral activity against amantadine-sensitive Influenza A virus (A/FM/1/47 (H1N1)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID482706	Antiviral activity against TK-deficient acyclovir-resistant HSV1 KOS infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID1571900	Displacement of [125I]N6-(4-amino-3-iodobenzyl)adenosine-5-N-methyluronamide from human A3A adenosine receptor expressed in CHO cell membranes at 10 uM after 60 mins by scintillation proximity assay relative to adenosine 5-N-ethyluronamide	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design and in Vivo Characterization of A
AID416765	Cytotoxicity against african green monkey Vero cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1081163	In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 100 ug/ml	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1435487	Antiviral activity against Coxsackievirus B5 Faulkner infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Synthesis and evaluation of halogenated 12N-sulfonyl matrinic butanes as potential anti-coxsackievirus agents.
AID421726	Cytotoxicity against human Hep2 cells	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Antiviral constituents against respiratory viruses from Mikania micrantha.
AID1536096	Antiviral activity against Junin virus IV4454 infected in human A549 cells assessed as reduction in vrius yield after 48 hrs by plaque assay	2019	Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4	Modified ribavirin analogues as antiviral agents against Junín virus.
AID1433147	Antiviral activity against Punta Toro virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID216971	Minimum inhibitory conc. for 50% inhibition of forest virus induced cytopathicity in Vero cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID1186329	Cytotoxicity against mock-infected MDBK cells after 48 to 96 hrs by MTT assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID88523	Inhibitory concentration against respiratory syncytial virus in HeLa cells	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID1293609	Antiviral activity against Influenza A virus PR/8/34 infected in MDCK cells assessed as inhibition of plaque formation treated for 1 hr measured after 2 days by toluidine blue staining-based assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.
AID432179	Cytotoxicity against african green monkey Vero cells assessed as minimum cytotoxic concentration required to cause microscopically detectable alteration in normal cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID383513	Antiviral activity against HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID383518	Antiviral activity against in Vesicular stomatitis virus in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1118653	Cytotoxicity against human HEL cells assessed as concentration required to cause microscopically visible alternation of cell morphology	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1486231	Cytotoxicity against bovine MDBK cells assessed as reduction in cell viability after 3 days by MTS/PES assay
AID1379364	Toxicity in ICR mouse infected with EV71 695F assessed as death at 100 mg/kg, ip qd administered for 7 days measured on day 5	2017	ACS medicinal chemistry letters, Aug-10, Volume: 8, Issue:8	Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD.
AID360168	Ratio of IC50 for HCV 1b with NS3-4A R155G mutation to IC50 for wild type HCV 1b	2007	The Journal of biological chemistry, Aug-03, Volume: 282, Issue:31	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
AID1687967	Antiproliferative activity against human IGROV-1 cells assessed as reduction in cell growth incubated for 3 days by trypan blue exclusion assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID1729929	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase.
AID751219	Antiviral activity against Influenza A virus H1N1 infected in dog MDCK cells after 48 hrs by CPE inhibition assay	2013	Journal of natural products, Jun-28, Volume: 76, Issue:6	Antiviral alkaloids produced by the mangrove-derived fungus Cladosporium sp. PJX-41.
AID220033	Antiviral activity against coxsackie B4 in Vero cell culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID768199	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID648650	Selectivity index, ratio of TC50 for MDCK cells to IC50 for influenza A virus H1N1	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Synthesis and anti-influenza activity of aminoalkyl rupestonates.
AID432177	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID468105	Antiviral activity against SFV infected in BHK cells assessed as surviving virus fraction at 200 uM after 14 hrs by luciferase reporter gene assay in presence of 50 ug/ml guanosine	2009	Journal of natural products, Nov, Volume: 72, Issue:11	Betulin-derived compounds as inhibitors of alphavirus replication.
AID1432507	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza B virus infected in MDCK cells	2017	Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6	Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses.
AID634759	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1253091	Antiviral activity against HCV JFH1 infected in human HuH7-J20 cells assessed as inhibition of viral life cycle by measuring secreted alkaline phosphatase level preincubated with cells for 1 hr followed by viral inoculation for 3 hrs measured at 72 hrs	2015	Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22	Rethinking the old antiviral drug moroxydine: Discovery of novel analogues as anti-hepatitis C virus (HCV) agents.
AID555931	Antiviral activity against HCV genotype 1b infected in human Huh-9-13 cells assessed as reduction in viral replication selected after 3 passages at 30 ug/ml by quantitative RT-PCR	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors.
AID1651271	Cytotoxicity against African green monkey Vero E6 cells assessed as cell viability at 40 uM relative to control	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Design, synthesis, and evaluation of novel 4-amino-2-(4-benzylpiperazin-1-yl)methylbenzonitrile compounds as Zika inhibitors.
AID217267	Effective concentration required to inhibit parainfluenza-3 virus-induced cytopathicity by 50% in Vero cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID1336610	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones.
AID688918	Antiviral activity against Bovine viral diarrhea virus 1-NADL ATCC VR534 infected in MDBK cells assessed as reduction of viral cytopathic effect after 2 days bt MTS assay	2012	Bioorganic & medicinal chemistry, Oct-01, Volume: 20, Issue:19	Synthesis and biological evaluation of novel homochiral carbocyclic nucleosides from 1-amino-2-indanols.
AID86799	Effects on cell morphology of HeLa cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID1082993	Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus inactivation effect at 500 ug/mL measured 3 to 4 days post inoculation	2012	Journal of agricultural and food chemistry, Sep-05, Volume: 60, Issue:35	Design, synthesis, and antiviral activity evaluation of phenanthrene-based antofine derivatives.
AID395681	Selectivity index, ratio of CC50 for african green monkey Vero cells to EC50 for Pichinde virus An 4763	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID361407	Antiviral activity against Coxsackievirus B3 Nancy infected in human HeLa assessed as inhibition of virus-induced cytopathic effect after 2 days by MTT assay	2002	Journal of natural products, Nov, Volume: 65, Issue:11	New saponins from the starfish Certonardoa semiregularis.
AID88277	Evaluated for minimum inhibitory concentration against KOS, F, McIntyre strains of Herpes simplex virus (HSV-1) in primary rabbit kidney cells	1990	Journal of medicinal chemistry, May, Volume: 33, Issue:5	Stereospecific synthesis and antiviral properties of different enantiomerically pure carbocyclic 2'-deoxyribonucleoside analogues derived from common chiral pools: (+)-(1R,5S)- and (-)-(1S,5R)-2-oxabicyclo[3.3.0]oct-6-en-3-one.
AID86357	Minimum inhibitory conc. for 50% inhibition of Polio-1 virus induced cytopathicity in HeLa cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID1241028	Cytotoxicity against African green monkey Vero 76 cells	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	2- and 3-Fluoro-3-deazaneplanocins, 2-fluoro-3-deazaaristeromycins, and 3-methyl-3-deazaneplanocin: Synthesis and antiviral properties.
AID1398131	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 48 hrs by crystal violet staining based method	2018	Bioorganic & medicinal chemistry letters, 09-15, Volume: 28, Issue:17	Generation of methylated violapyrones with improved anti-influenza A virus activity by heterologous expression of a type III PKS gene in a marine Streptomyces strain.
AID216348	Tested for antiviral activity against Sindbis virus in African green monkey kidney cell (Vero)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID402537	Selectivity index, ratio of IC50 for MDCK cells to EC50 for influenza A virus NWS33	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus.
AID1113463	Antiviral activity against Vesicular stomatitis virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID83887	Compound was tested for antiviral activity against herpes simplex virus-1(KOS) in primary rabbit kidney cells	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID383521	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID535515	Transport through ENT2 in rat hepatocytes by oil filtration assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID88279	In vitro antiviral activity against herpes simplex virus/1(HSV/1) expressed as viral rating (VR)	1981	Journal of medicinal chemistry, Oct, Volume: 24, Issue:10	Synthesis and biological activity of certain derivatives of oxazinomycin and related oxadiazole nucleosides.
AID543660	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by luciferase reporter gene assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID774864	Antiviral activity against HCV expressing pFL-J6/JFH/JC1 infected in human Huh7.5 cells assessed as inhibition of viral RNA synthesis after 96 hrs by one-step RT-PCR analysis	2013	European journal of medicinal chemistry, Nov, Volume: 69	Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.
AID87281	Minimum inhibitory concentration (MIC) required to reduce virus-induced cytopathogenicity by 50% against Vesicular stomatitis virus in HeLa cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID1205004	Antiviral activity against Coxsackievirus B6 infected in african green monkey Vero cells assessed as reduction in viral-induced cytopathic effect	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID225768	Antiviral activity against polio virus type 1 in HeLa cell culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1687957	Antiproliferative activity against mouse B16-F10 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID63940	concentration required to inhibit HSV-1/TK (B2006) or VMW1837-induced cytopathicity by 50% in E6SM cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID81802	Antiviral activity against (HIV-1) in MT-4 cells Value in parentheses is inhibitory concentration for cell growth (MT-4)	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1886811	Antiviral activity against HHV-1 29R strain infected in African green monkey Vero E6 cells assessed as reduction factor at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID395974	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1261318	Selectivity index, ratio of CC50 for MDBK cells to EC50 for BVDV	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1181485	Cytotoxicity against MDCK cells assessed as change in cell morphology after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID1261324	Antiviral activity against HIV-1 infected in MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1135742	Antiviral activity against Rhinovirus type 13 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Synthesis and antiviral acticity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin).
AID1731874	Antiviral activity against RSV Long expressing mGFP infected in HEp-2 cells assessed as reduction in viral replication after 48 hrs by MTS assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Synthesis and antiviral activity of a series of novel quinoline derivatives as anti-RSV or anti-IAV agents.
AID164602	Tested for inhibition of virus-induced cytopathogenic effect and cytotoxicity of compound against Punta toro virus with adames strain in vero cell	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.
AID1783387	Antiviral activity against SARS-COV 2 infected in human Huh-7 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID1858560	Cytotoxicity against African green monkey Vero cells by CCK8 assay method	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Primed for global coronavirus pandemic: Emerging research and clinical outcome.
AID765050	Antagonist activity at human PPARdelta assessed as effect on TIPP-703-induced activity	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
AID63763	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (Lyons strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID1364944	Antiviral activity against Chikungunya virus C347 infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect after 2 days by microscopic analysis	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	The medicinal chemistry of Chikungunya virus.
AID611768	Antiviral activity against Influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathicity	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID419598	Antiviral activity against VSV infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID1611058	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of virus replication compound incubated with uninfected host cell for 1 hr followed by viral infection for 24 hrs measured after vi	2019	Bioorganic & medicinal chemistry letters, 12-01, Volume: 29, Issue:23	Synthesis and structure-activity relationships of novel camphecene analogues as anti-influenza agents.
AID763924	Antiviral activity against Influenza A virus (A/duck/Minnesota/1525/1981(H5N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.
AID278379	Decrease in GTP level in Vero E6 cells at 40 ug/ml after 24 h	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID368964	Therapeutic index, CC50 for human Hep2 cells to EC50 for RSV RSS	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID668365	In vivo antiviral activity against TMV assessed as protection effect at 500 ug/ml	2012	European journal of medicinal chemistry, Aug, Volume: 54	Design, synthesis and antiviral activity of novel pyridazines.
AID1433141	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID416769	Antiviral activity against Reovirus 1 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1710774	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID543661	Cytotoxicity against African green monkey Vero cells by luciferase-based cell viability assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1113457	Antiviral activity against Human coxsackievirus B4 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID634838	Antiviral activity against Human immunodeficiency virus 1 infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1536098	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by MTT assay	2019	Bioorganic & medicinal chemistry letters, 02-15, Volume: 29, Issue:4	Modified ribavirin analogues as antiviral agents against Junín virus.
AID84611	Minimum inhibitory concentration required to reduce Herpes simplex virus type 2 (HSV-2 strain G) induced cytopathogenicity by 50%	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID1349209	Cytotoxicity against human Ava5 cells assessed as decrease in cell viability after 72 hrs by XTT assay	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression.
AID68130	Tested for inhibitory effect on RNA virus cell morphology in ESM cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID763864	Antiviral activity against Influenza A virus (A/Perth/16/2009(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by cell-based neutral red uptake assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis and biological activity evaluation of 5-pyrazoline substituted 4-thiazolidinones.
AID54474	Tested for its anti-polio activity against Coxsackie B virus type-3	2002	Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10	Heterocyclic nucleoside analogues: design and synthesis of antiviral, modified nucleosides containing isoxazole heterocycles.
AID68127	Tested for inhibitory effect on DNA virus TK-HSV-1 (B2006) in ESM cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID548432	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID395676	Antiviral activity against Junin virus Candid-1 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID464183	Cytotoxicity against PIV 3 infected african green monkey Vero cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1443863	Antiviral activity against full length Gaussia princeps Gluc-tagged Chikungunya virus IMT infected in HEK293T cells assessed as reduction in virus infection after 24 hrs by Gaussia luciferase reporter gene assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus.
AID766706	Cytotoxicity against MDCK cells assessed as morphological changes	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID81897	In vitro antiviral activity against vaccinia(VV) virus was determined in human laryngeal epithelioma (HEp-2,H)expressed as virus rating. Toxic level(>1000 ug/mL)	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID1293613	Inhibition of Influenza A virus RdRp transfected in HEK293T cells at 24 hrs by dual luciferase reporter gene-based minireplicon assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.
AID546577	Inhibition of recombinant GSK3-beta Z'-LYTE kinase assay kit method	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
AID1135720	Immunosuppressive activity against PHA-stimulated proliferation in rat T-lymphocytes assessed as cell viability at 1 uM after 6 days by [3H]thymidine incorporation method relative to control	1978	Journal of medicinal chemistry, Jul, Volume: 21, Issue:7	Synthesis of branched-chain apiosylpyrimidines and their inhibition of lymphocyte proliferation.
AID427566	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36A/R155T double mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1135408	Toxicity in mouse assessed as survival at 99 mg/kg, po	1977	Journal of medicinal chemistry, Feb, Volume: 20, Issue:2	Synthesis and antiviral activity of certain thiazole C-nucleosides.
AID1472387	Antiviral activity against Influenza A virus (A/Virginia/ATCC3/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by microscopic method	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID1773425	Antiviral activity against Enterovirus E LCR-4 infected in A549 cells assessed as inhibition of viral adsorption at early stage of replication treated for 1 hr during viral infection followed by replacement with fresh medium and measured after 72 hrs by M	2021	European journal of medicinal chemistry, Dec-05, Volume: 225	Novel betulin dicarboxylic acid ester derivatives as potent antiviral agents: Design, synthesis, biological evaluation, structure-activity relationship and in-silico study.
AID1558305	Inhibition of RNA-dependent RNA polymerase in Zika virus MR766 infected in African green monkey Vero cells assessed as antiviral activity after 72 hrs by DAPI staining based assay	2020	Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2	Drugs for the Treatment of Zika Virus Infection.
AID63948	Tested for minimum cytotoxic concentration on virus-induced cytopathicity in E6SM cells	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID63942	concentration required to inhibit VSV-induced cytopathicity by 50% in E6SM cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID1118631	Antiviral activity against Herpes simplex virus type 1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID84084	Inhibitory activity against HSV-1 (F) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID94762	Inhibitory dose of compound required to inhibit cytopathogenic effects of Japanese encephalitis virus with najayama strain in vero cells	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.
AID1783393	Antiviral activity against SARS-COV 2 infected in monkey Vero E6 cells assessed as inhibition of viral replication at MOI of 0.01 and incubated after 2 hrs post infection for 48 hrs by direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID216973	Minimum inhibitory conc. for 50% inhibition of alteration of morphology in Vero cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID229022	Concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID156708	Evaluation for antiviral activity against herpes simplex virus-2(Lyons) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1229714	Cytotoxicity against african green monkey Vero B cells	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases.
AID220038	Concentration required to reduce coxsackie virus B4 induced cytopathogenicity by 50% in vero cell cultures.	1984	Journal of medicinal chemistry, Mar, Volume: 27, Issue:3	Antiviral activity of C-5 substituted tubercidin analogues.
AID65709	Antiviral activity against herpes simplex virus-1 TK-KOS ACV (HSV-1) in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID1131476	Antiviral activity against Vaccinia virus infected in primary rabbit kidney cells assessed as inhibition of virus-induced cytopathogenicity treated immediately after virus adsorption measured 2 days after virus infection	1977	Journal of medicinal chemistry, Oct, Volume: 20, Issue:10	Synthesis and determination of antiviral activity of the 2'(3')-O-methyl derivatives of ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide).
AID1427861	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3 infected in African green monkey Vero cells
AID1261308	Cytotoxicity against human MT4 cells assessed as cell viability after 96 hrs by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID82048	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with HSV-2 virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID1249921	Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in HEK293T cells assessed as reduction in viral RNP reconstitution measured at 24 hrs by luciferase reporter gene assay	2015	ACS medicinal chemistry letters, Aug-13, Volume: 6, Issue:8	Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors.
AID64120	Tested for minimum inhibitory concentration against Vaccinia virus in E6SM cells	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID275088	Cytotoxicity against HeLa cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID370203	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID65710	Antiviral activity against herpes simplex virus-1 TK-VMW 1837 (HSV-1) in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID216184	Tested for inhibitory effect on RNA virus cell morphology in Vero cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1773038	Antiviral activity against RSV Long infected in BALB/c mouse assessed as improvement in lung congestion at 25 to 100 mg/kg/day observed on day 6 after infection by H and E staining based microscopic analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID535517	Transport through CNT2 in rat hepatocytes by oil filtration assay	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID658745	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity after 4 days	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID1118634	Antiviral activity against Vaccinia virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1546422	Therapeutic Index, ratio of TC50 for African green monkey Vero cells to IC50 for CVB3 infected in African green monkey Vero cells	2020	Bioorganic & medicinal chemistry letters, 01-01, Volume: 30, Issue:1	Synthesis and anti-CVB3 activity of 4-amino acid derivative substituted pyrimidine nucleoside analogues.
AID416775	Antiviral activity against Vaccinia virus Lederle in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID712795	Cytotoxicity against dog MDCK cells assessed as cell viability after 72 hrs by MTS assay	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID1687960	Antiproliferative activity against human DU-145 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID216508	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with sindbis virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID273211	Viability of human HeLa S3 cells	2006	Journal of medicinal chemistry, Oct-19, Volume: 49, Issue:21	Synthesis and antiviral activity of 5-substituted cytidine analogues: identification of a potent inhibitor of viral RNA-dependent RNA polymerases.
AID200185	Antiviral activity at 100 uM determined in a culture of Rhinovirus type 1-A; IA = inactive	1989	Journal of medicinal chemistry, Jun, Volume: 32, Issue:6	Synthesis and biological properties of purine and pyrimidine 5'-deoxy-5'-(dihydroxyphosphinyl)-beta-D-ribofuranosyl analogues of AMP, GMP, IMP, and CMP.
AID765048	Antagonist activity at human PPARdelta assessed as effect on TIPP-703-induced activity at 10 uM	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
AID1132065	Antiviral activity against influenza A virus NWS/H0N1 infected in BHK cells at 1 mg/ml by agar diffusion assay	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID432173	Antiviral activity against thymidine kinase-deficient ACV-resistant HSV1 KOS infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID216183	Tested for inhibitory effect on RNA virus TV in Vero cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1241019	Antiviral activity against Rift Valley fever virus infected in African green monkey Vero 76 cells after 3 days by neutral red dye-based plaque reduction assay	2015	Bioorganic & medicinal chemistry, Sep-01, Volume: 23, Issue:17	2- and 3-Fluoro-3-deazaneplanocins, 2-fluoro-3-deazaaristeromycins, and 3-methyl-3-deazaneplanocin: Synthesis and antiviral properties.
AID416779	Cytotoxicity against MDCK cells by MTS assay	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1249919	Antiviral activity against Influenza A virus (A/PR/8/1934(H1N1)) infected in MDCK cells assessed as 2-log10 reduction in viral RNA copy number after 24 hrs by quantitative RT-PCR analysis	2015	ACS medicinal chemistry letters, Aug-13, Volume: 6, Issue:8	Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors.
AID156687	Antiviral activity was measured against Herpes simplex virus (HSV-1 KOS) in rabbit kidney cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID1081551	In vitro antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves at 100 ug/ml	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID376989	Antiviral activity against Cox B3 virus in human Hep2 cells assessed as reduction of virus induced cytopathic effect	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID216939	In vitro antiviral activity against HSV-1 virus in (vero) V cells of african green monkey kidney	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID235890	Ratio of minimum toxic compound concentration to inhibitory dose against Parainfluenza type 3 viral strain Huebner C243 in H.Ep-2 cell line	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1485235	Antiviral activity against Yellow fever virus infected in African green monkey Vero cells assessed as inhibition of viral-induced cytopathic effect measured after 3 to 6 days post infection by microscopic analysis	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID1261317	Antiviral activity against Human poliovirus 1 Sabin infected in african green monkey Vero76 cells assessed as inhibition of virus-induced cytopathogenicity by plaque reduction assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID156843	Minimum inhibitory concentration required to reduce herpes simplex virus-1 (KOS)induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK)	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID1252402	Cytotoxicity against African green monkey Vero cells assessed as alteration in cell morphology by microscopy	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of L-ascorbic or imino-L-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations.
AID87149	Evaluation for antiviral activity against vesicular stomatitis virus in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID475860	Cytotoxicity against human HeLa cells	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID1261312	Antiviral activity against BVDV infected in MDBK cells assessed as inhibition of virus-induced cytopathogenicity after 3 to 4 days by MTT assay	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID539914	Cytotoxicity against human HEL cells assessed as minimum concentration required to cause microscopically detectable alteration after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID105787	Antiviral activity tested against influenza A,H1N1 virus infected MDCK cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID475857	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID370202	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID634748	Antiviral activity against thymidine kinase-deficient acv-resistant Herpes simplex virus 1 KOS infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1154644	Antiviral activity against Respiratory syncytial virus infected in human Hep2 cells assessed as virus-induced cytopathicity by XTT assay	2014	Journal of natural products, Jun-27, Volume: 77, Issue:6	Antiviral C-25 epimers of 26-acetoxy steroids from the South China Sea gorgonian Echinogorgia rebekka.
AID300574	Weight change in mouse at 100 mg/kg, ip bid after 14 days	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID535520	Transport through ENT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID765053	Antiviral activity against HCV infected in african green monkey OR6 cells assessed as inhibition of viral RNA replication after 72 hrs by luciferase reporter gene assay	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
AID622447	Cytotoxicity against african green monkey Vero cells infected with Enterovirus 71 assessed as growth inhibition after 48 hrs by Reed-Muench analysis	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis, structure-activity relationship and in vitro biological evaluation of N-arylethyl isoquinoline derivatives as Coxsackievirus B3 inhibitors.
AID217993	Minimum cytotoxic concentration against vaccinia virus in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID1152078	Inhibition of Influenza A virus RdRP infected in human HEK293T cells after 24 hrs by dual luciferase reporter gene assay	2014	Journal of medicinal chemistry, May-22, Volume: 57, Issue:10	Optimization of small-molecule inhibitors of influenza virus polymerase: from thiophene-3-carboxamide to polyamido scaffolds.
AID360164	Ratio of IC50 for HCV 1b with NS3-4 R155K mutation to IC50 for wild type HCV 1b	2007	The Journal of biological chemistry, Aug-03, Volume: 282, Issue:31	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
AID244765	Minimum cytotoxicity concentration to HeLa cell line was determined	2005	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6	QSAR for anti-RNA-virus activity, synthesis, and assay of anti-RSV carbonucleosides given a unified representation of spectral moments, quadratic, and topologic indices.
AID658611	Cytotoxicity against african green monkey Vero cells assessed as minimum compound concentration required to causes microscopically detectable alteration of normal cell morphology	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID370220	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as animals with detectable virus level in serum at 10 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1543376	Selectivity index, ratio of TC50 against African green monkey Vero cells infected with Herpes simplex virus 1 after 72 hrs by MTT assay to IC50 against Herpes simplex virus 1 infected in African green monkey Vero cells assessed as inhibition of virus-indu	2019	Bioorganic & medicinal chemistry, 06-15, Volume: 27, Issue:12	Antiviral activities of Janus-type nucleosides and their related oxime-intermediates.
AID1186338	Antiviral activity against Vesicular stomatitis virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 2 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID482703	Antiviral activity against HSV2 G infected in human E6SM cell assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID155599	Compound was tested for antiviral activity (minimum inhibition concentration) in Vero cells parainfluenza virus type 3	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID1753364	Antiviral activity against pseudotyped recombinant vesicular stomatitis virus delta G Gn-Gc infected HEK293T cells assessed as reduction in virus replication incubated for 48 hrs by luminescence assay	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
AID1066051	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID218253	Evaluation for antiviral activity against Sindbis virus in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID768190	Cytotoxicity against african green monkey Vero cells	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID434321	Cytotoxicity against african green monkey Vero cells assessed as change in cell morphology	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID1433154	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID1127181	Cytotoxicity against human HuH7 cells assessed as cell viability at 20 uM after 3 days by XTT assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives.
AID1151007	Antiviral activity against Influenza A virus A2/Asian/J305 infected in Swiss albino mouse assessed as increase in host survival at 50 mg/kg, ip administered as 7 doses immediately before virus inoculation and at 1, 5, 24, 30, 48 and 72 hrs after virus inf	1976	Journal of medicinal chemistry, Aug, Volume: 19, Issue:8	Synthesis of tetrazole ribonucleosides and their evaluation as antiviral agents. 2. 5-Amino-1-(beta-D-ribofuranosyl)-1H-tetrazole and 5-amino-2-(beta-D-ribofuranosyl)-2H-tetrazole.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID767054	Selectivity index, ratio of CC50 for human HepG2 cells to EC50 for Coxsackievirus B5 infected in human HepG2 cells	2013	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 23, Issue:18	Novel cycloalkylthiophene-imine derivatives bearing benzothiazole scaffold: synthesis, characterization and antiviral activity evaluation.
AID659155	Antiviral activity against Human immunodeficiency virus 2 ROD infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID1436800	Antiviral activity against Coxsackievirus B6 (strain Schmitt) infected in African green monkey Vero cells assessed as reduction in viral-induced cytopathic effect by Reed and Muench analysis	2017	Bioorganic & medicinal chemistry letters, 02-15, Volume: 27, Issue:4	Novel 12N-substituted matrinanes as potential anti-coxsackievirus agents.
AID622445	Antiviral activity against Coxsackievirus B3 infected in african green monkey vero cells assessed as inhibition of viral replication by Reed-Muench analysis	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis, structure-activity relationship and in vitro biological evaluation of N-arylethyl isoquinoline derivatives as Coxsackievirus B3 inhibitors.
AID659289	Cytotoxicity against human HeLa cells assessed as morphological changes by microscopic analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID99696	In vitro antiviral activity against HSV-1 virus in human laryngeal epithelioma cell line	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID1542951	Antiviral activity against Dengue virus type 2 NGC infected in African green monkey Vero B cells assessed as reduction in virus yield	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication.
AID1336608	Antiviral activity against Para-influenza-3 virus infected in African green monkey Vero cells assessed as protection against virus-induced cytopathic effect measured after 3 to 5 days by microscopic analysis	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones.
AID368978	Antiviral activity against plaque picked A-33903-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID82050	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on HEF cell line infected with thymidine kinase-deficient herpes simplex virus type 1 (TK-HSV-1)	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID472791	Antiviral activity against Human coxsackievirus B2 Ohio-1 infected in african green monkey Vero cells after 3 days by plaque reduction assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID1408323	Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells after 3 days by MTS assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID593223	Antiviral activity against Human enterovirus 71 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
AID535532	Transport through ENT1 in mouse hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID64115	Minimum inhibitory concentration (MIC) required to elicit a microscopically visible alteration of cell morphology in E6SM cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID463991	Antiviral activity against Vaccinia virus infected in HEL cells assessed as protection from virus-induced cytopathogenicity after 2 to 3 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1610158	Antiviral activity against Influenza A virus (A/Ned/378/05(H1N1)) infected in dog MDCK cells assessed as reduction in virus-induced cytopathogenicity incubated for 7 days by MTS assay	2019	European journal of medicinal chemistry, Dec-15, Volume: 184	Antitumor and antiviral activities of 4-substituted 1,2,3-triazolyl-2,3-dibenzyl-L-ascorbic acid derivatives.
AID288920	Antiviral activity against thymidine kinase deficient HSV1 VMW1837 in E6SM cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Jun-14, Volume: 50, Issue:12	5-alkynyl analogs of arabinouridine and 2'-deoxyuridine: cytostatic activity against herpes simplex virus and varicella-zoster thymidine kinase gene-transfected cells.
AID1349206	Cytotoxicity against human Ava5 cells assessed as cell viability at 20 uM after 72 hrs by XTT assay relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression.
AID1265174	Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of nsP3 protein expression at 5 uM measured at 24 hrs postinfection by Western blot method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID535512	Transport through CNT2 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1852996	Cytotoxicity against in human HCT-116 cells overexpressing human BCRP assessed as DNA damage by measuring fluorescence intensity at 100 uM incubated for 30 mins by Hoechst 33342 staining accumulation assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID1495713	Cytotoxicity against MDCK cells after 48 hrs by MTT assay	2018	Bioorganic & medicinal chemistry letters, 06-15, Volume: 28, Issue:11	Highly potent activity of isopulegol-derived substituted octahydro-2H-chromen-4-ols against influenza A and B viruses.
AID376985	Selectivity index, CC50 for african green monkey Vero cells to IC50 for HSV1 15577	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID1886814	Antiviral activity against CHIKV infected in African green monkey Vero E6 cells assessed as concentration required for higher viral reduction factor measured after 72 hrs by crystal violet staining based inverted microscopic analysis	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID261046	Efficacy in cotton rat measured as reduction in log TCID50 of RSV per gram of lung at 90 mg/kg, ip	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo.
AID1146291	Antiviral activity against Rhinovirus 30 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs by microscopic analysis relative to control	1978	Journal of medicinal chemistry, Sep, Volume: 21, Issue:9	Imidazo[1,2-a]-s-triazine nucleosides. Synthesis and antiviral activity of the N-bridgehead guanine, guanosine, and guanosine monophosphate analogues of imidazo[1,2-a]-s-triazine.
AID1071700	Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza A virus H1N1	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID1118635	Antiviral activity against Vesicular stomatitis virus infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1200484	Cytotoxicity against MDCK cells assessed as cell growth after 40 hrs by CellTiter-Glo assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID217991	Minimum cytotoxic concentration against vaccinia virus in Vero cell cultures	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID156704	Evaluation for antiviral activity against herpes simplex virus-1 (McIntyre) in primary rabbit kidney cell cultures(PRK) (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID546578	Inhibition of recombinant CDK2 at 10 uM by Z'-LYTE kinase assay kit method	2010	Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24	Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
AID622446	Selectivity index, ratio of TC50 for african green monkey vero cells to IC50 for Coxsackievirus B3	2011	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 21, Issue:19	Synthesis, structure-activity relationship and in vitro biological evaluation of N-arylethyl isoquinoline derivatives as Coxsackievirus B3 inhibitors.
AID548425	Antiviral activity against Herpes simplex virus 2 G infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID1273995	Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as maximal non toxic concentration causing inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining based inverted microscopic a	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID472793	Antiviral activity against HSV1 KOS infected in african green monkey Vero cells after 3 days by plaque reduction assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID395678	Antiviral activity against Tacaribe virus TRVL11573 in Vero cells assessed as inhibition of virus-induced visual cytopathic effect after 7 to 8 days	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1427835	Antiviral activity against Human coronavirus 229E infected in HEL cells assessed as reduction in virus-induced cytopathogenicity
AID257900	Antiviral activity against Coxsackie virus B4 in HeLa cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID66003	50% Minimum inhibitory concentration which is required to reduce cytopathogenicity induced by (G) strain of HSV-2 virus on human E6SM cells.	1997	Journal of medicinal chemistry, Feb-14, Volume: 40, Issue:4	Novel 3'-C/N-substituted 2',3'-beta-D-dideoxynucleosides as potential chemotherapeutic agents. 1. Thymidine derivatives: synthesis, structure, and broad spectrum antiviral properties.
AID1118633	Antiviral activity against Herpes simplex virus type 2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1773006	Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as early apoptotic cells at 25 uM measured after 60 hrs by Annexin V-FITC/PI staining based flow cytometry analysis (Rvb = 10.3%)	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID218406	Minimum inhibitory concentration required to reduce semliki forest virus induced cytopathogenicity by 50% in african green monkey (VeroB) cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID1298254	Antiviral activity against Influenza A virus A/PR/8/34 infected in MDCK cells assessed as reduction of virus-induced cytopathic effect measured after 4 days by formazan-based MTS assay	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1265180	Antiviral activity against wild type Sindbis virus infected in HEK293T cells assessed as inhibition of infectivity measured at 24 hrs postinfection by FITC/DAPI staining based array scan VTI HCS reader analysis	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID535525	Transport through ENT1 in rat hepatocytes by oil filtration assay in presence of sodium ions in Kreb-henseleit buffer containing 100 uM NBMPR and 1 mM uridine	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID1409611	AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID277831	Antiviral activity against RSV	2007	Journal of natural products, Feb, Volume: 70, Issue:2	Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa.
AID1066041	Antiviral activity against Influenza B virus (B/Lee/1940) clinical isolate infected in MDCK cells assessed as inhibition of viral replication after 2 days by toluidine blue staining assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID1783390	Cytotoxicity against human Caco2 cells infected with SARS-COV-2 assessed as reduction in cell viability by celltiter-glo luminescent cell viability assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID92309	Antiviral activity at 10-30 uM determined in a culture of Influenza A; IA = inactive	1989	Journal of medicinal chemistry, Jun, Volume: 32, Issue:6	Synthesis and biological properties of purine and pyrimidine 5'-deoxy-5'-(dihydroxyphosphinyl)-beta-D-ribofuranosyl analogues of AMP, GMP, IMP, and CMP.
AID1135413	Antiviral activity against type 1 parainfluenza virus infected in mouse assessed as mouse mean death day at 49.5 mg/kg, po thrice a day for 8 days after 1 hr viral infection (Rvb = 8.9 days)	1977	Journal of medicinal chemistry, Feb, Volume: 20, Issue:2	Synthesis and antiviral activity of certain thiazole C-nucleosides.
AID1069922	Cytotoxicity against human HuH7 cells assessed as beta-actin levels relative to control	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	Dual inhibition of HCV and HIV by ring-expanded nucleosides containing the 5:7-fused imidazo[4,5-e][1,3]diazepine ring system. In vitro results and implications.
AID427549	Antiviral activity against wild type Con1-mADE HCV replicon in human HuH7 cells after 48 hrs by RNA replicon assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1594640	Antiviral activity against Dengue virus 1 DGL2 replicon infected in BHK cells assessed as inhibition of viral replicon RNA replication incubated for 72 hrs by Gaussia-luciferase reporter gene assay	2019	Bioorganic & medicinal chemistry, 06-01, Volume: 27, Issue:11	Synthesis and biological evaluation of novel imidazole nucleosides as potential anti-dengue virus agents.
AID1687961	Antiproliferative activity against human SNB-75 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID98936	Tested for inhibitory effect on RNA virus cell growth in L1210 cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1472388	Antiviral activity against Influenza A virus (A/Virginia/ATCC3/2009(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID85279	Antiviral activity against HSV-2(G) strain in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1773051	Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of IL-6 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 days post infection by RT-PCR analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID87033	Antiviral activity at 1-3 uM determined in a culture of Herpes simplex virus type 2; IA = inactive	1989	Journal of medicinal chemistry, Jun, Volume: 32, Issue:6	Synthesis and biological properties of purine and pyrimidine 5'-deoxy-5'-(dihydroxyphosphinyl)-beta-D-ribofuranosyl analogues of AMP, GMP, IMP, and CMP.
AID1077000	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus A/hanfang/359/95(H3N2)	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID1409408	Cytotoxicity against chicken embryo fibroblasts assessed as reduction in cell viability after 48 hrs by CCK-8 assay	2018	Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22	Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID674876	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/Tianjin-Jinnan/15/2009(H1N1))	2012	European journal of medicinal chemistry, Sep, Volume: 55	Synthesis and antiviral activity of substituted bisaryl amide compounds as novel influenza virus inhibitors.
AID1076996	Antiviral activity against Influenza B virus jifang/13/97 infected in MDCK cells assessed as inhibition of plaque formation after 3 to 4 days by crystal violet staining-based assay	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID1274009	Antiviral activity against HHV-2 VR-734-G infected in African green monkey Vero cells assessed as reduction in plaque formation administered post viral infection after 72 hrs by crystal violet staining technique	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID1472386	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 72 hrs by MTS assay	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID1201122	Antiviral activity against Influenza B virus (B/Hong Kong/05/1972) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	2015	European journal of medicinal chemistry, Apr-13, Volume: 94	A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID1691560	Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) clone 1 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by MTS assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.
AID1407824	Antiviral activity against Newcastle disease virus	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Pyrrolopyrimidines: An update on recent advancements in their medicinal attributes.
AID284540	Antiviral activity against in Vesicular stomatitis virus- induced cytopathogenicity in HeLa cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID659288	Cytotoxicity against HEL cells assessed as morphological changes by microscopic analysis	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID1783364	Antiviral activity against Influenza A Puerto Rico/8/34/H1N1 infected in MDCK cells assessed as inhibition of viral replication measured in supernatants of infected cells after 24 hrs by hemagglutination assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID535539	Transport through CNT2 in rat hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in Kreb-henseleit buffer	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID648645	Antiinfluenza activity against influenza A virus H3N2 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Synthesis and anti-influenza activity of aminoalkyl rupestonates.
AID1433132	Cytotoxicity against human HeLa cells assessed as alteration of normal cell morphology by microscopic analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID535533	Transport through ENT1 in rat hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID766707	Cytotoxicity against african green monkey Vero cells assessed as morphological changes	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID87148	Compound was evaluated for antiviral activity against respiratory syncitial virus (long) in HeLa cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID443832	Antiviral activity against Influenza B virus (B/Hong Kong/5/72) assessed as cell viability by cell-based MTS assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1249922	Cytotoxicity against HEK293T cells assessed as cell viability measured at 24 hrs by MTS assay	2015	ACS medicinal chemistry letters, Aug-13, Volume: 6, Issue:8	Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors.
AID220034	Antiviral activity against coxsackie B4 virus in HeLa cell culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1229723	Antiviral activity against DENV serotype 2 strain New Guinea V infected in African green monkey Vero B cells assessed as inhibition of virus replication after 4 days by qRT-PCR analysis	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Discovery of Multitarget Antivirals Acting on Both the Dengue Virus NS5-NS3 Interaction and the Host Src/Fyn Kinases.
AID1133180	Antiviral activity against Vaccinia virus infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.
AID1167620	Selectivity index, ratio of CC50 for human ORL8 cells to EC50 for Hepatitis C virus infected in African green monkey OR6 cells	2014	Bioorganic & medicinal chemistry, Nov-01, Volume: 22, Issue:21	Synthesis of 3',4'-difluoro-3'-deoxyribonucleosides and its evaluation of the biological activities: discovery of a novel type of anti-HCV agent 3',4'-difluorocordycepin.
AID370225	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as survival at 30 mg/kg, po twice daily for 6 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID416785	Antiviral activity against influenza B virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1133193	Inhibition of adenine nucleotide biosynthesis in human EAC assessed as [14C]hypoxanthine incorporation at 1 mM after 60 mins by TLC analysis	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.
AID1272968	Antiviral activity against Influenza A virus H3N2 A3/JINGKE/30/95 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	The semi-synthesis of novel andrographolide analogues and anti-influenza virus activity evaluation of their derivatives.
AID1647355	Antiviral activity against Zika virus infected in African green monkey Vero cells assessed as reduction in viral replication treated with compound at 1 hr post-viral infection	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors.
AID1349205	Antiviral activity against HCV infected in human Ava5 cells assessed as inhibition of viral RNA replication at 20 uM after 3 days by RT-qPCR method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression.
AID1349208	Antiviral activity against HCV infected in human Ava5 cells assessed as inhibition of viral RNA replication after 3 days by RT-qPCR method	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression.
AID1113462	Antiviral activity against Respiratory syncytial virus infected human HeLa cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID345886	Cytotoxicity against human HuH6 cells	2009	Journal of medicinal chemistry, Feb-26, Volume: 52, Issue:4	Discovery of novel arylethynyltriazole ribonucleosides with selective and effective antiviral and antiproliferative activity.
AID1443880	Antiviral activity against full length gluc-tagged Chikungunya virus 2008 Singapore SGP11 infected in HEK293T cells assessed as reduction in virus infection after 24 hrs by gaussia luciferase reporter gene assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus.
AID1503652	Cytotoxicity against human HuH7 cells assessed as cell viability at 20 uM after 3 days by XTT method relative to control	2017	European journal of medicinal chemistry, Dec-01, Volume: 141	Discovery of novel diarylpyrazolylquinoline derivatives as potent anti-dengue virus agents.
AID217905	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against sindbis virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID766708	Cytotoxicity against human HeLa cells assessed as morphological changes	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1265175	Antiviral activity against wild type Chikungunya virus IMT infected in HEK293T cells assessed as inhibition of viral capsid protein at 5 uM measured at 24 hrs postinfection by Western blot method	2015	Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23	Trisubstituted Thieno[3,2-b]pyrrole 5-Carboxamides as Potent Inhibitors of Alphaviruses.
AID1753728	Cytotoxicity against African green monkey Vero cells by MTT assay	2021	Journal of natural products, 04-23, Volume: 84, Issue:4	Semisynthesis of Dolabellane Diterpenes: Oxygenated Analogues with Increased Activity against Zika and Chikungunya Viruses.
AID1725100	Antiviral activity against Zika virus 976 Uganda infected in human HepG2 cells assessed as protection against viral infection by measuring cell survival at 100 uM measured after 4 days by CellTiter-Glo luminescent cell viability assay relative to control	2020	ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10	Discovery of Zika Virus NS2B/NS3 Inhibitors That Prevent Mice from Life-Threatening Infection and Brain Damage.
AID1181493	Antiviral activity against Influenza B virus (B/HK/05/1972) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID92457	Tested for inhibition of virus-induced cytopathogenic effect and cytotoxicity of compound against influenza virus with A2/Aichi/2/68 strain in MDCK cell	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.
AID275075	Antiviral activity against Sindbis virus in Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID395712	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as inhibition of liver damage at 40 mg/kg, po twice daily for 7 days administered 4 hrs before viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID257887	Antiviral activity against vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID275074	Antiviral activity against reovirus 1 in Vero cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID249268	Minimum inhibitory concentration against respiratory syncytial virus was determined	2005	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6	QSAR for anti-RNA-virus activity, synthesis, and assay of anti-RSV carbonucleosides given a unified representation of spectral moments, quadratic, and topologic indices.
AID482712	Antiviral activity against Reovirus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID634758	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID533317	Cytotoxicity against human NTZ-11 cell harboring HCV genotype 1b after 4 days by neutral red dye uptake assay	2008	Antimicrobial agents and chemotherapy, Nov, Volume: 52, Issue:11	Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide.
AID105775	Tested for inhibitory effect on RNA virus Influenza A in MDCK cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1486230	Antiviral activity against Bovine viral diarrhea virus 1-NADL infected in bovine MDBK cells assessed as reduction in plaque forming units after 72 hrs by crystal violet staining-based assay
AID1081548	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as curative effect at 500 ug/ml treated after viral inoculation measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID1273994	Antiviral activity against DENV-2 New guinea infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect after 3 days by crystal violet staining based inverted microscopic analysis relative to control	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Anti-herpetic and anti-dengue activity of abietane ferruginol analogues synthesized from (+)-dehydroabietylamine.
AID370198	Toxicity in po dosed C57BL/6 mouse administered twice daily for 5 days administered 4 hrs before viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID156694	Evaluation in PRK cell cultures for cytotoxicity that is to cause microscopically detectable alteration of normal cell morphology	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1783358	Antiviral activity against West Nile virus lineage 1 (Italy/2009) infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 48 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID87045	Virus rating of against herpes simplex virus type 2	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Analysis of the in vitro antiviral activity of certain ribonucleosides against parainfluenza virus using a novel computer aided receptor modeling procedure.
AID438029	Inhibition of Dengue virus IMPDH	2009	Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24	The medicinal chemistry of dengue fever.
AID665009	Cytostatic activity against human CEM/0 after 72 hrs by cell counting	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations.
AID1194167	Selectivity index, CC50 for african green monkey Vero B cells to EC50 for DENV serotype 2 strain New Guinea C by virus yield-reduction assay	2015	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 25, Issue:8	Design, synthesis, optimization and antiviral activity of a class of hybrid dengue virus E protein inhibitors.
AID768212	Cytotoxicity against MDCK cells assessed as cell viability after 4 days by MTS assay	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID105968	Minimum inhibitory concentration required to reduce influenza A H3N2 (X31) virus induced cytopathogenicity by 50% in madin-Darby canine kidney cells (MDCK)	2001	Bioorganic & medicinal chemistry letters, Aug-20, Volume: 11, Issue:16	Novel 3-(2-adamantyl)pyrrolidines with potent activity against influenza A virus-identification of aminoadamantane derivatives bearing two pharmacophoric amine groups.
AID368963	Cytotoxicity against RSV RSS infected human Hep2 cells after 6 days by XTT assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID371498	Antiviral activity against bovine viral diarrhoea virus type-1 NADL in MDBK cells assessed as inhibition of virus-induced cytopathic effect	2008	European journal of medicinal chemistry, Aug, Volume: 43, Issue:8	New 1-indanone thiosemicarbazone derivatives active against BVDV.
AID634092	Therapeutic index, ratio of CC50 for human HuH7 cells infected with HCV1b to EC50 for HCV genotype 1b	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID416770	Antiviral activity against Sindbis virus in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID776644	Cytotoxicity against mouse Gardner lymphosarcoma cells assessed as growth inhibition	2013	European journal of medicinal chemistry, Nov, Volume: 69	Pyrazole containing natural products: synthetic preview and biological significance.
AID1408126	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 48 hrs by MTT assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction.
AID774116	Selectivity index, ratio of TC50 for African green monkey Vero cells to IC50 for Coxsackievirus B3	2013	Journal of natural products, Oct-25, Volume: 76, Issue:10	Diterpenoids and sesquiterpenoids from the roots of Illicium majus.
AID1773055	Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of IL-10 expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID432182	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity after 3 days postinfection	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID155591	Viral rating activity against Parainfluenza type 3 viral strain Huebner C243 in H.Ep-2 cell line	1989	Journal of medicinal chemistry, Jul, Volume: 32, Issue:7	Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities.
AID717170	Cytotoxicity against dog MDCK cells assessed as cell morphology alterations by microscopic analysis	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID432170	Antiviral activity against HSV2 G infected in human HEL cells assessed as inhibition of virus-induced cytopathicity after 3 days	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis and antiviral activity of new pyrazole and thiazole derivatives.
AID536238	Antiviral activity against Influenza A virus (A/Hong Kong/7/1987(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity by MTS assay	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Design and synthesis of bioactive adamantanaminoalcohols and adamantanamines.
AID1654876	Selectivity index, ratio of CC50 for cytotoxicity in African green monkey Vero E6 cells to EC50 for Antiviral activity against Zika virus infected in Vero E6 cells	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID87134	Antiviral activity was measured against Vesicular stomatitis virus in HeLa cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID416768	Antiviral activity against Parainfluenza virus type 3 in african green monkey Vero cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1571894	Displacement of [3H]2-[p-(2-carboxyethyl)phenylethylamino]-5-N-ethylcarboxamidoadenosine from human A2A adenosine receptor expressed in HEK293 cell membranes at 10 uM after 60 mins by scintillation proximity assay relative to adenosine 5-N-ethyluronamide	2019	Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3	Design and in Vivo Characterization of A
AID1647356	Selectivity index, ratio of CC50 for African monkey Vero cells to EC50 for Zika virus infected in African green monkey Vero cells	2020	Bioorganic & medicinal chemistry letters, 01-15, Volume: 30, Issue:2	Quinolone-N-acylhydrazone hybrids as potent Zika and Chikungunya virus inhibitors.
AID474550	Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza B virus Malaysia/2506/2004 by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1687959	Antiproliferative activity against human HuH-7 cells assessed as reduction in cell growth at 100 uM incubated for 72 hrs by MTT assay relative to control	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID297319	Antiviral activity against Sindbis virus in Vero cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID548427	Antiviral activity against Vesicular stomatitis virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID257889	Antiviral activity against Herpes simplex virus 1 KOS strain in HEL cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID387575	Cytotoxicity against MDCK cells assessed as alteration in cell morphology by MTS assay	2008	Bioorganic & medicinal chemistry, Sep-15, Volume: 16, Issue:18	Synthesis and antiviral evaluation of acyclic azanucleosides developed from sulfanilamide as a lead structure.
AID1781227	Inhibition of Infectious hematopoietic necrosis virus glycoprotein G assessed as antiviral activity at 25 uM measured by RT-qPCR method relative to control	2021	European journal of medicinal chemistry, Nov-05, Volume: 223	Synthesis and biological evaluation of novel coumarin derivatives in rhabdoviral clearance.
AID1252405	Antiviral activity against Sindbis virus expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of L-ascorbic or imino-L-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations.
AID1650127	Cytotoxicity against MDCK cells assessed as reduction in cell viability after 4 days by MTS assay	2020	Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1	Superior inhibition of influenza virus hemagglutinin-mediated fusion by indole-substituted spirothiazolidinones.
AID33367	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology and show antiviral activity in african green monkey (Vero B) cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID1651274	Selectivity index, ratio of CC50 for African green monkey Vero E6 cells to EC50 for Zika virus infected in African green monkey Vero E6 cells assessed as inhibition of viral induced cytopathic effect	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Design, synthesis, and evaluation of novel 4-amino-2-(4-benzylpiperazin-1-yl)methylbenzonitrile compounds as Zika inhibitors.
AID229236	Antiviral activity against vesicular stomatitis virus (VSV) in primary rabbit kidney (PRK) / embryonic skin-muscle (E6SM) fibroblast culture lines	1992	Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24	Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.
AID1655772	Antiviral activity against Dengue virus serotype 2 New Guinea C infected at 50 TCID50 in human HuH7 cells assessed as inhibition of viral replication and 72 hrs later re-infected pre-seeded HuH7 cells with viral supernatant collected from previous infecte	2020	ACS medicinal chemistry letters, May-14, Volume: 11, Issue:5	Exploring the Implication of DDX3X in DENV Infection: Discovery of the First-in-Class DDX3X Fluorescent Inhibitor.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1226137	Inhibition of Influenza A virus (A/PR/8/34) RNA-dependent-RNA polymerase transfected in HEK293T cells after 24 hrs by renilla luciferase activity/minireplicon assay	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits.
AID1886815	Antiviral activity against Zika 459148 infected in African Green monkey Vero E6 cells assessed as reduction in plaque formation measured after 72 hrs by crystal violet staining based analysis	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID539955	Antiviral activity against influenza B virus infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1858561	Selectivity index, ratio of IC50 for African green monkey Vero cells to IC50 for antiviral activity against SARS-CoV 2 nCoV-2019BetaCoV/Wuhan/WIV04/2019	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Primed for global coronavirus pandemic: Emerging research and clinical outcome.
AID66943	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in E6SM cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID283443	Inhibition of Influenza A virus (A/gull/Pennsylvania/4175/83 (H5N1)) replication in MDCK cells by virus yield reduction assay	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice.
AID1066049	Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID218006	Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 1	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID360165	Ratio of IC50 for HCV 1b with NS3-4A R155T mutation to IC50 for wild type HCV 1b	2007	The Journal of biological chemistry, Aug-03, Volume: 282, Issue:31	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
AID419595	Antiviral activity against VSV infected in human HEL cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID1249920	Cytotoxicity against MDCK cells assessed as cell viability measured at 24 hrs by MTS assay	2015	ACS medicinal chemistry letters, Aug-13, Volume: 6, Issue:8	Virtual Screening and Biological Validation of Novel Influenza Virus PA Endonuclease Inhibitors.
AID1135872	Toxicity in ferret infected with Influenza A virus Port Chalmers/1/73 (H3N2) assessed as change in body weight at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day 3 measured after 7 days relative to untreated control	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID1638587	Antiviral activity against West Nile virus infected in human HuH7 cells incubated for 4 days by crystal violet staining based plaque reduction assay	2019	Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5	DDX3X Helicase Inhibitors as a New Strategy To Fight the West Nile Virus Infection.
AID691392	Cytotoxicity against human HuH7 cells after 2 days by XTT assay	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
AID216947	In vitro antiviral activity against VSV virus in (vero) V cells	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID34142	Virus rating against adenovirus type 2	1989	Journal of medicinal chemistry, Apr, Volume: 32, Issue:4	Analysis of the in vitro antiviral activity of certain ribonucleosides against parainfluenza virus using a novel computer aided receptor modeling procedure.
AID543658	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect by microscopic analysis	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID392724	Antiviral activity against EMCV assessed as inhibition of virus-induced cytopathicity	2009	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 19, Issue:4	Synthesis of 5-isoxazol-5-yl-2'-deoxyuridines exhibiting antiviral activity against HSV and several RNA viruses.
AID370233	Antiviral activity against Punta Toro virus Adames infected Syrian golden hamster assessed as animals with detectable virus level in liver at 30 mg/kg, po twice daily administered 4 hrs before viral challenge measured on day 4 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID593222	Antiviral activity against Coxsackievirus A16 infected in african green monkey Vero cells assessed as inhibition of viral growth after 24 hrs by Reed-Muench method	2011	Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8	Inhibitory properties of 2-substituent-1H-benzimidazole-4-carboxamide derivatives against enteroviruses.
AID416777	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human HEL cells assessed as protection against virus-induced cytopathicity	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1485245	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability measured after 5 to 6 days by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID401226	Selectivity index, ratio of CC50 for MDCK cells to IC50 for RSV Long	2004	Journal of natural products, Apr, Volume: 67, Issue:4	Antiviral flavonoids from the seeds of Aesculus chinensis.
AID217904	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against semliki forest virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID81760	In vitro antiviral activity against herpes simplex type 1 (HSV-1) virus was determined in human laryngeal epithelioma (HEp-2,H)expressed as virus rating. Toxic level(>1000 ug/mL)	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID86683	Effective concentration required to inhibit respiratory synaptial(RSV) virus-induced cytopathicity by 50% in HeLa cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID105770	Inhibitory concentration against influenza virus B in MDCK cells	1995	Journal of medicinal chemistry, Sep-01, Volume: 38, Issue:18	Synthesis and antiviral activity of benzyl-substituted imidazo [1,5-a]-1,3,5-triazine (5,8-diaza-7,9-dideazapurine) derivatives.
AID543662	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as reduction in virus yield	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID766693	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID1118632	Antiviral activity against thymidine kinase-deficient Herpes simplex virus type 1 infected in human HEL cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID658749	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathogenicity after 4 days by colorimetric formazan-based MTS assay	2012	European journal of medicinal chemistry, Jun, Volume: 52	2-Aminopyrimidine based 4-aminoquinoline anti-plasmodial agents. Synthesis, biological activity, structure-activity relationship and mode of action studies.
AID400424	Selectivity index, ratio of EC50 for RSV long by cytopathic effect over IC50 for human Hep2 cells	1998	Journal of natural products, May, Volume: 61, Issue:5	Antiviral phenylpropanoid glycosides from the medicinal plant Markhamia lutea.
AID1687970	Cytotoxicity against human MET5A cells assessed as effect on cell morphology at 20 ug/ml measured upto 7 days by laser scanning confocal microscopy	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID257896	Antiviral activity against Sindbis virus in vero cells	2006	Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2	Synthesis and biological activity of isoxazolidinyl polycyclic aromatic hydrocarbons: potential DNA intercalators.
AID63764	The minimum inhibitory concentration was measured on E6SM cells against TK+/TK-Herpes simplex virus type 1 (VMW1837 strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID82035	Antiviral activity against HSV-2 virus infected HEF cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID368977	Drug resistance, ratio of EC50 for plaque picked RSV604-resistant RSV RSS from passage 2 to EC50 for DMSO-passaged wild type RSV RSS	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID474351	Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 42 to 46 hrs by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID539953	Antiviral activity against influenza A virus H1N1 infected in MDCK cells assessed as protection against virus-induced cytopathogenicity after 2 days	2010	European journal of medicinal chemistry, Nov, Volume: 45, Issue:11	Synthesis, antiviral activity and cytotoxicity evaluation of Schiff bases of some 2-phenyl quinazoline-4(3)H-ones.
AID1831639	Antiviral activity against Dengue virus infected in human Huh-7 cells assessed as inhibition of viral replication at 12.5 uM measured after 48 hrs by plaque assay relative to control	2021	ACS medicinal chemistry letters, Dec-09, Volume: 12, Issue:12	Nanoparticular Inhibitors of Flavivirus Proteases from Zika, West Nile and Dengue Virus Are Cell-Permeable Antivirals.
AID1132056	Antiviral activity against influenza A virus NWS/H0N1 infected in BHK cells by agar diffusion assay	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID1181482	Antiviral activity against Influenza A virus (A/HK/7/1987(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 72 hrs by microscopy	2014	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 24, Issue:15	Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.
AID235800	Selectivity index which is the ratio of IC50 to EC50 of R-MuLV.	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID691388	Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells at 20 to 50 ug/mL after 2 days by q-PCR analysis	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
AID1767878	Cytotoxicity against dog MDCK cells assessed as reduction in cell viability	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1.
AID427560	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36L mutation in human HuH7 cells after 48 hrs by RNA replicon assay relative to wild type	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1767879	Selectivity index, ratio of CC50 for cytotoxicity against dog MDCK cells to IC50 for antiviral activity against Influenza A virus HINI infected in dog MDCK cells	2021	European journal of medicinal chemistry, Oct-15, Volume: 222	Optimization and SAR research at the piperazine and phenyl rings of JNJ4796 as new anti-influenza A virus agents, part 1.
AID1773014	Inhibition of RSV induced apoptosis in human HEp-2 cells assessed as reduction in cleaved caspase-9 expression measured after 48 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID1066044	Antiviral activity against influenza A virus A/Padova/253/2011(H1N1) clinical isolate infected in MDCK cells assessed as inhibition of plaque formation after 2 days by toluidine blue staining assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly.
AID1364926	Antiviral activity against Chikungunya virus KC969207 infected in African green monkey Vero cells after 48 hrs by MTT dye-based assay	2017	Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16	The medicinal chemistry of Chikungunya virus.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID218072	Toxicity level was reported; none	1985	Journal of medicinal chemistry, Aug, Volume: 28, Issue:8	Synthesis and biological activity of 6-azacadeguomycin and certain 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides.
AID1651272	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Design, synthesis, and evaluation of novel 4-amino-2-(4-benzylpiperazin-1-yl)methylbenzonitrile compounds as Zika inhibitors.
AID1886809	Antiviral activity against DENV2 infected in golden hamster BHK-21 cells assessed as inhibition of plaque formation by measuring reduction in PFU per well at 12.4 to 100 ug/ml incubated for 6 days by crystal violet staining based assay relative to control	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID366288	Antiviral activity against Influenza A virus Jinan/15/90 H3N2 assessed as reduction of virus-induced cytopathic effect	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID1435480	Cytotoxicity against African green monkey Vero cells assessed as cytopathic effect after 48 hrs	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Synthesis and evaluation of halogenated 12N-sulfonyl matrinic butanes as potential anti-coxsackievirus agents.
AID297317	Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Aug-23, Volume: 50, Issue:17	Synthesis and antiviral and cytostatic evaluations of the new C-5 substituted pyrimidine and furo[2,3-d]pyrimidine 4',5'-didehydro-L-ascorbic acid derivatives.
AID434313	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID218404	Minimum inhibitory concentration required to reduce parainfluenza virus-3 induced cytopathogenicity by 50% in african green monkey (VeroB) cells	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID284525	Antiviral activity against HSV1 KOS-induced cytopathogenicity in E6SM cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID142441	Cytotoxicity was evaluated	1991	Journal of medicinal chemistry, Jan, Volume: 34, Issue:1	Unsaturated and carbocyclic nucleoside analogues: synthesis, antitumor, and antiviral activity.
AID1524778	Cytotoxicity against MDCK cells assessed as reduction in cell viability measured on day 5 by Celltiter-Glo luminescence assay	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.
AID1687954	Antiproliferative activity against human A-431 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID648685	Cytotoxicity against human RD cells	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Antiviral effect of geraniin on human enterovirus 71 in vitro and in vivo.
AID368975	Antiviral activity against DMSO-passaged wild type RSV RSS infected human Hep2 cells by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID611771	Cytotoxicity against human HeLa cells assessed as growth inhibition after 3 days by coulter counting analysis	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	New prodrugs of Adefovir and Cidofovir.
AID1682703	Cytotoxicity against MDCK cells assessed as cell death incubated for 48 hrs by MTT assay
AID226099	Minimum inhibitory concentration against Herpes simplex virus 2 (G) in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID1443673	Cytotoxicity against human 293T cells expressing Gluc assessed as inhibition of cell proliferation at 20 uM after 24 hrs by CCK8 assay relative to control	2017	Bioorganic & medicinal chemistry letters, 04-15, Volume: 27, Issue:8	Anti-influenza triterpenoid saponins (saikosaponins) from the roots of Bupleurum marginatum var. stenophyllum.
AID64116	Tested for minimum inhibitor concentration against vesicular stomatitis virus (VSV) in E6SM cells	1993	Journal of medicinal chemistry, Oct-01, Volume: 36, Issue:20	Antiviral activity of C-alkylated purine nucleosides obtained by cross-coupling with tetraalkyltin reagents.
AID1391709	Antiviral activity against Influenza A virus (A/WSN/1933(H1N1)) infected in MDCK cells cocultured with human 293T-Gluc cells preincubated with compound for 2 hrs followed by virus infection measured after 24 hrs by luciferase reporter gene assay	2018	Bioorganic & medicinal chemistry letters, 05-15, Volume: 28, Issue:9	Secoiridoid analogues from the fruits of Ligustrum lucidum and their inhibitory activities against influenza A virus.
AID1077001	Antiviral activity against Influenza A virus A/hanfang/359/95(H3N2) infected in MDCK cells assessed as inhibition of virus-induced cytopathicity after 40 hrs	2014	European journal of medicinal chemistry, Apr-09, Volume: 76	1,2,3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses.
AID261060	Efficacy in BALB/c mouse measured as reduction in log TCID50 of RSV per gram of lung at 90 mg/kg, sc	2006	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5	Respiratory syncytial virus fusion inhibitors. Part 3: Water-soluble benzimidazol-2-one derivatives with antiviral activity in vivo.
AID370205	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 mL of serum at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID198426	Percent increase in survival rate of Rift Valley fever virus infected mice on day 21, by administering 100 (mg/kg)/day of compound	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID300561	Antiviral activity against influenza A/Hanfang/359/95 (H3N2) virus in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID665834	In vivo antiviral activity against TMV assessed as viral inactivation effect at 500 ug/mL	2012	European journal of medicinal chemistry, Jul, Volume: 53	Design, synthesis and antiviral activity of novel quinazolinones.
AID548449	Antiviral activity against Coxsackie virus B4 infected in african green monkey Vero cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID691389	Antiviral activity against Hepatitis C virus subtype 1a infected in human HuH7 cells at 10 ug/mL after 2 days by q-PCR analysis	2012	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 22, Issue:20	A new class of pyrimidine nucleosides: inhibitors of hepatitis B and C viruses.
AID548429	Cytotoxicity against human HeLa cells assessed as cell viability by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID475853	Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	2010	Bioorganic & medicinal chemistry, Apr-01, Volume: 18, Issue:7	Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin.
AID88195	Cytotoxic concentration required to cause microscopically detectable alteration of normal cell morphology of HeLa cells	1996	Journal of medicinal chemistry, Jul-05, Volume: 39, Issue:14	Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents.
AID717174	Antiviral activity against Influenza A virus (A/X-31(H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect after 3 days by microscopic analysis	2012	Bioorganic & medicinal chemistry, Dec-15, Volume: 20, Issue:24	Microwave assisted synthesis and anti-influenza virus activity of 1-adamantyl substituted N-(1-thia-4-azaspiro[4.5]decan-4-yl)carboxamide derivatives.
AID1133179	Antiviral activity against HSV2 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect after 72 hrs relative to control	1978	Journal of medicinal chemistry, Dec, Volume: 21, Issue:12	Synthesis and antiviral and enzymatic studies of certain 3-deazaguanines and their imidazolecarboxamide precursors.
AID1731878	Cytotoxicity against human HEK-293T cells assessed as reduction in cell viability after 48 hrs by CCK-8 assay	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	Synthesis and antiviral activity of a series of novel quinoline derivatives as anti-RSV or anti-IAV agents.
AID1778627	Antiviral activity against Influenza A virus A/PR/8/34(H1N1) infected in MDCK cells assessed as inhibition of plaque formation for 48 hrs by plaque reduction assay	2021	European journal of medicinal chemistry, Oct-05, Volume: 221	1,2,4-Triazolo[1,5-a]pyrimidines: Efficient one-step synthesis and functionalization as influenza polymerase PA-PB1 interaction disruptors.
AID401224	Antiviral activity against RSV Long in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2004	Journal of natural products, Apr, Volume: 67, Issue:4	Antiviral flavonoids from the seeds of Aesculus chinensis.
AID424778	Antiviral activity against Coxsackie virus B3 Nacy infected in human HeLa cells assessed as reduction of virus-induced cytopathic effect by MTT assay	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Anti-coxsackie virus B3 norsesquiterpenoids from the roots of Phyllanthus emblica.
AID1135883	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 13 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to da	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID1336607	Cytotoxicity against African green monkey Vero cells assessed as alterations in cell morphology by microscopic analysis	2017	Bioorganic & medicinal chemistry letters, 01-15, Volume: 27, Issue:2	Synthesis and in vitro antiviral evaluation of 4-substituted 3,4-dihydropyrimidinones.
AID217996	Compound was tested for antiviral activity against vaccinia virus in primary rabbit kidney cells	1984	Journal of medicinal chemistry, Jul, Volume: 27, Issue:7	Biological activity and a modified synthesis of 8-amino-3-beta-D-ribofuranosyl-1,2,4-triazolo[4,3-a]pyrazine, an isomer of formycin.
AID1135741	Antiviral activity against Parainfluenza virus type 3 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Synthesis and antiviral acticity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin).
AID1710795	Antiviral activity against influenza A virus infected in dog MDCK cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1773040	Antiviral activity against RSV Long infected in BALB/c mouse assessed as inhibition of alveolar infiltrates accumulation at 50 mg/kg/day observed on day 6 after infection by H and E staining based microscopic analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID366290	Cytotoxicity against MDCK cells assessed as maximal non-cytotoxic concentration by MTT assay	2008	Bioorganic & medicinal chemistry, Aug-01, Volume: 16, Issue:15	Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities.
AID1498140	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced visual cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID1753363	Cytotoxicity against human HEK293T cells measured after 72 hrs by MTT assay	2021	Bioorganic & medicinal chemistry letters, 05-15, Volume: 40	New class of hantaan virus inhibitors based on conjugation of the isoindole fragment to (+)-camphor or (-)-fenchone hydrazonesv.
AID63941	concentration required to inhibit HSV-2(G)-induced cytopathicity by 50% in E6SM cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID275086	Antiviral activity against HSV1 KOS in HEL cells	2006	Journal of medicinal chemistry, Dec-28, Volume: 49, Issue:26	Synthesis, in vitro antiviral evaluation, and stability studies of novel alpha-borano-nucleotide analogues of 9-[2-(phosphonomethoxy)ethyl]adenine and (R)-9-[2-(phosphonomethoxy)propyl]adenine.
AID472792	Antiviral activity against Polio virus type1 Sabin strain Chat infected in african green monkey Vero cells after 2 days by plaque reduction assay	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID216230	Selectivity index as the ratio of CC50/EC50 against Vesicular stomatitis virus	2002	Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10	Heterocyclic nucleoside analogues: design and synthesis of antiviral, modified nucleosides containing isoxazole heterocycles.
AID1081161	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 100 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis of 4-methyl-1,2,3-thiadiazole derivatives via Ugi reaction and their biological activities.
AID63914	Effective concentration required to inhibit Herpes simplex virus-1 (HSV-1) induced cytopathicity by 50% in E6SM cell lines	2001	Journal of medicinal chemistry, Aug-16, Volume: 44, Issue:17	Synthesis, mechanism of action, and antiviral activity of a new series of covalent mechanism-based inhibitors of S-adenosyl-L-homocysteine hydrolase.
AID1651269	Antiviral activity against Zika virus infected in African green monkey Vero E6 cells assessed as inhibition of viral induced cytopathic effect at 40 uM relative to control	2020	Bioorganic & medicinal chemistry letters, 02-15, Volume: 30, Issue:4	Design, synthesis, and evaluation of novel 4-amino-2-(4-benzylpiperazin-1-yl)methylbenzonitrile compounds as Zika inhibitors.
AID1710796	Antiviral activity against influenza B virus infected in dog MDCK cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID63762	The minimum inhibitory concentration was measured on E6SM cells against Herpes simplex virus type 2 (G strain)	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID1691540	Antiviral activity against Influenza A virus (A/PR 8/34 (H1N1)) infected in MDCK cells assessed as reduction in virus-induced cytopathic effect measured after 72 hrs by MTS assay	2020	European journal of medicinal chemistry, May-15, Volume: 194	N-benzyl 4,4-disubstituted piperidines as a potent class of influenza H1N1 virus inhibitors showing a novel mechanism of hemagglutinin fusion peptide interaction.
AID474541	Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus California/07/2009 /H1N1 by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID774866	Cytotoxicity against african green monkey Vero cells after 96 hrs by MTT assay	2013	European journal of medicinal chemistry, Nov, Volume: 69	Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.
AID395965	Antiviral activity against 500 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean day of death at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID524794	Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay	2009	Nature chemical biology, Oct, Volume: 5, Issue:10	Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1252403	Antiviral activity against Parainfluenza virus 3 expressed in African green monkey Vero cells assessed as reduction in cytopathogenicity	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Novel halogenated 3-deazapurine, 7-deazapurine and alkylated 9-deazapurine derivatives of L-ascorbic or imino-L-ascorbic acid: Synthesis, antitumour and antiviral activity evaluations.
AID1200495	Antiviral activity against OSV-resistant influenza A virus A/LiaoNing-ZhenXing/1109/2010 (H1N1) strain	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Neoechinulin B and its analogues as potential entry inhibitors of influenza viruses, targeting viral hemagglutinin.
AID1127179	Antiviral activity against DENV2 16681 infected in human Huh-7 cells at 5 uM after 3 days by luciferase reporter gene assay	2014	European journal of medicinal chemistry, May-22, Volume: 79	Synthesis, antiproliferative and anti-dengue virus evaluations of 2-aroyl-3-arylquinoline derivatives.
AID1450223	Selectivity index, ratio of MCC for African green monkey Vero E6 cells to IC50 for acyclovir and foscarnet-resistant HSV-1 L2 infected in African green monkey Vero E6 cells	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID360158	Antiviral activity against HCV 1b Con1 with NS3-4A R155K mutation in human Huh7 cells after 48 hrs by replicon cell assay	2007	The Journal of biological chemistry, Aug-03, Volume: 282, Issue:31	Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon alpha.
AID106223	Tested for inhibitory effect on RNA virus HIV-1 in MT-4 cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID383520	Antiviral activity against thymidine kinase deficient and acyclovir resistant HSV1 KOS in human E6SM cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1435488	Antiviral activity against Coxsackievirus B6 Schmitt infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Synthesis and evaluation of halogenated 12N-sulfonyl matrinic butanes as potential anti-coxsackievirus agents.
AID535535	Transport through ENT2 in rat hepatocytes by oil filtration assay in presence 100 uM of transporter inhibitor NBMRP	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID217893	Minimum inhibitory concentration against forest virus in Vero cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID223416	Concentration required to reduce influenza virus B (singapore) induced cytopathogenicity by 50%	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID1071702	Selectivity index, ratio of CC50 for cytotoxicity to EC50 for Influenza B virus	2014	European journal of medicinal chemistry, Mar-03, Volume: 74	Synthesis and biological evaluation of 2-oxonicotinonitriles and 2-oxonicotinonitrile based nucleoside analogues.
AID443828	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) assessed as cell viability by cell-based MTS assay	2009	Journal of medicinal chemistry, Oct-08, Volume: 52, Issue:19	Diazo transfer-click reaction route to new, lipophilic teicoplanin and ristocetin aglycon derivatives with high antibacterial and anti-influenza virus activity: an aggregation and receptor binding study.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1303367	Antiviral activity against BVDV NADL infected in MDBK cells assessed as inhibition of virus induced cytopathogenicity after 3 to 4 days by MTT assay	2016	European journal of medicinal chemistry, Jul-19, Volume: 117	A combined in silico/in vitro approach unveils common molecular requirements for efficient BVDV RdRp binding of linear aromatic N-polycyclic systems.
AID1433153	Cytotoxicity against MDCK cells assessed as inhibition of cell viability by colorimetric formazan-based MTS assay	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID438025	Antiviral activity against Dengue virus	2009	Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24	The medicinal chemistry of dengue fever.
AID280198	Antiviral activity against reovirus1 in Vero cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID216503	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with Reo 1 virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID712796	Cytotoxicity against dog MDCK cells assessed as cell morphology alterations	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID217591	In vitro antiviral activity against vaccinia virus in Vero cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and biological activity of certain nucleoside and nucleotide derivatives of pyrazofurin.
AID217892	Minimum inhibitory concentration against Coxsackie virus B4 in Vero cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID395933	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 50 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID312073	Antiviral activity against poliovirus infected HeLa S3 cells assessed as plaque formation at 0.5 mM relative to control	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Effects of introduction of hydrophobic group on ribavirin base on mutation induction and anti-RNA viral activity.
AID89114	Minimum cytotoxic concentration in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID1687951	Antiproliferative activity against human DU-145 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID1710781	Antiviral activity against Human parainfluenza virus 3 infected in African green monkey Vero cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID1542950	Antiviral activity against Zika virus	2019	ACS medicinal chemistry letters, Apr-11, Volume: 10, Issue:4	Scaffold Morphing Approach To Expand the Toolbox of Broad-Spectrum Antivirals Blocking Dengue/Zika Replication.
AID1186335	Antiviral activity against Coxsackievirus B5 infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 3 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1710775	Antiviral activity against Human coxsackievirus B4 infected in human HeLa cells assessed as reduction in virus-induced cytopathic effect incubated for 3 to 6 days by light microscopic analysis	2016	Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2	Synthesis and antiviral properties of novel indole-based thiosemicarbazides and 4-thiazolidinones.
AID217262	In vitro antiviral activity against vaccinia(VV) virus was determined in african green monkey kidney (vero,V) expressed as virus rating. Toxic level(>1000 ug/mL)	1982	Journal of medicinal chemistry, Nov, Volume: 25, Issue:11	Synthesis and antiviral activity of certain carbamoylpyrrolopyrimidine and pyrazolopyrimidine nucleosides.
AID65712	Antiviral activity against vesicular simplex virus-1 in E6SM cell cultures	2001	Journal of medicinal chemistry, Aug-02, Volume: 44, Issue:16	Design, synthesis, DNA binding, and biological evaluation of water-soluble hybrid molecules containing two pyrazole analogues of the alkylating cyclopropylpyrroloindole (CPI) subunit of the antitumor agent CC-1065 and polypyrrole minor groove binders.
AID277832	Cytotoxicity against HeLa cells	2007	Journal of natural products, Feb, Volume: 70, Issue:2	Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa.
AID648680	Antiviral activity against C4 type Human enterovirus 71 MP10 infected in ICR mouse assessed as increase in survival rate at 50 mg/kg, ip administered 2 hrs post infection qd for 7 days measured up to 14 days	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Antiviral effect of geraniin on human enterovirus 71 in vitro and in vivo.
AID427552	Antiviral activity against HCV Con1-mADE replicon with NS3 serine protease V36M/R155K double mutation in human HuH7 cells after 48 hrs by RNA replicon assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
AID1205008	Selectivity index, ratio of TC50 for african green monkey Vero cells to IC50 for Coxsackievirus B6 infected in african green monkey Vero cells	2015	ACS medicinal chemistry letters, Feb-12, Volume: 6, Issue:2	Novel N-benzenesulfonyl sophocarpinol derivatives as coxsackie B virus inhibitors.
AID216823	In vitro antiviral activity against COXB1 virus in (vero) V cells	1981	Journal of medicinal chemistry, Aug, Volume: 24, Issue:8	Synthesis and antiviral activity of certain 9-beta-D-ribofuranosylpurine-6-carboxamides.
AID257340	Cytotoxicity against Huh7ET cell line containg HCV replicon at 10 uM assessed by measuring the beta-actin RNA level relative to control	2005	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 15, Issue:24	Synthesis and in vitro anti-hepatitis B and C virus activities of ring-expanded ('fat') nucleobase analogues containing the imidazo[4,5-e][1,3]diazepine-4,8-dione ring system.
AID464001	Antiviral activity against Influenza A virus H3N2 infected in MDCK cells assessed as protection from virus-induced cytopathogenicity after 6 to 7 days by MTT assay	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID218036	Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with Vero B cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID1498120	Antiviral activity against Reovirus-1 infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Expedient synthesis and biological evaluation of alkenyl acyclic nucleoside phosphonate prodrugs.
AID474549	Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza B virus Malaysia/2506/2004	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID86492	Tested for antiviral activity against coxsackie-B4 virus in human epithelial cell line	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID301699	Inhibition of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID376988	Selectivity index, CC50 for MDCK cells to IC50 for influenza A virus H1N1 A/NWS/33	2006	Journal of natural products, May, Volume: 69, Issue:5	Antiviral flavans from the leaves of Pithecellobium clypearia.
AID1132066	Antiviral activity against Coxsackievirus B1 infected in human HeLa cells at 1 mg/ml by agar diffusion assay	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID280193	Antiviral activity against VSV in HeLa cells assessed as inhibition of virus-induced cytopathicity	2007	Journal of medicinal chemistry, Mar-08, Volume: 50, Issue:5	Antiviral activity of triazine analogues of 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]cytosine (cidofovir) and related compounds.
AID278349	Inhibition of viral RNA levels in HTNV 76-118-infected Vero E6 cells at 40 ug/ml after 3 days	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID402532	Antiviral activity against influenza A virus NWS33 in MDCK cells assessed as inhibition of viral cytopathic effect by neutral red assay	1997	Journal of natural products, Jun, Volume: 60, Issue:6	Two new lignans with activity against influenza virus from the medicinal plant Rhinacanthus nasutus.
AID1783346	Antiviral activity against Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID419605	Antiviral activity against Coxsackievirus B4 infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity after 3 days	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID1261340	Antiviral activity against HSV1	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1687949	Antiproliferative activity against human CaCo-2 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Feb-15, Volume: 188	Synthesis and antitumor activities investigation of a C-nucleoside analogue of ribavirin.
AID1306317	Cytotoxicity against African green monkey Vero E6 cells	2016	Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14	An alternative route to the arylvinyltriazole nucleosides.
AID1135886	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 14 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to da	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID1135740	Antiviral activity against HSV1 infected in human KB cells assessed as inhibition of virus-induced cytopathic effect at 1 to 1000 ug/ml after 72 hrs	1978	Journal of medicinal chemistry, Aug, Volume: 21, Issue:8	Synthesis and antiviral acticity of some phosphates of the broad-spectrum antiviral nucleoside, 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (ribavirin).
AID1783349	Selectivity index, ratio of CC50 for human Huh-7 cells to IC50 for Dengue virus serotype 2 New Guinea C infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based plaque reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID548426	Antiviral activity against Vaccinia virus infected in HEL cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID478325	Antiviral activity against influenza B virus assessed as cell viability by cell based MTS assay	2010	Bioorganic & medicinal chemistry letters, May-01, Volume: 20, Issue:9	Click reaction synthesis of carbohydrate derivatives from ristocetin aglycon with antibacterial and antiviral activity.
AID768194	Antiviral activity against Reovirus-1 infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID1298255	Cytotoxicity against MDCK cells assessed as cell viability measured after 4 days by formazan-based MTS assay	2016	Bioorganic & medicinal chemistry, 06-01, Volume: 24, Issue:11	1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
AID1443881	Antiviral activity against full length gluc-tagged Chikungunya virus 2013 Caribbean CNR20235 infected in HEK293T cells assessed as reduction in virus infection after 24 hrs by gaussia luciferase reporter gene assay	2017	Journal of medicinal chemistry, 04-13, Volume: 60, Issue:7	Structural Optimizations of Thieno[3,2-b]pyrrole Derivatives for the Development of Metabolically Stable Inhibitors of Chikungunya Virus.
AID82039	Effects on cell morphology of HEF cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID766687	Antiviral activity against Punta Toro virus infected in african green monkey Vero cells assessed as reduction in virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Sep, Volume: 67	Regioselective synthesis of 6-substituted-2-amino-5-bromo-4(3H)-pyrimidinones and evaluation of their antiviral activity.
AID87157	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in HeLa cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID416783	Antiviral activity against influenza H3N2 virus in MDCK cells assessed as reduction of virus-induced cytopathicity by MTS method	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1450212	Cytotoxicity against African green monkey Vero E6 cells measured after 3 days by trypan blue assay	2017	Bioorganic & medicinal chemistry letters, 06-01, Volume: 27, Issue:11	New modified 2-aminobenzimidazole nucleosides: Synthesis and evaluation of their activity against herpes simplex virus type 1.
AID1852994	Cytotoxicity against paclitaxel-resistant human HCT116tax cells assessed as DNA damage by measuring fluorescence intensity incubated for 30 mins by Hoechst 33342 staining accumulation assay	2022	ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12	ATP Mimetic Attack on the Nucleotide-Binding Domain to Overcome ABC Transporter Mediated Chemoresistance.
AID765051	Selectivity index, ratio of CC50 for african green monkey OR6 cells to ED50 for HCV	2013	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17	Peroxisome proliferator-activated receptor delta antagonists inhibit hepatitis C virus RNA replication.
AID1716987	Antiviral activity against H3N2 infected in MDCK cells measured after 24 hrs by Gaussia luciferase reporter gene method	2020	European journal of medicinal chemistry, Jan-15, Volume: 186	Design and synthesis of 2-((1H-indol-3-yl)thio)-N-phenyl-acetamides as novel dual inhibitors of respiratory syncytial virus and influenza virus A.
AID421727	Therapeutic index, ratio of TC50 for human Hep2 cells to IC50 for Respiratory syncytial virus infected in human Hep2 cells	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Antiviral constituents against respiratory viruses from Mikania micrantha.
AID86483	Minimum inhibitory conc. for 50% inhibition of morphology virus induced cytopathicity in HeLa cells	1997	Journal of medicinal chemistry, Apr-25, Volume: 40, Issue:9	Carbocyclic oxetanocins lacking the C-3' methylene.
AID648647	Antiinfluenza activity against influenza B virus infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 36 hrs	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Synthesis and anti-influenza activity of aminoalkyl rupestonates.
AID1132059	Cytotoxicity against human HeLa cells by neutral red assay	1978	Journal of medicinal chemistry, Jan, Volume: 21, Issue:1	Thiazolinone analogues of indolmycin with antiviral and antibacterial activity.
AID1293610	Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay	2016	Journal of medicinal chemistry, Mar-24, Volume: 59, Issue:6	4,6-Diphenylpyridines as Promising Novel Anti-Influenza Agents Targeting the PA-PB1 Protein-Protein Interaction: Structure-Activity Relationships Exploration with the Aid of Molecular Modeling.
AID105790	Antiviral activity against influenza A,H3N2 virus infected MDCK cell lines.	1996	Journal of medicinal chemistry, Aug-16, Volume: 39, Issue:17	Synthesis and antiviral activity evaluation of some new aminoadamantane derivatives. 2.
AID474345	Selectivity ratio of IC50 for MDCK cells to EC50 for Influenza A virus Hong Kong/213/2003/H5N1 by neutral red dye uptake assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID1433145	Antiviral activity against Sindbis virus infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID1082991	Antiviral activity against Tobacco mosaic virus (TMV) inoculation on Nicotiana tabacum L. whole leaves assessed as virus infection protective effect at 500 ug/mL measured 3 to 4 days post inoculation	2012	Journal of agricultural and food chemistry, Sep-05, Volume: 60, Issue:35	Design, synthesis, and antiviral activity evaluation of phenanthrene-based antofine derivatives.
AID419601	Cytotoxicity against african green monkey Vero cells assessed as alteration in cell morphology	2009	European journal of medicinal chemistry, Jun, Volume: 44, Issue:6	Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives.
AID218031	Antiviral activity was measured against Reo virus-1 in african green monkey kidney (Vero B) cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID474347	Selectivity ratio of IC50 for MDCK cells to EC50 for inhibition of virus-induced cytopathic effect of Influenza A virus Vietnam/1203/ 2004H/H5N1	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID383509	Antiviral activity against respiratory syncytial virus in human HeLa cells assessed as inhibition of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID472789	Antiviral activity against Bovine viral diarrhea virus NADL infected in MDBK cells assessed as protection from virus-induced cytopathogenicity after 3 to 4 days by MTT method	2010	Bioorganic & medicinal chemistry, Apr-15, Volume: 18, Issue:8	Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives.
AID634089	Cytotoxicity against human HuH7 cells infected with HCV1b assessed as cell viability at 10 uM after 3 days by MTS assay	2012	Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1	The design, synthesis and biological evaluations of C-6 or C-7 substituted 2-hydroxyisoquinoline-1,3-diones as inhibitors of hepatitis C virus.
AID218449	Percent purine synthesized in human B lymphoblast WI-L2 cells was determined	1988	Journal of medicinal chemistry, Feb, Volume: 31, Issue:2	Synthesis and evaluation of 5-amino-1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamidine and certain related nucleosides as inhibitors of purine nucleoside phosphorylase.
AID1280362	Antiviral activity against amantadine-resistant influenza A virus JX/312 (H3N2) infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID535537	Transport through CNT2 in rat hepatocytes by oil filtration assay pre-incubated with 20 ng/mL rotenone for 15 mins and 2 mM 2-deoxyglucose for 10 mins at 37 degC in presence of sodium ions in Kreb-henseleit buffer containing 100 nM NBMPR	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Striking species difference in the contribution of concentrative nucleoside transporter 2 to nucleoside uptake between mouse and rat hepatocytes.
AID336178	Antiviral activity against Potato virus X in half leaf of Chenopodium quinoa at 9.3 mg/mL after 10 days	2002	Journal of natural products, Oct, Volume: 65, Issue:10	Bioactive constituents from Iryanthera megistophylla.
AID1578007	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition in virus-induced cytopathic effect incubated for 40 hrs	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	Novel amides modified rupestonic acid derivatives as anti-influenza virus reagents.
AID63767	The minimum inhibitory concentration was measured on E6SM cells against Vesicular stomatitis virus	1994	Journal of medicinal chemistry, Sep-16, Volume: 37, Issue:19	Tricyclic analogues of acyclovir and ganciclovir. Influence of substituents in the heterocyclic moiety on the antiviral activity.
AID368976	Antiviral activity against plaque picked RSV604-resistant RSV RSS from passage 2 in human Hep2 cells by plaque reduction assay	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	RSV604, a novel inhibitor of respiratory syncytial virus replication.
AID1773057	Antiviral activity against RSV infected in BALB/c mouse assessed as downregulation of iNOS expression in lung tissue infected with RSV at 50 mg/kg/day measured after 2 to 6 days post infection by RT-PCR analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID1830602	Antiviral activity against HSV-1 infected in human Huh-7 cells assessed as reduction in plaque forming units at 1 uM measured after 48 hrs by virus titre method	2021	Bioorganic & medicinal chemistry letters, 11-15, Volume: 52	Synthesis and antiviral effect of phosphamide modified vidarabine for treating HSV 1 infections.
AID1427859	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus (A/95-359) infected in MDCK cells
AID1272970	Therapeutic index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus H3N2 A3/JINGKE/30/95	2016	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3	The semi-synthesis of novel andrographolide analogues and anti-influenza virus activity evaluation of their derivatives.
AID1783351	Antiviral activity against Zika virus H/PF/2013 infected in pre-seeded Huh-7 cells assessed as inhibition of viral replication incubated for 72 hrs by immunodetection based direct yield reduction assay	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID218127	Minimum inhibitory concentration against vaccinia virus in primary rabbit kidney cell cultures of experiment 2	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID1135878	Antiviral activity against Influenza A virus Port Chalmers/1/73 (H3N2) infected in ferret assessed as reduction in viral excretion by measuring hemagglutination units per ml at 7 mg/kg administered intranasally 7 times on day 0 and 9 times on day 1 to day	1979	Journal of medicinal chemistry, Feb, Volume: 22, Issue:2	Easily hydrolyzable, water-soluble derivatives of (+/-)-alpha-5-[1-(indol-3-yl)ethyl]-2-methylamino-delta2-thiazoline-4-one, a novel antiviral compound.
AID246507	Effective concentrations at which 2-fold depression of HCV RNA was observed in AVA5 cells (Huh 7 cells with subgenomic HCV replicon BB7)	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	5'-Homoneplanocin A inhibits hepatitis B and hepatitis C.
AID1113459	Antiviral activity against Mammalian orthoreovirus 1 infected African green monkey Vero cells assessed as reduction of virus-induced cytopathic effect after 3 days by colorimetric formazan-based MTS assay	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID167151	Minimum cytotoxic concentration required to cause a microscopically detectable alteration of normal cell morphology in primary rabbit kidney cells	1987	Journal of medicinal chemistry, Mar, Volume: 30, Issue:3	Nucleic acid related compounds. 51. Synthesis and biological properties of sugar-modified analogues of the nucleoside antibiotics tubercidin, toyocamycin, sangivamycin, and formycin.
AID395930	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as mean day of death at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID395934	Antiviral activity against Pichinde virus An 4763 infected Syrian golden hamster assessed as animals with detectable virus level in liver at 20 mg/kg, po twice daily for 7 days administered 24 hrs post viral-challenge measured on day 7 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID1415636	Selectivity index, ratio of CC50 for MDCK cells to EC50 for Influenza A virus (A/Puerto Rico/8/34(H1N1))	2017	MedChemComm, May-01, Volume: 8, Issue:5	Synthesis and
AID1082995	Antiviral activity against Tobacco mosaic virus (TMV) assessed as inhibition of viral growth at 500 ug/mL	2012	Journal of agricultural and food chemistry, Sep-05, Volume: 60, Issue:35	Design, synthesis, and antiviral activity evaluation of phenanthrene-based antofine derivatives.
AID1261322	Selectivity index, ratio of CC50 for african green monkey Vero76 cells to EC50 for human RSV	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID370201	Antiviral activity against 5000 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as mean viral titer per 0.1 g of liver at 30 mg/kg, po twice daily administered 24 hrs post viral challenge measured on day 3 of viral infection	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID87320	Minimum inhibitory concentration against Herpes simplex virus 2(G)	1989	Journal of medicinal chemistry, Oct, Volume: 32, Issue:10	Novel linked antiviral and antitumor agents related to netropsin and distamycin: synthesis and biological evaluation.
AID474548	Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Wisconsin/67/2005/H3N2 by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID300563	Antiviral activity against influenza B/Jingfang/76/98 in MDCK cells by CPE assay	2007	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17	Synthesis and anti-influenza activities of carboxyl alkoxyalkyl esters of 4-guanidino-Neu5Ac2en (zanamivir).
AID88687	Tested for inhibitory effect on RNA virus VSV in HeLa cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID1186337	Antiviral activity against Respiratory syncytial virus infected in african green monkey Vero 76 cells assessed as reduction in plaque number after 5 days by plaque reduction assay	2014	Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17	Antiviral activity of benzimidazole derivatives. III. Novel anti-CVB-5, anti-RSV and anti-Sb-1 agents.
AID1408127	Cytotoxicity against HEK293T cells assessed as decrease in cell viability after 24 hrs by MTT assay	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Synthesis and biological evaluation of a library of hybrid derivatives as inhibitors of influenza virus PA-PB1 interaction.
AID156849	Minimum inhibitory concentration required to reduce vaccinia virus induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK)	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID1773037	Antiviral activity against RSV Long infected in BALB/c mouse assessed as reduction in lung tissue damage by measuring lung index at 50 mg/kg/day measured after 4 to 6 days of virus infection	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID216396	Compound was tested for antiviral activity in HeLa Cell cultures, against vesicular stomatitis virus (VSV)	1985	Journal of medicinal chemistry, Jun, Volume: 28, Issue:6	Synthesis and antiviral evaluation of nucleosides of 5-methylimidazole-4-carboxamide.
AID155439	In vitro antiviral activity was tested against, parainfluenza type 3 (Para 3) virus	1985	Journal of medicinal chemistry, Oct, Volume: 28, Issue:10	Synthesis and biological activity of certain 6-substituted and 2,6-disubstituted 2'-deoxytubercidins prepared via the stereospecific sodium salt glycosylation procedure.
AID1360700	Antiviral activity against Respiratory syncytial virus Long infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect after 3 to 6 days by MTS based microscopy	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID1118640	Antiviral activity against Vesicular stomatitis virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathicity	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1432506	Selectivity index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus H1N1 infected in MDCK cells	2017	Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6	Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses.
AID383519	Antiviral activity against in Vesicular stomatitis virus in human HEL cells assessed as reduction of virus-induced cytopathogenicity	2008	European journal of medicinal chemistry, Feb, Volume: 43, Issue:2	Synthesis of some novel thiourea derivatives obtained from 5-[(4-aminophenoxy)methyl]-4-alkyl/aryl-2,4-dihydro-3H-1,2,4-triazole-3-thiones and evaluation as antiviral/anti-HIV and anti-tuberculosis agents.
AID1226133	Inhibition of Influenza A virus (A/PR/8/34) (H1N1) RNA-dependent-RNA polymerase 6His-tagged-PA/GST-tagged-BP 1 interaction by ELISA	2015	Journal of medicinal chemistry, May-14, Volume: 58, Issue:9	A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits.
AID1886807	Antiviral activity against DENV2 infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis relative to c	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID1886804	Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect measured after 72 hrs by crystal violet staining based inverted microscopic analysis	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID87160	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against vesicular stomatitis virus in HeLa cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID277830	Antiviral activity against VSV	2007	Journal of natural products, Feb, Volume: 70, Issue:2	Cinnamacrins A-C, cinnafragrin D, and cytostatic metabolites with alpha-glucosidase inhibitory activity from Cinnamosma macrocarpa.
AID63947	Tested for cytotoxic activity in human embryonic skin muscle fibroblast (E6SM)	2002	Bioorganic & medicinal chemistry letters, Mar-11, Volume: 12, Issue:5	New 2-(1-adamantylcarbonyl)pyridine and 1-acetyladamantane thiosemicarbazones-thiocarbonohydrazones: cell growth inhibitory, antiviral and antimicrobial activity evaluation.
AID68125	Tested for inhibitory effect on DNA virus HSV-1(KOS) in ESM cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID301695	Inactivation of human recombinant S-adenosyl-L-homocysteine hydrolase NADH form expressed in Escherichia coli JM109 assessed by measuring fluorescence	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID218062	Maximum tolerated concentration against Vero cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Synthesis and biological activity of certain nucleoside and nucleotide derivatives of pyrazofurin.
AID84228	Inhibitory activity against HSV-1 (McIntyre) replication in E6SM cell cultures of human embryonic skin-muscle	2002	Journal of medicinal chemistry, Dec-05, Volume: 45, Issue:25	A thymidine phosphorylase-stable analogue of BVDU with significant antiviral activity.
AID217592	In vitro antiviral activity against vaccinia virus was evaluated.	1985	Journal of medicinal chemistry, Aug, Volume: 28, Issue:8	Synthesis and biological activity of 6-azacadeguomycin and certain 3,4,6-trisubstituted pyrazolo[3,4-d]pyrimidine ribonucleosides.
AID108464	The minimum inhibitory concentration required to reduce measles virus induced cytopathogenicity in primary rabbit kidney cells by 50%	1984	Journal of medicinal chemistry, Dec, Volume: 27, Issue:12	Synthesis and biological evaluation of 6-amino-1H-pyrrolo[3,2-c]pyridin-4(5H)-one (3,7-dideazaguanine).
AID164600	Inhibitory dose of compound required to inhibit cytopathogenic effects of Punta toro virus with adames strain in vero cells	1988	Journal of medicinal chemistry, Sep, Volume: 31, Issue:9	Cyclopentenylcytosine. A carbocyclic nucleoside with antitumor and antiviral properties.
AID232125	Ratio measured as the VR of C-3''-deoxyribofuranoside to the VR at a MIC of 14 ug/mL	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Synthesis and antiviral evaluation of carbocyclic analogues of 2-amino-6-substituted-purine 3'-deoxyribofuranosides.
AID774867	Antiviral activity against Coxsackie B3 virus Nancy in african green monkey Vero cells assessed as inhibition virus-induced cytopathic effect after 48 hrs	2013	European journal of medicinal chemistry, Nov, Volume: 69	Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.
AID1472404	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) clone 1 infected in MDCK cells assessed as inhibition of virus-induced cytopathicity measured after passage in absence of 2-Isopropyl-N-[2-(piperidin-1-yl)ethyl]aniline hydrochloride	2018	Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1	Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion.
AID1349204	Antiviral activity against HCV infected in human Ava5 cells assessed as inhibition of viral RNA replication at 5 uM after 3 days by RT-qPCR method relative to control	2018	European journal of medicinal chemistry, Jan-01, Volume: 143	Discovery of naphtho[1,2-d]oxazole derivatives as potential anti-HCV agents through inducing heme oxygenase-1 expression.
AID1261311	Cytotoxicity against african green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining method	2015	Bioorganic & medicinal chemistry, Nov-01, Volume: 23, Issue:21	Antiviral activity of benzotriazole derivatives. 5-[4-(Benzotriazol-2-yl)phenoxy]-2,2-dimethylpentanoic acids potently and selectively inhibit Coxsackie Virus B5.
AID1524781	Selectivity index, ratio of CC50 for cytotoxicity against MDCK cells to EC50 for Influenza A virus (A/California/7/2009(H1N1)) infected in MDCK cells	2019	Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9	Identification, design and synthesis of novel pyrazolopyridine influenza virus nonstructural protein 1 antagonists.
AID1118643	Antiviral activity against HIV-1 3B infected in human CEM cells assessed as inhibition of virus-induced giant cell formation after 4 days by microscopic analysis	2011	MedChemComm, Jul-01, Volume: 2, Issue:7	Carbocyclic 5'-nor "reverse" fleximers. Design, synthesis, and preliminary biological activity.
AID1360696	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as protection against virus-induced reduction in cell viability after 3 to 6 days by MTS assay	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Synthesis, biological evaluation and molecular modeling of novel azaspiro dihydrotriazines as influenza virus inhibitors targeting the host factor dihydrofolate reductase (DHFR).
AID253328	Cytotoxic concentration against HCV replication in AVA5 cell culture	2005	Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15	5'-Homoneplanocin A inhibits hepatitis B and hepatitis C.
AID1886818	Antiviral activity against ZIKV COL345Si infected in African Green monkey Vero E6 cells assessed as reduction in plaque formation measured after 6 days by crystal violet staining based analysis	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID436476	Cytotoxicity against human MT4 cells after 96 hrs by MTT assay	2009	Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13	Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives.
AID1081550	In vivo antiviral activity against Tobacco mosaic virus (TMV) infected tobacco leaves assessed as protective effect at 500 ug/ml treated 12 hr before viral inoculation measured at 2-3 days after viral challenge	2010	Journal of agricultural and food chemistry, Jul-14, Volume: 58, Issue:13	5-Methyl-1,2,3-thiadiazoles synthesized via ugi reaction and their fungicidal and antiviral activities.
AID712808	Antiviral activity against Influenza A virus (A/Ishikawa/7/82 (H3N2)) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID226100	Minimum inhibitory concentration against Vaccinia virus in primary rabbit kidney cell cultures	1989	Journal of medicinal chemistry, Aug, Volume: 32, Issue:8	Synthesis and antiviral activity of 3'-C-cyano-3'-deoxynucleosides.
AID659151	Antiviral activity against Vesicular stomatitis virus infected in HeLa cells	2012	Bioorganic & medicinal chemistry, May-01, Volume: 20, Issue:9	Synthesis and biological evaluation of a series of thieno-expanded tricyclic purine 2'-deoxy nucleoside analogues.
AID301693	Inactivation of human recombinant S-adenosyl-L-homocysteine hydrolase NAD+ form expressed in Escherichia coli JM109 assessed as increase in fluorescence at 200 uM	2007	Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23	The antiviral drug ribavirin is a selective inhibitor of S-adenosyl-L-homocysteine hydrolase from Trypanosoma cruzi.
AID434316	Antiviral activity against Reovirus 1 infected in african green monkey Vero cells assessed as protection against virus-induced cytopathogenicity	2009	European journal of medicinal chemistry, Sep, Volume: 44, Issue:9	Synthesis, antiviral and anticancer activity of some novel thioureas derived from N-(4-nitro-2-phenoxyphenyl)-methanesulfonamide.
AID216178	Tested for inhibitory effect on RNA virus JV in Vero cell line	1993	Journal of medicinal chemistry, Nov-12, Volume: 36, Issue:23	Synthesis and antiviral activity of 5'-deoxypyrazofurin.
AID768192	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID1773030	Antiviral activity against RSV infected in human HEp-2 cells assessed as downregulation of NF-kappaB expression at 25 uM treated 48 hpi and measured after 48 hrs by Western blot analysis	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID216505	Tested for minimum inhibitory concentration required to reduce virus-induced cytopathicity by 50% on vero cell line infected with parainfluenza 3 virus	1994	Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18	Synthesis and antiviral activity evaluation of some aminoadamantane derivatives.
AID218251	Evaluation for antiviral activity against Coxsackie virus B4 in Vero cell cultures (Concentration required to reduce virus-induced cytopathogenicity by 50%)	1992	Journal of medicinal chemistry, Aug-21, Volume: 35, Issue:17	Antiviral and antitumor structure-activity relationship studies on tetracyclic eudistomines.
AID218431	Antiviral activity was measured against Rhino virus-9 in human diploid (WI-38) cells.	1986	Journal of medicinal chemistry, Feb, Volume: 29, Issue:2	Systematic synthesis and biological evaluation of alpha- and beta-D-xylofuranosyl nucleosides of the five naturally occurring bases in nucleic acids and related analogues.
AID543675	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as serum ALT level at 10 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID718742	Antiviral activity against Influenza A virus (A/Puerto Rico/8/1934(H1N1)) H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Synthesis of isoindole and benzoisoindole derivatives of teicoplanin pseudoaglycon with remarkable antibacterial and antiviral activities.
AID482713	Antiviral activity against Sindbis virus infected in african green monkey Vero cells assessed as inhibition of virus-induced cytopathicity	2010	Journal of medicinal chemistry, May-13, Volume: 53, Issue:9	"Viologen" dendrimers as antiviral agents: the effect of charge number and distance.
AID1772993	Selectivity index, ratio of CC50 for human HEp-2 cells to EC50 for Respiratory syncytial virus infected in human HEp-2 cells	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	Design, synthesis, in vitro and in vivo anti-respiratory syncytial virus (RSV) activity of novel oxizine fused benzimidazole derivatives.
AID1654874	Cytotoxicity in African green monkey Vero E6 cells assessed as reduction in cell viability	2020	Journal of medicinal chemistry, 06-11, Volume: 63, Issue:11	2-((4-Arylpiperazin-1-yl)methyl)benzonitrile Derivatives as Orally Available Inhibitors of Hepatitis C Virus with a Novel Mechanism of Action.
AID1081201	Antiviral activity against Tobacco mosaic virus (TMV) infected leaves assessed as viral inhibition at 50 ug/mL at 25 degC for 72 hr	2010	Journal of agricultural and food chemistry, Mar-10, Volume: 58, Issue:5	Synthesis, crystal structure, and biological activity of 4-methyl-1,2,3-thiadiazole-containing 1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles.
AID217899	Minimum inhibitory concentration required to reduce virus induced cytopathicity by 50% was determined against coxsackie B4 virus in Vero cells	1992	Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18	Synthesis and antiviral properties of (+/-)-5'-noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design.
AID1409613	Selectivity ratio: ratio of AUC (viral infection %) of SARS-CoV-2 in the Vero E6 cell line compared to AUC (cytotoxicity %) of compound against Vero E6 cells by MTT assay.	2020	Nature, 07, Volume: 583, Issue:7816	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
AID156851	Minimum inhibitory concentration required to reduce vesicular stomatitis virus induced cytopathogenicity by 50% in primary rabbit kidney cells (PRK)	1989	Journal of medicinal chemistry, May, Volume: 32, Issue:5	Synthesis, DNA binding, and biological evaluation of synthetic precursors and novel analogues of netropsin.
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID218432	Minimum cytotoxic concentration (MCC) required to cause a microscopically detectable alteration of host cell morphology, when incubated with WI-38 cells	1987	Journal of medicinal chemistry, Jun, Volume: 30, Issue:6	Systematic synthesis and biological evaluation of alpha- and beta-D-lyxofuranosyl nucleosides of the five naturally occurring nucleic acid bases.
AID543686	Antiviral activity against 10'2 CCID50 Yellow fever virus Jimenez infected in syrian golden hamster assessed as mean day of death of mice at 50 mg/kg/day, po administered twice daily for 8 days started 4 hrs prior to viral infection relative to control	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID768198	Antiviral activity against Coxsackievirus B4 infected in human HeLa cells assessed as reduction of virus-induced cytopathogenicity	2013	European journal of medicinal chemistry, Aug, Volume: 66	Synthesis of 4-aminoquinoline-pyrimidine hybrids as potent antimalarials and their mode of action studies.
AID569232	Antiviral activity against thymidine kinase deficient acyclovir-resistant HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect	2011	European journal of medicinal chemistry, Feb, Volume: 46, Issue:2	Synthesis of new C5-(1-substituted-1,2,3-triazol-4 or 5-yl)-2'-deoxyuridines and their antiviral evaluation.
AID303232	Antiviral activity against RSV in HeLa cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID1592372	Antiviral activity against Tobacco mosaic virus inoculated in Nicotiana tabacum leaves assessed as passivation by measuring local lesion numbers at 500 mg/l pre-incubated with virus for 30 mins followed by inoculation and measured up to 4 days	2019	European journal of medicinal chemistry, Apr-01, Volume: 167	Chemical synthesis, crystal structure, versatile evaluation of their biological activities and molecular simulations of novel pyrithiobac derivatives.
AID1600736	Antiviral activity against Pichinde virus infected in African green monkey Vero cells assessed as reduction in virus induced cytopathic effect	2019	Bioorganic & medicinal chemistry letters, 10-01, Volume: 29, Issue:19	l-like 3-deazaneplanocin analogues: Synthesis and antiviral properties.
AID1729928	Antiviral activity against Influenza A virus A/PR/8/34 (H1N1) infected in MDCK cells assessed as reduction in plaque formation treated 1 hr post viral infection and measured after 48 hrs post-infection by toluidine blue staining based plaque reduction ass	2021	European journal of medicinal chemistry, Jan-01, Volume: 209	Synthesis and characterization of 1,2,4-triazolo[1,5-a]pyrimidine-2-carboxamide-based compounds targeting the PA-PB1 interface of influenza A virus polymerase.
AID1433142	Antiviral activity against Respiratory syncytial virus infected in human HeLa cells assessed as inhibition of virus-induced cytopathic effect by visual scoring analysis	2015	European journal of medicinal chemistry, Aug-28, Volume: 101	Synthesis, antiplasmodial activity and mechanistic studies of pyrimidine-5-carbonitrile and quinoline hybrids.
AID1435484	Antiviral activity against Coxsackievirus B1 Conn 5 infected in African green monkey Vero cells assessed as inhibition of virus-induced cytopathic effect	2017	European journal of medicinal chemistry, Jan-27, Volume: 126	Synthesis and evaluation of halogenated 12N-sulfonyl matrinic butanes as potential anti-coxsackievirus agents.
AID1886803	Antiviral activity against ZIKV infected in African green monkey Vero E6 cells assessed as inhibition of virus induced cytopathic effect at 3.1 to 25 ug/ml measured after 72 hrs by crystal violet staining based inverted microscopic analysis relative to co	2022	Journal of natural products, 08-26, Volume: 85, Issue:8	Antiviral Profiling of C-18- or C-19-Functionalized Semisynthetic Abietane Diterpenoids.
AID1113461	Cytotoxicity against Chlorocebus aethiops (African green monkey) Vero cells assessed as change in cellular morphology	2013	Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, , Volume: 22, Issue:4	Synthesis and biological evaluation of 2-(5-substituted-1-((diethylamino)methyl)-2-oxoindolin-3-ylidene)-
AID464177	Cytotoxicity against Respiratory syncytial virus infected human HeLa cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID548444	Antiviral activity against Influenza B virus infected in MDCK cells assessed as inhibition of virus induced cytopathicity after 2 to 4 days by MTS assay	2010	European journal of medicinal chemistry, Dec, Volume: 45, Issue:12	4-[1-(Substituted aryl/alkyl carbonyl)-benzoimidazol-2-yl]-benzenesulfonic acids: synthesis, antimicrobial activity, QSAR studies, and antiviral evaluation.
AID693524	Antiviral activity against Influenza A/PR/8/34 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect measured on day 3 post infection by MTS assay	2012	European journal of medicinal chemistry, Dec, Volume: 58	Synthesis of fluorescent ristocetin aglycon derivatives with remarkable antibacterial and antiviral activities.
AID1869554	Therapeutic index, ratio of CC50 for Cytotoxicity against human HEp-2 cells to IC50 for Antiviral activity against Respiratory syncytial virus infected in human HEp-2 cells
AID416764	Cytotoxicity against human HeLa cells assessed as drug level causing microscopically detectable alteration of normal cell morphology after 3 days	2009	Journal of medicinal chemistry, Apr-09, Volume: 52, Issue:7	Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus.
AID1201118	Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as cell viability after 72 hrs by MTS assay	2015	European journal of medicinal chemistry, Apr-13, Volume: 94	A few atoms make the difference: synthetic, CD, NMR and computational studies on antiviral and antibacterial activities of glycopeptide antibiotic aglycon derivatives.
AID648651	Selectivity index, ratio of TC50 for MDCK cells to IC50 for influenza B virus	2012	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 22, Issue:6	Synthesis and anti-influenza activity of aminoalkyl rupestonates.
AID1783339	Selectivity index, ratio of CC50 for human A549 cells to IC50 for Influenza A Puerto Rico/8/34/H1N1 infected in human A549 cells	2021	European journal of medicinal chemistry, Nov-15, Volume: 224	System-oriented optimization of multi-target 2,6-diaminopurine derivatives: Easily accessible broad-spectrum antivirals active against flaviviruses, influenza virus and SARS-CoV-2.
AID634747	Antiviral activity against Herpes simplex virus 2 G infected in human HEL cells assessed as inhibition of viral plaque formation at 250 uM	2012	European journal of medicinal chemistry, Jan, Volume: 47, Issue:1	Design, synthesis, antiviral and cytostatic evaluation of novel isoxazolidine nucleotide analogues with a 1,2,3-triazole linker.
AID1636356	Drug activation in human Hep3B cells assessed as human CYP2C9-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA	2016	Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16	Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID474352	Antiviral activity against Influenza A virus California/07/2009 /H1N1 infected MDCK cells after 3 days by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID303228	Antiviral activity against VSV in HEL cells assessed as reduction of virus-induced cytopathogenicity	2007	Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23	Ester prodrugs of cyclic 1-(S)-[3-hydroxy-2-(phosphonomethoxy)propyl]-5-azacytosine: synthesis and antiviral activity.
AID1485250	Antiviral activity against Influenza A virus A/Virginia/ATCC3/2009(H1N1) infected in MDCK cells assessed as host cell viability measured after 3 to 6 days post infection by MTS assay	2017	European journal of medicinal chemistry, Jul-28, Volume: 135	Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
AID712812	Antiviral activity against amantidine and rimantadine-resistant Influenza B virus (B/HK/5/72) infected in MDCK cells assessed as virus-induced cytopathic effect measured 3 days post infection by microscopic analysis	2012	ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12	Synthesis and Anti-influenza A Virus Activity of 2,2-Dialkylamantadines and Related Compounds.
AID421732	Therapeutic index, ratio of TC50 for MDCK cells to IC50 for Influenza A virus infected in MDCK cells	2009	Journal of natural products, May-22, Volume: 72, Issue:5	Antiviral constituents against respiratory viruses from Mikania micrantha.
AID1432503	Antiviral activity against Influenza A virus H1N1 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 40 hrs	2017	Bioorganic & medicinal chemistry letters, 03-15, Volume: 27, Issue:6	Structure-activity relationship studies of 1-(1'-hydroxyalkyl)rupestonic acid methyl esters against influenza viruses.
AID284538	Antiviral activity against Coxsackie virus B4-induced cytopathogenicity in Vero cells	2007	Bioorganic & medicinal chemistry, Jan-15, Volume: 15, Issue:2	The novel C-5 aryl, alkenyl, and alkynyl substituted uracil derivatives of L-ascorbic acid: synthesis, cytostatic, and antiviral activity evaluations.
AID86836	concentration required to inhibit VSV-induced cytopathicity by 50% in HeLa cells	1998	Journal of medicinal chemistry, Sep-24, Volume: 41, Issue:20	Inactivation of S-adenosyl-L-homocysteine hydrolase and antiviral activity with 5',5',6',6'-tetradehydro-6'-deoxy-6'-halohomoadenosine analogues (4'-haloacetylene analogues derived from adenosine).
AID278350	Inhibition of viral RNA levels in HTNV76-118-infected Vero E6 cells at 0.5 ug/ml	2007	Antimicrobial agents and chemotherapy, Jan, Volume: 51, Issue:1	Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
AID1408328	Antiviral activity against Influenza B virus B/Ned/537/05 infected in MDCK cells assessed as reduction in virus-induced cytopathic effect after 3 days by microscopic method	2018	European journal of medicinal chemistry, Sep-05, Volume: 157	Structure-activity relationship studies of lipophilic teicoplanin pseudoaglycon derivatives as new anti-influenza virus agents.
AID1140809	Cytotoxicity against MDBK cells after 48 hrs by MTT assay	2014	Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10	Synthesis and anti-BVDV activity of novel δ-sultones in vitro: implications for HCV therapies.
AID370209	Antiviral activity against 50 PFU Punta Toro virus Adames infected C57BL/6 mouse assessed as survival at 30 mg/kg, po twice daily for 5 days administered 24 hrs post viral challenge	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections.
AID474545	Selectivity ratio of IC50 for MDCK cells to EC90 for Influenza A virus Solomon Islands/03/2006/H1N1 by virus yield reduction assay	2010	Bioorganic & medicinal chemistry letters, Apr-15, Volume: 20, Issue:8	(-)-Carbodine: enantiomeric synthesis and in vitro antiviral activity against various strains of influenza virus including H5N1 (avian influenza) and novel 2009 H1N1 (swine flu).
AID464180	Cytotoxicity against Vaccinia virus infected HEL cells by trypan blue exclusion method	2010	European journal of medicinal chemistry, Mar, Volume: 45, Issue:3	Synthesis, antibacterial and antiviral properties of curcumin bioconjugates bearing dipeptide, fatty acids and folic acid.
AID1280364	Antiviral activity against influenza B virus B/SZ/155 infected in dog MDCK cells assessed as inhibition of virus induced cytopathic effect after 40 hrs by Cell-Titer-Glo assay	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus.
AID1082873	In vivo antiviral activity against Tobacco mosaic virus (TMV) inoculated right side of Nicotiana. tabacum L. leaves assessed as protection effect at 500 ug/mL preincubated 12 hr before viral challenge measured after 3 to 4 days	2012	Journal of agricultural and food chemistry, Jun-13, Volume: 60, Issue:23	Design, synthesis, antiviral activity, and SARs of 14-aminophenanthroindolizidines.
AID543659	Antiviral activity against Yellow fever virus 17D infected in African green monkey Vero cells assessed as inhibition of virus induced cytopathic effect after 2 hrs by NR dye uptake assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106.
AID1246934	Selectivity index, ratio of CC50 for MDCK cells by neutral red method to EC50 for Influenza A virus (A/California/07/2009(H1N1) virus by neutral red method	2015	European journal of medicinal chemistry, Sep-18, Volume: 102	Synthesis and antiviral activity of some new bis-1,3-thiazole derivatives.
AID87822	Evaluation for antiviral activity against herpes simplex virus type 2 (strain G) in primary rabbit kidney cell culture	1986	Journal of medicinal chemistry, Jul, Volume: 29, Issue:7	Structure-activity relationship of novel oligopeptide antiviral and antitumor agents related to netropsin and distamycin.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607	Screen for inhibitors of RMI FANCM (MM2) intereaction	2016	Journal of biomolecular screening, Jul, Volume: 21, Issue:6	A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).	2014	Journal of biomolecular screening, Jul, Volume: 19, Issue:6	A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808	Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1804127	No assay is provided from Article 10.1002/med.21724: \\The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.\\	2021	Medicinal research reviews, 01, Volume: 41, Issue:1	The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
AID1802102	Radioligand Binding Assay from Article 10.1021/acschembio.6b00357: \\Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists\\	2016	ACS chemical biology, 10-21, Volume: 11, Issue:10	Structure-Based Screening of Uncharted Chemical Space for Atypical Adenosine Receptor Agonists.
AID1346059	Human inosine monophosphate dehydrogenase 2 (Nucleoside synthesis and metabolism)	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations.
AID1346128	Human inosine monophosphate dehydrogenase 1 (Nucleoside synthesis and metabolism)	2012	Bioorganic & medicinal chemistry, Jun-01, Volume: 20, Issue:11	Novel 1,2,4-triazole and imidazole derivatives of L-ascorbic and imino-ascorbic acid: synthesis, anti-HCV and antitumor activity evaluations.
AID977611	Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB	2014	eLife, Jul-31, Volume: 3	Structural basis of nucleoside and nucleoside drug selectivity by concentrative nucleoside transporters.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	592 (5.16)	18.7374
1990's	781 (6.80)	18.2507
2000's	4114 (35.84)	29.6817
2010's	5382 (46.88)	24.3611
2020's	611 (5.32)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1,880 (15.26%)	5.53%
Reviews	2,023 (16.43%)	6.00%
Case Studies	1,245 (10.11%)	4.05%
Observational	196 (1.59%)	0.25%
Other	6,972 (56.61%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (762)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Does Vitamin D Supplement Improve SVR in Chronic Hepatitis C (Genotype 2,3) in naïve Patients Treated With Peginterferon Alpha and Ribavirin [NCT01146626]		60 participants (Anticipated)	Interventional	2011-08-31	Not yet recruiting
A Multi-center, Sequential-cohort, Placebo-controlled, 7-day Treatment Period Study of the Safety and Pharmacokinetics of Multiple Ascending Oral Doses of INX-08189 in Chronically-infected Genotype 1 HCV, Treatment-naïve Subjects [NCT01250366]	Phase 1	70 participants (Actual)	Interventional	2010-10-31	Completed
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Received Prior Treatment [NCT00336479]	Phase 2	263 participants (Actual)	Interventional	2006-06-30	Completed
A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus [NCT01263860]	Phase 3	242 participants (Actual)	Interventional	2010-12-31	Completed
A Phase III, Multicentre, Double Blinded Study In Patients With Chronic Hepatitis C Who Are Non-Responders To Prior Peginterferon Alpha + Ribavirin Therapy Comparing Treatment With Thymosin Alpha 1 + Peginterferon Alpha-2a Plus Ribavirin With Peginterfero [NCT01178996]	Phase 3	552 participants (Actual)	Interventional	2004-12-31	Completed
Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3 [NCT00056862]	Phase 4	58 participants (Actual)	Interventional	2003-03-31	Completed
A Multiple-Dose Study To Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted RO5190591 in Combination With Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1 [NCT01185860]	Phase 1	59 participants (Actual)	Interventional	2009-08-31	Completed
Comparison of Three Regimens of PEG-Intron and Ribavirin in the Treatment of Chronic Hepatitis C, Genotype 2 or 3, in Previously Untreated Patients [NCT00302081]	Phase 3	696 participants (Actual)	Interventional	2003-08-31	Completed
An Open-label, Dose Escalation Phase I/II Study of Ribavirin Given as Monotherapy in Solid Tumour Cancer Patients Expressing Elevated eIF4E [NCT01309490]	Phase 1/Phase 2	37 participants (Anticipated)	Interventional	2011-03-31	Recruiting
Use of Immune Modulatory Properties of Ribavirin to Enhance Hepatitis B Virus Nucleotide Analog Antiviral Activity: Proposal for Pilot Clinical Trial [NCT03759782]	Phase 3	24 participants (Anticipated)	Interventional	2019-01-10	Recruiting
A Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin for 12 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Infection [NCT01371604]	Phase 2	68 participants (Actual)	Interventional	2011-07-31	Completed
A Randomized, Placebo-controlled, Phase 2a Study of BMS-824393 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype I [NCT01142700]	Phase 2	0 participants (Actual)	Interventional	2010-07-31	Withdrawn
Ribavirin Dose Optimization for the Treatment of Hepatitis C: A Pilot Study [NCT01289496]	Phase 2	13 participants (Actual)	Interventional	2011-02-28	Completed
A Multicenter, Randomized, Open-label, Phase 2b Study to Evaluate the Efficacy and Safety of Two Regimens of All-oral Triple Therapy (VX-222 in Combination With Telaprevir [Incivek™] and Ribavirin [Copegus®]) in Treatment-Naïve Subjects With Genotype 1a C [NCT01581138]	Phase 2	64 participants (Actual)	Interventional	2012-07-31	Completed
A Triple Combination Antiviral Coronavirus Therapy (TriACT) RCT Comparing Nitazoxanide, Ribavirin and Hydroxychloroquine vs. Placebo [NCT04605588]	Phase 2	7 participants (Actual)	Interventional	2020-12-02	Terminated(stopped due to Lack of participants willing to enroll)
A Study to Investigate HCV Response Rates in Real World Patients Traditionally Excluded From Clinical Trials: The HEARTLAND Study [NCT03710252]	Phase 4	100 participants (Actual)	Interventional	2016-03-31	Completed
Does 3 Months Therapy With Vitamin D + Peg + Ribavirin Improve SVR in Genotype 2,3 Chronic Hepatitis C Patients? [NCT01151397]		60 participants (Anticipated)	Interventional	2011-08-31	Not yet recruiting
A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Subjects With Chronic Genotype 1 or 2 HCV Infection Who Have Previously Failed [NCT02822794]	Phase 3	117 participants (Actual)	Interventional	2016-07-25	Completed
A Phase IIb/IIIa, Randomized Study to Evaluate the Efficacy and Safety of PPI-668 (NS5A Inhibitor) Plus Sofosbuvir, With or Without Ribavirin, in Patients With Chronic Hepatitis C Genotype-4 [NCT02371408]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2015-01-31	Active, not recruiting
An Open-label, Randomized, Active Control Study to Demonstrate Non-Inferiority in Efficacy, and to Compare Safety and Tolerability of P1101 + Ribavirin to PEG-Intron + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic HCV Genotype 2 Infection [NCT04382937]	Phase 3	222 participants (Actual)	Interventional	2016-01-12	Completed
A Prospective, Randomized, Open-label Study Evaluating the Viral Kinetics and Pharmacokinetics of Pegasys® Plus Copegus® and PEG-Intron® Plus Rebetol® in Interferon-naïve Patients With Chronic Hepatitis C. [NCT00087607]	Phase 4	385 participants (Actual)	Interventional	2004-01-31	Completed
A Multicenter, Randomized, Phase 3, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Subjects With Chronic HCV Infection and Decompensated Cirrhosis [NCT02996682]	Phase 3	102 participants (Actual)	Interventional	2016-12-26	Completed
Pilot Study of PegInterferon-Ribavirin-Telaprevir Efficacy and Tolerability in HIV-HCV Coinfected Patients Who Had Previously Failed a PegInterferon-Ribavirin Regimen. (ANRS HC26 TelapreVIH) [NCT01332955]	Phase 2	70 participants (Actual)	Interventional	2011-04-30	Completed
Pilot Study to Assess the Efficacy and Safety of Boceprevir, in Combination With Peg-Interferon Alfa and Ribavirin, in Patients With HCV/HIV Co-infection Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin [NCT01335529]	Phase 2	69 participants (Actual)	Interventional	2011-05-31	Completed
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C - An Observational Study in Israel (CITRINE STUDY) [NCT02803138]		256 participants (Actual)	Observational	2016-07-07	Completed
Sofosbuvir /Simeprevir/ Daclatasvir/Ribavirin Versus Sofosbuvir /Ombitasvir/ Paritaprevir /Ritonavir/Ribavirin in the Management of Hepatitis C Patients Fauilre to Prior Sofosbuvir/ Daclatasvir (An Open-labeled Randomized Trial) [NCT03549832]		40 participants (Actual)	Interventional	2018-01-01	Completed
A Phase III Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Treatment-Naïve Patients With Chronic Hepatitis C Infection [NCT01370642]	Phase 3	294 participants (Actual)	Interventional	2011-06-27	Completed
Demonstration Project on Assessment of Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar [NCT03579576]		803 participants (Actual)	Observational	2017-12-20	Completed
An Interferon Sparing Strategy of Sofosbuvir Plus Ribavirin for the Treatment of Recently Acquired Hepatitis C Infection [NCT02156570]	Phase 4	20 participants (Anticipated)	Interventional	2014-10-31	Completed
A Phase 3b, Multi-Center, Randomized, Open-Label, Pragmatic Study of Glecaprevir/Pibrentasvir (G/P) +/- Ribavirin for GT1 Subjects With Chronic Hepatitis C Previously Treated With an NS5A Inhibitor + Sofosbuvir Therapy [NCT03092375]	Phase 3	177 participants (Actual)	Interventional	2017-04-20	Completed
Boceprevir Treatment in Liver Pre-transplant HCV Patients [NCT02160080]	Phase 3	20 participants (Anticipated)	Interventional	2014-01-31	Recruiting
A Phase 1b/2a Open-label, Multi-center Study to Assess the Safety, Efficacy and Pharmacokinetics of Intrapatient Dose-adjusted Brequinar and Inhibition of Dihydroorotate Dehydrogenase (DHODH) in Adult Subjects With AML [NCT03760666]	Phase 1/Phase 2	17 participants (Actual)	Interventional	2018-12-20	Terminated(stopped due to No efficacy observed, COVID-19 caused sites to shut down)
SEASON South East Asian Study Of Novel Genotypes in Hepatitis C Infection: Pegylated-Interferon and Ribavirin Therapy (PEGATRON REDIPEN Combination Therapy (PEG-Intron® REDIPEN Plus REBETOL®)) in Treatment Naive Patients With Genotypes 1, 6, 7, 8, 9: A Co [NCT00255008]	Phase 4	121 participants (Actual)	Interventional	2005-03-31	Terminated(stopped due to Slow enrollment)
A Randomized, Open-label Study of the Effect of PEGASYS and Ribavirin Combination Therapy on Sustained Virologic Response in Interferon-naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection [NCT00077636]	Phase 4	1,469 participants (Actual)	Interventional	2003-12-31	Completed
Randomized, Multicenter, Double-blind, Phase IV Pilot Study Evaluating the Effect of PEGASYS Doses of 180 ug or 270 ug in Combination With Copegus Doses of 1200 mg or 1600 mg on Viral Kinetics, Virological Response, Pharmacokinetics, and Safety in Interfe [NCT00077649]	Phase 4	188 participants (Actual)	Interventional	2004-01-31	Completed
Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial (HALT-C) [NCT00006164]	Phase 3	1,050 participants (Actual)	Interventional	2000-06-30	Completed
PROTECT - Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation: Efficacy and Safety in Hepatitis C Recurrence Therapy [NCT00378599]	Phase 3	125 participants (Actual)	Interventional	2006-05-31	Completed
A Phase 3 Safety and Efficacy Study of Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin [NCT00708500]	Phase 3	404 participants (Actual)	Interventional	2008-08-31	Completed
Randomized, Multi-Center, Phase IV, Comparative Study to Assess the Efficacy and Safety of Combined Peg-Interferon Alpha-2a (40 kD) With Ribavirin Combined Therapy for 48 or 72 Weeks of Treatment and 24 Weeks of Follow-Up in Patients With Chronic Hepatiti [NCT02761629]	Phase 4	180 participants (Actual)	Interventional	2005-04-30	Completed
Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of Sofosbuvir Tablet Plus Ribavirin Tablet (Part A) Versus Single Dose (2 Tablets) of EHCV Containing Sofosbuvir, Ribavirin, and Natural Anti-hemolytic (B) in Egyptian Adults With Chronic G [NCT02483156]	Phase 2/Phase 3	80 participants (Actual)	Interventional	2015-07-31	Completed
A Randomized, Open-Label, Active Comparator, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepatitis C Virus Infection (CERTAIN-2) [NCT02723084]	Phase 3	136 participants (Actual)	Interventional	2016-04-08	Completed
Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program. [NCT00704522]		601 participants (Actual)	Observational	2005-03-31	Completed
Observational Multicenter Study to Evaluate Influence of Insulin Resistance on the Safety and Efficacy (as Measured by Sustained Virological Response) of Treatment With Any Pegylated Interferon and Ribavirin (Standard of Care) in Different Populations of [NCT00705224]		250 participants (Actual)	Observational	2008-05-31	Completed
A Phase 2A Study of BMS-791325 in Combination With Peg Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naïve Subjects With Chronic Hepatitis C Virus Genotype 1 Infection [NCT01193361]	Phase 2	39 participants (Actual)	Interventional	2010-10-31	Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of 2 Regimens of Telaprevir (With and Without Delayed Start) Combined With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Subjects With Chronic, Genotype 1, Hepatitis C Inf [NCT00703118]	Phase 3	663 participants (Actual)	Interventional	2008-10-31	Completed
A Randomized, Double-blind, Multicenter, Dose and Duration Finding Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug (RO5024048) in Combination With Pegasys® and Ribavirin® (SOC) Versus SOC in Treatment-Naïve Patie [NCT00869661]	Phase 2	413 participants (Actual)	Interventional	2001-02-28	Completed
Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney [NCT03296930]	Phase 4	100 participants (Anticipated)	Interventional	2017-10-01	Not yet recruiting
Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus [NCT03250910]	Phase 4	228 participants (Actual)	Interventional	2016-08-01	Completed
A Phase 2, Randomized, Open-Label Study Of The Safety, Antiviral Activity, And Pharmacokinetics Of HCV-796 Administered In Combination With Peginterferon Alfa 2B (Peg-Intron) Plus Ribavirin (Rebetol) Versus Peg-Intron Plus Rebetol In Subjects With Hepatit [NCT00367887]	Phase 2	246 participants (Actual)	Interventional	2006-10-31	Completed
Peginterferon Plus Ribavirin Combination Therapy for Hepatitis C Six Months After Onset of Acute Infection [NCT02377856]	Phase 4	20 participants (Actual)	Interventional	2007-06-30	Completed
A Randomized, Pilot, Open-Label, Monocenter, Efficacy and Safety Study Examining the Effects of Peginterferon Alfa-2a (Pegasys) With or Without Ribavirin (Copegus) in Patients With Chronic Hepatitis D [NCT02731131]	Phase 2	12 participants (Actual)	Interventional	2004-09-30	Completed
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) Compared With GS-5885, GS-9451 With Tegobuvir or RBV in Treatment-Experienced Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) I [NCT01435226]	Phase 2	170 participants (Actual)	Interventional	2011-09-30	Completed
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy Using Combinations of Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Ch [NCT01371578]	Phase 2	163 participants (Actual)	Interventional	2011-07-31	Completed
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Antiviral Activity of Ritonavir-Boosted DANOPREVIR and RO5024048 in Different Combinations in Null Responder or Treatment Naïve Patients With Chronic Hepatitis C and Compensated Cirrhosis [NCT01483742]	Phase 2	43 participants (Actual)	Interventional	2012-04-30	Completed
A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects With Chronic Genotype 1 HCV Infection [NCT01353248]	Phase 2	141 participants (Actual)	Interventional	2011-05-31	Completed
Phase 3 Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b in Combination With Ribavirin Compared With Peginterferon Alfa-2a in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 1. ACHIEVE-1 [NCT00402428]	Phase 3	1,331 participants (Actual)	Interventional	2006-12-31	Completed
Efficacy and Safety of the Combination Vitamin D (Vit D), With Pegylated Interferon Alpha-2b (PEG-IFN)/Ribavirin (RBV) in Egyptian Patients With Untreated Chronic Hepatitis C: A Phase III Randomized Open-label Clinical Trial [NCT02099604]	Phase 3	0 participants (Actual)	Interventional	2014-04-30	Withdrawn(stopped due to Study objectives were considered as obsolete regarding the new AAD arrival)
A Multicenter Compassionate Use Program of Daclatasvir (BMS-790052) in Combination With Sofosbuvir With or Without Ribavirin for the Treatment of Subjects With Chronic Hepatitis C [NCT02097966]		0 participants	Expanded Access		No longer available
Prospective, Single-Center, Open Label, Pilot Study of Safety and Efficacy of Triple Anti-Viral Therapy With Pegylated Interferon, Ribavirin, and Boceprevir in Patients With Genotype 1 Chronic HCV With End Stage Renal Disease [NCT02112630]		0 participants (Actual)	Interventional	2013-05-31	Withdrawn(stopped due to Poor enrollment)
480 STUDY: Phase 2b Open-label, Randomized Study in Treatment Naïve Subjects With HCV G1 to Compare the Efficacy, Safety, and Tolerability of the 480 µg Dose of Locteron™ Plus Ribavirin Given Bi-Weekly to PEG-Intron™ Plus Ribavirin Given Weekly [NCT00953589]	Phase 2	74 participants (Actual)	Interventional	2009-07-31	Completed
A Phase 2, Open-Label Clinical Trial to Study the Efficacy and Safety of 12 Weeks of the Combination Regimen of MK-3682 + Ruzasvir in Subjects With Chronic Hepatitis C Virus (HCV) Genotype 1, 2, 3, 4, 5 or 6 Infection [NCT02956629]	Phase 2	282 participants (Actual)	Interventional	2016-11-16	Terminated(stopped due to The study was terminated based on review of Phase 2 efficacy data)
A Phase III, Open-Label Study in Japan to Assess the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2b and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects [NCT01366638]	Phase 3	79 participants (Actual)	Interventional	2011-05-31	Completed
Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron® Plus REBETOL® in Pediatric Patients With Chronic Hepatitis C [NCT00104052]	Phase 3	107 participants (Actual)	Interventional	2005-02-28	Completed
Open Label, Study to Determine the Pharmacokinetic Interactions of Steady State Tipranavir/Ritonavir (500/200 mg) and Steady State Ribavirin and Pegylated Interferon Alfa 2a in HIV Negative, HCV Infected Subjects With Mild Hepatic Impairment and the Pharm [NCT02259855]	Phase 1	36 participants (Actual)	Interventional	2006-01-31	Completed
A Phase II, Randomized, Multicenter, Placebo-Controlled, Double-Blind, Parallel-Group Study, With an Open-Label Extension, to Evaluate the Efficacy, Safety, and Pharmacokinetics of E5501 in Subjects With Chronic Hepatitis C Virus Related Thrombocytopenia [NCT01355289]	Phase 2	65 participants (Actual)	Interventional	2011-11-30	Completed
A Phase 2a Trial to Evaluate the Safety, Tolerability, and Efficacy of 12 Weeks of Sovaprevir, ACH-0143102 and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotype-1 Viral Infection [NCT01849562]	Phase 2	30 participants (Actual)	Interventional	2013-04-30	Completed
A Phase 1b, Open-label, Pilot Study to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0143102 Administered in Combination With Ribavirin for 12 Weeks in Treatment-naive Subjects With Chronic Hepatitis C Virus Infection Genotype 1b [NCT01700179]	Phase 1	8 participants (Actual)	Interventional	2012-09-30	Completed
QUANTUM: An International, Multi-center, Blinded, Randomized Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Administration of Regimens Containing PSI-352938, PSI-7977, and Ribavirin in Patients With Chronic Hepa [NCT01435044]	Phase 2	239 participants (Actual)	Interventional	2011-09-30	Completed
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of GS-5885, GS-9451, Tegobuvir and Ribavirin; GS-5885, GS-9451 and Tegobuvir; GS-5885, GS-9451 and Ribavirin in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b HCV In [NCT01434498]	Phase 2	163 participants (Actual)	Interventional	2011-09-30	Completed
A Phase II, Randomized, Double-Blind, Multicenter, Parallel Group Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination With Telaprevir and Pegasys®/Copegus® in Patients With Chronic Hepatitis [NCT01482390]	Phase 2	80 participants (Actual)	Interventional	2011-11-30	Completed
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Response Guided Therapy With GS-9190, GS-9256, Ribavirin (Copegus®) and Peginterferon Alfa 2a (Pegasys®) in Treatment Naïve Subjects With Chronic Genotype 1 Hepat [NCT01225380]	Phase 2	324 participants (Actual)	Interventional	2010-10-31	Completed
Open-Label, Multiple-Dose, Dose Escalation Study to Evaluate the Pharmacodynamics, Pharmacokinetics, and Safety of Coadministration of BMS-650032, BMS-790052, and BMS-791325 When Administered for 24 or 12 Weeks in Treatment-Naïve Subjects Infected With He [NCT01455090]	Phase 2	320 participants (Actual)	Interventional	2011-11-30	Completed
A Randomized Open-label Study to Evaluate the Sustained Virologic Response of Danoprevir/Ritonavir and Copegus in Combination With RO5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients Who Failed Previous Standard Therapy [NCT01331850]	Phase 2	381 participants (Actual)	Interventional	2011-05-31	Completed
A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) an [NCT01309932]	Phase 2	165 participants (Actual)	Interventional	2011-03-31	Completed
A Relative Bioavailability Study of Ribavirin 200 mg Tablets Under Non-Fasting Conditions [NCT00835536]	Phase 1	27 participants (Actual)	Interventional	2003-09-30	Completed
A Relative Bioavailability Study of Ribavirin 200 mg Tablets Under Fasting Conditions [NCT00835146]	Phase 1	28 participants (Actual)	Interventional	2003-09-30	Completed
An Open-Label, Multicenter, Parallel-Group, Randomized, Phase II/III Study to Evaluate the Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 [NCT04828564]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2021-04-30	Not yet recruiting
Pilot Study to Assess Efficacy and Safety of a Quadruple Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Non-responders to Pegylated Interferon-Ribavirin Regimen [NCT02107365]	Phase 2	60 participants (Actual)	Interventional	2013-11-30	Completed
Investigating the Effects of Camel Milk Products on the Laboratory Markers in the Patients With Chronic Hepatitis C, Genotype 2 & 3 [NCT02216045]	Phase 2	40 participants (Actual)	Interventional	2014-06-30	Completed
Phase 2a, Randomized, Double-Blind Study to Investigate the Safety and Efficacy of Faldaprevir in Combination With Ribavirin and TD-6450 for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 4 Hepatitis C Virus [NCT02593162]	Phase 2	16 participants (Actual)	Interventional	2015-10-31	Completed
Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study [NCT02220868]	Phase 4	10 participants (Actual)	Interventional	2014-07-31	Completed
A Phase II, Randomized, Multi-center, Two Part Study of the Safety and Efficacy of Double-blind, Placebo-controlled INX-08189 in Adjunctive Treatment With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Study Part A, and Open-label INX-08189 [NCT01425970]	Phase 2	210 participants (Actual)	Interventional	2012-05-31	Terminated(stopped due to Termination of study was due to safety reasons)
A Phase 3, Randomized, Double-Blind, Controlled Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a, With and Without Daclatasvir, Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naïve Genotype 2 [NCT01616524]	Phase 3	880 participants (Actual)	Interventional	2012-07-31	Completed
A Multicenter, Open-Label Phase 2b Pilot Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir, Peginterferon-Alfa-2, and Ribavirin) in Subjects With Genotype 1 Chronic Hepatitis C With Compensated Cirrhosis [NCT01516918]	Phase 2	103 participants (Actual)	Interventional	2012-02-29	Completed
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy With GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Vi [NCT01356160]	Phase 2	351 participants (Actual)	Interventional	2011-07-31	Completed
A Phase 2a/2b Study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects With Genotypes 1 and 4 Chronic Hepatitis C Infection [NCT01030432]	Phase 2	285 participants (Actual)	Interventional	2010-02-28	Completed
Randomized Controlled Study of Off-Label Use of Ribavirin in Management of Mucocutaneous Extrahepatic Manifestations of HCV Infection [NCT02261662]		30 participants (Anticipated)	Interventional	2014-06-30	Recruiting
PEG-Intron Plus REBETOL for the Treatment of Subjects With Chronic Hepatitis C Who Failed to Respond to Previous Combination Therapy (Any Alpha Interferon Treatment in Combination With Ribavirin) [NCT00039871]	Phase 3	2,333 participants (Actual)	Interventional	2002-05-31	Completed
Treatment of Recently Acquired Hepatitis C Virus Infection [NCT01336010]	Phase 4	82 participants (Actual)	Interventional	2011-08-31	Completed
Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes [NCT01120795]	Phase 4	55 participants (Actual)	Interventional	2004-02-29	Completed
A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials [NCT00943761]	Phase 2	45 participants (Actual)	Interventional	2009-10-23	Completed
Multicenter Study on Efficacy of New Therapeutic Schedules With Peg-Interferon alpha2b and Ribavirin in Patients With Genotype 3 Chronic HCV( Hepatitis C Virus) Infection [NCT01121705]	Phase 3	360 participants (Actual)	Interventional	2007-01-31	Completed
Insulin Resistance and Resistin In Non-Diabetic Patients With Chronic Hepatitis C Before and After Direct-Acting Antiviral Drugs. [NCT04457050]	Phase 4	160 participants (Actual)	Interventional	2017-10-30	Completed
[NCT01226771]	Phase 3	105 participants (Actual)	Interventional	2010-09-30	Completed
Evaluation of Adherence Rate in Patients Receiving PegIntron / Rebetol (Weight Based) for Hepatitis C in Conjunction With a Patient Assistance Program. [NCT00723879]		115 participants (Actual)	Observational	2004-10-31	Terminated(stopped due to Because of slow recruitment; Despite the study was started long time ago (Oct 2004), we have not reached the projected number of patients (150 patients))
Safety and Efficacy of Locally Manufactured Pegylated Interferon in Hepatitis C Patients [NCT01137383]	Phase 3	108 participants (Actual)	Interventional	2007-12-31	Completed
A Double-Blind, Placebo-controlled Phase II Study to Assess the Efficacy and Safety of Romiplostim, Administered Once Weekly to Thrombocytopenic Hepatitis C (HCV) Infected Subjects Who Are Not Candidates for Antiviral Treatment With Pegylated Interferon a [NCT01153919]	Phase 2	27 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Approval of several new agents for the treatment of HCV infection would mitigate the future need for interferon HCV treatment)
A Phase 3 Study With Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin (P/R), Intolerant or Ineligible to P/R Subjects and Treatment-Naive Subjects With Chronic Hepatitis C Genotype 1b Infection [NCT01581203]	Phase 3	748 participants (Actual)	Interventional	2012-05-31	Completed
Open-label, Multicenter, Non-Comparative Prospective Study to Assess the Safety of Individualized Combination Therapy With Ribavirin And Peginterferon Alfa-2a (40 kD) in Patients With Chronic Hepatitis C (CHC) (MASTER Study) [NCT01296971]	Phase 3	0 participants (Actual)	Interventional	2009-12-31	Withdrawn(stopped due to study was not started due to an administrative reason on the part of the local Health Authority)
Improvement of the Surveillance and Control of Liver Disease and Complication Due to Chronic Hepatitis C: Project A) Antiviral Drugs Use, Efficacy, Safety and Costs; Project B) Kinetics of Virological Response. [NCT01195181]	Phase 4	506 participants (Actual)	Interventional	2005-09-30	Completed
PREDICT - Prospective Observational Study Of A Cohort Of Naïve Patients With Chronic Hepatitis C Infected With Hepatitis C Virus Genotype 1 Low Viral Load (HCV LVL G1) And Treated With Peg-Intron 1.5 ug/Kg/Week Plus Rebetol 800-1200 mg/Day Who Achieved A [NCT00709228]		496 participants (Actual)	Observational	2006-05-31	Completed
Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients. [NCT02890719]	Phase 3	0 participants (Actual)	Interventional	2017-05-02	Withdrawn(stopped due to impossibility of supplying the medication in research of the study by the pharmaceutical company that gave it to the trial)
An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hep [NCT01306617]	Phase 2	50 participants (Actual)	Interventional	2011-02-28	Completed
High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4 [NCT00662220]	Phase 3	110 participants (Actual)	Interventional	2008-04-30	Terminated(stopped due to Due to the arrival of DAAs replacing standard of care for genotype 1 patients the VIRID study had to be terminated.)
A Phase III, Randomized, Open-label, Two-arm Trial in Japan to Investigate the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Hepatitis C, Genotype 1-Infected Subjects Who Failed to Respond to [NCT01288209]	Phase 3	106 participants (Actual)	Interventional	2011-02-28	Completed
Randomized, Multicenter Study to Compare the Efficacy of Pegylated Interferon Alfa (PEG-IFN) in Combination With Two Different Doses of Ribavirin in Patients With Chronic Hepatitis C and Subtype 2/3 [NCT01258101]	Phase 4	395 participants (Actual)	Interventional	2003-05-31	Completed
A Phase 2B Pilot Study of Short-Term Treatment of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 2 or 3 Infection [NCT01257204]	Phase 2	196 participants (Actual)	Interventional	2010-12-31	Completed
A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 4 Hepatitis C Infection [NCT00580801]	Phase 2	24 participants (Actual)	Interventional	2008-01-31	Completed
Boceprevir and Peginterferon/Ribavirin for the Treatment of Chronic Hepatitis C in Treatment-Naive Subjects: A Comparison of Erythropoietin Use Versus Ribavirin Dose Reduction for the Management of Anemia [NCT01023035]	Phase 3	687 participants (Actual)	Interventional	2009-12-07	Completed
A Phase 2a Study of Daclatasvir in Combination With Peginterferon Alfa-2a(Pegasys®) and Ribavirin (Copegus®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection [NCT01017575]	Phase 2	55 participants (Actual)	Interventional	2009-12-31	Completed
Antiviral Effect and Safety of Once Daily BI 201335 NA in Hepatitis C Virus Genotype 1 Infected Treatment-naive Patients for 12 or 24 Weeks as Combination Therapy With Pegylated Interferon-alpha 2a and Ribavirin (Randomised, Open Label, Phase II) [NCT00984620]	Phase 2	160 participants (Actual)	Interventional	2009-09-30	Completed
A Prospective Observational Post-Marketing Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection [NCT02537379]		552 participants (Actual)	Observational	2015-09-15	Completed
An Open-label, Multi-center Study to Evaluate Sustained Virologic Response With Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With and Without Ribavirin in Genotype 1 Chronic Hepatitis C Virus Infected Patients With Past PI Failure [NCT02646111]	Phase 3	120 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
Evaluation of Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron / Rebetol in Conjunction With a Patient Assistance Program - Non Interventional Observational Study. [NCT00728494]		99 participants (Actual)	Observational	2005-10-31	Completed
Observational,Post-authorization Prospective Study to Develop and Validate a Prognostic Tool for Optimizing Therapy in Patients With Hepatitis C Virus (HCV) Genotype 1 and 4. [NCT01884402]		770 participants (Actual)	Observational	2010-10-31	Completed
Relapse Rate and Predictive Factors in the Treatment of Hepatitis C in Common Clinical Practice [NCT00725842]		97 participants (Actual)	Observational	2009-01-31	Terminated(stopped due to Low enrollment)
Observatory on Treatment Adhesion in Patients Suffering From Hepatitis C Chronic Treated With ViraferonPeg® Injected / Rebetol® in Conjunction With a Psychotherapeutic Assistance Program [NCT00723892]		614 participants (Actual)	Observational	2005-07-31	Completed
A Pilot Study of Therapy With Pioglitazone Prior to HCV Treatment in HIV-1 and HCV Genotype 1-Infected Subjects With Insulin Resistance Who Are Prior Nonresponders to Peginterferon and Ribavirin Therapy [NCT00665353]	Phase 2	19 participants (Actual)	Interventional	2009-03-31	Completed
The Activity of Nitazoxanide in Addition to Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Treatment-Naive Genotype 1 Subjects With HIV Coinfection [NCT00991289]	Phase 2	68 participants (Actual)	Interventional	2010-01-31	Completed
Non-insulin-dependent Diabetes Mellitus and Insulin Resistance in Chronic Hepatitis C Patients Treated With Combination Therapy With Pegylated Interferon and Ribavirin in Taiwan [NCT00687999]		400 participants (Actual)	Interventional	2005-12-31	Completed
A Randomized, Open-Label Study of Daclatasvir and Sofosbuvir With or Without Ribavirin for 8 Weeks in Treatment-Naïve, Non-Cirrhotic Subjects Infected With Chronic HCV Genotype 3 [NCT02551861]	Phase 2	0 participants (Actual)	Interventional	2015-12-31	Withdrawn
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (Protocol No. P05411) [NCT00959699]	Phase 2	99 participants (Actual)	Interventional	2009-11-30	Completed
Phase 2B, Partially Blinded, Randomized Study in Treatment Naive HCV G1 to Compare the Efficacy, Safety, and Tolerability of Three Doses of Locteron Plus Ribavirin Given Bi-weekly in Comparison With PEG-Intron Plus Ribavirin Given Weekly [NCT00863239]	Phase 2	116 participants (Actual)	Interventional	2009-03-31	Completed
A Phase III, Randomised, Double-blind and Placebo Controlled Study of Once Daily BI 201335, 240 mg for 12 or 24 Weeks in Combination With Pegylated interferon-a (PegIFNa) and Ribavirin (RBV) in Patients With Genotype 1 Chronic Hepatitis C Infection Who Fa [NCT01358864]	Phase 3	678 participants (Actual)	Interventional	2011-06-30	Completed
[NCT02557646]		697 participants (Actual)	Observational	2009-05-31	Completed
A Phase 3, Open-Label Study With Asunaprevir and Daclatasvir Plus Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) (P/R) (QUAD) for Subjects Who Are Null or Partial Responders to Peginterferon Alfa 2a or 2b Plus Ribavirin With Chronic Hepatitis C G [NCT01573351]	Phase 3	398 participants (Actual)	Interventional	2012-05-31	Completed
A Phase II, Randomized, Double-Blind, Multicenter, Parallel Group Study to Evaluate the Sustained Virologic Response of the HCV Polymerase Inhibitor Prodrug RO5024048 in Combination With Boceprevir and Pegasys®/Copegus® in Patients With Chronic Hepatitis [NCT01482403]	Phase 2	58 participants (Actual)	Interventional	2011-11-30	Completed
A Phase 2 Open-Label Study in Patients With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant to Explore the Safety And Efficacy of Simeprevir and Sofosbuvir With and Without Ribavirin [NCT02165189]	Phase 2	46 participants (Actual)	Interventional	2014-08-31	Completed
TAC (Treatment Africa Hepatitis C) : Feasibility, Tolerance and Efficacy of Interferon-free, Antiviral Treatment With Sofosbuvir + Ribavirin for the Treatment of Genotype 2 and Sofosbuvir/Ledipasvir for the Treatment of Genotype 1 and 4 Hepatitis C Virus- [NCT02405013]	Phase 2	120 participants (Actual)	Interventional	2015-10-31	Completed
Phase3 Study to Evaluate the Efficacy and Safety of AlbuminInterferon in Combination With Ribavirin Compared With Peginterferon in Combination With Ribavirin in Interferon Alfa Naive Subjects With CHC Genotype 2/3. [NCT00411385]	Phase 3	933 participants (Actual)	Interventional	2007-02-28	Completed
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT3, GT4, GT5, and GT6 Infection [NCT02332720]	Phase 2	413 participants (Actual)	Interventional	2015-01-28	Completed
A Non-interventional Phase IV Survey to Assess the Antiviral Effectiveness of PegIntron® and Rebetol® Treatment According to the Stage of Liver Fibrosis in Previously Untreated Patients With Genotype 1/4/5/6 Chronic Hepatitis C (CHC) (PRACTICE) [NCT00709059]		538 participants (Actual)	Observational	2004-12-31	Completed
An Open-label Randomised Controlled Trial on IFN Beta-1b and Ribavirin Combination, as Treatment for Covid-19 Infection [NCT04494399]	Phase 2	96 participants (Anticipated)	Interventional	2020-07-29	Recruiting
Safety and Efficacy of Hansenula-Derived Pegylated-Interferon Alpha-2a and Ribavirin Customized Combination Therapy in Egyptian Children With Chronic Hepatitis C Infection [NCT02027493]		46 participants (Actual)	Interventional	2009-02-28	Completed
Assessing the Effectiveness of Integrative Treatment That Combines Interior and Exterior Treatment Plans in Pediatric Pneumonia: a Program by PRC National Clinical Research Base of Traditional Chinese Medicine for Major Diseases [NCT02069665]		451 participants (Actual)	Interventional	2011-12-31	Completed
Randomized, Multicentric, Partially Double-Blinded Placebo-Controlled Phase II Study for Examining the Influence of Ribavirin on the Initial Virological Response With Treatment of Peginterferon Alfa-2a (40KD) and Ribavirin With a Six Week Pretreatment-Pha [NCT02716779]	Phase 2	68 participants (Actual)	Interventional	2007-04-30	Completed
Effect and Safety of Recombinant Human Interferon α-2b Spray on Herpangina in Pediatric Patients [NCT03266601]	Phase 4	668 participants (Actual)	Interventional	2016-06-01	Completed
A Randomized, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment-Naïve Patients With Ch [NCT01353911]	Phase 2	368 participants (Actual)	Interventional	2011-06-27	Completed
A Prospective, Observational Study to Assess the Virological Response at Week 4 to the Therapy With PEGASYS® (Peginterferon Alfa 2a) Plus COPEGUS® (Ribavirin) in a Population of Treatment Naïve Patients With Chronic Hepatitis C, Genotype 2 or 3. [NCT00700401]		262 participants (Actual)	Observational	2008-11-30	Completed
Comparison of Maintenance Treatment by Ribavirin to a Placebo, After an Initial One-year Treatment With Pegylated Interferon-α2a - Ribavirin Association in Hepatitis C Viral Recurrence After Liver Transplantation [NCT00151580]	Phase 3	200 participants (Actual)	Interventional	2002-02-28	Completed
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir and Re-assessment of Treatment Duration in Patients With Chronic Hepatitis C [NCT02113631]		50 participants (Actual)	Interventional	2011-09-30	Completed
Parallel, Open-Label, Randomized Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of PSI-7977 in Combination With BMS-790052 With or Without Ribavirin in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotypes 1, [NCT01359644]	Phase 2	350 participants (Actual)	Interventional	2011-06-30	Completed
Real Life Experience in the Management of HCV Related Decompensated Cirrhosis With Direct Antiviral Agents [NCT03547895]		80 participants (Actual)	Interventional	2015-06-01	Completed
Observational Cohort Study of Clinical Outcomes After Antiviral Therapy in Chronic Hepatitis C Patients [NCT04071353]		1,000 participants (Anticipated)	Observational	2019-08-01	Recruiting
Pegylated Interferon Alpha-2b Plus Ribavirin Combination Treatment for Older Patients With Chronic Hepatitis C [NCT00956982]		1,251 participants (Anticipated)	Interventional	2004-12-31	Recruiting
A Phase 2 Randomized, Open Label, Multi-center, Therapeutic Trial of the Efficacy, Immunogenicity, and Safety of GI-5005; an Inactivated Recombinant Saccharomyces Cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, Combined With Pegylated I [NCT00606086]	Phase 2	140 participants (Actual)	Interventional	2007-12-31	Completed
PEG Intron/REBETOL Combination Therapy Special Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C- [NCT00724295]		1,077 participants (Actual)	Observational	2005-04-30	Completed
Phase 2 Comparison of Weight-based Doses of Taribavirin Combined With Peginterferon Alfa-2b Versus Ribavirin Combined With Peginterferon Alfa-2b in Therapy-naïve Patients With Chronic Hepatitis C Virus Genotype 1 Infection [NCT00446134]	Phase 2	278 participants (Actual)	Interventional	2007-03-31	Completed
Prospective, Open-label, Randomised Controlled Trial on Efficacy and Tolerability of PegIFN-alpha 2a + Serum Level-adapted RBV vs. PegIFN-alpha 2a + Weight-based RBV in Treatment-naive Patients With Chronic Hepatitis C Genotype 1 [NCT00944684]	Phase 2	32 participants (Actual)	Interventional	2007-11-30	Completed
Prospective Anti-HCV Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity: PRAIRIE Study [NCT00957866]	Phase 4	160 participants (Anticipated)	Interventional	2009-05-31	Completed
A Prospective, Multicenter, Open-label, Comparative, Efficacy Study of Pegasys® Plus Copegus® in Treatment-naïve Latino Patients With Chronic Hepatitis C-genotype 1, as Compared to Treatment-naïve Non- Latino Caucasian Patients With Chronic Hepatitis C-ge [NCT00107653]	Phase 4	569 participants (Actual)	Interventional	2004-10-31	Completed
Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b in CHC Patients With genotype1 High Viral Load and Low Body Weight [NCT00686777]	Phase 4	75 participants (Actual)	Interventional	2008-01-31	Completed
Neurobehavioral Deficits in HIV/HCV Infection Pre/Post Anti-HCV Therapy [NCT00747539]		330 participants (Actual)	Observational	2008-07-31	Completed
A Safety and Efficacy Study of SCH 503034 in Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 [NCT00423670]	Phase 2	765 participants (Actual)	Interventional	2007-01-31	Completed
A Phase 2 Study of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response With a Prior Course of Interferon Based Therapy [NCT00420784]	Phase 2	465 participants (Actual)	Interventional	2007-02-28	Completed
Double Filtration Plasmapheresis (DFPP) in Combination With Pegylated Interferon Alfa-2a and Ribavirin for Patients With Chronic Hepatitis C With Genotype 1 and High Viral Load: a Randomized Controlled Trial [NCT00977054]	Phase 4	59 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Novel HCV DAA approved by FDA)
Phase 2 Randomized Multicenter Controlled Study of Ribavirin Pre-treatment (8 Weeks) Followed by Standard Therapy With Ribavirin and Pegylated Interferon (48 Weeks) in Transplanted Patients With Recurrence of Chronic Hepatitis C [NCT00993122]	Phase 4	100 participants (Actual)	Interventional	2009-10-31	Completed
A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in the 121st Combat Support Hospital (Seoul, Korea) [NCT00623168]	Phase 2	50 participants (Anticipated)	Interventional	2008-02-29	Enrolling by invitation
EXtended Therapy in Genotype 3 Infected Patients Who do Not AChieve a Treatment Response at Week 4 (RVR) But do Achieve a Complete Early Virologic Response (cEVR) [NCT01095445]	Phase 3	2 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Unlikely to recruit the adequate number of patients within a reasonable timeline)
Optimization of Treatment for Patients With Chronic Hepatitis C Infected With HCV-genotype 2 or 3: 12 vs. 24 Weeks of Treatment Extension for Patients Without Rapid Virological Response [NCT00803309]	Phase 4	99 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to At the end of the planned recruitment period the expected number of subjects could not be included in the trial.)
Inhibition of Disease Progression in Hepatitis C-infected Patients With Compensated Liver Cirrhosis [NCT00811967]	Phase 3	50 participants (Actual)	Interventional	2003-02-28	Terminated
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29 Administered in Combination With Ribavirin to Treatment-Naive Subjects With Chronic Hepatitis C Virus Infection [NCT01001754]	Phase 2	600 participants (Anticipated)	Interventional	2010-05-31	Active, not recruiting
Effect of High Dose vs. Standard Dose of Ribavirin in Patients With Chronic Hepatitis C, Genotype 3, High Viral Load Without Rapid Virological Response [NCT00830609]	Phase 4	101 participants (Actual)	Interventional	2008-11-30	Completed
Determining the Sustained Virologic Response of Declatasvir in Egyptian Patients With Hepatitis C Virus Genotype 4 [NCT02772744]		250 participants (Anticipated)	Observational	2017-11-01	Not yet recruiting
A Phase 2, Open-Label Study to Investigate the Safety and Efficacy of Faldaprevir and TD 6450 Alone and in Combination With Other Antivirals for 12 Weeks in Treatment-Naive Patients Chronically Infected With Genotype 1 Hepatitis C Virus [NCT02716428]	Phase 2	25 participants (Actual)	Interventional	2016-05-31	Completed
An Open-label Pilot Study of Dose Escalation of PEGASYS on Virological Response in Patients With Chronic Hepatitis C Viral Infection Showing an Early Non-response to a Standard Course of PEGASYS Plus Ribavirin [NCT02791256]	Phase 3	23 participants (Actual)	Interventional	2005-06-30	Terminated
Ribavirin, Its Dosing Regime [NCT00484328]	Phase 4	15 participants (Actual)	Interventional	2007-07-31	Completed
Sustained Viral Response Rate in 50 Subjects With Cirrhosis Due to Hepatitis C, Genotype 1, Treated With 12 Weeks of Sofosbuvir, Ledipasvir and Ribavirin [NCT02705534]	Phase 3	50 participants (Actual)	Interventional	2016-09-30	Completed
Study to Assess Efficacy and Safety of Grazoprevir/Elbasvir Associated With Sofosbuvir and Ribavirin in HCV Genotype 1 or 4-infected Patients Who Failed Direct Acting Antivirals (DAA) Bitherapy With Sofosbuvir [NCT02647632]	Phase 2	26 participants (Actual)	Interventional	2016-01-31	Completed
An Open-label Multicenter Study Evaluating the Efficacy and Safety of 24 or 48 Weeks Pegylated Interferon Alfa-2a 40 kD (PEGASYS) Combination Therapy With Ribavirin (Copegus) in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Ha [NCT00641654]	Phase 4	75 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Recruitment problems in Denmark and Norway)
A Randomized, Open-label Study of the Effect of PEGASYS ® Plus COPEGUS® With or Without Concomitant Pioglitazone (Actos®) on Early Viral Kinetics in Treatment-naive Patients With Chronic Hepatitis C, Genotype-1, and Insulin Resistance [NCT00545233]	Phase 4	155 participants (Actual)	Interventional	2008-01-31	Completed
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC [NCT02771405]	Phase 3	150 participants (Anticipated)	Interventional	2016-03-31	Recruiting
New Drugs And New Concerns: Gaining Insight Through Pharmacovigilance Of Direct Acting Anti-Viral's In Chronic HCV Patients [NCT04664894]		511 participants (Actual)	Observational	2018-05-15	Completed
A Prospective Randomized, Open Labeled, Phase IV, Multicenter Study for Peginterferon Alfa-2a and Weight-based Ribavirin for 16 or 24 Weeks in genotype2 Chronic Hepatitis C Patients Who Achieved Rapid Virologic Response [NCT01056172]	Phase 4	164 participants (Anticipated)	Interventional	2010-01-31	Recruiting
A Phase IIa Randomized, Open-Label Study of Telaprevir (VX-950) Administered Every 12 or Every 8 Hours in Combination With Either Peg-IFN alfa2a (Pegasys) and Ribavirin (Copegus) or Peg-IFN alfa2b (PegIntron) and Ribavirin (Rebetol) in Treatment-Naive Sub [NCT00528528]	Phase 2	166 participants (Actual)	Interventional	2007-10-31	Completed
Phase IV Study of Effectiveness of Interferon and Ribavirin Treatment in Thalassemia Major Patients With Chronic Viral Hepatitis C [NCT00887081]	Phase 4	150 participants (Anticipated)	Interventional	2009-01-31	Recruiting
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs [NCT04278404]		5,000 participants (Anticipated)	Observational	2020-03-05	Recruiting
Multicentre, Randomised, Open-label Study Comparing the Tolerability and Viral Reduction of the Combination of IFN Alpha-2b XL + Ribavirin Versus Peg IFN Alpha-2b + Ribavirin in Patients With Chronic Hepatitis C, Genotype 1 or 4. [NCT01010646]	Phase 2	84 participants (Anticipated)	Interventional	2010-03-31	Active, not recruiting
Effects of S-Adenosyl Methionine (SAMe) on Viral and Cell Signaling Response to Combination Therapy for Chronic Hepatitis C [NCT00475176]	Phase 2	24 participants (Actual)	Interventional	2007-05-31	Completed
A Blinded, Randomized, Placebo-controlled Trial in Genotype 1 Hepatitis C-Infected Subjects to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Repeated Doses of TMC435350, With or Without Peginterferon Alpha-2a and Ribavirin [NCT00561353]	Phase 2	121 participants (Actual)	Interventional	2008-01-31	Completed
A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Non-Fasting Conditions. [NCT00959933]	Phase 1	24 participants (Actual)	Interventional	2001-04-30	Completed
A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Fasting Conditions. [NCT00960479]	Phase 1	38 participants (Actual)	Interventional	2001-01-31	Completed
The Individualized Management With Pegasys and Ribavirin Offering Viral Eradication (IMPROVE) Trial [NCT00483938]	Phase 3	236 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who Did Not Achieve [NCT00535847]	Phase 2	117 participants (Actual)	Interventional	2007-10-31	Completed
A Randomized, Open-label Study of the Effects of 24 vs 48 Weeks of Combination Therapy With PEGASYS (Peginterferon Alfa-2a 40KD) Plus COPEGUS (Ribavirin) on Sustained Virological Response in Patients With Chronic Hepatitis C, Genotype 2 or 3 Who do Not Ac [NCT00623428]	Phase 3	235 participants (Actual)	Interventional	2008-06-30	Completed
Influence of Ribavirin and Interferon on Semen Quality, IRIS Study [NCT00455832]		23 participants (Actual)	Observational	2006-11-30	Completed
Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin [NCT00495391]	Phase 2	64 participants (Actual)	Interventional	2007-07-31	Completed
A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes [NCT00559091]	Phase 2	18 participants (Actual)	Interventional	2007-04-30	Completed
A Prospective Observational Post-Marketing Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection [NCT02562742]		554 participants (Actual)	Observational	2015-11-12	Completed
A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48 Weeks in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response While Receiving Telaprevir, Peginterferon Alfa2a (Pegasys [NCT00758043]	Phase 3	540 participants (Actual)	Interventional	2008-10-31	Completed
Treatment of Acute Hepatitis C Virus in HIV Co-Infection [NCT00845676]	Phase 4	21 participants (Actual)	Interventional	2008-03-31	Completed
A Phase II Randomized Placebo-controlled Study to Evaluate the Safety and Efficacy of MK-7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Japanese Treatment-Experienced Patients With Chronic Hepatitis C Infection [NCT00880763]	Phase 2	90 participants (Actual)	Interventional	2009-04-20	Completed
Effect of Boceprevir Therapy on HCV-specific T Cell Responses: Perspectives of Immune Monitoring and Immune Therapy [NCT01403181]		30 participants (Actual)	Observational	2012-04-30	Completed
A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Hemophilic Patients With Chronic Hepatitis C Infection [NCT00707772]	Phase 4	400 participants (Anticipated)	Interventional	2007-03-31	Completed
A Phase III, Multicenter, Open-labeded Study To Evaluate Efficacy and Safety of TG-2349 in Combination With DAG181 and Ribavirin for 12 Weeks of Treatment in HCV Genotype I Infected Patients [NCT04155515]	Phase 3	370 participants (Actual)	Interventional	2019-06-13	Completed
Multicentric, Controlled and Randomised Open Clinical Trial Investigating the Efficacy and Safety of Dose Adaptation of Ribavirin Using Pharmacologic Measures of Ribavirin Exposition During Combination Peginterferon Alfa-2 and Ribavirin Treatment in Naive [NCT00485342]	Phase 3	236 participants (Anticipated)	Interventional	2006-04-30	Recruiting
Treatment of Chronic Hepatitis C With PegIntron Injector and Rebetol (Post Marketing Surveillance Study) [NCT00727311]		2,302 participants (Actual)	Observational	2005-08-31	Completed
Patient Compliance During PegIntron (Injection Pen) and Rebetol Combination Therapy in Chronic Hepatitis C [NCT00725205]		294 participants (Actual)	Observational	2006-03-31	Completed
Pegetron® Redipen™ Prospective Optimal Weight-based Dosing Response Program [NCT00724893]		2,430 participants (Actual)	Observational	2005-08-31	Completed
An Open-label, Multicenter Protocol Providing Pegylated-interferon Alfa-2a (PEGASYS®) as Monotherapy or in Combination With Ribavirin (COPEGUS®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols [NCT00800735]	Phase 3	30 participants (Actual)	Interventional	2009-04-30	Completed
A Phase III, Randomized, Double-blind, Placebo-controlled Trial in Japan to Investigate the Efficacy and Safety of TMC435 vs. Placebo as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment-Naive, Genotype 1, Hepatitis C- [NCT01292239]	Phase 3	183 participants (Actual)	Interventional	2011-02-28	Completed
Evaluation of Rapid Virological Response in HCV Patients Treated With PegIntron and Ribavirin - APEGIN Trial [NCT00724854]		1,146 participants (Actual)	Observational	2006-08-31	Completed
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin (RBV) in Subjects With (Genotype 1) Hepatitis C Who Did Not Respond to Previous Treatment [NCT00781274]	Phase 3	32 participants (Actual)	Interventional	2008-12-31	Completed
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Treatment-Naïve Subjects With Genotype 1 Hepatitis C [NCT00780416]	Phase 3	189 participants (Actual)	Interventional	2008-11-30	Completed
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Combination With Sofosbuvir and Ribavirin in Chronic Hepatitis C (HCV) Infected Subjects Who Have Experienced Virologic Failure in AbbVie HCV Clinical Studies (MAGE [NCT02939989]	Phase 3	33 participants (Actual)	Interventional	2016-11-21	Completed
An Observational Multi-Center Study Exploring the Association of Safety, Patient Characteristics, Virological, and Histological Parameters With Patient Outcome (Relapse Rate, Achievement of Sustained Viral Response in Daily Clinical Practice in Belgium- P [NCT00704756]		0 participants (Actual)	Observational	2009-01-31	Withdrawn
A Phase II/III Study of Peginterferon Alfa-2a in Combination With Ribavirin for the Treatment of CHC With Compensated LC [NCT00304551]	Phase 3	180 participants (Anticipated)	Interventional	2006-06-30	Completed
An Open-label, Randomized Pilot Study to Compare the Effectiveness of Peginterferon-alfa-2b Plus Ribavirin to Peginterferon-alfa-2b Plus Epoetin-alfa and Two Doses of Ribavirin in the Treatment of Chronic Hepatitis C Virus Infection [NCT00248339]	Phase 3	150 participants (Actual)	Interventional	2002-05-31	Completed
Treatment of Chronic Hepatitis C in Children With Intron Vial or Pen and Rebetol According to German Law (§ 67 Abs 6 AMG) [NCT00727077]		3 participants (Actual)	Observational	2006-06-30	Terminated(stopped due to Study halted due to low recruitment. The 3 participants at time of termination transferred into study P04538 (NCT00727077). See NCT00727077 for details/results.)
A Pilot Trial to Determine the Safety and Efficacy of Fluvastatin in Previous Partial Responders to Pegylated Interferon and Ribivirin in Patients With Genotype 1 Hepatitis C [NCT00814606]	Phase 2	0 participants (Actual)	Interventional	2010-02-28	Withdrawn(stopped due to no one ever enrolled)
Treatment of Patients With Compensated Liver Cirrhosis With SCH 54031 + Ribavirin [NCT00687219]	Phase 3	102 participants (Actual)	Interventional	2007-06-30	Completed
An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-week Course of PEG-Interferon Alpha-2b Versus a 12-week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C [NCT00686517]	Phase 3	130 participants (Actual)	Interventional	2003-12-31	Completed
Non-Randomized, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Peginterferon Alfa-2a and Copegus Combination Therapy After Single and Multiple Doses in Patients With Chronic Hepatitis C and Moderate Renal Impairment, Severe Renal Impairm [NCT02864199]	Phase 4	63 participants (Actual)	Interventional	2004-02-29	Completed
A Randomized Double-Blind Placebo-Controlled Phase III Study To Evaluate The Safety And Efficacy Of Palivizumab Combined With Aerosolized Ribavirin Compared To Ribavirin Alone To Treat RSV Pneumonia In Patients With Bone Marrow Transplants (BMT) [NCT00014391]	Phase 3	0 participants	Interventional	1999-02-28	Completed
A Trial of CTS-1027 in Interferon-Naive Hepatitis C Patients [NCT00925990]	Phase 2	70 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized, Open Labeled, Active-Controlled Trial of 24-Week Versus 48-Week Courses of Peg-Interferon Alpha Plus Ribavirin for Genotype-1 Infected Chronic Hepatitis C Patients [NCT00629967]	Phase 4	200 participants (Actual)	Interventional	2005-04-30	Completed
Tailored Treatment of Hepatitis C Genotype 1 [NCT00910975]	Phase 4	100 participants (Actual)	Interventional	2007-11-30	Completed
A Study of SCH 900518 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C (Protocol No. P05104) [NCT00797745]	Phase 2	111 participants (Actual)	Interventional	2008-11-30	Completed
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C [NCT00718172]	Phase 1	81 participants (Actual)	Interventional	2008-07-11	Completed
Safety, Pharmacokinetics and Antiviral Effect of BI 201335 NA in HCV-1 Infected Patients Treated for 28 Days for Treatment naïve and Experienced Patients Treated in Combination With Peg Interferon Alfa-2a and Ribavirin [NCT00947349]	Phase 2	22 participants (Actual)	Interventional	2009-07-31	Completed
A Phase II, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MK7009 Administered Concomitantly With Pegylated-Interferon and Ribavirin for 28 Days in Treatment-Naive Patients With Chronic Hepatitis C Infection [NCT00704184]	Phase 2	95 participants (Actual)	Interventional	2008-07-25	Completed
[NCT00216775]		50 participants (Actual)	Observational	2004-12-31	Completed
Analysis of Gene Expression of PBMC in the Hepatitis C Virus Genotype 1b-infected Patients During Peg-interferon-α Plus Ribavirin Combination Therapy [NCT00680173]	Phase 4	30 participants (Actual)	Interventional	2006-08-31	Completed
A Multicenter, Randomized, Open-label, Dose-ranging, Phase II Study to Evaluate the Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in Treatment naïve Subjects With Chronic Hepatic C Virus Genotype I Infection [NCT03593447]	Phase 2	133 participants (Actual)	Interventional	2018-03-15	Completed
A Phase III, Multi-center, Open-label Trial to Investigate the Impact of a Treat, Counsel and Cure Strategy in Men Who Have Sex With Men With Hepatitis C Infection in the Swiss HIV Cohort Study [NCT02785666]	Phase 3	150 participants (Actual)	Interventional	2016-06-30	Completed
Safety, Antiviral Effect and Pharmacokinetics of BI 207127 in Combination With BI 201335 and With or Without Ribavirin for 4, 16, 24, 28 or 40 Weeks in Patients With Chronic HCV Genotype 1 Infection (Randomized Phase Ib/II) [NCT01132313]	Phase 2	488 participants (Actual)	Interventional	2010-05-31	Completed
Phase II Trial of Long-term Monotherapy With Ribavirin Against Colchicine on Progression of Chronic Hepatitis C With Advanced Fibrosis in Patients With Non-response to Standard Antiviral Therapy [NCT00840489]	Phase 2	50 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to Preliminary analysis)
Safety and Tolerability of Ribavirin (Ro 20-9963) in Combination With Peginterferon Alfa in Patients With Chronic Hepatitis C [NCT00940420]	Phase 4	2,695 participants (Actual)	Interventional	2002-10-31	Completed
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®), With and Without Ribavirin (Copegus®) in Subjects With Hepatitis C [NCT00372385]	Phase 2	334 participants (Actual)	Interventional	2006-08-31	Completed
Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1 [NCT00948220]	Phase 4	26 participants (Actual)	Interventional	2003-07-31	Completed
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 Versus Placebo as Part of a Treatment Regimen Including Peginterferon α-2a (Pegasys®) and Ribavirin (Copegus®) or Peginterferon α- [NCT01290679]	Phase 3	393 participants (Actual)	Interventional	2011-03-31	Completed
Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C - An Epidemiological Study [NCT01402583]		1,000 participants (Actual)	Observational	2011-07-31	Completed
A Phase 2 Treatment Protocol of Intravenous Ribavirin in Adult Subjects With Hemorrhagic Fever With Renal Syndrome (HFRS) in Landstuhl Regional Medical Center (Landstuhl, Germany) IND 16,666 [NCT00868946]	Phase 2	0 participants (Actual)	Interventional	2009-10-31	Withdrawn(stopped due to Lack of enrollment)
A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and Ribavirin in Treatment-naïve Patients With Chronic Genotype 1 Hepatitis C. [NCT01055821]	Phase 2	140 participants (Actual)	Interventional	2010-05-31	Completed
Hepatitis C Virus Dynamic and Immune Activation in HIV-1 Coinfected Patients Treated With Pegylated Interferon Alfa-2a and Ribavirin [NCT00909129]		25 participants (Actual)	Interventional		Completed
A Phase I/II Exploratory Study of Ribavirin in Metastatic Breast Cancer Expressing Elevated eIF4E [NCT01056757]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2009-12-31	Terminated(stopped due to Study closed because of new overlapping study with ribavirin.)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C [NCT00689390]	Phase 2/Phase 3	1,954 participants (Actual)	Interventional	2007-02-20	Terminated(stopped due to The study was terminated due to satisfaction of post-marketing commitments)
A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 With Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combina [NCT01074008]	Phase 2	74 participants (Actual)	Interventional	2010-03-31	Completed
A Blinded, Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Ge [NCT00851890]	Phase 2	30 participants (Actual)	Interventional	2009-03-31	Completed
An Open, Phase IV, Multicentric Study, Evaluating Safety and Efficacy of Ribavirin (Copegus®) and Peginterferon Alfa-2a (Pegasys®) Combination in Specific Groups [NCT00800748]	Phase 4	372 participants (Actual)	Interventional	2006-02-01	Completed
Clinical Study of a Biological Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for the Treatment of Hepatitis C Infection [NCT02690103]	Phase 2	37 participants (Actual)	Interventional	2012-07-31	Completed
A Phase IIa Randomized, Partially Blinded Trial of Telaprevir (VX-950) in Treatment-Naive Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection [NCT00561015]	Phase 2	52 participants (Actual)	Interventional	2007-12-31	Completed
Randomized Study of Two Treatment Strategies With Ribavirin for Chronic Hepatitis E and Severe Acute Forms [NCT02558114]	Phase 4	5 participants (Actual)	Interventional	2015-12-31	Terminated(stopped due to Lack of recruitment)
Assessment of the Safety, Efficacy, Tolerability and Pharmacokinetics of PEG-Intron® Plus REBETOL® in Pediatric Patients With Chronic Hepatitis C [NCT00761735]	Phase 3	94 participants (Actual)	Interventional	2007-07-31	Completed
A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2b (PegIntron®) and Ribavirin (Rebetol®) in Japanese Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection [NCT01016912]	Phase 2	51 participants (Actual)	Interventional	2009-12-31	Completed
Efficacy and Safety of Sofosbuvir/Simeprevir Plus a Flat Dose of Ribavirin in Genotype 1 Elderly Cirrhotic Patients: a Real Life Study [NCT02702739]	Phase 4	270 participants (Actual)	Interventional	2015-01-31	Completed
A Randomized Study to Evaluate the Safety and Efficacy of IDX719 in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Subjects With Chronic Hepatitis C Infection [NCT01852604]	Phase 2	143 participants (Actual)	Interventional	2013-03-31	Completed
"Prospective Observational Study to Assess Personality Disorders in Prison Populations for Hepatitis C Treatment. " [NCT01900886]		263 participants (Anticipated)	Observational	2010-12-31	Active, not recruiting
Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort (Second Phase) [NCT01760148]		300 participants (Anticipated)	Observational	2012-07-31	Recruiting
Open Label, Randomised, Pilot Trial of Pegylated Interferon, Ribavirin & Telaprevir vs Pegylated Interferon & Ribavirin Alone in Response Guided Treatment of Acute Hepatitis C Genotype 1 Virus Infection in Patients With HIV-1 Co-infection [NCT02006745]	Phase 3	20 participants (Actual)	Interventional	2014-01-31	Completed
A Multicentre, Randomised, Double-blind, Placebo-controlled, Parallel-group Phase II Study on the Efficacy and Safety of Debio 025 Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients [NCT00854802]		290 participants (Actual)	Interventional	2009-01-31	Completed
Combination of Alpha Interferon With Long Term Ribavirin Therapy for Patients With Chronic Hepatitis C [NCT00001729]	Phase 3	120 participants	Interventional	1997-10-31	Completed
An Open-label, Randomized, 5-arm, Parallel-group Study of the Effects on Viral Kinetics, Safety and Pharmacokinetics of Different Dosing Regimens of Debio 025 in Combination With Peginterferon Alpha-2a and Ribavirin in Chronic HCV Genotype 1 Patients Who [NCT00537407]	Phase 2	50 participants (Actual)	Interventional	2007-09-30	Completed
A Pilot Study of Low Dose Interleukin-2 (IL-2) With the Addition of Pegylated Interferon (PEG-IFN Alfa-2b) and Ribavirin (RBV) for the Treatment of Hepatitis C Infection in Subjects With HIV Coinfection [NCT00015652]		24 participants	Interventional		Completed
Study of Cerebral Function in Patients With Chronic Hepatitis C Infection Before and After Pegylated Interferon Alfa-2a and Ribavirin Therapy [NCT00788918]		100 participants (Actual)	Interventional	2008-11-30	Completed
Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C [NCT00727259]		1,995 participants (Actual)	Observational	2004-10-31	Completed
Quality Assurance of HCV-therapy With PegIntron® Plus Rebetol® in Drug-substituted Patients - SUPPORT Project Post-Marketing Surveillance Study [NCT00726557]		246 participants (Actual)	Observational	2005-10-31	Completed
Improving Hepatitis C Treatment in Injection Drug Users [NCT00148031]	Phase 4	111 participants (Actual)	Interventional	2003-09-30	Completed
Prospective, Observational, Multicentre Study Evaluating HCV Patients Characteristics of Eligibility and Disease Management in Real Clinical Practice [NCT00724451]		1,128 participants (Actual)	Observational	2008-07-31	Completed
Retrospective Data Study of HCV Genotype 1 Patients in the UK Treated With ViraferonPeg and Rebetol [NCT00724373]		442 participants (Actual)	Observational	2007-11-30	Completed
Open-label Study of Efficacy and Safety of Generic Sofosbuvir/Ledipasvir±Ribavirin in Iranian Patients With Hepatitis C Virus Genotype 1 Infection [NCT03061032]	Phase 3	200 participants (Anticipated)	Interventional	2017-03-31	Not yet recruiting
ANRS HC20 Pilot Study, Multicenter, Assessing the Effectiveness of an Optimized Anti HCV (360μg/Week Induction of PegIFN-alpha2a + 18mg/kg/j of RBV for 6 Months and Then Depending on the Virological Response to S12, Elongation up S72 to the Dual Anti HCV, [NCT00901524]	Phase 2	58 participants (Actual)	Interventional	2009-06-30	Completed
A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naive Subjects With Genotype 1 Chronic Hepatitis C [NCT00627926]	Phase 3	1,095 participants (Actual)	Interventional	2008-03-31	Completed
Treatment of Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever) With Intravenous Ribavirin in Department of Defense (DOD) Associated Medical Treatment Facilities: A Phase 2 Study [NCT00992693]	Phase 2	0 participants (Actual)	Interventional	2009-09-30	Withdrawn
Efficacy of High Doses of Both Pegylated Interferon Alfa-2a and Ribavirin for Retreatment of HIV-coinfected Patients With Liver Cirrhosis Due to HCV Genotype 1 or 4 Nonresponders to Previous Standard Therapy. [NCT01006031]	Phase 2/Phase 3	25 participants (Actual)	Interventional	2009-10-31	Completed
Efficacy and Safety of PEG-Intron Plus Rebetol in Subjects With Chronic Hepatitis C Genotype 1 Non Responder to Pegasys [NCT00441584]	Phase 3	117 participants (Actual)	Interventional	2005-07-31	Terminated(stopped due to Subject accrual was prematurely terminated due slow enrollment.)
Hepatitis C in a Cohort of Patients With Maintenance Therapy for Opiate Dependence - Prevalence, Severity and Outcome of Antiviral Therapy [NCT01045278]	Phase 4	277 participants (Actual)	Interventional	2008-04-30	Completed
Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) Therapy (1.5 mcg/kg/Week + 800-1200 mg/Day) in Naïve Genotype 1 Hepatitis C Patients With High Baseline Viral Load Who Are HCV-RNA Negative at Week 4 and Week 12 [NCT00423800]	Phase 3	56 participants (Actual)	Interventional	2006-12-31	Terminated(stopped due to The study was terminated due to difficulty in recruiting participants.)
A Study to Assess Treatment With PEG-Intron® and Rebetol® in Naïve Patients With Genotype 1 Chronic Hepatitis C and Slow Virological Response [NCT00265395]	Phase 3	1,428 participants (Actual)	Interventional	2004-12-31	Completed
Phase IV Study of Tailored Therapy With Peg Interferon Alfa 2b and Ribavirin for Patients With Genotype 3 and High Viral Load. Genotype 3 Extended Treatment for HCV (GET-C Study) [NCT00255034]	Phase 4	146 participants (Actual)	Interventional	2005-02-28	Terminated(stopped due to Recruitment targets were unachievable in the currently available population.)
A Phase 2, Randomized, Open-Label Trial of GS-9256 Plus GS-9190 Alone and in Combination With Ribavirin for 28 Days in Treatment Naïve Subjects With Chronic Genotype 1 Hepatitis C Virus Infection (Protocol No. GS-US-196-0112) [NCT01072695]	Phase 2	46 participants (Actual)	Interventional	2010-02-28	Completed
Comparison of the Sustained Response of Peg-Intron/Ribavirin Combination Therapy in Genotype 1-Infected Hepatitis C Patients for Non-extended Versus 24-week Extended Treatment After 24 Weeks Pilot Treatment in Taiwan [NCT00202839]	Phase 4	160 participants (Actual)	Interventional	2005-03-31	Completed
Efficacy and Tolerability of Escitalopram for the Prevention of Pegylated Interferon Alfa Associated Depression in Patients With Chronic Hepatitis C Infection: a Randomized Controlled Trial. [NCT00136318]	Phase 3	208 participants (Actual)	Interventional	2004-01-31	Completed
PEG-Intron/REBETOL vs PEG-Intron/ SCH 503034 With and Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 (HCV-1) Peginterferon Alfa/Ribavirin Nonresponders: A SCH 503034 Dose-Finding Phase 2 Study [NCT00160251]	Phase 2	357 participants (Actual)	Interventional	2005-09-30	Completed
Efficacy of Low Dose Pegylated Interferon-α 2a Plus Ribavirin for the Treatment of Chronic Hepatitis C, Genotypes 2 or 3, in HIV-coinfected Patients. [NCT00553930]	Phase 4	71 participants (Anticipated)	Interventional	2007-11-30	Completed
Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With Chronic Hepatitis C [NCT00207363]	Phase 4	610 participants (Actual)	Interventional	2002-02-28	Completed
A Pilot Trial of Combination Therapy With Interferon Alfacon1, Ribavirin, & Rosiglitazone in a Group of Insulin Resistant, Chronic Hepatitis C, GT 1 Patients Who Are Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin [NCT00207402]	Phase 4	34 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized, Multicenter, Open Label Study Evaluating the Efficacy and Safety of Tailored Regimens With Peginterferon Alfa-2a Plus Ribavirin According Viral Kinetics for Genotype 1 Chronic Hepatitis C Patients [NCT01937728]	Phase 4	542 participants (Actual)	Interventional	2010-03-31	Completed
Effectiveness of Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C [NCT00203606]	Phase 4	66 participants (Actual)	Interventional	2004-01-31	Completed
Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C [NCT00230958]	Phase 3	900 participants	Interventional	2003-12-31	Completed
Phase 2a Study of Boceprevir for the Treatment of Genotype 6 Hepatitis C [NCT01949168]	Phase 2	30 participants (Anticipated)	Interventional	2013-09-30	Not yet recruiting
A Multicenter, Open-label, Randomized, 3-arm, Phase II Profiling Trial of Pharmacokinetics, Pharmacodynamics and Safety of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients [NCT01970904]		147 participants (Actual)	Interventional	2013-10-31	Completed
Syndrome of Fever Associated With Bleeding of Chinese and Western Medicine Diagnosis and Treatment of Infectious Diseases Plans and Severe Clinical Treatment Research [NCT01973855]	Phase 2	300 participants (Anticipated)	Interventional	2012-01-31	Recruiting
Effect of Long-term Vitamin D Therapy on IL-6, Visfatin and Hyaluronic Acid in Hepatitis C Virus Patients' Assessment [NCT01997203]	Phase 3	100 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to complete patients samples required)
UMIT-1 Trial: Favipiravir & Ribavirin Phase IB A Randomised Phase Ib Study to Determine the Phase II Dose and to Evaluate the Safety and Efficacy of Intravenous (IV) Favipiravir & Ribavirin [NCT05940545]	Phase 1/Phase 2	24 participants (Anticipated)	Interventional	2023-07-12	Recruiting
Evaluation of Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Adults Chronically Infected With Genotype 2 Hepatitis C Virus: an Open-label, Multicenter Confirmatory Study [NCT03453346]		136 participants (Actual)	Interventional	2016-08-05	Completed
Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9: a Phase IV, Randomized, Open-labeled, Multicenter Trial Comparing 24-week vs. 48-week Therapy [NCT00575224]	Phase 4	60 participants (Actual)	Interventional	2004-10-31	Completed
A Phase III, Open-label Trial in Japan to Investigate the Efficacy and Safety of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Genotype 1, Hepatitis C-infected Subjects Who Relapsed After Previous IFN-based Therapy [NCT01290731]	Phase 3	49 participants (Actual)	Interventional	2011-01-31	Completed
A Randomized, Open-Label, Phase 3 Study of Telaprevir Administered Twice Daily or Every 8 Hours in Combination With Pegylated Interferon Alfa-2a and Ribavirin in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection [NCT01241760]	Phase 3	744 participants (Actual)	Interventional	2010-12-31	Completed
"Diagnostic Value of Plasma Ribavirin Assay During the Combination Therapy Pegylated Interferon + Ribavirin in Chronic Hepatitis C." [NCT00209755]		40 participants	Interventional	2003-10-31	Terminated
Treatment of Japanese Encephalitis - a Double Blind Placebo Controlled Trial [NCT00216268]	Phase 2	200 participants	Interventional	2005-07-31	Recruiting
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study [NCT02717949]	Phase 4	1 participants (Actual)	Interventional	2016-02-25	Terminated(stopped due to failure to recruit)
A Prospective, Multicenter, Phase II/III, Open-Label, Controlled, Randomized Trial Evaluating the Efficacy, Safety, and Tolerability of Interferon-alfa-2a Plus Ribavirin Versus PEG-interferon-alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus (HCV) Infe [NCT00008463]	Phase 2	132 participants	Interventional	2000-11-30	Completed
Treatment of Chronic Hepatitis C Patients With Persistently Normal Alanine Aminotransferase Levels With Peginterferon α-2a (40 kDa) Plus Ribavirin [NCT00575627]	Phase 4	150 participants (Anticipated)	Interventional	2007-09-30	Recruiting
Phase 2, Open-Label, Clinical Trial of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Null Responders to Pegylated-Interferon Alpha Plus Ribavirin Subjects With Chronic Hepatitis C Virus Genotype 1 Infection [NCT01872936]	Phase 2	20 participants (Anticipated)	Interventional	2013-06-30	Active, not recruiting
A Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination With and Without Peginterferon-Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve S [NCT01080222]	Phase 2	152 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to Study discontinued)
A Phase IV, Randomised, Multicentre, Efficacy and Safety Study Examining the Effect of Induction Dosing With the Combination of Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Infected With Hepatitis C Genotype 1 [NCT00192647]	Phase 4	896 participants (Actual)	Interventional	2004-08-31	Completed
An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 [NCT04551768]	Phase 1	51 participants (Actual)	Interventional	2021-02-10	Completed
A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory Syndrome [NCT00578825]		340 participants (Anticipated)	Interventional		Not yet recruiting
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I) [NCT02219490]	Phase 3	1,596 participants (Actual)	Interventional	2014-10-30	Completed
An Open-Label Study to Assess the Safety and Tolerability of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Vietnamese Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Any Interferon Plus R [NCT01641666]	Phase 3	0 participants (Actual)	Interventional	2014-05-31	Withdrawn
A Study on PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin) in Iranian Thalassemic Patients With Chronic Hepatitis C Infection [NCT00707850]	Phase 4	300 participants (Anticipated)	Interventional	2007-05-31	Completed
Open Multicentre, Phase IV Study to Evaluate Efficacy and Safety of Pegylated Interferon Alpha-2a (40 KD) Plus Ribavirin for Chronic Hepatitis C With Normal Transaminases in Human Immunodeficiency Virus-infected Patients [NCT01684787]	Phase 4	80 participants (Actual)	Interventional	2006-09-30	Completed
Open-label, Multicenter, Non-Comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) or Compensated Liver Cirrhosis in Real Cl [NCT01609049]		1,496 participants (Actual)	Observational	2011-12-07	Completed
Post Marketing Observational/Non-Interventional Study Of Retreatment Of Chronic Hepatitis C With Peginterferon Alpha And Ribavirin [NCT01098097]		963 participants (Actual)	Observational	2009-06-30	Completed
A Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics, and Antiviral Activity of ABT-267 in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Treatment-Naïve Subjects With Genotype 1 Chr [NCT01314261]	Phase 2	37 participants (Actual)	Interventional	2011-03-31	Completed
A Pilot Study to Assess the Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma [NCT01268579]		9 participants (Actual)	Interventional	2010-12-28	Completed
A Phase I/II Study of Ribavirin and Low-dose Cytarabine Arabinoside (Ara-C) in Acute Myeloid Leukemia (AML) M4 and M5 Subtypes, and AML With High eIF4E Expression [NCT01056523]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2010-01-31	Completed
Usefulness of Adding Thalidomide to Peginterferon and Ribavirin in Patients With Hepatitis C and Resistance to Interferon. Phase II [NCT00856804]	Phase 2	10 participants (Anticipated)	Interventional	2009-03-31	Recruiting
[NCT00723242]		0 participants	Interventional	2002-04-30	Completed
"PegIntron/REBETOL Combination Therapy Designated Drug Use Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C Excluding Those With IFN Naive Low Viral Load and Genotype [NCT00724230]		505 participants (Actual)	Observational	2006-02-28	Completed
Open Multicenter Study of Combination Therapy With Weight-Based PEG-IFN Alfa-2b Plus Ribavirin for Treatment of Mexican naïve Patients With Chronic Hepatitis C Infected With Genotype 1. Impact of the Combination Therapy on Sustained Virological Response a [NCT00724620]	Phase 4	103 participants (Actual)	Interventional	2005-06-30	Completed
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 [NCT00895882]	Phase 2	0 participants (Actual)	Interventional	2010-11-30	Withdrawn
Title: Evaluation of Systemic IDO Levels After Various Immunotherapeutics [NCT00897312]		7 participants (Actual)	Observational	2006-10-31	Terminated(stopped due to slow accrual)
A Phase I, Randomized, Single-Blind, Placebo-Controlled Dose-Escalation Study of SD-101 to Assess the Safety, Pharmacodynamics, and Preliminary Evidence of Anti-Viral Effect in Subjects Diagnosed With Chronic Hepatitis C, Genotype 1 [NCT00823862]	Phase 1	34 participants (Actual)	Interventional	2008-10-31	Completed
The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Hepatocellular Carcinoma [NCT00834860]	Phase 4	179 participants (Actual)	Interventional	2007-01-31	Active, not recruiting
A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1 [NCT00874770]	Phase 2	74 participants (Actual)	Interventional	2009-06-30	Completed
)A Study to Evaluate the Erythropoietic Response in HCV/HIV Co-Infected Patients Receiving Combination Ribavirin/Interferon Therapy [NCT00315432]	Phase 2	91 participants (Actual)	Interventional	2000-09-30	Completed
A Randomized, Multi-Center, Open-Label Study To Evaluate The Efficacy And Safety Of Albuferon (HGS 1008, Recombinant Human Albumin-Interferon Alfa Fusion Protein) In Combination With Ribavirin In Interferon Alfa Naive Subjects With Chronic Hepatitis C Gen [NCT00656006]	Phase 2	43 participants (Actual)	Interventional	2005-11-30	Completed
A Randomized, Multicenter, phaseIIIB, Two Arm Study Evaluating the Tolerability of Peginterferon Alfa-2a Plus Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Infection co-Infected With Human Immunodeficiency Virus Receiving HAART Versus Not Rece [NCT00296972]	Phase 3	100 participants	Interventional	2005-07-31	Terminated(stopped due to not funded)
Open, Randomized, Multicenter Phase IV Study to Evaluate Efficacy and Safety to Extend Treatment 24 Weeks in co-Infected HIV-HCV Patients Genotype 1 and/or 4 [NCT00612755]	Phase 4	43 participants (Actual)	Interventional	2005-10-31	Completed
Open, Randomized and Multicenter Phase IV Study to Compare the Efficacy and Safety of Two Different Treatments Duration 24 Versus 48 Weeks in Chronic Hepatitis C Genotypes 2 and/or 3 co-Infected HIV-HCV Patients. [NCT00611819]	Phase 4	59 participants (Actual)	Interventional	2005-11-30	Active, not recruiting
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin In Treatment-Naive Genotype 1 Hep [NCT00882908]	Phase 2	386 participants (Actual)	Interventional	2009-06-30	Completed
Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Who Fail Interferon Alfa or Pegylated Interferon Alfa Monotherapy - a Pilot Study [NCT00491179]	Phase 4	35 participants (Actual)	Interventional	2006-06-30	Completed
Hepatitis C Virus Infection Induced Insulin Resistance: Different Contribution From Liver and Extrahepatic Sites as Inferred by Treating Chronic Hepatitis C Patients With an Interferon-free Antiviral Combination [NCT02760355]		17 participants (Actual)	Interventional	2016-03-31	Completed
A Single-Arm Study to Provide Boceprevir Treatment in Subjects With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies [NCT00910624]	Phase 3	168 participants (Actual)	Interventional	2009-06-22	Completed
Safety and Tolerability of Ribavirin (RO 20-9963) in Combination With Peginterferon Alfa-2a (40 kD)in Patients With Chronic Hepatitis C [NCT00922779]	Phase 4	6,661 participants (Actual)	Interventional	2002-06-30	Completed
A Phase 3 Safety and Efficacy Study of Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin [NCT00845065]	Phase 3	202 participants (Actual)	Interventional	2009-02-28	Completed
A Phase 2B Study of BMS-790052 in Combination With Peginterferon Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Infected Subjects Who Are Null or Partial Responders to Prior Treatment With Peginterferon Alfa Plus Ribavirin Therapy [NCT01170962]	Phase 2	512 participants (Actual)	Interventional	2010-08-31	Completed
A Prospective Study of Peginterferon Alfa-2a and Ribavirin: Outcomes Assessment in Chronic Hepatitis C Patients [NCT02850289]		385 participants (Actual)	Observational	2006-04-30	Completed
Long-Term Therapy With Ribavirin for Chronic Hepatitis C [NCT00001854]	Phase 4	50 participants	Interventional	1999-02-12	Completed
The Response and Outcomes of Pegylated Interferon Plus Ribavirin Combination Therapy for Chronic Hepatitis C Patients Concomitant With Malignancy Other Than Hepatocellular Carcinoma [NCT00630084]	Phase 4	120 participants (Actual)	Interventional	2006-08-31	Completed
Efficacy and Safety of Pegylated Interferon Plus Ribavirin Combination Therapy in Treating Older Patients With Chronic Hepatitis C [NCT00629824]	Phase 4	250 participants (Anticipated)	Interventional	2007-02-28	Completed
Efficacy and Safety of High-dose Vitamin C Combined With Traditional Chinese Medicine in the Treatment of Moderate and Severe Coronavirus Pneumonia (COVID-19) [NCT04664010]		30 participants (Actual)	Interventional	2020-02-06	Completed
Interferon-gamma With Interferon Alpha and Ribavirin for Hepatitis C Patients Who Are Non-responders to Interferon Alpha Plus Ribavirin [NCT00538811]	Phase 2/Phase 3	40 participants (Anticipated)	Interventional		Completed
Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium [NCT02799355]		1,203 participants (Actual)	Observational	2016-05-31	Completed
An Open Label Study to Evaluate the Safety of NeoRecormon in the Treatment of Anemia in Patients With Chronic Hepatitis C Who Are Treated With Pegylated Interferon + Ribavirin Combination Therapy [NCT00560274]	Phase 4	190 participants (Actual)	Interventional	2008-03-31	Completed
A Randomized Trial of Telaprevir, Peginterferon, and Ribavirin Versus Peginterferon and Ribavirin for Treatment of Genotype 1 Hepatitis C Virus With Host Interleukin 28B CC Polymorphism [NCT01415141]	Phase 4	0 participants (Actual)	Interventional	2011-07-31	Withdrawn(stopped due to Lack of funding)
A Pilot Study Of Interferon Alpha 2b Plus Ribavirin In The Treatment Of Patients With Chronic Hepatitis B [NCT00275938]	Phase 2/Phase 3	120 participants	Interventional	1998-10-31	Completed
A Prospective, Randomized, Multi-center, Open-label, Comparative Safety and Efficacy Study of Prophylactically Administered Pegylated Interferon Alfa-2a(Pegasys) Plus Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C. [NCT00275548]	Phase 4	12 participants (Actual)	Interventional	2004-07-31	Completed
A Phase 2b Study of Merimepodib in Combination With Pegylated Interferon Alfa-2a (Pegasys®) and Ribavirin in Subjects With Chronic Hepatitis C Non-Responsive to Prior Therapy With Pegylated Interferon Alfa and Ribavirin [NCT00088504]	Phase 2	315 participants	Interventional	2004-07-31	Completed
Phase 2 Study of Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C [NCT00097045]	Phase 2	90 participants	Interventional	2004-11-30	Completed
A Multi-Center, Randomized, Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Treatment Experienced Subjects With Chronic [NCT00097435]	Phase 2	115 participants (Actual)	Interventional	2004-10-31	Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype 1 Patients With Chronic Hepatitis C Infection [NCT01903954]	Phase 2	283 participants (Actual)	Interventional	2011-01-31	Completed
A Phase II, Randomized, Double-Blind Study to Evaluate the Safety and Antiviral Activity of IDX184 in Combination With Pegylated Interferon and Ribavirin in Subjects With Genotype 1 Chronic Hepatitis C Infection [NCT01011166]	Phase 2	81 participants (Actual)	Interventional	2009-11-30	Completed
A Phase 2a Study of PPI-668 in Combination With BI 207127 and Faldaprevir, With and Without Ribavirin, in Treatment-Naive Patients With Chronic Hepatitis C (HCV Genotype 1a) [NCT01859962]	Phase 2	38 participants (Actual)	Interventional	2013-05-31	Completed
A Phase 3 Evaluation of Daclatasvir in Combination With Peginterferon Lambda-1a and Ribavirin (RBV) or Telaprevir in Combination With Peginterferon Alfa-2a and RBV in Patients With Chronic Hepatitis C Genotype 1b Who Are Treatment naïve or Prior Relapsers [NCT01718158]	Phase 3	444 participants (Actual)	Interventional	2013-01-31	Completed
An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C Patients [NCT04301882]		1,000 participants (Anticipated)	Observational [Patient Registry]	2019-09-01	Recruiting
Efficacy and Safety of Interferon Based Therapy and Interferon-free Direct-acting Antivirals in Cirrhotic Patients With Hepatitis C. Impact of Antiviral Therapy on Gastroesophageal Varices. [NCT02758509]		237 participants (Actual)	Observational	2010-01-01	Completed
Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin HCV Therapy on Insulin Resistance and Lipid Profile [NCT02734173]	Phase 4	24 participants (Actual)	Interventional	2015-07-31	Completed
Efficacy and Safety of Switching From Pegylated Interferon/Ribavirin (PR) to Direct-acting Antiviral Agents (DAAs) for Chinese With CHC Genotype 1b Infection (SWITCH-1) [NCT02583685]	Phase 2	160 participants (Anticipated)	Interventional	2015-05-31	Recruiting
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 1 Hepatitis C Who Relapsed After Previous Treatment [NCT00780910]	Phase 3	109 participants (Actual)	Interventional	2008-11-30	Completed
Clinical Trial of the Efficacy of the Combination of Pegylated Interferon (PEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C [NCT00158496]	Phase 3	100 participants	Interventional	2002-08-31	Completed
Factors Associated to Success of Hepatitis C Therapy [NCT00514111]		100 participants (Actual)	Observational	2007-08-31	Completed
An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection [NCT02950870]	Phase 4	75 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
A Phase III, Randomised, Open Label, Active-controlled Study of an Interferon-free Regimen of BI 207127 in Combination With Faldaprevir and Ribavirin Compared to Telaprevir in Combination With Pegylated interferon-a and Ribavirin in Treatment-naive Patien [NCT01858961]	Phase 3	0 participants (Actual)	Interventional	2013-05-31	Withdrawn
Australian Trial in Acute Hepatitis C [NCT00192569]	Phase 4	167 participants (Actual)	Interventional	2004-07-31	Completed
A Randomized, Single Center, Comparative Study to Evaluate the Efficacy and Safety of Silibinin (Legalon® SIL) in Combination With Ribavirin or With Peginterferon and Ribavirin, Versus Peginterferon and Ribavirin Based Standard of Care (SoC) in Treatment [NCT01871662]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2013-08-31	Withdrawn
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Treatment-naïve, Genotype 1 Hepatitis Cinf [NCT01289782]	Phase 3	395 participants (Actual)	Interventional	2011-02-28	Completed
Effect and Safety of Adding Metformin to the Standard Treatment of Hepatitis C on Sustained Viral Response [NCT00560690]	Phase 4	140 participants (Actual)	Interventional	2007-12-31	Completed
A Phase 3 Evaluation of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination in Subjects With Genotype 1 Chronic Hepatitis C and Compensated Cirrhosis [NCT01973049]	Phase 3	202 participants (Actual)	Interventional	2013-12-31	Completed
An Open Label Randomized Controlled Trial To Prevent the Progression of Respiratory Syncytial Virus Upper Respiratory Tract Infection to Lower Respiratory Tract Infection in Patients After Hematopoietic Stem Cell Transplant [NCT01502072]	Phase 2	48 participants (Actual)	Interventional	2011-12-28	Completed
A Phase 3, Open Label Study of Safety and Efficacy With BMS-790052 Plus Peg-Interferon Alfa 2a and Ribavirin in Previously Untreated HCV Patients Coinfected With Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) [NCT01471574]	Phase 3	549 participants (Actual)	Interventional	2011-12-31	Completed
A Phase 2,Multicenter,Open-Label Study to Investigate the Efficacy, Safety and Pharmacokinetics of Ritonavir-boosted Danoprevir in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis GT1 [NCT03020004]	Phase 2	70 participants (Actual)	Interventional	2016-01-31	Completed
A Multi-centered, Open Label, Phase III Study on Efficacy, Safety of Ritonavir-boosted ASC08 (Danoprevir) in Combination With Peg-IFN and RBV in Treatment-Naive Non-Cirrhotic Patients Who Have Chronic Hepatitis Genotype 1 [NCT03020082]	Phase 3	141 participants (Actual)	Interventional	2016-06-30	Completed
A Randomized, Phase 2a, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C [NCT01790100]	Phase 2	20 participants (Actual)	Interventional	2013-02-28	Completed
Study of Viral Resistance to Antiviral Therapy of Chronic Hepatitis C (Virahep-C) [NCT00038974]	Phase 3	401 participants (Actual)	Interventional	2002-08-31	Completed
Phase 4 Study Using Infergen and Ribavirin in Patients With Chronic Hepatitis C Virus Who Achieved Partial Response to Peginterferon-alfa and Ribavirin Therapy [NCT00456248]	Phase 4	5 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to slow enrollment)
Thalassemia Clinical Research Network - Hepatitis C Clinical Trial [NCT00502788]	Phase 2	21 participants (Actual)	Interventional	2003-05-31	Completed
A Randomized Trial Comparing a Short Course Versus Standard Treatment in Patients With Chronic Hepatitis C Virus Infection [NCT00502970]	Phase 4	150 participants (Actual)	Interventional	2004-05-31	Completed
Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection [NCT01097395]	Phase 4	35 participants (Actual)	Interventional	2010-02-28	Completed
Open, Multicentre,Randomized Phase IV Trial to Evaluate Efficacy/Safety to Extend Treatment Duration With Peginterferon Alfa-2a+High Dose of Ribavirin Supporting Epo β in Treatment of CHC in HIV-HCV Patients Who Not Clear Virus at Week 4 [NCT00526448]	Phase 4	384 participants (Anticipated)	Interventional	2007-06-30	Recruiting
Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C [NCT00527540]	Phase 3	60 participants (Anticipated)	Interventional	2007-02-28	Completed
Treatment of Patients With Chronic Hepatitis C Co-infected With HIV Relapsers or Non Responders, Previous Exposed to Sub-optimal Therapies: Open, Pilot Trial [NCT00530972]	Phase 4	50 participants (Actual)	Interventional	2006-03-31	Completed
Retrospective Study to Evaluate the Impact of Using Interferon (Pegylated or Not) in the Treatment of Patients With Chronic Hepatitis C in Brazil (DECISION) [NCT01280656]		660 participants (Actual)	Observational	2010-01-31	Completed
Peginterferon Alfa-2a Plus Ribavirin in Patients With Genotype 2 Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose Stratified by Rapid Virologic Response [NCT00532701]	Phase 4	880 participants (Actual)	Interventional	2007-11-30	Completed
Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks or Sofosbuvir/Velpatasvir/Voxilaprevir for 12 Weeks in DAA Treatment Naïve HCV Subjects With GT3b, Compensated Cirrhosis in China [NCT05467826]	Phase 4	100 participants (Anticipated)	Interventional	2022-09-01	Not yet recruiting
Treatment Protocol for Adults With Hemorrhagic Fever With Renal Syndrome (HFRS) With Intravenous (IV) Ribavirin [NCT04283513]	Phase 2	50 participants (Anticipated)	Interventional	2022-10-31	Not yet recruiting
Four Arms, Multicenter, Open Label Study of Tailored Regimens With Peginterferon Plus Ribavirin for Genotype 2 Chronic Hepatitis C [NCT00540345]	Phase 4	300 participants (Actual)	Interventional	2006-10-31	Completed
A Randomized Double-Blind Phase 2 Study Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications [NCT01227967]	Phase 2	881 participants (Actual)	Interventional	2010-09-30	Completed
Randomized, Open-Label, Multicenter Study of Safety, Efficacy, and Tolerability of the Combination of RO5466731, RO5190591, Ritonavir, and Copegus With or Without RO5024048 in HCV Genotype 1 Infected Patients Who Are Either Treatment Naïve or Null Respond [NCT01628094]	Phase 2	110 participants (Actual)	Interventional	2012-06-30	Completed
A Phase 3, Comparative Study of Asunaprevir and Daclatasvir (DUAL) Combination Therapy Versus Telaprevir Therapy in Japanese Genotype 1b Chronic Hepatitis C IFN Eligible-naive Subjects With a Single Arm Assessment of DUAL Therapy in IFN-therapy Relapsers [NCT01718145]	Phase 3	258 participants (Actual)	Interventional	2012-11-30	Completed
Safety and Efficacy of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin for Treatment of Chronic Hepatitis C Genotype 1 in Russia: Previously Untreated Patients and Patients Who Failed Prior Treatment With Pegylated-Interferon Plus Riba [NCT01425203]	Phase 3	238 participants (Actual)	Interventional	2011-11-23	Completed
Evaluation of the Health-Related Quality of Life During Combined Treatment of Chronic Hepatitis Due to Hepatitis C Virus Under Habitual Clinical Practise Conditions. [NCT00863109]		133 participants (Actual)	Observational	2009-04-30	Completed
Safety and Efficacy of Gratisovir (Sofosbuvir)- Ribavirin Daul Therapy in Egyptian Pediatric Patients With Chronic Hepatitis C Infection. A Prospective, Randomized, Multicenter Study [NCT02985281]	Phase 2/Phase 3	41 participants (Anticipated)	Interventional	2016-12-31	Enrolling by invitation
Open-Label, Single Arm Evaluation of BMS-790052 (Daclatasvir) in Combination With Peg-Interferon Alfa-2a and Ribavirin in Black-African Americans, Latinos and White-Caucasians With Chronic Hepatitis C Genotype 1 Infection [NCT01389323]	Phase 3	448 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1a Chronic Hepatitis [NCT01833533]	Phase 3	305 participants (Actual)	Interventional	2013-03-31	Completed
A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma [NCT03585725]	Early Phase 1	3 participants (Actual)	Interventional	2018-09-26	Terminated(stopped due to low accrual)
Suppressive Long-Term Antiviral Management of Hepatitis C Virus (HCV) and HIV-1 Coinfected Subjects (SLAM-C) [NCT00078403]	Phase 2	333 participants (Actual)	Interventional	2004-07-31	Completed
A Study to Evaluate Safety and Efficacy of Boceprevir-response Guided Therapy in Controlled HIV Patients With Chronic Hepatitis C Genotype 1 Infection Who Failed Previously to Peginterferon /Ribavirin Eudra CT2012-003984-23 [NCT01718301]	Phase 3	128 participants (Actual)	Interventional	2013-03-31	Completed
The SIM-SOF Trial: A Randomized Trial Comparing Simeprevir-Sofosbuvir Versus Peginterferon/Ribavirin/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype-1a-infected Patients With Cirrhosis [NCT02168361]	Phase 4	93 participants (Actual)	Interventional	2013-12-31	Completed
Long-Term Efficacy and Tolerance of Oral Ribavirin Compared to Placebo as a Preventative in Early Stages of Human Immunodeficiency Virus Infection - United States [NCT00002298]		0 participants	Interventional		Terminated
A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 Chronic Hepatitis C Subjects [NCT01754974]	Phase 3	40 participants (Actual)	Interventional	2013-03-31	Completed
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24 Weeks of Four-Drug Regimen and 24 Weeks of a Three-Drug Regimen of GS-9451, Peginterferon Alfa 2a (PEG, Pegasys®) and Ribavirin (RBV, Copegus®) With and Without Tegobuvir [NCT01271790]	Phase 2	245 participants (Actual)	Interventional	2010-10-31	Completed
Effectiveness and Tolerability of Hepatitis C Treatment in HIV Co-infected Patients in Routine Care Services in Asia: A Pilot Model of Care Project [NCT01838772]	Phase 4	188 participants (Actual)	Interventional	2013-12-31	Completed
A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of DEB025/Alisporivir in Combination With Peg-IFNα2a and Ribavirin in Hepatitis C Genotype 1 Treatment-naïve Patients [NCT01318694]	Phase 3	1,081 participants (Actual)	Interventional	2011-03-31	Completed
Effect of Infliximab in Hepatitis-C Genotype 1 Naïve Patients With High TNF-alpha on the Efficacy of Pegylated Interferon Alfa-2b/Ribavirin Therapy [NCT00237484]	Phase 3	89 participants (Actual)	Interventional	2005-07-18	Completed
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin in Subjects With Genotype 2 Hepatitis C, Who Relapsed After Previous Treatment [NCT01466192]	Phase 3	108 participants (Actual)	Interventional	2012-05-31	Completed
Phase IV Study of Treatment of Acute Hepatitis C With Pegylated Interferon [NCT00241618]	Phase 4	180 participants	Interventional	2002-01-31	Completed
An Open-Label, Randomized Study to Determine the Impact of Antiretroviral Treatment in HCV/HIV-Coinfected Subjects With High CD4+ Cell Count on the Efficacy of Hepatitis C Treatment With Pegylated Interferon Alfa-2A and Ribavirin [NCT00100581]		2 participants (Actual)	Interventional		Completed
A Phase 2 Study of VX-950 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C [NCT00262483]	Phase 2	12 participants	Interventional	2005-12-31	Completed
Randomized Placebo-Control Pilot Study Evaluating the Efficacy and Safety of Rosiglitazone Combined With Pegylated Interferon Plus Ribavirin Versus Pegylated Interferon Plus Ribavirin Alone in Genotype 1 Hepatitis C With Steatosis [NCT00274495]	Phase 4	30 participants (Anticipated)	Interventional	2006-01-31	Terminated
Pilot Study to Determine the Efficacy and Safety of Combining Boceprevir With Peginterferon Alfa-2b and Ribavirin in the Treatment-naive Patients Infected With Genotype 4 Chronic Hepatitis C Infection [NCT01653236]	Phase 3	40 participants (Anticipated)	Interventional	2013-12-31	Recruiting
Randomized, Controlled Study of Buprenorphine and Methadone in Hepatitis C Patients in Need of Treatment [NCT00279565]	Phase 4	128 participants	Interventional	2005-08-31	Terminated(stopped due to The trial was terminated because of deviations from the protocol.)
Randomized, Open-Label, Multicenter Study Examining the Effects of Duration of Treatment of PEGASYS® in Combination With Daily COPEGUS® + Amantadine in Patients With Chronic HCV After Relapse to Previous (Peg)IFN + Ribavirin Therapy. [NCT00299923]	Phase 3	300 participants	Interventional	2005-11-30	Active, not recruiting
A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) Plus Ribavirin Administered Daily for 48 Weeks Versus No Treatment in Hepatitis C Infected Patients Who Are Nonresponders to Pre [NCT00086541]	Phase 3	515 participants (Actual)	Interventional	2004-06-30	Completed
A Randomized, Phase IIb Clinical Trial to Evaluate the Safety and Antiviral Activity of NM283 and the Combination of Pegylated Interferon Plus NM283, in Patients With Chronic Hepatitis C Who Have Previously Failed to Respond to Standard Therapy [NCT00120861]	Phase 2	0 participants	Interventional	2005-01-31	Completed
Chronic Hepatitis C: Treatment of (Peg)Interferon Alpha - Ribavirin Non-Responders With Pegylated Interferon alpha2b, Ribavirin, AdoMet and Betaine [NCT00310336]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2006-08-31	Completed
Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and C Hepatitis Who Failed to Active Treatment for HCV. ANRSHC12 Fibrostop [NCT00122616]	Phase 3	52 participants (Actual)	Interventional	2003-11-30	Completed
[NCT01441804]	Phase 3	200 participants (Anticipated)	Interventional	2011-05-31	Recruiting
A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN [NCT00328549]	Phase 2	105 participants (Actual)	Interventional	2001-10-31	Completed
Randomized, Double-Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C [NCT00093093]	Phase 3	900 participants	Interventional	2004-06-30	Completed
A Phase II Randomized, Active-Controlled Study to Assess the Safety, Antiviral Effect, and Pharmacokinetics of Celgosivir in Combination With Peginterferon Alfa-2b and Ribavirin Over 12 Weeks in Treatment-Naïve Patients With Chronic Hepatitis C [NCT00332176]	Phase 2	50 participants (Anticipated)	Interventional	2006-06-30	Recruiting
A Pilot Study to Treat Patients With Chronic HCV Genotype 1 and ESRD Receiving Hemodialysis and Naïve to Prior HCV Therapy With Peginterferon Alfa-2b, the Maximally Tolerated Ribavirin Dose and Boceprevir [NCT01731301]	Phase 4	20 participants (Anticipated)	Interventional	2013-01-31	Not yet recruiting
An Open-label, Single-arm, Roll-over Trial of Telaprevir in Combination With Pegylated Interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) for Subjects From the Control Group of the VX- 950-TiDP24-C216 Trial Who Failed Therapy for Virologic Reasons [NCT01054573]	Phase 3	90 participants (Actual)	Interventional	2010-04-30	Completed
An Open-Label Trial of Pegylated Interferon Plus Ribavirin in Combination With CTS-1027 in HCV Null-Responders [NCT01051921]	Phase 2	67 participants (Actual)	Interventional	2010-01-31	Completed
A Pilot Study of Treatment With Pegylated Interferon-Alpha2a, Ribavirin and Insulin Sensitizer Pioglitazone of Insulin Resistance (With the Exception of Diabetes) in Hepatitis C Virus Infection (The INSPIRED HCV Study) [NCT00433069]	Phase 2	5 participants (Actual)	Interventional	2007-01-31	Completed
Pilot, Multicenter, Randomized Study on Lopinavir/Ritonavir-Monotherapy vs Lopinavir/Ritonavir Plus Selected Nucs, in HIV/HCV ARV-Naive Coinfected Patients With Chronic Hepatitis C or Compensated Cirrhosis, Starting Treatment With Ribavirin and Pegylated [NCT00437476]	Phase 3	60 participants (Anticipated)	Interventional	2007-02-28	Recruiting
[NCT00466219]	Phase 3	25 participants	Interventional	2002-05-31	Completed
Individually Adapted Therapy Duration From 24 to 72 Weeks for the Treatment of a Chronic Hepatitis C Genotype 1 Infection With Peginterferon Alfa-2b Plus Ribavirin in Dependence of the Initial Concentration and the Decline of the HCV RNA [NCT00351403]	Phase 4	390 participants (Anticipated)	Interventional	2006-07-31	Completed
Influence of Marker of Insulin Resistance Upon HCV Treatment Responses to PEG Intron and Rebetol Therapy [NCT00351871]	Phase 4	400 participants (Actual)	Interventional	2002-04-30	Completed
A Phase 2b, Randomized, Multi-Center, Active-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Albuferon (Recombinant Human Albumin-Interferon Alfa Fusion Protein) in Combination With Ribavirin in Interferon Alfa Naive Subjects With Chro [NCT00115908]	Phase 2	458 participants (Actual)	Interventional	2005-05-31	Completed
An Open Label Study to Evaluate the Safety and Effect on Sustained Virological Response of PEGASYS Plus Ribavirin in Patients With Hemophilia A and Chronic Hepatitis C [NCT00475072]	Phase 4	14 participants (Actual)	Interventional	2003-06-30	Completed
A Pilot Study to Evaluate the Efficacy and Safety of Pegylated Interferon Alfa-2b Plus Ribavirin in the Treatment of Patients With Dual Chronic Hepatitis B and Delta [NCT00117533]	Phase 4	20 participants	Interventional	2005-09-30	Recruiting
An Open Label Non-Randomized Trial to Assess Safety and Tolerability of Alb-Interferon Alfa 2b Every Two Weeks With Ribavirin Among HIV/HCV Coinfected Individuals [NCT00489385]	Phase 1	41 participants (Actual)	Interventional	2007-06-18	Completed
Phase 4 Comparative Study of Pegasys vs Peg-Intron for Treatment of Chronic Hepatitis C Genotype 4 [NCT00502099]	Phase 4	217 participants (Actual)	Interventional	2006-01-31	Completed
An Open Label, Comparative, Multi-Center Study, to Evaluate the Efficacy and Safety of Peginterferon Alfa-2a Plus Ribavirin in the Treatment of Patients With Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C [NCT00154869]	Phase 3	320 participants (Anticipated)	Interventional	2004-06-30	Recruiting
Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever (Crimean-Congo Hemorrhagic Fever or Lassa Fever) [NCT02483260]		30 participants (Anticipated)	Interventional	2016-06-16	Recruiting
A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection [NCT00143000]	Phase 4	392 participants (Actual)	Interventional	2004-04-30	Completed
Pilot Study on Interferon Gamma in Association With Peg-Interferon Alpha 2a and Ribavirin Among Patients With a Chronic Hepatitis C and Non Responders to the Association of Peg-Interferon Alpha 2b or 2a and Ribavirin ANRS HC16 Gammatri [NCT00148863]	Phase 2	65 participants	Interventional	2004-06-30	Completed
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Versus Pegylated Interferon Alfa-2a Alone for Treatment-naïve Hemodialysis Patients With Chronic Hepatitis C [NCT00491244]	Phase 4	377 participants (Actual)	Interventional	2007-06-30	Completed
Efficacy of Ombitasvir With Paritaprevir/Ritonavir Plus Ribavirin on the Treatment naïve Patients With Chronic Hepatitis C Virus Genotype 4 [NCT04378608]	Phase 1/Phase 2	100 participants (Actual)	Interventional	2017-01-05	Completed
A Greek Observational Study on Relapse Rate and Sustained Virological Response in Naive CHC Patients, Treated With Pegylated Interferon Alpha-2b and Ribavirin in Daily Clinical Practice [NCT00724464]		332 participants (Actual)	Observational	2007-12-31	Completed
Sustained Viral Response Rate in 100 Subjects With Cirrhosis Due to Hepatitis C Treated With 12 Weeks of Sofosbuvir, Daclatasvir and Ribavirin [NCT02596880]	Phase 3	100 participants (Actual)	Interventional	2015-09-30	Completed
A Randomized, Multicenter, Double Blinded Study Comparing the Safety and Efficacy of Pegasys® 180 ug Plus Copegus® 1000 or 1200 mg to the Currently Approved Combination of Pegasys® 180 ug Plus Copegus® 800 mg in Interferon-naïve Patients With Chronic Hepa [NCT00353418]	Phase 4	415 participants (Actual)	Interventional	2006-06-30	Completed
A Phase 3 Study of MP-424 in Combination With Peginterferon Alfa-2b and Ribavirin, in Subjects With Genotype 2 Hepatitis C, Who Did Not Respond to Previous Treatment [NCT01468584]	Phase 3	10 participants (Actual)	Interventional	2011-11-30	Completed
A Randomized Phase III Study To Evaluate The Safety And Efficacy Or Ribavirin Inhaled Solution In Preventing Progression Of Upper Respiratory Tract Respiratory Syncytial Virus (RSV) Infection To RSV Pneumonia In Blood And Bone Marrow Transplant (BMT) Reci [NCT00016081]	Phase 3	0 participants	Interventional	1998-03-31	Completed
Early Prediction of Successful Treatment for Chronic Hepatitis C Virus Infection in Taiwan [NCT00543244]		300 participants (Anticipated)	Observational	2006-01-31	Recruiting
A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) Plus Ribavirin Administered Daily for 48 Weeks Versus No Treatment in Hepatitis C Infected Patients Who Are Nonresponders to Pre [NCT00162734]	Phase 3	144 participants (Actual)	Interventional	2005-02-28	Completed
Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C Non 2 -3 Genotype naïve Patients Treated With a 12 Weeks Bitherapy of Peginterferon Alpha 2a-Ribavirin, and Followed by a Tritherapy of Peginterferon Alpha 2a-Ribavirin [NCT00199719]	Phase 2	30 participants (Actual)	Interventional	2003-06-30	Completed
Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers [NCT00211848]	Phase 2	207 participants (Anticipated)	Interventional	2000-06-30	Completed
HRN 003PEG-Interferon a-2b + Ribavirin for Treatment of Patients With Chronic Hepatitis C Who Have Previously Failed to Achieve a Sustained Virologic Response Following Interferon Alfa or Interferon a-2b + Ribavirin Therapy [NCT00215865]	Phase 3	600 participants	Interventional		Completed
Pilot Study of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin for the Treatment of Chronic Hepatitis C in HIV-HCV Coinfected Patients Non Responders to Three Months of Therapy With Pegylated Interferon Alpha 2a and Ribavirin. ANRS HC09 SE [NCT00196586]	Phase 2	75 participants	Interventional	2003-04-30	Completed
PEG-Interferon a-2b + Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon [NCT00215891]	Phase 3	300 participants	Interventional		Completed
Antiviral Effect of 4 Regimens of PEGASYS Plus Copegus in Patients With Genotype 1 Chronic Hepatitis C Non-responder to Previous Peginterferon Alfa-2a Plus Ribavirin Therapy [NCT00412334]	Phase 4	104 participants (Actual)	Interventional	2007-01-31	Completed
Randomized Placebo-Controlled Trial of a Triple Therapy Combining Peginterferon Alfa-2a Plus Ribavirin Plus Amantadine Versus Peginterferon Alfa-2a Plus Ribavirin Plus Placebo in Hepatitis C-Infected Patients Non Responders to a First-Line Therapy of Inte [NCT00221624]	Phase 3	131 participants (Actual)	Interventional	2001-11-30	Completed
COPE-HCV: Continuous Interferon Delivery Via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV [NCT00919633]	Phase 2	116 participants (Actual)	Interventional	2009-06-30	Completed
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Tolerability of TMC435 vs Placebo as Part of a Treatment Regimen Including Peginterferon α-2a and Ribavirin in Hepatitis C, Genotype 1 Infected Subjects [NCT01281839]	Phase 3	394 participants (Actual)	Interventional	2011-02-28	Completed
A Phase 2b Study of Daclatasvir in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 1 and 4 Infection [NCT01125189]	Phase 2	558 participants (Actual)	Interventional	2010-07-31	Completed
Efficacy and Safety of Continuing for a Total of 48 or Prolonging for a Total of 72 Weeks of Combined Treatment of Patients Receiving Pegasys and Copegus Who Are Biochemical Responders But Virological Non-Responders at Week 12 or Week 24 [NCT00336518]	Phase 3	100 participants	Interventional	2006-06-30	Recruiting
A Pilot, Open Label, Multicenter, Randomized Clinical Trial on Lopinavir/Ritonavir-Monotherapy vs Lopinavir/Ritonavir Plus Selected Nucs, in HIV/HCV Coinfected Patients With Chronic Hepatitis C or Compensated Cirrhosis, Starting Treatment With Ribavirin a [NCT00437684]	Phase 3	50 participants (Anticipated)	Interventional	2007-02-28	Recruiting
Efficacy and Safety of High-dose Ribavirin (1600 mg/d) Boosted With Epoetin β (450 IU/kg/wk) in HIV/HCV Coinfected Patients Not Responding to Previous Treatment Regimens [NCT00470210]	Phase 4	10 participants (Actual)	Interventional	2007-05-31	Completed
Open-Label, Phase 3b Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Virus Treatment-Naïve and Treatment-Experienced Subjects With Genotype 1 Chronic Hepatitis C and Human Immunodeficiency Vi [NCT01513941]	Phase 3	163 participants (Actual)	Interventional	2012-04-30	Completed
24 VS 48-WEEK TREATMENT WITH PEG-IFN ALPHA-2A IN PATIENTS WITH GENOTYPE 2/3 CHRONIC HEPATITIS C, RELAPSERS TO PEG-IFN + RIBAVIRIN TREATMENT. A RANDOMIZED CONTROLLED TRIAL [NCT01517308]	Phase 3	0 participants (Actual)	Interventional	2012-05-31	Withdrawn(stopped due to Time elapsed to require permissions and a recent paper showed a high efficacy of a 48-week regimen in this setting. It seems non-ethical to start this trial)
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland [NCT02582671]		101 participants (Actual)	Observational	2015-11-05	Completed
[NCT02556307]		270 participants (Actual)	Observational	2009-03-31	Completed
A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients [NCT00867139]	Phase 1/Phase 2	7 participants (Actual)	Interventional	2009-03-31	Completed
A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-5172 in Participants With Chronic Hepatitis C [NCT01547312]	Phase 1	0 participants (Actual)	Interventional	2012-05-31	Withdrawn
Peginterferon Alfa-2a and Ribavirin Combination Therapy in Patients With HBeAg-negative Chronic HBV Infection (PARC Study) [NCT00114361]	Phase 3	138 participants (Actual)	Interventional	2005-03-31	Completed
Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous HCV Non Responders ANRSHC03 BITRI [NCT00122629]	Phase 3	405 participants	Interventional	2000-10-31	Terminated
A Multicenter, Open-label, Randomized, 2-arm, Phase II Trial of Pharmacodynamics, Pharmacokinetics and Safety of Two Dose Regimens of DEB025/Alisporivir in Combination With Ribavirin Therapy in Chronic Hepatitis C Genotype 2 and 3 Patients Who Have Previo [NCT02094443]	Phase 2	52 participants (Actual)	Interventional	2014-03-31	Completed
The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients [NCT01770483]	Phase 4	66 participants (Actual)	Interventional	2011-07-31	Completed
Safety, Efficacy, and Changes in Traditional and Novel Biomarkers of Kidney Function in Patients With Hepatitis C and Advanced Chronic Kidney Disease Treated With Abbvie Viekira Pak or Mavyret Regimen [NCT02946034]	Phase 4	10 participants (Actual)	Interventional	2017-02-01	Completed
[NCT00062816]	Phase 1/Phase 2	22 participants	Interventional	2003-06-30	Completed
A Phase II, Multi-center, Open Label, Randomized Study of Ribavirin and Hedgehog Inhibitor With or Without Decitabine in Acute Myeloid Leukemia (AML) [NCT02073838]	Phase 2	23 participants (Actual)	Interventional	2015-05-31	Completed
A Randomized Phase III Study to Evaluate the Safety and Efficacy of Ribavirin Inhaled Solution in Preventing Progression of Upper Respiratory Tract Respiratory Syncytial Virus Infection to RSV Pneumonia in Blood and Bone Marrow Transplant (BMT) Recipient [NCT00031473]	Phase 3	90 participants	Interventional	1997-11-30	Terminated
An Open-Label Study to Evaluate the Efficacy, Safety and Tolerability of Ribavirin Monotherapy Followed by Combined Treatment With Ribavirin and Hydroxychloroquine in Patients Infected With Hepatitis C [NCT01833845]	Phase 1/Phase 2	4 participants (Actual)	Interventional	2013-04-30	Terminated(stopped due to due to failure to recruit subjects)
A Prospective Multicenter, Phase II, Open Label, Controlled Trial Evaluating the Response of Hepatitis C Virus (HCV) to Pegylated Interferon Alpha-2A and Ribavirin in Hemophilic Patients With and Without Coinfection With the Human Immunodeficiency Virus ( [NCT00055341]	Phase 2	22 participants	Interventional	2002-03-31	Completed
Pharmacological Interactions Between Zidovudine and Ribavirin in HCV-HIV Co-Infected Patients Treated With Rebetron or Peg-Intron Plus Ribavirin [NCT00059358]	Phase 1/Phase 2	16 participants (Anticipated)	Interventional	2001-09-30	Completed
Comparison of PEG-Intron 1.5µg/kg/wk Plus REBETOL vs PEG-Intron 1µg/kg/wk Plus REBETOL vs PEGASYS 180µg/wk Plus COPEGUS in Previously Untreated Adult Subjects With Chronic Hepatitis C Infected With Genotype 1 [NCT00081770]	Phase 3	4,469 participants (Actual)	Interventional	2004-03-31	Completed
A Multi-Center, Randomized, Open-Label, Phase IIIb Study Investigating the Safety and Efficacy of Peginterferon a-2a Plus Ribavirin for the Treatment of Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic [NCT00215839]	Phase 3	0 participants	Interventional		Active, not recruiting
Evaluation of a Multi-disciplinary Approach for the Treatment of Hepatitis C in IDUs (HI-LO Study) [NCT00399672]		370 participants (Actual)	Interventional	2007-06-30	Completed
Effects of Metformin, Pegylated Interferon Alpha and Ribavirin for Chronic Hepatitis C With Insulin Resistance [NCT01664845]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2012-08-31	Recruiting
HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a Methadone Maintenance Treated (MMT) Opioid Addicted Group. [NCT00147784]	Phase 3	10 participants (Anticipated)	Interventional	2006-03-31	Completed
Randomized Double Blind Trial Comparing the Efficacy of Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b and Ribavirin for Initial Treatment of Patients With Hepatitis C With Genotype 1 or 4 and Severe Fibrosis [NCT00148837]	Phase 2	112 participants (Actual)	Interventional	2004-09-30	Active, not recruiting
Analysis of the Duration of Combination Therapy That is Necessary for HCV Genotype 1 Eradication [NCT00152581]	Phase 4	40 participants	Interventional	2002-04-30	Completed
A Phase II Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV Infected Subjects With HIV Disease [NCT00051077]	Phase 2	0 participants (Actual)	Interventional		Withdrawn
Tacrolimus Monotherapy in OLT Recipients With HCV Under Preemptive Treatment With Interferon and Ribavirin [NCT00167557]	Phase 4	0 participants (Actual)	Interventional	2005-01-31	Withdrawn(stopped due to The PI left the institution.)
#0810010040: Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus Infection: A Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects With Hepatitis C [NCT00892697]	Phase 2	15 participants (Actual)	Interventional	2009-05-31	Completed
Safety and Tolerability of Consensus Interferon-Alpha (CIFN) Plus Interferon Gamma-1b (IFN-γ 1b) With or Without Ribavirin (RBV) in the Treatment of Patients With Chronic Hepatitis C Who Are Non-Responders to PEG-IFN-a (2a or 2b) Plus RBV [NCT00084279]	Phase 2	81 participants (Actual)	Interventional	2004-04-30	Completed
Efficacy and Safety of Peginterferon alfa2a and Ribavirin for the Second Line Treatment of Chronic Hepatitis C in HIV Infected Patients Previously Non Responders to a First Anti-HCV Treatment [NCT00221650]	Phase 2	17 participants (Actual)	Interventional	2002-04-30	Completed
Safety and Efficacy of Boceprevir in Combination With Peginterferon Plus Ribavirin for Treatment of Asia Pacific Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Pegylated Interferon Plus Ribavirin [NCT01390844]	Phase 3	282 participants (Actual)	Interventional	2011-10-21	Completed
Randomized, Multicenter, Double-blinded, Phase IV Study Evaluating the Efficacy (as Measured by Sustained Virological Response) and Safety of 360 μg Induction Dosing of Pegasys® in Combination With Higher Copegus® Doses in Treatment-naïve Patients With Ch [NCT00394277]	Phase 4	1,175 participants (Actual)	Interventional	2007-02-28	Completed
A Phase III Randomised, Partially Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Chronic Genotype 1 Hepatitis C Infection in an Extended Population of Treatment naïve Patients That Includes Those I [NCT01728324]	Phase 3	496 participants (Actual)	Interventional	2012-11-30	Completed
Boceprevir/Peginterferon Alfa (PegIFN α)-2b/Ribavirin (Riba) in Difficult-to-Treat Menopausal Women With Chronic Hepatitis C Genotype 1 (Gt 1), Either Deemed Nonresponders to Peginterferon/Ribavirin or Treatment-naives (MEN_BOC) [NCT01457937]	Phase 3	240 participants (Anticipated)	Interventional	2011-11-30	Recruiting
Study to Evaluate Response Rates in Chronic Hepatitis C (CHC) Patients Genotype 1 With Insulin Resistance and to Assess Prolonged Treatment Duration in Late Virological Responders [NCT00493805]	Phase 4	59 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to Slow Enrollment)
Sofosbuvir in Combination With Ribavirin or Simeprevir: Real-life Study of Patients With Hepatitis C Genotype 4 [NCT04385407]	Phase 2	203 participants (Actual)	Interventional	2015-04-30	Completed
A Randomized Study to Evaluate the Safety and Efficacy of Adding Daclatasvir to the Combination of Sofosbuvir (SOF) and Ribavirin (RBV) for 16 Weeks Versus 24 Weeks in Cirrhotic Subjects With Chronic Hepatitis C Infection Genotype 3 [NCT02304159]	Phase 4	39 participants (Actual)	Interventional	2015-01-31	Completed
Evaluation of Satisfaction in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C [NCT00704717]		185 participants (Actual)	Observational	2005-09-30	Completed
Evaluation of Adherence Rate in Patients Receiving PegIntron Pen / Rebetol for Hepatitis C [NCT00705107]		267 participants (Actual)	Observational	2004-11-30	Terminated
An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection [NCT04276688]	Phase 2	127 participants (Actual)	Interventional	2020-02-10	Completed
LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients [NCT02631772]	Phase 4	32 participants (Actual)	Interventional	2016-06-01	Completed
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study on Efficacy and Safety of DEB025 Combined With Peg-IFN Alfa-2a and Ribavirin in Chronic Hepatitis C Genotype 1 Relapsers and Non-responders to Previous Peg-IFN Alfa [NCT01183169]	Phase 2	459 participants (Actual)	Interventional	2010-08-31	Completed
A Randomized, Single Oral Dose, Two-way Crossover, Open-label, Laboratory Blind, Bioequivalence Study Comparing Ribavirin From Two Different Drug Products After Oral Administration to Healthy Adult Subjects Under Fed Conditions [NCT05532306]	Phase 1	36 participants (Actual)	Interventional	2020-10-11	Completed
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-5172 + MK-3682 + MK-8408 Fixed Dose Combination (FDC)) in Subjects With Chronic HCV GT1 or GT3 Infection Who Have Failed a Direct [NCT02613403]	Phase 2	94 participants (Actual)	Interventional	2015-12-10	Terminated
A Multi-center, Placebo-controlled, Multiple Dose, Study of the Safety and Pharmacokinetics and Pharmacodynamics of INX-08189 Dosed Either QD, BID or Adjunctively With Ribavirin, and a Study of the Food Effect, in Chronically-infected Genotype 1 HCV, Trea [NCT01445795]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized, Double-blinded, Multicenter Study to Evaluate the Antiviral Efficacy and Safety of Adding the HCV Polymerase Inhibitor Prodrug (RO5024048) for 24 Weeks to the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naïve Patient [NCT01057667]	Phase 2	168 participants (Actual)	Interventional	2010-02-28	Completed
Simeprevir (SMV) + Sofosbuvir (SOF) With or Without Ribavirin (RBV) for Interferon-intolerant or Ineligible (IFN-II) Patients With Chronic Hepatitis C (CHC) [NCT02214420]	Phase 4	24 participants (Actual)	Interventional	2014-10-31	Completed
Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever: A Randomized Controlled Open Label Phase II Clinical Trial [NCT04907682]	Phase 2	40 participants (Actual)	Interventional	2021-07-30	Completed
A Phase I Study of Low Dose Interleukin 2 (IL-2)Monotherapy, Followed by IL-2 Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I Infection [NCT00277758]	Phase 1	18 participants (Actual)	Interventional	2004-03-31	Terminated(stopped due to Insufficient rate of volunteer accrual.)
A Multicentre Phase III Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects [NCT00249860]	Phase 3	257 participants (Actual)	Interventional	2002-09-30	Completed
Direct Acting Antiviral (DAA) Based Therapy for Recently Acquired Hepatitis C [NCT01743521]	Phase 4	14 participants (Actual)	Interventional	2013-01-31	Completed
An Open-Label Re-Treatment Study With PegInterferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C [NCT01428063]	Phase 2	276 participants (Actual)	Interventional	2011-09-30	Completed
A Phase 4 Open-Label Pilot Study of the Safety and Tolerability of High Dosage of CIFN Plus RBV Administered Daily for 48 Weeks in HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Pegylated Interferon Alfa Plus RBV Therapy [NCT00266318]	Phase 4	40 participants	Interventional	2005-12-31	Completed
Outcome of Decompensated Hepatitis C Virus-Related Cirrhotic Patients Treated With Peginterferon Alfa-2b and Ribavirin: Results of a Controlled Study [NCT00301509]	Phase 2/Phase 3	0 participants	Interventional	2002-01-31	Completed
A Phase I/II, Open Clinical Trial to Assess the Safety, Tolerability and Efficacy of a Fixed Dose Combination Therapy of: Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN Alpha-2a) and Ribavirin (RBV) in Chronic Hepatitis C Genotype 1 Infe [NCT01272310]	Phase 1/Phase 2	36 participants (Anticipated)	Interventional	2011-01-31	Not yet recruiting
Role of Rapid Virologic Response in Determining Treatment Duration of Peginterferon Alfa-2b/Ribavirin in Chronic Hepatitis C Genotype 4 [NCT00277862]	Phase 4	280 participants (Actual)	Interventional	2002-04-30	Completed
Comparison of PEG Interferon Alfa-2b Plus Ribavirin Given as a Fixed Dose or on a Weight Optimized Basis for Treatment of Chronic Hepatitis C in Previously Untreated Adult Subjects [NCT00299936]	Phase 3	5,000 participants	Interventional		Completed
14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response [NCT00308048]	Phase 3	435 participants	Interventional	2004-03-31	Completed
Randomized Study of Nitazoxanide-Peginterferon, Nitazoxanide-Peginterferon-Ribavirin and Peginterferon-Ribavirin in the Treatment of Chronic Hepatitis C [NCT00421434]	Phase 2/Phase 3	121 participants (Actual)	Interventional	2006-06-30	Completed
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy [NCT05717400]	Phase 4	15 participants (Anticipated)	Interventional	2023-02-07	Recruiting
Multicenter, Open-label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirrhosis [NCT01508286]		0 participants	Expanded Access		No longer available
Phase 2b Evaluation of PegIFNα Free Combinations of BMS-986094 (INX-08189) and Daclatasvir, With or Without Ribavirin, in Treatment Naive and Treatment Experienced Patients With Chronic Hepatitis C [NCT01629732]	Phase 2	0 participants (Actual)	Interventional	2013-03-31	Withdrawn
A Pilot Study of Ribavirin for Patients With Recurrent/Metastatic (R/M) Human Papillomavirus (HPV)-Related Malignancies [NCT02308241]		12 participants (Actual)	Interventional	2014-12-02	Completed
A Randomized, Open-lable, Multicenter, Parallel Group Study to Compare SVR Rate of Pegasys Plus Ribavirin for 48 Weeks vs. 36 Weeks in Patients With Chronic Hepatitis C [NCT01639547]		410 participants (Anticipated)	Interventional	2012-07-31	Terminated(stopped due to early termination due to difficult collection of patients)
Phase 3 Open Label Study Evaluating the Efficacy and Safety of Pegylated Interferon Lambda-1a, in Combination With Ribavirin and Daclatasvir, for Treatment of Chronic HCV Infection With Treatment naïve Genotypes 1, 2, 3 or 4 in Subjects Co-infected With H [NCT01866930]	Phase 3	453 participants (Actual)	Interventional	2013-07-11	Terminated(stopped due to Sponsor decision not based on any new unexpected safety findings or efficacy observations.)
PREDICT (Part 2)- Prospective Observational Study Of A Cohort Of Naïve Patients With Chronic Hepatitis C Infected With HCV Genotype 1 Low Viral Load (HCV LVL 1) And Treated With Peg-Intron 1.5 ug/Kg/Week Plus Rebetol 800-1200 mg/Day Who Achieved A Negativ [NCT01054742]		2 participants (Actual)	Observational	2009-12-31	Completed
Vitamin D in Addition to Pegylated Interferon and Ribavirin Compared to Pegylated Interferon and Ribavirin Alone in the Treatment of Chronic Hepatitis C Genotype 4. [NCT01655966]	Phase 3	80 participants (Anticipated)	Interventional	2012-05-31	Active, not recruiting
Cost of Treatment of Chronic Hepatitis C Using Combination of Peginterferon α-2b Plus Ribavirin [NCT00723632]		901 participants (Actual)	Observational	2005-09-30	Completed
INFORM-SVR: A Randomized, Multi-Center Study of Interferon-Free Treatment With a Combination of a Polymerase Inhibitor (RO5024048) and a Ritonavir Boosted HCV Protease Inhibitor (RO5190591/r, DNV/r) With or Without Copegus® in Interferon Naïve HCV Genotyp [NCT01278134]	Phase 2	170 participants (Actual)	Interventional	2011-02-28	Completed
RCT Comparing Different Ribavirin Dosages and Durations of Treatment in Combination With Peginterferon in HCV Genotypes 2 and 3 (WRITE) [NCT01380938]	Phase 3	1,150 participants (Actual)	Interventional	2018-12-01	Completed
A Bioequivalence Study of Ribavirin Oral Solution (RO0209963) Versus the Reference Ribavirin Tablets (Copegus) Following Oral Administration in Healthy Adult Subjects [NCT01697436]	Phase 1	40 participants (Actual)	Interventional	2012-09-30	Completed
A Double Blind Placebo Controlled Randomized Trial of Ribavirin in Patients With Acute on Chronic Liver Failure Due to Hepatitis E Virus [NCT01698723]	Phase 2	40 participants (Anticipated)	Interventional	2012-09-30	Recruiting
Evaluate the Efficacy and Safety of TG-2349 in Combination With Peg-interferon and Ribavirin in Treatment naïve East Asian Subjects With Chronic Hepatitis C Virus Genotype 1b Infection. [NCT02340962]	Phase 2	25 participants (Actual)	Interventional	2015-05-31	Completed
A Phase 2, Multicenter, Dose-Ranging Study to Evaluate the Safety and Efficacy of VX-135 With Ribavirin in Treatment-Naïve Subjects With Chronic Hepatitis C [NCT01726946]	Phase 2	10 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized, Open-Label, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-493 and ABT-530 in Adult Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection [NCT01995071]	Phase 2	89 participants (Actual)	Interventional	2013-11-30	Completed
Is Hepcidin a Possible Contributor to Impaired Iron Mobilization and Anaemia in Hepatitis C Patients Treated With Pegylated Interferon Alpha and Ribavirin Therapy? A Pilot Study [NCT01726400]		15 participants (Actual)	Observational	2012-12-31	Completed
Effect and Safety of Xiao'er Jiebiao Oral Liquid in Combination With Standard Treatment on Hand-foot-mouth Disease in Pediatric Patients [NCT02328651]	Phase 4	24 participants (Actual)	Interventional	2014-10-31	Completed
STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTIVIRAL ACTIVITY OF RITONAVIR-BOOSTED DANOPREVIR IN COMBINATION WITH PEGINTERFERON ALFA-2A PLUS RIBAVIRIN IN TREATMENT-NAÏVE PATIENTS OF ASIAN ORIGIN WHO HAVE CHRONIC HEPATITIS C GENOTYPE 1 W [NCT01749150]	Phase 2	61 participants (Actual)	Interventional	2013-04-30	Completed
Open-Label, Randomized Study of Daclatasvir, Sofosbuvir, and Ribavirin for 12 vs. 16 Weeks in Treatment Naive and Treatment Experienced Patients With Genotype 3 Chronic Hepatitis C Infection Subjects With Compensated Advanced Fibrosis/Cirrhosis (F3/F4) [NCT02319031]	Phase 3	53 participants (Actual)	Interventional	2015-02-28	Completed
An Open Label Study Assessing SVR and Viral Resistance Profile With Boceprevir Plus PEG-IFN Plus Ribavirin Triple Therapy in HCV-1 Infected Patients With Insulin Resistance Who Have Failed PEG-IFN Plus Ribavirin Dual Therapy [NCT01770223]	Phase 4	0 participants (Actual)	Interventional	2014-01-31	Withdrawn
An Expanded Access Phase 2 Study of Sofosbuvir With Ribavirin and With or Without Pegylated Interferon for 24 Weeks in Subjects Who Have Undergone Liver Transplantation and Who Have Aggressive, Recurrent Hepatitis C Infection [NCT01779518]		0 participants	Expanded Access		Approved for marketing
Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan [NCT00495131]	Phase 4	308 participants (Actual)	Interventional	2006-06-30	Completed
Pharmacovigilance Study of the Interferon α 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigilância da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utiliz [NCT01841775]	Phase 4	85 participants (Actual)	Interventional	2009-05-31	Completed
A Phase 3, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin Administered for 12 Weeks in Treatment-Naïve Subjects With Chronic Genotype 1 or Genotype 4 HCV Infection [NCT01846832]	Phase 3	232 participants (Actual)	Interventional	2013-09-30	Completed
A Phase2/3, Multi-center, Randomized, Double-blind, Placebo-parallel Controlled Study to Investigate the Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Genotype [NCT03362814]	Phase 2/Phase 3	425 participants (Actual)	Interventional	2017-07-01	Completed
An Open Label,Phase 3 Study of Telaprevir in Combination With Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Coinfected With Genotype 1 Hepatitis C Virus and Human Immunodeficiency Virus Type 1(HCV/HIV-1) [NCT01467479]	Phase 3	185 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy endpoint as part of a decision to modify drug development plan.)
A Phase IV, Open-label, Multicentre, International Trial of Response Guided Treatment With Directly Observed Pegylated Interferon Alfa 2b (PEG-IFN-alfa 2b) and Self Administered Ribavirin (RBV) for Patients With Chronic HCV Genotype 2 or 3 and Injection D [NCT01364090]	Phase 4	93 participants (Actual)	Interventional	2012-06-30	Completed
A Pilot Study on the Efficicay and Safety of Pegylated Interferon, Ribavirin and Telaprevir in Recurrent Hepatitis C Virus (HCV) Infection in Orthotopic Liver Transplant (OLT) Recipients. [NCT01592006]	Phase 4	3 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to Low accrual)
Randomized Open Label Study to Assess the Efficacy and Safety of Short Course Therapy (24 Weeks) With Peginterferon Alpha-2b and Ribavirin for Chronic Hepatitis C (Genotype 4) Patients Who Achieve a Rapid Virological Response (HCV -RNA Undetectable at Wee [NCT01606800]	Phase 4	45 participants (Actual)	Interventional	2013-01-01	Terminated(stopped due to The trial was terminated due to change in new standard of therapy during the study period.)
An Open-Label, Treatment Duration-Ranging Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/ Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Direct-Acting Antivira [NCT02399345]	Phase 3	10 participants (Actual)	Interventional	2015-03-31	Completed
A Phase II Multicenter, Parallel-Group, Randomized, Dose-Ranging Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Following 12 Weeks of Oral Administration of GSK2336805 With Pegylated Interferon and Ribavirin in Treat [NCT01648140]	Phase 2	286 participants (Actual)	Interventional	2012-08-01	Completed
A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen MK-5172 and MK-8742 ± Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection [NCT01717326]	Phase 2	573 participants (Actual)	Interventional	2013-02-07	Completed
Open-Label, Bridging Study to Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Treatment- Naïve and Treatment-Experienced Russian Subjects With Genotype 1 Chronic Hepatitis C [NCT01498068]	Phase 3	36 participants (Actual)	Interventional	2012-01-31	Completed
A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients [NCT00000699]	Phase 1	20 participants	Interventional		Completed
Response to Pegylated Interferon and Ribavirin in Chinese Patients With Chronic [NCT01433887]	Phase 3	535 participants (Actual)	Interventional	2011-11-30	Completed
Study of Parameters of Early Hepatitis C Virus Dynamics for Predicting the Outcome of Standard Interferon Therapy With Chinese Cohort [NCT01434212]		40 participants (Anticipated)	Observational	2010-05-31	Active, not recruiting
A Single Center, Prospective Phase IV, Open-Label, Randomized Trial Comparing the Efficacy , Tolerability, and Safety of Quadritherapy Regimen (Reiferon Retard® + Ribavirin + Nitazoxanide + Alfacalcidol ( Bon-One ®) ) Versus Triple Therapy Regimen (Reifer [NCT01896609]	Phase 4	300 participants (Anticipated)	Interventional	2013-06-30	Recruiting
Directly Observed Hepatitis C Treatment in Methadone Clinics [NCT01442311]		80 participants (Actual)	Interventional	2007-10-31	Completed
A Double-Blinded Randomized Control Study Evaluating the Efficacy and Safety of Pegylated Lambda Interferon Compared to Pegylated Alfa-2a Interferon, Each in Combination With Ribavirin, in the Treatment of Naive Genotype 1 or 4 Chronic Hepatitis C Subject [NCT01447394]	Phase 3	0 participants (Actual)	Interventional	2012-03-31	Withdrawn
A Phase II Study of Pembrolizumab (MK-3475) in Hepatitis C Virus Positive and Negative Subjects With Advanced Hepatocellular Carcinoma Who Progressed on or Were Intolerant to First-Line Systemic Therapy [NCT02940496]	Phase 2	12 participants (Actual)	Interventional	2016-12-09	Completed
An Open Labelled, Active Controlled, Three Arm, Parallel- Group Study of the Safety and Efficacy of Renessans Administered Alone and in Combination With Standard Interferon Therapy in Patients Chronic HCV Hepatitis [NCT01463592]	Phase 3	90 participants (Actual)	Interventional	2010-06-30	Active, not recruiting
Pilot Study on the Efficacy of Pegylated Interferon-Ribavirin-Boceprevir Triple Therapy in Patients Infected With Genotype 1 HCV With Cirrhosis and Awaiting Liver Transplantation (ANRS HC 29 BOCEPRETRANSPLANT) [NCT01463956]	Phase 2	58 participants (Actual)	Interventional	2012-01-06	Completed
The Predictive Values of Rapid Virus Response and Complete Early Virus Response for Sustained Virus Response in Chronic Hepatitis C Treated With Individual Therapeutic Programme [NCT01464008]		297 participants (Actual)	Observational	2004-01-31	Completed
Pharmacokinetic Interactions of Ribavirin and Abacavir in Hepatitis-C Mono-infected Male Subjects Who Previously Failed Ribavirin-based Treatment [NCT01052701]	Phase 1	26 participants (Actual)	Interventional	2009-12-31	Completed
An Open-Label Study to Evaluate the Safety and Efficacy of VIRAZOLE® (RIBAVIRIN FOR INHALATION SOLUTION, USP) in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19 [NCT04356677]	Phase 1	0 participants (Actual)	Interventional	2021-05-31	Withdrawn(stopped due to Due to pandemic status changing in Canada prior to investigative sites being initiated for participation, and that concurrent participant recruitment in the global study BHC-RIB-5401-GL will achieve target enrollment across all countries.)
A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Efficacy, Tolerability, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including PegIFNa-2a and Ribavirin in HCV Genotype 1 Infected Subjects Who Fail [NCT00980330]	Phase 2	463 participants (Actual)	Interventional	2009-10-31	Completed
Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 in Combination in Null Responders to Standard of Care Infected With Chronic Hepatitis C Virus Genotype 1 [NCT01012895]	Phase 2	215 participants (Actual)	Interventional	2009-12-31	Completed
A Prospective, Open-label, Three Phase Pharmacokinetic Study, to Assess the Pharmacokinetic Profile and Safety of Raltegravir 400 mg Twice Daily and Ribavirin 800 mg Once Daily, When Dosed Separately and Together in Healthy Volunteers [NCT00982553]	Phase 1	14 participants (Actual)	Interventional	2009-09-30	Completed
A Phase l b/II a, Multicenter, Randomized, Double-Blinded, and Placebo-Controlled Study of the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of VCH-222 in Subjects With Chronic Hepatitis C-Infection [NCT00911963]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2009-04-30	Completed
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Ascending Multiple Dose Trial of the Safety, Efficacy, and Pharmacokinetics of ANA598 Administered With Pegylated Interferon and Ribavirin in Treatment-Naïve Genotype 1 Patients With Chronic Hepatit [NCT00978497]	Phase 2	97 participants (Actual)	Interventional	2009-09-30	Completed
A Multicenter, Single-arm Trial Evaluating the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-IFNα2a/RBV) in Protease Inhibitor Treatment Failure Patients With Chronic Hepatitis C Genotype 1 [NCT01500772]	Phase 3	6 participants (Actual)	Interventional	2012-03-31	Terminated
A Randomized, Open Label Trial of the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-INFα2a/RBV) and Boceprevir in Combination With Peg-INFα2a/RBV in African American Treatment-naïve Patients With [NCT01446250]	Phase 3	8 participants (Actual)	Interventional	2011-12-31	Terminated
A Phase III, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effects of Adding TCM-700C,Botanical Drug, on the Standard Treatment (Peginterferon and Ribavirin) for Subjects With Naive Genotype 1 Hepatitis C Infection [NCT01890200]	Phase 3	0 participants (Actual)	Interventional	2015-06-30	Withdrawn
A Phase I Open-Label Study of the Safety, Tolerance, and Pharmacokinetic Interactions of Combination Didanosine and Ribavirin in HIV-Positive Individuals [NCT00000772]	Phase 1	15 participants	Interventional		Completed
An Open Label, Multicentre, International Pilot Study of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir With or Without Ribavirin or Glecaprevir/Pibrentasvir for People With Recently Acquired Hepatitis C Virus Infection With or Without HIV Co-infection. [NCT02634008]	Phase 3	83 participants (Actual)	Interventional	2016-06-30	Completed
An Open-label, Multicenter, Efficacy and Safety Study of Pegasys® Plus Ribavirin in Patients With Chronic HCV Infection Who Are Unable to Tolerate or Who Do Not Respond to 12 Weeks of Therapy With PEGIntron ® Plus Ribavirin [NCT00087568]	Phase 4	57 participants (Actual)	Interventional	2003-01-31	Completed
A Multicenter, Randomized, Open Label, Parallel-group Phase IIB Study on the Efficacy and Safety of Oral Regimens of DEB025 Alone or in Combination With Ribavirin Versus Standard of Care (Peg-IFNα2a Plus Ribavirin) in Treatment-naïve Hepatitis C Genotype [NCT01215643]	Phase 2	340 participants (Actual)	Interventional	2010-10-31	Completed
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus In [NCT02219477]	Phase 3	36 participants (Actual)	Interventional	2014-11-24	Completed
A Phase 3 Evaluation of BMS-790052 (Daclatasvir) Compared With Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Chronic Hepatitis C [NCT01492426]	Phase 3	605 participants (Actual)	Interventional	2012-01-31	Completed
Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C) [NCT02128217]	Phase 1	44 participants (Actual)	Interventional	2014-05-30	Completed
A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 [NCT00705432]	Phase 3	1,472 participants (Actual)	Interventional	2008-08-31	Completed
Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: a Pilot Sequential Clinical Trial [NCT04392427]	Phase 3	100 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
Effect of a Combination of Nitazoxanide, Ribavirin and Ivermectin Plus Zinc Supplement on the Clearance of COVID-19: Extension Study [NCT04959786]	Phase 2/Phase 3	100 participants (Anticipated)	Interventional	2021-04-01	Recruiting
A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys®), and Ribavirin (Copegus®) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype [NCT01459913]	Phase 3	239 participants (Actual)	Interventional	2011-11-30	Terminated(stopped due to The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.)
A 2-Part, Open Label Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Chronically Infected With Genotype 1 Hepatitis C Virus Following Liver Transplantation [NCT01467505]	Phase 2	61 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to The study was terminated early by the sponsor on 13 January 2014 due to a decision to modify the drug development plan.)
A Phase II Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of 4 Different Regimens of MK-7009 When Administered Concomitantly With Pegylated Interferon and Ribavirin in Treatment-Experienced Patients With Chronic Ge [NCT00704405]	Phase 2	285 participants (Actual)	Interventional	2009-03-27	Completed
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (TURQUOIS [NCT01704755]	Phase 3	381 participants (Actual)	Interventional	2012-10-31	Completed
Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters [NCT05616598]	Phase 2/Phase 3	200 participants (Actual)	Interventional	2022-03-01	Completed
A Non-Randomized, Open Label, Study to Assess Hepatitis C Viral Kinetics in Predicting the Clinical Response in Patients With Hepatitis C Infection Coinfected With HIV-1 Treated With Peginterferon Alpha-2b and Ribavirin [NCT00018031]	Phase 2	36 participants (Actual)	Interventional	2001-06-30	Completed
Combination of Pegylated Interferon and Ribavirin as Therapy for Patients With Chronic Hepatitis C With and Without Renal Disease [NCT00028093]	Phase 4	50 participants (Actual)	Interventional	2001-12-31	Completed
An Exploratory Study to Evaluate Immune Restoration Following Removal of Viral Antigen in Treatment-Naïve and Treatment-Experienced Adults With Genotype (GT) 1a Chronic Hepatitis C Virus (HCV) Infection Administered Ombitasvir/ ABT-450/Ritonavir With Dasa [NCT02476617]	Phase 3	25 participants (Actual)	Interventional	2015-06-30	Completed
Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium [NCT02581163]		314 participants (Actual)	Observational	2015-10-07	Completed
An Exploratory Study to Evaluate the Kinetics of Viral Load Decline With Ombitasvir/ABT 450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Therapy With Low Dose Ribavirin (RBV), Full Dose RBV or RBV Add-On in Treatment Naïve Adults With Genotype 1a Chroni [NCT02493855]	Phase 2	46 participants (Actual)	Interventional	2015-06-30	Completed
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection (GEODE II) [NCT02609659]	Phase 3	105 participants (Actual)	Interventional	2015-10-28	Completed
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Canada (AMBER) [NCT02581189]		565 participants (Actual)	Observational	2015-10-13	Completed
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-3682 With Either MK-8742 or MK-8408 in Subjects With Chronic HCV GT1 and GT2 Infection [NCT02332707]	Phase 2	443 participants (Actual)	Interventional	2015-01-22	Completed
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Fai [NCT02446717]	Phase 2/Phase 3	141 participants (Actual)	Interventional	2015-04-30	Completed
The Role of DAA in Reducing the Risk of Recurrence After Curative Treatment of HCC in Patients With Chronic Hepatitis C and Early Stage HCC [NCT02959359]	Phase 4	0 participants (Actual)	Interventional	2016-11-30	Withdrawn(stopped due to The supplies of study drug were halted by Gilead Sciences Ltd.)
Open-Label, Phase 3b Study To Determine Efficacy and Safety of Telaprevir, Pegylated-Interferon-alfa-2a and Ribavirin in Hepatitis C Genotype 1 Infected, Stable Liver Transplant Subjects [NCT01571583]	Phase 3	74 participants (Actual)	Interventional	2012-02-29	Completed
[NCT01579019]	Phase 2	0 participants (Actual)	Interventional	2012-07-31	Withdrawn
A Phase 3 Study to Assess the Efficacy and Safety of Boceprevir in Combination With Peginterferon Alfa-2b Plus Ribavirin in Pediatric Subjects With Chronic Hepatitis C Genotype 1 [NCT01590225]	Phase 3	0 participants (Actual)	Interventional	2013-01-28	Withdrawn
Efficacy and Effectiveness of Combination Therapy With Pegylated Interferon Alfa-2a and Ribavirin in Korean Patients With Chronic Hepatitis C [NCT01596517]	Phase 4	272 participants (Actual)	Interventional	2003-06-30	Completed
An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders [NCT01185028]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2010-08-31	Completed
Prospective, Randomized, Single-blind, Cross-over, Comparative Study for Establishing Comparative Bioavailability of Copegus vs Vilona® in Healthy Volunteers [NCT01615393]	Phase 1	40 participants (Actual)	Interventional	2011-06-30	Completed
Multicenter Open-label Randomized Prospective Clinical Study of Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b) in Comparison With PegIntron (Peginterferon Alfa-2b) in the Combined Treatment of Chronic Hepatitis C [NCT01740089]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2011-11-30	Completed
Prospective Randomized Pilot Study of Daily Consensus Interferon (CIFN) and Ribavirin for 52 Wks vs Extended Duration 72 Wks Based on Virologic Response for the Initial Treatment of Difficult-to-treat Patients With Chronic HCV Genotype 1 [NCT00211692]	Phase 3	64 participants (Actual)	Interventional	2005-07-31	Completed
Interferon-Free Therapy for Chronic Hepatitis C Virus Genotype 1 Infection in Participants With HIV-1 Coinfection Receiving Concurrent Antiretroviral Therapy (C_ASCENT) [NCT02194998]	Phase 2	46 participants (Actual)	Interventional	2015-09-16	Terminated(stopped due to The study closed to accrual before the planned accrual goal was attained due to the availability of newer directly-acting antiviral (DAA) treatments for HCV.)
An Open-Label Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) in Treatment-Naive Subjects With Genotype 1 Chronic Hepati [NCT01221298]	Phase 2	11 participants (Actual)	Interventional	2010-10-31	Completed
Phase I Study of Induction Chemotherapy With Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) [NCT01721525]	Phase 1	10 participants (Actual)	Interventional	2012-11-30	Completed
Randomized, Double-blind, Placebo-controlled Multicenter Study Evaluating the Interest of a Long-term (3 Years) Treatment With Peginterferon Alfa-2b and Ribavirin on Liver Fibrosis in Non-responder Chronic Hepatitis C Patients. [NCT00323804]	Phase 2/Phase 3	372 participants (Actual)	Interventional	2006-05-31	Completed
A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are T [NCT00983853]	Phase 2	62 participants (Actual)	Interventional	2009-10-31	Completed
An Open-label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (Pegasys®) as Monotherapy or in Combination With Ribavirin (Copegus®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols [NCT01853254]	Phase 3	272 participants (Actual)	Interventional	2003-09-30	Completed
A Non-Interventional Trial of Pegasys/Copegus in HCV Patients for 12 Months [NCT02515279]		463 participants (Actual)	Observational	2008-11-30	Completed
Phase I Pharmacokinetic and Tolerance Study of Ribavirin in Human Immunodeficiency Virus (HIV) - Infected Patients [NCT00000733]	Phase 1	42 participants	Interventional		Completed
An Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Treatment-Naïve or Treatment-Experienced Adults in Brazil With Genotype 1 Chronic Hepatitis C Virus (HCV) [NCT02442271]	Phase 3	222 participants (Actual)	Interventional	2015-04-27	Completed
A Multicenter Phase I Clinical Trial of Ribavirin in the Treatment of Patients With AIDS and Advanced AIDS Related Illnesses [NCT00001015]	Phase 1	96 participants	Interventional		Completed
A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome [NCT00001123]		130 participants	Interventional		Completed
Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation [NCT00383864]	Phase 4	55 participants	Interventional	2001-07-31	Completed
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) [NCT02265237]	Phase 3	184 participants (Actual)	Interventional	2014-10-28	Completed
An Open-label Study to Assess the Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis With HCV Genotype 2 Infection [NCT04774107]	Phase 1	17 participants (Actual)	Interventional	2020-11-26	Completed
A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Experienced Subjects With Chronic HCV Infection [NCT01909804]	Phase 2	323 participants (Actual)	Interventional	2013-06-30	Completed
Noninterventional Study on the Quality Assurance of the Therapy of Chronic Hepatitis C With Peg-(40kd)-Interferon Alfa-2a (Pegasys®) and Ribavirin (e.g. Copegus®) With Main Focus Gastroenterologists - a Project in BNG (Association of German Resident Gastr [NCT02106156]		10,228 participants (Actual)	Observational	2008-01-31	Completed
A Phase II Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects With Chronic Hepatitis C Virus Infection Who Failed Prior Direct Acting Antiviral Therapy [NCT02105454]	Phase 2	79 participants (Actual)	Interventional	2014-05-23	Completed
Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl Alone or in Combination With Ribavirin in Patients With Chronic Hepatitis C [NCT02118012]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2014-03-20	Completed
A Phase III, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 Versus Sofosbuvir/Pegylated Interferon/Ribavirin (PR) in Treatment-Naïve and PR Prior Treatment Failure Subjects With Chronic HCV GT1, 4 [NCT02358044]	Phase 3	257 participants (Actual)	Interventional	2015-02-27	Completed
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of a Combination Regimen of MK-5172 With/Without MK-8742 and/or Ribavirin (RBV) in Treatment-naive Subjects With Chronic Hepatitis C Genotype 2, 4, 5 and 6 Infection [NCT01932762]	Phase 2	98 participants (Actual)	Interventional	2013-10-01	Completed
Non-Interventional Study Evaluating The Safety and Efficacy In Patients Receiving New PegIntron Pen for Hepatitis C [NCT01340573]		3 participants (Actual)	Observational	2007-03-31	Terminated(stopped due to Terminated early due to low enrollment.)
A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes [NCT02461745]	Phase 4	200 participants (Actual)	Interventional	2015-06-30	Completed
Open-label Study to Evaluate the Safety and Efficacy of the Combination of Ombitasvir, Paritaprevir/r ± Dasabuvir With or Without Ribavirin (RBV) in Adult Patients With GT1 or GT4 Chronic HCV Infection and Response to Prior Treatment of Early Stage Hepato [NCT02504099]	Phase 3	3 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to Study stopped due to low enrollment)
A Phase 3b, Multicenter, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin (± Pegylated Interferon) in Subjects With Chronic Genotype 1, 2, 3 and 6 HCV Infection [NCT02021643]	Phase 3	687 participants (Actual)	Interventional	2013-12-10	Completed
A Phase I Study of Combination Therapy With Didanosine (ddI) and Ribavirin in HIV-Infected Children. [NCT00000833]	Phase 1	20 participants	Interventional		Completed
A Comparative Study of High-dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV [NCT00381953]	Phase 3	33 participants (Actual)	Interventional	2003-02-28	Completed
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir With and Without Dasabuvir Coadministered With and Without Ribavirin in Adults With Genotype 1 or 4 Chronic Hepatitis C Virus Infection and Human Immuno [NCT01939197]	Phase 2/Phase 3	318 participants (Actual)	Interventional	2013-08-30	Completed
Comparison of Standard Therapy,Peginterferon Alpha-2a + Ribavirin for 48 Weeks VS Peginterferon Alph-2a + Ribavirin + Betaine for 12 Weeks Followed by 36 Weeks Standard Therapy in Untreated Adults With Chronic Hepatitis C Genotype 1 [NCT00571714]		0 participants (Actual)	Interventional	2008-04-01	Withdrawn(stopped due to lack of enrollment)
Open, Multicentre and Randomised Phase IV Study to Evaluate Viral Kinetics in the First 12 Weeks of Patients With Chronic Hepatitis C Genotypes 1 and 4 Coinfected by the Human Immunodeficiency Virus Treated With Induction Doses of Peginterferon Alpha-2a ( [NCT00356486]	Phase 4	74 participants (Actual)	Interventional	2005-10-31	Completed
Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment: A Pilot Project [NCT02460133]	Phase 4	44 participants (Actual)	Interventional	2015-07-31	Active, not recruiting
Pegintron Induction Therapy in Previous Non-Responders With Chronic HCV: A Dutch Multicenter Randomized Controlled Trial. (PIT-Study) [NCT00363259]	Phase 3	110 participants	Interventional	2002-07-31	Completed
Directly Observed Therapy for the Delivery of HCV Therapy Among HCV-infected Individuals in Chennai, India [NCT02541409]	Phase 2	50 participants (Actual)	Interventional	2015-09-30	Completed
Phase II Trial of Retreatment Strategies for Difficult-to-Treat Hepatitis C Virus (HCV)-Infected Individuals Who Have Failed Prior Direct Acting Antiviral (DAA)-Based Regimens [NCT02605304]	Phase 2	7 participants (Actual)	Interventional	2016-02-17	Terminated(stopped due to The study experienced enrollment difficulties.)
An Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection, With Severe Renal Impairment or End-Stage Renal [NCT02207088]	Phase 3	68 participants (Actual)	Interventional	2014-09-23	Completed
Cardiovascular Function and Ribavirin Pharmacokinetics and Pharmacodynamics in Patients With Lassa Fever [NCT03889106]		2 participants (Actual)	Observational	2019-03-01	Terminated(stopped due to insufficient amount of participants)
An Open-label Pilot Study to Determine the Tolerability and Efficacy of Fixed-dose Grazoprevir/Elbasvir Treatment in Hepatitis C Uninfected Recipients of Renal Transplants From Hepatitis C Infected Deceased Donors [NCT02781649]	Phase 4	10 participants (Actual)	Interventional	2016-07-20	Completed
Phase 2 Study To Investigate the Efficacy, Safety And Pharmacokinetics Of Ravidasvir In Combination With Ritonavir-boosted Danoprevir And Ribavirin In Treatment-naive Non-cirrhotic Taiwanese Patients Who Have Chronic Hepatitis C Genotype 1 [NCT03020095]	Phase 2	38 participants (Actual)	Interventional	2015-08-31	Completed
Phase 4 Study of Peg-interferon Plus Ribavirin Therapy for Prevention of Hepatocellular Carcinoma [NCT00375661]	Phase 4	100 participants (Actual)	Interventional	2006-09-30	Completed
Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis C (FOURward Study) [NCT02175966]	Phase 2	35 participants (Actual)	Interventional	2014-07-28	Completed
An Open-label, Ascending Dose, Phase II Study to Evaluate Tolerability, Safety, Antiviral Activity, and Pharmacokinetics of BI 207127 NA in Combination With BI 201335 NA and Ribavirin for 8 Weeks in Treatment-naïve Japanese Patients With Genotype 1chronic [NCT01528735]	Phase 2	25 participants (Actual)	Interventional	2012-02-29	Completed
Towards HCV Elimination: Evaluation of an Integrated Model of HCV Care Targeting People Who Inject Drugs in Hai Phong, Vietnam [NCT03537196]	Phase 4	979 participants (Actual)	Interventional	2018-11-13	Completed
A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects [NCT01482767]	Phase 3	262 participants (Actual)	Interventional	2012-04-30	Completed
An Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects [NCT01563536]	Phase 2	12 participants (Actual)	Interventional	2012-02-29	Completed
An Open-Label, Sequential Arm, Multicenter Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-267 With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Geno [NCT01458535]	Phase 2	61 participants (Actual)	Interventional	2011-09-30	Completed
A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics, of ABT-450 With Ritonavir (ABT-450/r) in Combination With ABT-267 and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatm [NCT01464827]	Phase 2	580 participants (Actual)	Interventional	2011-10-31	Completed
An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-II) [NCT02167945]	Phase 3	615 participants (Actual)	Interventional	2014-06-12	Completed
Sofosbuvir Plus Daclatasvir With or Without Ribavirin for Chronic Hepatitis C Infection: Impact of Drug Concentration on Viral Load Decay [NCT03318887]		130 participants (Actual)	Observational	2014-02-01	Completed
Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Slovenia [NCT00705263]		113 participants (Actual)	Observational	2005-10-31	Completed
"To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis - A Randomized Open- Label Study" [NCT02464631]		62 participants (Actual)	Interventional	2015-06-30	Terminated(stopped due to In view of recent approval of NS5A inhibitors for treatment of hepatitis C such as Declatasvir and Ledipasvir which have proven better efficacy in the HCV cure)
A Phase 2, Open-Label Study of Daclatasvir (BMS-790052) and TMC435 in Combination With or Without Ribavirin (RBV) For Treatment-Naive Subjects or Null Responders to Prior Peginterferon Alfa (PegIFN)/RBV Therapy With Genotype 1 Chronic Hepatitis C [NCT01628692]	Phase 2	230 participants (Actual)	Interventional	2012-07-31	Completed
The Diabetes Virus Detection and Intervention Trial [NCT04838145]	Phase 2	96 participants (Actual)	Interventional	2018-08-30	Completed
A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) With and Without Ribavirin (RBV) in Cirrhotic Subjects With Chronic HCV GT3 Infection [NCT02601573]	Phase 2	101 participants (Actual)	Interventional	2016-01-05	Completed
An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety, Tolerability, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-530, With and Without Ribavirin (RBV) in Treatment-Naïve Subjects With Genotype 3 [NCT02068222]	Phase 2	10 participants (Actual)	Interventional	2014-04-30	Completed
A Phase 3 Randomized, Open-Label, Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus (EPGCG, Sofosbuvir , Daclatasvir & Ribavirin) Versus Sofosbuvir + Daclatasvir + Ribavirin (Part A) and a Single Dose of Dactavira (EP [NCT03186313]	Phase 3	72 participants (Actual)	Interventional	2016-09-30	Completed
A Phase 2, Randomized, Open-Label Study of Sofosbuvir/Ledipasvir Fixed-Dose Combination With Ribavirin or GS-9669 250 mg or GS-9669 500 mg in Naive or Treatment-Experienced Cirrhotic Subjects With Chronic Genotype 1 HCV Infection [NCT01984294]	Phase 2	101 participants (Actual)	Interventional	2013-10-31	Completed
A Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Antiviral Activity of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin in Treatment-Experienced Subjects With Genotype 1b Chronic [NCT01674725]	Phase 3	187 participants (Actual)	Interventional	2012-08-31	Completed
Randomized, Multicenter Study to Find Optimal Treatment Duration in Patients With Chronic Hepatitis C and Subtype 1 or 4 Depending on HCV RNA Level at Week 8 and Week 12 [NCT02641379]	Phase 4	737 participants (Actual)	Interventional	2003-05-31	Completed
Impact of Interleukin 28B (rs12979860) Genotype on Virological Responses in Chronic Hepatitis C Treatment [NCT03090035]	Phase 3	98 participants (Actual)	Interventional	2014-01-01	Completed
A Phase III, Open Label, Multicentric Clinical Trial of a Single Arm of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotype 1,4 Who Have Failed to Treat With a [NCT03105349]	Phase 4	0 participants (Actual)	Interventional	2017-07-01	Withdrawn(stopped due to No availability of investigational medication.)
A Randomized, Partially Double-Blind, Active-Controlled, Dose-Ranging Estimation Study to Evaluate the Safety, Tolerability, and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment [NCT01440595]	Phase 2	5 participants (Actual)	Interventional	2011-11-28	Terminated(stopped due to Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir.)
An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1 [NCT01443923]	Phase 4	4 participants (Actual)	Interventional	2011-09-30	Terminated(stopped due to Unable to complete enrollment due to newly approved treatment options.)
Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Patients With Hepatitis C [NCT00637923]	Phase 2	112 participants (Actual)	Interventional	2008-03-31	Completed
A Proof of Concept Study for Preemptive Treatment With Grazoprevir and Elbasvir in Donor HCV-positive to Recipient HCV-negative Cardiac Transplant [NCT03026023]	Phase 4	0 participants (Actual)	Interventional	2018-08-01	Withdrawn(stopped due to moved forward with another protocol utilizing pan genotypic treatment once it became commercially available and FDA approved)
Boceprevir in Community Practice: Assessing Safety, Efficacy, Compliance and Quality of Life, Impact of an Education Program [NCT01405027]	Phase 4	197 participants (Actual)	Interventional	2011-12-31	Completed
A Multi-centre, Open Label, Parallel Group Trial to Evaluate the Pharmacokinetic Interactions Between BI 207127 (600 mg t.i.d. or 600 mg b.i.d.) and BI 201335 (120 mg q.d.) Given in Combination With Ribavirin for 24 Weeks, and Their Combined Effect on the [NCT01525628]	Phase 1	72 participants (Actual)	Interventional	2012-04-30	Completed
A Phase 2B, Randomized Study to Evaluate the Safety and Efficacy of Pegylated Interferon Lambda (BMS-914143) Administered With Ribavirin Plus a Single Direct Antiviral Agent (BMS-790052 or BMS-650032) Versus Pegasys Administered With Ribavirin (Part A) an [NCT01795911]	Phase 2	165 participants (Actual)	Interventional	2013-03-31	Completed
Evaluation of Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Patients With/Without Substitution Therapy in Austria [NCT00725751]		353 participants (Actual)	Observational	2007-09-30	Completed
An Open-Label Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 Coadministered With Ribavirin (RBV) in Treatment-Naïve and Treatment-Experienced Asian Adults With GT1b Chronic Hepatitis C Virus (HCV) In [NCT02517528]	Phase 3	104 participants (Actual)	Interventional	2015-07-20	Completed
Treatment Efficacy and Safety of 12 Weeks of Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without Baseline NS5A Resistance-associated Variants (DARING) [NCT03004625]	Phase 3	70 participants (Actual)	Interventional	2016-11-30	Completed
Pilot Study to Assess the Efficacy and Tolerance to a QUadruple Therapy With Asunaprevir , Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a, in HIV-HCV Genotype 1 or 4 Coinfected Patients Previously Null Responders to a Standard Pegylated Interfer [NCT01725542]	Phase 2	75 participants (Actual)	Interventional	2012-12-31	Completed
Telaprevir in Patients With Genotype 3 HCV: Pilot Clinical Study to Evaluate Efficacy and Predictability of Therapy in Patients Who Have Failed to Respond to Pegylated Interferon and Ribavirin [NCT02087111]	Phase 4	14 participants (Actual)	Interventional	2014-04-30	Completed
Viral Kinetic Models of HCV Clearance in Hemophiliacs With Telaprevir [NCT01704521]	Phase 1	5 participants (Actual)	Interventional	2012-12-31	Completed
An Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Ombitasvir (OBV), Paritaprevir (PTV), Ritonavir (RTV) With or Without Dasabuvir (DSV) and With or Without Ribavirin (RBV) in Pediatric Subjects With Genotype 1 or 4 [NCT02486406]	Phase 2/Phase 3	64 participants (Actual)	Interventional	2015-10-28	Completed
Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or [NCT02455167]	Phase 3	9 participants (Actual)	Interventional	2015-05-31	Terminated(stopped due to Study stopped due to low accrual and availability of other treatment options)
A Phase 3 Study Evaluating the Safety and Efficacy of Lambda/Ribavirin/Daclatasvir in Subjects With Chronic HCV Infection and Underlying Hemophilia Who Are Treatment Naïve or Are Prior Relapsers to Peginterferon Alfa-2a/Ribavirin [NCT01741545]	Phase 3	71 participants (Actual)	Interventional	2013-03-31	Completed
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Naïve Adults With Genotype 1 Chronic Hepatitis C Virus [NCT01716585]	Phase 3	636 participants (Actual)	Interventional	2012-11-30	Completed
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of ABT450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Treatment-Experienced Adults With Genotype 1 Chronic Hepatitis C V [NCT01715415]	Phase 3	395 participants (Actual)	Interventional	2012-11-30	Completed
A Two-Part, Open-Label, Single-Arm Phase 1/2 Study of Safety, Pharmacokinetics, and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Aged 3 to 17 Infected With Genotype 1 Hepatitis C Virus [NCT01701063]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2013-01-31	Terminated
A Phase II Randomized, Dose Ranging, Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Different Doses of MK-5172 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Treatment Naïve Subjects With Chronic Hepatiti [NCT01710501]	Phase 2	87 participants (Actual)	Interventional	2012-12-07	Completed
Part A: Drug Interaction Study Between GS-7977 and Antiretroviral Therapy (ARV) Combinations of Efavirenz, Tenofovir and Emtricitabine; Efavirenz, Zidovudine and Lamivudine; Atazanavir/Ritonavir, Tenofovir and Emtricitabine; Darunavir/Ritonavir, Tenofovir [NCT01565889]	Phase 1/Phase 2	52 participants (Actual)	Interventional	2012-03-31	Completed
A Randomized, Open-label Study of the Effect of PEGASYS Combined With Ribavirin on Sustained Virologic Response in Patients With Chronic Hepatitis C Who Did Not Respond to Previous Pegintron/Ribavirin Combination Therapy [NCT00087646]	Phase 4	948 participants (Actual)	Interventional	2003-09-30	Completed
A Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in Treatment-Naive Adults With Genotype 1b Chronic Hepatitis [NCT01767116]	Phase 3	419 participants (Actual)	Interventional	2012-12-31	Completed
An Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) and Dasabuvir Co-administered With or Without Sofosbuvir (SOF) and Ribavirin (RBV) in Direct-Acting Antiviral Agent (DAA) Tre [NCT02356562]	Phase 2	29 participants (Actual)	Interventional	2015-02-03	Completed
A Pilot Trial of the Safety and Efficacy of Telaprevir +Peginterferon +Ribavirin +Vitamin D3 Among Treatment-naive Veterans Infected With Genotype 1 Hepatitis C Virus [NCT01890772]	Phase 2/Phase 3	0 participants (Actual)	Interventional	2013-08-31	Withdrawn
Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection (PURGE-C) [NCT04042740]	Phase 2	45 participants (Actual)	Interventional	2019-11-15	Completed
A Phase IIa, Randomized, Double-blind (Participant and Investigator Blind, Sponsor Open), Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Antiviral Activity of Oral ACH-0141625 in Combination With Pegylated Interferon Alpha-2a and Ribav [NCT01180790]	Phase 2	122 participants (Actual)	Interventional	2010-09-30	Completed
A Phase III, Randomized, Partially Double-Blind and Placebo-Controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Treatment-Naive Patients With Chronic Genotype 1 HCV Infection [NCT01732796]	Phase 3	470 participants (Actual)	Interventional	2012-12-31	Completed
Double-Blind, Randomized, Placebo-Controlled Study to Assess Safety, Efficacy, and Pharmacokinetics (PK) of GSK2336805 in Combination With Peginterferon and Ribavirin in Treatment-naive Chronic Hepatitis C Subjects With Hepatitis C Virus Genotypes 1 or 4 [NCT01439373]	Phase 2	16 participants (Actual)	Interventional	2011-07-07	Completed
A Randomized Study Evaluating Two Different Schedules of Aerosolized Ribavirin For Treatment of RSV Upper Respiratory Infections in Patients With Hematological Malignancies [NCT00500578]	Phase 4	51 participants (Actual)	Interventional	2003-02-28	Completed
TCM-700C Phase II Trial The Effects of Adding a Chinese Formulation (TCM-700C) on the Standard Combination Treatment for Patients With Genotype 1 Hepatitis C Infection [NCT00556504]	Phase 2	84 participants (Actual)	Interventional	2007-07-31	Completed
A Phase IIb Open Label Study of BI 207127 in Combination With Faldaprevir and Ribavirin in Patients With Moderate Hepatic Impairment (Child-Pugh B) With Genotype 1b Chronic Hepatitis C Infection [NCT01830127]	Phase 2	35 participants (Actual)	Interventional	2013-04-30	Completed
A Randomized, Open-Label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With and Without Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon α-2a and Ribavirin in Treatment-Naïve A [NCT01854697]	Phase 3	311 participants (Actual)	Interventional	2013-03-31	Completed
Non-interventional, Observational Study on Retreatment of Chronic Hepatitis C Patients Previous Treatment Failure, Using Peginterferon Alfa-2a and Ribavirin Based Regimens [NCT01798576]		282 participants (Actual)	Observational	2012-11-30	Terminated
An Open-Label Study to Evaluate the Safety, Antiviral Activity and Pharmacokinetics of Direct-Acting Antiviral Agent (DAA) Treatment in Combination With Peginterferon Alpha-2a and Ribavirin (pegIFN/RBV) in Chronic Hepatitis C Virus (HCV) Infected Subjects [NCT01609933]	Phase 2	32 participants (Actual)	Interventional	2012-12-18	Completed
Efficacy and Safety of PegIntron Plus Ribavirin for Treatment of Chronic Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon [NCT00687544]	Phase 4	11 participants (Actual)	Interventional	2005-12-31	Terminated
Randomized Study for the Assessment of Nitazoxanide in the Treatment of Chronic Hepatitis C Genotype 4 [NCT01276756]	Phase 2/Phase 3	100 participants (Actual)	Interventional	2010-12-31	Completed
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of TMC435 vs. Placebo as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve, G [NCT01725529]	Phase 3	457 participants (Actual)	Interventional	2012-11-30	Completed
ATHENAS - Retrospective Analysis of Compliance to Treatment of Chronic Hepatitis C With Pegylated Interferon Alpha 2b Associated to Ribavirin Until Week 12 and Correlation With Virological Response in Brazil Health Centers [NCT00856024]		902 participants (Actual)	Observational	2008-07-31	Terminated
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 With Ritonavir (ABT-450/r) and ABT-267 in Adults With Chronic Hepatitis C Virus Infection (PEARL-I) [NCT01685203]	Phase 2	316 participants (Actual)	Interventional	2012-08-31	Completed
An Open-label, Single-Arm, Phase 2 Study to Evaluate the Combination of ABT-450/r/ABT-267 and ABT-333 Coadministered With Ribavirin (RBV) in Adults With Genotype 1 Hepatitis C Virus (HCV) Infection Taking Methadone or Buprenorphine [NCT01911845]	Phase 2	38 participants (Actual)	Interventional	2013-04-30	Completed
Response-guided Triple-therapy Using Boceprevir in Combination With PEGIFN/RBV in HIV/HCV-coinfected Patients [NCT01925183]	Phase 4	6 participants (Actual)	Interventional	2013-08-31	Completed
A Phase IIa, Open-label Trial to Evaluate the Safety, Tolerability and Efficacy of a 12 Weeks Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Chronic Genotype 1 Hepatit [NCT01724086]	Phase 2	90 participants (Actual)	Interventional	2012-10-31	Completed
An International, Multicenter, Open-Label Study Evaluating Sustained Virological Response and Safety With Boceprevir in Triple Combination Therapy With Peginterferon Alfa-2a (40KD) and Ribavirin in Treatment-Naïve Patients With Genotype 1 Chronic Hepatiti [NCT01591460]	Phase 4	165 participants (Actual)	Interventional	2012-08-31	Completed
Real Situation Observational Study of VIRAFERONPEG® in Patients With Chronic Hepatitis C [NCT00705666]		789 participants (Actual)	Observational	2006-02-28	Completed
A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Twice-Weekly Peginterferon Alpha 2a and Ribavirin Induction Therapy for Chronic Hepatitis C in Patients Who Are Coinfected With HIV-1 [NCT00085917]	Phase 2	29 participants (Actual)	Interventional	2004-06-30	Completed
Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C - An Observational Study in Greece [NCT02725866]		216 participants (Actual)	Observational	2016-04-05	Completed
The Role of Combined Ribavirin and Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment of Chronic Hepatitis C Non-responders; A Randomized Controlled Trial [NCT04695769]	Phase 4	281 participants (Actual)	Interventional	2020-11-21	Completed
Impact of Patient Support From Medical Staff on the Adherence to Therapy With PegIntron Plus Rebetol [NCT00704964]		746 participants (Actual)	Observational	2005-05-31	Completed
An Open-Label, Multi-Center, Randomized, Safety, Feasibility and Tolerability Pilot Study of Pegasys® (Peginterferon Alfa-2a) Plus Copegus® (Ribavirin) in Previous Intravenous Drug Users Who Are Currently Enrolled in a Methadone Maintenance Treatment Prog [NCT00087594]	Phase 4	48 participants (Actual)	Interventional	2003-11-30	Completed
Prospective, Observational Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Patients With Hepatitis C in Georgia [NCT01659567]		516 participants (Actual)	Observational	2011-04-06	Completed
Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Egyptian Patients With HCV [NCT03069001]	Phase 4	90 participants (Actual)	Interventional	2015-06-30	Completed
A Multi-centre Single-arm Study to Evaluate the Efficacy and Safety of BOCEPREVIR 44 Weeks in Addition to Standard of Care (SOC) in Previously Treatment Failure (Relapser, Non-responders, Both Partial and Null) Patients With Chronic Hepatitis C Genotype 1 [NCT01756079]	Phase 4	58 participants (Actual)	Interventional	2013-02-06	Completed
A Randomized, Open-Labeled Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 and ABT-333 Co-administered With Ribavirin Compared to Telaprevir Co-administered With Pegylated Interferon a-2a and Ribavirin in Treatment-Experienced Adult [NCT01854528]	Phase 3	148 participants (Actual)	Interventional	2013-06-30	Completed
Non-Interventional Cohort Study on the Utilization and Impact of Dual and Triple Therapies Based on Pegylated Interferon for the Treatment of Chronic Hepatitis C [NCT01447446]		4,442 participants (Actual)	Observational	2011-09-30	Completed
An Exploratory Phase IIa, Randomized, Open-Label Trial to Investigate the Efficacy and Safety of 12 Weeks or 24 Weeks of TMC435 in Combination With PSI-7977 (GS7977) With Or Without Ribavirin in Chronic Hepatitis C Genotype 1-Infected Prior Null Responder [NCT01466790]	Phase 2	168 participants (Actual)	Interventional	2012-01-31	Completed
A Phase 3 Randomized, Double Blind, Multi-National Evaluation of Daclatasvir in Combination With Peg Interferon Alfa-2a and Ribavirin in Treatment-Naive Subjects With Chronic Hepatitis C Genotypes 1 and 4 [NCT01797848]	Phase 3	0 participants (Actual)	Interventional	2014-06-30	Withdrawn
A Placebo-Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon Plus Ribavirin With or Without CTS-1027 in HCV Null-Responders [NCT01273064]	Phase 2	114 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to Risk-benefit ratio)
A Phase III Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Concomitantly Administered With Peginterferon Alfa-2b and Ribavirin in Japanese Patients With Chronic Hepatitis C Infection Who Relapsed After Previous Treatment [NCT01405937]	Phase 3	51 participants (Actual)	Interventional	2011-08-29	Completed
An Open-label Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) Co-administered With Ribavirin (RBV) for 12 or 16 Weeks in Treatment-Naïve and Treatment-Experienced Japanese Adults With Genotype 2 Chronic Hepatitis [NCT02023112]	Phase 3	171 participants (Actual)	Interventional	2014-01-31	Completed
A Randomized Controlled Study To Assess Safety, Tolerability And Efficacy Of GS-7977 In Combination With Full or Low Dose RBV In HCV Genotype 1, Monoinfected Treatment Naive Participants [NCT01441180]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2011-09-30	Completed
A Multi-Center Study Evaluating the Rate of Genotype 1, 2, 3 & 4 Chronic Hepatitis C Patients With Slow Response / Non-rapid Viral Response to Anti-Viral Treatment of Pegasys (Peginterferon Alfa 2a) in Combination With Copegus (Ribavirin) [NCT01429792]	Phase 4	1,013 participants (Actual)	Interventional	2008-09-25	Completed
Phase 2, Open-Label Study to Investigate the Pharmacokinetics, Efficacy, Safety, and Tolerability of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052) and Ribavirin (RBV) in Subjects With Recurrent Chronic Hepatitis C Genotype 1b Infection [NCT01938625]	Phase 2	35 participants (Actual)	Interventional	2013-12-12	Completed
Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of the Combination of ABT-450/Ritonavir/ABT-267 With ABT-333 and With or Without RBV in HCV Genotype 1 and ABT-450/r/ABT-267 With RBV in HCV GT4-Infected Adult Liver or Renal Transplant Recipie [NCT01782495]	Phase 2	129 participants (Actual)	Interventional	2013-02-25	Completed
A Phase 2, Multicenter, Randomized, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir + GS-5816 for 12 Weeks in Treatment-Naive Subjects With Chronic HCV Infection [NCT01858766]	Phase 2	379 participants (Actual)	Interventional	2013-04-30	Completed
Open, Multicenter Phase IV Study, Evaluating Drop of Hemoglobin in Association to the Rate of Sustained Virological Response in Chronic Hepatitis C Patients Treated With Ribavirin (Copegus®) in Combination With Standard Treatment (ANECO) [NCT01585324]	Phase 4	30 participants (Actual)	Interventional	2012-01-31	Completed
An Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 Co-administered With Ribavirin (RBV) in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (Turqu [NCT02216422]	Phase 3	36 participants (Actual)	Interventional	2014-09-30	Completed
International, Multicenter, Randomized, Double Blind, Active-controlled, Parallel-group Phase III Study of Narlaprevir/Ritonavir and Pegylated Interferon/Ribavirin in 2 Patient Populations - naïve and Treatment Failure Patients With Genotype 1 Chronic Hep [NCT03833362]	Phase 3	420 participants (Actual)	Interventional	2014-05-07	Completed
A Quality of Life Study of PEGASYS® (Peginterferon-Alfa2a) in Combination With COPEGUS® (Ribavirin) in Patients With Chronic Hepatitis C and Persistently Normal ALT Levels [NCT02726022]		114 participants (Actual)	Observational	2007-02-28	Completed
Evaluation of Quality of Life, Neurocognitive Performance, Fatigue, and Emotional State in HCV Patients Before, During, and in the (Long-term) Follow-up of an IFN-free Antiviral Therapy [NCT02469012]		30 participants (Anticipated)	Interventional	2014-10-31	Recruiting
A Phase 3 Clinical Trial to Study Short Duration Versus Standard Response-Guided Therapy With MK-3034 (SCH 503034)/Boceprevir Combined With PegIntron and Ribavirin in Previously Untreated Non-Cirrhotic Subjects With Chronic HCV Genotype 1 in Asia [NCT01945294]	Phase 3	257 participants (Actual)	Interventional	2013-10-10	Completed
A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of MK-5172 in Combination With Ribavirin (RBV) in Subjects With Chronic Hepatitis C Virus Infection [NCT01716156]	Phase 2	26 participants (Actual)	Interventional	2013-01-18	Completed
An Open-Label Study to Explore the Clinical Efficacy of GS-7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant [NCT01559844]	Phase 2	61 participants (Actual)	Interventional	2012-03-31	Completed
An Open-Label, Phase 4 Study of Telaprevir, Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C Who Have Not Achieved a Sust [NCT01467492]	Phase 4	121 participants (Actual)	Interventional	2012-01-31	Terminated(stopped due to It was decided by Sponsor on 13 January 2014 to terminate study early at primary efficacy endpoint as part of a decision to modify drug development plan.)
A Phase III Study to Evaluate the Safety, Tolerability, and Efficacy of MK-7009 When Administered Concomitantly With Peginterferon Alfa-2b and Ribavirin in Japanese Patients With Chronic Hepatitis C Infection Who Were Non-responders to Previous Treatment [NCT01405560]	Phase 3	42 participants (Actual)	Interventional	2011-09-02	Completed
Efficacy and Safety of Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV Genotype 4 and End-stage Kidney Disease With or Without Hemodialysis (An Open Label- Multicenter Prospective Study) [NCT03499639]	Phase 4	110 participants (Actual)	Interventional	2018-05-01	Completed
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Comparing 24 or 48 Weeks of GS 9190, in Combination With Peginterferon Alfa 2a and Ribavirin, to 48 Weeks of Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic Hepatit [NCT00743795]	Phase 2	252 participants (Actual)	Interventional	2008-10-31	Completed
A Phase 3, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of GS-7977 With Peginterferon Alfa 2a and Ribavirin for 12 Weeks in Treatment-Naive Subjects With Chronic Genotype 1, 4, 5, or 6 HCV Infection [NCT01641640]	Phase 3	328 participants (Actual)	Interventional	2012-06-30	Completed
An Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in US Veterans With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-VA) [NCT02442284]	Phase 3	99 participants (Actual)	Interventional	2015-05-13	Completed
A Randomized Clinical Trial Using Fine Needle Aspiration For Evaluation of Hepatic Pharmacokinetics of MK-7009 in Chronic Hepatitis C Patients [NCT01678131]	Phase 1	31 participants (Actual)	Interventional	2012-10-30	Completed
"Real World Administration of Zepatier (Grazoprevir Plus Elvasvir) in Chronic Hemodialysis Patients With Hepatitis C Infection. Strategies for Identification of Patients, Insurance Approval, Treatment , and Laboratory Monitoring" [NCT03365635]	Phase 4	6 participants (Actual)	Interventional	2019-09-22	Completed
THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders [NCT02786537]	Phase 4	1,275 participants (Actual)	Interventional	2016-06-30	Completed
A Phase 2, Open-Label, Multicenter, Multi-cohort Study to Investigate the Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection [NCT02249182]	Phase 2	226 participants (Actual)	Interventional	2014-11-05	Completed
Study of the Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With and Without Post-hepatitis C Cirrhosis [NCT02992457]	Phase 4	10,000 participants (Actual)	Interventional	2015-01-31	Completed
High Dose Ribavirin in Combination With Peginterferon for Patients With Chronic Hepatitis C Genotype 1 Infection Who Have Failed to Respond or Relapsed After Standard Therapy [NCT00735969]	Phase 2	21 participants (Actual)	Interventional	2008-08-31	Completed
A Randomized, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Inhaled Virazole Administered Via Air-Jet Nebulizer in Healthy Volunteers [NCT05229510]	Phase 1	32 participants (Actual)	Interventional	2021-03-12	Completed
A Phase 3, Safety and Efficacy Study of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Chronic HCV Genotype 1 IL28B CC Subjects [NCT01544920]	Phase 3	737 participants (Actual)	Interventional	2012-05-30	Completed
A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Subjects Who Have Failed Prior Treatment With Pegylated Interferon and Ribavirin (P/R) With Chronic HCV GT1, GT4, and GT6 Infection [NCT02105701]	Phase 3	420 participants (Actual)	Interventional	2014-06-05	Completed
A Phase 3 Blinded Randomized Study of Peginterferon Lambda-1a and Ribavirin Compared to Peginterferon Alfa-2a and Ribavirin, Each Administered With Telaprevir in Subjects With Genotype-1 Chronic Hepatitis C Who Are Treatment-naive or Relapsed on Prior Tre [NCT01598090]	Phase 3	881 participants (Actual)	Interventional	2012-06-14	Completed
A Phase III Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of TMC435 Plus PegIFNα-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Subjects Who Are Co-infected With Human Immunodeficiency V [NCT01479868]	Phase 3	109 participants (Actual)	Interventional	2011-10-31	Completed
Telaprevir in Combination With Standard of Care in Hepatitis C Genotype 1 Infection in Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation [NCT01821963]	Phase 3	1 participants (Actual)	Interventional	2013-04-30	Terminated(stopped due to Low referral rate due to new therapeutic options.)
A Phase 3 Evaluation of BMS-790052 in Combination With Peg-Interferon Alfa-2a and Ribavirin in Treatment Naive Subjects With Chronic Hepatitis C Genotype 4 [NCT01448044]	Phase 3	152 participants (Actual)	Interventional	2011-12-31	Completed
A Clinical Trial Comparing the Sustained Virological Response in Terms of Expression Profile of IL- 28B in Genotype 1 HCV-Infected Treatment-Naïve Subjects With Chronic Hepatitis C on Pegasys® (Peginterferon Alfa-2A) Plus Copegus® (Ribavirin) [NCT01447420]	Phase 4	129 participants (Actual)	Interventional	2011-02-28	Completed
Pilot Therapy Using Betaine in Combination With Peginterferon Alpha-2a Plus Ribavirin in Subjects With Genotype 1 Hepatitis C Who Have Not Achieved a Sustained Viral Response With a Prior Course of Pegylated Interferon and Ribavirin [NCT00882193]	Early Phase 1	2 participants (Actual)	Interventional	2009-05-01	Terminated(stopped due to new medications with improved response released)
Non-interventional Study to Observe Triple Combination Therapy With Boceprevir or Simeprevir Plus Peginterferon Alfa-2a Plus Ribavirin for Re-treatment of Chronic Hepatitis C in Hungary (IMPERIAL) [NCT02118597]		19 participants (Actual)	Observational	2014-05-31	Terminated(stopped due to Study terminated due to the Sponsor's decision.)
A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy [NCT02498015]	Phase 4	87 participants (Actual)	Interventional	2016-08-31	Completed
A Registry for Subjects With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection [NCT02292706]		1,609 participants (Actual)	Observational [Patient Registry]	2014-12-29	Terminated(stopped due to The study stopped early because the study objectives were met.)
Study of the Early Occurrence of Hepatocellular Carcinoma (HCC) in Egyptian HCV Infected Patients Receiving Sofosbuvir and Daclatasvir [NCT03247296]		200 participants (Actual)	Observational	2017-02-28	Active, not recruiting
Pegylated Interferon +/- Ribavirin for Children With Hepatitis C [NCT00100659]	Phase 3	114 participants (Actual)	Interventional	2004-12-31	Completed
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant [NCT01687270]	Phase 2	40 participants (Actual)	Interventional	2012-11-30	Completed
Response Evaluation of Peginterferon Alfa-2a 180µg 20kDa (Unipeg®) Plus Ribavirin (Ribazole®) in Treatment naïve Pakistani Population With Chronic Hepatitis C Infection [NCT02601976]	Phase 4	64 participants (Actual)	Interventional	2010-08-31	Completed
A Phase 3 Evaluation of Daclatasvir, Sofosbuvir, and Ribavirin in Genotype 1-6 Chronic Hepatitis C Infection Subjects With Cirrhosis Who May Require Future Liver Transplant and Subjects Post-Liver Transplant [NCT02032875]	Phase 3	116 participants (Actual)	Interventional	2014-03-31	Completed
A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection (SURVE [NCT02243293]	Phase 2/Phase 3	694 participants (Actual)	Interventional	2014-09-19	Completed
A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus [NCT02292719]	Phase 2	70 participants (Actual)	Interventional	2014-12-19	Completed
Response to Peg-interferon and Ribavirin for the Treatment of HCV Infection in HIV Co-infected Patients, Implemented in Public Hospitals in Thailand [NCT02247440]	Phase 4	18 participants (Actual)	Interventional	2014-08-31	Completed
A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection [NCT02175758]	Phase 2	106 participants (Actual)	Interventional	2014-07-07	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00006164 (15) [back to overview]	Development of Hepatocellular Carcinoma (HCC)
NCT00006164 (15) [back to overview]	SF-36 Mental Health Summary Score
NCT00006164 (15) [back to overview]	Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points
NCT00006164 (15) [back to overview]	Ascites
NCT00006164 (15) [back to overview]	Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits
NCT00006164 (15) [back to overview]	Death From Any Cause
NCT00006164 (15) [back to overview]	Hepatic Encephalopathy
NCT00006164 (15) [back to overview]	Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies
NCT00006164 (15) [back to overview]	Serious Adverse Events
NCT00006164 (15) [back to overview]	Spontaneous Bacterial Peritonitis
NCT00006164 (15) [back to overview]	Variceal Hemorrhage
NCT00006164 (15) [back to overview]	Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.
NCT00006164 (15) [back to overview]	SF-36 Vitality Summary Score
NCT00006164 (15) [back to overview]	Presumed Hepatocellular Carcinoma (HCC)
NCT00006164 (15) [back to overview]	SF-36 Physical Function Summary Score
NCT00018031 (1) [back to overview]	Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response
NCT00028093 (1) [back to overview]	Change in Hepatitis C Virus RNA Levels During Phase I
NCT00039871 (3) [back to overview]	Sustained Virologic Response (SVR) for Participants With Detectable But ≥2 Log Drop in HCV-RNA at Treatment Week 12
NCT00039871 (3) [back to overview]	Sustained Virologic Response (SVR) for Participants With Undetectable HCV-RNA at Treatment Week 12
NCT00039871 (3) [back to overview]	Sustained Virologic Response (SVR) Rate
NCT00056862 (5) [back to overview]	First Phase Decline in Logarithm of HCV RNA Level
NCT00056862 (5) [back to overview]	Slope of Second Phase Decline in HCV Levels
NCT00056862 (5) [back to overview]	Time to Negativity
NCT00056862 (5) [back to overview]	Virological Response (Intention to Treat)
NCT00056862 (5) [back to overview]	Virological Response Category (Per Protocol)
NCT00077636 (7) [back to overview]	Percentage of Participants With Marked Laboratory Abnormalities
NCT00077636 (7) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00077636 (7) [back to overview]	Participants With Marked Abnormal Vital Signs
NCT00077636 (7) [back to overview]	Number of Participants With Highest Triglyceride Level
NCT00077636 (7) [back to overview]	Percentage of Participants With Virological Response at The End of Study Treatment
NCT00077636 (7) [back to overview]	Percentage of Participants With Sustained Virological Response (SVR)
NCT00077636 (7) [back to overview]	Percentage of Participants Virological Response 12 Weeks Post-Treatment
NCT00077649 (10) [back to overview]	Percentage of Participants With Adverse Events and Serious Adverse Events
NCT00077649 (10) [back to overview]	Percentage of Participants With Marked Laboratory Abnormalities
NCT00077649 (10) [back to overview]	Percentage of Participants With Virological Response At 12 Weeks After The End of The Treatment Period
NCT00077649 (10) [back to overview]	Total BDI-II (Beck Depression Inventory) Scores
NCT00077649 (10) [back to overview]	Percentage of Participants With Virological Response at the End of the Treatment Period
NCT00077649 (10) [back to overview]	HCV RNA Profile During The First 24 Weeks
NCT00077649 (10) [back to overview]	Percentage of Participants With Virological Response Over Time to Week 24
NCT00077649 (10) [back to overview]	Percentage of Participants With Abnormal Vital Signs
NCT00077649 (10) [back to overview]	Percentage of Participants With Predicted Sustained Virological Response
NCT00077649 (10) [back to overview]	Percentage of Participants With Sustained Virological Response
NCT00078403 (16) [back to overview]	Number of Participants With High-grade Signs and Symptoms or Laboratory Values
NCT00078403 (16) [back to overview]	Sustained Virologic Response
NCT00078403 (16) [back to overview]	Number of Participants With Dose Modifications, Temporary Stops, and Premature Treatment Discontinuations
NCT00078403 (16) [back to overview]	Number of Participants With Neutropenia
NCT00078403 (16) [back to overview]	Number of Participants Who Used Antianorexia Agents, Such as Megestrol and Dronabinol
NCT00078403 (16) [back to overview]	Number of Participants With Anemia
NCT00078403 (16) [back to overview]	Number of Participants With Prescription as Needed of Erythropoietin (EPO), Granulocyte Colony-stimulating Factor (GCSF), and Granulocyte-monocyte Colony-stimulating Factor (GM-CSF)
NCT00078403 (16) [back to overview]	Weight
NCT00078403 (16) [back to overview]	Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)
NCT00078403 (16) [back to overview]	Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS)
NCT00078403 (16) [back to overview]	Number of Participants Adherent to Study Medications
NCT00078403 (16) [back to overview]	Time-scaled Change in Ishak Liver Inflammation Score (SCIIS)
NCT00078403 (16) [back to overview]	Number of Participants With Detectable HCV Viral Load (>= 60 IU/mL)
NCT00078403 (16) [back to overview]	Number of Participants With Depression and/or Other Psychological Events
NCT00078403 (16) [back to overview]	Number of Participants With Thrombocytopenia
NCT00078403 (16) [back to overview]	Number of Participants With Undetectable HIV Viral Load (<50 Copies/mL)
NCT00081770 (4) [back to overview]	Mean Change From Baseline in the Log Viral Load at Treatment Week 4
NCT00081770 (4) [back to overview]	Mean Change From Baseline in the Log Viral Load at Treatment Week 2
NCT00081770 (4) [back to overview]	Virologic Response Rate at Treatment Week 12
NCT00081770 (4) [back to overview]	Sustained Virologic Response (SVR) Rate
NCT00085917 (3) [back to overview]	Number of Participants With Sustained Virologic Response (SVR)
NCT00085917 (3) [back to overview]	Number of Participants With Adverse Events
NCT00085917 (3) [back to overview]	Number of Participants With Normalization of Liver Enzymes
NCT00087568 (10) [back to overview]	Mean Score of Beck Depression Inventory Over Time
NCT00087568 (10) [back to overview]	Mean Score for Overall Local Injection Site Reaction
NCT00087568 (10) [back to overview]	Number of Pegasys and Ribavirin Therapy Completers
NCT00087568 (10) [back to overview]	Number of Participants With Normal Serum Alanine Transaminase Levels Over Time
NCT00087568 (10) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT00087568 (10) [back to overview]	Mean Score of Fatigue Severity Over Time
NCT00087568 (10) [back to overview]	Number of Participants With >=2-log10 Decrease or Undetectable (<60 International Units Per Milliliter) Hepatitis C Virus-ribonucleic Acid Over Time
NCT00087568 (10) [back to overview]	Number of Participants With Serious Adverse Events and Adverse Events
NCT00087568 (10) [back to overview]	Number of Participants With Abnormal Vital Signs
NCT00087568 (10) [back to overview]	Number of Participants With Individual Flu-like Symptom
NCT00087594 (14) [back to overview]	Number of Participants With Marked Laboratory Abnormalities (Biochemistry)
NCT00087594 (14) [back to overview]	Number of Participants With Biochemical Response Rate at Weeks 12, 24, and 48 (G1 Only) During Treatment and at 12 and 24 Weeks After Treatment Completion
NCT00087594 (14) [back to overview]	Number of Participants With Any Adverse Events (AEs), Any Serious Adverse Events (SAEs), and Study Discontinuation
NCT00087594 (14) [back to overview]	Number of Participants With Abnormal Vital Signs
NCT00087594 (14) [back to overview]	Number of Participants With > =2 Log Drop From Baseline or Undetectable HCV-RNA (<10 IU/mL) at Week 12
NCT00087594 (14) [back to overview]	Mean Change From Baseline in BDI-II Score to EOT (Week 24/48) and EOS (Week 48/72) Visits
NCT00087594 (14) [back to overview]	Mean Absolute Scores for Hepatitis Quality-of-Life Questionnaire (HQLQ) at EOT (Week 24/48) Visit and 24 Weeks After EOT Visit
NCT00087594 (14) [back to overview]	Mean Absolute Score of Beck Depression Inventory, Second Edition (BDI-II)
NCT00087594 (14) [back to overview]	Number of Participants With Degrees of Depression as Defined by the BDI-II Score
NCT00087594 (14) [back to overview]	Number of Participants With Virological Response Rate at Weeks 12, 24, and 48 (G1 Only) During Treatment and at 12 Weeks After Treatment Completion
NCT00087594 (14) [back to overview]	Number of Participants With Treatment Completion Rate (TCR)
NCT00087594 (14) [back to overview]	Number of Participants With Compliance to the Prescribed Treatment Regimen
NCT00087594 (14) [back to overview]	Number of Participants With Sustained Virological Response (SVR) Rate at 24 Weeks Post Treatment (Week 48 for G2/3 and Week 72 for G1)
NCT00087594 (14) [back to overview]	Number of Participants With Marked Laboratory Abnormalities (Hematology)
NCT00087607 (15) [back to overview]	Weekly Viral Absolute Area Under the HCV RNA Curve Estimated in the Frequent-sampling Cohort for Weeks 1 and 8
NCT00087607 (15) [back to overview]	Mean Value of Area Under the HCV-RNA Curve Minus Baseline From Week 1 to Week 12
NCT00087607 (15) [back to overview]	Mean Trough Interferon Concentrations at Each Week
NCT00087607 (15) [back to overview]	Mean Change From Baseline in Viral Load (log10 Reduction) at Week 4 and Week 8
NCT00087607 (15) [back to overview]	The Area Under the HCV-RNA Curve Estimated From the Two Adjacent Pre-dose Assessments at Each Week
NCT00087607 (15) [back to overview]	Cumulative Viral Absolute Area Under the HCV RNA Curve Minus Baseline Averaged Over the 12-week Period
NCT00087607 (15) [back to overview]	Change From Baseline in Viral Load (log10 Reduction) at Week 12
NCT00087607 (15) [back to overview]	Number of Participants With Marked Biochemical Test Abnormalities
NCT00087607 (15) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events
NCT00087607 (15) [back to overview]	Area Under the Curve for Interferon in the Frequent-Sampling Cohort
NCT00087607 (15) [back to overview]	Percentage of Participants With Undetectable HCV RNA (< 60 International Units/Milliliter) at Each Visit
NCT00087607 (15) [back to overview]	Percentage of Participants With a ≥ 2-log10 Decrease or Undetectable (< 60 International Units Per Milliliter) HCV RNA at Each Visit
NCT00087607 (15) [back to overview]	Number of Participants With Marked Hematologic Abnormalities
NCT00087607 (15) [back to overview]	Number of Participants With Marked Abnormalities in Thyroid Function Tests
NCT00087607 (15) [back to overview]	Weekly Viral Load Assessed at Drug Trough
NCT00087646 (8) [back to overview]	Change From Baseline in Reduction of HCV Viremia (Groups A + B vs Groups C + D)
NCT00087646 (8) [back to overview]	Percentage of Participants With Relapse After End of Treatment
NCT00087646 (8) [back to overview]	Percentage of Participants With Maintenance of Actual End-of-Treatment Virological Response
NCT00087646 (8) [back to overview]	Number of Participants With Sustained Virological Response Rate
NCT00087646 (8) [back to overview]	Number of Participants With Sustained Virological Response (Groups A + C vs Groups B + D)
NCT00087646 (8) [back to overview]	Number of Participants With Sustained Virological Response (Groups A + B vs Groups C + D)
NCT00087646 (8) [back to overview]	Percentage of Participants With Undetectable HCV-RNA
NCT00087646 (8) [back to overview]	Percentage of Participants With >=2log Drop in HCV-RNA
NCT00100659 (2) [back to overview]	Adverse Events
NCT00100659 (2) [back to overview]	Sustained Viral Response (SVR)
NCT00104052 (1) [back to overview]	Number of Participants With a Sustained Virologic Response (SVR) at 24 Weeks Post-treatment
NCT00107653 (21) [back to overview]	Mean Change From Baseline in Fibrosis Score Based on ISHAK at Week 72
NCT00107653 (21) [back to overview]	Percentage of Participants With Early Virologic Response at Week 12
NCT00107653 (21) [back to overview]	Mean Change From Baseline in ISHAK HAI Activity (Necroinflammatory) at Week 72
NCT00107653 (21) [back to overview]	Mean Change From Baseline in Fat Score at Week 72
NCT00107653 (21) [back to overview]	Percentage of Participants With Improved, Stable and Worsened Fat Score From Baseline to Week 72
NCT00107653 (21) [back to overview]	Number of Participants With Any Adverse Events and Serious Adverse Events
NCT00107653 (21) [back to overview]	Mean Change in Fatigue Severity Scale Score and Fatigue Severity Scale Score Item 10 Visual Analog Scale Score From Baseline at Week 48 and Week 72
NCT00107653 (21) [back to overview]	Mean Change in 36-item Short Form Health Survey Total and Domain Scores From Baseline at Week 48 and 72
NCT00107653 (21) [back to overview]	Percentage of Participants With Early Virologic Response at Week 4
NCT00107653 (21) [back to overview]	Mean Change From Baseline in Activity and Fibrosis Scores Based on METAVIR Activity at Week 72
NCT00107653 (21) [back to overview]	Change From Baseline in HCV-RNA Log10 Titers Over the Period Of Time
NCT00107653 (21) [back to overview]	Percentage of Participants With Sustained Virologic Response at Week 72
NCT00107653 (21) [back to overview]	Percentage of Participants With ISHAK Histological Activity Index Response
NCT00107653 (21) [back to overview]	Number of Participants With Premature Withdrawals Due to Adverse Events or Laboratory Abnormalities
NCT00107653 (21) [back to overview]	Number of Participants With Marked Abnormal Laboratory Parameters
NCT00107653 (21) [back to overview]	Percentage of Participants Achieving Virologic Response
NCT00107653 (21) [back to overview]	Percentage of Participants With Non-zero Nonalcoholic Steatohepatitis Score
NCT00107653 (21) [back to overview]	Percentage of Participants With Biochemical Response
NCT00107653 (21) [back to overview]	Percentage of Participants With Improved, Stable and Worsened ISHAK Fibrosis Score
NCT00107653 (21) [back to overview]	Percentage of Participants With Improved, Stable, and Worsened METAVIR Activity Score
NCT00107653 (21) [back to overview]	Percentage of Participants With Improved, Stable, and Worsened METAVIR Fibrosis Score
NCT00136318 (5) [back to overview]	Sustained Virologic Response
NCT00136318 (5) [back to overview]	Severe Depression Defined as a MADRS Score of 25 or Higher
NCT00136318 (5) [back to overview]	Proportion of Patients Without Depression (Defined as a MADRS Score of 13 or Higher)
NCT00136318 (5) [back to overview]	Incidence of Major Depression Defined by Diagnostic and Statistical Manual IV (DSM-IV) Criteria
NCT00136318 (5) [back to overview]	Montgomery Asberg Depression Scale (MADRS) With a Score of 13 or Higher
NCT00160251 (12) [back to overview]	Percent of Participants Who Achieved Sustained Virologic Response (SVR)
NCT00160251 (12) [back to overview]	Peak Plasma Concentration of Boceprevir (BOC)
NCT00160251 (12) [back to overview]	Percent of Participants Who Achieved Sustained Viral Response (SVR) by Time to First Negative HCV-RNA
NCT00160251 (12) [back to overview]	Trough Plasma Concentration Level
NCT00160251 (12) [back to overview]	Percent of Participants Who Were Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative at the End of Treatment (EoT)
NCT00160251 (12) [back to overview]	Percentage of Participants Who Were HCV-RNA Negative at EoT After Receiving 1 Week of Treatment With PegIntron (PEG) by Log Drop
NCT00160251 (12) [back to overview]	Percent of Participants With Virologic Response Prior to Amendment 2
NCT00160251 (12) [back to overview]	Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on Arms 2 (PEG+BOC 100), 3 (PEG+BOC 200), 4 (PEG+BOC 400 [48 Weeks]), 6 (PEG+BOC 400 [24 Weeks])
NCT00160251 (12) [back to overview]	Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Rebetol (RVB) + Boceprevir (BOC) 400 (Arm 5)
NCT00160251 (12) [back to overview]	Number of Participants Who Were HCV-RNA Negative During Amendment 2 (AM2) for Those Who Started on PegIntron (PEG) + Boceprevir (BOC) 800 (Arm 7)
NCT00160251 (12) [back to overview]	Area Under the Plasma Concentration-time Curve of Boceprevir Plasma Concentration for an 8-hour Dosing Period
NCT00160251 (12) [back to overview]	Change in Alanine Aminotransferase (ALT) Levels
NCT00192647 (6) [back to overview]	Percentage of Participants With Virological Responses Over Time
NCT00192647 (6) [back to overview]	Percentage of Participants With Predictive Values of Virological Response for Sustained Virological Response
NCT00192647 (6) [back to overview]	Percentage of Participants With Sustained Virological Response According to Scheduled Treatment Period
NCT00192647 (6) [back to overview]	Percentage of Participants With Relapse of End-of-treatment Virological Response
NCT00192647 (6) [back to overview]	Percentage of Participants With End-of-Treatment Virological Response According to Scheduled Treatment Period
NCT00192647 (6) [back to overview]	Change From Baseline in Log10 HCV RNA Values
NCT00202839 (2) [back to overview]	The Percentage of Participants Who Achieved a Virologic Response 48 Weeks After Randomization.
NCT00202839 (2) [back to overview]	The Percentage of Participants Who Achieved a Sustained Virologic Response (SVR)
NCT00211692 (4) [back to overview]	Overall Number of Serious Adverse Events
NCT00211692 (4) [back to overview]	The Primary Endpoint Would be the Number Who Achieve a Sustained Virologic Response.
NCT00211692 (4) [back to overview]	Participants Achieving SVR Categorized by Time of Response
NCT00211692 (4) [back to overview]	Number of Participants Discontinuing Early From Study Treatment
NCT00255008 (1) [back to overview]	Number of Subjects Who Achieved a Sustained Virologic Response (SVR)
NCT00255034 (1) [back to overview]	Sustained Virological Response (SVR), Defined by Undetectable HCV RNA in Serum at 24 Weeks After Completion of Therapy
NCT00265395 (1) [back to overview]	Sustained Virologic Response, Defined as a Plasma HCV-RNA (Hepatitis C Ribonucleic Acid) Level Below the LLQ (Lower Level of Quantitation) at 24 Weeks Post-treatment.
NCT00302081 (1) [back to overview]	The Number of Participants Who Achieve a Sustained Virologic Response (SVR)
NCT00336479 (5) [back to overview]	Number of Subjects With Viral Relapse
NCT00336479 (5) [back to overview]	Percentage of Subjects With Undetectable Plasma HCV RNA at Week 12 After the Completion of Study Drug Dosing
NCT00336479 (5) [back to overview]	Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00336479 (5) [back to overview]	Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir
NCT00336479 (5) [back to overview]	Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing
NCT00353418 (7) [back to overview]	Incidence of Adverse Events, Dose Reductions and Withdrawals Due to Anemia
NCT00353418 (7) [back to overview]	Early Virological Response (EVR), Partial EVR and Complete EVR by Week 12
NCT00353418 (7) [back to overview]	Virological Response at Weeks 4, 12 and 24
NCT00353418 (7) [back to overview]	Virological Response at End of Treatment Period
NCT00353418 (7) [back to overview]	Sustained Virological Response (SVR)
NCT00353418 (7) [back to overview]	Relapse of Virological Response
NCT00353418 (7) [back to overview]	Rapid Virological Response (RVR) by Week 4
NCT00372385 (6) [back to overview]	Percentage of Subjects With Undetectable Plasma HCV RNA at Week 12 After the Completion of Study Drug Dosing
NCT00372385 (6) [back to overview]	Number of Subjects With Viral Relapse
NCT00372385 (6) [back to overview]	Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing
NCT00372385 (6) [back to overview]	Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir
NCT00372385 (6) [back to overview]	Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00372385 (6) [back to overview]	Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing
NCT00378599 (1) [back to overview]	A Sustained Virologic Response (SVR), Defined as a Plasma HCV RNA Level Below the Lower Level of Quantitation (LLQ) at 24 Weeks Post-treatment
NCT00394277 (4) [back to overview]	SVR-24 (Actual Treatment Period)
NCT00394277 (4) [back to overview]	SVR-12 (Scheduled Treatment Period)
NCT00394277 (4) [back to overview]	SVR-12 (Actual Treatment Period)
NCT00394277 (4) [back to overview]	Sustained Virological Response (SVR)-24 (Scheduled Treatment Period)
NCT00420784 (6) [back to overview]	Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00420784 (6) [back to overview]	Number of Subjects With Viral Relapse
NCT00420784 (6) [back to overview]	Percentage of Subjects With Undetectable Plasma HCV RNA
NCT00420784 (6) [back to overview]	Percentage of Subjects With Undetectable Plasma HCV RNA at Completion of Study Drug Dosing
NCT00420784 (6) [back to overview]	Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Study Drug Dosing
NCT00420784 (6) [back to overview]	Maximum (Cmax), Minimum (Cmin) and Average (Cavg) Plasma Concentration of Telaprevir
NCT00423670 (8) [back to overview]	Number of Participants With a Virologic Response at Follow-up Week 12 That Achieved SVR
NCT00423670 (8) [back to overview]	Number of Participants Negative for HCV-RNA at FW 12
NCT00423670 (8) [back to overview]	Number of Participants Negative for HCV-RNA at 72 Weeks Post Randomization
NCT00423670 (8) [back to overview]	Number of Participants With SVR Based on Duration of Boceprevir Treatment
NCT00423670 (8) [back to overview]	Number of Participants With a Virologic Response at 72 Weeks Post Randomization That Achieved SVR
NCT00423670 (8) [back to overview]	Number of Participants With SVR Based on a 4-week lead-in Treatment With PegIntron and Ribavirin
NCT00423670 (8) [back to overview]	Number of Participants With Sustained Virologic Response (SVR)
NCT00423670 (8) [back to overview]	Number of Participants With an Early Virologic Response (EVR) That Achieved SVR
NCT00423800 (2) [back to overview]	Number of Participants With a Virological Relapse
NCT00423800 (2) [back to overview]	Number of Participants With a Sustained Virologic Response
NCT00441584 (1) [back to overview]	Number of Subjects Who Have Achieved Sustained Virological Response (SVR) at 24 Weeks Post End of Treatment
NCT00446134 (4) [back to overview]	Patients With Either Undetectable Serum HCV RNA (<100 Copies/ml) or at Least a 2-log Decrease From Baseline in Serum Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Treatment Week 12.
NCT00446134 (4) [back to overview]	Patients With Anemia (Hemoglobin <10 g/dL) Up to Follow-up Week 24
NCT00446134 (4) [back to overview]	Relapsers at Follow-Up Visit 24
NCT00446134 (4) [back to overview]	Patients With Undetected Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) (<100 Copies/mL) at Treatment Week Follow-Up 24
NCT00475176 (2) [back to overview]	Improvement in Viral Kinetics During the First 2 Weeks of Therapy
NCT00475176 (2) [back to overview]	2-log Decline in HCV RNA by Week 12 (Early Virological Response) and Sustained Eradication of HCV RNA (Sustained Virological Response).
NCT00483938 (3) [back to overview]	Percentage of Participants With SVR (Groups C, D, E, and F)
NCT00483938 (3) [back to overview]	Percentage of Participants With Virological Responses (Groups A, B, C, D, E, and F)
NCT00483938 (3) [back to overview]	Percentage of Participants With Sustained Virological Response (SVR) (Groups A and B)
NCT00491179 (2) [back to overview]	Number of Participants With Histologic Response(HR)
NCT00491179 (2) [back to overview]	1.Number of Participants With Sustained Virologic Response (SVR) 2.Number of Participants Who Droppoed Out of the Study Prematurely Due to Adverse Events (AEs)
NCT00491244 (2) [back to overview]	Adverse Event (AE)-Related Withdrawal Rate
NCT00491244 (2) [back to overview]	Sustained Virologic Response (SVR)Rate
NCT00493805 (2) [back to overview]	Early Virological Response in Participants With and Without Insulin Resistance
NCT00493805 (2) [back to overview]	Sustained Virological Response (PCR 24 Weeks After End of Treatment)
NCT00495131 (4) [back to overview]	Histologic Response
NCT00495131 (4) [back to overview]	Sustained Virologic Response
NCT00495131 (4) [back to overview]	Treatment-related Withdrawal Rate
NCT00495131 (4) [back to overview]	Sustained Biochemical Response
NCT00495391 (8) [back to overview]	End of Treatment Response (HCV RNA Below Lower Limit of Detection)
NCT00495391 (8) [back to overview]	Early Virologic Response (HCV RNA Below Lower Limit of Detection)
NCT00495391 (8) [back to overview]	Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)
NCT00495391 (8) [back to overview]	Changes in ALT
NCT00495391 (8) [back to overview]	Changes in ALT
NCT00495391 (8) [back to overview]	Changes in ALT
NCT00495391 (8) [back to overview]	Changes in ALT
NCT00495391 (8) [back to overview]	Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)
NCT00500578 (1) [back to overview]	Occurrences of Pneumonia
NCT00528528 (7) [back to overview]	Percentage of Participants With Sustained Viral Response 24 Weeks After End of Treatment (SVR24)
NCT00528528 (7) [back to overview]	Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at Week 12
NCT00528528 (7) [back to overview]	Percentage of Participants With Virologic Response at Week 12
NCT00528528 (7) [back to overview]	Percentage of Participants With Partial Response
NCT00528528 (7) [back to overview]	Number of Participants With Viral Breakthrough at End of Treatment (EOT)
NCT00528528 (7) [back to overview]	Time to First Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level
NCT00528528 (7) [back to overview]	Change From Baseline in Log 10-Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values at End of Treatment (EOT)
NCT00535847 (6) [back to overview]	Cross Tabulation of Extended Rapid Viral Response (eRVR) and Sustained Viral Response (SVR) in With Prior Response
NCT00535847 (6) [back to overview]	Percentage of Prior Relapsers With Undetectable HCV RNA
NCT00535847 (6) [back to overview]	Percentage of Subjects With End of Treatment Response
NCT00535847 (6) [back to overview]	Percentage of Subjects With Undetectable HCV RNA at Week 48 After Completion of Treatment Among Subjects Who Completed Assigned Treatment
NCT00535847 (6) [back to overview]	Percentage of Subjects With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 24 After the Completion of Treatment
NCT00535847 (6) [back to overview]	Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00537407 (7) [back to overview]	Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Triple Therapy Treatment Arms (A, D, and E)
NCT00537407 (7) [back to overview]	log10 Hepatitis C Virus RNA at Day 29
NCT00537407 (7) [back to overview]	Percentage of Participants With a Rapid Viral Response at Day 29
NCT00537407 (7) [back to overview]	Percentage of Participants With a Sustained Viral Response 24 Weeks After the End of Treatment (Week 72 or 96)
NCT00537407 (7) [back to overview]	Percentage of Participants With an Early Viral Response at Week 12
NCT00537407 (7) [back to overview]	Percentage of Participants With an End-of-treatment Response at the End of Treatment (Week 48 or 72)
NCT00537407 (7) [back to overview]	Change From Baseline in log10 Hepatitis C Virus RNA at Day 29 in the Debio 025 Monotherapy and Dual Therapy Treatment Arms (B and C)
NCT00545233 (22) [back to overview]	Change From Baseline in Fasting Hemoglobin A1C (HbA1c) Concentrations at Each Time Point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in Fasting Insulin Levels at Each Time Point Assessed.
NCT00545233 (22) [back to overview]	Change From Baseline in Fasting Plasma Glucose Levels at Each Time Point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in Free Fatty Acid Levels at Each Time Point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in High-density Lipoprotein (HDL-cholesterol) Levels at Each Time-point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in Homeostasis Model Assessment (HOMA) Scores at Each Time Point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in Leptin Levels at Each Time Point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in Low-density Lipoprotein (LDL-cholesterol) Levels at Each Time-point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in Serum Triglyceride Concentrations at Each Time-point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in Total Cholesterol Levels at Each Time-point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in Transforming Growth Factor Beta (TGF-β) Levels at Each Time Point Assessed
NCT00545233 (22) [back to overview]	Change From Baseline in Tumor Necrosis Factor Alpha (TNF-α) at Each Time Point Assessed
NCT00545233 (22) [back to overview]	Change From Initiation of Pegasys Plus Copegus in log10 HCV RNA Viral Load to Week 24 and Week 48 of Anti-HCV Therapy
NCT00545233 (22) [back to overview]	Change in Log10 HCV RNA Viral Load at Assessments From Randomization to 16 Weeks of Pioglitazone Pretreatment Run-In Period for the Pioglitazone Arm Only
NCT00545233 (22) [back to overview]	Percentage of Participants Achieving Virologic Response
NCT00545233 (22) [back to overview]	Percentage of Participants With a ≥ 2 log10 Decrease in HCV RNA From Initiation of Pegasys Plus Copegus to Weeks 4, 12, 24, 48, 60, 72
NCT00545233 (22) [back to overview]	Percentage of Participants With Beck Depression Inventory Fast Screen (BDI-FS) Score ≥ 4 at Each Time Point Assessed
NCT00545233 (22) [back to overview]	Percentage of Participants With a Confirmed Virological Breakthrough up to 48 Weeks
NCT00545233 (22) [back to overview]	Percentage of Participants With a Virological Relapse at Week 72 (24 Weeks After the End of Anti-HCV Treatment)
NCT00545233 (22) [back to overview]	Change From Baseline in Adiponectin Levels at Each Time Point Assessed
NCT00545233 (22) [back to overview]	Change From Initiation of Pegasys Plus Copegus in log10 Hepatitis C Virus Ribonucleic Acid (HCV RNA) Viral Load to Week 12 of Anti-HCV Therapy
NCT00545233 (22) [back to overview]	Percentage of Nonresponders During the 48 Week Anti-HCV Treatment Period
NCT00556504 (7) [back to overview]	Virologic Response
NCT00556504 (7) [back to overview]	Immune Cell Normalization
NCT00556504 (7) [back to overview]	Sustained Virologic Response (SVR)
NCT00556504 (7) [back to overview]	Sustained ALT Response
NCT00556504 (7) [back to overview]	Combined ALT and Virologic Response
NCT00556504 (7) [back to overview]	ALT Response
NCT00556504 (7) [back to overview]	Immune Cell Normalization
NCT00561015 (13) [back to overview]	Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Day 15
NCT00561015 (13) [back to overview]	Maximum Plasma Concentration (Cmax) for Telaprevir on Day 1
NCT00561015 (13) [back to overview]	Maximum Plasma Concentration (Cmax) for Telaprevir on Day 15
NCT00561015 (13) [back to overview]	Median Time to Virological Response (HCV RNA Level < 10 IU/ml)
NCT00561015 (13) [back to overview]	Minimum Plasma Concentration (Cmin) for Telaprevir on Day 15
NCT00561015 (13) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) for Telaprevir on Day 1
NCT00561015 (13) [back to overview]	Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 1
NCT00561015 (13) [back to overview]	Area Under Plasma Concentration-Time Curve Over Dosing Interval (AUCtau) for Telaprevir on Day 15
NCT00561015 (13) [back to overview]	Percentage of Participants Achieving Virological Response (HCV RNA Level < 10 IU/ml)
NCT00561015 (13) [back to overview]	Percentage of Participants Who Achieved Sustained Virological Response (SVR)
NCT00561015 (13) [back to overview]	Percentage of Participants Who Demonstrated Virological Relapse
NCT00561015 (13) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT00561015 (13) [back to overview]	Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level at Week 24 and Week 26
NCT00561353 (28) [back to overview]	Viral Relapse in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)
NCT00561353 (28) [back to overview]	Viral Relapse in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Viral Breakthrough in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1, Panel A and B)
NCT00561353 (28) [back to overview]	Viral Breakthrough in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Sustained Virologic Response (SVR) in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)
NCT00561353 (28) [back to overview]	Sustained Virologic Response (SVR) in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Maximum Plasma Concentration (Cmax) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)
NCT00561353 (28) [back to overview]	Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B)
NCT00561353 (28) [back to overview]	Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A)
NCT00561353 (28) [back to overview]	Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) on Day 7 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel B)
NCT00561353 (28) [back to overview]	Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Naïve HCV-Infected Participants (Cohort 1 and 2, Panel A)
NCT00561353 (28) [back to overview]	Change From Baseline in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels (log10 IU/mL) at Week 4 in Treatment-Experienced HCV-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)
NCT00561353 (28) [back to overview]	Predose Plasma Concentration (C0h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)
NCT00561353 (28) [back to overview]	Virologic Responses Following Treatment With TMC435 in Treatment-Naive Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)
NCT00561353 (28) [back to overview]	Virologic Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Virologic Response Parameters in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B Combined)
NCT00561353 (28) [back to overview]	Predose Plasma Concentration (C0h) of TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Average Steady-state Plasma Concentration (Css,av) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)
NCT00561353 (28) [back to overview]	Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h) of TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A and B)
NCT00561353 (28) [back to overview]	Virologic Response Parameters Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00561353 (28) [back to overview]	Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel B)
NCT00561353 (28) [back to overview]	Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Naïve Hepatitis C Virus (HCV)-Infected Participants (Cohort 1 and 2, Panel A)
NCT00561353 (28) [back to overview]	Initial Suboptimal Responses Following Treatment With TMC435 in Treatment-Experienced Hepatitis C Virus (HCV)-Infected Participants (Cohort 4, Panel C and Cohort 5, Panel D)
NCT00580801 (12) [back to overview]	Maximum Serum Concentration (Cmax) of Telaprevir
NCT00580801 (12) [back to overview]	Minimum Serum Concentration (Cmin) of Telaprevir on Day 15
NCT00580801 (12) [back to overview]	Median Time to First Viral Response (Undetectable HCV RNA)
NCT00580801 (12) [back to overview]	Average Steady-State Serum Concentration (Css,av) of Telaprevir
NCT00580801 (12) [back to overview]	Time to Reach the Maximum Serum Concentration (Tmax) of Telaprevir
NCT00580801 (12) [back to overview]	Percentage of Participants With Viral Response (Undetectable HCV RNA)
NCT00580801 (12) [back to overview]	Percentage of Participants With Sustained Viral Response (SVR)
NCT00580801 (12) [back to overview]	Number of Participants With Viral Breakthrough (Detectable HCV RNA)
NCT00580801 (12) [back to overview]	Change From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Day 15
NCT00580801 (12) [back to overview]	Area Under the Serum Concentration-Time Curve (AUC)
NCT00580801 (12) [back to overview]	Pre-Dose Serum Concentration (C[0h]) of Telaprevir
NCT00580801 (12) [back to overview]	Percentage of Participants With Relapse
NCT00606086 (1) [back to overview]	EVR (Early Virologic Response)
NCT00623428 (7) [back to overview]	Percentage of Participants With a Sustained Virologic Response 12 Weeks After Actual End of Treatment
NCT00623428 (7) [back to overview]	Percentage of Participants With a Sustained Virologic Response 24 Weeks After Actual End of Treatment
NCT00623428 (7) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00623428 (7) [back to overview]	Percentage of Participants With Virological Response at End of Treatment
NCT00623428 (7) [back to overview]	Percentage of Participants With Virological Response 72 Weeks After Treatment Initiation
NCT00623428 (7) [back to overview]	Percentage of Participants With Virological Relapse
NCT00623428 (7) [back to overview]	Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment
NCT00627926 (13) [back to overview]	Number of Subjects With Undetectable HCV RNA at Week 72
NCT00627926 (13) [back to overview]	Biochemical Response: Number of Subjects With Grade 3 and 4 Shifts From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels
NCT00627926 (13) [back to overview]	Fatigue Severity Scale (FSS) Total Score
NCT00627926 (13) [back to overview]	Number of Subjects With Undetectable HCV RNA 24 Weeks After Last Actual Dose of Study Treatment
NCT00627926 (13) [back to overview]	Number of Subjects With Undetectable HCV RNA 12 Weeks After Last Planned Dose of Study Treatment
NCT00627926 (13) [back to overview]	Number of Subjects Achieving Rapid Viral Response (RVR), Demonstrated by Achieving Undetectable HCV RNA 4 Weeks After Starting Study Treatment
NCT00627926 (13) [back to overview]	Number of Subjects Achieving Extended Rapid Viral Response (eRVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12
NCT00627926 (13) [back to overview]	Number of Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels 24 Weeks After Last Planned Dose of Study Treatment
NCT00627926 (13) [back to overview]	Noninvasive Markers of Fibrosis: Number of Subjects With Improvement in FibroTest Analysis
NCT00627926 (13) [back to overview]	Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00627926 (13) [back to overview]	Number of Subjects With Viral Relapse Planned and Viral Relapse Actual
NCT00627926 (13) [back to overview]	Number of Subjects With Undetectable HCV RNA at End of Treatment (EOT)
NCT00627926 (13) [back to overview]	Number of Subjects With Undetectable HCV RNA at Week 12
NCT00637923 (8) [back to overview]	Changes in ALT
NCT00637923 (8) [back to overview]	Changes in ALT
NCT00637923 (8) [back to overview]	Early Virologic Response (HCV RNA Below Lower Limit of Detection)
NCT00637923 (8) [back to overview]	Changes in ALT
NCT00637923 (8) [back to overview]	Changes in ALT
NCT00637923 (8) [back to overview]	Sustained Virologic Response (HCV RNA Below Lower Limit of Detection)
NCT00637923 (8) [back to overview]	Rapid Virologic Response (HCV RNA Below Lower Limit of Detection)
NCT00637923 (8) [back to overview]	End of Treatment Response (HCV RNA Below Lower Limit of Detection)
NCT00665353 (7) [back to overview]	Absolute Change From Entry to Week 24 of Step 1 in Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR)
NCT00665353 (7) [back to overview]	Safety and Tolerability
NCT00665353 (7) [back to overview]	Safety and Tolerability
NCT00665353 (7) [back to overview]	The Proportion of All Subjects With HCV Viral Load < 60 IU/mL at Week 24 of Step 2.
NCT00665353 (7) [back to overview]	The Proportion of All Subjects With HCV Viral Load < 60 IU/mL at Week 72of Step 2.
NCT00665353 (7) [back to overview]	Absolute Change From Entry to Week 24 of Step 1 in Fasting Total Cholesterol and Triglycerides.
NCT00665353 (7) [back to overview]	Absolute Change From Entry to Week 24 of Step 1 in AST and ALT.
NCT00686517 (5) [back to overview]	Virologic Response at 12 Months Post-treatment Follow-up (Long-term Response, [LTR]).
NCT00686517 (5) [back to overview]	Virologic Response at the End of Treatment Follow-up (ETR)
NCT00686517 (5) [back to overview]	Number of Participants With Sustained Response (SR) at the End of the 6-month Follow-up Period
NCT00686517 (5) [back to overview]	Number of Participants Presenting With Alanine Transferase (ALT) Level Normalization
NCT00686517 (5) [back to overview]	Number of Participants With Rapid Virologic Response (RVR)
NCT00686777 (3) [back to overview]	Percentage of Participants With HCV-RNA Negativity at 24 Weeks of Treatment and at EOT
NCT00686777 (3) [back to overview]	Number of Participants Discontinuing Treatment
NCT00686777 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 24 Weeks After the End of Treatment (EOT) or Discontinuation
NCT00687219 (3) [back to overview]	Number of Participants With Undetectable HCV-RNA at Week 72 (Sustained Virologic Response)
NCT00687219 (3) [back to overview]	Number of Participants With Undetectable HCV-RNA at End of Treatment
NCT00687219 (3) [back to overview]	Number of Participants With Undetectable HCV-RNA at Week 24
NCT00687544 (2) [back to overview]	Number of Participants Who Died
NCT00687544 (2) [back to overview]	Number of Participants Experiencing Adverse Events
NCT00689390 (5) [back to overview]	Kaplan-Meier Exposure-adjusted Relapse Rate
NCT00689390 (5) [back to overview]	Number of Participants That Discontinued the LTFU Due to SAEs
NCT00689390 (5) [back to overview]	Number of Participants With Relapse During the LTFU Among Sustained Responders From Previous Treatment Studies With Boceprevir or Narlaprevir (Durability of Virologic Response)
NCT00689390 (5) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) Reported During the LTFU
NCT00689390 (5) [back to overview]	Number of Participants With HCV Treatment-Emergent Resistance Associated Variants (TE-RAVs) of NS3/4A Protease Loci
NCT00700401 (8) [back to overview]	Number of Participants With Any Adverse Events and Any Serious Adverse Events
NCT00700401 (8) [back to overview]	Percentage of Participants With Positive Predictive Value
NCT00700401 (8) [back to overview]	Percentage of Participants With Rapid Virological Response at Week 4
NCT00700401 (8) [back to overview]	Percentage of Participants With Sustained Virological Response at Week 48
NCT00700401 (8) [back to overview]	Percentage of Participants With Virological Relapse
NCT00700401 (8) [back to overview]	Percentage of Participants With Virological Response at Week 24
NCT00700401 (8) [back to overview]	Mean Percent Change From Baseline in Biochemistry Parameters at Weeks 4, 12, 24 and 48
NCT00700401 (8) [back to overview]	Mean Percent Change From Baseline in Hematology Parameters at Weeks 2, 4, 12, 24, and 48
NCT00703118 (8) [back to overview]	Number of Participants Acheiving Rapid Virologic Response (RVR) at Week 4
NCT00703118 (8) [back to overview]	Number of Participants Acheiving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 48 (End of Treatment)
NCT00703118 (8) [back to overview]	Number of Participants Who Have Viral Relapse During Entire Follow-up Period (up to Week 72)
NCT00703118 (8) [back to overview]	Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Medication - SVR12 Planned
NCT00703118 (8) [back to overview]	Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned
NCT00703118 (8) [back to overview]	Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4
NCT00703118 (8) [back to overview]	Number of Participants Acheiving Extended Rapid Virologic Response at Week 4 and Week 12
NCT00703118 (8) [back to overview]	Number of Participants Who Meet the Telaprevir Stopping Rule at Week 4, Week 6, or Week 8
NCT00704184 (6) [back to overview]	Percentage of Participants Achieving RVR
NCT00704184 (6) [back to overview]	Number of Participants With ≥3-log10 Decrease in HCV RNA
NCT00704184 (6) [back to overview]	Number of Participants With ≥2-log10 Decrease in HCV RNA
NCT00704184 (6) [back to overview]	Number of Participants Discontinuing From Study Therapy Due to AEs
NCT00704184 (6) [back to overview]	Mean Log Change From Baseline in HCV RNA
NCT00704184 (6) [back to overview]	Number of Participants Experiencing an Adverse Event (AE)
NCT00704405 (6) [back to overview]	Percentage of Participants Achieving SVR24 After 24 Weeks of Vaniprevir 600 mg b.i.d.
NCT00704405 (6) [back to overview]	Number of Participants Experiencing an Adverse Event (AE)
NCT00704405 (6) [back to overview]	Number of Participants Discontinuing From Study Treatment Due to AEs
NCT00704405 (6) [back to overview]	Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 600 mg b.i.d.
NCT00704405 (6) [back to overview]	Percentage of Participants Achieving cEVR
NCT00704405 (6) [back to overview]	Percentage of Participants Achieving SVR24 Following Treatment With Vaniprevir 300 mg b.i.d.
NCT00704522 (2) [back to overview]	Number of Participants Who Complete Treatment With PegIntron Pen/Rebetol Therapy for Hepatitis C When Administered With a Patient Assistance Program
NCT00704522 (2) [back to overview]	Average Length of Treatment With PegIntron/Rebetol
NCT00704717 (1) [back to overview]	Satisfaction of Patients Receiving PegIntron Pen Plus Rebetol Therapy, Assessed by a Survey.
NCT00704964 (2) [back to overview]	Number of Participants With Adherence to Therapy According to Physician Approximation
NCT00704964 (2) [back to overview]	Number of Participants With Biometrical Adherence to Therapy
NCT00705107 (2) [back to overview]	Number of Subjects Who Completed Treatment.
NCT00705107 (2) [back to overview]	Average Length of Treatment.
NCT00705224 (5) [back to overview]	Percentage of Participants Who Achieved Sustained Virological Response as Assessed at End of Study by HCV Genotype and Presence of Insulin-Resistance at Baseline
NCT00705224 (5) [back to overview]	Percentage of Participants Who Demonstrated Virological Relapse as Assessed at End of Study by HCV Genotype and Presence of Insulin-Resistance at Baseline
NCT00705224 (5) [back to overview]	Percentage of Participants Who Achieved Response Following Treatment as Assessed at End of Treatment by HCV Genotype and Presence of Insulin-Resistance at Baseline
NCT00705224 (5) [back to overview]	Percentage of Participants Who Achieved Sustained Virological Response as Assessed at End of Study
NCT00705224 (5) [back to overview]	Percentage of Participants Who Achieved Early Virological Response as Assessed at Visit 2 by HCV Genotype and Presence of Insulin-Resistance at Baseline
NCT00705263 (1) [back to overview]	Number of Participants Satisfied With the PegIntron Pen, Including the Assessment of the Device Accuracy and Ease of Use.
NCT00705432 (5) [back to overview]	Sustained Virologic Response (SVR) Rate
NCT00705432 (5) [back to overview]	Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 4, 8, 12, 16, or 20) Who Achieved SVR
NCT00705432 (5) [back to overview]	Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.
NCT00705432 (5) [back to overview]	Sustained Virologic Response (SVR) Rate in Participants Treated With Study Drug (Boceprevir or Placebo)
NCT00705432 (5) [back to overview]	Number of Participants With Early Virologic Response (Undetectable HCV-RNA at Treatment Week 2, 4, 8, 12, 16, or 20)
NCT00705666 (1) [back to overview]	The Number of Participants Receiving the Recommended Treatment Duration (24 Weeks for Genotypes 2 and 3 and 48 Weeks for Genotype 1 According to the French 2002 Consensus Meeting).
NCT00708500 (4) [back to overview]	Sustained Virologic Response (SVR) Rate in the Modified Intent to Treat (mITT) Population.
NCT00708500 (4) [back to overview]	Number of Participants With Early Virologic Response.
NCT00708500 (4) [back to overview]	Number of Participants With Undetectable HCV-RNA at Follow-up Week 12 and at 72 Weeks After Randomization.
NCT00708500 (4) [back to overview]	Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population.
NCT00709059 (1) [back to overview]	Number of Study Participants Who Had a Virological Response (VR) at Week-72
NCT00709228 (1) [back to overview]	Number of HCV LVL G1 Participants Who Relapsed
NCT00723632 (3) [back to overview]	Average Cost Per Participant With Sustained Virologic Response (SVR) Stratified by Weight Category
NCT00723632 (3) [back to overview]	Average Cost Per Participant With SVR Stratified by Prior Treatment Status
NCT00723632 (3) [back to overview]	Average Cost Per Participant With SVR Stratified by Ribavirin Dosage
NCT00723892 (2) [back to overview]	the Average Length of Treatment for Participants on Treatment for Hepatitis C With PegIntron Pen/Rebetol
NCT00723892 (2) [back to overview]	Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C When Administered With a Patient Psychotherapy Support Program as Compared to a Group Without a Psychotherapy Support Program.
NCT00724373 (1) [back to overview]	Participants With Treatment Success
NCT00724451 (3) [back to overview]	Number of Participants Discontinued From Treatment by Reason for Discontinuation
NCT00724451 (3) [back to overview]	Number of Participants Not Eligible for Antiviral Treatment by Reason for Non-eligibility
NCT00724451 (3) [back to overview]	Number of Participants With Treatment Failure by Reason for Failure
NCT00724464 (8) [back to overview]	Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Liver Fibrosis Stage at Baseline
NCT00724464 (8) [back to overview]	Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on HCV-RNA Viral Load at Baseline
NCT00724464 (8) [back to overview]	Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on HCV Genotype at Baseline
NCT00724464 (8) [back to overview]	Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Alanine Aminotransferase (ALT) Levels at Baseline
NCT00724464 (8) [back to overview]	Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Achievement of Rapid Virological Response
NCT00724464 (8) [back to overview]	Number of Participants Who Demonstrated Virological Relapse as Assessed at 24-week Post-treatment Follow-up
NCT00724464 (8) [back to overview]	Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up
NCT00724464 (8) [back to overview]	Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up by Subgroups Based on Study Treatment Dosage Modification
NCT00724854 (5) [back to overview]	Assessment of Response at Treatment Week 48 for Genotypes 2 and 3, and Treatment Week 72 for Genotypes 1, 4, and 5, in Participants With RVR
NCT00724854 (5) [back to overview]	Assessment of Baseline Characteristics in Participants With SVR
NCT00724854 (5) [back to overview]	Number of Participants With RVR Who Also Achieved SVR
NCT00724854 (5) [back to overview]	Number of Participants With Rapid Virologic Response After 4 Weeks of Treatment
NCT00724854 (5) [back to overview]	Number of Participants Who Achieved Sustained Virologic Response (SVR)
NCT00724893 (49) [back to overview]	Number of Participants With EVR by Selected Chronic HCV Genotypes (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants With EOT Response by Chronic HCV Genotype (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Chronic HCV Genotype + Liver Fibrosis Stage (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Chronic HCV Genotype (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving RVR by Weight (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Liver Fibrosis Stage (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Liver Fibrosis Score (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving RVR by Race (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving RVR by Liver Fibrosis Stage (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Discontinued From Study Drug Due to Adverse Events by Chronic HCV Genotype (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Weight + Chronic HCV Genotype (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Weight (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Human Immunodeficiency Virus (HIV) Status (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Gender (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Gender (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by EVR Type (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Chronic HCV Genotype 1 Subtype (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Chronic HCV Genotype + Viral Load (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving Viral Response at 12 Weeks After EOT (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR, Excluding Participants Who Discontinued Prior to EVR Evaluation (Stage 1)
NCT00724893 (49) [back to overview]	The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Liver Fibrosis Stage (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving Sustained Viral Response (SVR) (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving Rapid Virologic Response (RVR) (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving EVR Who Achieved SVR (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving EVR (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving EVR (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Weight (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Viral Load (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Race (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving SVR by Race (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving RVR Who Achieved SVR (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving RVR by Gender (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving RVR by Chronic HCV Genotype 1 Subtype (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving EVR by Weight (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving EVR by Race (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving EVR by Liver Fibrosis Stage (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving EVR by Gender (Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving EVR by Chronic HCV Genotype 1 Subtype (Stage 2)
NCT00724893 (49) [back to overview]	The Number of Participants Achieving Viral Response at 12 Weeks After EOT, Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1)
NCT00724893 (49) [back to overview]	The Number of Participants Achieving SVR Excluding Participants Who Discontinued Prior to EVR Evaluation and Participants With Missing Data (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants With End of Treatment (EOT) Response (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Discontinued From Study Treatment Due to Adverse Events (Stage 1 and Stage 2)
NCT00724893 (49) [back to overview]	Number of Participants Achieving Viral Response at Any Evaluation Point, Excluding Participants Who Discontinued Treatment Prior to Early Virologic Response (EVR) Evaluation (Stage 1)
NCT00724893 (49) [back to overview]	Number of Participants Achieving Viral Response at Any Evaluation Point (Stage 1)
NCT00724893 (49) [back to overview]	The Number of Participants Achieving Viral Response at 12 Weeks After EOT by Chronic HCV Genotype (Stage 1)
NCT00724893 (49) [back to overview]	Relapse Rate by HCV Genotype (Stage 1)
NCT00724893 (49) [back to overview]	Percentage of Compliance for Participants Achieving SVR Based on Medication Adherence Questionnaire (MAQ) (Stage 2)
NCT00725205 (3) [back to overview]	Number of Participants Who Are Triple-80 Compliant
NCT00725205 (3) [back to overview]	Number Of Participants Self-Administering Pegylated Interferon Alfa-2b
NCT00725205 (3) [back to overview]	Number of Participants Who Achieved Sustained Virological Response as Assessed at 24-week Post-treatment Follow-up
NCT00725751 (3) [back to overview]	Number of Participants Who Received Antiviral Treatment Who Were Also on Substitution Therapy
NCT00725751 (3) [back to overview]	Number of Participants Who Completed Treatment With PegIFN-2b/Ribavirin
NCT00725751 (3) [back to overview]	Number of Participants Who Achieved Sustained Virologic Response (SVR)
NCT00725842 (2) [back to overview]	Number of Participants With Positive HCV-RNA at 72 Weeks Off-treatment
NCT00725842 (2) [back to overview]	Number of Participants With Positive Hepatitis C Virus (HCV)-Ribonucleic Acid (RNA) at 24 Weeks Off-treatment
NCT00726557 (2) [back to overview]	Number of Drug-substituted Participants Who Achieved Sustained Virological Response (SVR) With PegIntron 1.5 μg/kg/Week and Rebetol (10.6 mg/kg/Day) in Substitution Centers Under Routine Conditions
NCT00726557 (2) [back to overview]	Number of Participants Who Tolerated Treatment With PegIntron 1.5 mcg/kg/Week + Rebetol 10.6 mg/kg/Week
NCT00727259 (1) [back to overview]	Evaluation of the Satisfaction of the PegPen (PegIntron Preparation and Injection Easiness) Using a Patient Questionnaire Answered at 1 Month and 3 Months
NCT00727311 (4) [back to overview]	Number of Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Negative Participants at End of Therapy (EoT)
NCT00727311 (4) [back to overview]	Number of Participants With Early Virologic Response (EVR)
NCT00727311 (4) [back to overview]	Number of Participants With Sustained Virologic Response (SVR)
NCT00727311 (4) [back to overview]	Number of HCV-RNA Negative Participants at Follow-up
NCT00728494 (6) [back to overview]	The Number of Participants Who Relapsed at 6 Months Post-treatment
NCT00728494 (6) [back to overview]	The Number of Participants Who Complete Treatment With PegIntron/Rebetol Therapy for Hepatitis C
NCT00728494 (6) [back to overview]	Average Dosage of Rebetol
NCT00728494 (6) [back to overview]	Average Dosage of PegIntron
NCT00728494 (6) [back to overview]	Average Length of Treatment
NCT00728494 (6) [back to overview]	The Number of Participants With a Sustained Virologic Response at 6 Months Post-treatment
NCT00735969 (1) [back to overview]	Sustained Virological Response, (HCV RNA Neg.) in Serum 24 Weeks Off Therapy.
NCT00758043 (8) [back to overview]	Proportion of Randomized Subjects Who Relapse
NCT00758043 (8) [back to overview]	Proportion of Randomized Subjects Who Have Undetectable HCV RNA 12 Weeks After Last Dose of Study Treatment
NCT00758043 (8) [back to overview]	Proportion of Randomized Subjects Achieving Sustained Viral Response (SVR), Demonstrated by Achieving Undetectable HCV RNA 24 Weeks After Last Dose of Study Treatment (SVR24)
NCT00758043 (8) [back to overview]	Safety and Tolerability as Assessed by Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00758043 (8) [back to overview]	Proportion of Subjects Achieving eRVR (Extended RVR), Demonstrated by Achieving Undetectable HCV RNA at Week 4 and at Week 12
NCT00758043 (8) [back to overview]	Proportion of Subjects Who Have Undetectable HCV RNA at the EOT (Week 24 or Week 48 Respectively)
NCT00758043 (8) [back to overview]	Proportion of Subjects Who Have Undetectable HCV RNA at Week 72
NCT00758043 (8) [back to overview]	Proportion of Enrolled Subjects Who Relapse
NCT00761735 (5) [back to overview]	Mean Weight Percentiles of Participants Over LTFU
NCT00761735 (5) [back to overview]	Mean Height Percentiles of Participants Over LTFU
NCT00761735 (5) [back to overview]	Mean Body Mass Index (BMI) Percentiles of Participants Over LTFU
NCT00761735 (5) [back to overview]	Number of Participants Who Relapsed At End of LTFU Year 5
NCT00761735 (5) [back to overview]	Mean Age at Attained Tanner Stages (Sexual Maturity) at End of LTFU (Last Observation) By Gender
NCT00780416 (1) [back to overview]	The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
NCT00780910 (1) [back to overview]	The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
NCT00781274 (1) [back to overview]	The Percentage of Subjects Achieving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
NCT00800735 (1) [back to overview]	Percentage of Participants Who Experienced at Least 1 Adverse Event.
NCT00835146 (2) [back to overview]	AUC0-72 (Area Under the Concentration-time Curve From Time Zero to Time of 72 Hours)
NCT00835146 (2) [back to overview]	Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
NCT00835536 (2) [back to overview]	Cmax (Maximum Observed Concentration of Drug Substance in Plasma)
NCT00835536 (2) [back to overview]	AUC0-72 (Area Under the Concentration-time Curve From Time Zero to Time of 72 Hours)
NCT00845065 (5) [back to overview]	Mean Log Change From Baseline to TW 4 in Viral Load by Visit
NCT00845065 (5) [back to overview]	Number of Participants With Undetectable HCV-RNA at Follow-up Week 12
NCT00845065 (5) [back to overview]	Sustained Virologic Response (SVR) Rate in Full Analysis Set (FAS) Population.
NCT00845065 (5) [back to overview]	SVR Rate in the Modified Intent-to-Treat (mITT) Population
NCT00845065 (5) [back to overview]	Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR
NCT00845676 (1) [back to overview]	Sustained Virologic Response (SVR)
NCT00851890 (14) [back to overview]	Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels Through Day 28
NCT00851890 (14) [back to overview]	Plasma Concentrations of Ribavirin (RBV)
NCT00851890 (14) [back to overview]	Number of Participants With Maximal Phenotypic Resistance to ABT-333 >10 Fold Relative to Baseline Through Day 28
NCT00851890 (14) [back to overview]	Number of Participants With Resistance-Associated Variants in Non-structural Viral Protein 5B (NS5B) Through Day 28
NCT00851890 (14) [back to overview]	Number of Participants Having Treatment-emergent Adverse Events (AEs)
NCT00851890 (14) [back to overview]	Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels Through Day 28 or Final Visit
NCT00851890 (14) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of ABT-333
NCT00851890 (14) [back to overview]	Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels ≤ 25 IU/mL (the Lower Limit of Quantitation [LLOQ]) at Day 28 or Final Visit
NCT00851890 (14) [back to overview]	Maximum Plasma Concentration (Cmax) of ABT-333
NCT00851890 (14) [back to overview]	Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels ≤ 10 IU/mL (Lower Limit of Detection [LLOD]) at Day 28 or Final Visit
NCT00851890 (14) [back to overview]	Percentage of Participants With at Least a 2 log10 Maximal Decrease in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-333 Treatment
NCT00851890 (14) [back to overview]	Mean Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-333 Monotherapy Treatment
NCT00851890 (14) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 12 Hours Post-dose (AUC12) of ABT-333
NCT00851890 (14) [back to overview]	Serum Concentrations of Pegylated Interferon (pegIFN)
NCT00856024 (3) [back to overview]	Percent of Participants Who Achieved Early Virologic Response (EVR)
NCT00856024 (3) [back to overview]	Percent of Participants Who Achieved Rapid Virologic Response (RVR)
NCT00856024 (3) [back to overview]	Percent of Participants Who Were Compliant to Treatment in the First 12 Weeks
NCT00863109 (7) [back to overview]	Change From Baseline (BL) to Week 72 (WK72) in 36-Item Short-Form Health Survey (SF-36) Scores
NCT00863109 (7) [back to overview]	Change From Baseline (BL) to Week 72 (WK72) in Chronic Liver Disease Questionnaire-Hepatitis C Virus (CLDQ-HCV)
NCT00863109 (7) [back to overview]	Change From Baseline to Week 72 (WK72) in CLDQ-HCV Scores Among Participants Who Completed Treatment and Participants Who Had Early End of Treatment (Subset Analysis)
NCT00863109 (7) [back to overview]	MCID in CLDQ-HCV Scores
NCT00863109 (7) [back to overview]	Change From Baseline to Week 72 (WK72) in SF-36 Scores Among Participants Who Completed Treatment and Participants Who Had Early End of Treatment (Subset Analysis)
NCT00863109 (7) [back to overview]	Minimal Clinically Important Difference (MCID) in SF-36 Scores
NCT00863109 (7) [back to overview]	Percentage of Participants Who Were Compliant With Treatment According To Medication Count (Subset Analysis)
NCT00867139 (12) [back to overview]	Frequency of Confirmed Pneumonia
NCT00867139 (12) [back to overview]	Duration of Symptoms
NCT00867139 (12) [back to overview]	Duration of Hospitalization
NCT00867139 (12) [back to overview]	Days on Supplemental Oxygen
NCT00867139 (12) [back to overview]	Number of Deaths
NCT00867139 (12) [back to overview]	Number of Patients Not Shedding Virus at Day 5 +/-1 and Day 10 +/- 1
NCT00867139 (12) [back to overview]	Pharmacokinetics (AUC0-last) of TCAD
NCT00867139 (12) [back to overview]	Number of Participants With Viral Resistance as a Function of Drug Exposure
NCT00867139 (12) [back to overview]	Number of Participants With Viral Load Decrease as a Function of Time
NCT00867139 (12) [back to overview]	Number of Participants With Intubations
NCT00867139 (12) [back to overview]	Number of Participants With ICU Admissions
NCT00867139 (12) [back to overview]	Number of Participants With Adverse Events (AEs), Drug Specific AEs or AEs Resulting in Treatment Interruption
NCT00874770 (7) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Treatment-related AEs and Who Died in Treatment Phase
NCT00874770 (7) [back to overview]	Percentage of Participants With Early Virologic Response (EVR) at Week 12
NCT00874770 (7) [back to overview]	Percentage of Participants With a Complete Early Virologic Response (cEVR) at Week 12
NCT00874770 (7) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Treatment-related AEs and Who Died in Follow-up Period
NCT00874770 (7) [back to overview]	Number of Participants With Grade 3 to 4 Abnormalities on Laboratory Test Results
NCT00874770 (7) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
NCT00874770 (7) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR) at Weeks 4 and 12
NCT00880763 (6) [back to overview]	Percentage of Participants Achieving a > or = 3-log10 Decrease in HCV RNA From Baseline to Week 4
NCT00880763 (6) [back to overview]	Number of Participants Who Experienced at Least One Adverse Event
NCT00880763 (6) [back to overview]	Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT00880763 (6) [back to overview]	Percentage of Participants Achieving a > or = 2-log10 Decrease in HCV RNA From Baseline to Week 4
NCT00880763 (6) [back to overview]	Percentage of Participants Achieving Rapid Viral Response
NCT00880763 (6) [back to overview]	Change From Baseline in HCV RNA in log10 at Week 4
NCT00882908 (14) [back to overview]	The Percentage of Participants Achieving an Early Virologic Response (EVR)
NCT00882908 (14) [back to overview]	The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)
NCT00882908 (14) [back to overview]	Plasma Concentrations of TMC435
NCT00882908 (14) [back to overview]	The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Greater Than or Equal to 2 log10 Drop During Treatment
NCT00882908 (14) [back to overview]	The Percentage of Participants Achieving Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Undetectable During Treatment and Follow-up
NCT00882908 (14) [back to overview]	The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)
NCT00882908 (14) [back to overview]	The Percentage of Participants Achieving a Rapid Virologic Response (RVR)
NCT00882908 (14) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)
NCT00882908 (14) [back to overview]	Number of Participants With Viral Breakthrough
NCT00882908 (14) [back to overview]	The Percentage of Participants Who Achieved Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels of Less Than 25 IU/mL Detectable or Undetectable During Treatment and Follow-up
NCT00882908 (14) [back to overview]	The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normalized ALT Levels at the End of Treatment (EOT)
NCT00882908 (14) [back to overview]	The Number of Participants With Viral Relapse
NCT00882908 (14) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
NCT00882908 (14) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435
NCT00892697 (2) [back to overview]	Intrahepatic and Peripheral Pharmacokinetic Assessment of Telaprevir
NCT00892697 (2) [back to overview]	Intrahepatic and Plasma HCV Viral Kinetics
NCT00910624 (3) [back to overview]	Percentage of Participants With Early Virologic Response (EVR)
NCT00910624 (3) [back to overview]	Percentage of Participants With Adverse Events (AEs) Leading to Dose Modification (DM) or Discontinuation (DC), Treatment-Related Serious AEs (SAEs), Neutrophil Count <0.75 × 10^9/L, or Hemoglobin (Hgb) <10 g/dL
NCT00910624 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24);
NCT00919633 (3) [back to overview]	Early Virologic Response (EVR)
NCT00919633 (3) [back to overview]	Rapid Virologic Response (RVR)
NCT00919633 (3) [back to overview]	Viral Load: Incidence of Sustained Virologic Response (SVR)
NCT00922779 (4) [back to overview]	Percentage of Participants With Sustained Virological Response (SVR) at 24 Weeks After End of Therapy
NCT00922779 (4) [back to overview]	Percentage of Participants With Undetectable HCV RNA at Weeks 12, 24 and 48 After Therapy Initiation
NCT00922779 (4) [back to overview]	Percentage of Participants With Change in Hemoglobin Level
NCT00922779 (4) [back to overview]	Number of Participants With Non-Serious Adverse Events (AEs) And Serious Adverse Events (SAEs)
NCT00925990 (2) [back to overview]	Mean Change in Aminotransferases From Baseline to 24 Weeks of Treatment
NCT00925990 (2) [back to overview]	Mean Change in HCV-RNA (Hepatitis C Virus Ribonucleic Acid) Levels From Baseline Through 24 Weeks of Treatment
NCT00943761 (4) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to an Adverse Event
NCT00943761 (4) [back to overview]	Number of Participants Who Experienced a Serious Adverse Event
NCT00943761 (4) [back to overview]	Number of Participants Who Experienced an Adverse Event
NCT00943761 (4) [back to overview]	Percentage of Participants Who Achieved Sustained Viral Response 24 Weeks After the End of Treatment (SVR24)
NCT00947349 (33) [back to overview]	Number of Participants With Investigator Defined Drug-related Adverse Events in Standard of Care (SOC) With PegIFN α-2a and RBV
NCT00947349 (33) [back to overview]	Number of Participants With Investigator Defined Drug-related Adverse Events in Triple Combination Therapy
NCT00947349 (33) [back to overview]	Rapid Virological Response (RVR)
NCT00947349 (33) [back to overview]	Sustained Virologic Response (SVR)
NCT00947349 (33) [back to overview]	t1/2,ss for BI 201335 ZW
NCT00947349 (33) [back to overview]	Tmax for BI 201335 ZW
NCT00947349 (33) [back to overview]	Tmax for RBV
NCT00947349 (33) [back to overview]	Tmax, ss for BI 201335 ZW
NCT00947349 (33) [back to overview]	Tmax, ss for RBV
NCT00947349 (33) [back to overview]	Week 2 Virological Response (W2VR)
NCT00947349 (33) [back to overview]	Week 4 Virological Response (W4VR)
NCT00947349 (33) [back to overview]	Assessment of Tolerability in Standard of Care (SOC) With PegIFN α -2a and RBV
NCT00947349 (33) [back to overview]	Assessment of Tolerability in Triple Combination Therapy
NCT00947349 (33) [back to overview]	Number of Patients With Possible Clinically Significant Laboratory Abnormalities in Standard of Care (SOC) With PegIFN α-2a and RBV
NCT00947349 (33) [back to overview]	Number of Patients With Possible Clinically Significant Laboratory Abnormalities in Triple Combination Therapy
NCT00947349 (33) [back to overview]	AUCτ,ss of RBV
NCT00947349 (33) [back to overview]	AUCτ,1 for BI 201335 ZW
NCT00947349 (33) [back to overview]	AUCτ,1 for Ribavirin (RBV)
NCT00947349 (33) [back to overview]	AUCτ,ss of BI 201335 ZW
NCT00947349 (33) [back to overview]	Cavg for BI 201335 ZW
NCT00947349 (33) [back to overview]	Cavg for RBV
NCT00947349 (33) [back to overview]	Change From Baseline in HCV Viral Load
NCT00947349 (33) [back to overview]	CL/F,ss for BI 201335 ZW
NCT00947349 (33) [back to overview]	Cmax of BI 201335 ZW
NCT00947349 (33) [back to overview]	Cmax of RBV
NCT00947349 (33) [back to overview]	Cmax,ss of BI 201335 ZW
NCT00947349 (33) [back to overview]	Cmax,ss of RBV
NCT00947349 (33) [back to overview]	Cmin,ss for BI 201335 ZW
NCT00947349 (33) [back to overview]	Cmin,ss for RBV
NCT00947349 (33) [back to overview]	Complete Early Virological Response (cEVR)
NCT00947349 (33) [back to overview]	Day 28 Virologic Response
NCT00947349 (33) [back to overview]	Early Virological Response (EVR)
NCT00947349 (33) [back to overview]	End of Treatment Response (ETR)
NCT00959699 (6) [back to overview]	Percentage of Participants With Early Virologic Response (EVR) Who Achieved SVR24
NCT00959699 (6) [back to overview]	Change From Baseline in log10 HCV-RNA at Treatment Week 4 (TW4)
NCT00959699 (6) [back to overview]	Percentage of Participants With Undetectable HCV-RNA at Follow-up Week 12 (FW12)
NCT00959699 (6) [back to overview]	Percentage of Participants Achieving SVR24 Among Randomized Participants Who Received At Least One Dose of Boceprevir (Experimental) or Placebo (Control)
NCT00959699 (6) [back to overview]	Percentage of Participants Achieving Sustained Viral Response (SVR) at Follow-up Week 24 (FW24) Among Randomized Participants Who Received At Least One Dose of Trial Medication
NCT00959699 (6) [back to overview]	Percentage of Participants With HCV Virologic Breakthrough or Incomplete Virologic Response/Rebound
NCT00980330 (13) [back to overview]	The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Detectable or Undetectable During Treatment and Follow-up
NCT00980330 (13) [back to overview]	Plasma Concentrations of TMC435
NCT00980330 (13) [back to overview]	The Percentage of Participants With Viral Relapse
NCT00980330 (13) [back to overview]	The Percentage of Participants With Viral Breakthrough
NCT00980330 (13) [back to overview]	The Percentage of Participants Achieving an Early Virologic Response (EVR)
NCT00980330 (13) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the EOT (SVR24)
NCT00980330 (13) [back to overview]	The Number of Participants Who Achieved Normalized Alanine Aminotransferase (ALT) Levels at the End of Treatment (EOT)
NCT00980330 (13) [back to overview]	The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)
NCT00980330 (13) [back to overview]	The Percentage of Participants With a Greater Than 2 log10 Drop in Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Time Points During Treatment
NCT00980330 (13) [back to overview]	The Percentage of Participants Achieving Plasma Levels of Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable During Treatment and Follow-up
NCT00980330 (13) [back to overview]	The Percentage of Participants Achieving a Rapid Virologic Response (RVR)
NCT00980330 (13) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
NCT00980330 (13) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435
NCT00982553 (4) [back to overview]	Ribavirin Minimum Plasma Concentration
NCT00982553 (4) [back to overview]	Raltegravir Maximum Plasma Concentration
NCT00982553 (4) [back to overview]	Raltegravir Minimum Plasma Concentrations
NCT00982553 (4) [back to overview]	Ribavirin Maximum Plasma Concentration
NCT00983853 (6) [back to overview]	Proportion of Subjects Achieving Undetectable HCV RNA at Week 12
NCT00983853 (6) [back to overview]	Proportion of Subjects Who Have Undetectable HCV RNA 12 Weeks (SVR12) and 24 Weeks (SVR24) After Last Planned Dose of Study Treatment
NCT00983853 (6) [back to overview]	Proportion of Subjects Achieving Undetectable HCV RNA at Week 4 and Week 12
NCT00983853 (6) [back to overview]	Median Trough Plasma Concentration (Ctrough) Ratios of Efavirenz and Tenofovir (Part B Only, Subjects on EFV-based HAART)
NCT00983853 (6) [back to overview]	Median Trough Plasma Concentration (Ctrough) Ratios of Atazanavir (ATZ), Ritonavir, and Tenofovir (Part B Only, Subjects on ATV-based HAART)
NCT00983853 (6) [back to overview]	Effect of Efavirenz-based (EFV) and Atazanavir-based (ATV/r) Highly Active Antiretroviral Therapy(HAART) on Telaprevir Exposure
NCT00984620 (16) [back to overview]	Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (5)
NCT00984620 (16) [back to overview]	Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (6)
NCT00984620 (16) [back to overview]	Viral Load (HCV RNA) at All Visits During Treatment and Follow-up
NCT00984620 (16) [back to overview]	Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (4)
NCT00984620 (16) [back to overview]	End of Treatment Response (ETR)
NCT00984620 (16) [back to overview]	Number of Participants With Clinically Relevant Abnormalities Vital Signs, and Physical Examination
NCT00984620 (16) [back to overview]	Rapid Virological Response at Week 4 (RVR)
NCT00984620 (16) [back to overview]	Sustained Virological Response (SVR24) at 24 Weeks After Completion of All Therapy
NCT00984620 (16) [back to overview]	Time to Reach a Plasma HCV RNA Level BLD While on Treatment
NCT00984620 (16) [back to overview]	Virological Response at Week 28 (W28VR)
NCT00984620 (16) [back to overview]	Virological Response at Week 36 (W36VR)
NCT00984620 (16) [back to overview]	Laboratory Test Abnormalities and Study Medication Tolerabilities
NCT00984620 (16) [back to overview]	Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (1)
NCT00984620 (16) [back to overview]	Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (2)
NCT00984620 (16) [back to overview]	Laboratory Test Value Changes Over Time for Selected Lab Test Parameters (3)
NCT00984620 (16) [back to overview]	Virological Response at Week 24 (W24VR)
NCT00991289 (11) [back to overview]	Change in log10 HCV Viral Load After 4 Weeks of Nitazoxanide (NTZ) Monotherapy.
NCT00991289 (11) [back to overview]	Percent Change in Fasting Insulin Level From Study Entry
NCT00991289 (11) [back to overview]	Percent Change in Homeostasis Model Assessment of Insulin Resistance (HOMA-IR) From Study Entry
NCT00991289 (11) [back to overview]	Change in Hemoglobin Level From Study Entry
NCT00991289 (11) [back to overview]	Percentage of Participants With Early Virologic Response (EVR)
NCT00991289 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR)
NCT00991289 (11) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR)
NCT00991289 (11) [back to overview]	Number of Participants With Adverse Events of Grade 2 or Higher
NCT00991289 (11) [back to overview]	Number of Participants With HCV Genotype 1
NCT00991289 (11) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR)
NCT00991289 (11) [back to overview]	Percent Change in Fasting Glucose Level From Study Entry
NCT01016912 (7) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR)
NCT01016912 (7) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR)
NCT01016912 (7) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Treatment-related AEs, and Death as Outcome
NCT01016912 (7) [back to overview]	Number of Participants With Grade 3 to 4 Abnormalities on Laboratory Test Results
NCT01016912 (7) [back to overview]	Percentage of Participants With a Sustained Virologic Response (SVR) at Weeks 4, 12, and 24
NCT01016912 (7) [back to overview]	Percentage of Participants With Virologic Failure
NCT01016912 (7) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR)
NCT01017575 (6) [back to overview]	Percentage of Participants With a Complete Early Virologic Response (cEVR)
NCT01017575 (6) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR)
NCT01017575 (6) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR)
NCT01017575 (6) [back to overview]	Percentage of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 and Follow-up Week 24
NCT01017575 (6) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Who Died.
NCT01017575 (6) [back to overview]	Number of Participants With Grade 3 to 4 Laboratory Abnormalities
NCT01023035 (2) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR)
NCT01023035 (2) [back to overview]	Percentage of Participants Who Discontinued Treatment
NCT01052701 (2) [back to overview]	Ribavirin Triphosphate (RBV-TP) Intracellular Concentrations
NCT01052701 (2) [back to overview]	Plasma RBV Trough Concentrations
NCT01054573 (10) [back to overview]	Percentage of Participants Achieving Rapid Virologic Response (RVR)
NCT01054573 (10) [back to overview]	Percentage of Participants Achieving Extended Rapid Virologic Response (eRVR)
NCT01054573 (10) [back to overview]	Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue Telaprevir and Continue Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) at Week 4 or Week 8
NCT01054573 (10) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT01054573 (10) [back to overview]	Percentage of Participants Who Met a Virologic Stopping Rule That Required Them to Permanently Discontinue All Study Drugs at Week 12, 24, or 36
NCT01054573 (10) [back to overview]	Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values Over Time
NCT01054573 (10) [back to overview]	The Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected at Different Time Points
NCT01054573 (10) [back to overview]	Change From Baseline in Log 10 Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Level
NCT01054573 (10) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response (SVR) 24 Weeks After the Last Dose of Study Drug (SVR24 Actual)
NCT01054573 (10) [back to overview]	Percentage of Participants Who Relapsed During Follow-Up
NCT01054742 (1) [back to overview]	Number of Participants With Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Levels During Part 2 of the Study
NCT01056523 (5) [back to overview]	Overall Response Rate
NCT01056523 (5) [back to overview]	Recommended Phase II Dose (RP2D) of Ribavirin When Given in Combination With Low-dose Ara-C
NCT01056523 (5) [back to overview]	Partial Response
NCT01056523 (5) [back to overview]	Complete Response Rate
NCT01056523 (5) [back to overview]	Blast Response
NCT01074008 (24) [back to overview]	Maximum Plasma Concentration (Cmax) of ABT-450
NCT01074008 (24) [back to overview]	Maximum Plasma Concentration (Cmax) of ABT-333
NCT01074008 (24) [back to overview]	Maximum Plasma Concentration (Cmax) of ABT-072
NCT01074008 (24) [back to overview]	Maximal Change From Baseline in Hepatitis C Virus Ribonucleic Acid (HCV RNA) Levels During ABT-450/r, ABT-333, or ABT-072 Monotherapy Treatment
NCT01074008 (24) [back to overview]	Change From Baseline in SF-36 Physical Component Summary (PCS)
NCT01074008 (24) [back to overview]	Change From Baseline in SF-36 Mental Component Summary (MCS)
NCT01074008 (24) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-072
NCT01074008 (24) [back to overview]	Change From Baseline in Hepatitis C Virus Patient-reported Outcomes (HCV-PRO) Total Score
NCT01074008 (24) [back to overview]	Change From Baseline in EQ-5D (3 Level) Health Index Score
NCT01074008 (24) [back to overview]	Change From Baseline in ED-5D Visual Analog Scale (ED-5D VAS) Score
NCT01074008 (24) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of Ritonavir
NCT01074008 (24) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-450
NCT01074008 (24) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 12 Hours (AUC12) Post-dose of ABT-333
NCT01074008 (24) [back to overview]	Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-450 in Non-structural Viral Protein 3 (NS3)
NCT01074008 (24) [back to overview]	Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-333 in Non-structural Viral Protein 5B (NS5B)
NCT01074008 (24) [back to overview]	Number of Participants With Resistance-Associated Variants and Phenotypic Resistance to ABT-072 in Non-structural Viral Protein 5B (NS5B)
NCT01074008 (24) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of ABT-072
NCT01074008 (24) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of Ritonavir
NCT01074008 (24) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of ABT-450
NCT01074008 (24) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of ABT-333
NCT01074008 (24) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
NCT01074008 (24) [back to overview]	Percentage of Participants With Partial Early Virologic Response (EVR) at Week 12
NCT01074008 (24) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR) at Week 12
NCT01074008 (24) [back to overview]	Maximum Plasma Concentration (Cmax) of Ritonavir
NCT01097395 (3) [back to overview]	Ribavirin AUC-12 Variability
NCT01097395 (3) [back to overview]	Safety - Absolute Hemoglobin Declines
NCT01097395 (3) [back to overview]	Sustained Virologic Response (i.e., Cure)
NCT01098097 (6) [back to overview]	Incidence of Treatment Discontinuations Due to Adverse Events
NCT01098097 (6) [back to overview]	Incidence of Serious Adverse Events (SAEs) and/or Clinically Significant Adverse Events (AEs)
NCT01098097 (6) [back to overview]	Incidence of Particular Adverse Events Resulting in Treatment Discontinuation
NCT01098097 (6) [back to overview]	Incidence of Dose Modifications Due to Adverse Events
NCT01098097 (6) [back to overview]	Proportion of Participants Who Achieve Undetectable Hepatitis C Virus Ribonucleic Acid (HCV-RNA)
NCT01098097 (6) [back to overview]	Incidence of Thrombocytopenia
NCT01125189 (7) [back to overview]	Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Rapid Virologic Response (RVR)
NCT01125189 (7) [back to overview]	Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Sustained Virologic Response (SVR24)
NCT01125189 (7) [back to overview]	Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Extended Rapid Virologic Response (eRVR)
NCT01125189 (7) [back to overview]	Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With Complete Early Virologic Response (cEVR)
NCT01125189 (7) [back to overview]	Percentage of Hepatitis C Virus (HCV) Genotype 1 Participants With 12-week Sustained Virologic Response (SVR12)
NCT01125189 (7) [back to overview]	Percentage of Resistant Variants Associated With Virologic Failure
NCT01125189 (7) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), and Who Died
NCT01132313 (9) [back to overview]	Part 2: Time to Virological Response
NCT01132313 (9) [back to overview]	Part 1 and 2: Plasma HCV RNA Level Not Detectable at Week 4
NCT01132313 (9) [back to overview]	Part 1: Rapid Virological Response (RVR)
NCT01132313 (9) [back to overview]	Part 2: Sustained Virological Response (SVR)
NCT01132313 (9) [back to overview]	Part 3 and 4: Plasma HCV RNA Level <25 IU/mL at Week 4 and 12 of Treatment
NCT01132313 (9) [back to overview]	Part 3 and 4: Sustained Virological Response (SVR)
NCT01132313 (9) [back to overview]	Part 3 and 4: Sustained Virological Response (SVR) at 4 Weeks After End of Treatment
NCT01132313 (9) [back to overview]	Part 1: Time to Virological Response
NCT01132313 (9) [back to overview]	Part 2: Sustained Virological Response at 4 and 24 Weeks After End of Treatment
NCT01170962 (9) [back to overview]	Percentage of Participants With 24-week Sustained Virologic Response (SVR24)
NCT01170962 (9) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR)
NCT01170962 (9) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR)
NCT01170962 (9) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR)
NCT01170962 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12)
NCT01170962 (9) [back to overview]	Number of Participants With Genotypic-1A Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures
NCT01170962 (9) [back to overview]	Number of Participants With Genotypic-1B Substitution at Baseline, On-treatment and During Follow-up Associated With Virologic Failures
NCT01170962 (9) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) and Who Died During Follow-up Period
NCT01170962 (9) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died On-treatment
NCT01180790 (11) [back to overview]	Segment 2: Complete Early Virologic Response (cEVR)
NCT01180790 (11) [back to overview]	Segment 2: Safety
NCT01180790 (11) [back to overview]	Segment 1: Safety
NCT01180790 (11) [back to overview]	Segment 1: Rapid Viral Response At Week 4 (RVR4)
NCT01180790 (11) [back to overview]	Segment 2: RVR4
NCT01180790 (11) [back to overview]	Segment 1: cEVR
NCT01180790 (11) [back to overview]	Segment 1 And Segment 2: Sustained Virologic Response 24 Weeks (6 Months Post-dosing) (SVR24)
NCT01180790 (11) [back to overview]	Segment 1 And Segment 2: Sustained Virologic Response 12 Weeks (3 Months Post-dosing) (SVR12)
NCT01180790 (11) [back to overview]	Segment 1 And Segment 2: HCV RNA Change From Baseline
NCT01180790 (11) [back to overview]	Segment 1 And Segment 2: End Of Treatment Response
NCT01180790 (11) [back to overview]	Segment 1 And Segment 2: HCV RNA Change From Baseline
NCT01183169 (10) [back to overview]	Percentage of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Had Normalized ALT at Treatment End and Study End
NCT01183169 (10) [back to overview]	Percentage of Participants With Rapid Viral Response (RVR)-LOQ and RVR-LOD
NCT01183169 (10) [back to overview]	Percentage of Participants With Complete Early Viral Response Below the Limit of Quantification (cEVR-LOQ)
NCT01183169 (10) [back to overview]	Percentage of Participants With On-treatment Viral Breakthrough
NCT01183169 (10) [back to overview]	Percentage of Participants With Viral Relapse
NCT01183169 (10) [back to overview]	Percentage of Participants Who Achieved Sustained Viral Response 12 Weeks After Treatment (SVR12)-LOQ and SVR12-LOD
NCT01183169 (10) [back to overview]	Percentage of Participants Who Achieved Sustained Viral Response 24 Weeks After Treatment (SVR24)-LOQ and SVR24-LOD
NCT01183169 (10) [back to overview]	Percentage of Participants With End of Treatment Response (ETR)-LOQ and ETR-LOD
NCT01183169 (10) [back to overview]	Percentage of Participants With Partial Early Virologic Response After 12 Weeks of Treatment (pEVR)-LOQ and pEVR-LOD
NCT01183169 (10) [back to overview]	Percentage of Participants With Complete Early Viral Response Below the Limit of Detection (cEVR-LOD)
NCT01185028 (3) [back to overview]	Number of Participants With Adverse Events
NCT01185028 (3) [back to overview]	Tolerability of Study Drug Measured as Discontinuation.
NCT01185028 (3) [back to overview]	Sustained Viral Response Rate
NCT01215643 (18) [back to overview]	Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 2)
NCT01215643 (18) [back to overview]	Percentage of Participants With RVR Who Achieved SVR at 24 Weeks After the End of Treatment (SVR24LOQ and SVR24LOD)
NCT01215643 (18) [back to overview]	Percentage of Participants With End of Treatment Response (ETR) Within 24 Weeks (ETR24LOQ and ETR24LOD)
NCT01215643 (18) [back to overview]	Percentage of Participants With On-treatment Viral Breakthrough
NCT01215643 (18) [back to overview]	Percentage of Participants With Rapid Viral Response (RVR) After 4 Weeks of Treatment < the Limit of Quantification (RVR4LOQ)
NCT01215643 (18) [back to overview]	Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 2)
NCT01215643 (18) [back to overview]	Percentage of Participants With Complete Early Viral Response (cEVR) After 12 Weeks of Treatment (cEVR12LOQ and cEVR12LOD)
NCT01215643 (18) [back to overview]	Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 2)
NCT01215643 (18) [back to overview]	Percentage of Participants With Viral Relapse
NCT01215643 (18) [back to overview]	Percentage of Participants With RVR Who Achieved SVR12LOQ and SVR12LOD (Genotype 3)
NCT01215643 (18) [back to overview]	Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 3)
NCT01215643 (18) [back to overview]	Percentage of Participants With cEVR12LOQ and cEVR12LOD (Genotype 3)
NCT01215643 (18) [back to overview]	Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 2)
NCT01215643 (18) [back to overview]	Percentage of Participants With RVR4LOQ and RVR4LOD (Genotype 3)
NCT01215643 (18) [back to overview]	Percentage of Participants With RVR Who Achieved Sustained Viral Response (SVR) 12 Weeks After the End of Treatment (SVR12LOQ and SVR12LOD)
NCT01215643 (18) [back to overview]	Percentage of Participants With ETR24LOQ and ETR24LOD (Genotype 3)
NCT01215643 (18) [back to overview]	Percentage of Participants With RVR After 4 Weeks of Treatment < the Limit of Detection (RVR4LOD)
NCT01215643 (18) [back to overview]	Percentage of Participants With RVR Who Achieved SVR24LOQ and SVR24LOD (Genotype 2)
NCT01221298 (7) [back to overview]	Time to Virologic Relapse Through 24 Weeks Post-treatment
NCT01221298 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment
NCT01221298 (7) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12
NCT01221298 (7) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Below the Lower Limit of Quantitation (LLOQ) at Week 4
NCT01221298 (7) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) < 1000 International Units Per Milliliter (IU/mL)
NCT01221298 (7) [back to overview]	Time to Failure to Suppress or Rebound During Treatment
NCT01221298 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment
NCT01227967 (14) [back to overview]	Number of Participants by Virus Detection Status
NCT01227967 (14) [back to overview]	qPCR Viral Shedding
NCT01227967 (14) [back to overview]	Time to Feeling as Good as Before the Onset of the Influenza Illness
NCT01227967 (14) [back to overview]	Percentage of Participants Who Required Hospitalization.
NCT01227967 (14) [back to overview]	28-day Mortality
NCT01227967 (14) [back to overview]	Time to Resolution of All Symptoms AND Fever
NCT01227967 (14) [back to overview]	Time to Return of Physical Function to Pre-illness Leve
NCT01227967 (14) [back to overview]	Percentage of Participants Who Required New or Increased Use of Supplemental Oxygen
NCT01227967 (14) [back to overview]	Percentage of Participants With Clinical Failure at Day 5
NCT01227967 (14) [back to overview]	Percentage of Participants With Virus Detectable by Quantitative PCR (qPCR) in Nasopharyngeal (NP) Swabs
NCT01227967 (14) [back to overview]	Time to Absence of Fever
NCT01227967 (14) [back to overview]	Time to Alleviation of Influenza Clinical Symptoms.
NCT01227967 (14) [back to overview]	Time to Return to Pre-influenza Function
NCT01227967 (14) [back to overview]	Percentage of Participants Who Develop Bronchitis, Pneumonia, or Other Complications of Influenza After Day 0.
NCT01241760 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 72 Weeks After the Start of Study Medication (SVR72 Planned)
NCT01241760 (7) [back to overview]	Percentage of Participants With On-treatment Virologic Failure Which Required Them to Permanently Discontinue All Study Drugs
NCT01241760 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned)
NCT01241760 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Planned Dose of Study Drugs (SVR24 Planned)
NCT01241760 (7) [back to overview]	Percentage of Participants of Each IL28B Genotype Achieving Sustained Virologic Response 12 Weeks After the Last Planned Dose of Study Medication (SVR12 Planned)
NCT01241760 (7) [back to overview]	Percentage of Participants Achieving Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Values of Less Than 25 IU/ml, Target Not Detected, at Different Time Points.
NCT01241760 (7) [back to overview]	Percentage of Participants Who Relapsed During Follow-up Period
NCT01257204 (12) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) for Hepatitis C Virus (HCV) Genotype 2
NCT01257204 (12) [back to overview]	Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4 for Hepatitis C Virus (HCV) Genotype 3
NCT01257204 (12) [back to overview]	Percentage of Participants Achieving Rapid Virologic Response (RVR) at Week 4 for Hepatitis C Virus (HCV) Genotype 2
NCT01257204 (12) [back to overview]	Percentage of Participants Achieving Complete Early Virologic Response (cEVR) at Week 12 for Hepatitis C Virus (HCV) Genotype 3
NCT01257204 (12) [back to overview]	Percentage of Participants Achieving Complete Early Virologic Response (cEVR) at Week 12 for Hepatitis C Virus (HCV) Genotype 2
NCT01257204 (12) [back to overview]	Number of Participants With Virologic Failure for Hepatitis C Virus (HCV) Genotype 3
NCT01257204 (12) [back to overview]	Number of Participants With Virologic Failure for Hepatitis C Virus (HCV) Genotype 2
NCT01257204 (12) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Treatment-related AEs and Who Died During Treatment Period
NCT01257204 (12) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died During Follow-up Period
NCT01257204 (12) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 3
NCT01257204 (12) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 24 (SVR24) for Hepatitis C Virus (HCV) Genotype 2
NCT01257204 (12) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12) for Hepatitis C Virus (HCV) Genotype 3
NCT01258101 (11) [back to overview]	Number of Participants With Any Adverse Events and Any Serious Adverse Events
NCT01258101 (11) [back to overview]	Percentage of Participants With Virologic Response Rates as Per Genotype at End of Treatment
NCT01258101 (11) [back to overview]	Mean SF-36 Scores at Baseline and Weeks 16, 24 and 48
NCT01258101 (11) [back to overview]	Mean FSS Scores at Baseline and Weeks 16, 24 and 48
NCT01258101 (11) [back to overview]	Median Hemoglobin Levels at End of Treatment
NCT01258101 (11) [back to overview]	Mean Beschwerdeliste Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 16, 24 and 48
NCT01258101 (11) [back to overview]	Beck Depression Inventory Mean Score for Participants Receiving an Opioid Maintenance Therapy At Baseline and Weeks 4, 8, 12, 24 and 48
NCT01258101 (11) [back to overview]	Time to Viral Response
NCT01258101 (11) [back to overview]	Percentage of Participants With Virological Response at the End of the Treatment
NCT01258101 (11) [back to overview]	Percentage of Participants Who Achieve Sustained Virologic Response Rate At 24 Weeks Post Completion of the Treatment
NCT01258101 (11) [back to overview]	Percentage of Participants With Hepatitis C Virus-RNA Determined by AMPLICOR HCV Test At Week 24 and Week 48
NCT01276756 (5) [back to overview]	Sustained Virologic Response
NCT01276756 (5) [back to overview]	Early Virological Response
NCT01276756 (5) [back to overview]	Rapid Virological Response
NCT01276756 (5) [back to overview]	Safety of Nitazoxanide (Number of Participants Experiencing Adverse Events)
NCT01276756 (5) [back to overview]	End-of-treatment Response
NCT01280656 (13) [back to overview]	Number of Participants With Any Adverse Events and Any Serious Adverse Events
NCT01280656 (13) [back to overview]	Percentage of Participants Who Were Treated at Interferon Application Centers and at Home and Discontinued Treatment
NCT01280656 (13) [back to overview]	Mean Percentage Reduction of Hemoglobin in Treatment Responders and Treatment Non-Responders
NCT01280656 (13) [back to overview]	Percentage of Participants With Virologic Response at End of Treatment
NCT01280656 (13) [back to overview]	Percentage of Participants With Virologic Relapse up to Week 72
NCT01280656 (13) [back to overview]	Percentage of Participants With Sustained Virologic Response at 24 Weeks After End of Treatment
NCT01280656 (13) [back to overview]	Percentage of Participants With Sustained Virologic Response at 12 Weeks After End of Treatment
NCT01280656 (13) [back to overview]	Percentage of Participants With Rapid Virologic Response at Week 4
NCT01280656 (13) [back to overview]	Percentage of Participants With Null Response or No Responder at End of Treatment
NCT01280656 (13) [back to overview]	Percentage of Participants With Early Virologic Response at Week 12
NCT01280656 (13) [back to overview]	Number of Participants With Interferon Dose Reduction Rates in Function of the Interferon Type Being Used
NCT01280656 (13) [back to overview]	Percentage of Participants With Sustained Virologic Response Treated at Interferon Application Centers and Treated at Home
NCT01280656 (13) [back to overview]	Percentage of Participants Who Discontinued Treatment Due to Adverse Events
NCT01281839 (30) [back to overview]	The Percentage of Participants With Viral Breakthrough
NCT01281839 (30) [back to overview]	The Percentage of Participants With Viral Relapse
NCT01281839 (30) [back to overview]	Time From End-of-treatment to Viral Relapse
NCT01281839 (30) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <100 IU/mL
NCT01281839 (30) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <1000 IU/mL
NCT01281839 (30) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable
NCT01281839 (30) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable or Detectable
NCT01281839 (30) [back to overview]	Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
NCT01281839 (30) [back to overview]	The Percentage of Participants With On-treatment Virologic Response at All Time Points
NCT01281839 (30) [back to overview]	The Percentage of Participants With Viral Breakthrough at Different Time Points
NCT01281839 (30) [back to overview]	Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
NCT01281839 (30) [back to overview]	Median Time to Normalization of Alanine Aminotransferase (ALT) Levels
NCT01281839 (30) [back to overview]	Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels >1000 IU/mL at Week 4
NCT01281839 (30) [back to overview]	Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)
NCT01281839 (30) [back to overview]	Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)
NCT01281839 (30) [back to overview]	Plasma Concentration of TMC435: Systemic Clearance (CL)
NCT01281839 (30) [back to overview]	The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)
NCT01281839 (30) [back to overview]	The Percentage of Participants Achieving a Early Virologic Response (EVR)
NCT01281839 (30) [back to overview]	The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)
NCT01281839 (30) [back to overview]	The Percentage of Participants Achieving a Rapid Virologic Response (RVR)
NCT01281839 (30) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
NCT01281839 (30) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)
NCT01281839 (30) [back to overview]	The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)
NCT01281839 (30) [back to overview]	The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)
NCT01281839 (30) [back to overview]	The Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule
NCT01281839 (30) [back to overview]	The Percentage of Participants With <1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4
NCT01281839 (30) [back to overview]	The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)
NCT01281839 (30) [back to overview]	The Percentage of Participants With Null Response
NCT01281839 (30) [back to overview]	The Percentage of Participants With On-treatment Failure
NCT01281839 (30) [back to overview]	The Percentage of Participants With Partial Response
NCT01288209 (11) [back to overview]	The Number of Participants With Viral Breakthrough During the Study
NCT01288209 (11) [back to overview]	The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)
NCT01288209 (11) [back to overview]	Plasma Concentrations of TMC435
NCT01288209 (11) [back to overview]	The Number of Participants Demonstrating Viral Relapse During the Study
NCT01288209 (11) [back to overview]	The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)
NCT01288209 (11) [back to overview]	The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels During Treatment for Participants Who Did Not Achieve Undetectable Plasma HCV RNA Levels at Week 12
NCT01288209 (11) [back to overview]	The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up
NCT01288209 (11) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435
NCT01288209 (11) [back to overview]	The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)
NCT01288209 (11) [back to overview]	The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFNα-2a) and Ribavirin (RBV) at Week 24
NCT01288209 (11) [back to overview]	The Number Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)
NCT01289782 (34) [back to overview]	Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule
NCT01289782 (34) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
NCT01289782 (34) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable or Detectable
NCT01289782 (34) [back to overview]	Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment
NCT01289782 (34) [back to overview]	Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
NCT01289782 (34) [back to overview]	Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels >1000 IU/mL at Week 4
NCT01289782 (34) [back to overview]	The Percentage of Participants Achieving a Early Virologic Response (EVR)
NCT01289782 (34) [back to overview]	The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)
NCT01289782 (34) [back to overview]	The Percentage of Participants Achieving a Rapid Virologic Response (RVR)
NCT01289782 (34) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)
NCT01289782 (34) [back to overview]	The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)
NCT01289782 (34) [back to overview]	Time From End-of-treatment to Viral Relapse
NCT01289782 (34) [back to overview]	The Percentage of Participants With Viral Breakthrough at Different Time Points
NCT01289782 (34) [back to overview]	Percentage of Participants With On-treatment Virologic Response at All Time Points
NCT01289782 (34) [back to overview]	Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activity Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment
NCT01289782 (34) [back to overview]	Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores
NCT01289782 (34) [back to overview]	Plasma Concentration of TMC435: Systemic Clearance (CL)
NCT01289782 (34) [back to overview]	Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)
NCT01289782 (34) [back to overview]	Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)
NCT01289782 (34) [back to overview]	Percentage of Participants With Viral Relapse
NCT01289782 (34) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT01289782 (34) [back to overview]	The Percentage of Participants With <1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4
NCT01289782 (34) [back to overview]	Percentage of Participants With Partial Response
NCT01289782 (34) [back to overview]	Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
NCT01289782 (34) [back to overview]	Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) in Work Productivity and Activity (WPAI) Absenteeism Scores Due to Hepatitis C Virus (HCV) Infection and Its Treatment
NCT01289782 (34) [back to overview]	The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)
NCT01289782 (34) [back to overview]	The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)
NCT01289782 (34) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <100 IU/mL
NCT01289782 (34) [back to overview]	The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)
NCT01289782 (34) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <1000 IU/mL
NCT01289782 (34) [back to overview]	Percentage of Participants With Null Response
NCT01289782 (34) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable
NCT01289782 (34) [back to overview]	Median Time to Normalization of Alanine Aminotransferase (ALT) Levels
NCT01289782 (34) [back to overview]	Percentage of Participants With On-treatment Failure
NCT01290679 (34) [back to overview]	Plasma Concentration of TMC435: Predose Plasma Concentration (C0h)
NCT01290679 (34) [back to overview]	Plasma Concentration of TMC435: Area Under the Plasma Concentration-time Curve From the Time of Administration to 24 Hours After Dosing (AUC24h)
NCT01290679 (34) [back to overview]	The Percentage of Participants With Normalization of Alanine Aminotransferase (ALT)
NCT01290679 (34) [back to overview]	Percentage of Participants With Viral Relapse
NCT01290679 (34) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12)
NCT01290679 (34) [back to overview]	Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
NCT01290679 (34) [back to overview]	Percentage of Participants With On-treatment Virologic Response at All Time Points
NCT01290679 (34) [back to overview]	The Percentage of Participants With Viral Breakthrough at Different Time Points
NCT01290679 (34) [back to overview]	Actual Values of log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
NCT01290679 (34) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable or Detectable
NCT01290679 (34) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <25 IU/mL Undetectable
NCT01290679 (34) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <1000 IU/mL
NCT01290679 (34) [back to overview]	Time to Reach Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) <100 IU/mL
NCT01290679 (34) [back to overview]	Time From End-of-treatment to Viral Relapse
NCT01290679 (34) [back to overview]	The Percentage of Participants Achieving a Sustained Virologic Response at Week 72 (SVRW72)
NCT01290679 (34) [back to overview]	The Percentage of Participants Who Achieved a Sustained Virologic Response 24 Weeks After the Planned End of Treatment (SVR24)
NCT01290679 (34) [back to overview]	The Percentage of Participants Who Achieved a Sustained Virologic Response 4 Weeks After the Planned End of Treatment (SVR4)
NCT01290679 (34) [back to overview]	The Percentage of Participants With <1 log10 Decrease in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) From Baseline at Week 4
NCT01290679 (34) [back to overview]	The Percentage of Participants Achieving a Rapid Virologic Response (RVR)
NCT01290679 (34) [back to overview]	The Percentage of Participants Achieving a Extended Rapid Virologic Response (eRVR)
NCT01290679 (34) [back to overview]	The Percentage of Participants Achieving a Early Virologic Response (EVR)
NCT01290679 (34) [back to overview]	The Percentage of Participants Achieving a Complete Early Virologic Response (cEVR)
NCT01290679 (34) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT01290679 (34) [back to overview]	Percentage of Participants With Partial Response
NCT01290679 (34) [back to overview]	Percentage of Participants With On-treatment Failure
NCT01290679 (34) [back to overview]	Percentage of Participants With Null Response
NCT01290679 (34) [back to overview]	Percentage of Participants With in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels >1000 IU/mL at Week 4
NCT01290679 (34) [back to overview]	Percentage of Participants Who Completed All Study Treatment at Week 24 Because of the Treatment Duration Rule
NCT01290679 (34) [back to overview]	Median Time to Normalization of Alanine Aminotransferase (ALT) Levels
NCT01290679 (34) [back to overview]	Plasma Concentration of TMC435: Systemic Clearance (CL)
NCT01290679 (34) [back to overview]	Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Daily Activities Due to Hepatitis C Virus (HCV) Infection and Its Treatment
NCT01290679 (34) [back to overview]	Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Impairment in Overall Work Productivity Due to Hepatitis C Virus (HCV) Infection and Its Treatment
NCT01290679 (34) [back to overview]	Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for the Fatigue Severity Scale (FSS) Total Scores
NCT01290679 (34) [back to overview]	Area Under the Curve From Baseline to Week 60 (AUC60) and Week 72 (AUC72) for Time Missed From Work Due to Hepatitis C Virus (HCV) Infection and Its Treatment
NCT01290731 (9) [back to overview]	The Percentage of Participants With Undetectable Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)
NCT01290731 (9) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 24 Hrs (AUC24h) for TMC435
NCT01290731 (9) [back to overview]	The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)
NCT01290731 (9) [back to overview]	The Number of Participants With Viral Breakthrough
NCT01290731 (9) [back to overview]	The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)
NCT01290731 (9) [back to overview]	The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)
NCT01290731 (9) [back to overview]	Plasma Concentrations of TMC435
NCT01290731 (9) [back to overview]	The Number of Participants Demonstrating Viral Relapse
NCT01290731 (9) [back to overview]	The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up
NCT01292239 (10) [back to overview]	The Percentage of Participants in the TMC435 Treatment Group Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2a (PegIFN Alpha-2a) and Ribavirin (RBV) at Week 24
NCT01292239 (10) [back to overview]	The Number of Participants With Viral Breakthrough
NCT01292239 (10) [back to overview]	The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 12 Weeks After the Last Dose of Treatment (SVR12)
NCT01292239 (10) [back to overview]	The Percentage of Participants With Undetectable Plasma Levels of Hepatitis C Virus Ribonucleic Acid (HCV RNA) During Treatment and at the End of Treatment (EOT)
NCT01292239 (10) [back to overview]	The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up
NCT01292239 (10) [back to overview]	Plasma Concentrations of TMC435
NCT01292239 (10) [back to overview]	The Percentage of Participants With a Sustained Virologic Response at the End of Treatment (EOT) and 24 Weeks After the Last Dose of Treatment (SVR24)
NCT01292239 (10) [back to overview]	The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal ALT Levels at the End of Treatment (EOT)
NCT01292239 (10) [back to overview]	The Number of Participants Demonstrating Viral Relapse
NCT01292239 (10) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24h) for TMC435
NCT01306617 (12) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment
NCT01306617 (12) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment
NCT01306617 (12) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) From Week 4 Through Week 12
NCT01306617 (12) [back to overview]	Percentage of Participants With HCV RNA Below the Lower Limit of Quantitation (LLOQ; <25 IU/mL) at Week 4
NCT01306617 (12) [back to overview]	Percentage of Participants With HCV RNA < 1000 International Units Per Milliliter (IU/mL)
NCT01306617 (12) [back to overview]	Time to Failure to Suppress or Rebound During Treatment
NCT01306617 (12) [back to overview]	Resistance-Associated Variants and Phenotypic Resistance
NCT01306617 (12) [back to overview]	Time to Virologic Relapse Post-treatment
NCT01306617 (12) [back to overview]	Pharmacokinetics (C Trough) of Ritonavir in HCV Infected Participants
NCT01306617 (12) [back to overview]	Pharmacokinetics (C Trough) of Ribavirin in HCV Infected Participants
NCT01306617 (12) [back to overview]	Pharmacokinetics (C Trough) of ABT-333 in HCV Infected Participants
NCT01306617 (12) [back to overview]	Pharmacokinetics (C Trough) of ABT 450 in HCV Infected Participants
NCT01314261 (12) [back to overview]	Percentage of Participants With Partial Early Virologic Response (pEVR)
NCT01314261 (12) [back to overview]	Time to Maximum Plasma Concentration (Tmax) of ABT-267
NCT01314261 (12) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing
NCT01314261 (12) [back to overview]	Area Under the Plasma Concentration-time Curve From 0 to 24 Hours (AUC24) Post-dose of ABT-267
NCT01314261 (12) [back to overview]	Median Time to Suppression of Hepatitis C Virus Ribonucleic Acid (HCV RNA)
NCT01314261 (12) [back to overview]	Percentage of Participants With 4-week Rapid Virologic Response (RVR)
NCT01314261 (12) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR)
NCT01314261 (12) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-pegylated Interferon/Ribavirin (pegIFN/RBV) Dosing
NCT01314261 (12) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR)
NCT01314261 (12) [back to overview]	Plasma Concentrations of Ribavirin (RBV)
NCT01314261 (12) [back to overview]	Maximum Plasma Concentration (Cmax) of ABT-267
NCT01314261 (12) [back to overview]	Serum Concentrations of Pegylated Interferon (pegIFN)
NCT01318694 (12) [back to overview]	Percentage of Participants With End of Treatment Response (ETR) at Treatment End Within 48 Weeks
NCT01318694 (12) [back to overview]	Percentage of Participants With Early Virologic Response (EVR) After 12 Weeks of Treatment
NCT01318694 (12) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR) After 12 Weeks of Treatment
NCT01318694 (12) [back to overview]	Percentage of Participants Who Achieved SVR 24 Weeks After the End of Treatment (SVR24)
NCT01318694 (12) [back to overview]	Percentage of Participants Who Achieved Sustained Virologic Response (SVR) 12 Weeks After the End of Treatment (SVR12)
NCT01318694 (12) [back to overview]	Percentage of Participants With Grade 3 or 4 Thrombocytopenia During Treatment Within 48 Weeks
NCT01318694 (12) [back to overview]	Percentage of Participants With Partial Early Virologic Response (pEVR) After 12 Weeks of Treatment
NCT01318694 (12) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR) From 4 to 12 Weeks of Treatment
NCT01318694 (12) [back to overview]	Percentage of Participants With Grade 3 or 4 Neutropenia During Treatment Within 48 Weeks
NCT01318694 (12) [back to overview]	Percentage of Participants With Grade 3 or 4 Anemia During Treatment Within 48 Weeks
NCT01318694 (12) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) Abnormalities Within 48 Weeks
NCT01318694 (12) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR) After 4 Weeks of Treatment (RVR4)
NCT01353911 (8) [back to overview]	Number of Participants Experiencing Adverse Events (AEs) During the Treatment Period and First 14 Follow-up Days
NCT01353911 (8) [back to overview]	Median Time to First Achievement of Undetectable HCV RNA During Treatment
NCT01353911 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After the End of Study Therapy (SVR24)
NCT01353911 (8) [back to overview]	Percentage of Participants Achieving Complete Early Viral Response (cEVR)
NCT01353911 (8) [back to overview]	Percentage of Participants Achieving Rapid Viral Response (RVR)
NCT01353911 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of Study Therapy (SVR12)
NCT01353911 (8) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA at Week 72
NCT01353911 (8) [back to overview]	Number of Participants Who Discontinued Study Medication Due to AEs During the Treatment Period and First 14 Follow-up Days
NCT01355289 (4) [back to overview]	Number of Participants Who Achieved Platelet Response (Greater Than or Equal to 100 x 10^9/L) by Day 21 of Treatment Period A1 of Core Study
NCT01355289 (4) [back to overview]	Number of Participants Who Achieved Platelet Count Greater Than 30 X 10^9/L From Baseline to Day 21 During Treatment Period A1 of Core Study
NCT01355289 (4) [back to overview]	Change From Baseline of Local Platelet Count by Visit During Treatment Period A1 of Core Study
NCT01355289 (4) [back to overview]	Number of Participants Who Initiated Antiviral Treatment by Day 21 of Period A1 of Core Study
NCT01358864 (11) [back to overview]	AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, SVR12=YES
NCT01358864 (11) [back to overview]	AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=NO
NCT01358864 (11) [back to overview]	AST Normalisation: AST in Normal Range at End of Treatment, When SVR12=YES
NCT01358864 (11) [back to overview]	AST Normalisation: AST in Normal Range 12 Weeks Post Treatment, When SVR12=NO
NCT01358864 (11) [back to overview]	Early Treatment Success (ETS)
NCT01358864 (11) [back to overview]	Sustained Virological Response 12 Weeks Post Treatment (SVR12)
NCT01358864 (11) [back to overview]	Virological Response After 24 Weeks of Treatment Discontinuation (SVR24)
NCT01358864 (11) [back to overview]	ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, SVR12=YES
NCT01358864 (11) [back to overview]	ALT Normalisation: ALT in Normal Range 12 Weeks Post Treatment, When SVR12=NO
NCT01358864 (11) [back to overview]	ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=NO
NCT01358864 (11) [back to overview]	ALT Normalisation: ALT in Normal Range at End of Treatment, When SVR12=YES
NCT01359644 (7) [back to overview]	Percentage of Participants With Viral Breakthrough During the Treatment Period
NCT01359644 (7) [back to overview]	Change From Baseline in log10 Hepatitis C Virus (HCV) RNA at Follow-up Week 24
NCT01359644 (7) [back to overview]	Number of Participants Who Died and With Serious Adverse Events (SAEs) and Grade 3-4 Adverse Events (AEs), During the Treatment Period Prior to Addition of Rescue Therapy
NCT01359644 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response at Post Treatment Week 12 (SVR12)
NCT01359644 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response at Post Treatment Week 24 (SVR24)
NCT01359644 (7) [back to overview]	Percentage of Participants Who Experienced Viral Relapse During Follow-up Period
NCT01359644 (7) [back to overview]	Number of Participants Who Died and With Serious Adverse Events (SAEs), Grade 3-4 Adverse Events (AEs), and Grade 3-4 Abnormalities on Laboratory Test Results During Follow-up Period
NCT01364090 (1) [back to overview]	Treatment Efficacy
NCT01366638 (10) [back to overview]	The Area Under the Plasma Concentration-Time Curve (From 0 to 24 Hours) (AUC24h)
NCT01366638 (10) [back to overview]	The Number of Participants Demonstrating Viral Relapse
NCT01366638 (10) [back to overview]	The Number of Participants With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at the End of Treatment (EOT)
NCT01366638 (10) [back to overview]	The Number of Participants With Viral Breakthrough
NCT01366638 (10) [back to overview]	The Percentage of Participants Who Met Response Guided Treatment (RGT) Criteria and Completed Treatment With Peginterferon Alpha-2b (PegIFNα-2b) and Ribavirin (RBV) at Week 24
NCT01366638 (10) [back to overview]	Plasma Concentrations of TMC435
NCT01366638 (10) [back to overview]	The Percentage of Participants Who Achieved a Greater Than or Equal to 2 log10 IU/mL Drop From Baseline in Plasma Hepatitis C Virus Ribonucleic Acid (HCV RNA) at Each Time Point During Treatment and Follow-up
NCT01366638 (10) [back to overview]	The Percentage of Participants With Undetectable Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During Treatment and at the End of Treatment
NCT01366638 (10) [back to overview]	The Percentage of Participants With a Sustained Virologic Response 24 Weeks After the Actual End of Treatment (SVR24)
NCT01366638 (10) [back to overview]	The Percentage of Participants With a Sustained Virologic Response 12 Weeks After the Actual End of Treatment (SVR12)
NCT01370642 (8) [back to overview]	Least Squares (LS) Mean Change From Baseline in HCV RNA (Log 10)
NCT01370642 (8) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an AE
NCT01370642 (8) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA at the End of Treatment (EOT)
NCT01370642 (8) [back to overview]	Percentage of Participants Achieving SVR12
NCT01370642 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)
NCT01370642 (8) [back to overview]	Percentage of Participants Achieving Rapid Virologic Response (RVR)
NCT01370642 (8) [back to overview]	Percentage of Participants Achieving Complete Early Virologic Response (cEVR)
NCT01370642 (8) [back to overview]	Percentage of Participants With One or More Tier 1 Adverse Events (AEs) During the Study
NCT01389323 (5) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels
NCT01389323 (5) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) RNA Levels
NCT01389323 (5) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12) With rs12979860 Single Nucleotide Polymorphisms at Baseline in the Interleukin-28B Gene
NCT01389323 (5) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), Treatment-related AEs, and Who Died
NCT01389323 (5) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response at Post-treatment Week 12 (SVR12)
NCT01390844 (10) [back to overview]	Percentage of Participants With an AE of Neutropenia in India
NCT01390844 (10) [back to overview]	Percentage of Participants With an AE of Neutropenia in Korea and Taiwan
NCT01390844 (10) [back to overview]	Percentage of Participants in India Achieving EVR at Treatment Week 8
NCT01390844 (10) [back to overview]	Percentage of Participants in India With SVR at Follow-Up Week 24 - FAS Population
NCT01390844 (10) [back to overview]	Percentage of Participants in India With SVR at Follow-Up Week 24 - mITT Population
NCT01390844 (10) [back to overview]	Percentage of Participants in Korea and Taiwan Achieving Early Virologic Response (EVR) at Treatment Week 8
NCT01390844 (10) [back to overview]	Percentage of Participants in Korea and Taiwan With Sustained Virologic Response (SVR) at Follow-Up Week 24 - Full Analysis Set (FAS) Population
NCT01390844 (10) [back to overview]	Percentage of Participants in Korea and Taiwan With SVR at Follow-Up Week 24 - Modified Intent-to-Treat (mITT) Population
NCT01390844 (10) [back to overview]	Percentage of Participants With an Adverse Event (AE) of Anemia in Korea and Taiwan
NCT01390844 (10) [back to overview]	Percentage of Participants With an AE of Anemia in India
NCT01405027 (5) [back to overview]	Number of Participants With Adverse Events
NCT01405027 (5) [back to overview]	Determination of the Rate of Sustained Viral Response (SVR) for HCV Patients Treated With Boceprevir, Peginterferon and Ribavirin at Community Sites and at HCEEs.
NCT01405027 (5) [back to overview]	Drug Exposure
NCT01405027 (5) [back to overview]	Treatment Duration Compliance Rate
NCT01405027 (5) [back to overview]	Short Form Health Survey Measuring Quality of Life Reported at Baseline, End of Treatment, and Follow-up Week 24 (36 Multiple Choice Questions)
NCT01405560 (8) [back to overview]	Percentage of Participants Achieving SVR12
NCT01405560 (8) [back to overview]	Percentage of Participants With One or More Specific Adverse Events (AEs) of Special Interest During the Study
NCT01405560 (8) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an AE
NCT01405560 (8) [back to overview]	Percentage of Participants Achieving Undetectable HCV Ribonucleic Acid (RNA) at the End of Treatment (EOT)
NCT01405560 (8) [back to overview]	Mean Change From Baseline in HCV RNA (Log 10)
NCT01405560 (8) [back to overview]	Percentage of Participants Achieving Complete Early Virologic Response (cEVR)
NCT01405560 (8) [back to overview]	Percentage of Participants Achieving Rapid Virologic Response (RVR)
NCT01405560 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response (SVR)24
NCT01405937 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Completion of All Study Therapy (SVR24)
NCT01405937 (8) [back to overview]	Percentage of Participants Achieving Rapid Virologic Response (RVR)
NCT01405937 (8) [back to overview]	Percentage of Participants Achieving Complete Early Virologic Response (cEVR)
NCT01405937 (8) [back to overview]	Percentage of Participants Who Discontinued Study Drug Due to an AE
NCT01405937 (8) [back to overview]	Percentage of Participants With One or More Specific Adverse Events (AEs) of Special Interest During the Study
NCT01405937 (8) [back to overview]	Mean Change From Baseline in HCV RNA (Log 10)
NCT01405937 (8) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA at the End of Treatment (EOT)
NCT01405937 (8) [back to overview]	Percentage of Participants Achieving SVR12
NCT01425203 (3) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response At Follow-up Week 24 (SVR24) Among Participants Who Received At Least One Dose of Any Trial Medication (Full Analysis Set Population)
NCT01425203 (3) [back to overview]	Percentage of Participants Achieving SVR24 Among Participants Who Received At Least One Dose of Experimental Trial Drug (Modified Intent-To-Treat [mITT] Population)
NCT01425203 (3) [back to overview]	Percentage of Participants Achieving Early Virologic Response (EVR) At Treatment Week (TW) 8
NCT01428063 (8) [back to overview]	Percentage of Participants With End of the Treatment Response (EOTR)
NCT01428063 (8) [back to overview]	Percentage of Participants Other Than Genotype 1 With Sustained Virologic Response at Post Treatment Week 12 (SVR12)
NCT01428063 (8) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR)
NCT01428063 (8) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR)
NCT01428063 (8) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR) at Post Treatment Week 4
NCT01428063 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response at Post Treatment Week 24 (SVR24)
NCT01428063 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) for All Nonresponders With Genotype 1 Hepatitis C Virus (HCV)
NCT01428063 (8) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to AEs, and Who Died During the Study
NCT01429792 (6) [back to overview]	Percentage of Participants Without a RVR (Non-RVR) at Week 4 of Standard Treatment
NCT01429792 (6) [back to overview]	Percentage of Participants With Undetectable HCV-RNA at End of Treatment Response (ETR) at Week 24
NCT01429792 (6) [back to overview]	Percentage of Participants With Partial Early Virological Response (pEVR) to Study Treatment
NCT01429792 (6) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
NCT01429792 (6) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR) to Study Treatment
NCT01429792 (6) [back to overview]	Percentage of Participants With Non-RVR and Undetectable HCV-RNA at Week 24
NCT01439373 (21) [back to overview]	Mean Change From Baseline in Serum HCV RNA Levels at Day 2 and Day 28
NCT01439373 (21) [back to overview]	Mean Area Under the Concentration-time Curve (AUC[0-24]), AUC From Time 0 Extrapolated to Infinity (AUC[0-inf]) of GSK2336805, at Day 1
NCT01439373 (21) [back to overview]	Mean Pre-dose Concentration and Concentration at 2 to 4 h Post-dose of GSK2336805 at Days 7, 14, 21, and 28
NCT01439373 (21) [back to overview]	Median Serum Alanine Aminotransferase at Baseline, Day 7, 14, 21, 28 and 42
NCT01439373 (21) [back to overview]	Mean Serum HCV RNA Levels at Baseline (Day 1), Day 2 and Day 28
NCT01439373 (21) [back to overview]	Mean Maximum Plasma Concentration of GSK2336805 (Cmax) and Concentration at 24 h (C24) at Day 1
NCT01439373 (21) [back to overview]	Probability of Participants With HCV Genotype 1 Achieving RVR At Day 28, Nominal Analysis
NCT01439373 (21) [back to overview]	Probability of Participants With HCV Genotype 1 Achieving RVR at Day 28, Primary and Supportive Analyses
NCT01439373 (21) [back to overview]	Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Event (SAE) During Treatment Period
NCT01439373 (21) [back to overview]	Number of Participants With Shift From Baseline to Worst Post Baseline Toxicity Grade Hematology Parameters for Day 1 to Day 28
NCT01439373 (21) [back to overview]	Number of Participants With Shift From Baseline to Worst Post Baseline Toxicity Grade for Serum Chemistry Parameters for Day 1 to Day 28
NCT01439373 (21) [back to overview]	Number of Participants With Vital Signs of Potential Clinical Concern
NCT01439373 (21) [back to overview]	Number of Participant Achieving RVR at Day 28, (Primary and Supportive Analyses)
NCT01439373 (21) [back to overview]	Mean Apparent Clearance (CL/F) of GSK2336805
NCT01439373 (21) [back to overview]	Change From Baseline in HCV Viral Load During 24 Hour (h) Following a Single Dose of GSK2336805 on the Log 10 Scale
NCT01439373 (21) [back to overview]	Change From Baseline in QTcF Interval at Day 2 and 28
NCT01439373 (21) [back to overview]	Change From Baseline in Serum Alanine Aminotransferase Levels
NCT01439373 (21) [back to overview]	Median Time of Maximal Plasma Concentration (Tmax) of GSK2336805 and Lag Time Before First Observation of Quantifiable Concentration (Tlag) at Day 1
NCT01439373 (21) [back to overview]	Number of Participants With Shifts in Urinalysis Parameters From Normal at Baseline to Abnormal
NCT01439373 (21) [back to overview]	Number of Participant Achieving Rapid Virological Response (RVR) at Day 28, Nominal Analysis
NCT01439373 (21) [back to overview]	Number of Participants With HCV Genotype 1 With Virologic Response
NCT01441180 (2) [back to overview]	Participants With Adverse Events
NCT01441180 (2) [back to overview]	Sustained Virologic Response
NCT01447420 (5) [back to overview]	Percentage of Participants With Sustained Virological Response Rate in Relation to Interleukin 28B Expression
NCT01447420 (5) [back to overview]	Number of Participants With Viral Load Reduction (HCV-RNA Levels) at Week 4 and 12
NCT01447420 (5) [back to overview]	Number of Participants With Sustained Virological Response and Occurrence of Anemia During The First Month of Treatment and After the First Month of Treatment
NCT01447420 (5) [back to overview]	Percentage of Participants With Incidence of Anemia
NCT01447420 (5) [back to overview]	Number of Participants With Viral Response Rate (Rapid/Early/End of Treatment) in Relation to IL28-B Expression
NCT01447446 (12) [back to overview]	Percentage of Participants With Concomitant Medical Condition at Baseline
NCT01447446 (12) [back to overview]	Virological Relapse After End of Treatment
NCT01447446 (12) [back to overview]	Percentage of Participants Who Discontinued Treatment With Direct-Acting Anti-viral (DAA)
NCT01447446 (12) [back to overview]	Percentage of Participants Who Discontinued Treatment With PEG-IFN and Ribavirin (RBV)
NCT01447446 (12) [back to overview]	Percentage of Participants With Sustained Virological Response (SVR) in Participants With Dose Reductions or Treatment Interruptions
NCT01447446 (12) [back to overview]	Percentage of Participants With Sustained Virological Response at 24 Weeks Post Completion of the Treatment Period (SVR24)
NCT01447446 (12) [back to overview]	Percentage of Participants With Sustained Virological Response at 12 Weeks Post Completion of the Treatment Period (SVR12)
NCT01447446 (12) [back to overview]	Virological Response at Various on Treatment Time Points and End of Treatment (EOT)
NCT01447446 (12) [back to overview]	Percentage of Participants With Adverse Events (AE)
NCT01447446 (12) [back to overview]	Percentage of Participants Achieving Extended (Rapid) Virological Response (eRVR)
NCT01447446 (12) [back to overview]	Duration of Overall Treatment
NCT01447446 (12) [back to overview]	Virological Breakthrough
NCT01448044 (5) [back to overview]	Percentage of Participants With Undetectable Hepatitis C Virus (HCV) RNA Levels
NCT01448044 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) or Sustained Virologic Response at Follow-up Week 24 (SVR24) by rs12979860 Single Nucleotide Polymorphism (SNP) in the IL28B Gene
NCT01448044 (5) [back to overview]	Percentage of Participants Who Achieve HCV Ribonucleic Acid (RNA) < Limit of Quantification (LLOQ)
NCT01448044 (5) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs) and Who Died
NCT01448044 (5) [back to overview]	Percentage of Participants With 12 Week Sustained Virologic Response (SVR12)
NCT01458535 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment
NCT01458535 (7) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT01458535 (7) [back to overview]	Percentage of Participants Who Experienced Virologic Relapse Through End of Post Treatment Period (up to 48 Weeks)
NCT01458535 (7) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) < 1000 International Units Per Milliliter (IU/mL)
NCT01458535 (7) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Below the Lower Limit of Quantitation (LLOQ) at Week 4 Rapid Virologic Response (RVR)
NCT01458535 (7) [back to overview]	Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Quantitation (LLOQ) From Week 4 Through Week 12 [(Extended Rapid Virologic Response (eRVR)]
NCT01458535 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment
NCT01459913 (9) [back to overview]	Percentage of Subjects With Sustained Viral Response 4 Weeks After Last Planned Dose of Study Drug (SVR4)
NCT01459913 (9) [back to overview]	Number of Subjects With Extended Rapid Viral Response (eRVR)
NCT01459913 (9) [back to overview]	Percentage of Subjects With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
NCT01459913 (9) [back to overview]	Percentage of Subjects With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
NCT01459913 (9) [back to overview]	Percentage of Subjects With On-Treatment Virologic Failure
NCT01459913 (9) [back to overview]	Number of Subjects With Rapid Viral Response (RVR)
NCT01459913 (9) [back to overview]	Percentage of Subjects With Viral Relapse
NCT01459913 (9) [back to overview]	Percentage of Subjects With Sustained Viral Response at Week 72 (SVR72)
NCT01459913 (9) [back to overview]	Number of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01464827 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 2 DAAs and Ribavirin Versus 3 DAAs and Ribavirin
NCT01464827 (6) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01464827 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose in Treatment-naïve Versus Null-responders
NCT01464827 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose for 8 Weeks Versus 12 Weeks of Treatment With 3 DAAs and Ribavirin
NCT01464827 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment of Different Durations With 3 Direct-acting Antiviral Agents (DAAs) and Ribavirin
NCT01464827 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks Post-dose Following Treatment for 12 Weeks With 3 DAAs With Versus Without Ribavirin
NCT01466192 (1) [back to overview]	Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
NCT01466790 (7) [back to overview]	Number of Participants With Viral Breakthrough
NCT01466790 (7) [back to overview]	Number of Participants With Viral Relapse
NCT01466790 (7) [back to overview]	Number of Participants With a Sustained Virologic Response (SVR) 12 Weeks After the Planned End of Treatment (EOT)
NCT01466790 (7) [back to overview]	Number of Participants With a Sustained Virologic Response (SVR) 24 Weeks After the Planned End of Treatment (EOT)
NCT01466790 (7) [back to overview]	Number of Participants With a Sustained Virologic Response (SVR) 4 Weeks After the Planned End of Treatment (EOT)
NCT01466790 (7) [back to overview]	Number of Participants With a Sustained Virologic Response (SVR) at Week 48
NCT01466790 (7) [back to overview]	Number of Participants With Inadequate Virologic Response
NCT01467479 (8) [back to overview]	Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR 24)
NCT01467479 (8) [back to overview]	Percentage of Participants With Rapid Viral Response (RVR)
NCT01467479 (8) [back to overview]	Percentage of Participants With Extended Rapid Viral Response (eRVR)
NCT01467479 (8) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01467479 (8) [back to overview]	Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
NCT01467479 (8) [back to overview]	Maximum (Cmax), Minimum (Cmin), and Average Plasma Concentration (Cavg)
NCT01467479 (8) [back to overview]	Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
NCT01467479 (8) [back to overview]	Percentage of Participants With Undetectable HCV RNA at End of Treatment (EOT)
NCT01467492 (8) [back to overview]	Percentage of Participants With On Treatment Virologic Failure
NCT01467492 (8) [back to overview]	Percentage of Participants With Sustained Viral Response 12 Weeks After Last Actual Dose of Study Drug (SVR12)
NCT01467492 (8) [back to overview]	Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
NCT01467492 (8) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01467492 (8) [back to overview]	Percentage of Participants With Extended Rapid Viral Response (eRVR)
NCT01467492 (8) [back to overview]	Percentage of Participants With Relapse
NCT01467492 (8) [back to overview]	Percentage of Participants With Virologic Breakthrough
NCT01467492 (8) [back to overview]	Percentage of Participants With Sustained Viral Response 24 Weeks After Last Actual Dose of Study Drug (SVR24)
NCT01467505 (6) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01467505 (6) [back to overview]	Percentage of Participants With Sustained Viral Response 24 Weeks After Last Planned Dose of Study Drug (SVR24)
NCT01467505 (6) [back to overview]	Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
NCT01467505 (6) [back to overview]	Percentage of Participants With Rapid Viral Response (RVR)
NCT01467505 (6) [back to overview]	Percentage of Participants With Extended Rapid Viral Response (eRVR)
NCT01467505 (6) [back to overview]	Percentage of Participants With On-Treatment Virologic Failure
NCT01468584 (1) [back to overview]	Undetectable HCV RNA at 24 Weeks After Completion of Drug Administration (SVR, Sustained Viral Response)
NCT01471574 (6) [back to overview]	Number of Participants Who Died and With Serious Adverse Event (SAEs), Grade 3 to 4 Adverse Events (AEs), and AEs Leading to Discontinuation
NCT01471574 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)
NCT01471574 (6) [back to overview]	Percentage of Participants Who Achieved Hepatitis C Virus (HCV) RNA Levels Lower Than the Lower Limit of Quantitation (LLOQ), Target Not Detected (TND)
NCT01471574 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR12) by rs12979860 Single Nucleotide Polymorphism (SNP) in the IL28B Gene
NCT01471574 (6) [back to overview]	Percentage of Participants Who Received Highly Active Antiretroviral Therapy (HAART), Maintained HIV RNA <40 Copies/mL, and Experienced Confirmed HIV RNA ≥400 Copies/mL
NCT01471574 (6) [back to overview]	Percentage of Participants Who Achieved Hepatitis C Virus (HCV) RNA Levels Lower Than The Lower Limit of Quantitation (LLOQ), Target Detected (TD) or Target Not Detected (TND)
NCT01479868 (12) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT01479868 (12) [back to overview]	Mean Change From Baseline in Log10 Plasma Human Immunodeficiency Virus (HIV) Viral Load
NCT01479868 (12) [back to overview]	Mean Change From Baseline in CD4+ Cell Count
NCT01479868 (12) [back to overview]	Change From Baseline in CD4+ Cell Count in Percentage
NCT01479868 (12) [back to overview]	Percentage of Participants With Sustained Virologic Response at Week 24 (SVR 24)
NCT01479868 (12) [back to overview]	Percentage of Participants With Sustained Virologic Response at Week 12 (SVR 12)
NCT01479868 (12) [back to overview]	Percentage of Participants With On-treatment Failure
NCT01479868 (12) [back to overview]	Percentage of Participants With Normalized Alanine Aminotransferase Levels
NCT01479868 (12) [back to overview]	Percentage of Participants With Viral Relapse
NCT01479868 (12) [back to overview]	Percentage of Participants With Hepatitis C Virus Ribonucleic Acid (HCV-RNA) Less Than (<) 25 International Units (IU/mL) Undetectable or Detectable/Undetectable
NCT01479868 (12) [back to overview]	Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
NCT01479868 (12) [back to overview]	Percentage of Human Immunodeficiency Virus (HIV) Participants With Virologic Failure
NCT01482767 (6) [back to overview]	Percentage of Participants With HIV-1 Viral Load <50 Copies/mL
NCT01482767 (6) [back to overview]	Number of Participants With Undetectable HCV RNA at Week 4, 8 and 12 Study Visits
NCT01482767 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12)
NCT01482767 (6) [back to overview]	Percentage of Participants With Grade 3 or Higher Adverse Events (AEs)
NCT01482767 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24)
NCT01482767 (6) [back to overview]	CD4+ T-Cell Count (CD4) Change From Baseline
NCT01492426 (6) [back to overview]	Percentage of Genotype 1a Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)
NCT01492426 (6) [back to overview]	Percentage of Genotype 1b Participants With Rapid Virologic Response (RVR) at Week 4
NCT01492426 (6) [back to overview]	Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12)
NCT01492426 (6) [back to overview]	Percentage of Genotype 1b Participants With Sustained Virologic Response at Follow-up Week 24 (SVR24)
NCT01492426 (6) [back to overview]	Percentage of Genotype 1b Participants With Complete Early Virologic Response (cEVR)
NCT01492426 (6) [back to overview]	Percentage of Genotype 1b Participants With Extended Rapid Virologic Response (eRVR) at Both Week 4 and Week 12
NCT01498068 (6) [back to overview]	Median Change in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA)
NCT01498068 (6) [back to overview]	Number of Participants in Each Specific Category of Treatment Outcome
NCT01498068 (6) [back to overview]	Number of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Less Than 25 IU/mL, (Target Not Detected) at Weeks 8, 12, 24, 32, 40 and 48
NCT01498068 (6) [back to overview]	Number of Participants With Rapid Virologic Response (RVR) at Week 4
NCT01498068 (6) [back to overview]	Number of Participants With Extended Rapid Virologic Response (eRVR)
NCT01498068 (6) [back to overview]	Number of Participants With Virologic Failure
NCT01502072 (1) [back to overview]	Percentage of Participants With Progression to Lower Respiratory Tract Infection (LRI)
NCT01525628 (24) [back to overview]	Cmax of Deleobuvir Metabolite CD 6168 ag (Acylglucuronide)
NCT01525628 (24) [back to overview]	C6hr of Deleobuvir (BI 207127)
NCT01525628 (24) [back to overview]	Cmax of Deleobuvir Metabolite Acyl-glucuronide (BI 208333)
NCT01525628 (24) [back to overview]	AUC 0-infinity of Tolbutamide
NCT01525628 (24) [back to overview]	AUC 0-infinity of Midazolam
NCT01525628 (24) [back to overview]	AUC 0-infinity of Caffeine
NCT01525628 (24) [back to overview]	AUC 0-infinity of 1-OH-Midazolam (1-hydroxy-midazolam)
NCT01525628 (24) [back to overview]	AUC 0-6hr of Deleobuvir Reduction Metabolite CD 6168
NCT01525628 (24) [back to overview]	AUC 0-6hr of Deleobuvir Metabolite CD 6168 ag (Acylglucuronide)
NCT01525628 (24) [back to overview]	AUC 0-6hr of Deleobuvir Metabolite Acyl-glucuronide (BI 208333)
NCT01525628 (24) [back to overview]	Cmax of Deleobuvir (BI 207127)
NCT01525628 (24) [back to overview]	C6hr of Deleobuvir Reduction Metabolite CD 6168
NCT01525628 (24) [back to overview]	Cmax of 1-OH-Midazolam (1-hydroxy-midazolam)
NCT01525628 (24) [back to overview]	Cmax of Deleobuvir Reduction Metabolite CD 6168
NCT01525628 (24) [back to overview]	Cmax of Caffeine
NCT01525628 (24) [back to overview]	Cmax of Faldaprevir (BI 201335)
NCT01525628 (24) [back to overview]	C24hr of Faldaprevir (BI 201335)
NCT01525628 (24) [back to overview]	C6hr of Deleobuvir Metabolite Acyl-glucuronide (BI 208333)
NCT01525628 (24) [back to overview]	Cmax of Midazolam
NCT01525628 (24) [back to overview]	Cmax of Tolbutamide
NCT01525628 (24) [back to overview]	Area Under the Concentration-time Curve (AUC) of Faldaprevir (BI 201335) From 0 to 24 Hours
NCT01525628 (24) [back to overview]	Number of Participants With Sustained Virological Response (SVR12)
NCT01525628 (24) [back to overview]	C6hr of Deleobuvir Metabolite CD 6168 ag (Acylglucuronide)
NCT01525628 (24) [back to overview]	AUC 0-6hr of Deleobuvir (BI 207127)
NCT01528735 (42) [back to overview]	Maximum Measured Concentration (Cmax) of CD 6168
NCT01528735 (42) [back to overview]	Maximum Measured Concentration (Cmax) of CD 6168-AG
NCT01528735 (42) [back to overview]	Maximum Measured Concentration (Cmax) of Deleobuvir
NCT01528735 (42) [back to overview]	Maximum Measured Concentration (Cmax) of Faldaprevir
NCT01528735 (42) [back to overview]	Maximum Measured Concentration (Cmax) of RBV
NCT01528735 (42) [back to overview]	Predose Measured Concentration of BI 208333
NCT01528735 (42) [back to overview]	Predose Measured Concentration of CD 6168
NCT01528735 (42) [back to overview]	Predose Measured Concentration of CD 6168-AG
NCT01528735 (42) [back to overview]	AUC Accumulation Ratio of Deleobuvir
NCT01528735 (42) [back to overview]	AUC Accumulation Ratio of CD 6168-AG
NCT01528735 (42) [back to overview]	Predose Measured Concentration of Deleobuvir
NCT01528735 (42) [back to overview]	AUC Accumulation Ratio of BI 208333
NCT01528735 (42) [back to overview]	Area Under the Curve (AUC) of RBV
NCT01528735 (42) [back to overview]	Area Under the Curve (AUC) of Faldaprevir
NCT01528735 (42) [back to overview]	Area Under the Curve (AUC) of Deleobuvir
NCT01528735 (42) [back to overview]	Area Under the Curve (AUC) of CD 6168
NCT01528735 (42) [back to overview]	Area Under the Curve (AUC) of BI 208333
NCT01528735 (42) [back to overview]	Predose Measured Concentration of Faldaprevir
NCT01528735 (42) [back to overview]	Predose Measured Concentration of RBV
NCT01528735 (42) [back to overview]	Time From Last Dosing to the Maximum Concentration (Tmax) of BI 208333
NCT01528735 (42) [back to overview]	Percentage of Participants With Virological Response at Week 8
NCT01528735 (42) [back to overview]	Percentage of Participants With Virological Response at Week 4
NCT01528735 (42) [back to overview]	Number of Patients With Drug-related Adverse Events
NCT01528735 (42) [back to overview]	Mean Residence Time (MRTpo,ss) of Deleobuvir
NCT01528735 (42) [back to overview]	Cmax Accumulation Ratio (RA,Cmax,57) of RBV
NCT01528735 (42) [back to overview]	AUC Accumulation Ratio of RBV
NCT01528735 (42) [back to overview]	Apparent Clearance (CL/F,ss) of Faldaprevir
NCT01528735 (42) [back to overview]	Apparent Clearance (CL/F,ss) of Deleobuvir
NCT01528735 (42) [back to overview]	Time From Last Dosing to the Maximum Concentration (Tmax) of CD 6168
NCT01528735 (42) [back to overview]	Time From Last Dosing to the Maximum Concentration (Tmax) of CD 6168-AG
NCT01528735 (42) [back to overview]	Time From Last Dosing to the Maximum Concentration (Tmax) of Deleobuvir
NCT01528735 (42) [back to overview]	AUC Accumulation Ratio of CD 6168
NCT01528735 (42) [back to overview]	Cmax Accumulation Ratio (RA,Cmax,N) of Faldaprevir
NCT01528735 (42) [back to overview]	Cmax Accumulation Ratio (RA,Cmax,N) of Deleobuvir
NCT01528735 (42) [back to overview]	AUC Accumulation Ratio of Faldaprevir
NCT01528735 (42) [back to overview]	Time From Last Dosing to the Maximum Concentration (Tmax) of Faldaprevir
NCT01528735 (42) [back to overview]	Time From Last Dosing to the Maximum Concentration (Tmax) of RBV
NCT01528735 (42) [back to overview]	Area Under the Curve (AUC) of CD 6168-AG
NCT01528735 (42) [back to overview]	Cmax Accumulation Ratio of BI 208333
NCT01528735 (42) [back to overview]	Cmax Accumulation Ratio of CD 6168
NCT01528735 (42) [back to overview]	Cmax Accumulation Ratio of CD 6168-AG
NCT01528735 (42) [back to overview]	Maximum Measured Concentration (Cmax) of BI 208333
NCT01544920 (2) [back to overview]	Percentage of Participants Who Had Undetectable HCV RNA at Week 4 Achieving SVR24
NCT01544920 (2) [back to overview]	Percentage of Participants With Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) 24 Weeks After Completing Study Treatment (SVR24)
NCT01559844 (8) [back to overview]	Percentage of Participants Experiencing Any Adverse Event Leading to Permanent Discontinuation of Sofosbuvir Prior to Receiving Transplant
NCT01559844 (8) [back to overview]	Percentage of Participants With Graft Loss Following Transplant
NCT01559844 (8) [back to overview]	HCV RNA and Change From Baseline in HCV RNA Through Week 8
NCT01559844 (8) [back to overview]	Number of Participants Who Died
NCT01559844 (8) [back to overview]	Percentage of Participants With HCV RNA < LLOQ (ie, 25 mL/IU) During Treatment Through Week 48
NCT01559844 (8) [back to overview]	Percentage of Participants With Posttransplant Virologic Response (pTVR) at Posttransplant Week 12
NCT01559844 (8) [back to overview]	Proportion of Participants With Virologic Failure Prior to Transplant
NCT01559844 (8) [back to overview]	Percentage of Participants With Posttransplant Virologic Response (pTVR) Through Posttransplant Week 48
NCT01563536 (12) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks and 24 Weeks After Combination Therapy
NCT01563536 (12) [back to overview]	Percentage of Participants With Rapid Virologic Response
NCT01563536 (12) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response
NCT01563536 (12) [back to overview]	Percentage of Participants With End-of-Treatment Response
NCT01563536 (12) [back to overview]	Mean Maximal Decrease From Baseline in Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) During ABT-267 Monotherapy
NCT01563536 (12) [back to overview]	Maximum Plasma Concentration (Cmax) of ABT-267 Following Monotherapy on Day 1
NCT01563536 (12) [back to overview]	Time of Maximum Plasma Concentration (Tmax) of ABT-267 Following Monotherapy on Day 1
NCT01563536 (12) [back to overview]	Mean Change in Viral Load From Baseline to Pre-dose on Day 2 and Day 3 of ABT-267 Monotherapy
NCT01563536 (12) [back to overview]	Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC[24]) of ABT-267 Following Monotherapy on Day 1
NCT01563536 (12) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT01563536 (12) [back to overview]	Resistance-Associated Variants and Phenotypic Resistance
NCT01563536 (12) [back to overview]	Plasma Concentration of ABT-267 Pre-dose (Ctrough) on Day 2 and Day 3
NCT01565889 (8) [back to overview]	Part B: Percentage of Participants Experiencing Viral Breakthrough or Viral Relapse
NCT01565889 (8) [back to overview]	Part B: On-treatment HIV RNA
NCT01565889 (8) [back to overview]	Part B: On-treatment HCV RNA
NCT01565889 (8) [back to overview]	Part A: Plasma Pharmacokinetics of SOF, EFV, TFV, and FTC: Cmax at Day 7
NCT01565889 (8) [back to overview]	Part A: Plasma Pharmacokinetics of SOF, EFV, Tenofovir (TFV), and FTC: AUCtau at Day 7
NCT01565889 (8) [back to overview]	Part B: Percentage of Participants With Sustained Virologic Response (SVR) at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01565889 (8) [back to overview]	Incidence of Adverse Events Leading to Permanent Discontinuation of Study Drug(s)
NCT01565889 (8) [back to overview]	Part B: Percentage of Participants With Sustained Virologic Response at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01585324 (7) [back to overview]	Number of Participants With Neutropenia Among Participants With or Without SVR
NCT01585324 (7) [back to overview]	Percentage of Participants With Sustained Virological Response (SVR) 24 Weeks After End of Treatment
NCT01585324 (7) [back to overview]	Number of Participants With Thrombocytopenia Among Participants With or Without SVR
NCT01585324 (7) [back to overview]	Change From Baseline in Hemoglobin Level at Week 12 of Treatment Among Participants With or Without SVR
NCT01585324 (7) [back to overview]	Lowest Hemoglobin Level During Treatment Among Participants With or Without SVR
NCT01585324 (7) [back to overview]	Number of Participants With Reduction in Ribavirin Dose Due to Drop in Hemoglobin Among Participants With or Without SVR
NCT01585324 (7) [back to overview]	Number of Participants With Decrease in Hemoglobin
NCT01591460 (17) [back to overview]	HCV RNA Levels
NCT01591460 (17) [back to overview]	Percentage of Participants With Virological Response
NCT01591460 (17) [back to overview]	Percentage of Participants With Treatment Discontinued Based Upon Elevated (Week 12) or Detectable (Week 24) HCV RNA
NCT01591460 (17) [back to overview]	Percentage of Participants With at Least a 1-Log, 2-Log, or 3-Log Reduction in HCV RNA
NCT01591460 (17) [back to overview]	Percentage of Participants With a Dose Modification of PEG-IFN, RBV, or Boceprevir By Reason
NCT01591460 (17) [back to overview]	Percentage of Participants With a Concomitant Disease Prior to or During the Study
NCT01591460 (17) [back to overview]	Percentage of Participants Using Concomitant Medications During Treatment and Follow-Up
NCT01591460 (17) [back to overview]	Percentage of Participants Receiving Target Administrations of PEG-IFN, RBV, and Boceprevir
NCT01591460 (17) [back to overview]	Duration of Treatment With PEG-IFN, RBV, and Boceprevir
NCT01591460 (17) [back to overview]	Time to Safety-Related Dose Modification
NCT01591460 (17) [back to overview]	Percentage of Participants With Virological Relapse Following EOT Response
NCT01591460 (17) [back to overview]	Percentage of Participants With Virological Rebound Following On-Treatment Decline in HCV RNA
NCT01591460 (17) [back to overview]	Percentage of Participants With Virological Breakthrough Following On-Treatment Response
NCT01591460 (17) [back to overview]	Percentage of Participants With SVR at 24 Weeks After EOT
NCT01591460 (17) [back to overview]	Percentage of Participants With Sustained Virological Response (SVR) at 12 Weeks After End of Treatment (EOT)
NCT01591460 (17) [back to overview]	Percentage of Participants Using Concomitant Hematopoietic Stimulants During Treatment and Follow-Up
NCT01591460 (17) [back to overview]	Number of Participants With a Safety-Related Dose Modification
NCT01592006 (2) [back to overview]	The Efficacy of Triple Antiviral Therapy
NCT01592006 (2) [back to overview]	Safety of Triple Antiviral Therapy in HCV Infected OLT Recipients
NCT01598090 (11) [back to overview]	Percentage of Participants With On-Treatment Flu-Like Symptoms And Musculoskeletal Symptoms- Part B
NCT01598090 (11) [back to overview]	Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Drug Related AEs, Discontinuation Due to AEs, Dose Reductions and Death - Part A
NCT01598090 (11) [back to overview]	Percentage of Treatment-Naïve Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part B
NCT01598090 (11) [back to overview]	Percentage of Subjects With Sustained Virologic Response at Follow-Up Week 24 (SVR24) - Part A
NCT01598090 (11) [back to overview]	Percentage of Participants With Treatment Emergent Cytopenic Abnormalities - Part B
NCT01598090 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part B
NCT01598090 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response at Follow-up Week 12 (SVR12) - Part A
NCT01598090 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response at Follow- upWeek 24 (SVR24) - Part B
NCT01598090 (11) [back to overview]	Percentage of Participants With Rash
NCT01598090 (11) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR) - Part B
NCT01598090 (11) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR) - Part A
NCT01606800 (1) [back to overview]	Number of Participants Achieving Sustained Virologic Response (SVR)
NCT01609933 (4) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post Treatment (SVR12)
NCT01609933 (4) [back to overview]	Number of Participants With Adverse Events
NCT01609933 (4) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR)
NCT01609933 (4) [back to overview]	Percentage of Participants Achieving Virologic Response 24 Weeks Post Treatment (SVR24)
NCT01628692 (7) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR)
NCT01628692 (7) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR)
NCT01628692 (7) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
NCT01628692 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response Rate at Post-treatment Week 12 (SVR12)
NCT01628692 (7) [back to overview]	Number of Participants With Serious Adverse Events (SAEs) and Discontinuations Due to Adverse Events (AEs) and Who Died
NCT01628692 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response at Week 12 (SVR12) by rs12979860 Single Nucleotide Polymorphisms in the IL-28B Gene Categories
NCT01628692 (7) [back to overview]	Percentage of Participants With End of Treatment Response (EOTR)
NCT01641640 (6) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT01641640 (6) [back to overview]	Percentage of Participants With Viral Relapse
NCT01641640 (6) [back to overview]	Number of Participants Experiencing Adverse Events Leading to Permanent Discontinuation of Study Drug
NCT01641640 (6) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response (SVR)12
NCT01641640 (6) [back to overview]	Percentage of Participants Achieving SVR24
NCT01641640 (6) [back to overview]	Percentage of Participants Achieving SVR4
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Creatinine Clearance at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/BUN at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Hematocrit at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Heart Rate at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Electrocardiographic (ECG) Heart Rate Values at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Chloride, Bicarbonate, Glucose, Potassium, Sodium, Inorganic Phosphorus and Urea/Blood Urea Nitrogen (BUN) at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell Count at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in ALP, ALT, AST, CK and GGT at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Alkaline Phosphatase (ALP), Alanine Amino Transferase (ALT), Aspartate Amino Transferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT) at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Albumin at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Albumin at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Maximum Plasma Concentration (Cmax) and Concentration at the End of the Dosing Interval (Ctau) of GSK2336805 at Week 4
NCT01648140 (35) [back to overview]	Time of Maximal Plasma Concentration (Tmax) of GSK2336805 at Week 4
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count and White Blood Cell Count at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Number of Participants With Shift From Baseline in Urinalysis Data up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Apparent Clearance (CL/F) at Week 4
NCT01648140 (35) [back to overview]	Apparent Volume of Distribution (Vz/F) at Week 4
NCT01648140 (35) [back to overview]	Area Under the Concentration-time Curve Over the Dosing Interval (AUC[0-tau]) at Week 4
NCT01648140 (35) [back to overview]	Number of Participants Achieving eRVR
NCT01648140 (35) [back to overview]	Number of Participants With Any AEs and Any SAEs After Week 12
NCT01648140 (35) [back to overview]	Number of Participants With Any Adverse Events (AEs) and Any Serious Adverse Events (SAEs) up to Week 12
NCT01648140 (35) [back to overview]	Number of Participants Achieving Very Rapid Virologic Response (vRVR), Rapid Virologic Response (RVR), Complete Early Virologic Response (cEVR), Sustained Virologic Response 12 and 24 (SVR12 and SVR24) With Response Guided Treatment (RGT)
NCT01648140 (35) [back to overview]	Mean GSK2336805 Plasma Concentrations on Day 1, Day 2, Week 4, and Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Total Bilirubin and Creatinine at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Direct Bilirubin, Total Bilirubin and Creatinine at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Red Blood Cell Count at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in PR Interval, QRS Duration, Uncorrected QT Interval and QT Interval Corrected Bazett's Formula (QTcB), QT Interval Corrected Using Fridericia's Formula (QTcF) Values at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Mean Corpuscle Volume at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Hemoglobin at the Indicated Time Points up to Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Hemoglobin at the Indicated Time Points After Week 12
NCT01648140 (35) [back to overview]	Mean Change From Baseline in Hematocrit at the Indicated Time Points up to Week 12
NCT01659567 (14) [back to overview]	OR for Impact of Baseline Alanine Transaminase (ALT) Level on SVR
NCT01659567 (14) [back to overview]	OR for Impact of Baseline Level of Fibrosis (kPa) on SVR
NCT01659567 (14) [back to overview]	OR for Impact of Baseline Viral Load Count on SVR
NCT01659567 (14) [back to overview]	Positive Predictive Value (PPV) of Rapid Viral Response (RVR) on SVR
NCT01659567 (14) [back to overview]	Odds Ratio (OR) for Impact of Age on SVR
NCT01659567 (14) [back to overview]	PPV of Complete Early Viral Response (cEVR) on SVR
NCT01659567 (14) [back to overview]	Percentage of Participants Achieving Sustained Virological Response (SVR)
NCT01659567 (14) [back to overview]	OR for Impact of Overall Duration of Treatment on SVR
NCT01659567 (14) [back to overview]	OR for Impact of Gender on SVR
NCT01659567 (14) [back to overview]	OR for Impact of Cumulative Doses of Pegylated Interferon Alfa-2a on SVR
NCT01659567 (14) [back to overview]	OR for Impact of Body Weight on SVR
NCT01659567 (14) [back to overview]	OR for Impact of Duration of Treatment After Achieving RVR on SVR
NCT01659567 (14) [back to overview]	OR for Impact of Duration of Treatment After Achieving cEVR on SVR
NCT01659567 (14) [back to overview]	OR for Impact of Cumulative Doses of Ribavirin on SVR
NCT01674725 (5) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT01674725 (5) [back to overview]	Percentage of Participants With Virologic Relapse After Treatment
NCT01674725 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Secondary Analyses
NCT01674725 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses
NCT01674725 (5) [back to overview]	Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment
NCT01678131 (1) [back to overview]	Number of Participants From Whom Detectable Concentrations of Hepatic Vaniprevir Are Obtained by FNA
NCT01685203 (5) [back to overview]	Percentage of Participants in Each Treatment Group With Sustained Virologic Response 12 Weeks Post-treatment
NCT01685203 (5) [back to overview]	Percentage of Participants in Each Treatment Group With Sustained Virologic Response 24 Weeks Post-treatment
NCT01685203 (5) [back to overview]	Percentage of Participants in Each Treatment Group With Treatment-emergent Adverse Events
NCT01685203 (5) [back to overview]	Percentage of Participants in Each Treatment Group With On-treatment Virologic Failure.
NCT01685203 (5) [back to overview]	Percentage of Participants in Each Treatment Group With Post-treatment Virologic Relapse.
NCT01687270 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01687270 (6) [back to overview]	HCV RNA and Change From Baseline at Weeks 2, 4, and 8
NCT01687270 (6) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Weeks 12 and 24
NCT01687270 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) at 4, 24, and 48 Weeks After Discontinuation of Therapy (SVR4, SVR24, and SVR48)
NCT01687270 (6) [back to overview]	Percentage of Participants With Virologic Failure
NCT01687270 (6) [back to overview]	Percentage of Participants Who Discontinue Study Drug Due to an Adverse Event
NCT01700179 (1) [back to overview]	Sustained Virologic Response At 12 Weeks (SVR12)
NCT01701063 (11) [back to overview]	Maximum Plasma Concentration (Cmax) of Telaprevir
NCT01701063 (11) [back to overview]	Number of Participants With Telaprevir Resistant HCV Variant at Non-Structural Viral Protein 3-4A (NS3-4A) Region
NCT01701063 (11) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01701063 (11) [back to overview]	Area Under the Plasma Concentration Versus Time Curve (AUC) of Telaprevir
NCT01701063 (11) [back to overview]	Time to Reach Maximum Plasma Concentration (Tmax) of Telaprevir
NCT01701063 (11) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response (eRVR)
NCT01701063 (11) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT01701063 (11) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR)
NCT01701063 (11) [back to overview]	Percentage of Participants With Sustained Viral Response 12 Weeks After Last Planned Dose of Study Drug (SVR12)
NCT01701063 (11) [back to overview]	Percentage of Participants With Undetectable HCV RNA at Week 12
NCT01701063 (11) [back to overview]	Percentage of Participants With Virologic Relapse
NCT01704521 (1) [back to overview]	Number of Participants With Sustained Virological Response at Week 12 (SVR12)
NCT01704755 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment in the 24-week Arm Compared to the 12-week Arm
NCT01704755 (4) [back to overview]	Percentage of Participants in Each Arm With On-treatment Virologic Failure During the Treatment Period
NCT01704755 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment
NCT01704755 (4) [back to overview]	Percentage of Participants With Virologic Relapse After Treatment
NCT01710501 (8) [back to overview]	Number of Participants Discontinued From Study Treatment Due to AEs During the Treatment Period and First 14 Follow-up Days
NCT01710501 (8) [back to overview]	Number of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period and First 14 Follow-up Days
NCT01710501 (8) [back to overview]	Number of Participants Developing Post-baseline Antiviral Resistance to Grazoprevir Among Participants Not Achieving SVR24 Response
NCT01710501 (8) [back to overview]	Percentage of Participants Achieving SVR4
NCT01710501 (8) [back to overview]	Percentage of Subjects Achieving SVR24
NCT01710501 (8) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA During Treatment by Time Point
NCT01710501 (8) [back to overview]	Percentage of Participants Achieving HCV RNA <25 IU/mL During Treatment by Time Point
NCT01710501 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of Treatment (SVR12)
NCT01715415 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment
NCT01715415 (6) [back to overview]	Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm
NCT01715415 (6) [back to overview]	Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period
NCT01715415 (6) [back to overview]	Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment
NCT01715415 (6) [back to overview]	Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm
NCT01715415 (6) [back to overview]	Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment
NCT01716156 (8) [back to overview]	Percentage of Participants With Undetectable HCV RNA by Time Point
NCT01716156 (8) [back to overview]	Percentage of Participants With HCV RNA <25 IU/mL by Time Point
NCT01716156 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12)
NCT01716156 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After the End of Study Therapy (SVR 24)
NCT01716156 (8) [back to overview]	Percentage of Participants Discontinuing Study Therapy Due to an AE
NCT01716156 (8) [back to overview]	Percentage of Participants Experiencing at Least One Adverse Event (AE) on Study
NCT01716156 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks After Ending Study Therapy (SVR4)
NCT01716156 (8) [back to overview]	Time to Achievement of First Undetectable HCV RNA
NCT01716585 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment
NCT01716585 (6) [back to overview]	Percentage of HCV Genotype 1a-infected Participants With Sustained Virologic Response 12 Weeks After Treatment
NCT01716585 (6) [back to overview]	Percentage of HCV Genotype 1b-infected Participants With Sustained Virologic Response 12 Weeks After Treatment
NCT01716585 (6) [back to overview]	Percentage of Participants With Normalization of Alanine Aminotransferase (ALT) at Final Treatment Visit During the Double-Blind Treatment Period
NCT01716585 (6) [back to overview]	Percentage of Participants With On-treatment Virologic Failure During the Double-blind Treatment Period: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm
NCT01716585 (6) [back to overview]	Percentage of Participants With Virologic Relapse After Treatment: ABT-450/r/ABT-267 and ABT-333, Plus RBV Arm
NCT01717326 (12) [back to overview]	Percentage of Participants Achieving HCV RNA <25 IU/mL at Week 2
NCT01717326 (12) [back to overview]	Percentage of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period and First 14 Follow-up Days
NCT01717326 (12) [back to overview]	Percentage of Participants Discontinuing Study Therapy Due to an AE During the Treatment Period and First 14 Follow-up Days
NCT01717326 (12) [back to overview]	Mean Time to First Achievement of Undetectable Hepatitis C Virus Ribonucleic Acid (HCV RNA)
NCT01717326 (12) [back to overview]	Percentage of Participants Achieving HCV RNA <25 IU/mL at Week 12
NCT01717326 (12) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA at Week 2
NCT01717326 (12) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA at Week 12
NCT01717326 (12) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 4 Weeks After the End of All Therapy (SVR4)
NCT01717326 (12) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After the End of All Study Therapy (SVR24)
NCT01717326 (12) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12)
NCT01717326 (12) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA at Week 4
NCT01717326 (12) [back to overview]	Percentage of Participants Achieving HCV RNA <25 IU/mL at Week 4
NCT01725529 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12)
NCT01725529 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks After End of Study Drug Treatment (SVR24)
NCT01725529 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response at Week 72 (SVRW72)
NCT01725529 (7) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT01725529 (7) [back to overview]	Percentage of Participants With On-treatment Normalization of Alanine Aminotransferase Level
NCT01725529 (7) [back to overview]	Percentage of Participants With On-treatment Failure
NCT01725529 (7) [back to overview]	Percentage of Participants With Viral Relapse
NCT01728324 (5) [back to overview]	SVR24: Plasma HCV RNA Level <25 IU/mL at 24 Weeks After EOT.
NCT01728324 (5) [back to overview]	Prognostic Value of SVR12 Predicting SVR24
NCT01728324 (5) [back to overview]	SVR12 Rates With Historical Control
NCT01728324 (5) [back to overview]	SVR4: Plasma HCV RNA Level <25 IU/mL at 4 Weeks After EOT.
NCT01728324 (5) [back to overview]	Comparisons of SVR12 Rates Across Treatment Arms
NCT01732796 (4) [back to overview]	SVR4
NCT01732796 (4) [back to overview]	SVR24
NCT01732796 (4) [back to overview]	SVR12 Rates With Historical Control
NCT01732796 (4) [back to overview]	Comparisons of SVR12 Rates Across Treatment Arms
NCT01740089 (5) [back to overview]	Immunogenicity
NCT01740089 (5) [back to overview]	Number of Patients Who Have Undetectable HCV RNA (< 15 IU/ml) at the End of Treatment.
NCT01740089 (5) [back to overview]	Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) or ≥ 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment.
NCT01740089 (5) [back to overview]	Number of Randomized Patients Achieving Rapid Virologic Response (RVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) After 4 Weeks of Treatment.
NCT01740089 (5) [back to overview]	Number of Randomized Patients Achieving Sustained Virologic Response (SVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) 24 Weeks After Last Dose of Study Treatment.
NCT01741545 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24)
NCT01741545 (9) [back to overview]	Percentage of Participants With Treatment-Emergent Cytopenic Abnormalities On-Treatment
NCT01741545 (9) [back to overview]	Number of Participants With Treatment Emergent Grade 3 to 4 Laboratory Abnormalities
NCT01741545 (9) [back to overview]	Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Leading to Discontinuation, Dose Reductions, And Death
NCT01741545 (9) [back to overview]	Percentage of Participants With Flu-Like Symptoms and Musculoskeletal Symptoms On-Treatment
NCT01741545 (9) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR)
NCT01741545 (9) [back to overview]	Percentage of Participants With Complete Early Virologic Response (cEVR)
NCT01741545 (9) [back to overview]	Percentage of Participants Who Achieved Sustained Virologic Response (SVR12) at Follow-Up Week 12
NCT01741545 (9) [back to overview]	Percentage of Participants With End of the Treatment Response (EOTR)
NCT01743521 (10) [back to overview]	Undetectable HCV RNA (Week 1)
NCT01743521 (10) [back to overview]	Undetectable HCV RNA (Week 3)
NCT01743521 (10) [back to overview]	Undetectable HCV RNA (Week 4)
NCT01743521 (10) [back to overview]	Decrease in Absolute Neutrophil Count (ANC) ≤0.75
NCT01743521 (10) [back to overview]	Change in Hemoglobin at End of Treatment
NCT01743521 (10) [back to overview]	Decrease in Platelets <50
NCT01743521 (10) [back to overview]	SVR12 (Sustain Virological Response, HCV RNA Undetectable 12 Weeks Post-treatment)
NCT01743521 (10) [back to overview]	SVR24
NCT01743521 (10) [back to overview]	Undectectable HCV RNA (Week 2)
NCT01743521 (10) [back to overview]	Undetectable HCV RNA (ETR)
NCT01756079 (3) [back to overview]	Percentage of Participants With One or More Adverse Events
NCT01756079 (3) [back to overview]	Percentage of Participants Who Achieve Sustained Virological Response at Follow-up Week 24 (SVR24)
NCT01756079 (3) [back to overview]	Percentage of Participants With an Adverse Event Leading to Discontinuation of Study Medication
NCT01767116 (6) [back to overview]	Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment
NCT01767116 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analyses of Each Treatment Arm Compared to Historical Rate
NCT01767116 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Noninferiority Analysis of ABT-450/r/ABT-267 and ABT-333, Plus Placebo RBV Compared With ABT-450/r/ABT-267 and ABT-333, Plus RBV
NCT01767116 (6) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT01767116 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Superiority Analyses of Each Treatment Arm Compared to Historical Rate
NCT01767116 (6) [back to overview]	Percentage of Participants With Virologic Relapse After Treatment
NCT01770483 (2) [back to overview]	Normalization of Alanine Transferase Test
NCT01770483 (2) [back to overview]	Sustained Viral Response,
NCT01782495 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT01782495 (4) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT01782495 (4) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT01782495 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks Post-treatment (SVR24)
NCT01830127 (2) [back to overview]	SVR4: Plasma HCV RNA Level Less Than 25 IU/mL at 4 Weeks After End of Treatment (EOT)
NCT01830127 (2) [back to overview]	SVR12: Plasma HCV RNA Level Less Than 25 IU/mL at 12 Weeks After End of Treatment (EOT)
NCT01833533 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Secondary Analyses
NCT01833533 (5) [back to overview]	Percentage of Participants With Virologic Relapse After Treatment
NCT01833533 (5) [back to overview]	Percentage of Participants With Hemoglobin Decrease to Below the Lower Limit of Normal (LLN) At End of Treatment
NCT01833533 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment; Primary Analyses
NCT01833533 (5) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT01833845 (1) [back to overview]	Safety: Number of Participants With Adverse Events
NCT01849562 (2) [back to overview]	Safety And Tolerability Of 12 Weeks Of Sovaprevir And ACH-3102 In Combination With RBV In GT-1 HCV Participants
NCT01849562 (2) [back to overview]	Incidence Of Sustained Virologic Response 4 Weeks (SVR4) After The Completion Of Treatment
NCT01853254 (1) [back to overview]	Percentage of Participants With at Least 1 Adverse Event
NCT01854528 (6) [back to overview]	Mean Change From Baseline to Final Treatment Visit in the Physical Component Summary (PCS) Score of the Short-Form 36 Health Survey - Version 2 (SF-36v2)
NCT01854528 (6) [back to overview]	Mean Change From Baseline to Final Treatment Visit in the Mental Component Summary (MCS) Score of the Short-Form 36 Health Survey - Version 2 (SF-36v2)
NCT01854528 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment
NCT01854528 (6) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT01854528 (6) [back to overview]	Percentage of Participants With Virologic Relapse After Treatment
NCT01854528 (6) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment
NCT01854697 (7) [back to overview]	Percentage of Participants With SVR12 - Secondary Efficacy Analyses
NCT01854697 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks After Treatment (SVR24)
NCT01854697 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Treatment (SVR12) - Primary Efficacy Analyses
NCT01854697 (7) [back to overview]	Mean Change From Baseline to the Final Treatment Visit in Short-Form 36 Version 2 Health Status Survey (SF-36V2) Mental Component Summary (MCS)
NCT01854697 (7) [back to overview]	Mean Change From Baseline to the Final Treatment Visit in SF-36V2 Physical Component Summary (PCS)
NCT01854697 (7) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT01854697 (7) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT01858766 (4) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01858766 (4) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT01858766 (4) [back to overview]	Percentage of Participants With Virologic Failure
NCT01858766 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01866930 (12) [back to overview]	Mean Change in Platelet Count From Baseline to End of Treatment
NCT01866930 (12) [back to overview]	Number of Participants With On-treatment IFN-associated Flu-like or Musculoskeletal Symptoms
NCT01866930 (12) [back to overview]	Number of Participants Who Died or Experienced Severe Adverse Events (SAEs), Dose Reductions of Lambda or Discontinuation Due to Adverse Events (AEs)
NCT01866930 (12) [back to overview]	Number of Participants With Treatment Emergent Cytopenic Abnormalities
NCT01866930 (12) [back to overview]	Number of Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)
NCT01866930 (12) [back to overview]	Mean Change in Absolute CD4 T Lymphocyte Count From Baseline to End of Treatment
NCT01866930 (12) [back to overview]	Mean Percent Change in Total Lymphocyte Count From Baseline to End of Treatment
NCT01866930 (12) [back to overview]	Number of Participants With Treatment-emergent Grade 3/4 Lab Abnormalities
NCT01866930 (12) [back to overview]	Number of Participants With Rapid Virologic Response (RVR) and Extended Rapid Virologic Response (eRVR)
NCT01866930 (12) [back to overview]	Mean Percent Change in Platelet Count From Baseline to End of Treatment
NCT01866930 (12) [back to overview]	Mean Percent Change in Absolute CD4 T Lymphocyte Count From Baseline to End of Treatment
NCT01866930 (12) [back to overview]	Mean Change in Total Lymphocyte Count From Baseline to End of Treatment
NCT01909804 (4) [back to overview]	Percentage of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT01909804 (4) [back to overview]	Percentage of Participants With Virologic Failure
NCT01909804 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01909804 (4) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT01911845 (7) [back to overview]	Percentage of Participants With Virologic Relapse Post-treatment
NCT01911845 (7) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT01911845 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment
NCT01911845 (7) [back to overview]	Area Under the Plasma Concentration-time Curve (AUC) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin
NCT01911845 (7) [back to overview]	Maximum Plasma Concentration (Cmax) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin
NCT01911845 (7) [back to overview]	Time to Maximum Plasma Concentration (Tmax) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin
NCT01911845 (7) [back to overview]	Plasma Trough Concentration (Ctrough) for ABT-450, Ritonavir, ABT-267, ABT-333, ABT-333 M1 Metabolite, and Ribavirin
NCT01925183 (2) [back to overview]	Proportion of Subjects With Sustained Virologic Response (SVR12)
NCT01925183 (2) [back to overview]	Proportions of Subjects With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01932762 (7) [back to overview]	Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Drug-Related AEs, Drug-Related SAEs, or Discontinuation of Study Treatment Due to AE During the Treatment Period and First 14 Follow-up Days
NCT01932762 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)
NCT01932762 (7) [back to overview]	Percentage of Participants Achieving SVR4
NCT01932762 (7) [back to overview]	Percentage of Participants Achieving SVR24
NCT01932762 (7) [back to overview]	Mean Time to First Achievement of Undetectable HCV RNA During Treatment
NCT01932762 (7) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA During Treatment By Timepoint
NCT01932762 (7) [back to overview]	Percentage of Participants Achieving HCV RNA <25 IU/mL During Treatment By Timepoint
NCT01938625 (8) [back to overview]	Percentage of Participants With HCV RNA (< 25 IU/mL Undetectable) and HCV RNA < 25 IU/mL Detectable
NCT01938625 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 Weeks After the End of Treatment (SVR 24)
NCT01938625 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After the End of Treatment (SVR 12)
NCT01938625 (8) [back to overview]	Percentage of Participants With HCV RNA (<) 100 IU/mL at Week 4
NCT01938625 (8) [back to overview]	Number of Participants With Viral Relapse
NCT01938625 (8) [back to overview]	Number of Participants With Viral Breakthrough
NCT01938625 (8) [back to overview]	Number of Participants With On-Treatment Failure
NCT01938625 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks After the End of Treatment (SVR 4)
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 2 With On-Treatment HCV Virologic Failure During the Treatment Period
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 2 With Relapse12
NCT01939197 (14) [back to overview]	Percentage of Participants With GT4 HCV in Part 2 Achieving SVR12, by Arm and Overall
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 1a With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 1b With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 2 With Plasma HIV-1 RNA Suppression at End of Treatment and 12 Weeks Post-Treatment
NCT01939197 (14) [back to overview]	Percentage of Participants in Arm F and Arm G of Part 2 Achieving SVR12
NCT01939197 (14) [back to overview]	Percentage of Participants in GT1 Analysis Group 1 in Part 2 Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12)
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 1a With On-Treatment HCV Virologic Failure During the Treatment Period
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 1a With Relapse12
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 1b Achieving SVR12
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 1b With On-Treatment HCV Virologic Failure During the Treatment Period
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 1b With Relapse12 for Each Arm and Overall
NCT01939197 (14) [back to overview]	Percentage of Participants in Part 1a Achieving SVR12
NCT01945294 (8) [back to overview]	Percentage of Participants With Undetectable HCV RNA Who Achieve Sustained Viral Response at Follow-up Week 12 (SVR12) [16-Week Arm vs. 28-Week Arm]
NCT01945294 (8) [back to overview]	Percentage of Participants With Anemia
NCT01945294 (8) [back to overview]	Percentage of Participants With Neutropenia
NCT01945294 (8) [back to overview]	Percentage of Participants With Relapse
NCT01945294 (8) [back to overview]	Percentage of Participants With Treatment-Related Serious AEs (SAEs)
NCT01945294 (8) [back to overview]	Percentage of Participants Achieving SVR12 Among Participants With Undetectable HCV RNA Across Treatment
NCT01945294 (8) [back to overview]	Percentage of Participants With Dose Discontinuation Due to Adverse Events (AEs)
NCT01945294 (8) [back to overview]	Percentage of Participants With Undetectable HCV RNA Across Treatment
NCT01984294 (5) [back to overview]	Percentage of Participants Experiencing Viral Relapse
NCT01984294 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT01984294 (5) [back to overview]	Percentage of Participants Experiencing On-treatment Virologic Failure
NCT01984294 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response at 2, 4, 8, and 24 Weeks After Discontinuation of Therapy (SVR2, SVR4, SVR8, and SVR24)
NCT01984294 (5) [back to overview]	Percentage of Participants Permanently Discontinuing Any Study Drug Due to an Adverse Event
NCT01995071 (4) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT01995071 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT01995071 (4) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT01995071 (4) [back to overview]	Maximal Decrease From Baseline in log10 HCV RNA Levels During ABT-493 or ABT-530 Monotherapy Treatment
NCT02021643 (8) [back to overview]	Change From Baseline in HCV RNA (log10 IU/mL)
NCT02021643 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)
NCT02021643 (8) [back to overview]	Change From Baseline in HCV RNA (log10 IU/mL)
NCT02021643 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02021643 (8) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02021643 (8) [back to overview]	Percentage of Participants With On-Treatment Virologic Failure
NCT02021643 (8) [back to overview]	Percentage of Participants With Viral Relapse
NCT02021643 (8) [back to overview]	Change From Baseline in HCV RNA (log10 IU/mL)
NCT02023112 (6) [back to overview]	Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period for Each Treatment Arm Within Different Subpopulations
NCT02023112 (6) [back to overview]	Percentage of Participants With SVR12 Weeks Post-treatment for Each Treatment Arm Within Different Subpopulations
NCT02023112 (6) [back to overview]	Percentage of Participants With Post-treatment Relapse Within Different Subpopulations
NCT02023112 (6) [back to overview]	Percentage of Non-cirrhotic, Treatment-naive Participants in Each Treatment Group With a Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02023112 (6) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02023112 (6) [back to overview]	Percentage of Participants in Each Treatment Arm With On-treatment Virologic Failure During the Treatment Period
NCT02032875 (8) [back to overview]	Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels Below the Lower Limit of Quantitation Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment
NCT02032875 (8) [back to overview]	Percentage of Genotype-1 Infected Cirrhotic Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)
NCT02032875 (8) [back to overview]	Percentage of HCV Genotype-1 Infected Post-liver Transplanted Participants With Sustained Virologic Response at Post-treatment Week 12 (SVR12)
NCT02032875 (8) [back to overview]	Number of Participants With Serious Adverse Events (SAEs), Discontinuations Due to Adverse Events (AEs), AEs Leading to Interruption, Treatment-related AEs/SAEs, Grade 3 to 4 AEs/SAEs, and Death
NCT02032875 (8) [back to overview]	Number of Participants With Treatment Emergent Grade 3-4 Laboratory Abnormalities
NCT02032875 (8) [back to overview]	Percentage of Participants Who Achieve Hepatitis C Virus RNA Levels Below the Lower Limit of Quantitation Target Detected or Target Not Detected at Each of the Following Weeks: 1, 2, 4, 6, 8, 12, End of Treatment; Follow Up Weeks 4, 8, and 24
NCT02032875 (8) [back to overview]	Percentage of Participants Who Achieved Sustained Virologic Response at Post-treatment Week 12 (SVR12) for All Genotypes and Genotypes 2, 3, 4, 6
NCT02032875 (8) [back to overview]	Percentage of Participants With CC or Non-CC Genotype Who Achieved Sustained Virologic Response at 12 Weeks After the Last Dose of Study Drug (SVR12)
NCT02068222 (4) [back to overview]	The Percentage of Subjects Who Achieve 12-week Sustained Virologic Response (SVR12)
NCT02068222 (4) [back to overview]	The Percentage of Subjects Who Achieve 24-week Sustained Virologic Response (SVR24)
NCT02068222 (4) [back to overview]	The Percentage of Subjects With Post-Treatment Relapse
NCT02068222 (4) [back to overview]	The Percentage of Subjects With Virologic Failure During Treatment
NCT02094443 (7) [back to overview]	Percentage of Participants With Abnormal Alanine Aminotransferase (ALT) at Baseline Who Had Normalized ALT at Treatment End and Study End
NCT02094443 (7) [back to overview]	Change From Baseline in Hepatitis C Virus Ribonucleic Acid Viral Load at Week 12
NCT02094443 (7) [back to overview]	Change From Baseline in Alanine Aminotransferase (ALT) at Week 12
NCT02094443 (7) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR)
NCT02094443 (7) [back to overview]	Percentage of Participants With End of Treatment Response (ETR)
NCT02094443 (7) [back to overview]	Percentage of Participants With Extended Rapid Virologic Response
NCT02094443 (7) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response (SVR) 4, 12, and 24 Weeks After Treatment
NCT02105454 (4) [back to overview]	Percentage of Participants Discontinuing Study Drug Due to an Adverse Event
NCT02105454 (4) [back to overview]	Percentage of Participants Experiencing Adverse Events
NCT02105454 (4) [back to overview]	Percentage of Participants Achieving SVR12 by Prior Direct-acting Antiviral (DAA) Therapy
NCT02105454 (4) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response (SVR) at 12 Weeks After the End of All Study Therapy (SVR12)
NCT02105701 (4) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA 12 Weeks After Completing Study Therapy (SVR12)
NCT02105701 (4) [back to overview]	Number of Participants Discontinuing Study Treatment Due to an AE
NCT02105701 (4) [back to overview]	Percentage of Participants Achieving Undetectable HCV RNA 24 Weeks After the End of All Treatment (SVR24)
NCT02105701 (4) [back to overview]	Number of Participants Experiencing Adverse Events (AE)
NCT02106156 (9) [back to overview]	Percentage of Participants With End of Treatment (EOT) Response
NCT02106156 (9) [back to overview]	Percentage of Participants With Serious Adverse Drug Reactions (SADR)
NCT02106156 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR)
NCT02106156 (9) [back to overview]	Percentage of Participants With the Most Frequent Concomitant Medications
NCT02106156 (9) [back to overview]	Percentage of Participants With Early Virologic Response (EVR)
NCT02106156 (9) [back to overview]	Percentage Cumulative Dose of Ribavirin Received
NCT02106156 (9) [back to overview]	Percentage Cumulative Dose of Peginterferon Alfa-2a Received
NCT02106156 (9) [back to overview]	Duration of Peginterferon Alfa-2a Therapy
NCT02106156 (9) [back to overview]	Percentage of Participants With Rapid Virologic Response (RVR)
NCT02118012 (4) [back to overview]	Change in Alanine Aminotransferase (ALT) Levels From Baseline to 28 Days
NCT02118012 (4) [back to overview]	Change in Serum HCV RNA Viral Titer From Baseline to 28 Days
NCT02118012 (4) [back to overview]	Maximum Chlorcyclizine HCL Weeks 1-4
NCT02118012 (4) [back to overview]	Number of Participants Who Tolerated the Drug at the Prescribed Dose for the Duration of Therapy
NCT02118597 (7) [back to overview]	Number of Participants With Virological Breakthrough
NCT02118597 (7) [back to overview]	Number of Participants With Virological Relapse
NCT02118597 (7) [back to overview]	Number of Participants With Adverse Events
NCT02118597 (7) [back to overview]	Sustained Virological Response 24 (SVR24) Rate
NCT02118597 (7) [back to overview]	Percentage of Participants With Virological Response
NCT02118597 (7) [back to overview]	Number of Participants With Treatment Discontinuation Due to Futility
NCT02118597 (7) [back to overview]	Number of Participants With Treatment Discontinuation
NCT02128217 (19) [back to overview]	Concentration of Tenofovir (TFV) in Plasma
NCT02128217 (19) [back to overview]	Concentration of Tenofovir Diphosphate (TFV-DP) in Peripheral Blood Mononuclear Cells (PBMCs)
NCT02128217 (19) [back to overview]	Count and Percentage of Participants With an Adverse Event by Type.
NCT02128217 (19) [back to overview]	Percentage of Participants With HCV RNA Undetectable After End of Study Treatment
NCT02128217 (19) [back to overview]	Percentage of Participants With HCV RNA Undetectable During Study Treatment
NCT02128217 (19) [back to overview]	Ribavirin Concentration in Plasma
NCT02128217 (19) [back to overview]	Self-reported Adherence to LDV/SOF
NCT02128217 (19) [back to overview]	Self-reported Adherence to RBV
NCT02128217 (19) [back to overview]	Count of Participants With HIV-1 RNA <50 Copies/mL
NCT02128217 (19) [back to overview]	Adherence as Measured by SOF Pill Count
NCT02128217 (19) [back to overview]	Adherence as Measured by RBV Pill Count
NCT02128217 (19) [back to overview]	Change in CD4+ Cell Count
NCT02128217 (19) [back to overview]	Number of Participants Who Had HCV Virologic Relapse
NCT02128217 (19) [back to overview]	Percentage of HCV Virologic Failure Participants That Developed SOF- or LDV-Associated Resistance Mutations
NCT02128217 (19) [back to overview]	Self-reported Adherence to SOF
NCT02128217 (19) [back to overview]	Cellular Concentration of Tenofovir Diphosphate (TFV-DP)
NCT02128217 (19) [back to overview]	Percentage of Participants With an Occurrence of a Grade ≥ 2 Adverse Event, Serious AE According to ICH Criteria, or Treatment-limiting AE.
NCT02128217 (19) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 (SVR12)
NCT02128217 (19) [back to overview]	Adherence as Measured by LDV/SOF Pill Count
NCT02167945 (11) [back to overview]	Mean Change From Baseline in Short Form 36 Version 2.0 (SF-36 V2) Mental Component Summary (MCS) Score at Post-Treatment Week 12 and Post-Treatment Week 24
NCT02167945 (11) [back to overview]	Mean Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) Total Score at Post-Treatment Week 12 and Post-Treatment Week 24
NCT02167945 (11) [back to overview]	Treatment Compliance: Percentage of Tablets Taken Relative to the Total Tablets
NCT02167945 (11) [back to overview]	Hepatocellular Carcinoma: Time to Event
NCT02167945 (11) [back to overview]	All-Cause Death: Time to Event
NCT02167945 (11) [back to overview]	All-Cause Death, Liver-Related Death, Liver Decompensation, Liver Transplantation, Hepatocellular Carcinoma: Time to Event
NCT02167945 (11) [back to overview]	Liver-Related Death: Time to Event
NCT02167945 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02167945 (11) [back to overview]	Mean Change From Baseline in Short Form 36 Version 2.0 (SF-36 V2) Physical Component Summary (PCS) Score at Post-Treatment Week 12 and Post-Treatment Week 24
NCT02167945 (11) [back to overview]	Liver Transplantation: Time to Event
NCT02167945 (11) [back to overview]	Liver Decompensation: Time to Event
NCT02168361 (2) [back to overview]	Serum HCV RNA Level
NCT02168361 (2) [back to overview]	Proportion of Participants With Sustained Virologic Response 12 (SVR-12)
NCT02175758 (25) [back to overview]	For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in Height
NCT02175758 (25) [back to overview]	For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair
NCT02175758 (25) [back to overview]	For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF)
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02175758 (25) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
NCT02175758 (25) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
NCT02175758 (25) [back to overview]	For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
NCT02175758 (25) [back to overview]	For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in HCV RNA
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in HCV RNA
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in Height
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in Weight
NCT02175758 (25) [back to overview]	For the Treatment Phase, Change From Baseline in Weight
NCT02175758 (25) [back to overview]	For the Treatment Phase, Palatability of SOF Granules at Day 1 as Assessed by the Percentage of Participants Able/Unable to Taste the SOF Oral Granules
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
NCT02175758 (25) [back to overview]	For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
NCT02175758 (25) [back to overview]	For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development
NCT02175758 (25) [back to overview]	For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair
NCT02175966 (8) [back to overview]	Percentage of Participants With End of Treatment Response (EOTR)
NCT02175966 (8) [back to overview]	Number of Participants With Selected Grade 3/4 Laboratory Abnormalities
NCT02175966 (8) [back to overview]	Percentage of Participants Who Achieved SVR12 Associated With Interleukin-28B (IL28B) rs12979860 SNP Status (CC Genotype or Non-CC Genotype)
NCT02175966 (8) [back to overview]	Percentage of Participants Who Achieved SVR12 Associated With HCV Geno Subtype 1a vs 1b
NCT02175966 (8) [back to overview]	Percentage of Participants Who Achieved HCV RNA
NCT02175966 (8) [back to overview]	Percentage of Participants Who Achieved HCV RNA < LLOQ TND
NCT02175966 (8) [back to overview]	Number of Participants With Deaths, Serious Adverse Events (SAEs) and AEs Leading to Discontinuation From Treatment
NCT02175966 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 (SVR12)
NCT02194998 (13) [back to overview]	Percentage of Participants With Sustained Virologic Response at 12 Weeks After HCV Treatment Discontinuation (SVR12)
NCT02194998 (13) [back to overview]	Number of Participants With Selected HIV-1 Resistance Mutations Among Participants Who Experience HIV-1 Virologic Failure (VF)
NCT02194998 (13) [back to overview]	Number of Participants With an Occurrence of Signs/Symptoms Grade 3 or Higher
NCT02194998 (13) [back to overview]	Number of Participants With an Occurrence of Serious Adverse Events (SAEs) as Defined by International Conference on Harmonisation (ICH) Criteria
NCT02194998 (13) [back to overview]	Levels of Soluble CD14 (sCD14)
NCT02194998 (13) [back to overview]	Number of Participants With an Occurrence of Laboratory Abnormality Grade 3 or Higher.
NCT02194998 (13) [back to overview]	Number of Participants With an Occurrence of Diagnoses Leading to Premature HCV Study Treatment or HIV-1 Antiretroviral (ARV) Discontinuation.
NCT02194998 (13) [back to overview]	Number of Participants Who Prematurely Discontinued HCV Study Treatment for Any Reason Other Than HCV Virologic Failure (VF)
NCT02194998 (13) [back to overview]	Number of Participants Who Experienced HIV-1 Virologic Failure (VF)
NCT02194998 (13) [back to overview]	Levels of IP-10 Concentration.
NCT02194998 (13) [back to overview]	Change in Soluble CD14 (sCD14)
NCT02194998 (13) [back to overview]	Change in IP-10 Concentration.
NCT02194998 (13) [back to overview]	Percentage of Participants With Sustained Virologic Response at 24 Weeks After HCV Treatment Discontinuation (SVR24)
NCT02207088 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment
NCT02207088 (3) [back to overview]	Percentage of Participants With Post-Treatment Relapse
NCT02207088 (3) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02214420 (1) [back to overview]	Sustained Viral Response
NCT02216422 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment
NCT02216422 (3) [back to overview]	Percentage of Participants With On-Treatment Virologic Failure
NCT02216422 (3) [back to overview]	Percentage of Participants With Post-Treatment Relapse
NCT02219477 (9) [back to overview]	Percentage of Participants With SVR12 Non-Response Due to Experiencing Relapse˅12
NCT02219477 (9) [back to overview]	Percentages of Participants With Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) in Group 1 and in Group 2
NCT02219477 (9) [back to overview]	Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Hepatic Function Tests
NCT02219477 (9) [back to overview]	Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in FibroTest
NCT02219477 (9) [back to overview]	Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Chld-Pugh Score
NCT02219477 (9) [back to overview]	Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Model for End-Stage Liver Disease (MELD) Score
NCT02219477 (9) [back to overview]	Percentage of Participants With SVR12 in Group 3
NCT02219477 (9) [back to overview]	Percentage of Participants With SVR12 Non-Response Due to Experiencing On-Treatment Virologic Failure
NCT02219477 (9) [back to overview]	Percentage of Participants With Improvement From Baseline to Post-Treatment Week 12 in Hepatic Function Tests
NCT02219490 (8) [back to overview]	Liver-Related Death: Time to Event
NCT02219490 (8) [back to overview]	Liver Transplantation: Time to Event
NCT02219490 (8) [back to overview]	Liver Decompensation: Time to Event
NCT02219490 (8) [back to overview]	Hepatocellular Carcinoma: Time to Event
NCT02219490 (8) [back to overview]	Change From Baseline in FibroScan Score by SVR12 Status
NCT02219490 (8) [back to overview]	All-Cause Death: Time to Event
NCT02219490 (8) [back to overview]	All-Cause Death, Liver-Related Death, Liver Decompensation, Liver Transplantation, Hepatocellular Carcinoma: Time to Event
NCT02219490 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02243293 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)
NCT02243293 (5) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02243293 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02243293 (5) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02243293 (5) [back to overview]	Percentage of Genotype 2 (GT2) Direct-acting Antiviral Agents (DAA)-Naive Participants (in Part 4, Arm S1) With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) as Compared to Historical Control
NCT02247440 (7) [back to overview]	Number of Participants Grouped by HIV-1 RNA Concentrations
NCT02247440 (7) [back to overview]	Number of Participants Completed the First 24 and 48 Weeks of Treatment
NCT02247440 (7) [back to overview]	Number of Participants With at Least a Serious Adverse Events Associated With Study Treatment (Peg-interferon and Ribavirin)
NCT02247440 (7) [back to overview]	Number of Participants With Sustained Virological Response 6 Months After Treatment Discontinuation
NCT02247440 (7) [back to overview]	Number of Adverse Events by Severity Grade
NCT02247440 (7) [back to overview]	Number of Participants Able to Perform Self-injections of Peg-interferon
NCT02247440 (7) [back to overview]	Number of Participants With Ribavirin Compliance at ≥ 95%, 80% - 95%, and < 80%
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With SVR at 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With Alanine Aminotransferase (ALT) Normalization
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With HCV RNA < LLOQ While On Treatment
NCT02249182 (26) [back to overview]	Acceptability of LDV/SOF Granules as Measured by Palatability at Day 1
NCT02249182 (26) [back to overview]	For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Pubic Hair
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in Weight
NCT02249182 (26) [back to overview]	For Participants in the PK Lead-in Phase, Pharmacokinetic (PK) Parameter: AUCtau of GS-331007 (Metabolite of SOF), LDV, and SOF
NCT02249182 (26) [back to overview]	For Participants in the PK Lead-in Phase, Change From Baseline in HCV RNA
NCT02249182 (26) [back to overview]	Acceptability of LDV/SOF Tablets as Measured by the Percentage of Participants Able/Unable to Swallow Placebo Tablet at Day 1
NCT02249182 (26) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase or the Treatment Phase
NCT02249182 (26) [back to overview]	For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Pubic Hair
NCT02249182 (26) [back to overview]	For the Treatment Phase, Number of Female Participants With a Change From Baseline in Tanner Stage for Breast Development
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in HCV RNA
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants With Sustained Virologic Response (SVR) at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in HCV RNA
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in Height
NCT02249182 (26) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event During the PK Lead-in Phase
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in Height
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants Experiencing Viral Relapse
NCT02249182 (26) [back to overview]	For the Treatment Phase, Percentage of Participants Experiencing Viral Breakthrough
NCT02249182 (26) [back to overview]	For the Treatment Phase, Number of Male Participants With a Change From Baseline in Tanner Stage for Genitalia Development
NCT02249182 (26) [back to overview]	For the Treatment Phase, Change From Baseline in Weight
NCT02265237 (5) [back to overview]	Percentage of Participants in Arms A, B and C With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02265237 (5) [back to overview]	Percentage of Participants With SVR12 in Participants Receiving 12 Weeks (Arm A) of Treatment Compared to Participants Receiving 16 Weeks of Treatment (Arm B)
NCT02265237 (5) [back to overview]	Percentage of Participants With SVR12 in Participants Receiving 16 Weeks (Arm B) of Treatment Compared to Participants Receiving 24 Weeks of Treatment (Arm C)
NCT02265237 (5) [back to overview]	Percentage of Participants in Arms A, B and C With Post-treatment Relapse
NCT02265237 (5) [back to overview]	Percentage of Participants in Arms A, B and C With On-treatment Virologic Failure
NCT02292706 (6) [back to overview]	Number of Participants With Detectable HCV RNA Due to Re-infection Through Week 240
NCT02292706 (6) [back to overview]	Number of Participants With Detectable HCV Resistance Mutations Through Week 240
NCT02292706 (6) [back to overview]	Number of Participants With Detectable HCV RNA Due to Re-emergence of Pre-existing Virus Through Week 240
NCT02292706 (6) [back to overview]	Percentage of Participants With Any Liver-Associated Events
NCT02292706 (6) [back to overview]	Percentage of Participants Who Developed Hepatocellular Carcinoma (HCC) Through Week 240
NCT02292706 (6) [back to overview]	Percentage of Participants Maintaining Sustained Virologic Response (SVR) at Week 240
NCT02292719 (3) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02292719 (3) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02292719 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02304159 (3) [back to overview]	Number of Participants With Abnormal Safety Laboratory Tests (ALT and/or Total Bilirubin) That Required Discontinuing Study Drugs
NCT02304159 (3) [back to overview]	Number of Participants With Adverse Events
NCT02304159 (3) [back to overview]	Number of Participants With Undetectable HCV Virus 12 Weeks After Stopping Study Drugs
NCT02308241 (1) [back to overview]	Number of Participants Evaluated for Toxicity
NCT02319031 (3) [back to overview]	Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 12 (SVR12)
NCT02319031 (3) [back to overview]	Number of Participants With Death, Serious Adverse Events (SAEs), Discontinuation Due to Adverse Events (AEs), Grade 3 or Grade 4 (Grade 3/4) AEs, and Grade 3/4 Laboratory Abnormalities
NCT02319031 (3) [back to overview]	Percent of Participants With a Sustained Virologic Response (SVR) at Follow-up Week 4 (SVR4) and Follow-up Week 24 (SVR24)
NCT02332707 (4) [back to overview]	Percentage of Participants Experiencing an Adverse Event (AE)
NCT02332707 (4) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After Completing Treatment (SVR12)
NCT02332707 (4) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)
NCT02332707 (4) [back to overview]	Percentage of Participants Discontinuing From Study Treatment Due to an AE
NCT02332720 (4) [back to overview]	Percentage of HCV GT3-infected Participants Achieving Sustained Virologic Response at Follow-up Week 12 (SVR12)
NCT02332720 (4) [back to overview]	Percentage of GT3-infected Participants Achieving SVR at Follow-up Week 24 (SVR24)
NCT02332720 (4) [back to overview]	Number of Participants Who Had Study Drug Discontinued Due to an AE
NCT02332720 (4) [back to overview]	Number of Participants Experiencing an Adverse Event (AE)
NCT02340962 (8) [back to overview]	Mean Absolute Values in HCV RNA (log10 IU/mL)
NCT02340962 (8) [back to overview]	Proportion of Subjects Achieving Sustained Viral Response at 4, 8, and 24 Weeks After the End of Treatment (SVR4, SVR8, and SVR24)
NCT02340962 (8) [back to overview]	Proportion of Subjects Achieving HCV RNA < Lower Limit of Quantification, Target Detected or Target Not Detected (< LLOQ, TD or TND)
NCT02340962 (8) [back to overview]	Proportion of Subjects Achieving HCV RNA < LLOQ, TND
NCT02340962 (8) [back to overview]	Change From Baseline in HCV RNA (log10 IU/mL)
NCT02340962 (8) [back to overview]	Proportion of Subjects Achieving Sustained Viral Response at 12 Weeks After the End of Treatment.
NCT02340962 (8) [back to overview]	Proportion of Subjects With Abnormal Alanine Aminotransferase (ALT) Levels at Baseline Who Achieved Normal Limit of ALT at Final Treatment Visit.
NCT02340962 (8) [back to overview]	Proportion of Subjects Experiencing Virologic Failure During Treatment and Viral Relapse After the End of Treatment.
NCT02356562 (4) [back to overview]	Percentage of Participants With Post-Treatment Relapse
NCT02356562 (4) [back to overview]	Percentage of Part 1 Participants With Sustained Virologic Response 12 (SVR12) Weeks Posttreatment
NCT02356562 (4) [back to overview]	Percentage of Part 2 Participants With Sustained Virologic Response 12 (SVR12) Weeks Post-treatment
NCT02356562 (4) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02358044 (6) [back to overview]	Percentage of Participants Discontinuing Study Treatment Due to an AE
NCT02358044 (6) [back to overview]	Percentage of Participants Experiencing at Least One Adverse Event (AE) During the Treatment Period Plus First 14 Follow-up Days
NCT02358044 (6) [back to overview]	Primary: Percentage of Participants Achieving Sustained Virologic Response at 12 Weeks After the End of All Treatment (SVR12)
NCT02358044 (6) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 24 Weeks After Ending Study Treatment (SVR24)
NCT02358044 (6) [back to overview]	Percentage of Participants Experiencing at Least One Tier 1 Safety Event (Key Safety Parameter) During the Treatment Period and First 14 Follow-up Days
NCT02358044 (6) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 4 Weeks After Ending Study Treatment (SVR4)
NCT02399345 (3) [back to overview]	Percentage of Subjects With On-treatment Virologic Failure
NCT02399345 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment
NCT02399345 (3) [back to overview]	Percentage of Subjects With Post-treatment Relapse
NCT02442271 (7) [back to overview]	Hepatitis C Virus Patient-Reported Outcomes Instrument (HCV-PRO) Total Score: Change From Baseline to 12 Weeks After the Last Dose of Study Drug
NCT02442271 (7) [back to overview]	(SF-36v2) Mental Component Summary (MCS) Scores: Change From Baseline to 12 Weeks After the Last Dose of Study Drug
NCT02442271 (7) [back to overview]	Percentage of Participants With SVR12 by Participant Prior HCV Treatment Experience
NCT02442271 (7) [back to overview]	Percentage of Participants With SVR12 by Participant Eligibility for Treatment With Interferon (IFN) at Screening
NCT02442271 (7) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02442271 (7) [back to overview]	Short-Form 36 Version 2 Health Survey (SF-36v2) Physical Component Summary (PCS) Scores: Change From Baseline to 12 Weeks After the Last Dose of Study Drug
NCT02442271 (7) [back to overview]	Percentage of Participants With SVR12 by Fibrosis Stage
NCT02442284 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) Among Participants With Ongoing Psychiatric Disorders
NCT02442284 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02442284 (4) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02442284 (4) [back to overview]	Percentage of Participants With Virologic Failure During Treatment
NCT02446717 (4) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02446717 (4) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02446717 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02446717 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 4 Weeks Post-treatment (SVR4)
NCT02455167 (3) [back to overview]	Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: Baseline
NCT02455167 (3) [back to overview]	Hepatic Improvement During and After Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) Treatment Using a New Test of Liver Function, HepQuant-SHUNT: 12 Weeks
NCT02455167 (3) [back to overview]	The Sustained Virologic Response (SVR) in Patients Infected With HCV Genotype 1, Cirrhosis, and Early Clinical Decompensation
NCT02461745 (2) [back to overview]	Sustained Virological Response (SVR) at Week 4
NCT02461745 (2) [back to overview]	Sustained Virological Response (SVR) at Week 12
NCT02476617 (1) [back to overview]	Change in Interferon (IFN)-Stimulated Genes (ISG) Expression in Peripheral Blood Mononucleated Cells (PBMCs) for Participants Achieving SVR12
NCT02486406 (16) [back to overview]	Part 1: Maximum Plasma Concentration (Cmax) of Ombitasvir (OBV)
NCT02486406 (16) [back to overview]	Part 1: Maximum Plasma Concentration (Cmax) of Paritaprevir (PTV)
NCT02486406 (16) [back to overview]	Part 1: Maximum Plasma Concentration (Cmax) of Ritonavir (RTV)
NCT02486406 (16) [back to overview]	Parts 1 & 2: Percentage of Participants With Sustained Virologic Response 24 Weeks After the Last Actual Dose of Study Drug (SVR24), Summarized by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations
NCT02486406 (16) [back to overview]	Parts 1 and 2: Percentage of Participants With Alanine Aminotransferase (ALT) Normalization During Treatment by Formulation, Age and Weight Group, Across All Subjects, and Across All Subjects on the Adult Formulations
NCT02486406 (16) [back to overview]	Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12)
NCT02486406 (16) [back to overview]	Parts 1 and 2: Percentage of Participants With Sustained Virologic Response 12 Weeks After the Last Actual Dose of Study Drug (SVR12) Summarized by Formulation, Age and Weight Group, and Across All Subjects on the Adult Formulations
NCT02486406 (16) [back to overview]	Part 1: Lowest Plasma Concentration (Ctrough) of Dasabuvir (DSV)
NCT02486406 (16) [back to overview]	Part 1: Lowest Plasma Concentration (Ctrough) of Ombitasvir (OBV)
NCT02486406 (16) [back to overview]	Part 1: Maximum Plasma Concentration (Cmax) of Dasabuvir (DSV)
NCT02486406 (16) [back to overview]	Part 1: Lowest Plasma Concentration (Ctrough) of Paritaprevir (PTV)
NCT02486406 (16) [back to overview]	Part 1: Lowest Plasma Concentration (Ctrough) of Ritonavir (RTV)
NCT02486406 (16) [back to overview]	Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Paritaprevir (PTV)
NCT02486406 (16) [back to overview]	Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ombitasvir (OBV)
NCT02486406 (16) [back to overview]	Part 1: Concentration of Drug in Blood Plasma Against Time [Area Under the Curve (AUC)] of Dasabuvir (DSV)
NCT02486406 (16) [back to overview]	Part 1: Concentration of Drug in Blood Plasma Over Time [Area Under the Curve (AUC)] of Ritonavir (RTV)
NCT02493855 (1) [back to overview]	Slope of the Second Phase Decline in Plasma HCV Ribonucleic Acid (RNA) Levels During Treatment
NCT02515279 (3) [back to overview]	Percentage of Participants With End of Treatment Response
NCT02515279 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response 24 (SVR24)
NCT02515279 (3) [back to overview]	Percentage of Participants With Serious Adverse Events (SAEs) and Adverse Events (AEs)
NCT02517528 (5) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-Treatment (SVR12)
NCT02517528 (5) [back to overview]	Percentage of Participants With Virologic Relapse by Post-Treatment Week 24
NCT02517528 (5) [back to overview]	Percentage of Participants With On Treatment Virologic Failure
NCT02517528 (5) [back to overview]	Percentage of Participants With Virologic Relapse
NCT02517528 (5) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 24 Weeks Post-Treatment (SVR24)
NCT02541409 (4) [back to overview]	Sustained Virologic Response (SVR)
NCT02541409 (4) [back to overview]	Serious Adverse Events
NCT02541409 (4) [back to overview]	Change in Insulin Resistance
NCT02541409 (4) [back to overview]	HCV Treatment Completion
NCT02556307 (7) [back to overview]	Percentage of Participants Achieving Sustained Virological Response (SVR) According to Genotype and Previous Treatment
NCT02556307 (7) [back to overview]	Percentage of Participants With Undetectable HCV RNA
NCT02556307 (7) [back to overview]	Thrombocyte Values
NCT02556307 (7) [back to overview]	Leukocyte Values
NCT02556307 (7) [back to overview]	HCV RNA Values
NCT02556307 (7) [back to overview]	Hemoglobin Values
NCT02556307 (7) [back to overview]	Treatment Duration (in Weeks) With Peginterferon Alfa-2a and Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With Viral Relapse or Breakthrough According to Body Weight-normalized Dose of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With Virologic Response According to Body Weight-normalized Dose of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With Viral Relapse or Breakthrough According to Cumulative Dose of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With Virologic Response According to Starting Dose of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With Virologic Response According to Interleukin-28B (IL-28B) Polymorphism
NCT02557646 (15) [back to overview]	Percentage of Participants With Virologic Response According to Dose Reduction of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With Virologic Response
NCT02557646 (15) [back to overview]	Percentage of Participants With Viral Relapse or Breakthrough According to Starting Dose of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With Viral Relapse or Breakthrough According to Dose Reduction of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants Achieving Sustained Virological Response (SVR) According to Cumulative Dose of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With SVR According to Body Weight-normalized Dose of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With SVR According to Dose Reduction of Ribavirin
NCT02557646 (15) [back to overview]	Percentage of Participants With SVR According to IL-28B Polymorphism
NCT02557646 (15) [back to overview]	Percentage of Participants With Viral Relapse or Breakthrough
NCT02557646 (15) [back to overview]	Percentage of Participants With SVR According to Starting Dose of Ribavirin
NCT02581163 (8) [back to overview]	Percentage of Participants With Virologic Response at End of Treatment (EoT)
NCT02581163 (8) [back to overview]	Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria
NCT02581163 (8) [back to overview]	Percentage of Participants Meeting Relapse Criteria
NCT02581163 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02581163 (8) [back to overview]	Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria
NCT02581163 (8) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT02581163 (8) [back to overview]	Percentage of Participants With Relapse
NCT02581163 (8) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02581189 (8) [back to overview]	Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria
NCT02581189 (8) [back to overview]	Percentage of Participants Meeting Relapse Criteria
NCT02581189 (8) [back to overview]	Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria
NCT02581189 (8) [back to overview]	Percentage of Participants With Relapse
NCT02581189 (8) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT02581189 (8) [back to overview]	Percentage of Participants With Virologic Response at End of Treatment (EoT)
NCT02581189 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02581189 (8) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02582671 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02582671 (8) [back to overview]	Percentage of Participants With Virologic Response at End of Treatment (EOT)
NCT02582671 (8) [back to overview]	Percentage of Participants Meeting Relapse Criteria
NCT02582671 (8) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT02582671 (8) [back to overview]	Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria
NCT02582671 (8) [back to overview]	Percentage of Participants With Relapse
NCT02582671 (8) [back to overview]	Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria
NCT02582671 (8) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02601573 (4) [back to overview]	Percentage of Participants Discontinuing From Study Therapy Due to an AE
NCT02601573 (4) [back to overview]	Percentage of Participants Achieving SVR12 (Sustained Virologic Response 12 Weeks After the End of All Study Therapy)
NCT02601573 (4) [back to overview]	Percentage of Participants Experiencing an Adverse Event (AE)
NCT02601573 (4) [back to overview]	Percentage of Participants Achieving SVR24 (Sustained Virologic Response 24 Weeks After the End of All Study Therapy)
NCT02601976 (5) [back to overview]	Number of Participants With Rapid Virological Response (RVR)
NCT02601976 (5) [back to overview]	Number of Participants With Sustained Virological Response (SVR)
NCT02601976 (5) [back to overview]	Mean of Physical Component Score & Mental Component Score to Determine Quality of Life
NCT02601976 (5) [back to overview]	Number of Participants With End Treatment Response
NCT02601976 (5) [back to overview]	Number of Participants Who Reported Adverse Events
NCT02605304 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response at 24 Weeks After Treatment Discontinuation (SVR24)
NCT02605304 (11) [back to overview]	Percentage of Participants With Protocol-specified Renal Events
NCT02605304 (11) [back to overview]	Percentage of Participants With Grade 3 or Higher Adverse Event (AE), Serious AE (SAE), or AE Reported as the Reason for Permanent Discontinuation of Study Treatment
NCT02605304 (11) [back to overview]	Number of Participants With Unquantifiable HCV RNA
NCT02605304 (11) [back to overview]	Number of Participants With Unquantifiable HCV RNA
NCT02605304 (11) [back to overview]	Number of Participants With HIV-1 RNA >50 Copies/mL
NCT02605304 (11) [back to overview]	Number of Participants With HIV-1 RNA >50 Copies/mL
NCT02605304 (11) [back to overview]	CD4+ T-cell (CD4) Count Change From Baseline
NCT02605304 (11) [back to overview]	CD4+ T-cell (CD4) Count Change From Baseline
NCT02605304 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response at 4 Weeks After Treatment Discontinuation (SVR4)
NCT02605304 (11) [back to overview]	Percentage of Participants With Sustained Virologic Response at 12 Weeks After Treatment Discontinuation (SVR12)
NCT02609659 (5) [back to overview]	Percentage of Participants With Hemoglobin < 10 g/dL During Treatment
NCT02609659 (5) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02609659 (5) [back to overview]	Mean Change in Hemoglobin Values From Baseline to End of Treatment
NCT02609659 (5) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02609659 (5) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02613403 (8) [back to overview]	Number of Participants Who Experienced a Non-Overdose Event of Clinical Interest
NCT02613403 (8) [back to overview]	Number of Participants Who Experienced a Serious Adverse Event
NCT02613403 (8) [back to overview]	Number of Participants Who Experienced a Serious and Drug-Related Adverse Event
NCT02613403 (8) [back to overview]	Number of Participants Who Experienced an Adverse Event
NCT02613403 (8) [back to overview]	Number of Participants Who Discontinued Study Drug Due to an Adverse Event
NCT02613403 (8) [back to overview]	Number of Participants Who Experienced a Drug-Related Adverse Event
NCT02613403 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After The End of Study Therapy (SVR12)
NCT02613403 (8) [back to overview]	Number of Participants Who Experienced AST/ALT >5x Upper Limit Normal (ULN)
NCT02631772 (3) [back to overview]	Hemoglobin Levels
NCT02631772 (3) [back to overview]	Treatment Efficacy
NCT02631772 (3) [back to overview]	Number of Participants With Virologic Failure
NCT02641379 (15) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events (Part 2)
NCT02641379 (15) [back to overview]	Number of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 1)
NCT02641379 (15) [back to overview]	Number of Participants With Fibrosis Grades 0 to 4 at Baseline (Part 2)
NCT02641379 (15) [back to overview]	Percentage of Participants Achieving Sustained Virological Response in Groups A1, B1, and E by Genotype at the End of Follow-up (Part 2)
NCT02641379 (15) [back to overview]	Percentage of Participants With Relapse Rate in Groups A and B by Genotype at the End of Follow-up (Part 1)
NCT02641379 (15) [back to overview]	Percentage of Participants Achieving Sustained Virological Response in Groups A, B, C, and D at the End of Follow-up (Part 1)
NCT02641379 (15) [back to overview]	Percentage of Participants Achieving Sustained Virological Response in Groups C and D by Genotype at the End of Follow-up (Part 2)
NCT02641379 (15) [back to overview]	Percentage of Participants With Relapse Rates in Groups A1 and B1 at the End of Follow-up (Part 2)
NCT02641379 (15) [back to overview]	Percentage of Participants With Virological Response Rates in Group A1, B1, C and D at the End of the Treatment Period (Part 2)
NCT02641379 (15) [back to overview]	Mean Fatigue Severity Scale Scores for Groups A and B Over Time (Part 1)
NCT02641379 (15) [back to overview]	Mean Fatigue Severity Scale Scores for Groups A1, B1 and C Over Time (Part 2)
NCT02641379 (15) [back to overview]	Mean Short Form-36 Questionnaire Scores for Groups A and B Over Time (Part 1)
NCT02641379 (15) [back to overview]	Percentage of Participants With Virological Response Rate in Groups A, B, C, and D at the End of Treatment Period (Part 1)
NCT02641379 (15) [back to overview]	Mean Short Form-36 Questionnaire Scores for Groups A1, B1, and C Over Time (Part 2)
NCT02641379 (15) [back to overview]	Number of Participants With Adverse Events and Serious Adverse Events (Part 1)
NCT02716779 (12) [back to overview]	Time to Maximum Concentration (Tmax) of Ribavirin
NCT02716779 (12) [back to overview]	Maximum Concentration (Cmax) of PEG-IFN
NCT02716779 (12) [back to overview]	Time to Maximum Concentration (Tmax) of GPT
NCT02716779 (12) [back to overview]	Time to Maximum Concentration (Tmax) of PEG-IFN
NCT02716779 (12) [back to overview]	Maximum Concentration (Cmax) of Ribavirin
NCT02716779 (12) [back to overview]	Area Under the Concentration-Time Curve (AUC) of Glutamate-Pyruvate Transaminase (GPT)
NCT02716779 (12) [back to overview]	Area Under the Concentration-Time Curve (AUC) of Ribavirin
NCT02716779 (12) [back to overview]	Maximum Concentration (Cmax) of GPT
NCT02716779 (12) [back to overview]	Area Under the Concentration-Time Curve (AUC) of PEG-IFN
NCT02716779 (12) [back to overview]	Log Likelihood Median Values of Hepatitis C-Virus (HCV) Kinetic Models for Quantitative HCV Ribonucleic Acid (RNA) Measurement With Various Assumptions of Ribavirin Mechanism of Action
NCT02716779 (12) [back to overview]	Percentage of Participants With Treatment Response
NCT02716779 (12) [back to overview]	Score in Quality of Life Assessed Using Short Form-36 (SF-36) Health Questionnaire
NCT02723084 (4) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12): Non-inferiority of Arm A to Arm B
NCT02723084 (4) [back to overview]	Percentage of Participants With Post-Treatment Relapse
NCT02723084 (4) [back to overview]	Percentage of Participants With With On-treatment Virologic Failure
NCT02723084 (4) [back to overview]	Percentage of Participants in Arm A With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02725866 (8) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02725866 (8) [back to overview]	Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria
NCT02725866 (8) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02725866 (8) [back to overview]	Percentage of Participants Meeting Relapse Criteria
NCT02725866 (8) [back to overview]	Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria
NCT02725866 (8) [back to overview]	Percentage of Participants With Relapse
NCT02725866 (8) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT02725866 (8) [back to overview]	Percentage of Participants With Virologic Response at End of Treatment (EoT)
NCT02726022 (6) [back to overview]	Change From Baseline in SF-36 PCS at 24 Weeks After EOT
NCT02726022 (6) [back to overview]	Change From Baseline in SF-36 Physical Component Summary (PCS) at EOT
NCT02726022 (6) [back to overview]	Change From Baseline in SF-36 Mental Component Summary (MCS) at EOT
NCT02726022 (6) [back to overview]	Change From Baseline in SF-36 MCS at 24 Weeks After EOT
NCT02726022 (6) [back to overview]	Change From Baseline in SF-36 General Health Domain at 24 Weeks After EOT
NCT02726022 (6) [back to overview]	Change From Baseline in 36-Item Short-Form Health Survey (SF-36) General Health Domain at End of Treatment (EOT)
NCT02731131 (6) [back to overview]	Number of Participants With ALT Normalization at 48 Weeks After End of Treatment
NCT02731131 (6) [back to overview]	Number of Participants With Negative HDV RNA at End of Treatment
NCT02731131 (6) [back to overview]	Number of Participants With ALT Normalization at End of Treatment
NCT02731131 (6) [back to overview]	Number of Participants With Negative HDV RNA at 48 Weeks After End of Treatment
NCT02731131 (6) [back to overview]	Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment
NCT02731131 (6) [back to overview]	Number of Participants With ALT Normalization Plus Negative HDV RNA at End of Treatment
NCT02761629 (8) [back to overview]	Change From Baseline in Cluster of Differentiation (CD) 4 (CD4) Cell Counts at Weeks 4, 12, 24, 48, 72, and 96
NCT02761629 (8) [back to overview]	Change From Baseline in CD4/CD8 Ratio at Weeks 4, 12, 24, 48, 72, and 96
NCT02761629 (8) [back to overview]	Percentage of Participants Without SVR Among Participants With Undetectable HCV RNA at the End of Treatment
NCT02761629 (8) [back to overview]	Percentage of Participants With Undetectable HCV RNA 12 Weeks After the Last Dose of Peg-IFN-Alpha-2A
NCT02761629 (8) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR)
NCT02761629 (8) [back to overview]	Serum Human Immunodeficiency Virus (HIV) RNA Levels
NCT02761629 (8) [back to overview]	Percentage of Participants With Undetectable HCV RNA
NCT02761629 (8) [back to overview]	Percentage of Participants With Alanine Aminotransferase (ALT) Level Categories
NCT02781649 (6) [back to overview]	Kidney Function at 6 Months
NCT02781649 (6) [back to overview]	Number of Participants With Grade 3 or Higher Treatment-related Adverse Events as US Department of Health and Human Services Common Terminology of Adverse Events (CTCAE) Version 4
NCT02781649 (6) [back to overview]	Number of Participants With Nonstructural Protein 5A (NS5A) Resistance Mutations in the HCV Population From the Deceased Donors
NCT02781649 (6) [back to overview]	Viral Response
NCT02781649 (6) [back to overview]	Antibody Development
NCT02781649 (6) [back to overview]	Kidney Function at 12 Months
NCT02786537 (28) [back to overview]	Median Change in Headache-Phase 2
NCT02786537 (28) [back to overview]	Mean Change in Fatigue PRO -EBR/GZR vs SOF/LDV
NCT02786537 (28) [back to overview]	16 Wk EBR/GZR With RBV Efficacy on Patients With HCV RASs
NCT02786537 (28) [back to overview]	HCV SVR Durability -No Cirrhosis
NCT02786537 (28) [back to overview]	HCV SVR Durability-Patients With Cirrhosis
NCT02786537 (28) [back to overview]	Mean Change in Fatigue PRO Score -Phase 1
NCT02786537 (28) [back to overview]	Mean Change in HCV- PRO- Phase 1
NCT02786537 (28) [back to overview]	Mean Change in HCV-PRO (Functional Well-being) EBR/GZR vs. SOF/LDV Score-Phase 2
NCT02786537 (28) [back to overview]	Mean Change in Headache-EBR/GZR and SOF/LDV
NCT02786537 (28) [back to overview]	Mean Change in Headache-PRO Scores -Phase 1
NCT02786537 (28) [back to overview]	Mean Change in Nausea/Vomiting PRO Score -Phase 1
NCT02786537 (28) [back to overview]	Mean Change in Nausea/Vomiting PROMIS Score -EBR/GZR vs. LDV/SOF
NCT02786537 (28) [back to overview]	Median Change in Fatigue -Phase 1
NCT02786537 (28) [back to overview]	Median Change in Fatigue-Phase 2
NCT02786537 (28) [back to overview]	Median Change in HCV-PRO (Overall Well Being) -Phase 1
NCT02786537 (28) [back to overview]	Median Change in Headache -Phase 1
NCT02786537 (28) [back to overview]	Phase 1 Number of Participants With Sustained Virologic Response (SVR12-mITT Without Imputation)
NCT02786537 (28) [back to overview]	Phase 1-Sustained Virologic Response (SVR12) mITT With Imputation
NCT02786537 (28) [back to overview]	Sustained Virologic Response (SVR12) mITT With Imputation-Phase 1 and 2 EBR/GZR, SOF/LDV
NCT02786537 (28) [back to overview]	Phase 1/2 Number of Participants With Sustained Virologic Response (SVR12-mITT Without Imputation)
NCT02786537 (28) [back to overview]	Post-treatment Progression/Regression of Liver Disease-Fib-4
NCT02786537 (28) [back to overview]	Treatment Non-Adherence Probability Estimates
NCT02786537 (28) [back to overview]	Change in Functional Status (HCV-PRO) Within Treatment
NCT02786537 (28) [back to overview]	Change in HCV-associated Symptoms (PROMIS Measures) After HCV Treatment Initiation
NCT02786537 (28) [back to overview]	Impact of Baseline NS5A RASs on Treatment Outcomes-Phase 2
NCT02786537 (28) [back to overview]	Number of Participants With Adverse Events That Caused Treatment Discontinuation-EBR/GZR vs. LDV/SOF
NCT02786537 (28) [back to overview]	Median Change in Nausea PROMIS Score-EBR/GZR SOF/LDV
NCT02786537 (28) [back to overview]	Median Change in Nausea PRO Score -Phase 1
NCT02803138 (9) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02803138 (9) [back to overview]	Percentage of Participants With Viral Breakthrough
NCT02803138 (9) [back to overview]	Percentage of Participants With Sufficient Follow-up Who Achieved Sustained Virological Response 12 Weeks Posttreatment
NCT02803138 (9) [back to overview]	Percentage of Participants With Virologic Response at End of Treatment (EoT)
NCT02803138 (9) [back to overview]	Percentage of Participants With Missing Sustained Virologic Response 12 Weeks Post-Treatment (SVR12) Data and/or Nonresponders Who Did Not Meet Specific SVR12 Nonresponder Criteria
NCT02803138 (9) [back to overview]	Percentage of Participants Achieving Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02803138 (9) [back to overview]	Percentage of Participants Meeting Premature Study Drug Discontinuation Criteria
NCT02803138 (9) [back to overview]	Percentage of Participants Meeting Relapse Criteria
NCT02803138 (9) [back to overview]	Percentage of Participants With Relapse
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 10
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 12
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 24
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 3
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 3
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 24
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 20
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 2
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 4
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 5
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 6
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 16
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 12
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 8
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 4
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 16
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 5
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 10
NCT02822794 (29) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02822794 (29) [back to overview]	Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02822794 (29) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02822794 (29) [back to overview]	Percentage of Participants With Overall Virologic Failure
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 2
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 20
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 1
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 6
NCT02822794 (29) [back to overview]	Change From Baseline in HCV RNA at Week 8
NCT02822794 (29) [back to overview]	Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
NCT02822794 (29) [back to overview]	Percentage of Participants With HCV RNA < LLOQ at Week 1
NCT02939989 (3) [back to overview]	Percentage of Participants With Post-treatment Relapse
NCT02939989 (3) [back to overview]	Percentage of Participants With On-treatment Virologic Failure
NCT02939989 (3) [back to overview]	Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12)
NCT02946034 (8) [back to overview]	Average Change in Plasma Interferon Gamma-induced Protein 10 (IP-10) From Baseline to Post-treatment
NCT02946034 (8) [back to overview]	Average Change in Plasma Interferon (IFN)-Gamma From Baseline to Post-treatment
NCT02946034 (8) [back to overview]	Average Change in Urine Tumor Necrosis Factor (TNF)-Alpha From Baseline to Post-treatment
NCT02946034 (8) [back to overview]	Number of Patients Who Suffered Adverse Events Related to Study Drug (Safety and Tolerability)
NCT02946034 (8) [back to overview]	Average Change in Urine Interleukin (IL)-6 From Baseline to Post-treatment
NCT02946034 (8) [back to overview]	Average Change in Plasma Interleukin (IL)-6 From Baseline to Post-treatment
NCT02946034 (8) [back to overview]	Number of Patients Who Had Sustained Virologic Response at 12-weeks (SVR12) Post-treatment (Efficacy of Treatment)
NCT02946034 (8) [back to overview]	Average Change in Plasma Tumor Necrosis Factor (TNF)-Alpha From Baseline to Post-treatment
NCT02956629 (9) [back to overview]	Percentage of Participants With Virologic Failure
NCT02956629 (9) [back to overview]	Percentage of Participants Discontinuing Study Therapy Due to an AE
NCT02956629 (9) [back to overview]	Percentage of Participants Experiencing a Drug-related AE
NCT02956629 (9) [back to overview]	Percentage of Participants With SVR 24 Weeks After Completing Study Therapy (SVR24)
NCT02956629 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Completing Study Therapy (SVR12)
NCT02956629 (9) [back to overview]	Percentage of Participants Experiencing an AE of Clinical Importance (ECI)
NCT02956629 (9) [back to overview]	Percentage of Participants Experiencing an Adverse Event (AE)
NCT02956629 (9) [back to overview]	Percentage of Participants Experiencing a Drug-related SAE
NCT02956629 (9) [back to overview]	Percentage of Participants Experiencing a Serious Adverse Event (SAE)
NCT02996682 (9) [back to overview]	Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
NCT02996682 (9) [back to overview]	Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)
NCT02996682 (9) [back to overview]	Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
NCT02996682 (9) [back to overview]	Percentage of Participants With Virologic Failure
NCT02996682 (9) [back to overview]	Change From Baseline in HCV RNA
NCT02996682 (9) [back to overview]	Percentage of Participants Who Discontinued Treatment (SOF/VEL or RBV) Early Due to an Adverse Event
NCT02996682 (9) [back to overview]	Percentage of Participants Who Had HCV RNA < LLOQ by Visit While on Treatment
NCT02996682 (9) [back to overview]	Percentage of Participants With Improved and Worsened Child-Pugh-Turcotte (CPT) Class
NCT02996682 (9) [back to overview]	Percentage of Participants With a Decrease, No Change, or Increase in Model for End Stage Liver Disease (MELD) Score
NCT03020004 (1) [back to overview]	Percentage of Subjects With Sustained Virologic Response (SVR12) 12 Weeks Post-treatment
NCT03020082 (1) [back to overview]	Proportion of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
NCT03020095 (1) [back to overview]	Percentage of Subjects With Sustained Virologic Response (SVR12) 12 Weeks Post-treatment
NCT03092375 (7) [back to overview]	Difference in SVR12 Rates for 12-wk vs 16 wk
NCT03092375 (7) [back to overview]	Comparison of Cirrhotic Participants Achieving SVR 12 After G/P Plus RBV for 12 Wks vs. G/P for 16 Wks
NCT03092375 (7) [back to overview]	Tolerability of G/P +/-RBV
NCT03092375 (7) [back to overview]	Difference in Relapse Between Arms A & B in Non-cirrhotic Subjects
NCT03092375 (7) [back to overview]	Difference in On-Treatment Virologic Failure Between Arms C and D in Cirrhotic Subjects
NCT03092375 (7) [back to overview]	Difference in On-Treatment Virologic Failure Between Arms A & B (Non-cirrhotic Subjects)
NCT03092375 (7) [back to overview]	Difference in % of Relapse Between Cirrhotic Arms C & D
NCT03365635 (2) [back to overview]	Approval for DAA by Third Party Payers
NCT03365635 (2) [back to overview]	SVR - Sustained Virologic Response
NCT03760666 (2) [back to overview]	Number of Participants With Treatment-Related Adverse Events
NCT03760666 (2) [back to overview]	Brequinar Pharmacokinetics - Area Under the Curve (AUC)

Development of Hepatocellular Carcinoma (HCC)

"A diagnosis of development of hepatocellular carcinoma (HCC) was based on either~Histology showing HCC (from a biopsy, surgery, or autopsy) or~A new hepatic defect on imaging with an alpha-fetoproteion (AFP) level rising to > 1,000 ng/ml." (NCT00006164)
Timeframe: 1400 days (3.85 years) post randomization

Intervention	Participants (Count of Participants)
Peginterferon Alfa-2a 90 mcg/Week	13
Standard of Care Followup	16

Intervention	units on a scale (Mean)
	0.5 years	1.5 years	2.5 years	3.5 years
Peginterferon Alfa-2a 90 mcg/Week	-2.62	-2.22	-2.65	-2.84
Standard of Care Followup	-1.08	-1.67	-2.15	-1.85

Intervention	participants (Number)
	Sustained Virological Response (SVR)	Relapse/breakthrough	Nonresponse	Treatment stopped for adverse event	Lost to follow-up
Low Dose Group	19	7	3	0	1
Standard Dose Group	21	2	1	3	0

Intervention	Percentage of participants (Number)
	Hematocrit (fraction)- low n=731,728	Hemoglobin (g/dL)- low, n=731,727	Platelets(10^9/L)- low,n=731,727	Basophils(10^9/L)- high, n=731,727	WBC (10^9/L)- low, n=731,727	WBC (10^9/L)- high, n=731,727	Eosinophils (10^9/L )- high, n=731,727	Lymphocytes (10^9/L)- low, n=731,727	Monocytes (10^9/L )- low, n=731,727	Neutrophils (10^9/L)- low, n=731,727	Partial throm.(seconds)- high, n=730,728	Liver function: ALAT (SGPT) (U/L)- HIGH n=731,728	Albumin (g/L)- low, n=730,728	Alk. Phos.(U/L)- high,n=731,728	ASAT (SGOT) (U/L)- high,n= 731,727	GGT (U/L)- high,n=731,728	Total bilirubin (umol/L)- high, n=731,728	Total protein (g/L)- high, n=731,728	Renal function: bun (mmol/L)- high, n=731,728	Chloride (mmol/L)- high, n=731,728	Chloride (mmol/L)- low, n=731,728	Creatinine (umol/L)- high, n=731,728	Potassium (mmol/L)- high, n=731,728	Potassium (mmol/L)- low, n=731,728	Sodium (mmol/L) - high, n=731,728	Sodium (mmol/L)- low,n=731,728	Thyroid function: free T4 (pmol/)- high, n=716,715	Free T4 (pmol/L)- low, n=716,715	TSH (mU/L)- high, n=716,715	Miscellaneous: calcium (mmol/L)- low, n= 731,728	Cholesterol (mmol/L)- high, n=730,728	Phosphate (mmol/L)- high, n=730,728	Phosphate (mmol/L)- low, n=730,728	Random glucose (mmol/L)- high, n= 731,728	Random glucose (mmol/L)- low, n= 731,728	Triglycerides (mmol/L)- high, n=730,728	Uric acid (umol/L)- high, n=730,728	Urinalysis: glycosuria (0 to 4+)- high, n= 721,71	Hematuria (0 to 4+) high, n= 721,716	Proteinuria (0 to 4+) - high, n= 721,716
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks	18	15	24	0	64	0	0	49	0	69	0	15	0	0	15	12	0	0	0	0	0	0	0	0	0	0	0	0	2	1	0	2	18	2	2	31	2	0	4	0
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks	21	16	22	0	71	0	0	57	0	75	0	10	0	0	10	10	0	0	0	0	0	0	0	0	0	0	0	0	6	0	0	2	21	1	0	33	2	1	4	2

Intervention	Percentage of participants (Number)
	Any AE	Any SAE
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks	97	5
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks	99	6

Intervention	participants (Number)
	Diastolic BP, High, n=729,726	Systolic BP, High, n=729,726	Systolic BP, Low, n=729,726	Heart Rate, High, n=728,725	Heart Rate, Low, n=728,725
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks	4	2	9	2	4
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks	3	2	2	3	4

Intervention	participants (Number)
	200 - 400 mg/dL	>400 - 1000 mg/dL	>1000 mg/dL
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 16 Weeks	280	117	17
PEG-IFN Alfa-2a 180μg + Ribavirin 800 mg 24 Weeks	284	138	14

Intervention	percentage of participants (Number)
	Any AE	SAE
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1200 mg	100	9
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1600 mg	100	13
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1200 mg	100	13
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1600 mg	100	11

Intervention	percentage of participants (Number)
	Hematocrit (fraction) Low, (n=45,47,46,47)	Hemoglobin (g/dl) - Low, (n= 45,47,46,47)	Platelets Low, (n= 45,47,46,47)	WBC - High, [n= 45,47,46,47]	WBC - Low, (n= 45,47,46,47)	Lymphocytes High, (n= 45,47,46,47)	Lymphocytes Low (n= 45,47,46,47)	Neutrophils Low, (n= 45,47,46,47)	SGPT High, (n= 45,47,46,47)	Albumin Low, (n= 45,47,46,47)	Alkaline Phosphate High, (n= 45,47,46,47)	SGOT High, (n= 45,47,46,47)	GGT High, (n= 45,47,46,47)	Total Bilirubin High, (n= 45,47,46,47)	Total Protein High, (n= 45,47,46,47)	Bun High, (n= 45,47,46,47)	Chloride High, (n= 45,47,46,47)	Chloride Low (n= 45,47,46,47)	Creatinine High, (n= 45,47,46,47)	Potassium Low, (n= 45,47,46,47)	Sodium High, (n= 45,47,46,47)	Sodium Low, (n= 45,47,46,47)	TSH High, (n= 45,46,43,46)	Calcium Low, (n= 45,47,46,47)	Phosphate High, (n= 45,47,46,47)	Phosphate Low, (n= 45,47,46,47)	Random glucose High, (n= 45,47,46,47)	Triglycerides High, (n= 45,47,46,47)	Uric acid High (n= 45,47,46,47)	Glycosuria High, (n= 44,46,44,45)	Hematuria High, (n= 44,46,44,45)	Proteinuria High, (n= 44,46,44,45)
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1600 mg	53	57	26	2	72	0	68	79	19	0	0	17	19	6	0	2	0	2	2	2	4	0	7	4	0	36	11	38	11	0	2	2
PEG-IFN Alfa-2a 180 mcg +Ribavirin 1200 mg	44	42	27	0	76	0	73	82	20	0	0	16	27	9	0	0	0	0	0	0	2	0	0	0	2	31	2	60	9	7	5	2
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1200 mg	41	48	28	0	70	0	72	74	15	2	2	22	15	2	0	0	2	0	0	0	0	0	5	0	7	20	4	57	2	5	7	5
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1600 mg	64	55	21	0	74	2	72	74	13	2	0	26	19	2	4	0	0	2	0	0	2	2	9	2	0	30	6	49	15	2	0	0

Intervention	percentage of participants (Number)
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1200 mg	28.3
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1600 mg	29.8
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1200 mg	34.0
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1600 mg	46.8

Intervention	Units on a scale (Mean)
	Baseline, n=46,46,47,46	Week 1, (n=43,44,43,45)	Week 2, (n=43,44,43,47)	Week 4, (n=42,45,44,45)	Week 6, (n=41,41,43,44)	Week 8, (n=38,42,42,40)	Week 12, (n=44,46,42,44)	Week 18, (n=43,44,42,40)	Week 24, (n=43,45,41,37)	Week 30, (n=38,42,39,34)	Week 36, (n=36,42,37,33)	Week 42, (n=35,37,35,32)	Week 48, (n=34,40,31,29)	Week 52, (n=31,36,32,28)	Week 60, (n=34,34,31,28)	Week 72, (n=28,37,28,29)
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1200 mg	3.52	4.24	4.84	6.31	6.32	6.20	6.82	8.04	7.07	8.03	7.50	7.49	7.48	4.56	4.47	5.00
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1600 mg	4.39	4.45	4.71	5.79	6.49	6.24	7.09	8.31	7.43	7.89	8.63	8.33	7.89	6.62	5.18	5.14
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1200 mg	4.23	4.81	5.60	7.21	8.19	8.02	8.09	8.62	8.80	9.35	7.82	8.00	7.92	4.22	3.40	2.92
PEG-IFN Alfa-2a 270 mcg+ Ribavirin 1600 mg	4.43	3.96	5.22	6.07	6.64	7.69	8.09	8.13	8.05	7.74	9.45	8.13	7.93	4.21	3.12	2.80

Intervention	log(IU/mL) (Median)
Peginterferon+Ribavirin	0.50
Peginterferon	0.70

Intervention	percentage of participants (Number)
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1200 mg	45.7
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1600 mg	57.4
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1200 mg	55.3
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1600 mg	55.3

Intervention	log 10 copies/mL (Mean)
	Baseline, (n=46,47,47,47)	At Hour 72, (n=41,41,42,46)	At Week 1, (n=44,47,45,46)	At Week 2, (n=43,45,43,46)	At Week 4, (n=44,45,44,46)	At Week 12, (n=45,45,41,44)	At Week 24, (n=42,45,40,37)
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1200 mg	6.50	5.80	5.74	5.32	4.35	2.99	2.76
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1600 mg	6.61	5.82	5.81	5.37	4.62	3.10	2.82
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1200 mg	6.55	5.52	5.42	4.83	3.94	2.52	2.25
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1600 mg	6.53	5.49	5.45	4.84	3.85	2.75	2.21

Intervention	percentage of participants (Number)
	At Hour 72	At Week 1	At Week 2	At Week 4	At Week 12	At Week 24
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1600 mg	0.0	0.00	2.1	8.5	38.3	55.3
PEG-IFN Alfa-2a 180 mcg +Ribavirin 1200 mg	0.0	0.00	0.00	2.2	47.8	56.5
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1200 mg	0.0	0.00	2.1	10.6	53.2	59.6
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1600 mg	0.0	0.00	2.1	12.8	51.1	68.1

Intervention	percentage of participants (Number)
	Diastolic BP, High (n=45,47,46,47)	Systolic BP High, (n=45,47,46,47)	Systolic BP Low, (n=45,47,46,47)	Heart Rate Low, (n=45,47,46,47)	Heart Rate, High, (n=45,47,46,47)
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1200 mg	0	0	0	2	0
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1600 mg	0	2	0	0	0
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1200 mg	0	0	2	0	0
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1600 mg	0	4	0	0	0

Intervention	percentage of participants (Number)
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1200 mg	40.9
PEG-IFN Alfa-2a 180 mcg + Ribavirin 1600 mg	31.1
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1200 mg	47.7
PEG-IFN Alfa-2a 270 mcg + Ribavirin 1600 mg	50.0

Intervention	Participant (Number)
	Any Grade 3 or higher	Grade 3	Grade 4
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	22	15	7
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	20	15	5
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	84	73	11

Intervention	Participant (Number)
	Premature treatment discontinuation	Temporarily off treatment	Reduced dose
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	16	7	2
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	57	29	33

Intervention	Participant (Number)
	Neutropenia >= Grade 2	Grade 2	Grade 3	Grade 4
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	20	7	10	3
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	10	4	5	1
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	96	38	37	21

Intervention	Participant (Number)
	Number of participants who used megestrol	Number of participants who used dronabinol
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	2	4
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	1	4
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	6	22

Intervention	Participant (Number)
	Anemia >= Grade 2	Grade 2	Grade 3	Grade 4
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	1	0	0	1
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	0	0	0	0
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	6	3	1	2

ribavirin

Description

Cross-References

Synonyms (208)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (5)

Drug Classes (4)

Pathways (2)

Protein Targets (83)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (377)

Molecular Functions (115)

Ceullar Components (86)

Bioassays (2691)

Research

Studies (11,480)

Study Types

Clinical Trials (762)

Trial Overview

Trial Outcomes

Development of Hepatocellular Carcinoma (HCC)

SF-36 Mental Health Summary Score

Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points

Ascites

Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits

Death From Any Cause

Hepatic Encephalopathy

Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies

Serious Adverse Events

Spontaneous Bacterial Peritonitis

Variceal Hemorrhage

Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy.

SF-36 Vitality Summary Score

Presumed Hepatocellular Carcinoma (HCC)

SF-36 Physical Function Summary Score

Participants With Viral Decline at Day 3 & 28 With Predictors of Post Treatment Response

Change in Hepatitis C Virus RNA Levels During Phase I

Sustained Virologic Response (SVR) for Participants With Detectable But ≥2 Log Drop in HCV-RNA at Treatment Week 12

Sustained Virologic Response (SVR) for Participants With Undetectable HCV-RNA at Treatment Week 12

Sustained Virologic Response (SVR) Rate

First Phase Decline in Logarithm of HCV RNA Level

Slope of Second Phase Decline in HCV Levels

Time to Negativity

Virological Response (Intention to Treat)

Virological Response Category (Per Protocol)

Percentage of Participants With Marked Laboratory Abnormalities

Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Participants With Marked Abnormal Vital Signs

Number of Participants With Highest Triglyceride Level

Percentage of Participants With Virological Response at The End of Study Treatment

Percentage of Participants With Sustained Virological Response (SVR)

Percentage of Participants Virological Response 12 Weeks Post-Treatment

Percentage of Participants With Adverse Events and Serious Adverse Events

Percentage of Participants With Marked Laboratory Abnormalities

Percentage of Participants With Virological Response At 12 Weeks After The End of The Treatment Period

Total BDI-II (Beck Depression Inventory) Scores

Percentage of Participants With Virological Response at the End of the Treatment Period

HCV RNA Profile During The First 24 Weeks

Percentage of Participants With Virological Response Over Time to Week 24

Percentage of Participants With Abnormal Vital Signs

Percentage of Participants With Predicted Sustained Virological Response

Percentage of Participants With Sustained Virological Response

Number of Participants With High-grade Signs and Symptoms or Laboratory Values

Sustained Virologic Response

Number of Participants With Dose Modifications, Temporary Stops, and Premature Treatment Discontinuations

Number of Participants With Neutropenia

Number of Participants Who Used Antianorexia Agents, Such as Megestrol and Dronabinol

Number of Participants With Anemia

Number of Participants With Prescription as Needed of Erythropoietin (EPO), Granulocyte Colony-stimulating Factor (GCSF), and Granulocyte-monocyte Colony-stimulating Factor (GM-CSF)

Weight

Homeostasis Model Assessment of Insulin Resistance (HOMA-IR)

Time-scaled Change in Metavir Liver Fibrosis Score (SCMFS)

Intervention	Participant (Number)
	Number of participants who used EPO	Number of participants who used GCSF	Number of participants who used GM-CSF
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	14	17	0
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	13	8	0
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	70	60	0

Intervention	kilograms (Median)
	Week 0: Weight (N=43 in A, 42 in B, 169 in C)	Week 4: Weight (N=43 in A, 35 in B, 161 in C)	Week 8: Weight (N=39 in A, 34 in B, 162 in C)	Week 12: Weight (N=42 in A, 30 in B, 157 in C)	Week 16: Weight (N=39 in A, 35 in B, 164 in C)	Week 24: Weight (N=39 in A, 36 in B, 165 in C)	Week 32: Weight (N=37 in A, 35 in B)	Week 36: Weight (N=162 in C)	Week 40: Weight (N=32 in A, 29 in B)	Week 48: Weight (N=33 in A, 31 in B, 153 in C)	Week 56: Weight (N=31 in A, 24 in B)	Week 64: Weight (N=26 in A, 24 in B)	Week 72: Weight (N=26 in A, 27 in B, 141 in C)	Week 84: Weight (N=140 in C)	Week 96: Weight (N=138)
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	74.9	74.7	74.9	76.3	77.4	75.5	76.5	NA	75.7	78.2	79.7	78.5	81.6	NA	NA
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	79.8	80.4	80.8	81.1	79.9	79.4	80.4	NA	83.1	80.4	81.6	84.0	85.4	NA	NA
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	75.8	75.8	75.8	76.3	76.3	75.8	NA	75.0	NA	75.1	NA	NA	75.6	77.0	78.4

Intervention	mg/dL x uIU/mL (Median)
	Week 0: HOMA-IR (N=32 in A, 32 in B, 72 in C)	Week 12: HOMA-IR (N=72 in C)	Week 24: HOMA-IR (N=34 in A, 30 in B, 73 in C)	Week 36: HOMA-IR (N=66 in C)	Week 48: HOMA-IR (N=30 in A, 24 in B, 74 in C)	Week 72: HOMA-IR (N=67 in C)	Week 84: HOMA-IR (N=63 in C)	Week 96: HOMA-IR (N=65 in C)
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	3.84	NA	3.08	NA	3.53	4.79	NA	NA
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	2.49	NA	4.78	NA	2.84	4.82	NA	NA
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	2.37	2.47	2.58	2.41	3.25	2.69	2.99	2.30

Intervention	Participant (Number)
	Week 0: Number of participants with adherence data	Week 0: Number of participants adherent to meds	Week 12:Number of participants with adherence data	Week 12:Number of participants adherent to meds	Week 24:Number of participants with adherence data	Week 24:Number of participants adherent to meds	Week 48:Number of participants with adherence data	Week 48:Number of participants adherent to meds	Week 60:Number of participants with adherence data	Week 60:Number of participants adherent to meds	Week 72:Number of participants with adherence data	Week 72:Number of participants adherent to meds
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	0	NA	37	32	32	28	22	19	0	NA	8	7
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	158	132	150	125	145	118	120	95	91	79	0	NA

Intervention	Ishak units per one year (52 weeks) (Median)
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	0
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	1.31

Intervention	Participant (Number)
	Week 0--Number of participants with HCV RNA data	Week 0--Number of participants with detectable HCV	Week 12--Number of participants with HCV RNA data	Week 12-Number of participants with detectable HCV	Week 24--Number of participants with HCV RNA data	Week 24-Number of participants with detectable HCV	Week 36--Number of participants with HCV RNA data	Week 36-Number of participants with detectable HCV	Week 48--Number of participants with HCV RNA data	Week 48-Number of participants with detectable HCV	Week 60--Number of participants with HCV RNA data	Week 60-Number of participants with detectable HCV	Week 72--Number of participants with HCV RNA data	Week 72-Number of participants with detectable HCV	Week 84--Number of participants with HCV RNA data	Week 84-Number of participants with detectable HCV
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	44	42	42	40	36	35	0	NA	31	31	0	NA	27	27	0	NA
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	42	42	34	34	35	35	0	NA	28	28	0	NA	22	22	0	NA
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	164	53	158	31	163	39	158	41	0	NA	137	34	135	51	137	50

Intervention	Participant (Number)
	Any psychological	Grade 3	Grade 4
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	3	2	1
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	1	1	0
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	19	18	1

Intervention	Participant (Number)
	Thrombocytopenia >= Grade 2	Grade 2	Grade 3	Grade 4
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	14	10	4	0
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	4	3	1	0
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	31	25	5	1

Intervention	Participant (Number)
	Week 0: Number of participants with HIV RNA data	Week 0: No. of participants with undetectable VL	Week 12: Number of participants with HIV RNA data	Week 12: No. of participants with undetectable VL	Week 24: Number of participants with HIV RNA data	Week 24: No. of participants with undetectable VL	Week 36: Number of participants with HIV RNA data	Week 36: No. of participants with undetectable VL	Week 48: Number of participants with HIV RNA data	Week 48: No. of participants with undetectable VL	Week 60: Number of participants with HIV RNA data	Week 60: No. of participants with undetectable VL	Week 72: Number of participants with HIV RNA data	Week 72: No. of participants with undetectable VL	Week 84: Number of participants with HIV RNA data	Week 84: No. of participants with undetectable VL
A: Open Label (OL) (PEG-IFN, RBV); OL Randomized (PEG-IFN)	44	32	0	NA	39	25	0	NA	35	24	0	NA	27	19	0	NA
B: OL (PEG-IFN, RBV) Then OL Randomized (Observation)	42	34	0	NA	39	25	0	NA	33	25	0	NA	27	20	0	NA
C: OL (PEG-IFN, RBV) Then OL (PEG-IFN, RBV)	169	146	164	138	165	141	160	134	150	125	140	113	140	107	136	108

Intervention	Log10 IU/mL (Mean)
PegIntron 1.5 ug/kg/wk Plus REBETOL	-2.32
PegIntron 1.0 ug/kg/wk Plus REBETOL	-2.02
PEGASYS 180 ug/wk Plus COPEGUS	-2.45